[{"article": ".\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nThe findings bordered on statistical significance, suggesting that future clinical trials with a greater number of patients are needed to show similar benefits.\nThis takes a certain amount of time from the patient's symptom onset which prompted the 9-1-1 call.\nResearchers analyzed results from 658 stroke patients who were treated with tPA - a drug that dissolves blood clots.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does raise risks in a meaningful way. It says:\n\u201cBut tPA is not indicated and could hurt a patient\u2019s chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures. That is why patients need a CT scan to confirm the type of stroke before receiving tPA.\u201d\nHowever,\u00a0that statement could have gone further and noted that some patients with a negative CT scan may have a hemorrhage after getting tPA.  ", "answer": 1}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\nTreating more Americans with statins is worth the small risk of side-effects and would be cost-effective, a new report finds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NBC did a better job than the Times in answering the question about risks. NBC wrote that statins \u201ccan damage muscle in 5 to 15 percent of patients. In 2012, the Food and Drug Administration\u00a0updated labeling on statins to\u00a0include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\u201d This is a nice addition to the overall coverage of the new statin studies and a step we wish more reporters had taken.", "answer": 1}, {"article": "Scientists still haven\u2019t discovered a cure for the common cold, but researchers now say zinc may be the next best thing.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nIn some of the cited studies, the benefits of zinc were significant.\nThe authors declined to make recommendations about the optimal dose, formulation or duration of zinc use, saying that more work was needed before they could make recommendations.\nThe Cochrane report did not review any studies of nasal zinc products.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pointed out that nasal zinc products, associated with loss of smell, were not evaluated in the Cochrane review and it\u00a0quotes one of the authors of the study suggesting that the potential harms of zinc products are limited to a bad taste and some nausea. However, the full listing includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. \u00a0\u00a0 \n\u00a0", "answer": 0}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nThis study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nUsing this test, troponin levels were measured in over 6000 patients with chest pain admitted to four hospitals in Scotland and the USA.\nThe overwhelming majority of these patients do not have a heart attack.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of this test \u2014 discharging a patient who may be having a heart attack and be at risk of dying \u2014 can only be adequately assessed in prospective evaluations using this new test as part of routine care. The release doesn\u2019t adequately address this or describe what might happen if the test is wrong. We also think that the release could have done a better job of explaining that this new test is only one part of the assessment of patients presenting with chest pain. Other factors that are likely to be important that could have been mentioned from the paper include changes in the EKG (electrical test of the heart) that is also part of standard care. In addition, the duration of symptoms is also important. For patients who have had pain for less than 2 hours, the test may not be as effective.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of the \ntreatment were not mentioned", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does mention that all the women experienced side effects. It left out some potential harms and didn\u2019t quantify any specific adverse events, simply noting that side effects were \"typically the fatigue and nausea often seen with chemotherapy.\" The Genentech press release mentions and quantifies severe adverse events that were not mentioned here, including low platelet levels in about 6% of patients.\u00a0\nThe article does describe a death that occurred during the trial, although see the \"sources\" criterion for a comment about the outside source that provided the interpretation. Especially because it doesn\u2019t present how many women were enrolled in the trial, the article needs a truly outside expert\u2019s interpretation of this death. In general, more discussion and quantification of the harms would have matched the quantified benefits.\nAlso not noted are the potential risks associated with Herceptin, a component of T-DM1. For instance, this drug is associated with\u00a0cardiac toxicity;\u00a0while the risk of heart failure may at present not be a dominant concern in the treatment of metastatic breast cancer, the risk could become more relevant if T-DM1 were truly able to increase lifespan. Other\u00a0black box warnings\u00a0of Herception not mentioned include the potential for serious infusion reactions, sometimes fatal.", "answer": 0}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there appears to be little risk of harm from the new\u00a0testing procedure itself, the\u00a0story makes no mention of the\u00a0downside that can accompany\u00a0a faulty diagnosis\u2013whether a false positive or negative. False positive tests (diagnosing asthma when the patient has another disease) and false negatives (failing to diagnose asthma) can have significant consequences.\u00a0A brief comment on the potential harms associated with a faulty test would have been helpful.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. ", "answer": 0}, {"article": "The Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\nResearchers found avocado consumption (1 to 1.5 per day) significantly reduced total cholesterol (TC), \"bad\" low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) when they were substituted for sources of saturated fat.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\nAdditionally, avocado consumption did not impact \"good\" high density lipoprotein cholesterol (HDL).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It could have been noted that adding an avocado or two a day to one\u2019s diet would also add to daily caloric intake. An average avocado has around 250 calories and 21 grams (about one-third of the recommended daily allowance) of fat.\u00a0Additional caloric intake can result in weight gain and stored fat, which in turn impacts metabolic markers (such as increased insulin production and inflammatory markers) and cardiovascular risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed the increase in colorectal cancer incidence that has been observed.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms. From a bioethics standpoint, there is concern that\u00a0the use of a placebo without the patient\u2019s knowledge may undermine trust between the physician and patient, thereby leading to medical harm. (More background on these concerns in this Science-Based Medicine post.) In addition, patients receiving placebo treatments in clinical studies commonly complain of adverse drug reactions. The story also could have discussed the potential for harm resulting from the participants\u2019 interruption of active drug therapy for the study.", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nBy developing more specifically targeted drugs, Zarate noted, it may be possible to treat patients effectively while avoiding these symptoms.\nKetamine could improve treatment of bipolar illness and depression in a variety of ways, Zarate said; for example, as a means to jump-start standard drug treatment, or as an anesthetic before ECT.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify the potential harms. In fact, it minimizes the potential harms by saying there were no \"serious adverse events,\" while listing side effects that\u00a0included anxiety, feeling woozy or loopy, headache, and dissociative symptoms, meaning a temporary sense of disconnection from reality.\" People on ketamine may have a different perception of what is serious. ", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\nFor the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\nIn this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention potential harms. Like any diagnostic or screening test, IMS carries a risk of a false negative and false-positive tests that could lead to a false sense of security or anxiety/unnecessary treatment. In addition, a biopsy is required to test\u00a0a tissue sample (for both a standard evaluation and IMS). Though generally safe, a biopsy can result in scarring, bleeding, infection or allergic reaction to a topical antibiotic. The release could have mentioned these potential harms.", "answer": 0}, {"article": "On weekends, even though hospitals have lower levels of staffing, stroke patients arriving at the hospital may have greater access to equipment and doctors who might be busier during the week than they are on weekends.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\n(See Reuters Health report, March 17, 2007).\n(See Reuters Health report, March 8, 2007).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of the serious risks associated with tPA therapy.", "answer": 0}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nMore than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no\u00a0discussion of any potential harms from\u00a0aromatase inhibitors.\u00a0These drugs can cause joint pain and sexual problems which lead many women to discontinue using them.\u00a0There also is concern that these estrogen-lowering drugs may decrease bone density and increase the risk of osteoporotic fractures.\u00a0This is an outcome\u00a0that\u00a0can\u00a0have severe health consequences for older women.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nThe treatment, in which the podiatrist aims a laser beam at the patient\u2019s toenails to kill the organisms that cause the fungus, costs about $1,000 and is not covered by insurance because it is considered an aesthetic procedure.\nPodiatrists have begun using a laser treatment that combats the infection \u2014 or wastes their patients\u2019 money because it doesn\u2019t work, depending on whom you ask.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on harms or potential harms of the laser approach. While the risk may be low, lasers do present risks. Instead, the story says, \u201cKominsky has treated 400 to 500 patients with the PinPointe laser. Compared with oral medication, he says, \u2018the odds of success are better with the laser; plus, there\u2019s no side effects.'\u201d A\u00a0doctor selling laser treatments should not be allowed to make these kinds of claims without proof. The folks at Novartis have every right to be miffed that they were held to a higher standard. We did appreciate that the story mentioned reinfection. \u201cEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\u201d", "answer": 0}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nBut those experiencing hip pain or stiffness have had more-limited options.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe news story fails to mention potential harms of hip arthroscopy. A recent review suggests the rate of complications for all indications is \u201cgenerally less than 1.5%.\u201d (Clin Orthop Rel Res 2009;467:760-8) Various sources suggest complications include: scuffing of the articular cartilage and chondral surface from instrument breakage and inadequate distraction (separation of the femoral head from the hip socket); iatrogenic dislocation; nerve damage (sciatic, superior gluteal, lateral femorocutaneous); removal of too much labral tissue; removal of too much bone, thus weakening the bone and causing a fracture; damaging the blood supply to the femoral head, leading to avascular necrosis; temporary numbness of the perineum or foot (a distraction neuropraxia); and scrotal necrosis. Although an expert says that the procedure is meant to prevent future arthritis, this is not quantified; without good data on people who did not have the procedure, it is conceivable that arthroscopy could promote arthritis.", "answer": 0}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nPatients don't care much about the finer points of diagnostic accuracy.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nBut some pain experts defend the value of the diagnostic tests.\nDoctors may not change their approach anytime soon, however.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms incurred or avoided. ", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nHowever, if this test could be done in really young children, it might help identify autism so that treatment can begin early, Lopez-Alberola suggested.\nThere are important limitations to the study, Adesman said.\nThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\nFurther work is needed to refine the test, Hirsch added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms quantified or even mentioned, which is disappointing. The harms from an inaccurate diagnosis of autism or any other disorder can be real and devastating.", "answer": 0}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nThe study is published in Drug and Alcohol Dependence.\n\"They still drank, but they drank less.\"\nHe studied the extract puerarin.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno serious side effects\u201d in the study, but one week of treatment in 10 people isn\u2019t going to provide an adequate picture of the potential harms \u2014 a shortcoming the story should have alerted readers to. In addition, we were a little concerned by the notion that this supplement \u201cmay deliver alcohol to the brain\u2019s reward center faster. So you get an effect sooner; therefore, you don\u2019t drink as much.\u201d Getting people drunker faster may well cut down on the amount of alcohol they consume in a night, but it might also result in unintended consequences like an increase in impaired driving or other risky behaviors. We think the story was too quick to give a free pass on safety without exploring some of these concerns.\nThe nature of a daily habit like drinking demands long-term treatment, thus increasing the time that side effect incidence could accumulate.", "answer": 0}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nHowever, Dr. Modic said, there was one effect of being told \u2014 patients felt worse about themselves when they knew they had a bulging disk.\nIt\u2019s one of only two body parts \u2014 the other is the back \u2014 where there are good data on abnormalities that turn up in people who feel just fine, indicating that the abnormalities may not be so abnormal after all.\nAfter Dr. Modic and others scanned hundreds of asymptomatic people, they learned abnormalities were common.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions unnecessary surgery\u00a0as the most serious\u00a0harm of scanning, as well as needless worry and potentially, feeling worse about the diagnosis. The story could have mentioned more common problems with MRI (claustrophobia) and CT scans (radiation exposure), but the real concern is that the imaging test makes the patient and physician more likely to chose an invasive treatment such as surgery.", "answer": 1}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention or discuss the potential harms of consuming a daily portion of blueberries or blueberry product. But since it\u2019s difficult to imagine what these would be, we\u2019ll rule this not applicable.", "answer": 2}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t include any discussion of potential harms that could be attributable to \u2018Mediterranean diet\u2019 adherence.", "answer": 2}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nEven individuals with normal levels of low-density lipoprotein (LDL), known as the so-called \u201cbad\u201d cholesterol, but still at risk, seem to be identified, according to Mayo Clinic research being presented at the American College of Cardiology\u2019s 66th Annual Scientific Session.\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nIn patients without coronary artery disease following angiography, the rate of cardiovascular events was only 3.1 percent, lower than the average overall.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Presumably, there is little risk to individuals from the blood test itself. However, it\u2019s important to note that among individuals with low LDL and the highest levels of blood ceramides, 83.6% did not experience cardiovascular disease. This raises the concern that use of the blood ceramide test might increase overtreatment, depending on what a patient\u2019s doctor recommends if the test reveals high ceramide levels. It is not clear what, if anything, individuals can do to reduce their blood ceramide levels. While there\u2019s certainly no harm in encouraging people to change their lifestyles to reduce their risk of heart disease and stroke, some health experts now argue that statins, often prescribed to decrease patients\u2019 cholesterol levels, might do more harm than good for individuals at lower risk of heart disease.", "answer": 0}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nThe peer-reviewed published multi-center Freespira clinical trial, presented by Dr. Tolin, demonstrated that 71% of patients were panic attack free immediately after treatment and 79% of patients were panic attack free 12 months post-treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms.\n(For a tutorial on how unsafe medical devices have been allowed into the marketplace, see our toolkit article.)", "answer": 0}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nThe incidence has more than doubled in developed countries in recent decades.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that no adverse events were associated with the intervention. However, the harms assessed by the researchers were things like maternal or infant death, emergency caesarean delivery, and preterm birth. They didn\u2019t assess (and the story didn\u2019t mention) less serious harms like fishy taste, nausea, belching, and heartburn that are commonly associated with fish oil capsules and which might make this regimen burdensome for pregnant women.\nMoreover, it would have been useful if the story had also noted that the reason researchers want to replicate the results in a larger group of women is to make sure these very high doses of fish oil are indeed safe.", "answer": 0}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nAfter the patients were also fitted with contact lenses, which is common after corneal transplants, their vision was comparable with that of patients who undergo regular human corneal tissue transplants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The last sentence of the story says, \"Fagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\" This is about as much space as any of the stories devoted to the harms. It would have been nice to see a little more detail here, but, if after two years there were not any side effects, this is a satisfactory quantification.", "answer": 1}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nMistiming light therapy can make jet lag worse, cautioned Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report indicated there was no harm involved: \u00a0\u201cIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality.\u201d This report also indicated helpful additional information from an outside observer, Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study, who said: \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 1}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nThe results were especially dramatic for men who had prostate-specific antigen (PSA) levels above .07 ng/ml when they started the trial.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "STAT does not mention any negative side effects (including hot flashes and sexual problems).", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nBut taking out wisdom teeth when there aren't any symptoms is where the professionals get into it.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks associated with wisdom tooth extraction are clearly spelled out in the story. These include \u201cpoor wound healing, infection, pain, and uncontrolled bleeding\u201d along with nerve injury which can, in rare cases, leave people with permanent facial numbness. As noted above, some quantification of these results would have been ideal.", "answer": 1}, {"article": "The millions of people with nocturia wake up two or more times a night to urinate.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThis suggests that the anti-inflammatory impact of routine exercise may minimize nocturia, he said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\nThe study team said two of the higher-dose patients developed significantly low blood sodium levels (hyponatremia) as did one person taking the placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes risks of\u00a0using this drug in the elderly, and mentions that it is already on a list of drugs not to be given to the elderly.\u00a0 The story also discusses incidences of low blood sodium levels that sometimes occur with this drug.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of outlining the complicated history of findings from hormone replacement studies, and the harms and risks, and uses numbers to explain the risks.\nThere is great nuance in the findings, which can be interpreted differently for women of different ages seeking HRT. Women bring different life risks of cardiovascular disease or breast cancer with them into any discussion of HRT.\nThe conclusion quoted in the story may be less-than-reassuring, but is here:\n\u201cHormone therapy has been in and out of favor \u2013 first it was good for all menopausal women, then it was dangerous for all women,\u201d McNeil said. \u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d", "answer": 1}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\nIndeed, those who had laparoscopy were younger and usually had less severe disease, which could have biased the results in favor of the minimally invasive procedure.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job comparing death rate, readmission rate and hospital stays between the two procedures.", "answer": 1}, {"article": "While many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\n\"Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.\"\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The word \u201charms\u201d does not appear in the news release. During intravenous infusions there are complications that may arise. The release does not mention harm, even to dismiss the probability as rare.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The CCTA test was reported as a non-invasive alternative to angiography. \u00a0But there was no mention of the harms associated with this test which includes radiation exposure, which is higher than that associated with angiography; the potential for allergic reaction to the material injected to allow the vessels to be seen; and the potential for there to be harms from following up on something seen on the CCTA which turns out to be nothing.\n(A sad, but fascinating case report can be found in the Archives of Internal Medicine Dec 14, 2010)", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nSome harms were mentioned, but oddly the story then referred to this hormone therapy not causing harms associated with chemotherapy. The story does not mention other harms linked to hormone therapy, such as osteoporosis, fractures, diabetes, and heart disease.  We aren\u2019t provided any information on these outcomes or cause of death. Since these results were presented at a medical meeting (which means it is likely the full data have not been reviewed by independent experts) and because the trial was halted early, there is much that remains unknown.", "answer": 0}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nOn each visit, the participants ate a weight-maintaining diet for five days.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not contain a single sentence regarding whether there might be harms if this technique were expanded and used in a wider setting as a treatment for obesity. We wondered: Would people get used to the stimulation if it were used on a long-term basis and stop showing the \u201cbenefit?\u201d Are there other cognitive abilities that are in any way muffled by the stimulation? The release should at least acknowledge that there could be potential harms uncovered in further study. The limitations section of the paper itself even states that is was not entirely clear that the treatment reached the targeted brain areas and not other areas. We find this concerning if not a bit alarming.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\nThe other two-thirds of the reduction is probably due to such factors as increased cancer awareness, improved therapy and use of more sensitive diagnostic tools, the study authors suggest.\nMaybe Not and Here's Why, suggested that with better treatment and increased awareness of the importance of seeking care for breast abnormalities, screening mammography may be less important now than in the past.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the fourth graph, we are given this great quote from the lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston. \"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress.\" Given how thorough the story was\u00a0in other areas, we hoped to see some of these potential\u00a0harms actually broken down later in the story.\u00a0What\u00a0has research shown to be the estimated\u00a0amount of overdiagnosis, false-negatives and false-positives? Some of\u00a0these numbers would have been a nice counterpoint to some of the statements\u00a0elsewhere in the story touting\u00a0the benefits\u00a0of mammograms.\u00a0", "answer": 0}, {"article": "Rising levels of PSA (prostate-specific antigen) are a sign that prostate cancer may be getting worse.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\u201d", "answer": 1}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\nBy addressing the issue, SpermCheck will join a crowded infertility market that includes more than 20 types of female-fertility tests in Walgreen stores alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The specificity of the test was not discussed; it was 94% according to FDA documents. It\u2019s only half the story to tell what the sensitivity was.\u00a0 Sensitivity doesn\u2019t tell you about false-positive results, and specificity does not tell you about false-negative results. Why not report both?\nIn addition, a test that tells you about sperm count doesn\u2019t necessarily tell you anything about sperm quality \u2013 another part of the picture. So any man who truly wants the complete picture would need to see the doctor anyway.\u00a0 This isn\u2019t exactly a \u201charm\u201d but it is part of the reality that a news story should have reported \u2013 or else men may feel drawn in by the story\u2019s promotional tone, not realizing the full ramifications of the \u201cdebut\u201d of this \u201cfirst at-home test.\u201d\n\u00a0", "answer": 0}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nThis study published reports that topical curcumin gel applied soon after mild to moderate burns and scalds appears to be remarkably effective in relieving symptoms and improved healing of the affected skin.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nIn a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen School of Medicine, stresses that use of topical curcumin gel for treating skin problems, like burns and scalds, is very different, and appears to work more effectively, when compared to taking curcumin tablets by mouth for other conditions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Curcumin, the active ingredient of tumeric, is considered to be an alternative therapy. Neither turmeric nor curcumin has been extensively studied in clinical trials, but animal studies have shown that chronic use could lead to stomach ulcers. In addition, the American Herbal Products Association classifies turmeric as a menstrual stimulant. Turmeric should be avoided in patients with bleeding disorders and bile duct obstruction.\nExperts believe tumeric is generally safe, although the quality of the available clinical studies is questionable.\nAn additional potential harm is failure to be treated with appropriate care. We would not want parents of kids with severe burns to forgo appropriate, evidence-based medical care in favor of an alternative over-the-counter product with no scientific evidence to support its use. The last sentence of the news release states that the doctor uses curcumin gel in addition to standard medical treatment. That important bit of information should have been highlighted more prominently in the release so that people skimming the release wouldn\u2019t assume they could attempt to self-treat burns or scalds with curcumin alone.\nSince harms weren\u2019t mentioned in the news release we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nBy showing that there really might be other effective options out there, the research provides hope that there may be a better \u2014 or at least more complete \u2014 solution out there for alcohol addiction.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there is no well-established quantification of harms of mutual-help groups, we feel this potential should be borne in mind, just as we would expect reports of negative side effects and adverse events in a medication study. The story doesn\u2019t mention potential downsides to any of these programs.\nFor example, as a ProPublica investigation\u00a0pointed out in 2014, some who participate in AA meetings are forced to do so by the criminal justice system. This group of mandatory members may include violent felons who are trading attendance for a lighter sentence. ProPublica noted that in some cases, this can create \u201ca combustible mix of violent ex-felons and newcomers who assume that others \u2018in the rooms\u2019 are there voluntarily.\u201d\u00a0 These conditions may increase the potential for sexual and financial abuse of AA members.", "answer": 0}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did an adequate job mentioning the harms from zinc. This story did an especially good job providing a range of side effects. \u201cExperts stress that more research is needed before the most effective kind of zinc can be determined, and they caution that in high doses \u2014 more than 40 milligrams per day \u2014 zinc can cause dizziness, headache, drowsiness, increased sweating, loss of muscle coordination, alcohol intolerance, hallucinations, and anemia.\u201d", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0mentions potential harms from screening, namely \"serious health risks from examining and treating tumors that may not be harmful.\"\u00a0 The story could have been clearer about what some of these risks are (like undergoing unnecessary surgery with all of its risks and anxiety to the patient), but it appropriately mentions that screening may have harms, which is often overlooked.\u00a0 ", "answer": 1}, {"article": "But none of these works for everybody, and the immune suppressant drugs can raise the risk of cancers such as lymphoma.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\nThe agency gave it both priority review and breakthrough therapy status, speeding it through the approval process.\n\u201cBy binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis,\u201d the FDA said in a statement.\n\u201cThe Wholesale Acquisition Cost (WAC) of Dupixent in the United States is $37,000 annually.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cthe drug can cause serious allergic reactions and eye inflammation. \u2018The most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u2019 the FDA notes.\u201d\nThis is sufficient, but one important detail we think is worth noting: The FDA gave the drug \u201cbreakthrough therapy status,\u201d meaning that long-term impacts were not studied.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note the potential harms of treatment, such as dry and irritated eyes and blurry vision, but we are not told how often these happens. The story only provides one patient's anecdotal evidence that the surgery did not work well for him due to lasting uncomfortable side effects. \n\u00a0\n\u00a0", "answer": 1}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses concerns about ulcers and other bleeding caused by aspirin. Indeed, the last sentence of the story in fact says the risk is trivial. ", "answer": 0}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\nThe drug has not yet been approved by the U.S. Food and Drug Administration.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms from long term or short term use of apixaban.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \"had to have a significant amount of damage to begin with and weren't squeezing [blood into the body] as well as they should have,\" says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\nA patient's own heart cells can be used to regrow new heart tissue and help undo damage caused by a heart attack, according to early research published on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story at least mentioned harms. Another story on the study, by WebMD, did not. This one says, \u201cAfter 12 months, researchers report only one patient appeared to have a serious side effect that may have been connected to the experimental cells.\u201d Competing coverage discussed a broader group of patients who had bad outcomes, although it is not clear that all of those outcomes were a result of the treatment. Pinpointing the cause of a side effect can be tricky, and given the lead researcher\u2019s financial interest in this stem cell therapy, we think stories should err on the side of providing more information about potential harms.", "answer": 1}, {"article": "She\u2019s healed, basically,\u201d she said.\n\u201cSix weeks into her treatment, the skin lesions were gone, her itchiness went away.\nThis patient is at a late stage of her disease.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\nIt\u2019s quite a dramatic response.\u201d\n\nSo dramatic, in fact, that Yuan refers to Young as her \u201cmiracle patient.\u201d\n\n\u201cThis in some ways is pretty unprecedented.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of side effects of the combination treatment and only a brief mention that this drug combination showed no clinical benefit in other patients.", "answer": 0}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story used terms like \"no harm\u2026safe\u2026and apparently has few downsides.\"\u00a0 Well, which is it?\u00a0 No harm or few downsides?\u00a0 And if the latter, then how few and of what kind?\u00a0 This is too vague and confusing. \nThis may also be an area in which products that are not as tightly regulated as prescription drugs carry a potential downside.\u00a0 Again, it\u2019s hard to get real information about purity, quality standards and bioavailability for supplements.\u00a0 ", "answer": 0}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nWhen blood pressure rises, it strains the tiny blood vessels that keep brain cells alive, Koroshetz says.\nKoroshetz is using all of these approaches.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, we wouldn\u2019t expect a story like this to cover all the side effects of the myriad treatments.\nBut we do think it could have noted that one reason blood pressure drugs are prescription-only is because they can cause side effects that may need medical management. Unlike what the story said, it is not as simple and carefree as taking \u201ca pill\u2026 to help keep [your] brain healthy and sharp.\u201d", "answer": 2}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe volunteers got one of three doses - low, medium, or high - and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides just enough information to get a flavor for the potential harms without overly dramatizing them. Example: \u201cThe volunteers got one of three doses \u2013 low, medium, or high \u2013 and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\u201d And: \u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish.\u201d", "answer": 1}, {"article": "For more about cryoablation, visit the U.S. National Cancer Institute.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nThe procedure is performed by an interventional radiologist on patients coping with metastasized lung tumors, the researchers noted.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was cautious in reporting:\n\u201cThe authors noted that side effects were minimal, typically involving air or fluid around the lungs after the procedure, and in all cases were resolved quickly.\nThe team concluded that cryoablation appears to be both safe and effective, at least in the short-term. But they acknowledged that more research needs to be done to track the treatment\u2019s impact over the long haul.\u201d\nA further caution could have been that we don\u2019t know what patients think about such side effects being described as \u201cminimal\u201d and that we were only hearing this from the researchers announcing their findings.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When quitting, heavy smokers can experience\u00a0withdrawal symptoms\u2013such as depression, insomnia and decreased heart rate\u2013even if they use nicotine replacement products.\nThe article did refer to \u201cwithdrawal\u201d and \u201curge intensities\u201d and so we\u2019ll considered that sufficient.\u00a0However, the piece would have been stronger had it specifically discussed the withdrawal symptoms mentioned above.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nPatients with the condition say it\u2019s time for better treatments.\nStudies have found it significantly reduces heavy menstrual bleeding and decreases the thickness of the endometrium by six months.\nIf a woman has no symptoms, treatment of fibroids isn\u2019t necessary, experts say.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes the side effects of UA and potentially two other similar drugs in the pipeline. The main concern about these agents is the effects they may have on the endometrium (uterine lining) over time.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms of far-UVC light are mentioned; in fact, in the opening sentence we read:\u00a0 \u201cresearchers have developed an ultraviolet (UV) lamp that kills influenza virus but isn\u2019t harmful to human skin or eyes\u2026.\u201d\nBut, again, we\u2019re given no data regarding safety.\u00a0We are not told if the previous skin or eye studies (which we\u2019re told prove the safety of this approach) were done in the laboratory or on real humans.", "answer": 0}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": ".\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\n\u201cSuch evidence may lead to new insights into the relationships between diet and health, updated dietary recommendations, and the development of new therapies,\u201d they write.\nFor the study, researchers at the Larner College of Medicine at the University of Vermont analyzed data on more than 16,000 Americans using the National Health and Nutritional Examination Survey (NHANES).\nThe authors say capsaicin also possesses antimicrobial properties that \u201cmay indirectly affect the host by altering the gut microbiota.\u201d\n\nThe research corroborates a 2015 study conducted in China and published in the BMJ that found regular consumption of spicy food is associated with a lower risk of death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0addresses potential harms from eating red hot chili peppers, by quoting\u00a0an expert source warning about discomfort and worsening symptoms\u00a0in people with\u00a0digestive disorders such as stomach ulcers.", "answer": 1}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nTwo experts agreed that early intervention is key.\nThe research involved 54 families of babies who were at increased risk for autism because they had an older sibling with the condition.\n\"Children with autism typically receive treatment beginning at 3 to 4 years old,\" he explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of this intervention could include the time and expense of an experimental approach whose benefits were not shown to be statistically significant in the one study reported on herein. The study abstract notes the possibility of negative effects\u00a0in language and responsivity to vowel change. The story didn\u2019t touch on any of this.\u00a0 It emphasized potential benefits and ignored potential harms.\u00a0 In our view, there is a harm in this kind of reporting.", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nThose findings appear in a separate report in the journal Menopause.\nAnd for now, he noted, it\u2019s also not clear why antidepressants would have effects on hot flashes.\nAnd right now, HRT is the only treatment approved by the U.S. Food and Drug Administration for cooling hot flashes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss some of the side effects of antidepressants.", "answer": 1}, {"article": "\"This is really the gold standard.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two\u00a0main drawbacks of the xTag test, that it is expensive and can\u00a0take up to a day or two to get the results, are presented.\u00a0\u00a0Expense is an important\u00a0issue given the volume of acute febrile illnesses in children, particularly if this test were given routinely in an outpatient setting.\u00a0 In addition, if the processing time at the specific location is is too long, the test may not have any practical benefit in the treatment decision window.\u00a0\u00a0 ", "answer": 1}, {"article": "It defines low birthweight as being when a baby is born weighing less than 5 pounds, 8 ounces.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nThey found that babies held upright and close to bare skin and breastfed, instead of being left in incubators, grew up with fewer social problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention, although the story does note the finding that children given standard incubator care had higher math and language scores in school even though IQ levels were similar in both groups.\nA 2012 Cochrane review of multiple studies found no negative outcomes associated with skin-to-skin contact for healthy newborns except for one study\u2019s report of longer duration of breastfeeding in a control group.", "answer": 1}, {"article": "\"Certainly, however, this solid paper adds to the literature and paves the way for additional research on this interesting topic.\"\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\n\"The body composition at age 6 years in children given fish oil supplementation was characterized by a proportional increase in lean, bone and fat mass, suggesting a general growth-stimulating effect,\" the researchers, who were led by Hans Bisgaard, from the University of Copenhagen, wrote in the report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any risks of taking fish oil. But these include belching, bad breath, heartburn, nausea, loose stools, rash, and nosebleeds. For pregnant women who have to be vigilant about even seemingly harmless side effects (nausea can be a serious symptom in the third trimester, for example), these details are important.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author of this story makes possible harms of the therapy clear: testosterone therapy\u00a0increased fatty plaque in coronary arteries, a risk factor for heart disease. It also talked about the possible risk of stroke in a subset of men.", "answer": 1}, {"article": "Dr. Gheorghe Doros has received payment for statistical analysis from Bayer Pharma.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nInsufficient levels of circulating T in men, contributes to frailty and bone loss.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not on this text\u2019s radar screen. Testosterone treatment does have a few side effects including sleep apnea, stimulation of benign growths in the prostate, enlarged breasts and increased risk of blood clots. The study on which this release was based does not appear to discuss these outcomes either, but their inclusion here would have been helpful.", "answer": 0}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nBut having had the procedures, many say they wish they\u2019d done it sooner.\nAnd, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\nThe average age of patients listed in the American Joint Replacement Registry is about 66.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned at least some potential harms:\nIn patient-reported surveys, some still complain of pain and tissue inflammation after their procedures. Smaller numbers suffer serious complications, ranging from blood clotting to hospital-acquired infections.\nStill, it could have devoted more attention to risks, including the lax regulation of implantable devices.", "answer": 1}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nThe SelectMDx test can help predict the likelihood that clinically significant prostate cancer will be found by a biopsy.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although providing urine for the test involves little to no risk, choosing not to move forward with a biopsy as a result of the test does bring with it a risk of being wrong, should the cancer be aggressive (a false negative). The likelihood of that error would be an important piece of information.\nThe study cites a reference suggesting that the sensitivity for detecting high-risk cancers was 95.7%.", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nThe researchers found that these people were 50 percent less likely to catch cold if they took vitamin C daily.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report fails to indicate that taking high levels of vitamin C, as some advocates\u00a0suggest, can have serious health consequences, from dental erosion to kidney toxicity. It can also interact with aspirin and other drugs.\u00a0 ", "answer": 0}, {"article": "Learn more at www.genomedx.com and follow us on Twitter at Twitter @GenomeDx, Facebook, LinkedIn and YouTube.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\nUse of this test therefore has the potential to assist clinicians to better direct utilization of secondary therapy after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t explain what sorts of risks a patient faces from radiation, hormone, and other \u201cadjuvant\u201d therapies after surgery, and avoiding these seems to be a key point of the Decipher test.\u00a0We also don\u2019t get\u00a0any words on how reliable the test actually test is and how often it might return inaccurate results, which is its own kind of risk.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Without discussing sensitivity or specificity, the news release gives no picture of the potential for false positives or false negatives \u2013 always potential harms with any test.", "answer": 0}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nWith this in mind, researchers developed a probiotic supplement aimed at reducing inflammation caused by microbial imbalances in the gut.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms of probiotics nor the fact that they are not regulated for safety and effectiveness.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\nThey suggested a number of steps people can take to improve their level of optimism.\nWhile the study is observational and cannot prove a cause-and-effect relationship between optimism and a longer life, the researchers have some theories for what might be behind the connection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being\u00a0overly\u00a0optimistic\u00a0can\u00a0put\u00a0people\u00a0into\u00a0harm\u2019s way \u2014 say, thinking they\u2019re better drivers than they really are, and upping the risk of an accident. (There are a number of studies about this very thing.) But that\u2019s a kind of common sense we don\u2019t think needs calling out in a story.", "answer": 2}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential side effects of aromatase inhibitors. Both hormone therapies may increase menopausal symptoms such as hot flashes or vaginal discomfort, though\u00a0anstrozole slightly less so than tamoxifen.\u00a0 Anastrozole may increase the risk of bone or joint pain and\u00a0possibly may increase cholesterol. ", "answer": 0}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\nFewer children in the treated group had an allergic reaction to the peanuts, and they also showed smaller reactions to skin prick tests with peanut allergen.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t mentioned, which is problematic. The type of immunotherapy used in conjunction with probiotics for this study is called peanut oral immunotherapy. In a 2016 research summary document, the American Academy of Allergy, Asthma & Immunology describe this type of immunotherapy as \u201cone of the more promising new treatments\u201d for peanut allergies. Specifically, the summary noted that \u201cMultiple studies have now shown [oral immunotherapy] to be efficacious at desensitizing peanut-allergic children, but this efficacy comes at the expense of high rates of allergic adverse events, and the risk/benefit ratio of [oral immunotherapy] is an area requiring more study.\u201d This is a complex area, and the research summary is worth reading, but the key point here is that there are risks associated with oral immunotherapy \u2014 and this story doesn\u2019t acknowledge them.", "answer": 0}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this approach to vaccination. ", "answer": 0}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nEating fish is not a guarantee of having high levels of DHA.\nBut, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms from fish oil consumption and included speculation on potential harms from fish consumption.", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\n\"So for this population of patients who can't tolerate cheaper medications, rilonacept may be a necessary indication.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The standard line about \u201cappears safe and well tolerated\u201d is all we hear about harms.\nEven the news release did better than that, stating: \u201d Common adverse events included infections reported in 15% of the rilonacept group compared with 26% with the placebo.\u201d", "answer": 0}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nOne gastroenterologist said the results were \u201cimportant\u201d but should not change practice.\nAllen, of Minnesota Gastroenterology PA, said this risk factor might be taken into consideration when deciding when to screen, but that so far more studies were needed before recommending colonoscopy at younger ages.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms of colonoscopy, such as bleeding and perforation.", "answer": 1}, {"article": "When all seizures were taken into account, children who did not have surgery were four times more likely to have a seizure during that year than youngsters in the surgery group, the researchers calculated.\nYet the cases were judged to be a success because the seizures decreased in frequency over time.\nThey are left with this minor deficit.\nSurgery improved quality of life and social well-being, and it didn\u2019t affect IQ, something that can decline with ongoing seizures.\n\u201cThe study in kids shows if you reduce the time from the onset of seizures from the 15 to 20 years you see in adults down to four to five years, the outcome is much better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained but again without much quantification.", "answer": 1}, {"article": "Thanks to members Drs.\nThere is a general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nUsing a network meta-analysis we are able to compare the multiple studies done on viscosupplementation and have found that people are more likely to show clinical improvement with viscosupplementation over placebo (saline) and intra-articular steroids.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems intuitive that injection of a solution into the joint space of the knee should have some downsides. Indeed, a 2012 meta-analysis of 89 clinical trials involving over 12,000 subjects published in Annals of Internal Medicine concluded, \u201cIn patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events.\u201d\nCommon side effects of short duration following viscosupplementation include swelling, and feelings of pain and warmth at the injection site. Serious but rare complications include infection, allergic reaction and bleeding.", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nIf we haven\u2019t yet processed the prior set of information, we can\u2019t understand it.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine what harms there might be, but it would have been helpful to know something about the drop-out rate that would have done at least a bit of financial damage to the trainees.", "answer": 2}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\nThe patches also deliver their medicine directly to the site of a person's pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are quantified. Instead, the story relies on quotes that merely mention side effects. Interestingly, the story gives more space to the possibility of a skin reaction from the patches than it does the more serious potential harm. In one sentence it says, \u201cOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\u201d\u00a0 The story should have given some estimate of how often that\u2019s happened.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nThree months ago, he noticed his vision was distorted.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nShe's had two doses of Lucentis.\nIt's not a cure, but it's a blessing for Rochelle Faller.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention side effects, such as inflammation, infection, and detached retina.", "answer": 1}, {"article": "\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that there were \u201cno negative side effects\u201d in the literature review. So, for that, we\u2019ll give it a satisfactory score.\u00a0 But a broader perspective on this issue could have addressed the potential for harm in hospitalization-associated diarrhea.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\nThe results of a calcium scan can be reassuring for people with few or no calcium deposits, and can provide people with high calcium levels with added impetus to take better care of themselves, Shaw said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms of CAC testing. It fails to tell readers that the researchers noted in their article that for every 10,000 people screened, about 12 would develop cancer. That means that subjecting 100 million adults to this test would be expected to result in 120,000 additional cancers.\nEven if that cancer burden were deemed acceptable, patients sent for additional testing (such as catheter imaging) or prescribed drugs or procedures would be exposed to the risks and costs of those tests and treatments.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story provides readers with some potentially interesting questions to raise with a doctor (e.g. how many of these surgeries have you done using this equipment; is this approach the best for the type of cancer I have, i.e. early or more advanced). \u00a0The story mentions in passing potential harms such as impotence and incontinence, referencing a study published in October. \u00a0\nHowever \u2013 the story did not really follow-up on one of the key issues it raised. \u00a0For example, the story mentioned that a surgeon will have to do 80 procedures with this equipment to ensure that they don\u2019t leave any cancerous tissue behind. \u00a0The story could have completed this thought and indicated the ramifications of leaving cancerous tissue behind in terms of health consequences.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\nThey found 5,930 cases of Type 2 diabetes.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms.\u00a0 Aside from the fact that walnuts carry a significant amount of fat and protein and should be eaten in moderation, we don\u2019t know of other harms worthy of mention.", "answer": 2}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\nNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\u201d\u00a0 The researchers reported a very complete breakdown of intraoperative and post-operative complications \u2013 including what differences were statistically significant or not.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\nFor his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nThe effect of the drug was substantially better than seen with other antidepressants, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The lead researcher is quoted as saying, \u201cIn addition, we have shown little or no side effects with our compound.\u201d And the story does caution that many unknowns remain about GLYX-13, including its long-term effects and the effects of stopping its use. The story also adds that the drug does not display side effects of hallucinations and schizophrenia-like symptoms.\nHowever, here\u2019s why we rule this one unsatisfactory on the harms criterion:\u00a0 A single dose of a medication (which appears to be the design here) can\u2019t establish harms.\u00a0 The story should have been less accepting of the statement that there were no side effects.\u00a0 The compare-and-contrast to other drugs targeting the same receptors and the apparent lack of short-term and severe side effects (e.g., hallucinations) was useful but not close to the whole story.", "answer": 0}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned some of the disadvantages associated with this use of the medication reported on. \u00a0It did not specifically detail whether there were any harms associated with this medication or how well people in the study were able to stick with the dosing schedule.\nOn this issue, this story was not as complete as its HealthDay competition, which reported:\n\u201cThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns. In that trial, published in July in the New England Journal of Medicine, apixaban\u2019s use was associated with raised odds for bleeding \u2014 without providing patients with any reduction in heart attack risk.However, \u201cin that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,\u201d Ansell noted. \u201cThe three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population. But, that\u2019s an entirely different problem, compared with atrial fibrillation,\u201d he said.\u201d ", "answer": 0}, {"article": "But when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nLeaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s\u00a0no\u00a0discussion of risks here. Does an eSight cause eye strain? What about headaches? Nausea? Does all-day use impact sleep quality? Is there a feeling of detachment or foggy-headedness that sometimes accompanies use of the virtual reality headsets it takes after? These are but a few of the questions we had on the drawbacks.", "answer": 0}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\n\"We've been studying the impact of meditation on memory for more than 20 years, and are as encouraged as we've ever been on its powerful role in maximizing brain health,\" said Khalsa, president and medical director of the Alzheimer's Research and Prevention Foundation and a clinical associate professor of integrative medicine at the University of New Mexico School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not addressed in the release but meditation is not associated with any common health risks. We\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "While Drs.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\nThe present analysis was not supported by industry funding.\nThe FAME 2 trial was supported by St. Jude Medical.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms of the PCI procedure. According to the NIH these include:", "answer": 0}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\nOne cancer surgeon who reviewed the findings was impressed.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the most common side effects were fatigue and diarrhea. But the story also offers information about how common any adverse side effects were \u2014 for both Opdivo and Yervoy. That\u2019s valuable information. What\u2019s more, the story notes that Opdivo was less likely to cause adverse side effects than Yervoy, and that those side effects were less severe. Again, that\u2019s useful context.", "answer": 1}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nThe previous recommendation was to start Pap tests three years after becoming sexually active or at age 21, whichever came first.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes the potential harms of HPV DNA testing, most notably the high false positive rate \u2013 or the high number of tests that come back positive that would never progress on to cancer. Positive results require additional testing and follow-up, which in itself isn\u2019t particularly dangerous, but could cause anxiety and requires time off work and additional costs.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention the increased risk of strokes with Lucentis. The story should have also mentioned risk of inflammation and infection from injection into the eye.", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nThe volunteers took pills once a day for six weeks.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\nResults showed that resveratrol suppressed the generation of \u201cfree radicals\u201d -- unstable molecules known to cause oxidative stress and release pro-inflammatory substances into the blood, resulting in damage to the blood vessel lining.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Anything we put in our mouths has the potential to cause harm \u2013 a concept not recognized in this story. ", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similarly, this story doesn\u2019t discuss harms.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not cover harms.\u00a0A problem with these drugs is that they can cause amyloid-related imaging abnormalities (ARIAs), which are findings on brain scans that indicate swelling and small hemorrhages in portions of the brain. These were the most frequent adverse events in the Biogen study and occurred in a lot of people, especially at the higher doses.", "answer": 0}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nLeFevre added that while the new study did add extra evidence compared with earlier work, it failed to analyze the effects on men and women separately.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201caspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d", "answer": 1}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe improvements were more robust in those who were adherent to PAP therapy.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While CPAP therapy is relatively safe, there are still common side effects that were not mentioned in the news release. According to the National Sleep Foundation, most CPAP users will experience some mild side effects including congestion, runny nose, or stomach bloating. Though the harms are only mildly irritating, it would have been helpful if they were included in the release.", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nThe new stent is designed to gradually dissolve over three years.\nAmid these concerns, Abbott and others began developing dissolving stents that would slowly melt away like stitches, presumably reducing complications.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text offers a list of complications found with the new device, apparently recorded in the clinical trial: allergic reactions, infections, internal bleeding. And it gives us quantified information on \u201cheart-related complications\u201d for both the dissolvable and metal stents.\nBut the story\u2019s main message is that we simply do not know if these stents cause complications over the long term.\u00a0 It does quote a source who helped conduct the clinical trial for Abbott and who describes the \u201ctheoretical\u201d reason for the new stents as allowing arteries to return to their \u201cnormal\u201d shapes after the stents dissolve and, thus, prevent the kinds of problems that afflict permanent mesh stents, including a higher risk of blood clots.\u00a0 But the only study mentioned by the story, and by Abbot Labs in a news release, lasted a single year, while the stents are designed to completely dissolve over the course of three years.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\n\"Instead, this study suggests exercise can be a type of medicine.\"\nBYU professors Sarah Ridge and Ty Hopkins were also coauthors on the study.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are not discussed. The release hints that this benefit is there for \u201chealthy\u201d joints, but says nothing about joints with torn cartilage, already degrading joint surfaces or substantial osteoarthritis. The release notes that researchers plan more do more study of those with anterior cruciate ligament (ACL) injuries, but that is a tendon injury, not a joint injury.\nThere\u2019s a concern that this release could send the wrong message to some runners. What about people who experience pain when they run? Should they continue to run, despite the pain, because running might be \u201cchondroprotective.\u201d", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms. For example, the story does not mention how many calories are in the drinks and that overconsumption by non-elite athletes could contribute to weight gain.", "answer": 0}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nHowever, exercise did boost bone mineral density, a proxy for bone strength, their report shows.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, the story was all about a finding that might help people avoid the \u201charm\u201d\u00a0of thinking that supplements do more for them than they actually do.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself \u2014 using DNA taken from a cheek swab \u2014 carries no physical risks.\nBut the story needed more detail about the potential downsides. As noted in more detail in the TIME coverage of the story, the various \u201cscales\u201d that are used to assess drugs aren\u2019t organized by how effective the drugs might be based on genetics, but instead how many adverse events they might cause. So, a person is told to take certain drugs not because they\u2019ll be more effective than other drugs, they\u2019re just less likely to cause problems.\nCould selecting drugs based on how many problems they cause lead some people to choose drugs that aren\u2019t as effective for treating depression? That would seem to be biggest issue in terms of harms \u2014 that the test would simply be wrong for some people.\nAlso, the test appears to show results for drugs beyond antidepressants \u2014 including some drugs that are known to cause dependency or can be deadly when taken alone, mixed together or with other drugs, such as hypnotics and benzodiazepines (Ambien and Xanax, for example). This is important to consider in a group of people already at higher risk for suicide.\nAll of this means adverse event data is vital \u2014 was it indeed lower in the gene-tested group?\nIf adverse event data were not available from the company or the investigators at the University of Michigan who led the study, the article could have noted the fact.", "answer": 0}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the longest patients have been on one of these new therapies is one to two years.\nSo for those of us who get numerous migraines each month, the prospect of a new approach feels almost life-changing.\nYet, despite decades of research, there isn't a drug on the market today that prevents them by targeting the underlying cause.\nHe has good reason to be: Each of the therapies decreases migraine frequency by at least one to two days per month.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Initially the story says patients \u201creport limited side effects that consist mostly of pain at the injection site. Unlike the current preventive medications, there is no nausea, no fuzzy thinking, no nerve pain, no weight loss or gain.\u201d\nBut it also notes a lack of long-term safety data and \u201cpotential long-term effects on blood pressure or other cardiovascular function\u201d as well as potential effects on fertility or placental function.\nIn the end, the reporter reflects on her own migraines and her own choices: \u201cI think about my two young children and my risk tolerance. Perhaps in ten years I\u2019ll feel differently. For now, however, I pick up the phone and cancel my clinical trial appointment.\u201d\nWe also like this cautionary sentence: \u201cRight now, the longest patients have been on one of these new therapies is one to two years.\u201d", "answer": 1}, {"article": "Harder\u2019s PSA was 9.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nPrior to this, Yu\u2019s team had performed targeted MRI biopsies with the patient being moved in and out of the MRI scanner as the needle was guided to the target area \u2014 a sort of stop-motion procedure that could take up to an hour.\nHis doctor recommended the traditional next step: a transrectal ultrasound (TRUS) biopsy, which involves taking random tissue samples from 12 cross sections of the prostate.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible side effects of biopsies such as serious infections, pain, and bleeding. There\u2019s also no mention of the\u00a0 harms that can come from a false-positive test that can lead to more tests, mental anguish and unnecessary procedures.\nAlso, it does not mention that MRIs may be inappropriate for patients with kidney disease or implanted devices such as pacemakers, stents and inner ear implants, due to the strong magnetic field used.", "answer": 0}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nSome experts said they hope the findings will encourage more doctors to consider treating elderly men.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the article does mention some harms of aggressive treatment, impotence and incontinence, it doesn't provide readers with any context around how often these occur or how troubling men may find these.\u00a0 There are qualitative statements telling readers that\u00a0quality of life can be affected, but overall, the seriousness of treatment side effects seems to be minimized.\u00a0 ", "answer": 0}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nAlthough the cases are few, AGH's success rate points to the value of the therapy.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nClinical trials showed a 20 percent increase survival with hypothermia, Dr. Granato said.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms associated with this treatment or the frequency with which these are typically observed.\nThe person used as an example of the benefits of the treatment developed pneumonia in the course of his recovery from his cardiac arrest and his hypothemia treatment, which may be a side-effect of the treatment. ", "answer": 0}, {"article": ".\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\nDiagnosis and therapy with the theranostic agent PSMA-617 could offer more effective and sensitive visualization, better staging and significantly higher therapeutic potential.\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is not really addressed \u2014 or addressable \u2014 given that only one patient has been treated. The release discusses previous drugs of this type that had problems, and mentions \u201cadverse effects\u201d associated with existing therapies. The suggestion is that this drug does not have those problems and would be a safer alternative to existing therapies. But there\u2019s no way we can assess the safety of this approach based on results in only patient. So the release is incomplete and potentially misleading in its discussion on this point.", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\nA few previous small trials had already suggested that giving drugs like Prozac, which belongs to a drug class known as selective serotonin re-uptake inhibitors (SSRIs), might improve motor skill recovery after stroke.\nThere were also more independent patients and depression was less common in the Prozac group than in the placebo group, and side effects of the drug were rare and mild, researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Generally this isn\u2019t a risky medicine, but we ding the story here for not only failing to quantify harms, but perhaps mischaracterizing the safety data from the study. It quotes the researchers as stating that side effects were rare and mild. But in the actual study,\u00a025% of those taking fluoxetine had transient digestive problems (compared to 11% receiving placebo), and there were two serious side effects, a partial seizure and a serious case of low\u00a0sodium.\u00a0A more accurate summary would\u2019ve been the softer statement that MOST side effects were rare OR mild.", "answer": 0}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nIt might also help coaches or athletic trainers are sports events to determine which athletes who have had a concussion are able to return to the game and which, if they have higher levels of the blood marker, should not.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any harms, but all screening tests have harms associated with false positive and negative results. In athletes, for example, a false positive test keeps you off the field and creates\u00a0unnecessary anxiety. A false negative result\u00a0means you go back on the field with a concussion and potentially suffer another head injury that could have catastrophic consequences.", "answer": 0}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nA British study offers compelling -- though not clinching -- evidence that the humble aspirin tablet can prevent death from a variety of cancers, if you take the medicine long enough in middle age.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the few stories to put a number to the potential harms. \u201cBut aspirin carries risks. The biggest is stomach bleeding, although it also raises the risk of brain hemorrhage. Daily aspirin doubles a person\u2019s gastrointestinal bleeding risk to about 2 in every 1,000 people a year. But Rothwell says this bleeding hazard is \u201cdrowned out\u201d by the cancer benefit.\u201d", "answer": 1}, {"article": "\"The endometrium feeds the baby up until the eighth week of pregnancy.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\nThe researchers believe that the progesterone caused the patients' endometrium to produce more endometrial secretions.\nWomen in the study with an abnormal nCyclinE level were prescribed progesterone two days after ovulation, when the uterine lining matures in preparation for a possible pregnancy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With any drug treatment related to pregnancy it is absolutely essential to discuss the effects of the drug on both mother and child. This news release doesn\u2019t address safety risks to either.\nThe Mayo Clinic\u2019s website for patients offers a long list of possible side effects from progesterone in adults. Much less information is available about progesterone\u2019s risk to a developing fetus. ", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the estrogen-only part of the Women\u2019s Health Initiative was stopped early because the women taking estrogen had an increased risk of stroke. (But it also could have mentioned that possible harm again as a factor that women should consider when deciding about therapy for their menopausal symptoms.) Blood clots, another possible side effect of estrogen therapy, are mentioned only briefly.", "answer": 1}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story quantified the harms.\u00a0The obvious harm is parental anxiety and labeling an infant as having autism when there must be at least some risk of false positives.\nThis was framed as a potential screening test.\u00a0 All screening tests carry potential harms.\u00a0 Journalists often report only on screening tests\u2019 potential benefits.", "answer": 0}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story calls preventive surgery \u201cdrastic,\u201d but it doesn\u2019t provide any details about harms of the procedures. Also, the description of laparoscopic ovary removal makes the procedure seem entirely benign. No mention of how women might think about potential harms such as premature menopause, heart disease, osteoporosis, etc. ", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the harms of hormone pills. ", "answer": 1}, {"article": "Right now, the work done by Topakian's group is still \"experimental,\" he said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nIn addition, over the two years of the study, 10 people had TIAs.\nDr. Lars Marquardt,a professor of surgery at the University of Erlangen-Nuremberg in Germany and co-author of an accompanying journal editorial, said surgery for people with asymptomatic carotid steno sis is done too frequently.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported that 10 individuals in the study of 435 had TIAs. \u00a0While transient ischemic attacks is one outcome of interest, the study presented the number of study participants that had strokes, and died of either stroke or cardiovascular death.\nThe story reported the likelihood that individuals with one or another of the problems visualized with ultrasound would have a stroke \u2013 but did not report the absolute increase in stroke that was actually observed. \u00a0This information is essential for understanding the magnitude of benefit possible. \u00a0And although the story included quotes from clinicians indicating that the risk of stroke is higher with carotid endarterectomy, there should have been some number provided to enable readers to understand the risks associated with the intervention that might result from having undergone the tests.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough one to rate. On one hand, It is hard to envision harms arising from men participating in what appeared to be a safe screening and treatment program for high blood pressure. On the other, the journal paper about this study reported that three individuals experienced acute kidney injury, although that problem disappeared once medications were altered. So, there are risks, and the story would have been stronger had it included them.", "answer": 0}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\nThis project was funded in part by Shire Pharmaceuticals, the National Institute of Mental Health, the National Institute on Aging, and the National Institute on Drug Abuse.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any harms in this release, although the paper mentions that this drug can raise both heart rate and blood pressure, although not precipitously.", "answer": 0}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nOther minimally invasive treatments for enlarged prostate that are currently available are less effective and have a greater risk of a need for reoperation, according to background materials that accompanied the study.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nDr. Franklin Lowe, associate director of urology at St. Luke's-Roosevelt Hospital in New York City, said PAE was \"unlikely\" to be used much to treat enlarged prostate.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not report on any harms observed in the 67 men who took part in the study reported on.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nWhat he discovered during that experiment was that none of the patients suffered long-term effects (from either the surgical procedure or the implantation of stem cells), and no unusual acceleration of disease occurred.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\nUnfortunately, the procedure provided no benefit to patients, though it caused substantial pain to two of the study participants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a lot of detail on the harms noted in the study, earning it\u00a0a Satisfactory rating in this criterion, albeit with caveats.\nCertainly, the bar for safety may be lower for ALS than for other diseases, but we think the story misleads by calling the treatment \u201cgenerally safe.\u201d As the story explains,\u00a0two of the 15 patients developed \u201csevere complications,\u201d including partial paralysis and \u201cincapacitating pain.\u201d More detail is warranted here. In fact, the 15 patients in the study experienced\u00a0a total of 81 adverse events\u00a0that researchers said were probably or definitely related to the treatment, mainly surgery. While most of these were not serious, they may\u00a0have reduced the quality of life at least temporarily for patients who probably have little time left to live. In addition, these patients spent several days in a hospital going through an uncomfortable procedure.", "answer": 1}, {"article": ".\nBut few women are opting for this protection, which goes by the name chemoprevention.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\nIn part this may be because many doctors are not even discussing this option with their patients.\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We grant a passing grade for the inclusion of statements about increased risk of uterine cancer and other serious side effects. But we have to wish for some discussion of sexual side effects in more common language. Not everyone knows that \u201chot flashes\u201d and \u201cvaginal dryness\u201d are part of the menopause-like state that chemoprevention creates in some women. We suspect those potential side effects influence women\u2019s decisions.", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nHe says middle-aged adults should exercise moderately during the first 12 weeks and then slowly build up to more vigorous activity.\nAnd vigorous activity makes you fit, and fitness reduces your risk of disease and death,\u201d says Gary O\u2019Donovan, a researcher in physical activity and sedentary behavior at England\u2019s Loughborough University and lead author of the paper.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job highlighting some of the potential harms associated with vigorous physical activity: \u201cHowever, experts caution that it is possible to overdo it\u201d \u00a0and \u201cmore exercise than two and a half hours a week can actually be unhelpful and even harmful.\u201d\nAn expert in the field not associated with the study provides a bit of common sense to the discussion; \u201cThere are risks that come with a\u00a0weekend warrior exercise schedule, especially for people who aren\u2019t used to being active. \u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac\u00a0University.", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\nThere was also evidence suggesting improvement in working memory.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no statement about harms, not even a statement declaring there are none.", "answer": 0}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nThe study earlier this year also found that women who took supplements regularly reduced their chance of fracture more than those who didn't.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nResearchers studied the effect of 600-milligram calcium supplements twice a day on women over 70 and found that only those women who took 80 percent or more of their pills were less likely to experience fractures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. In the study, the researchers found that constipation was a side effect of taking the calcium supplement", "answer": 0}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t report on what side effects were observed in the study.\u00a0 But we\u2019ll give it the benefit of the doubt for at least citing the experience of one doctor who has used the drug:\nSeveral of her patients have exhibited side effects. One developed a serious allergic reaction, two had kidney insufficiencies that reversed when they stopped and a few have had mild skin rashes that went away as they stayed on the treatment.", "answer": 1}, {"article": "Symptoms include recurring headaches, loss of appetite, blurred vision, vomiting, shifts in personality and the ability to learn, seizures and the gradual loss of speech.\nA vaccine against the Zika virus could one day be used to fight the deadly brain cancer that claimed the life of Senator John McCain, according to a study in mice.\nCurrently, most people diagnosed with the condition die within two years.\nThe animals dosed only with the stem cells developed tumors.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that the Zika virus had no adverse health effects in mice, but that it is possible it might destroy healthy neural tissue in humans. Again, the story needed to caution that we have no idea how this might help\u2013or hurt\u2013humans.", "answer": 0}, {"article": "\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nThe rate of infections and other serious side effects was similar in the Stelara and placebo groups, researchers said.\nThat compared with a response rate of 23.5 percent of patients who received a placebo.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nThe DNA stool test methods were developed at the Mayo Clinic.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of false positives with this method. ", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\n\u201cThe high soy level patients were eating what the FDA has said is heart-healthy, or 25 grams of soy a day,\u2019 she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t address harms, but we\u2019re not sure that there are any harms worth mentioning when it comes to soy foods eaten in moderate amounts.\u00a0Hypothetical concerns that soy may promote estrogen-sensitive cancers have not been confirmed in large studies. And the story correctly\u00a0advises readers not to take soy supplements, which deliver a higher dose of soy isoflavones that might potentially increase\u00a0cancer risk. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of the potential harms from taking nicotine, as opposed to quitting without drug therapy. There\u2019s also the question of whether people are doing themselves more harm by continuing to smoke because they failed to quit with the help of a nicotine replacement product. If they had been able to more effectively quit earlier, would they live longer?", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nTopiramate also has blood pressure-lowering effects, she says.\nThose who took the medium dose of the pill lost 8% of their body weight at six months and 8.2% by one year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned specific side effects of this particular medication combination. \nTo be most informative to readers, the story should have mentioned that the potential for long-term harm is not known. \u00a0And the rate at which people stopped taking the drug due to side effects should have been included.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although some potential harms are mentioned, none are quantified.\nThe story states that NRT products \u201chave amassed a strong safety record\u201d but we never get any details on that record.\nWe wish the story had delivered a deeper exploration than one health behavior specialist saying, \u201cThere really doesn\u2019t appear to be any great harm.\u201d And a British regulatory proclamation that \u201cthere are no grounds to suspect appreciable long-term adverse effects.\u201d\u00a0 Statements like \u201cdoesn\u2019t appear to be\u201d and \u201cno grounds to suspect\u201d could be haunting some day.", "answer": 0}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nIn contrast, this retrospective study of over three years of clinical experience, shows lasting benefits for many patients, with no apparent risk of addiction.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nPatients in the study completed the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible side effects in the news release, other than to challenge the broader psychiatric community\u2019s belief that ketamine is addictive. The author is quoted saying, \u201cOur patients get better after a few infusions and from there treatments can be discontinued.\u201d\nIn contrast to the release, the study did point out some side effects, which should have been included in the PR release. It states, \u201cThe most common side effects in doses used for depression treatment include: dizziness, nausea, and a slight sense of dissociation. The side effects clear generally within 15-30 minutes after the infusion.\u201d", "answer": 0}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\nA University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\nPrevious work shows that metabolizing lipids helps prostate cancer escape anti-androgen therapy.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug\u2019s potential harms to people are known and reported in the New England Journal of Medicine. They include \u201cfatigue, constipation, and back and joint pain as well as hypertension.\u201d\nThe release doesn\u2019t tell us if the mice in the study experienced any side effects from the drug.  ", "answer": 0}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"Sometimes, a very simple intervention can have a powerful effect,\" wrote Lindsey Turner, of Boise State University, in Idaho, and Erin Hager, from the University of Maryland School of Medicine, in Baltimore.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Students in New York City schools had access to water through drinking fountains before this intervention study. This study looked at a new way to deliver New York city tap water to kids, which may have encouraged them to opt for water instead of sugary beverages, like soda.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "They found it would be.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nThey did not study actual people eating actual chocolate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the Harvard expert:\n\u201cThe researchers are ignoring some downsides, he says. \u201cThey are ignoring the dangers of too many calories and too much fat and sugar from the chocolate bar,\u201d he says.\u201d\nBut somewhere in this review, we must criticize the story for never offering any detailed analysis of the researcher\u2019s \u201cmodel.\u201d We could do it in the Evidence criterion, but we\u2019ll choose to do it here.\nSurprisingly the model used by these researchers did not account for the adverse effects (weight gain, etc) that might accrue from adding a daily 100 g chocolate bar, which might contain as much as 600 calories (!), to your diet for 10 years.\u00a0 Since the entire underpinning of the story was the validity of the model, this is a weakness in the story. ", "answer": 0}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe drug is associated with some serious side effects.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain: ", "answer": 1}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story summarizes the reported side effects of topical NSAIDS. What\u2019s more, the reporter points out that the potential risks in people who have other health problems or are taking other drugs have not been well studied. That insight is something we see too rarely.", "answer": 1}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\nAfter a median follow-up time of 10.5 months, Gandhi said, the patients in the combination group were 51 percent less likely to die, compared with patients in the chemo-only arm.\nNine of the 20 patients who got Opdivo had a \u201cmajor pathologic response\u201d \u2014 a sharp reduction in the number of cancer cells found in the tumors removed by surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects were not addressed. About 14% of the patients in the combination group dropped out of the trial due to adverse events, versus about 8% of those in the chemo-only group.\nAcute kidney injury and fever relating to neutropenia, a low white blood cell count, occurred more frequently in patients who received Keytruda.", "answer": 0}, {"article": "He noted that the technology's cost \"is not prohibitive, and it is safe.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nIn prior studies, they found that far-UVC light killed methicillin-resistant S. aureus (MRSA) bacteria -- a common and dangerous \"superbug\" -- without harming human or mouse skin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Based on earlier in vitro studies by the same authors, it\u2019s mentioned the antiviral effect can be achieved without harming human or mouse skin, or causing cataracts (cataracts and skin cancer are a\u00a0 well-documented side effect of full spectrum UVC exposure). It\u2019s not clear if these results would hold up in live subjects. No other side effects of far-UVC spectrum light are mentioned.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nResearchers have concluded that one glass of beetroot juice a day is enough to significantly reduce blood pressure in people with high blood pressure.\nDuring the 4 weeks in which they were taking the juice, patients in the active supplement group, whose beetroot juice contained inorganic nitrate, experienced a reduction in blood pressure of 8/4 millimeters of mercury (mmHg).\nProf. Ahluwalia advises that people looking to increase their daily nitrate intake should avoid boiling vegetables, as the nitrate dissolves in water.\nThe authors note that the reduction achieved in the active supplement group is close to that achieved by medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It may be reasonable to think that taking large amounts of nitrates for long periods of time is safe, but are we really sure? It\u2019s perhaps also worth mentioning that people should get their nitrate from foods, not supplements.\u00a0Cases in the medical literature have documented confusion between inorganic nitrate (found in beets) and \u00a0synthetic organic nitrate or nitrite (e.g. nitroglycerin or amyl nitrate). The latter agents cause potent dilation of the blood vessels at low doses and can precipitate fatal cardiovascular collapse.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nTheir approach detects micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nPrior to their study with this contrast agent, Lu\u2019s team had conducted studies to determine its clearance from the body after the imaging, which is essential for safe clinical use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release seems overly optimistic here. It says testing by the researchers \u201cshowed that the agent is readily cleared from the body and has a low level of retention in tissues. Therefore, they expect it will be safe if ultimately developed for clinical use.\u201d \u00a0We think it would be best to conduct the necessary studies before commenting optimistically on the potential safety of the agent \u2014 after all, the point of conducting the studies is that we don\u2019t know yet if the agent is safe or not. And even if it does turn out to be safe, there could be potential side effects that patients should know about. Also, the experiments involved mice, and it\u2019s not clear if this technique would require a patient to submit to a whole body MRI in order to find metastases.", "answer": 0}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nUrological experts are beginning to rethink treatments, too, based on symptoms and how much a man is bothered by them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm associated with any of the treatments was the possible need for additional treatment some time in the future for the minimally invasive and surgical options mentioned. \u00a0However \u2013 there was no mention of the sexual function and incontinence issues that may accompany these invasive treatments; nor was there discussion of the side effects associated with medication use.", "answer": 0}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nPatients began treatment within 2 weeks after this initial evaluation, as determined by the randomization procedure.22 Patients who underwent no surgery or less extensive operations were censored at death or date of last contact.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This comes back to cetuximab. As noted above, cetuximab is already sold under the trade name Erbitux. And Erbitux\u2019s own website notes that it can cause significant adverse health effects, including heart attacks and allergic reactions that resulted in death. We don\u2019t expect a news release to include a thorough recounting of every possible adverse health effect associated with a treatment, but we do expect there to be at least an acknowledgment of known health risks \u2014 and especially so when the relevant risks are so severe.", "answer": 0}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThis may be especially true for people with serious mental illness, a study finds.\nThe pets provided more than just emotional support and companionship, participants said.\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nThe animals also could distract them from their illness, even from severe psychosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. It is important to recognize that the patients reporting positive influences of pets are having a good experience already. Giving a pet to someone with a major mental illness, who has not previously cared for an animal, could go very poorly without the right support systems in place.", "answer": 0}, {"article": "Autologous CD34?\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nEncouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients, especially trials in which subjects were transplanted with autologous (self-donated) CD34+ cells.\"\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\nThe patients, who were unresponsive to other treatments, were considered to have no other options (refractory).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential risks associated with CD34+ treatment. The Cell Transplantation paper did not report significant adverse effects associated with the treatment, but noted that \u201cthe longer-term effects of this treatment are unknown.\u201d Even if there are no additional risks associated with a treatment, a release needs to tell readers that \u2014 and, in this case, the researchers themselves make clear that they do not yet have a clear assessment of potential risks.", "answer": 0}, {"article": "Please see paper for the complete list.\nWithout effective prevention and treatment, the prospects for the future are bleak.\nOther collaborators on the study include Edwin C. Amos, Jonathan Canick, Mary Ackerley, Cyrus Raji, Milan Fiala, and Jamila Ahdidan.\n\u201cThe magnitude of improvement in these ten patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,\u201d Bredesen said.\nShe no longer showed evidence of cognitive decline.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any potential risks of any aspect of the protocol. Since we do not really know what the protocol consists of we have no way of assessing potential risk.", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly\u00a0acknowledges that energy drinks have been linked to\u00a0reports of deaths and\u00a0injuries that may be related\u00a0to their high caffeine content, and there was an online link in the text to a previous story about these concerns. We\u2019ll call this good enough for a satisfactory. However,\u00a0considering that FDA reports\u00a0suggest that 18 deaths and more than 150 injuries\u00a0may be related to energy drinks, we don\u2019t think the story captures the full scope of the potential problem.\u00a0This deficiency was nicely described by Paul Raeburn at the Knight Science Journalism Tracker, who\u00a0noted that\u00a0in a 2,000-word piece, there was ample room\u00a0to do \u201ca more thorough job of reminding offline readers why these drinks have provoked concern.\u201d\nAdditional comment about kids and teens and use of these drinks along with alcohol would have strengthened the article.", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\nThe sixth man also had modified cells, but fewer than expected.\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\nThe only side effect was two days of flulike symptoms.\nThree months later, five men had three times the number of modified cells expected.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job in saying:\u00a0\u201cThe only side effect was two days of flulike symptoms. It will take longer to determine safety\u201d", "answer": 1}, {"article": "on Sept. 2.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nIn the clinical trial, the median duration of use was 70 days, which would cost roughly $70,000 to $80,000.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug\u2019s cost, it would have desriable to provide a brief comment on the toxicity of the drug as well.\u00a0 The addition of the information would help the reader place the value of the drug into a better perspective.\u00a0 According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug", "answer": 0}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nThe cardiology community now prefers the endovascular approach.\nThey are now training doctors nationally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential risks associated with this procedure or any stent insertions for abdominal aortic aneurysms. Further, there\u2019s no discussion of whether the procedures and devices involved have undergone safety trials.", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0discusses false positives & interval cancers & provides explanations of both of these problems associated with screening mammography.", "answer": 1}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\nBut at the same time, many of these substances were taken in uncontrolled settings by large numbers of people, and certain proselytizers (like Timothy Leary) advocated their widespread use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Obviously the harm potential of these drugs is probably what gave them a bad reputation in the first place\u2013particularly in their potential for abuse\u2013so it would have been useful to hear which adverse effects were experienced by these users in these small experiments. It was good that the story stipulated that the drugs were used under controlled and supervised conditions, and so the obvious question arises: is that how these drugs would be used in the wider population, and if not, would that not alter the harm/benefit potential of the drug?\nAs we circle back to re-evaluating these drugs, focusing on one specific area (anxiety/depression), it seems a little too easy to forget they are powerful drugs that affect multiple chemical and who knows what other\u00a0systems in the brain. Informed consent documents for future studies will be tricky.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although this story did mention two side effects of excessive intake of vitamin D, this list downplays the consequence of overdose. \u00a0For this, they could have simply gone to the Time archives and unearthed their piece from 1992: \u00a0http://www.time.com/time/magazine/article/0,9171,975464,00.html\u00a0\nThis is not a trivial point, especially since the clinician quoted in the piece mentioned personal consumption levels above those recommended. \u00a0Taking a supplement to match the intake mentioned, in concert with vitamin D containing foods, multivitamins, and exposure to sunlight \u2013 could result in people ending up with higher than intended levels.\nThere is also no mention of the lack of long term data on supra-therapeutic levels of the vitamin, and we can assume that the effects, good or bad, may be magnified by the longer duration of exposure and more sensitive developing body in the children and adolescents that were the focus of the piece.", "answer": 0}, {"article": "Co-authors include: Drs.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\nSignificant interventions in response to an adverse event were rare, occurring in only 1.4% of children.\nTwo other practices - receiving an opioid prior to sedation and having a laceration repair - were associated with the occurrence of vomiting, oxygen desaturation and need for significant interventions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did a good job of explaining possible harms that occur in relation to different types of sedation. A few words about the specific adverse events seen with ketamine would have been of value. \u00a0As a dissociative agent, ketamine is known for its ability to produce bizarre dreams, and hallucination as well as excessive salivation.\nHere is an excerpt from the release:\n\u201cThe overall incidence of adverse events in the study population was 11.7%. The most common events were a decrease in oxygen saturation (5.6%) and vomiting (5.2%). Significant interventions in response to an adverse event were rare, occurring in only 1.4% of children. Two other practices \u2013 receiving an opioid prior to sedation and having a laceration repair \u2013 were associated with the occurrence of vomiting, oxygen desaturation and need for significant interventions.\u201d", "answer": 1}, {"article": "\"There's lifestyle and diet, there is getting to the right doses of medications, there are adherence issues.\nThe procedure is safe as well as effective, the study authors said.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\n\"High blood pressure is a major contributor to heart attack, stroke, heart failure, and [kidney] failure,\" said Fonarow, who was not involved in the study.\nFonarow added: \"While this study demonstrates that renal denervation provides sustained reduction of blood pressure up to one year and appears safe, additional studies with longer-term follow-up are needed.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not sufficient to simply act as stenographer when study authors say \u201cthe procedure is safe as well as effective.\u201d In fact, a careful review of the actual journal paper contradicts the safety statement.\u00a0One subject in the crossover group suffered a renal artery dissection (tear) during placement of the guide catheter that required urgent repair. Not important enough to report?\nAnd it certainly isn\u2019t adequate to quote from a news release that \u201cparticipants\u2019 kidneys were not damaged or functionally impaired.\u00a0 We also found no ill effects on long-term health from the procedure.\u201d\u00a0 Would most blood pressure experts consider 6-12 months as \u201clong-term health\u201d?\nCan a procedure be proclaimed \u201csafe\u201d in the hands of one experienced team?\u00a0 What might the learning curve be for this approach?\nThese are not merely academic questions when a researcher \u2013 and a story \u2013 proclaim a tiny study as proof of safety.", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nTwo classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms of testing. Notably, since the researchers noted broad overlaps between cases and healthy controls in the levels of almost all the cytokines measured, it seems likely that test results could be easily misinterpreted to either label healthy people as sick or sick people as health.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not mention side effects of deep brain stimulation, which may include brain bleeding, stroke, seizure, and mood and cognitive changes.", "answer": 0}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\nHe says there\u2019s evidence to support the use of infrared saunas for high blood pressure, congestive heart failure and chronic pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Effect on sperm count is mentioned. But that\u2019s far from the only risk.\u00a0There are large segments of the population who are generally told not to use saunas\u2013such as pregnant women or people with chronic diseases.\u00a0What makes saunas inherently dangerous for them? Is it also true for infrared saunas?\u00a0We don\u2019t know or learn in this article.", "answer": 0}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\nRetested with the blood pressure cuff, the group eating the American Heart Association-style diet continued to display normal, healthy blood flow.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there were no harmful effects on the blood vessels observed in either group. \u00a0However \u2013 since people in the study were reported to have healthy vessels to begin with, combined with the short amount of time they were followed, it is very unlikely that any change would be seen. \u00a0So it is really insufficient evidence about lack of harm.\nThe story lacks perspective on the problem of knowing whether a treatment is safe or not. We need thousands of people in a clinical trial to determine cardiovascular safety, not 46.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with benefits, the potential harms of red palm oil are just generally summarized. Still, the story points out that this oil and others like it can produce harm (and clearly contain plenty of calories). A nice touch is that the potential harms addressed by the story include environmental damage caused by poor agricultural practices, as well as potential exploitation of workers in developing nations. While those domains are typically outside our scope, they are clearly relevant to consumers looking to make informed purchases.", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nIn one of those patients, the treatment resulted in complete remission of his metastatic melanoma and evidence that his immune system stands ready to fight any return of the cancer after three years.\nSeveral independent researchers said the study results were promising.\nThis type of \"adoptive immunotherapy\" could be effective against a wide range of cancers, Yee said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\n\u201cCurrently, the T cells have limited staying power and often die off before their work is done. Doctors give them a boost by administering a growth factor called interleukin-2. But at high doses, it can cause dangerously low blood pressure, breathing problems, kidney failure and heart arrhythmias.\nYee\u2019s group showed that by choosing T cells more selectively, patients can get by with much lower doses of interleukin-2, making the treatment less toxic.\u201d\nBut we\u2019re not told what side effects were observed in the 11 patients in the study. In reality the study originally involved a high dose (3 subjects) and low dose (8 subjects) IL-2 arm.\u00a0 The high dose arm was closed by the Data and Safety Monitoring Board prematurely due to unacceptable toxicity.\n\u00a0", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cBy detecting those individuals who don't have narrowing in their heart arteries, but they are in the process in developing them because the arteries are inflamed, we may be able to intervene early enough to prevent heart disease.\u201d\n\nThat's why surgeons do heart bypasses.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because there is so little information about the imaging technique and what it requires, it\u2019s hard to say what the harms or benefits might be, but certainly the story might have mentioned the potential risk of drug intervention (or non-intervention) if the inflammatory cell \u201cmarker\u201d is valid as a predictor of heart attack risk.\nAlso, it would have been worth discussing if the new imaging technique exposes patients to radiation, which has been shown to increase the risk of cancer if used repeatedly.", "answer": 0}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nPBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy.\nThe same spot scanning system has already been installed at Nagoya Proton Therapy Center and Hokkaido University in Japan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release gives the briefest mention of side effects, but we\u2019ll give it the benefit of the doubt.\u00a0The statement that PBT brings \u201cvery few side effects\u201d is understood to be true since proton beams deposit less radiation outside the tumor area than do photon-based treatments. However, there are few (if any) reports of clinical studies comparing the side effects of protons with those from photon treatments.\nIn addition, claiming that patients \u201cexperience no pain\u201d when undergoing proton therapy is slightly misleading, since the same can be said for photon-based radiation therapy.\nIt\u2019s important to point out that proton facilities don\u2019t typically use an advanced imaging technique (such as CT or MR) to verify the patient\u2019s position prior to administering radiation; whereas this is standard practice for photon IMRT techniques. That is troublesome, because the consequences of a geometric miss in proton therapy are expected to be greater than they would be for photon IMRT.", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nIn addition, a pooled analysis of data from the ZOE-70 and ZOE-50 trials showed that the candidate vaccine effectively reduced the risk of subsequent chronic neuropathic pain, also known as postherpetic neuralgia (PHN)1 which is the most common, and often severe, complication of shingles3,4.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release notes that serious adverse reactions occurred with about equal frequency among study participants who received the vaccine and those who had placebo injections.\u00a0Although the release acknowledges the most common injection site\u00a0and systemic adverse reactions, most commonly mild-to-moderate\u00a0pain at the injection site and fatigue, it could have been more forthcoming about how common these reactions were. The article on which the release is based states that 79% of participants who received the vaccine, versus 29.5% of placebo recipients, reported local and/or systemic side effects.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\nIf resveratrol does pan out in further research, it may add to the medications that are currently available, such as Aricept and Exelon, which slow, but do not halt, progression of the disease, Hendrix said.\nEven for the relatively small number of participants in the study, the researchers did see indication that resveratrol could improve cognition.\nAnd anecdotally, patients who took resveratrol told the researchers that they felt like they were maintaining their mental ability.\nUltimately, it will probably be a combination of several drugs, as well as diet, exercise and social and mental stimulation that help stave off the rapid mental decline that is often associated with Alzheimer's, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically discusses the safety of resveratrol, noting that the one concern researchers found was that there appeared to be a slight weight loss (two pounds) in patients taking resveratrol over the course of the one-year study, compared to a one pound weight gain in patients taking placebo. This is significant because weight loss can be a problem for Alzheimer\u2019s patients. The story could also have addressed the concerns raised in some quarters that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners.", "answer": 1}, {"article": ".\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nTheir study showed that small molecule analogs that target the functions of SecA, a central part of the general bacterial secretion system required for viability and virulence, have potent antimicrobial activities, reduce the secretion of toxins and can overcome the effect of efflux pumps, which are responsible for multi-drug resistance.\nThe inhibitors also reduced the secretion of three toxins from S. aureus and stopped three MRSA strains of bacteria from reproducing.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Any new drug developed from this research would have side effects. But whereas the release is optimistic in forecasting that such drugs would be effective treatments for MRSA, it doesn\u2019t also caution that such drugs might cause harm. At the very least, a statement about the fact that potential harms are unknown would have been helpful.", "answer": 0}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nThe MIND diet recommends eating berries at least twice a week.\nThe MIND diet recommends frequent servings of green leafy vegetables.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Following any of these three diets is better than the normal, high fat, salt and red meat standard American diet and even moderate adherence to these diets is thought to be heart healthy and perhaps brain healthy, too.", "answer": 2}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe researchers went one step further and gave contact lenses to the patients.\nThe study appears in the Aug. 25 issue of Science Translational Medicine.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that there were no adverse side effects. It should have been clear that the patients were followed for two years.", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit for noting that DXA scans involve radiation, and for explaining exactly how much radiation one may be exposed to during a scan. However, that information could have been placed in a more health-relevant context. The DXA scan, the story says, exposes someone to \u201cabout the same as one day of background radiation\u201d and compares the dose to chest x-rays and mammograms. The story would have have stronger if it had explained whether that means low risk or high. A few more details would have been helpful here.", "answer": 1}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nRome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release says: \u201cThere were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.\u201d\u00a0But it is not clear whether self-reported measures of disability are limited to the effects of rheumatoid arthritis, or whether they also include side effects that may have been caused by the drug.\u00a0According to the American College of Rheumatology, those side effects can include \u201can increased risk for all types of infections, including tuberculosis (TB) and fungal infections. Some of these infections may be severe.\u201d\nWhile the potential for side effects should have been mentioned, we\u2019d note that reducing the TNFi dose should theoretically reduce harms. But that is an assumption that needs to be studied. This study is too small to do that.", "answer": 0}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nPatients also could be susceptible to immune response side effects, such as low blood pressure or fever, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that two patients in the trial who received the highest doses fell ill with sepsis and gangrene. It also mentioned a need to \u201ckeep an eye on potential side effects\u201d in future trials.", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nAnd for one patient, it is promising.\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\nBut it's hard to know what would have happened without them.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. Any surgical procedure presents a risk. Since clinical trials of stem cell procedures for spinal cord injury are just beginning, they carry a risk of unforeseen adverse effects.", "answer": 0}, {"article": "Their median age was 63.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nWith better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nThat would include younger women whose cancers have not spread in great volume to other organs and who have certain kinds of cancers that respond better to drugs, Lisa Newman, medical director of the Henry Ford Health System's International Center for the Study of Breast Cancer Subtypes, said in an e-mail.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Breast surgery can lead to complications, such as bleeding and infection, like any major surgery. Patients usually choose between breast-sparing surgery (surgery that takes out the cancer and leaves most of the breast) and a mastectomy (surgery that removes the whole breast).\nAccording to cancer.gov, mastectomies can affect a woman\u2019s psychological well-being due to a change in body image and the loss of normal breast functions. Furthermore, women undergoing total mastectomies lose nipple sensation, which may impede sexual arousal.\nOther breast surgeries could lead to sudden drops in estrogen production, which could induce early menopause in premenopausal women.\nSince harms are not addressed, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\"In 2012, scientists took that particular frog and wanted to know why is it, why do these frogs keep milk fresh?\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nIf those studies prove to be successful, human testing could be next.\nGregory Chinchar, a professor in the University of Mississippi Medical Center's department of microbiology and immunology, said that he was surprised that the peptide targeted the hemagglutinin on the flu virus.\nIf there is a similarity, it may explain why H1 viruses are vulnerable to urumin's wrath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given the early nature of the research\u2013which the story makes clear is preliminary\u2013we\u2019ll rate this N/A.\nIdeally, we\u2019d like a statement to the effect that the safety is totally unknown.\u00a0However\u00a0the story does establish that future research might better pin down the harms, i.e.,\u00a0\u201cIf further studies show it has a low level of cytotoxicity\u2026\u201d", "answer": 2}, {"article": "For more information, visit http://www.\nAs more and more handheld ultrasound machines come to market, these results suggest that lung ultrasound has the potential to become the preferred choice for the diagnosis of pneumonia in children.\nLung ultrasound has been shown to be highly effective and safe for diagnosing pneumonia in children and a potential substitute for chest X-ray, according to a study conducted at the Icahn School of Medicine at Mount Sinai.\nChest X-ray is considered the test of choice for diagnosing pneumonia in children, but the WHO estimates three-quarters of the world's population does not have access to radiography.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that there was no increase in adverse events reported during the study, nor were there any cases where pneumonia was not appropriately diagnosed. There is the potential for some harms that aren\u2019t addressed, namely missed diagnosis and the identification of small pneumonias that don\u2019t need to be treated (overdiagnosis).\n\u201cIn the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\u201d according to the lead study author. This benefit in terms of harms reduction might have been stressed even more. Ultrasound screening could be safer in the long run for children than X-ray since repeated exposure to radiation presents a cumulative risk for cancer. Radiation oncology experts and the FDA have long called for reduced reliance on routine X-ray and computerized tomography (CT) screening in children unless the benefits outweigh the risks. More than 100 professional organizations including pediatricians, radiation physicists and oncologists have signed on to the \u201cImage Gently\u201d campaign which urges the use of ultrasound instead of radiation when feasible.", "answer": 1}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0mentions a few times the benefits of being freed from insulin injections, but offers no information on the potential harms of any therapy, including the one being proposed here, which would be invasive. Current islet transplant treatments contain a number of risks.\nThere also should be some discussion about what percentage of transplanted patients would see benefit. The article makes it seem as if all of them would be free from using insulin.", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cso far no negative side effects have been reported.\u201d This is insufficient.", "answer": 0}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nThe study showed that more children had epilepsy when they reached the age of four to eight years with seven per cent on regular medication.\nThe study examined how many babies were diagnosed with epilepsy and how many are on regular antiepileptic drug treatment at two and four to eight years of age.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Therapeutic hypothermia is widely regarded as safe, if the treatment is provided by practitioners with the right expertise to patients who meet the relevant criteria.\nForcing the human body to the wrong temperature can cause many potentially serious side effects, including bleeding, infection, dehydration and low magnesium. It is relatively safe only because of expert management by ICU personnel familiar with the procedure.\nAll of that needs to be mentioned, whereas the release doesn\u2019t address the risks.", "answer": 0}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\nIn a small trial, Patsalis\u2019 team were able to correctly diagnose 14 cases where there were extra copies of the chromosome, and 26 normal fetuses \u2014 results they said highlighted its clinical potential.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues that can only be established in a much larger trial.\u00a0 The need for a larger trial was mentioned, but no hint of unestablished potential harms.", "answer": 0}, {"article": "Larsson isn't sure why.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story warns that milk chocolate may be \u201chigh in sugar, fat, and calories,\u201d it doesn\u2019t spell out the implications of eating too much milk chocolate in an attempt to reap health benefits. (To the contrary, the story suggests that eating larger amounts of U.S. milk chocolate with low cocoa content might yield the same result\u00a0as eating less of the higher-cocoa Swedish chocolate.)\u00a0Eating\u00a0more than a modest amount of chocolate is likely to cause weight gain,\u00a0which would probably negate any beneficial effects on stroke and increase the risk for other health problems.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms beyond mention that the tracer was radioactive.\u00a0 What is the radiation burden? ", "answer": 0}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nParticipants were evaluated at baseline, six, 12, and 24 months.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The release could have noted that harm scores were pretty even among all of the study participants, regardless of the duration of their physical activity, and that the protocol was designed to keep the regimen safe for older, sedentary people.", "answer": 0}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor Siravo, she said her memory is back to 100 percent.\nIt's only for moderate to severe cases, and like any surgery, there is risk of infection.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n\"And then that didn't work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that \u201clike any surgery, there is risk of infection\u201d when Inspire is implanted.\nThat isn\u2019t enough.\u00a0A check of FDA\u2019s MAUDE database reveals patient complaints of slurred speech, difficulty breathing, and the device suddenly activating itself, among other problems.\nIn addition, there are questions particular to the use of an electrical device implanted in the chest \u2014 especially for a condition that is most common among patients who are \u201colder, overweight and male\u201d (as the story puts it). For example, can patients with pacemakers also use Inspire, or would they interfere with each other?", "answer": 0}, {"article": "It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland -- and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nThe study revealed telltale patterns of brain activity that, six months later, were associated with worse performance on behavioral and cognitive tests and were different from patterns seen in healthy control subjects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "MRIs are generally deemed to be a safe procedure, since no ionizing radiation is used. Adverse events for MRI scans are rare, but like any medical procedure, they do carry some risk, especially for patients with implants and external and accessory devices \u2014 like artificial joints, insulin pumps and\u00a0ventilators. For these patients, risks include device malfunction or heating of the implanted medical device and the surrounding tissue, which could lead to burns.\nAccording to the FDA, the use of gadolinium-based contrast agents (GBCAs) also carries some risk, including side effects such as allergic reactions. For patients with kidney disease, GBCAs could cause a rare and potentially fatal condition known as nephrogenic systemic fibrosis.\nSince harms are not mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": ".\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\nAt 18 months, abaloparatide-SC significantly increased bone mineral density from baseline at the lumbar spine by 9.2%, the total hip by 3.4% and the femoral neck by 2.9%, compared with placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A serious omission, the release is essentially silent about potential harms, which, according to other sources, may include \u201cback pain, arthralgia, upper-respiratory-tract infection, hypercalciuria, and dizziness.\u201d A mid-term post-marketing surveillance study of Forteo (teriparatide), a related drug on the market, observed an association but not causation with osteosarcoma (a rare malignant bone cancer) in people taking the drug. Osteosarcoma had been observed in animal trials of the drug that were dependent on dose and treatment duration. ", "answer": 0}, {"article": "In general, though, \"the more options that are available to migraine headache patients, the better,\" Waltman said.\nOne study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the story, \u201cThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\u201d We\u2019ll call this adequate for a satisfactory, but it would have been helpful to know how often these adverse effects occurred, especially since the FDA had previously delayed approval of the product based in part on safety concerns. In addition, there was no mention of other adverse effects\u00a0that have been associated with triptan use, such as atypical pain and pressure sensations (e.g. tightness in the chest and throat constriction). The story did mention that triptans can be harmful for\u00a0patients with heart disease or who are taking SSRI antidepressants.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explores the issue of whether Rituxan may suppress the immune response too much, making the patient vulnerable to other diseases. It also explains how this effect has been observed in the drug Tysabri, a different immune suppressant used for MS.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state \u201cPatients in the study experienced diarrhea, nausea, rash, fatigue decreased appetite, vomiting, itchiness and taste alteration.\u201d But we weren\u2019t told how many of the 97 experienced these.\u00a0 So the true scope of what was seen is not reported.", "answer": 0}, {"article": "\"It's premature to make any conclusions,\" he said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\nD'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms from taking vitamin D supplements were not mentioned (nor were those of surgery). \u00a0While toxicity is rare, studies suggest that long-term intakes of high doses are associated with adverse health effects. Perhaps more importantly, what about men possibly taking vitamin D when they really ought to have surgery because they have an aggressive tumor type?", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms of this device nor mention that medical devices are not required to provide robust safety data to go on the market in the U.S. According to the study, 3.4% of patients experienced complications related to the device within one year. It\u2019s important to keep in mind that this adverse event rate is under ideal conditions\u2013where patients are closely monitored by physicians because of clinical trial enrollment.\nWhile there may be smaller surgical incisions than standard surgery, is it still quite invasive to insert a metal clip into a heart valve. Post-surgery, the device can malfunction, and cause a host of problems, including death.", "answer": 0}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nThis is often not enough to make a meaningful improvement.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although TMS used for depression is associated with a low rate of adverse effects (mostly headache), we don\u2019t know if other problems might emerge when using it on patients who\u2019ve had a stroke. The story didn\u2019t discuss the potential for adverse effects or mention whether any adverse effects were seen in this study. Any new treatment \u2013 however theoretically safe \u2013 may cause unexpected harms in such a clinically fragile population. That is one of the limitations of a study of such a small number of highly selected individuals.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The anecdotes cited were all glowing. None included any mention of possible drawbacks. This surgery is associated with very significant risks, including risk of death\u2013typically from a blood clot. Now, those risks are with all hip replacements\u2013same day discharge and not\u2013but they are never mentioned and should have been.\nThe story leaves readers with the impression that they might all be going home maybe 10-12 hours after surgery as the 54-year old patient profiled did (no exact timing of his day was provided in the story). How representative was that? Didn\u2019t the age and conditioning of a 54-year old play a big factor here? What might change if he were a 64-year old or 74-year old reader of the WSJ? Or is this what gets hidden when joint replacement surgeries are increasingly marketed to younger and younger people? And when journalism fails to scrutinize that factor?", "answer": 0}, {"article": "For more information on healthful eating for kids, visit the U.S. Department of Agriculture.\nA more health-conscious diet was associated with small increases in IQ, she said.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, this story is all about the potential developmental harms of a high-calorie, nutrient poor diet.", "answer": 1}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\nBut, he added, \u201cIf we biopsied every man with a PSA below 4, we\u2019d be looking at a sea of cancers that would never grow to be life threatening.\u201d\n\nThese facts and the results of a recent study by Dr. Carter, among others, indicated that rather than acting on the basis of a single PSA test, the rate of change in levels over time is a better indicator of who might have a serious cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Specific harms of screening and its downstream consequences are not mentioned.\u00a0 For instance, the article only states prostate cancer surgery is debilitating, without stating why or how and without recognizing that other prostate cancer treatments, like radiation, can also have debilitating side effects, like problems with erections, leaking urine, and problems with bowel function (which is not stated).\u00a0 The article doesn't tell readers how severe these problems could be or how frequently they might occur.\u00a0 There is also harm in managing the many false positive test results that occur, which is not mentioned; the biopsies can be painful, are often not definitive because they are random, and there are psychological consequences, like anxiety, that men endure.\u00a0 ", "answer": 0}, {"article": "Proton therapy is an advanced type of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor, destroying cancer cells while sparing healthy tissues.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\nToxic effects of treatment in both the acute and late settings also were analyzed.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says:\n\u201cAmong the acute and late toxic effects diagnosed in patients were: esophagitis, pneumonitis and cardiac arrhythmia. Of note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\u201d\nSo we give the release credit for talking about harms. Some numbers to show how many of the 64 people enrolled had side effects would have been helpful.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nIn the latest trial to address those limitations, however, meditation does appear to have an effect on reducing heart attack, stroke and even early death from heart disease, at least among African-Americans.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Though it doesn\u2019t explicity report on harms, the story does imply that meditation \u201ccan\u2019t hurt you,\u201d which we\u2019ll agree is an accurate sentiment. Any harms are likely to be indirect \u2014 i.e. choosing meditation (a possibly ineffective treatment) over something that is more proven.\nHowever, the story whiffed on the important indirect harm of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants.\nAll interventions have costs.\u00a0 All interventions have harms.\u00a0\u00a0 All health care new stories \u2013 in our opinion \u2013 need to report on both.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Room for improvement. We give the article credit for noting that Avastin has limited safety information in this setting and that the investigator has noted no significant side effects in this cohort. It also gives some theoretical reasons to be optimistic. But what\u2019s missing from the story is the key line from the study: it \u201cwas too small to assess safety.\u201d You know the saying about absence of evidence and evidence of absence?\nAs noted, as readers we are unclear why Avastin is sparring with Lucentis. The article elevates Avastin because it \u201ccan\u2019t easily travel outside the eye,\u201d while Lucentis has a theoretical concern of systemic effects. That paragraph gave us several itches: \nThe article states that the 7 deaths in the study were unrelated to either treatment. We don\u2019t see that conclusion in the publication or editorial. Perhaps it was based on an interview with the lead researcher? If so we\u2019re unable to verify, since we can\u2019t interpret the raw\u00a0mortality\u00a0information on the 7 cases in the study report ourselves. With that caveat in mind, we note that, to us, the study report seems to suggest that their study was too small to determine whether Avastin is associated with more deaths than\u00a0is\u00a0laser therapy. Since there were more deaths in the Avastin group (5 vs 2), we would\u2019ve liked more clarity around this topic.", "answer": 0}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story regurgitates nearly word-for-word what\u2019s in the news release:\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said. No significant side-effects remained after two years.\nAs we mentioned in our review of the news release, it\u2019s a disservice to patients to downplay harms with the word \u201conly.\u201d\nThe story does not give the proportion of patients on VTP who experienced adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, both the story and the news release gloss over the fact that over 1/3 of patients needed repeat treatment within 2 years, and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\nWith ColonaryConcepts' lead formulation, 93.3% (14 of 15) of patients had a rating of excellent or good, with 40 of 45 colon segments rated as excellent or good on the Ottawa scale.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the text notes that individuals involved in the study experienced no \u201cserious adverse effects,\u201d it doesn\u2019t define what \u201cserious\u201d means. The use of that adjective implies that participants may have experienced some side effects, however modest. And although this prep is too new to have gathered data over time about possible harms, the release claims it is as \u201csafe\u201d as some already available options. These standard preps are purgatives that often come with mild side effects such as stomach pain, nausea and syncope from induced bowel movements, and the inevitable damage to intestinal flora. Those side effects deserved a mention here.", "answer": 0}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\nEach HSRx OTC drug product is proven in independently conducted clinical studies to provide superior treatment outcomes.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\nThe clinical studies support powerful marketing claims.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any potential harms of the topical cream or tablet \u2014 or whatever it truly is.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that acupuncture is safe\u00a0when performed by a\u00a0qualified and licensed acupuncturist, which is true. The story didn\u2019t report on the flip side of this statement,\u00a0which was addressed by another\u00a0recent review of the evidence \u2014 i.e. that when acupuncture\u00a0is delivered by unqualified practitioners, there\u00a0are dozens of published cases of\u00a0severe adverse reactions including\u00a0death. Tough call here, but we think the story didn\u2019t quite meet our standard.", "answer": 0}, {"article": "''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The I.V.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nSchwartz, though, said the supplements are completely safe.\nA longitudinal study would be needed to back those claims with evidence, she added.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The statement from the clinic that these IV infusions are safe was unchallenged. There is always a potential harm in an IV administration (infection, vein damage) and yes, receiving worthless treatments for what could be a serious condition is a potential. Also, there was no mention about what kind of testing is done before these treatments are administered, but it appeared to be minimal.", "answer": 0}, {"article": "That wouldn\u2019t be surprising.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\nA second, wider-ranging study found no heart risks and was the basis of new guidelines from two medical groups saying that calcium supplements should be considered heart safe.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\nSome people do need supplements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While we discussed benefits above, the focus of the story is primarily on potential harms. Namely, the story looks at potential risks to heart health associated with the use of calcium supplements. And the story does a fine job here, particularly given the fact that, as one source in the story notes, \u201cThe public has been receiving very confusing and alarming messages about calcium supplements.\u201d Specifically, the story explains that there is some concern that the use of calcium supplements may lead to a build-up of calcium in the arteries, which may contribute to risk of heart attack or stroke. The story then fleshes out the arguments of both sides in this debate, without making any sweeping judgments about which side of that argument is correct. In other words, the story gives readers information without telling readers what conclusions they should draw. In a case like this one, we think that\u2019s the responsible position to take.", "answer": 1}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\n(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\nPeggy O'Brien-Murphy was among the study participants.\nPrior studies of massage for back pain had tested only structural forms of massage, not relaxation massage.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t mentioned but it would have been easy to cite what the study reported: that adverse events, mainly increased pain, was uncommon (4-7%) in those treated with massage. Even saying that massage is generally a safe treatment would have been fine.", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article uses information from an FDA news release to discuss side effects:\nThe most common side effect in the clinical trial was headache, which occurred in 37.5% of the treatment group and 35.3% of the sham treatment group. Other possible side effects were mild, and included temporary jaw or face pain, muscle spasms or twitching, and neck pain.\nThis is enough to rate Satisfactory, but there is certainly more that could be said about side effects. We easily found evidence of short-term memory loss and patient complaints of significant\u00a0anxiety by doing a quick Google search.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We preferred the way the Boston Globe handled this question. It said:\n\u201cVirtual colonoscopy, with or without prep, has some limitations. About one in five patients must undergo a standard colonoscopy after the imaging procedure to have suspicious looking polyps snipped off and biopsied. The CT scan also delivers a dose of radiation that \u2014 while only one-fifth of the dose of an abdominal CT scan \u2014 was significant enough to raise the flags of the US Preventive Services Task Force.\u201d\nIn addition, MedPage Today reported:\nCT imaging picked up indeterminate or potentially clinically important findings outside the colon in 16% and 3% of patients, respectively. Medical record review showed that 5.5% of the cohort ended up getting additional diagnostic work-up due to such incidental findings.\nThat could be a good thing \u2013 but it could bring potential harm in additional workups for some incidentalomas \u2013 things you caught that you really didn\u2019t need to know about.", "answer": 0}, {"article": "But she added, \u201cThe community hopes that if telaprevir is approved by the F.D.A.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nIf approved, telaprevir would have to be used initially with the existing drugs to prevent the virus from evolving resistance.\nBut analysts expect the drug to cost tens of thousands of dollars for a course of treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes the standard treatment sound terrible. But it glosses over the side effects of the new treatment, saying only that it causes a \"nasty rash.\" Where is the rash?\u00a0That can make a world of difference. Does it cause the skin to break and bleed? Does it interfere with basic functions like sight, breathing, eating? It says that 7% of the people in the drug group dropped out, while about half that percentage dropped out of the placebo group.\u00a0Again, some absolute numbers would be good here, as would some context about what percentage of patients experience side effects with the standard treatment or with the competing drug in the same family\u00a0of drugs\u00a0mentioned earlier in the story. And the story could have been more clear that all patients get the standard therapy, IFN and ribavirin. So they will face the side effects of the current regimen, PLUS the side effects of this new agent.", "answer": 0}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nOn that front, long-term users and those who took NSAIDs at relatively higher doses appeared to benefit from the strongest protective effect, suggesting that when it comes to skin cancer risk reduction, more NSAID use is better.\nWhile the study found an association between skin cancer risk and NSAIDs, it did not prove a cause-and-effect relationship.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the harms associated with long-term use of aspirin, including bleeding in the gastrointestinal tract and brain. The suggestion that \u201cmost\u201d people are already taking aspirin for cardiovascular disease prevention is also potentially misleading, since regular aspirin use is recommended primarily for those at higher risk of heart disease.", "answer": 0}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nThey found that if Dr. Bear reverse-engineered his compounds, they seemed to slow brain transmissions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the big problems of reporting on research that hasn\u2019t been published or peer-reviewed is that harms don\u2019t get adequately quantified\u2013a\u00a0 drawback that was on\u00a0full display in this story. The report\u00a0didn\u2019t\u00a0even mention the possibility of patients being harmed by this experimental drug. \u00a0", "answer": 0}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\nAfter her surgery the difference was dramatic.\n\"She said 'no problem,' which was probably oversimplified.\nIn Manuela's case, Maguire was concerned about the damage already done by the disease to her retina.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a small hole that formed in one eye, thought not to be clinically meaningful.\u00a0 There is also not enough emphasis that this is a short term (weeks to months) trial and that problems (or improvement)\u00a0may well develop after a delay. The story also did not mention the past history of deaths which have been associated with some gene therapy trials. \u00a0", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\nThe UroLift System provides an alternative to tissue removing surgery for the treatment of an enlarged prostate.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn about a range of adverse effects ranging from blood in the urine to incontinence. \u201cMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure,\u201d we are told.\nWe\u2019ll award a satisfactory grade here because the release at least mentions some adverse effects associated with the procedure. But as with the benefits description, we again receive no sense of what this is compared to (drugs? surgery? watchful waiting?), how common these problems were, or what the release means when it describes them as \u201cmild to moderate in severity.\u201d\nUpdate: This rating has been changed to Not Satisfactory in order to be consistent with how this criterion has been applied in the past. As stated in the description of our review criteria, a news release or story may be rated Not Satisfactory if it:\u00a0", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nAnother sleep specialist said the findings show \"some potential benefit\" from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.\nOverall, Herring's team found, people slept better with the drug, although the improvement was not dramatic.\nThe medication is not available yet, but the U.S. Food and Drug Administration is reviewing it for possible approval, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\n\u201cthere were no serious side effects in this study.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\u201d", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provides ample reporting on the potential harms of minimally invasive surgery (e.g., \u201cuneven leg lengths, broken hip bones, slightly off-kilter knee joints and pain in the knee because of hardened cement left in the wound\u201d).", "answer": 1}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nHowever, this strong benefit only applies to the first couple of years following surgery, Chinnadurai said.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story a satisfactory rating for including the following statements:\n\u201cAbout 3 percent of kids who undergo the procedure experience bleeding during the two-week recovery period, Hackett said. \u201cThough a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\u201d Chinnadurai said.\nThe story would have been stronger if it had named the risk of infection following surgery and that general anesthesia carries its own important risks.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWe won\u2019t hold this story to this criterion because neither the journal article on the test nor an accompanying commentary noted any adverse events. However, the story could have pointed out that a trial this small generally would miss all but the most common problems. Also, the story could have pointed out that until further evidence is developed, it is not know for certain how this type of intervention compares with alternatives. If it turns out that for some people this treatment is less effective than alternatives, then prescribing it would mean leaving them at greater risk of being harmed by insomnia.", "answer": 2}, {"article": "\"That's the main natural compound in unroasted coffee, and roasted coffee has much, much less of it than unprocessed coffee,\" Vinson said.\nLona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern in Dallas, cautioned that the study is short on specifics, making it difficult to draw any conclusions.\n\"That means that in the past, various weight-loss supplements have been found to contain weight-loss drugs or other drugs at higher doses than what would be allowed in a prescription dose,\" Sandon added.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nVinson said his team was not focused on the weight-loss impact of caffeine as much as that of unprocessed, unroasted coffee's primary ingredient: chlorogenic acid.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes a researcher who says weight loss in the study was achieved \u201cwithout side effects.\u201d That\u2019s not good enough \u2013 not without any acknowledgment that a 16-person study can\u2019t tell us very much about the adverse effects of any treatment.\nThe story does make the point that weight loss supplements are not necessarily tested for purity and have been found to contain undeclared ingredients in the past.\u00a0 Although we\u2019d like to see some more detail on what adverse effects might be cause by these spiked supplements (for example: kidney failure, heart problems, etc).\nThe LA Times\u2019 story, by comparison, quoted an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 0}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were few side effects and mostly \u201cmild.\u201d But what were they?\u00a0 And what does \u201cmild\u201d mean?\u00a0 After all, PMS has a range of symptoms as well.\u00a0 So did this story really help women think about the tradeoffs?\u00a0 Nonetheless, since the story at least mentioned harms, we\u2019ll give it the benefit of the doubt \u2013 barely.", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\n\"This means that even a widespread and common use tool like video games can promote brain plasticity and can aid in cognitive rehabilitation for people with neurological diseases, such as multiple sclerosis.\"\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While there are no obvious harms that would come from playing the video game/training program used in the study we think addressing harms is applicable for this news release, and there was no mention. It is possible that focusing on training in one part of brain function may lead to lack of attention in other parts, and this imbalance may result in relative gains and losses in brain activity that may have negative impacts in certain cognitive or functional areas. It may also be worth noting that harm may come from overuse. In a controlled setting like this study, overuse may be preventable. But what if this was available at home and the person could use it 24/7?", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nScheduled biopsies were performed two and four years after they entered the trial.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\nThe risk reduction was similar to that seen in an earlier large trial of Proscar, another drug in the chemical class known as 5-alpha-reductase inhibitors.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing and quantifying the potential harms of the drug, which are significant.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nThe intensity was about equivalent to walking slowly, said study author Robert Ross, a kinesiologist at Queen's University.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The high-intensity exercisers in this study had higher rates of musculoskeletal issues (cramping, strains, bone breaks \u2014 several of which required hospitalization) than other groups. Adverse effects caused more people to drop out of the study in the high-intensity group compared with the other groups. The story did not mention this.", "answer": 0}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most common side effects in the study were quantified for each Xyrem group. It also mentions the high potential for abuse and \"date rape drug\" association. While the story quotes a consultant to the drug manufacturer without support regarding the lesser abuse risks in narcolepsy, there\u2019s evidence in the literature, such as in this article, to support the anecdote.\u00a0\nIt would have been nice to read some of the important drug interactions that are possible with Xyrem. It has a boxed warning in its\u00a0prescribing information.", "answer": 1}, {"article": "We share our bodies with trillions of microbes that live on our skin, in our noses, in the gut.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have explained that the harms are unknown\u2013more testing must be done before a better understanding of the risks and benefits emerge.", "answer": 0}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nThe test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of potential harms of the liquid biopsy itself or of guiding chemotherapeutic treatment decisions based on results of the liquid biopsy.\nWhat about false positives? And false negatives? Erroneous results from a \u201csimple\u201d blood test could lead to a patient stopping the drug prematurely or initiating erroneously. Stories about screening tests must include the false positive and false negative rates for these reasons\u2013they are a real risk.", "answer": 0}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\nThe trial included patients who had suffered a stroke or a ministroke and those who were asymptomatic.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the LA Times coverage,\u00a0this story gives us the key\u00a0essentials regarding what happened to patients in both studies and their risk of major complications such as stroke or heart attack.", "answer": 1}, {"article": "The retina is the light-sensing nerve tissue at the back of the eye.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\nThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\nThis protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.\nWhen animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any potential harms from the procedure, although it appears to involve\u00a0piercing of the eyeball and injecting cells inside.\u00a0 It would also appear that the procedure requires\u00a0a small slice through the cornea to release pressure within the eye from adding the stem cells.\u00a0 And while the eye is well-known to be one of the fastest healing of our organs, any surgery involves potential risks.\u00a0 While the release does point out that the cells, as they multiply, form a kind of protective layer in the back of the eye, it does not mention \u2014 as the actual research paper does \u2014 that that layer may interfere with the supply of nutrients to cells in the eye, leading to their death.\u00a0 Nor does the release mention the potential problem of rejection of the foreign cells, which the research paper explains.", "answer": 0}, {"article": "Dr. Michael Schwartz is director of laparoscopy and minimally invasive surgery at North Shore-LIJ Health System in Lake Success, N.Y.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nIf used on people, the researchers claimed that the radiotracer might someday help doctors \"personalize\" treatment strategies for prostate cancer and better manage the disease.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said nothing about potential harms.\nMedline Plus reminds consumers:\nThe amount of radiation used in a PET scan is low. It is about the same amount of radiation as in most CT scans. Also, the radiation doesn\u2019t last for very long in your body.\nIt is possible, although very unlikely, to have an allergic reaction to the radioactive substance. Some people have pain, redness, or swelling at the injection site.\nHarms also emerge from false positive and false negative test results \u2013 which could lead to unnecessary treatment or undertreatment.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of treatment, i.e. increased risk of advanced prostate cancer and fatal prostate cancer were mentioned.\u00a0 However, the source article for this story included estimates of the frequency with which these normally occur, so the story could have included this information and provided a more informative picture.", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nDon't start popping lutein in supplement form based on these results, he noted.\nTUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nModeration is the key with kiwis or any food, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s an odd cautionary quote that even 3 kiwis a day \u201cdoesn\u2019t sound like moderation and I would caution against eating that much.\u201d\u00a0 But the story never explains why.\u00a0 Is there a harm?\u00a0 This point was just left hanging unexplained.\nHere\u2019s some of the explanation that could have been given.\u00a0 Kiwi is rich in potassium, which may be one of the ways it helps lower blood pressure. People with kidney disease or other metabolic disorders predisposing them to high potassium could get into trouble with high intake of the fruit (theoretically). See Medlineplus for information about potassium-rich diets.", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not addressed. That may be for reasons that we\u2019ll address under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted privacy and data security concerns near the top and expanded on them in the body of the piece. The story would have been more balanced if it had declared more strongly that while these apps could be helpful, until studies are done, it is also just as possible that they could be useless or even harmful in ways that were not discussed in the story, such as diverting patients from proven interventions.", "answer": 1}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nThese analyses with tramiprosate in the APOE4 subgroups are compelling, and suggest a meaningful clinical benefit, on top of the existing symptomatic AD treatments, in Alzheimer's patients who are in great need of new treatments.\nThe results published in JPAD are the first evidence from a large clinical trial to associate efficacy of an amyloid-targeted agent with APOE4 status in AD patients.\nThe safety profile of tramiprosate in 2,025 AD patients across the two studies was favorable and similar in the APOE4 carriers and non-carriers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contained enough detail about safety issues to give it a satisfactory when it noted: \u201cThe safety profile of tramiprosate in 2,025 AD patients across the two studies was favorable and similar in the APOE4 carriers and non-carriers. The main adverse events were gastrointestinal (nausea, vomiting and weight loss), which were mild or moderate in severity.\u201d\nWe would have liked more discussion of how patients might use the drug and whether there are any other harms that could loom from treatment.", "answer": 1}, {"article": "On the flip side, a low-risk score \"doesn't give you a free pass,\" he added.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nThey estimated that up to 25 million Americans may have triple the average person's risk for coronary artery disease even if they haven't yet developed warning signs like high cholesterol.\nResearchers say a new way of analyzing genetic test data may one day help identify people at high risk of having a heart attack at a young age in time to help.\nThe scoring system can also predict an increased risk of Type 2 diabetes, inflammatory bowel disease, breast cancer and an irregular heartbeat called atrial fibrillation, the team reported in the journal Nature Genetics \u2014 noting that next steps include learning what might likewise lower those risks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention in the story about possible false positives or false negatives although both represent considerable concerns for individuals. False positives can cause patients unnecessary concern\u00a0while false negatives may embolden persons to be careless in controlling other risk factors that can lead to disease.\nFor example, people with a high score may want to take cholesterol-lowering medications, which will have costs and potential side effects, without knowing whether they are effective. There also can be psychological harms of telling someone that that they have a high risk for cardiovascular disease or other diseases.", "answer": 0}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from the use of tamsulosin mentioned in the news release, although a simple web search reveals a host of minor side effects \u2014 drowsiness, dizziness, blurred vision, lightheadedness, fainting, back pain, cough, decreased sexual ability, diarrhea, headache, runny or stuffy nose, sinus inflammation, trouble sleeping, or weakness \u2014 and possible severe side effects including severe allergic reactions, chest pain or irregular heartbeat, fever or chills, or other conditions.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nCAVEATS Most participants were white.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nMight fish consumption help the brain, too?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of eating fish are not in question \u2013 although the story could have mentioned concerns with mercury in some fish at some levels of consumption.", "answer": 2}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\nConducted in collaboration with Partnership for Health Analytic Research, this prospective study analyzed 115 patients from 10 cancer centers in the United States.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release emphasizes the potential beneficial effect of test results on refinement of treatment recommendations. It doesn\u2019t contemplate or even mention the possibility that an inaccurate test result could cause harm \u2014 for instance by recommending a conservative course of therapy when a more aggressive approach is warranted, or vice-versa. While the study itself didn\u2019t assess outcomes or potential for harm, as with Benefits we\u2019d expect some nod to the fact that this is an area of uncertainty that requires more research.", "answer": 0}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\n\"Prevention of fibrosis will extend the ability of the heart to function, even if at a reduced capacity.\nOnce that occurs, the team hopes to work with cardiologists to quickly move the research into clinical trials, involving chemotherapy and heart transplant patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The research paper does not include any statement about potential toxicity other than to point out that none of the 162 mice died prior to the conclusion of the study. The release is silent on the issue. A\u00a0few words about the potential toxicity (or the absence of risk if that\u2019s the case) of TUDCA which is commercially available and has been studied\u00a0for the treatment of biliary cirrhosis would have been in order.", "answer": 0}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly lays out some of the ways that testing can go awry. It reports that the CT scans expose people to about the same amount of radiation as a mammogram, implying a level that many people routinely accept, though it does not go into detail about potential radiation effects. The story also explains the risk of \u201cincidentalomas\u201d, things that can pop up on this sort of scan besides coronary artery calcium, such as nodules in lungs, that might lead a person down a path of further testing and treatment. And it spells out the potential consequences of having a scan that reveals high levels of calcium deposits, prompting further testing and treatments, perhaps leading to substantial harms.Overall, we think the harms are admirably covered.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nIn low-risk patients, the cancer control rates was superior to historical controls.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nActuarial five-year nadir+2 RFS was 97.1 percent for all patients, representing 97.3 percent of low-risk and 97.1 of intermediate-risk patients.\nBiochemical failure was assessed using the ASTRO-consensus and the nadir+2 definitions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that between half and two-thirds of patients experienced low, \u201cusually temporary\u201d rates of toxicities. It also notes that \u201cfewer than 2 percent of patients experienced severe toxicities in their gastrointestinal, reproductive, and urinary systems, and no patients reported life-threatening or fatal toxicity.\u201d A few more details here would be helpful. For example, how many patients experienced a decline in urinary or sexual function, and for what period of time? And what are other potential risks of radiation therapy? The real question is how do these harms compare to other treatments? That was not assessed in this study.", "answer": 1}, {"article": "It's the No.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nAll used the product for three months, for a total of 23,000 doses.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, this was the most complete story of the three reviewed in discussing side effects: \n\"A total of 6.1% of the men and 6.7% of their partners suffered at least one side effect. In men, the most frequent side effect was loss of erection; it occurred at least once in 3.1% of men. In the partners, the most frequent side effect was burning in the vulvovaginal area; 5% of women reported it at least once.\"", "answer": 1}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\n\"But [after several weeks of treatment], the cream made them look and feel better,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that women experienced no side effects from the cream.", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says up high that patients who fell outside the guidelines had a \u201chigher risk of dying in the hospital and of complications from the implantation.\u201d But there are no numbers provided. In fact, there are more percentages provided in this story about the stock prices of the various device makers involved than there are about the harms or benefits. This is the Wall Street Journal, of course, but we still thought some additional numbers about harms or benefits would have been helpful to any reader.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nThe potential market is huge: It\u2019s estimated that 50 million Americans have allergies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Particularly for the new-style food-desensitization therapies under development, the article explains potential (and even deadly) risks associated with them and it alludes to some of the downsides of immunotherapies (\u201callergy shots,\u201d for instance) that can take months or years to work. But it says essentially nothing about the potential or actual adverse effects of a DNA vaccine under development, noting only that it \u201chypothetically decreases the risk for adverse events.\u201d", "answer": 1}, {"article": "HDL cholesterol is not fully understood, but essentially sucks cholesterol out of cells, to be flushed from the body through the liver.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nThe study was sponsored by Merck, the drug\u2019s manufacturer.\nPeople who can\u2019t control cholesterol with diet, exercise and statin drugs could soon have a new option.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nReaders of this story are likely to conclude that anacetrapib is safe. They aren\u2019t told that what the researchers actually reported is that based on their statistical analysis, they are at least 94 percent sure that the drug doesn\u2019t cause the 25 percent increase in cardiovascular events that was seen in experiments with a similar drug, torcetrapib. That \u201cpromising\u201d drug was yanked from testing.\nThe story did report the dangerous turn taken in trials of torcetrapib, but it could have done a better job of explaining to readers that while researchers breathed a sigh of relief that the same sort of hazards weren\u2019t seen in this trial of anacetrapib, the safety picture is still only short-term and sketchy.", "answer": 0}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\nBudd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss harms. There don\u2019t appear to be any particular health risks associated with the use of underwater treadmills that wouldn\u2019t apply to beginning any exercise or rehabilitation regime \u2014 but that\u2019s actually a point worth making.\nHowever, exercising in a pool poses risks of its own \u2014 particularly for patients who may be recovering from surgery or stroke. As a result, it would be wise\u00a0to explain that these patients (or any patient who is not confident in the water) should have\u00a0supervision. And, this therapy may induce anxiety among people who can\u2019t swim or are anxious around water.", "answer": 0}, {"article": "\"Being impotent is no fun.\"\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\n\"The first importance of the trial is that it shows hepatic [liver] targeting of hormonal action,\" Ladenson said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that the drug \" did not cause the feared side effects on the heart and other organs that have plagued similar thyroid-based treatments.\" But can these side effects be expected to show up in a small, short-term trial? \nNonetheless, because of the strength of the concluding comments by the independent expert \u2013 \"But if there is one thing we\u2019ve learned about drugs in this arena, it\u2019s that we need large trials to see how they measure up in terms of risk and benefit\u2026I\u2019m not sure I\u2019d want to sign up for that one before I had longer-term results. Being impotent is no fun.\"- we\u2019ll give this story the benefit of the doubt.\u00a0", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the potential side effects associated with daily use of a nonsteroidal anti-inflammatory drug. Potential harms of ibuprofen taken for years can be substantial and include increased risk of stroke, heart attack, gastrointestinal bleeding and kidney disease.\nNo mention is made of the potential harms associated with either false-positive, or false-negative, tests for Abeta42.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nUse of Noctiva should be discontinued temporarily in patients with certain nasal conditions such as colds or allergies until those conditions have resolved.\nAlthough there are other FDA-approved medications that also contain desmopressin, none of those medications are approved to treat nocturia.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does well describing harms, providing extensive details on adverse effects, particularly warning that Noctiva can cause a potentially life-threatening drop in blood sodium and shouldn\u2019t be used by those at risk for that condition. The release says the drug will come with a boxed warning and a Medication Guide to draw attention to the risk. It also lists the most common side effects: nasal discomfort, cold symptoms, nasal congestion, sneezing, high or increased blood pressure, back pain, nose bleeds, bronchitis and dizziness.\nIt cautions against use in pregnant women and children as well as patients with symptomatic congestive heart failure or uncontrolled hypertension and patients with certain nasal conditions such as colds or allergies.\nWe would have liked to see the news release mention that 4 percent of patients in the trials stopped therapy due to adverse events. Also, an FDA document expressed concern that the drug could mask symptoms of underlying conditions, which was only alluded to in the news release with an advisory that doctors treat underlying conditions that could cause frequent urination.", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nCircumcision, of course, removes this protective environment.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of circumcision, such as pain, are not discussed.", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\nIt requires destruction of a patient\u2019s own bone marrow \u2014 itself a harrowing process \u2014 and then a transplant from a donor who has a near-exact blood and immune system type.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that bone marrow transplants are risky and in fact , \u201c\u2026can kill people.\u201d But it should have told readers that for some types of leukemia, up to 40 percent of patients die have receiving a bone marrow transplant from a donor. What\u2019s more the list of serious complications is harrowing. According to the National Cancer Institute, leukemia patients treated with a bone marrow transplant may have less than a 50-50 chance of successful treatment and even when the treatment works, it is often very painful and may cause serious to kidneys, liver, heart and lungs. So even though this story does tell readers that transplants are risky, it fails to provide numbers that would make clear just how perilous this course of treatment is.", "answer": 0}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions blood clots, stroke and breast cancer as potential harms of hormone therapy. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms of treatments mentioned. The article mentions in a general way that \u201cimpotence and incontinence are common following surgery to remove the prostate\u2026\u201d Yet presenting one person\u2019s very rosy experience with the new technology\u2013\u2026\u201dhad no difficulty with either incontinence or impotence\u201d\u2013seems unbalancing. ", "answer": 0}, {"article": "The machine, which is made by the Bedford company Hologic and developed partly at MGH under Rafferty\u2019s supervision, produces images that are so vivid and clear they seem to speak out loud: \u201cHey, right here!\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\nIf that sounds unimpressive, consider that 39 million women are screened each year; any significant reduction in callbacks for additional testing would mean hundreds of thousands of women would be spared painful, and expensive, follow-up.\nTrials like this are the gold standard of medical evidence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author does mention that a woman who has both 2-D and 3-D imaging, the protocol with the most benefit, would receive twice the radiation of 2-D imaging alone.\u00a0 While this is still under the FDA\u2019s permitted limit, the piece should also mention that patients need to consider\u00a0total radiation exposure from increased use of all high-tech diagnostic imaging equipment.\nIn addition to providing no evidence of improved sensitivity and specificity of 3-D imaging, the piece doesn\u2019t even mention the possibility of over-diagnosis and over-treatment of very early stage breast cancers that may never have needed treatment.\u00a0 Thus a woman may be harmed physically, emotionally\u00a0and financially because of over-treatment.", "answer": 0}, {"article": "\u201cDiet is a complicated business,\u201d he said.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cIf the goal is to prevent hypertension\u201d with lower sodium consumption, said the lead author, Dr. Jan A. Staessen, a professor of medicine at the University of Leuven, in Belgium, \u201cthis study shows it does not work.\u201d\n\nBut among the study\u2019s other problems, Dr. Briss said, its subjects who seemed to consume the smallest amount of sodium also provided less urine than those consuming more, an indication that they might not have collected all of their urine in an 24-hour period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of this story was avoiding harm by eating too much (or too little) salt. \u201cThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\u00a0And while those eating the most salt had, on average, a slight increase in systolic blood pressure \u2014 a 1.71-millimeter increase in pressure for each 2.5-gram increase in sodium per day \u2014 they were no more likely to develop hypertension.\u201d It does a great job presenting the numbers in absolute terms.", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\nHe also points out that both drugs do have side effects so patients have to be monitored.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a single word about potential harms, as opposed to a New York Times story, which described \u2013 variously for the two drugs:\nAgain, is this not worthy of at least a line?", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to\u00a0point out\u00a0that in terms of serious side effects (renal, cardiovascular, or cerebrovascular events), or of people discontinuing treatment because of side effects \u2013 there was no difference between those being treated or those who received the placebo.\u00a0 The story neglected to discuss the side effects commonly seen in the study participants given the treatment; there was a higher incidence of fever and musculoskeletal pain in those infused with the drug.\u00a0 \n\u00a0", "answer": 0}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\nThe results of the new study are published online in Tobacco Control.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe findings are at odds with clinical trials, Connolly says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\nDr. Lon S. Schneider, director of the state of California's Alzheimer's Disease Research and Clinical Center at the University of Southern California, Los Angeles, said that these findings were \"straightforward and expected.\"\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the study found that ginkgo was safe and no serious side effects were noted. But it could have noted that the National Center for Complementary and Alternative Medicine states that \"Side effects of ginkgo may include headache, nausea, gastrointestinal upset, diarrhea, dizziness, or allergic skin reactions. More severe allergic reactions have occasionally been reported.\" ", "answer": 1}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\nA study of more than 60,000 adults in England and Scotland found that \u201cweekend warriors\u201d lowered their risk of death by a similar margin to those who spread the same amount of exercise over the whole week.\nUlf Ekelund at the Norwegian School of Sport Sciences in Oslo said the study emphasised what researchers have found time and again: that even a small amount of regular exercise wards off death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit the story does provide some information on the potential harms before embarking on a \u201cweekend warrior\u201d status. \u00a0The lead author of the paper recommended, \u201c\u2026\u00a0to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury. \u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise.\u201d", "answer": 1}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nScientists have uncovered various markers that can be used to detect the cancer through a blood test, but those have been too unreliable to recommend widespread screening.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the story neglect to mention harms, it asserts that the still-to-be-developed test is 100 percent accurate. But as the competing stories on this study pointed out, that figure is based on testing in a very small number of people under favorable conditions. We now know from many decades of increased use of screening tests that these tests are fallible and there\u2019s no reason to to expect a new test would not offer up false positives and negatives when used in a broader population. Inconclusive and incorrect tests can lead to more invasive tests, increased patient anxiety and expensive and debilitating surgeries.", "answer": 0}, {"article": "\u201cIt\u2019s purely inertia\u201d that prevents a change, he said.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nSome doctors are hoping the results will persuade more hospitals to switch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this study is all about safety, we think the story should have provided more detail on the known harms of saline vs balanced fluids. The AP story does mention the kidney disease risk with saline, but doesn\u2019t explore why physicians might be leery to use balanced fluids. As CNN explained:", "answer": 0}, {"article": "\"We found comparable detection between self-collection and physician-collection,\" Des Marais said.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\nOffering HPV testing using self-collection by mail has a lot of potential to reach women who are the highest risk of being screened: those who don't access regular medical care.\"\nFor the study, researchers mailed at-home, self-collection kits to low-income women in North Carolina who were overdue for screening by national guidelines.\nResearchers provided study participants with self-collection brushes along with instructions for how to take a sample from inside the vagina.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address two key potential harms, namely the failure to identify someone who has high-risk HPV, and the \u201cfalse positive\u201d misdiagnosis of people who did not have high-risk HPV. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d\u00a0It\u2019s particularly relevant in this instance because HPV screening has a track record of problems with both specificity and sensitivity\u2014 and because the release itself makes clear that there were people diagnosed as at high risk in some of the screening tests, but not others. Missing someone who is at high risk is clearly problematic. But being told that one faces significant medical risks that one does not actually face can also have ramifications for future healthcare, with consequences both physical and financial.\nAnother potential harm could be having a certain rate of patients sending in the test but not following up, leaving clinicians with positive tests and patients lost to follow up which would skew the impact of the screening effort.", "answer": 0}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point out that a woman would be expected to suffer from post-menopausal symptoms after removal of her ovaries and that treatments are available. \u00a0However, no information is provided about the potential harms related to the surgical procedure.", "answer": 1}, {"article": "March 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, Virginia, screening tests do have potential harms. If we\u2019re ready to raise the possibility of benefits of a hypothetical test, we need to raise the equally unknown possibilities of false positives and false negatives. The authors do not address the risk that follows from misclassification of non-high-risk patients as high risk. These risks include exposure to unnecessary medical interventions, difficulties getting insurance, and other potential impacts on the way they plan their lives.", "answer": 0}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The results of this study support forgoing routine axillary (armpit)\u00a0sentinel lymph node biopsy to evaluate for cancer spread in cases where the invasive breast cancer is less than 1mm in size.\nA potential harm of this approach is missing metastatic cancer. This is not mentioned in the release.\nApropos of this, how long the patients were followed (the mean follow-up was 4.6 years, according to the published study) is a key piece of information and was also not included in the release.", "answer": 0}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nMenlo Park, California-based Asterias expects to release complete safety data from the first half of the study later in the year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "AST OPC-1 just completed its phase 1/2a clinical trial, which essentially evaluates the safety of the therapy. The three patients in the trial have not shown any serious adverse events, and the story reports this. However, we think the story could made it clearer that that is very early data, and that harms resulting from the therapy remain to be seen. This is the first stage of a three-step dose escalation trial and the dose used was the lowest envisioned. It\u2019s certainly possible that adverse events not seen at a low dose will occur more frequently with a higher dose of the therapy.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story has many levels of harm to cover, and it does so in Satisfactory fashion. First, it identifies that a recent study published in JAMA of 309 cases of the use of the Lariat device showed urgent follow-up required in seven patients \u2013 2.3 percent of the cases, and one death. Second, the story explains how and why some physicians choose to use a device off-label, not for a purpose identified at the time of its limited approval by the FDA. One of the physicians calls this a \u201cregulatory loophole\u201d and the JAMA study recommends further research before other doctors use the Lariat device for this purpose.\nOur wish list for this story would have included some yardstick or context to help us understand these harms. How often would patients getting some alternative to the Lariat be expected to have a bad outcome? And in any group of\u00a0309 sick old people with failing hearts, how many bad outcomes should you expect, no matter what device is used? Another missing piece is one of the timing of the harms. Presumably these reports refer to short-term complications, most commonly within 30 days of the procedure, that can most directly be attributable to the device and/or its placement. What isn\u2019t mentioned and warrants comment is that these devices are meant to make permanent changes. And we really don\u2019t know what the long-term issues are with such devices.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that taking cranberries as a health supplement is \u201clow risk.\u201d And that\u2019s true. But that doesn\u2019t mean that it\u2019s no risk. For example, the University of Maryland notes that one of the chemicals found in cranberries can increase the risk of kidney stones for some people \u2014 that\u2019s valuable information for readers who have a history of kidney stones. Even if the harms are minimal, it is important to note that fact explicitly.\u00a0", "answer": 0}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It is ludicrous to simply report \u201cThere were no serious side effects\u201d when the only data you\u2019ve reported is two hours of observation of healthy volunteers!\nFirst, were there ANY side effects?\u00a0 If so, what?\nSecond, how many people with diseased arteries (not healthy volunteers) would have to be treated and followed for how long in order to be able to say ANYTHING meaningful about side effects?", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss adverse events related to yoga or intensive stretching. Yet the authors of the study reported on both. These are important issues, as many patients with chronic back pain fear that becoming physically active will exacerbate their symptoms.\n\n\n\n ", "answer": 0}, {"article": "Friedman, who is now 70 and lives in Los Angeles, lost 175 pounds.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\nSo Friedman opted for a less invasive procedure to make her stomach smaller again.\nThere are no significant side effects to the surgery, and patients can return to work the day after they have the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects should be clearly stated. The randomized study notes that the majority of people who had the surgery (including, interestingly, those who underwent a sham procedure) had side effects including nausea and vomiting. The story states simply that there were \u201cno significant side effects.\u201d", "answer": 0}, {"article": "For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nNone of the patients in the HF10 therapy group experienced paresthesia.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nIdentifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these complex patients.\nHF10 therapy also provides pain relief without paresthesia \u2013 a stimulation-induced sensation commonly perceived as tingling or buzzing, which masks a patient\u2019s perception of pain \u2013 typical of traditional SCS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms except to note that the high-frequency group had no paresthesia. The study that\u2019s the basis for the release noted that \u201cnon-serious\u201d study-related adverse events occurred in about 30% of patients in both groups. These included implant site pain and lead migration resulting in \u201csurgical\u00a0revision\u201d (i.e. a second operation). But that begs the question: How can a second surgery be considered \u201cnon-serious\u201d?", "answer": 0}, {"article": "\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nBetter yet, the drug, fexaramine, works only in the intestine, never entering the bloodstream.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story passes along a claim that this drug would be safer than other treatments. This is irresponsible. Since the drug has yet to be tested in people, it is impossible to know what potential harms might be found later.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nArmed with new knowledge about how neurodegenerative diseases alter brain structures, increasing numbers of neurologists, psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThese imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.\nIt is estimated that as many as 3 million cases of Alzheimer's dementia worldwide can be prevented with as little as a 10% reduction in the burden of preventable lifestyle.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Procedures almost always carry risks, and MRI is no exception. Some physicians are concerned with \u201cMRI abuse,\u201d pointing out that MRIs often pick up abnormal \u2013 but harmless \u2013 findings that muddy up the clinical picture. These so-called \u201cincidentalomas\u201d can lead to more tests and treatments that cause harm and add to costs. Unnecessary imaging is a major contributor to spiraling health care costs in the US, since a single scan on average in the US costs $2,611, according to Medicare data.", "answer": 0}, {"article": "The 54-year-old said: \"I knew straight away that I had been given the drug.\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s particularly important to note side effects associated with new medications but the release makes no mention of any harms arising from the drug\u2019s use in the study. However, the full research paper (which unfortunately is behind a paywall) includes a table of adverse events experienced by both the experimental group and patients receiving a placebo that include problems such as infections, respiratory disorders, gastrointestinal and nervous system disorders. While these may ultimately have been minor problems, they deserve mentioning.", "answer": 0}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\nA new review of research on the link between lifestyle factors, like coffee and tea consumption, and diabetes risk suggests that drinking regular or decaffeinated coffee and tea all lower the risk of type 2 diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of the potential harms of drinking large quantities of coffee or tea.\u00a0 ", "answer": 0}, {"article": "2.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\n(Wender doesn\u2019t recommend the OTC tests that are available.)\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\nBecause although colonoscopy certainly has its advantages, direct evidence that it\u2019s the best way to prevent deaths from colorectal cancer is not one of them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a Satisfactory rating here since it does mention that with colonoscopy, there\u2019s \u201ca small but real risk of harm, such as a perforation\u201d from the screening test.\nBut, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues.\u00a0 We would have liked the story even better had it mentioned these factors.\u00a0 \u00a0", "answer": 1}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story rightly points out that there are few drawbacks to adopting a healthy lifestyle.", "answer": 1}, {"article": "She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nDr. Eric P. Winer, chief of women\u2019s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nAbout 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantified the risk of endometrial cancer and pulmonary blood clots.\nThis was the only one of the three stories that we reviewed that picked up on the high dropout rate in the study \u2013 an important addition:\n\u201cIn the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\u201d\n\u00a0", "answer": 1}, {"article": "Robotic surgery replaces a surgeon\u2019s hands with ultra-precise tools at the ends of mechanical arms, all operated by the surgeon from a console.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nHu and his team analyzed surgery data from a national government database to see if the costlier robotic surgeries were cost effective with extra benefits over older techniques.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits criterion above, the details provided were adequate.", "answer": 1}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of any potential harms associated with increasing the time periods between eating and decreasing overall calorie consumption. The\u00a0mean duration of nighttime fasting in the study was 12 hours, with discussion of \u201ceach three hour increase in nighttime fasting\u201d being associated with a lower glucose level. \u00a0It makes one wonder \u2013 but the release doesn\u2019t address this \u2013 just how long some women in the study fasted.", "answer": 0}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no risks mentioned for the lollipop device or for the ingredients but we give them a pass on this criteria since harms appear minimal. It\u2019s worth noting that there can be a harm if persistent ear pain that is not resolved by use of the lollipop is not given medical attention.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\nAnother measure, specificity, rules in disease with a high degree of confidence.\nThe new study looked at a highly sensitive type of troponin I test that may be more accurate in less time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Since the sensitivity and specificity of the new test was not quantified, the story provided only a glowing report of progress \u2013 of benefit.\u00a0 There was no discussion of potential harms.\nMost physicians and most organizations would frown on making a diagnosis of a heart attack based simply on a blood test.\u00a0 Up To Date, an authoritative resource suggests that patients with a suspicion of having a heart attack have an electrocardiogram, undergo a brief medical history, have a physical examination and have blood drawn for biologic markers.\u00a0 The story suggests that this new blood test can be used alone to make the diagnosis or rule it out.\u00a0 Exaggerating the benefits of a test without placing it into the context provides the readers with a false impression of the test and its utility.\u00a0 Making decisions on the basis of a single blood test could lead to patient harm.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\n\"The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action.\"\n\"With recent research indicating most babies born after 1980 do not acquire Bifidobacterium at birth, our ability to detect significant levels of Bifidobacterium gives pediatricians and parents an immediate indication of whether or not their baby has this beneficial gut bacteria that set them up for lifelong health.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The test itself is described as \u201cquick and non-invasive.\u201d However, the release transitions to the Evivo probiotic product, which is a live culture of Bifidobacterium\u00a0bacteria that\u2019s designed to augment such microbes in a baby\u2019s gut. There are no potential harms discussed here.\nHowever, the CDC\u2019s website states about probiotics (generally): \u201cIn healthy people, probiotics usually have only minor side effects, if any. However, in people with underlying health problems (for example, weakened immune systems), serious complications such as infections have occasionally been reported.\u201d", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any possible harms of treatment. Specifically, it would be important to mention that in new spine injuries with fractures, there can be instability that needs to be treated first. Mobilization activities such as these could be harmful in that situation.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The risk of harm in elective c-sections is the focus of the study, and the news report explains them well. ", "answer": 1}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\nThis poor prognosis is partially due to the fact that most patients are not diagnosed until they are already at a late stage of the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that \u201cthe most common side-effects reported were fatigue, nausea, loss of appetite, and dry mouth,\u201d but we have no idea of magnitude of those effects or whether more serious, less common effects may have occurred.\nThe study reported that 64% of the patients had a treatment related adverse effect, but this wasn\u2019t mentioned in the news release. Side effects directly relate to quality of life and could be a deal-breaker for many patients. \nWe\u2019ve outlined some of the common challenges in writing about harms from immunotherapy drugs in this guide for journalists.", "answer": 1}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nOMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nPrevious studies have also shown that OMT can improve the efficacy of antibiotics in pneumonia patients.\n\"This study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia.\"\nThe study results published in The Journal of the American Osteopathic Association.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it\u2019s commonly accepted that osteopathic manipulation is \u201charmless,\u201d the release should have addressed any potential complications, discomforts, cost issues or other side effects.", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have stated more explicitly the significant potential downsides (clinical and financial) of mass use of primary thrombocytosis screening, and even the harm that can potentially occur when an \u201cincidental\u201d finding of elevated platelet levels must be further investigated in the absence of other cancer risk factors or symptoms. It could raise anxiety levels of people who may have elevated platelet counts due to other reasons or younger people feeling they need to be tested because the results by age weren\u2019t mentioned.", "answer": 0}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not address potential harms. This study did not report adverse events, but the clinical trial that led to approval of the vaccine reported more than a third of participants had redness and pain after getting a shot. Although the original clinical trial (partially funded by the vaccine maker) concluded that adverse events were generally mild, the story still should have addressed this point.\u00a0 ", "answer": 0}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a news story can speculate about \u201cearly potential\u201d benefits in a headline from such early laboratory results, it can also speculate about potential harms from the pathway this proposed intervention takes.\nWhat could go wrong with this approach?\nWhat will scientists be concerned about as they move into clinical trials?\nThe story talks only about potential benefits.\u00a0 There are always potential harms on the horizon.", "answer": 0}, {"article": "\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure,\u201d he says.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nThe case study is published in the Jan. 25 issue of Neurology.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A tough call here. While the report is much more detailed than HealthDay about the potential risks of treatment, it features a clumsily worded quote from an expert who calls the risks of this surgery \u201ctiny, but important.\u201d\u00a0The use of the word \u201ctiny\u201d here tends to minimize the risks associated with the\u00a0procedure, which can be very serious.\u00a0A 2% risk of stroke\u00a0in patients undergoing the procedure (as reported on this UCSF Dept of Neurosurgery\u00a0FAQ about DBS) strikes us as\u00a0somewhat\u00a0more than \u201ctiny.\u201d", "answer": 0}, {"article": "Will they be habit forming?\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nIn each case, the minimum dose to achieve sleep was compared with the minimum dose that altered memory and thinking.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag.\nWhile the study did not examine the effects of DORA-22 in any detail it did in fact look at level of cognition in the animals studied.\u00a0 While the story notes, \u201cDORA-22 did not lead to the same mental impairments as the other three drugs. Rhesus monkeys and rats performed just as well on memory and attention tasks shortly after being administered DORA-22 as they did on an inactive placebo,\u201d it fails to note that cognition was impaired at higher doses.\u00a0 This is a major error in interpretation of the study results.\nAlthough we would prefer to see potential harms mentioned as high up in stories as potential benefits, this story does highlight questions about harms at the end, so at least those who read the whole story are alerted to the many unknowns.\nBecause of that ending, we\u2019ll give it the benefit of the doubt and grade it satisfactory on this criterion.\n\u00a0", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The extra olive oil consumed by participants amounts to more than 500 kcal per day, which could cause weight gain if not balanced by a similar reduction in other food intake. Weight effects weren\u2019t reported here and may not have been a problem in this study. But these were Spaniards already accustomed to consuming a lot of olive oil, vegetables, fruits, and legumes. We don\u2019t know if adding a lot of olive oil to the diets of Americans would yield the same results.\nBut the story makes no mention of this or other possible harms linked to the diet. If there really are none, that would have been nice to know and would have strengthened the story.\nSo too would have been a discussion of why, according to the study, more than 25% of the 447 participants \u201crefused to undergo a second procedure or abandoned the study for different reasons.\u201d", "answer": 0}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nThe study, in the Annals of Internal Medicine, argues that current medical guidelines haven't adequately considered the risks from these widely used drugs.\nHe notes that physician guidelines don't generally compare the relative value of these drugs, which are all available as inexpensive generics.\nPuhan says, based on his assessment, perhaps 15 to 20 percent of older adults should be taking statins \u2013 far less than the 30 or 40 percent suggested by current medical guidelines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a service by highlighting the harms of statins. It explains: \u201cThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines. People taking statins are also at a higher risk of developing diabetes, which is harder to reverse.\u201d\nIt also mentions the potential for overtreatment with the use of coronary calcium scans.\nHowever, we wish it had included absolute numbers. The story says harms are \u201cuncommon,\u201d but provides no data to back that up.\nRates of adverse effects with statins have been measured at 1 to 10%, which makes them \u201ccommon\u201d in the definition of the European Medicines Agency. Also noteworthy is that some contend that adverse effects of statins have not been reliably reported.", "answer": 1}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nIt revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.\nGrob\u2019s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nUsing next generation sequencing and integrative bioinformatics they found that serum exosome micro-RNA profiles not only distinguish MS from healthy controls, but also distinguish relapsing-remitting MS (RRMS) from progressive MS with high accuracy.\nMS is a chronic disease, so current diagnostic and monitoring tests are costly and still have limited utility to discriminate between different stages of the disease.\nA breakthrough study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with Multiple Sclerosis (MS) that could become definitive diagnostic biomarkers of the world's most common neurologic disability in young adults.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The possible debits of this blood test\u2014false positives and false negatives, for example\u2014are not broached. These are very likely to occur in a larger group of subjects.", "answer": 0}, {"article": "Her back hurts, and surgeons have replaced her left knee once and her right hip twice.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nOccasionally, other conditions must be addressed in addition to joint damage.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\n\"Some of the newer implant designs save a lot of the bone stock,\" said Collins, who performs about 10 wrist replacements a year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions a single disadvantage of the operation\u2014that patients can\u2019t lift heavy objects. But any patient undergoing joint replacement faces potential complications such as infection. In one recent study, 52% of patients had a complication after wrist replacement and 44% reported pain one to five years after surgery. (J Hand Surg [Am]. 2003;28:570-6). There is also the possibility of undergoing a second operation for fusion if the implant fails\u2014a risk that persists with newer implant designs as well as old ones. The article does not cite a source for the projected 10- to 15-year life of the device.", "answer": 0}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study was designed to determine if there is an\u00a0association between treatment for ED and death or cardiovascular outcomes after a first heart attack. Other side effects more commonly seen were not measured.\nWe\u2019d still like to see at least some mention of the common harms from ED drugs in a news release distributed to a wide audience, particularly one that touts its safety and potential benefits.", "answer": 0}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nA woman using Essure must do a test to confirm that the device is properly placed within three months of the procedure and until she receives a confirmation from her doctor, she must use alternate birth control methods, Bayer said in a statement on Wednesday.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of TVU are not addressed. Unlike the HSG, TVU does not emit ionizing radiation, which could potentially make it safer. However, some women do not tolerate TVU, which can last 45 minutes long, well. In addition, as the news release (but not the Reuters story) acknowledged, some women experience spotting or infection following a TVU test.", "answer": 0}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\nDr. Catherine Kwik-Uribe, human health and nutrition director at Mars, Incorporated, and co-author on this latest study, said, \"Since the brain is a heavily vascularized tissue, we might also be looking at vascular improvements as underlying the observed improvements in cognitive function.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms, potential or actual, in the release. Our main concern is that consumers will think these findings apply to your typical chocolate candy bar, which is full of sugar and fat. While the release notes dryly that commercially available chocolate, \u201cgiven its macronutrient profile \u2026 is not recommended as a health food,\u201d we don\u2019t think many readers will find this caveat that\u2019s buried in an editor\u2019s note at the end of the release. And even if they do, they might not understand what it\u2019s getting at.", "answer": 0}, {"article": "Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nSelvin's group analyzed that data, and reported that a positive result for glucose and HbA1c from just a single blood sample can confirm type 2 diabetes.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\n\"Diabetes moves fast, and the cost of diabetes has increased more than 20 percent since 2012,\" noted Dr. Robert Courgi.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story would have benefited from an exploration of the harms of overdiagnosis and overtreatment. Many of the patients who tested positive in both tests didn\u2019t develop diabetes until a decade or two later. Potentially, patients like that could be treated overly aggressively with drugs that could do them harm.\nLikewise, an accompanying editorial notes that the criteria proposed by the study might miss more people with diabetes than the conventional method of repeated blood glucose tests. In the data studied, simultaneous A1C and blood glucose tests agreed only about 40% of the time, versus 70% agreement for successive blood sugar tests.", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nScientists aren't sure what biological mechanism could explain how acupuncture might relieve pain, but the authors of the new study say the results suggest there's more involved than just a placebo effect.\nAcupuncture skeptic Dr. Stephen Barrett said the study results are dubious.\nThe researchers concluded that the needle remedy worked better than usual pain treatment and slightly better than fake acupuncture.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says acupuncture is \u201crelatively safe,\u201d but doesn\u2019t specify that safety can be improved by selecting licensed\u00a0practitioners. It also does not mention\u00a0that acupuncture is associated with rare reports of serious adverse events, most of which seem to occur with unqualified practitioners.", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of triggering a manic episode and reports (accurately) that there was no observed difference in the groups studied. The story could have gone further and discussed common harms from antidepressants stacked up against this finding of no benefit \u2013 strong incentive to stop giving antidepressants for bipolar disorder.", "answer": 1}, {"article": "The Centers for Disease Control and Prevention estimates there are 300,000 sports concussions among children each year.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nHe wants her to avoid exerting herself, physically and mentally, because a \"bump on the head\" is a lot more dangerous than it sounds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe broadcast does not mention potential harms of using the Impact system. Testing could cause an athlete needless anxiety. Unnecessarily withholding an athlete from play increases inactivity and the risk of depression. It is unclear who owns the sensitive information and how it is protected.\u00a0 And it is unclear whether the recommendation to wear headgear might make head-to-head collisions more dangerous for other players. \n", "answer": 0}, {"article": "You\u2019re shepherding a fixed amount of resources across a large population and trying to do it according to some sort of evidence-based system.\u201d\n\nKaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nSupporters such as those at TMS NeuroHealth say they are seeing better results than that among their patients, who can continue taking antidepressants along with their treatment.\n\u201cThe majority of studies that evaluated rTMS failed to find evidence of an enduring treatment effect after the initial response .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately addresses adverse effects. It says, \u201cStudies have shown that side effects are few and generally minor, such as headaches and scalp irritations.\u201d In addition, \u201cA few small studies have looked at its effects on cognitive function and found either no effect or slight improvement.\u201d\nInteresting, in the AHRQ report, rTMS vs ECT had about the same number of withdrawals due to adverse effects, so despite the scarier sounding potential adverse effects from ECT, dropouts due to actual adverse effects were about the same.", "answer": 1}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\nOnly 2 percent of women who had weight-loss surgery developed gestational diabetes, compared to 7 percent of the other group, the researchers said.\nAdditionally, the surgical group experienced a slight bump in the rate of stillbirths, the study found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story uses relative ratios to express the possible negative effects of bariatric surgery (e.g. \u201cthe weight-loss surgery group was twice as likely to give birth to babies considered small for their gestational age, and their pregnancies were also of slightly shorter duration.\u201d), which misses critical information needed to understand the clinical or real world significance of these results. What was the overall percentage of babies considered small in each group, and was this a small or a large number? How worried should people be about this? Another concern is that the story didn\u2019t emphasize or quantify the more important harmful outcomes. There was a higher rate of stillbirths and neonatal deaths in the surgery group (1.7% in the postsurgery group and 0.7% in the control group) which, while not quite statistically significant, provides cause for concern. \u00a0We think readers would be most interested in this \u2014 more deaths among babies of women who had bariatric surgery. But the story mentions merely \u201ca slight bump in the rate of stillbirths.\u201d", "answer": 0}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nThe hairs were removed in a diffuse pattern, so there were no bald spots on the legs after the procedure.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All surgeries carry the potential for harms. None of the harms were discussed in this story.\nThe story does not provide a true picture of the process involved in the two patients.\u00a0 Prior to the 8 hour transplant procedure, the patients underwent harvesting of leg hair, \u201c\u2026once or twice daily for a variable period of 6 weeks to 6 months before surgery.\u201d", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said.\nCT colonoscopies, so-called virtual colonoscopies, are not a solution, some screening experts said.\n\u201cColonoscopy is a good test, but it isn\u2019t completely effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of perforations, missed cancers and \"unpleasant\" preparation as the risks/side effects of colonoscopy.", "answer": 1}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nManipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nCancer cells can be destroyed more effectively and selectively with a unique new reusable treatment, activated with a substance found in stinging nettles and ants - thanks to new research by the University of Warwick.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched\u201d (emphasis added). What does \u201clargely untouched\u201d mean? Was there some level of harm or change induced in healthy cells? In the context of human health, vague statements like that make us nervous. That\u2019s particularly true when a release does not disclose what sort of testing has been done \u2014 and remains to be done \u2014 for a potential treatment. It\u2019s always a good idea to point out that in research this preliminary, we have almost no idea what kind of adverse effects might occur when the compound is actually administered to patients.\nThis also plays to the popularity of terms like \u201cprecision oncology\u201d and \u201cselective\u2019 or \u201ctargeted\u201d\u00a0 cancer treatment.\u201d We are finding more and more that lots of our targeted treatments still can and do have \u201coff target\u201d harms. Gleevec and subsequent generation molecules are examples (prototypes) of great \u201ctargeted therapies\u201d but they still have other common side effects. Also, always comparing targeted molecules to chemotherapy is becoming less fair these days given that we have a better understanding of how to anticipate and manage side effects in general.", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided accurate information about a potential harm of excess consumption of vitamin B-6.", "answer": 1}, {"article": "Sacroiliac joint dysfunction is a common cause of disabling pain in the lower back, buttocks, or groin.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\nThe study is the first randomized controlled trial to directly compare the results of surgical and nonsurgical treatment for SIJ dysfunction.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some harms are mentioned but in insufficient detail. The published study cites a small number of serious complications. Although the adverse events are rare, they should still be mentioned. The most common side effects among those receiving the procedure were leg and pelvic pain within the first year, according to the study.", "answer": 0}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nResearch pharmacist, Krista Bohlen, director of personalized pharmaceutical medicine at the Avera Institute for Human Genetics, believes that genetics play a large role in how different individuals react to certain medications, but cautions doctors and patients against relying solely on this method for answers.\nAccording to a study conducted by the Mayo Clinic that looked at one genetic test similar to many used in hospitals \u2014 GeneSight Psychotropic \u2014 symptoms of depression were reduced by 70 percent compared to treatments prescribed without genetic testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any potential harms of genetic testing, and the article also does not discuss the fact that some genetic tests may focus only on a single genetic marker, making them far less useful. Tests that are inaccurate may falsely suggest that patients will or will not respond to a specific drug, delaying effective treatment.\u00a0Moreover, genetic test results can have significant negative social, emotional and financial consequences for patients, including the possibility of employment and insurance discrimination based on the test results.", "answer": 0}, {"article": "Feifel recalls one patient whose depression would disappear like magic after a dose of ketamine.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nAnd for Paul, the benefits of ketamine became obvious soon after one of his early injections.\nAnd Paul has spent much of his adult life searching for a treatment that would give him some relief.\nHe didn't qualify for most research studies because of his suicidal thoughts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there is a brief mention of possible harms, including abuse and hallucinations, the soft warnings in the story are undercut by statements such as, \u201cketamine\u2019s safety record is so good that it\u2019s often the painkiller of choice for children who arrive in the emergency room with a broken bone.\u201d Again, readers and listeners are given the impression that the drug has been scrutinized far more carefully that it actually has.\nThere is a final cautionary note from a proponent of ketamine treatment of depression that wider use could mean \u201csomething bad will happen to a depressed patient\u201d. However, this risk is cast not as a hazard inherent in the drug, but as worry that a careless doctor will tarnish the drug\u2019s good name.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n\"It will probably be helpful to someone who gets a low-level exposure [to glutens] by accident,\" he said.\nSome experts identified limitations to the research.\nMurray said that dismantling 95 percent of the protein component that is thought to trigger celiac disease may still not be enough to provide celiac patients protection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harm, but in an unsatisfactory way, when it quotes a study author who says, \u201cIt shouldn\u2019t be toxic; it\u2019s just a protein you\u2019re eating.\u201d In fact, proteins can be plenty toxic, and until this new compound is tested in humans, we can\u2019t be certain of what its effects might be.\nAnd even if it\u2019s not directly toxic,\u00a0such a treatment might\u00a0give patients permission to indulge and overdo it with respect to gluten, a compensating behavior that might cancel out any benefit from neutralizing small amounts of dietary gluten.", "answer": 0}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nThe results mean that women like those in the study will still have to have at least one removed, to look for cancer and decide whether they will need more treatment.\nNor is it known whether the findings could be applied to other types of cancer.\nThe new research grew out of efforts in the 1990s to minimize lymph node surgery in the armpit, called axillary dissection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses several harms from lymph node removal, and shows that the difference in survival for women who had nodes removed and those who did not was not significant. \u201cIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit. They were also more likely to have lymphedema.\u201d", "answer": 1}, {"article": "Older adults who take college courses may increase their cognitive capacity and possibly reduce their risk for developing Alzheimer's disease or other forms of dementia, according to new research published by the American Psychological Association.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants' age, gender, feelings of well-being or level of social connectedness didn't affect the findings.\nSome participants in the control group may have been doing crossword puzzles or other mentally stimulating activities that boosted their cognitive capacity, Lenehan said.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were noted in the news release or the paper, and its hard to envision any, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\nStill, Thun said the results would favor broadening the aspirin guidelines to include cancer prevention based on an individual risk-benefit assessment.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged side effects such as serious stomach bleeds and pointed out that this study didn\u2019t look at overall death rates or side effects.", "answer": 1}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\nIncontinence may sound funny, but it\u2019s no joke, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Urinary tract infections were three times more common in the women who received Botox shots, and the reader is informed of this. But a lot is left out. We would have also liked to see noted other side effects of Botox for urinary incontinence, such as blood in the urine, fatigue, insomnia, and\u00a0inability to completely empty the bladder (in about 17% of people) \u2014 and the need to self-catheterize to relieve the problem.\nAnd then there are the more general side effects left out of the story, including \u201cdry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes,\u201d according to botoxforincontinence.com. And what of the harms of a neurostimulator implant? There\u2019s no mention of this, and the side effects are numerous.", "answer": 0}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nThe participants fell into four groups: those with no use or low use of marijuana, early chronic users, those who only smoked during their teens and those who began using it later and continued using the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides\u00a0a list of the potential harms associated with marijuana use but it over-emphasizes the importance of this relatively small study in downplaying them \u2013 calling it \u201csurprising news\u201d that is \u201call good\u201d in the headline. And the second sentence says the study \u201cshould alleviate some of the worst fears.\u201d \u00a0That is too big a leap.\nThe story tried to describe the context of previous studies on marijuana but used this language \u201cother studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations.\u201d\u00a0As readers, we want to ask \u2013 did previous studies conclude there were risks? How can a study \u201cseem to allude?\u201d\nA recent review (N Engl J Med 2014; 370:2219-222) cited 69 publications examining the potential harms of marijuana use by the general population. \u00a0This one study is simply an addition to the growing body of evidence.", "answer": 0}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nMONDAY, April 25, 2011 (HealthDay News) -- Acupuncture might help reduce the hot flashes that frequently affect prostate cancer patients while they're on hormone therapy, a small study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms.\u00a0 Maybe none were found.\u00a0 Some past acupuncture studies report discomfort at the needling sites. One line could have easily addressed what was seen in this study or in related work.", "answer": 0}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nMost participants were able to stay on both diets.\nAfter three months, the participants switched diets.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Both diets used in the study are generally safe for most people. Food intolerances aside, the only potential harm we could see in the diets used in the study is that the calorie quota (about 2100 calories per day) may not be appropriate for all people.", "answer": 2}, {"article": "Read more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\nPooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\nApproximately 37 percent of these people received no treatment.\nSome drugs more effective than others\n\nThe researchers analyzed existing studies of 21 different drugs, and found some were much more effective than others.\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the various side effects that can occur with antidepressant medication, such as weight gain, insomnia, and loss of sexual desire.\nThe study authors looked at which drugs were more or less tolerated, and their analysis did not include adverse effects or withdrawal symptoms. Those facts weren\u2019t included in the story.", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this was a study about a quality improvement initiative, we\u2019ll rate this N/A.\u00a0However, it might have been worth raising the question of whether the time and emphasis placed on this screening test by clinicians detracted from other work they could have been doing to improve patient care and outcomes.", "answer": 2}, {"article": ".\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nThere was also a lower positive biopsy rate among women ages 40-49 compared with women over 50.\nThe number of cancers detected in women ages 40-49 was not significantly different from women ages 50-59 or 60-69.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not explain additional harms of earlier mammogram screening, of which there are several. One is radiation exposure; though mammograms involve minimal radiation, the risk of exposure still exists. The larger harm, however, is the possibility of false-positives and false-negatives. Mammograms aren\u2019t foolproof tests; the American Cancer Society estimates that mammograms miss 1 in 5 breast cancers (false negatives). They also estimate that about half of women getting an annual mammogram over a 10-year period will have a false positive (where the screening indicates something abnormal, but in reality there is no cancer). False positives are more common in younger women, and can lead to additional tests, cost and anxiety for women when nothing is wrong. The higher rate of false positives in women ages 40-49 is one of the reasons that the mammogram age is so controversial. For the group 40-49 years of age about 3% of the callbacks resulted in an actual cancer detected while it was about 6% and 7% in the older age groups.", "answer": 0}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\nIn addition to this study, researchers will present the latest in Alzheimer's disease at the AACC Annual Scientific Meeting & Clinical Lab Expo, including:\n\u2022 New research explores using the level of angiotensin-converting enzyme (ACE) in the brain and spinal cord as a biomarker for neurodegenerative diseases, including Parkinson's disease and AD.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there are likely no direct harms from drawing a blood sample, the release could have noted the potential harm of any screening tests for AD risk factors \u2014 such as anxiety, depression, misdiagnosis or over-diagnosis\u00a0 \u2014 particularly if screening is conducted on those at potentially very low risk. To its credit, the release includes a quote from one of the investigators who makes it pretty clear that the test is intended for those with probable symptoms and family histories of AD.", "answer": 0}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\nNew, less toxic treatments for hepatitis C opened the door for transplanting infected kidneys and then successfully treating the infection, Reese said.\nAbout 15 percent of dialysis patients have HCV, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201csome patients might not want to take the risk associated with an infected kidney,\u201d but we think the potential risks of this strategy warranted more discussion.\nHepatitis C causes inflammation of the liver that can lead to diminished liver function or failure of that organ. According to the study, one patient in the study experienced a serious adverse event, protein in the urine, which indicated liver malfunction and could have been triggered by the HCV infection. The condition improved after treatment, according to the published study.\nModern HCV treatments are not 100% effective at curing the disease and come with \u201cblack box warnings\u201d for side effects such as low blood cell count, nausea, flulike symptoms, feeling tired, headache, and reduced appetite.", "answer": 0}, {"article": "\"We are not going to reverse any of the chronic diseases in this country by changing the composition of the diet,\" Dr. Howard said.\nThat could mean that fat in the diet may have a small effect, Dr. Rossouw said, perhaps in some subgroups of women or over a longer period of time.\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\nOf course, Dr. Libby acknowledged, the latest advice, to follow a Mediterranean diet and get regular exercise, has never been tested in a large randomized clinical trial.\nThese days, Dr. Libby said, most people have moved on from the idea of controlling total fat to the idea that people should eat different kinds of fat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes many questions about whether a low-fat diet is worth the trouble.", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the story is the harm of overselling the benefits of the procedure. There is no discussion of whether there are other significant harms to consider. Like all surgery, this procedure will have serious risks\u2013both within the joint that\u2019s being injected and throughout the body. (A similar injection into the spinal vertebrae, called vertebroplasty, comes with very serious potential risks.)", "answer": 0}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nThousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any of the possible side effects of taking a bisphosphonate. For some women, those side effects are significant and thus they should be included.\nAdditionally, we\u2019re wondering how the genetic test is performed since there was no description offered. Is it a blood test or is it more invasive, complex and risky, requiring acquisition of tumor tissue?", "answer": 0}, {"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that \u201cTreatment-related side effects included mainly low-grade fatigue, itching, elevated lipase, rash, nausea, joint pain and anemia. Grade 3 or 4 side effects occurred in 20.5 percent of patients. Two patients discontinued therapy because of adverse events related to the drug.\u201d That\u2019s enough to earn a satisfactory rating. However, it could have been better. The release says adverse effects \u201cincluded mainly\u201d manageable problems. But more than 20 percent of patients had \u201cgrade 3 or 4\u201d side effects \u2014 and that is not trivial. The release would have been much stronger if it had offered some insight into those more severe effects, or even explained what \u201cgrade 3 or 4\u201d effects means. Grade 3 effects, according to the National Cancer Institute, are \u201csevere\u201d \u2014 while grade 4 effects are \u201clife-threatening or disabling.\u201d That merits more discussion than it got.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nBottom Line: Obese patients who underwent weight-loss surgery had a lower rate of death from any cause compared with obese adults who received nonsurgical care to manage their obesity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss any potential harms associated with bariatric surgery \u2014 and there are several. While the focus of this study was on rates of death, not on other outcomes, any discussion of this surgery that might sway a reader to try it needs to include a summary of potential complications and risks.\nThe issue of harms might have been included in the \u201climitations\u201d section of the release.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the new drug was found to be \"safe and effective\" but provided no details on its potential harms and no detailed safety comparison with the current standard of treatment. \nIf the trial was small, it may be premature to assume cethromycin is as safe as Biaxin.\u00a0", "answer": 0}, {"article": "But on Oct. 23, the F.D.A.\nSome of the push to make the drug more widely available is coming from investors in BioCryst, including Kleiner Perkins Caufield & Byers, the prominent Silicon Valley venture capital firm.\nVirtually all the money to develop the drug comes from $180 million in grants from the Department of Health and Human Services.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\nHe said the drug should be distributed so that hospitals could have it in stock.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs.\nThese side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers:\n\u201cThe most common side effects of PERAMIVIR are:\n\u2022 diarrhea\n\u2022 nausea\n\u2022 vomiting\n\u2022 white blood cell count decreased\nThese side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time.\nOther medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. \nThese side effects include:\n\u2022 Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior.\n\u2022 Allergic reaction or severe rash\nNot a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot.\u201d\n\n\n\n \nPatient fact sheet available at:\nhttp://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf \nProvider fact sheet available at:\n http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf\u00a0 ", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nDr. Hunter Wessells, who wasn't involved in the study, called the additional fluid intake \"substantial,\" leading to a corresponding increase in urine output.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\n\"In addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Increasing intake of water carries a low risk of causing problems\u2013except for more bathroom trips. For women suffering from incontinence, this could be especially troublesome and a disincentive. The story indirectly addressed that, so we\u2019ll give credit:\n\u201cIn addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\u201d he said.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this treatment.", "answer": 0}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n\u201cCompared with self-care, yoga and stretching class participants were significantly more likely to rate their back pain as better, much better or completely gone at all follow-up times,\u201d the study noted.\nThe research found that yoga and stretching were equally effective in easing chronic back pain and improving function, but participants had to practice each regularly to see benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not discuss adverse events in any of the groups, though the study reported on them. This is an important point, as the New York Times article observed that many people with back pain shy away from exercise programs for fear of exacerbating their symptoms.\n\n\n\n ", "answer": 0}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nAnd heavy drinking is not good for anyone: It has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\nMike Daube, professor of health policy at Curtin University in Australia, writes that the once-touted benefits of moderate drinking \"are now evaporating.\"\nFor some people, even moderate drinking is clearly risky.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes a variety of potential harms associated with moderate drinking: excess calorie intake, increased blood pressure (among those with hypertension), and increased breast cancer risk in women.\nThe article also pointed out that heavy drinking is not good for anyone: \u201cIt has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\u201d", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is very safe, however there are some potential undesirable side effects that were reported in the study and that should have been mentioned.", "answer": 0}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nSince the study began about a year ago, 500 local teens have been screened and 26 diagnosed with heart abnormalities.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that of the first 500 high school athletes enrolled in this heart screening study, four were advised to drop out of sports and 22 more were told they needed lifetime monitoring. However, the costs and consequences of these recommendations are not addressed. How much does reduce physical activity increase other health risks, including obesity? Does a detection of an \u201cabnormality\u201d on this sort of test mean that these children may have difficulty getting life or disability insurance\u2026 or even health care coverage, if pending insurance reforms are repealed? Will they be barred from certain careers because they have been labeled as having abnormal heart conditions?\nBased on figures from the National Federation of State High School Associations (NFSHSA), if the rate of abnormal test results reported by these researchers were applied nationally, about 100,000 teens a year would be told they need lifelong monitoring and another 15,000 would be kicked out of high school sports activities. These are important consequences that the story should have addressed.\nNote: the NFSHSA reports almost 8 million high school students participate in sports (which means about 2 million new students begin each year).", "answer": 0}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\n\"Research like this study is leading to a series of new medications that promise high levels of response for an increasing number of patients,\" said first author Kenneth Gordon, MD, professor in Dermatology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms at all, which is problematic. The authors of the paper noted the difficulty in identifying true rates of adverse events in the study given the discrepancy in the number of subjects in each treatment group.\u00a0 There was a 6:1 ratio of guselkumab subjects compared to adalimumab in the post placebo phase of the trial.\u00a0 While the true incidence of harm is unclear at the moment, some comment is\u00a0necessary even in a press release.\u00a0 For example, according to the paper, 20 percent of patients who received guselkumab experienced \u201cadverse events of infection\u201d during the first 16 weeks of the trial, as compared to 14 percent among patients receiving a placebo and 12 percent of patients who received adalimumab. A higher rate of infection is certainly worth mentioning. Heck, even a comparable rate of infection is worth mentioning. Overall, patients who received guselkumab had lower rates of all \u201cadverse events\u201d compared to adalimumab over the first 16 weeks of treatment (50 percent versus 56 percent), and over weeks 16 through 52 of the study (49 percent versus 61 percent). But the rates of adverse events were still noteworthy, and the release should have addressed them.", "answer": 0}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nWHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of \"good\" cholesterol, despite being treated with statins.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All drugs come with some kind of risk profile. And, in this case, we are talking about treating patients with diabetes who, presumably, already are managing that disease with prescription medication. At a minimum, the release should mention any side effects or harms observed in the study.", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nScientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\nThey also improved their scores on the Global Assessment of Functioning (GAF) scale, which doctors use to rate the social, occupational and psychological functioning of adults.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that there are any potential harms associated with playing the game. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nWhen the SIPE participants were given sildenafil and then performed the same underwater exercise, the pressures were no longer as elevated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study itself is silent on the potential harms seen in the subjects treated with sildenafil, we think that the story should have noted that explicitly. Are four-hour erections an issue that swimmers need to be concerned about? Harmful side effects of ingesting sildenafil certainly\u00a0exist but are not broached\u00a0here.", "answer": 0}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nStudies show that for kids' ear infections, antibiotics work better than waiting\n\nBeing a parent these days sometimes entails this hypocrisy: Yes, I know overuse of antibiotics is creating superbugs that may soon conquer the universe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To its credit, this blog mentions some of the\u00a0most common\u00a0side effects associated antibiotic use such as diarrhea and eczema, and it mentions antibiotic resistance as a problem. However, it failed to put these harms into terms that understandable and useful to readers.\u00a0Clearly, data about the frequency of adverse effects would help readers weigh these downsides against potential benefits. In addition, while the story\u00a0says\u00a0that overuse of antibiotics might be \u201ccreating superbugs that may soon conquer the universe\u201d (a characterization that we understand is meant to be humorous),\u00a0the story should have explained that antibiotic overuse may have\u00a0real implications for children\u00a0who get treated unnecessarily. For example, there is some evidence that the use of antibiotics can lead to colonization of the child\u2019s nasal passages with resistant bacteria which can cause future infections that are\u00a0more difficult to treat. Parents need this kind of information before deciding whether to use drugs\u00a0on an infection that will probably clear up on its own anyway in most children \u2014 and can be effectively treated after a few days with antibiotics if it doesn\u2019t.", "answer": 0}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThese trials employed a simple, economical design in which participants acted as their own controls (i.e., change in metabolic markers was measured before and after eating the bar).\nDevelopment of the CHORI-bar has also been guided by Dr. Mark Shigenaga's insights into the importance of a healthy gut supported by optimal nutrition for disease prevention.\nThe CHORI-bar is intended as a non-traditional means to positively impact the obesity epidemic by initiating a healthier metabolism without requiring sudden drastic behavioral changes.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text extols the benefits of the bars with no mention of possible harms. \u00a0We\u2019d suggest that there is possible harm in replacing actual foods containing a wide variety of nutrients (and many potentially beneficial compounds that we don\u2019t know anything about) with a supplement bar processed in a factory. The peer-reviewed rendition of the study also finds no clear downsides, although it did note that \u201cchronic inflammation [which\u00a0can accompany obesity] blunted most improvements,\u201d suggesting that some folks will be helped far less by the bars than will others.", "answer": 0}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nPrevious MD Anderson research showed that bacteria in the gut influence patient response to ICI therapy, and other evidence suggests modifying the microbiome in mice can alter their response to immunotherapy.\nHowever, these treatments are often associated with significant immune-related toxicities.\nWith endoscopic evaluation before and after treatment, both patients displayed significant improvements in inflammation and ulcerations, including a reduction of inflammatory immune cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Risks of these transplants are not mentioned.\u00a0 Fecal material produced without careful screening could introduce microbes, including those linked to MS and Parkinson\u2019s.", "answer": 0}, {"article": "This article has been updated to include additional comment from Kathryn Cullen.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\nThe latest study involved 13 young people ages 12 to 18 who had failed two previous trials of antidepressants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story brushed over significant potential harms, including the potential for misuse. It stated that researchers \u201cfound that the treatment was well tolerated,\u201d and contained a quote stating \u201cwe still don\u2019t know about the long-term safety.\u201d\nAccording to the research paper, there were some issues the story ignored.\u00a0 Three participants became nauseous during the infusions, while two others experienced dysphoria (profound unease).\u00a0 One participant reported hand pain from the intravenous site that persisted for several days.\nAlso, with any invasive procedure \u2014 even infusions \u2014 there is always the risk of infections.\nBut most importantly, ketamine use requires considerable caution. It is now considered a misused recreational drug and some research indicates it can cause complications when used long-term.\nIt seems such cautions are particularly warranted due to the existence of clinics where ketamine is used off-label to treat depression.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not adequately list the harms of this treatment for women with and without polycystic ovarian syndrome (PCO). Instead the story focuses on the potential downsides of IVF and the risks of hormones for some women. \nThe target group, that is, women with subfertility, can enhance their likelihood of conceiving with modest weight loss and conventional medications as needed, but who might be lured into this \"tennis shoe\" treatment out of fear that they won\u2019t conceive rather than doing the harder thing of diet, activity, and physical activity. This is not dicussed. However, IVM requires egg retrieval and embryo transfer, the same as IVF, and these risks should be mentioned\u2013 the former with small risks of bleeding and infection and the latter with small risk of infection and poorer reproductive outcomes. ", "answer": 0}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\nAnd microRNAs offer a promising way to assess concussions in adults as well as children, says Bhomia, whose research involves a range of \"biomarkers\" for traumatic brain injury.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms, which would include false positive and false negative results. For example, if a child\u2019s test result erroneously said he would have prolonged symptoms (a false positive result), he may miss out on school or activities, for no good reason. And if the result instead erroneously said the child wouldn\u2019t have prolonged symptoms (a false negative result), the child may resume school or activities too early.", "answer": 0}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most troubling thing about this study and about the release is the inclusion of french fries and potato chips in the study as if they were equal in health value to other forms of potatoes. There is no discussion of the potential harms that come from foods high in sugar, salt, fat, and calories.", "answer": 0}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nIn a recent study from the Piglet Nutrition and Cognition Lab at U of I, scientists worked with piglets to show prebiotics included in infant formula can enhance memory and exploratory behavior.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known disadvantages of formula over breast milk so harms should be included in any discussion of changing infant nutrition patterns.", "answer": 0}, {"article": "February 28, 2017 - For infants with congenital malformations of the ear, a treatment system called EarWell can gently reshape the ear--avoiding the pain and cost of later surgery, reports a study in the March issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nEarWell treatment was highly successful in correcting or reducing the severity of congenital ear malformations.\nThe researchers review their experience with nonsurgical correction of congenital ear malformations in 175 infants.\nArticle: \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System\" (doi: 10.1097/PRS.0000000000003150)\n\nFor more than 70 years, Plastic and Reconstructive Surgery\u00ae (http://www. )\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly addresses the vast majority of the complications discussed in the journal article, which is enough to earn it a satisfactory rating. However, the release does not mention the possibility of infection. There was only one case identified in the article, but it is also the most significant of the complications that cropped up over the course of the (retrospective) study.", "answer": 1}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss the potential side effects of this new drug, nor does the story provide a caveat that the drug may not live up to its predicted effect in humans. The possibility of a negative interaction with other HIV drugs, or with drugs for co-existing medical conditions is also not mentioned. But this is one of the hazards of reporting on data that have not yet been peer-reviewed (Or have they? The story doesn\u2019t make it clear.) The company and the investigators certainly know what side effects have been experienced so far. Having the company president say that the drug has \u201ca great safety profile\u201d is inadequate. ", "answer": 0}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some forms of weight loss can pose risks for patients, such as various fad diets or when people with a sedentary lifestyle suddenly begin engaging in rigorous exercise. But this study does not appear to have evaluated how people tried to lose weight, instead focusing on the extent to which they were motived to make changes based on the intervention. Because of the nature of the study, we\u2019ll rate this as not applicable. However, it would have been valuable to include language encouraging people to talk to a health care provider before making abrupt changes to their lifestyle.", "answer": 2}, {"article": "\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nDr. Zhaoping Li, director of the UCLA Center for Human Nutrition, chief of the UCLA Division of Clinical Nutrition and the study's senior author, said the findings suggest that the health benefits of both green tea and black tea go beyond their antioxidant benefits, and that both teas have a strong impact on the gut microbiome.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of consuming black tea were mentioned. Black tea contains caffeine, which can cause a range of adverse effects in high doses.\nOf course, the manuscript that\u2019s the basis of the release specifies that the study tested decaffeinated black tea. However, the release doesn\u2019t mention this. Clarifying this point would have been helpful.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply stated:\u00a0\u201cAbbott said 6.9 percent of patients suffered major cardiac events \u2014 including heart attacks \u2014 over a 12-month period, which the device maker described as a low rate.\u201d\u00a0 Do independent experts consider that a low rate?\u00a0 We wouldn\u2019t know from the story.\u00a0 And is a 12-month period sufficient to call the device \u201cproven safe and effective\u201d as the opening sentence does?", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThere was photon therapy available in San Francisco, but, in my research, I found out the photon beams don't stop at the tumor and have a greater possibility of affecting surrounding organs, too.\nWhile proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.\nDr. Kabolizadeh explained, \"Image guidance allows doctors to visualize tumors during therapy to assess response and make sure the tumor is treated correctly every day.\"\n\"Definitive radiation therapy refers to curative radiation,\" explained Dr. Kabolizadeh.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release tells readers that proton beam treatment poses fewer risks than other forms of radiation therapy, but doesn\u2019t explain what those risks are \u2014 or what risks proton treatment does pose. As the Mayo Clinic notes on its site, \u201cProton therapy can cause side effects as the cancer cells die or when the energy from the proton beam damages healthy tissue.\u201d Common side effects range from headaches and fatigue to soreness and digestive problems.\nSide effects from proton beam are likely the same as photon beam radiation but the selling point of proton is that it is more precise and thus the overlapping side effects should be fewer. But there have been few, if any, trials to compare proton and photon therapies which would supply the needed evidence to support the claim.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the drug.\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms of treatment in the news story or in the published study. Other research suggests that main harm of taking the supplements is kidney stones.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nNow, a study shows that a simple intervention conducted by staff in emergency departments can reduce the risk of future attempts.\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Patients could be potentially harmed if a hospital relies too heavily on the SPI instead of more thorough and immediate psychiatric care. For example, if a patient with a serious mental illness isn\u2019t diagnosed and treated promptly.", "answer": 0}, {"article": "The condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\nTasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. Even a brief discussion with a specialist or generalist who prescribes the similar drug ramelteon would have yielded some information about possible harms.", "answer": 0}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nData on pain came from the participants' ratings; no information on side effects was collected.\nThe study did not assess longer-term pain reduction.\nWithin two hours, all participants reported essentially identical declines in pain, about four points on the scale.\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not delve into potential harms \u2014 but it does note that the study itself did not collect information on side effects. In a case like this one, simply reminding readers that there are potential side effects for all the drugs studied, and that the study did not address them, is sufficient for a Satisfactory rating.", "answer": 0}, {"article": "But on the other hand we have to be realistic and in many countries you cannot just switch traffic overnight to electric cars and do other drastic things.\u201d\n\n\u201cIt will take many more years, especially in countries like China, and I think there is an ethical need to provide something to the general population to protect them,\u201d he said.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nThe new inhaler has been developed by German medical devices company Bitop and is based on a molecule called ectoine, discovered in the 1980s in a desert bacterium which uses the compound to conserve water in 60C heat.\nA version of the product for use in nebulisers will be available this year in Germany and Poland, while an ectoine-based nasal spray for allergy relief is already available.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not explained. The comments of one doctor in the story\u00a0suggest that the compound is inert, supporting the notion that there are no harms. But a quick check of a material safety data sheet reveals some concern about the potential for ectoine to produce pulmonary edema if inhaled, in addition to eye and skin irritation.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story detailed the harms associated with the current means of testing for prostate cancer. \u00a0While suggesting that the new MSMB test was able to distinguish between aggressive and non-aggressive prostate cancer, the story did not provide details about how well the test was able to do this. In a nutshell, the story mentioned (though it didn\u2019t quantify) the high false positive rate associated with PSA, but it provided no detail on the relative false positive rate of MSMB. It also failed to mention whether the test failed to pick up on a percentage of prostate cancers that were present. ", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nAmong a number of cautions the researchers point to in this work is that physical activity is related to other behaviors and lifestyle factors, and women who are more physically active may be different from women who are less active in many ways.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms from walking are likely not significant enough to warrant mention here.\nHere\u2019s a minor point:\u00a0 since vigorous activity is noted as beneficial to conception, this might warrant mention as something that a woman with other health concerns might consider consulting her doctor about.\nOtherwise, the issue of harms seems negligible enough to consider this N/A.", "answer": 2}, {"article": "Their average age was 69.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nThere were no differences among the groups in other serious side effects, such as nausea and heart palpations, Miller said.\nAbaloparatide and Forteo are synthetic peptides that help grow and strengthen bone, Miller said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists nausea and heart palpitations among the serious side effects of both abaloparatide and Forteo.", "answer": 1}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that \u201cthe plant extracts didn\u2019t harm the skin tissues or the normal, healthy bacteria found on skin.\u201d It also wisely cautioned \u201cthe average person shouldn\u2019t try to use the weed to make their own medicine.\u201d\nWe\u2019ll award a satisfactory grade but note that the disclaimer could have been stronger, saying that the injections were prepared under laboratory conditions and could not be prepared by just crushing the berries. We also don\u2019t know how the extract might affect humans.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nWorld first research at the Victor Chang Institute has found that this deficiency can be particularly harmful during a pregnancy as it can cripple an embryo when it is forming.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\nCrucially, Australian scientists have also demonstrated a potential cure, in the form of a common dietary supplement.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release made no mention of harms of niacin supplements. Niacin supplements are used clinically and have side effects when used in high doses. According to WebMD, these include a hot \u201cflush\u201d reaction that can be frightening. As dosage increases, other side effects may occur, including liver problems, ulcers, loss of vision, and irregular heartbeat. \nThere have been enough people worried about niacin side effects that the British Columbia Drug and Poison Information Centre has an FAQ page\u00a0about the supplement. ", "answer": 0}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\nIn the study, investigators injected cardiosphere-derived cells, a specific type of stem cell, from newborn laboratory rats into the hearts of rats with an average age of 22 months, which is considered aged.\nGeneral support for Marb\u00e1n's laboratory is provided by the National Institutes of Health.\nCapricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of stem cell therapy are not mentioned, and it\u2019s impossible to know for sure what the risks of this intervention might be. Safety data appears to be limited. The published study states that cardiosphere-derived cells \u201care already in advanced clinical testing and have proven safe to date,\u201d but it cites just one article that was written by one of the same researchers, Eduardo Marban, who developed and owns a financial interest in the technology.", "answer": 0}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nThey also found the drug to be safe and well tolerated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s mentioned the researchers \u201cfound the drug to be safe and well tolerated.\u201d\u00a0 The associated research paper mentions \u201cthere were two serious adverse advents, both considered unrelated to the study drug.\u201d\u00a0 But no further information is provided. The release could have been more informative regarding potential harms from the drug.\nHumira has been documented to cause a host of side-effects. It carries a black box warning for compromising immunity, and has been reported to make people more prone to tuberculosis and skin cancer.\nOf note, these side effects were noted in patients given subcutaneous Humira. The Humira in this study was administered locally in the hand, which could be less likely to cause systemic side effects.", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\nZhang said his group may consider moving into another trial using only electroacupuncture on patients suffering milder depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\nThe journal article explained that adverse events (including dizziness, tiredness, nausea, excessive sweating, headache, transient tachycardia, insomnia, vomiting, unsteadiness and somnolence) occurred in at least 5% of the patients in either group and that two patients discontinued due to intolerance of acupuncture stimulation.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nIn those people, Provent typically doesn\u2019t work.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nDr. Lee A. Surkin, a cardiologist and sleep medicine specialist in Greenville, N.C., said patients typically start with a 10-day trial pack that costs $27.50.\n\u201cIt works like a champ in some people and doesn\u2019t work on other people,\u201d said Dr. Nancy Appelblatt, an ear, nose and throat surgeon in Sacramento who has prescribed it to about 100 patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in this story.\nBoth the Provent device and the sham device were very similar in design and use.\u00a0 Both were adhesive \u201cbandaids\u201d place over the nostrils and both restricted exhalation through the nose (although the sham device did so less).\u00a0 Although the device was shown to have no side effects in the published study, about 16% of those using the Provent device stopped doing so by month 3 (as compared to 13.6% who used the sham device).\u00a0 That means about 1 out of 6 patients using the nasal \u201cbandaids\u201d stopped doing so relatively soon.\u00a0 The reasons for stopping were not provided but we can assume that discomfort was at least one of the reasons.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the one major flaw in the reporting from our perspective. Harms are not mentioned anywhere. Threading a catheter into a blood vessel in the brain to retrieve a clot and giving a clot buster are not totally benign procedures. The Australian study did not see any differences in the incidence of bleeding or worsening of symptoms whereas the second study saw a slight but statistically insignificant increase in bleeding in the group who received alteplase and the clot removal. \u00a0Importantly, the study was conducted in centers where there is considerable expertise and availability. \u00a0These results may not be transferable to all hospitals.", "answer": 0}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nIt is unlikely that people could get too much vitamin E from food.\nExperts advise that adults consume no more than 1,000 mg of vitamin E per day.\nBut the finding is in line with a previous study of U.S. adults that found that a higher intake of vitamin E, but not vitamin C or beta-carotene, was related to a lower risk of developing Alzheimer\u2019s over two years.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no known harms to eating a diet rich in foods containing vitamin E, but this story goes the extra mile and notes that high vitamin E intake from supplements can cause excessive bleeding.", "answer": 1}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story at least mentioned potential harms and that \u201cit remains to be seen if the drug is safe for long-term, intermittent use.\u201d\nBut we think it is inadequate to simply state that those on the drug had \u201csignificantly fewer side effects.\u201d\u00a0 What does \u201csignificantly fewer\u201d mean?\u00a0 And what were they?\nBoth stories we reviewed could have talked a bit more about the experimental nature of this drug and the problems seen in the past with hormone-regulating drugs.", "answer": 0}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that none of the patients experienced serious side effects or adverse events.\u00a0 It could have emphasized that one can\u2019t draw much of a conclusion on safety after experiments in a few people. ", "answer": 1}, {"article": "Guadecitabine works to reverse a so-called epigenetic change in cancer cells known as methylation, which may alter genetic activity in cells in a way that can block the action of tumor-suppressing genes, pushing cells to become cancerous and resistant to therapy.\nThe clinical trial included 22 patients with metastatic colorectal cancer who had been treated previously with irinotecan and whose disease was progressing.\nThe study also showed signs that guadecitabine reduced methylation among the cancer cells.\nDuring the study, 15 patients had at least one imaging scan to retest the extent and location of their cancers -- with 12 patients experiencing stable disease -- for more than the four-month period, on average, and one patient experiencing a partial response to the treatment (measured as at least a 30 percent reduction in the size of the tumors.)\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The headline is problematic, but we\u2019ll talk about that under the \u201cUnjustifiable Language\u201d criterion. The rest of the release does a good job of describing potential harms. The release discusses eight potential harms, defines them and offers numbers on all of them (e.g., \u201ctwo patients developed thrombocytopenia, a lowered count of blood-clotting platelets\u201d). That\u2019s very good. Two things would have made it even better. First, the release could have included an explanation of what the observed adverse effects actually mean. For example, how severe was the thrombocytopenia? And how much of a risk does that pose to a patient\u2019s health \u2014 are we talking about the potential for bruising easily? Or a high risk of bleeding to death? Second, it wasn\u2019t clear if the dose of guadecitabine was related to observed effects. I.e., were patients who received higher doses of guadecitabine more likely to exhibit adverse effects?", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the potential harms of oophorectomy, including heart disease, hip fractures and now, potentially, neurological deficits.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that surgery has risks, but does not explain what the risks are, whether the patients enrolled in the studies were harmed by the treatments they received, or whether other research has documented potential long-term harms not reported in the current studies. For example, fusion eliminates movement in the fused segment of the spine. This not only reduces instability (as intended), but can add extra stress to the segments above and below the fused segment. This added stress often creates its own problems and may trigger additional fusions. ", "answer": 0}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nThe skin-like sweat patch adds a capability called microfluidics, capturing and analyzing tiny amounts of body fluid.\nA little larger than a quarter, it\u2019s almost like a tiny lab stuck to the skin \u2014 and a study published Wednesday found it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study doesn\u2019t contain data on adverse effects, and the story doesn\u2019t touch on potential harms. Have patches been tested for skin irritation, for example? More broadly, could skin patches give athletes a false sense of security, prompting them to ignore physical symptoms, or distract them from the basics of proper training, nutrition and hydration? That\u2019s not addressed.", "answer": 0}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nLower consumption levels were not associated with the risk.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since readers might interpret this study\u2019s results as supporting consuming more fermented dairy (much of which contains saturated fats), not mentioning the potential harms of consuming too much saturated fats is a shortcoming.", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study compared benefits and harms for three different situations: surgery, radiation and surveillance.", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was concerned primarily with the implications of a negative BRCA test result, so we won\u2019t fault it for not going into detail on the many potential harms of a positive or ambiguous test result. The story did stipulate that BRCA-negative women may still have an elevated risk of cancer if they have a family history of the condition, which is an important caveat.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are mentioned at different points in the report: maternal deaths; interventions and complications, such as cesarean sections, forceps delivery, infections and hemorrhage compared with hospital births; \u201ccomplications\u201d for the babies. But the story does not really explore the difference (if any) between risks that would be of potentially greater concern during home birth versus hospital birth \u2014 or vice versa. The story does note that the U.K. study behind the guidance found that there was a slightly increased risk of complications for babies born at home if it was the mother\u2019s first birth. We\u2019ll rule this Satisfactory with suggestions noted for next time.", "answer": 1}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\n\u201cWe want people to be aware that HSCT is an aggressive treatment that comes with significant risks.\nA treatment traditionally used on patients with certain cancers is being tried on a small number of people with multiple sclerosis with \u201cremarkable results\u201d, according to a professor involved in the research.\nDoctors at Royal Hallamshire hospital in Sheffield stress that the treatment, so far given to about 20 patients over three years, is not suitable for everyone with the disease, which attacks nerves in the brain and spinal column.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are left unexplained.\u00a0 One source notes that haematopoietic stem cell transplant (HSCT) \u201cis an aggressive treatment that comes with significant risks.\u201d\u00a0 And one patient who received the treatment noted that \u201cI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\u00a0 But none of that illuminates the nature of the risks that someone would encounter.\nThis is the weakest point of the story. This is a treatment with real risks. They way it is presented gives very little insight to the reader about what these risks are.", "answer": 0}, {"article": "Paul J.D.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nWhiteside, a doctoral candidate in the MU Division of Food Systems and Bioengineering, devised a system that will not only improve the process, but will be safer for both clinicians and patients.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\nWhiteside presented his technique to clinicians on April 9, 2017, at the annual conference of American Society for Laser Medicine and Surgery (ASLMS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release refers to \u201csafety concerns\u201d of existing laser devices, including eye damage, but there are no details about the level of risk presented by this new device. Oddly, the abstract of the conference presentation and the upcoming journal article in Lasers in Surgery and Medicine that were mentioned in the release both highlighted concerns about discoloring or burning skin, something not mentioned at all in the release.\nNote: The conference abstract was behind a paywall which requires a journal subscription. A draft of the accepted journal article was provided upon request, but we urge those who send out news releases to automatically include primary source material.", "answer": 0}, {"article": "This article has been updated to include more information on DMAU.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nResearchers analyzed the men\u2019s hormones and cholesterol with blood tests at the start and end of the study.\nResearchers have developed a prototype male pill that appears to be safe in a month-long trial.\nWhile some subjects on all doses experienced mild weight gain and decreases in so-called \"good\" HDL cholesterol, DMAU appeared safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the range of side effects found among study participants, though some of the characterizations appear to lack context. For example, the story mentions that some subjects experienced \u201cmild weight gain.\u201d Based on information in the study abstract, the mean weight gain was 1.5 to 3.9 kilograms. Given that 3.9 kilograms is 8.5 pounds, that\u2019s not inconsiderable. i.e., many men may balk at the idea of gaining more than eight pounds in a month. It\u2019s also not clear what sort of weight we\u2019re talking about. Muscle? Fat? Water retention? This may be particularly relevant (and worth articulating clearly) for a medical intervention aimed specifically at sexually active adults.\nBy the same token, the story notes that \u201ca minority of participants did experience decreased libido during the study.\u201d According to the study abstract, eight of the study participants who received the drug experienced decreased libido. Given that only 83 people completed the study, and that some of those study participants received a placebo, that means that more than 10 percent of men who received the drug experienced decreased libido.\nAgain, this seems particularly relevant for a drug aimed solely at people who are planning to have sex. In short, the story did not overlook any of the potential harms discussed in the abstract, but could have done a better job of placing those potential harms in relevant context. How appealing is a birth control pill for men if it makes more than 10 percent of them less interested in sex in the first place?", "answer": 1}, {"article": "Varenicline contains no nicotine.\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\n\"The trial and error approach is not optimal.\"\nResearchers did not test nicotine gum because it delivers a less consistent flow of nicotine to the user, she said.\nThe patch, worn on the skin, delivers a steady flow of the drug, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that side effects of\u00a0varenicline\u00a0include nausea, difficulty sleeping, and abnormal dreams. It also acknowledges that there is harm in pursuing a therapy that does not work if the quitter is discouraged. Excerpt: \u201cEach time somebody fails, it affects their self confidence,\u201d Lerman said. \u201cThe trial and error approach is not optimal.\u201d \u00a0We\u2019ll rate this borderline satisfactory, but ideally we would have liked to see some quantification of these side effects, especially since frequency of side effects is an important part of the rationale for choosing one approach over the other. Moreover, the story should have explored potential harms from the blood test used to classify nicotine metabolism. How accurate is it? And if the test is wrong, what does that mean for your chances of quitting successfully?", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that \u2018few side effects were reported\u2019.\u00a0 While it is true that \u2018few\u2019 is a subjective term, it would have been useful for readers to know that ~13% of those taking the 200 milligram dose experienced side effects; further \u2013 in order to have some idea about how to value the side effects, it would have been helpful to list that the side effects included fatigue, dry mouth, headache, and drowsiness.", "answer": 0}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nThe task force's final recommendation is likely to be controversial because some other groups say the screening should start earlier.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms briefly in two places. In one place, the story refers to \u201cthe anxiety and potential harm caused by over-diagnosis and false positives,\u201d though it doesn\u2019t explain what over-diagnosis or false positives mean (potentially leaving many readers in the dark). The story also notes that \u201cThe most serious potential harm is unneeded treatment for a type of cancer that would not have become a threat to a woman\u2019s health during her lifetime.\u201d But it doesn\u2019t give readers any idea of how serious this harm might be, or how common this scenario is. In short, the story does enough to earn a Satisfactory rating, but could have (and should have) done more. It\u2019s worth noting that the New York Times piece did a top-notch job discussing harms.\nThe story does, however, make clear that women should be informed consumers, and that \u2014 if well-informed \u2014 women should have the authority to weigh potential benefits against potential harms and make their own decisions about when and how often to get screened. That\u2019s an important point, and one worth making.", "answer": 1}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms, side effects, or anticoagulation effects with excess doses. The story also failed to mention that fish oil can be a source of mercury with its potential neurologic risks (although there was a brief mention of mercury without context). ", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were many stories about this study, and we could not find one that mentioned harms. This is unfortunate because screening tests do produce false positives and people do make choices based on those results. As a clinician in a New York Times piece about the relative weakness of treadmill tests as a predictor of health explained, \u201cIn my own practice I\u2019ve seen people who thought they shouldn\u2019t be exercising anymore because someone put them on a treadmill and got an abnormal test result when in fact there was nothing wrong with them.\u201d\nProviding this information could also be harmful in other ways. It might reassure someone that they\u2019re going to live a long time, and lead them to forego the things that they\u2019ve previously done to be healthy. Or for those at increased risk of dying, it might make them more fatalistic and less prone to take steps to improve their health.", "answer": 0}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nIt was neuroblastoma, a rare but deadly form of childhood cancer.\nAfter several trips to the doctor, the Mullins received the worst possible news.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to mention the side effects associated with the treatment. \u00a0This was a glaring omission. \u00a0The side effects of treatment includes pain, vascular leak syndrome, and allergic reaction. \u00a0", "answer": 0}, {"article": "Dana Greene, a nutritionist in Boston, regularly tells her patients to consume more fruits and vegetables, including berries.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\nDuring the study period, 405 participants had heart attacks.\nMen are likely to benefit from eating berries as well, although this study included only women, said Cassidy, who is head of the department of nutrition at Norwich Medical School at the University of East Anglia, in England.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms, but all health interventions have harms, as well as benefits.", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\nIn three papers presented at the American Association for Cancer Research annual meeting, and published simultaneously in the , lung cancer experts found innovative ways to weaken lung tumors to improve people\u2019s chances of surviving the disease.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects are mentioned, and this is a major oversight of the story.\nFor example, it could have mentioned that in the Keytruda study of patients with a common type of advanced disease, called non-squamous non-small-cell lung cancer, those in the immunotherapy group experienced more of certain adverse events, such as kidney problems, and were more likely to drop out of treatment due to side effects that those receiving chemotherapy alone.\nNot to mention that in general, immunotherapy can lead to many inflammatory conditions that can occur throughout the body as a result of treatment, such as colitis.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms or potential drawbacks to the surgery, nor does it describe which patients should not get the surgery. The FDA announcement (from which this story is partially based) noted that serious side effects of the surgery included nausea, pain at the device implant site, vomiting, and surgical complications. Less severe side effects included pain, heartburn, problems swallowing, belching, mild nausea and chest pain. In addition, the company disclosed in its announcement that the therapy is not suitable for a wide swath of the patient population including those with cirrhosis of the liver, portal hypertension, enlarged esophageal veins, certain types of hiatal hernia; patients who may undergo magnetic resonance imaging (MRI) or diathermy; patients at high risk for surgical complications; and patients who have a other implanted medical devices such as pacemakers, implanted defibrillators and neurostimulators.\nWe would add that when you start tinkering with the vagus nerve, there could possibly be many adverse effects over time, especially cardiac-related. Twelve months is too short a timeframe to establish these types of harms.", "answer": 0}, {"article": "\u201cAre DORAs the perfect hypnotics?\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\nOrexins originate in a specific region of the hypothalamus, so targeting them may have less impact on other brain functions, Renger said.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is one quote noting that further testing will need to be done to look for rare complications, including narcolepsy-like symptoms, but the story does not mention other side effects, such as sleep walking, balance issues, etc.\u00a0 About a similar drug, Suvorexant, it states that the most common side effects have been headache and sleepiness \u2013 but no data are provided.\nThroughout, the story is not clear in differentiating between Suvorexant and the similar drug tested in the latest trial \u2013 DORA-22.\u00a0 Suvorexant is mentioned in the second sentence but it is NOT the drug studied in the trial being reported on.", "answer": 0}, {"article": "A patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study should have mentioned whether the studied group that took statins showed any side effects compared to the group not taking the statins. \nThe story is implictly about the potential benefits of long-term, prophylactic use of statins for people at high risk for dementia and some vascular diseases. The possiblity of side effects in this group should have been mentioned.\u00a0\nThe journal\u2019s press release says \"the most common side effects of statins are headaches, nausea, fever and muscle pain.\" ", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\nIn addition, Dr. Saslow said, doctors in this country have been performing 15 million Pap tests a year to look for cervical cancer in women who have no cervix, because they have had hysterectomies.\nDebbie Saslow, director of breast and gynecologic cancer for the American Cancer Society, said professional groups were particularly concerned because many teenagers and young women were being tested and then needlessly subjected to invasive procedures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the harms of not catching cervical cancers early. It devotes some attention to the harms of over-treatment that follow unnecessary screening, particularly in low-risk younger women. \nThe story should have mentioned the likelihood of these risks.\n\u00a0", "answer": 1}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes prominently the possible harms: \u201cWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\u201d", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented the data on the combined outcome of being re-hospitalized or dying from cardiovascular problems, indicating that this occurred in a higher percentage of patients taking the combination of a PPI and Plavix than in those taking Plavix alone. \u00a0The story then went on to say that it appeared that this was due to an increase in re-hospitalization rather than cardiovascular death.\nIt would have been more informative to simply present the data on the individual endpoints of rehospitalization and revascularization \u2013 both of which were higher in the group taking the medication combination; but that dying of any cause did not differ among the two groups.", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\nThe patch tactic could have some advantages, said senior researcher Dr. Yoshiki Sawa, of Osaka University.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that the study was designed primarily to determine whether the technique was safe, and the researchers said it was. That\u2019s consistent with the relevant paper, which reports that patients showed \u201cno procedural-related complications.\u201d\nHowever, that does not mean the procedure is risk free and carries no harms. This is effectively heart surgery\u2013what are the risks? That needed at least a passing mention.", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the researchers\u2019 claim that there were no adverse effects to the oxygen treatment. \nBoth the study and the article fail to address potential future harms, and this should have been discussed. The story barely receives a \"satisfactory\" rating under this criterion. \nThis is one area where an independent perspective would have been helpful. ", "answer": 1}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\nAuxilium and BioSpecifics hope that the half-century-old collagenase might eventually become as versatile as Botox, another bacterial product.\nWhile collagenase itself is not patented, the companies do have patents on the use of the enzyme to treat Dupuytren\u2019s and Peyronie\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar mentions that Xiaflex can rupture tendons \"in rare circumstances\" and that the injections\u00a0\"often\" cause temporary pain\u00a0and bruising and \"sometimes\" cause allergic reactions.\u00a0\u00a0We wish that the story had been a bit more precise in its quantification of these adverse effects,\u00a0but we feel the descriptions provided are\u00a0enough to paint a reasonably accurate portrait of the drug\u2019s potential harms.", "answer": 1}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\n\"This finding requires a confirmatory trial, including whether high daily doses of vitamin D, rather than high monthly doses, makes patients less likely to fall,\" Ginde said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the higher doses of vitamin D also had unintended side effects. It reports that the number of falls in the high dose\u00a0group was significantly increased, although according to the study, the number of hip fractures was not different in the two groups.\nThe release meets our standard here, but the finding of more falls should arguably have received more emphasis. Falls might lead to more hip fractures, which could cancel out any \u201clifesaving\u201d benefits from reduced rates of respiratory infection. ", "answer": 1}, {"article": ".\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\nNon-clinical studies conducted by Sylentis with SYL1001 have demonstrated it has high ability to inhibit this specific target and block the perception of ocular pain in animals3.\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Likewise, there is no mention of potential harms that use of tivanisiran might cause to patients. Since one of the earlier studies was a safety trial it would have been appropriate to include those results in the release.\u00a0\u00a0", "answer": 0}, {"article": "and did not have celiac disease or a wheat allergy.\nWhat is less clear is whether there is another group of individuals whose digestive systems have some \u201cgluten sensitivity\u201d and who would, therefore, benefit from avoiding gluten.\nIf you don\u2019t have celiac disease or a wheat allergy and are experiencing distressing gastrointestinal symptoms after eating gluten \u2014 lack of satisfaction with your stool consistency, for example \u2014 there is something like a 1 in 30 chance that the gluten is potentially responsible.\nSince there is no test for gluten sensitivity, \u201cdiagnoses\u201d are based on whether people say they feel better when they avoid gluten.\nThe placebo effect may lead a researcher to falsely conclude that avoiding bread is beneficial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address the fact that adopting a gluten-free diet can pose nutritional risks. As a Harvard Medical School post notes, \u201ccutting out [gluten-containing] products may mean you\u2019re reducing your fiber intake from whole grains, or missing out on vitamins that you\u2019d normally get from fortified foods.\u201d For example, a 2000 study that compared the diets of a healthy control group with celiac disease patients who had gluten-free diets found that, among other things, \u201cthe diet of the [celiac] patients was unbalanced, with a higher percentage of energy as fat and a lower percentage of energy as carbohydrates.\u201d Children would likely be most impacted by nutritional deficits from a restrictive gluten-free diet.", "answer": 0}, {"article": "Since the 1990s, Japan has been an active center of research into the study of electrical motor cortex stimulation (EMCS) to treat post-stroke pain using surgically implanted devices.\nNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nAll patients received repetitive transcranial magnetic stimulation (rTMS) to their primary motor cortex once a week for at least 12 weeks.\nTwo patients reported transient, slight scalp discomfort after rTMS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Quoting from the release: \u201cNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold. Two patients reported transient, slight scalp discomfort after rTMS.\u201d", "answer": 1}, {"article": "The women were then followed for an average of three years.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nThe researchers hope their work sparks more discussion about how people\u2014especially older ones\u2014think about exercise and their goals for being active.\nThe authors say that improving doing more light and moderate physical activity could be almost as effective as rigorous exercise at preventing disease and prolonging life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the NIH has noted, the benefits of physical activity far outweigh the risks. For that reason, we won\u2019t ding this story for not going into details regarding the risks associated with light physical activity. Nonetheless, it would have been nice to see the story mention that older adults may want to consult with a health professional to determine what types of activity they should (or should not) engage in.", "answer": 2}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nWhile more research is needed, these results suggest individuals consuming a more plant-based diet may have a mix of gut bacteria that responds more positively and/or rapidly to tart cherry consumption.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned.\nSeveral tart cherry juices on the market contain substantial amounts of sugar. This is germane since \u2014 among the host of diseases cherry juice is claimed to be good for \u2014 there are claims that tart cherry juice is actually \u201cgood for diabetes.\u201d\nAlthough the amounts used in this study were modest, it\u2019s worth noting that some readers might think \u201cmore is better\u201d and drink enough to substantially elevate their blood sugar.\nFurther, most physicians do not recommend juice as a source of nutrition, but rather the whole fruit.", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nA task force of specialists appointed by the American Society for Bone and Mineral Research reported last month that long-term use of bisphosphonates, typically beyond five years, may increase a patient\u2019s risk of an unusual but serious type of thigh fracture.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nFor Dr. Douglas C. Bauer, a professor at the University of California-San Francisco and a researcher who also treats many osteoporosis patients, the hardest decision is when to stop the drugs in patients who still have low bone density after five years of treatment but are not especially frail.\nIt also called on the US Food and Drug Administration to change medication labeling to alert physicians and patients to the possibility of these unusual fractures, and to urge awareness of possible warning signs: prolonged groin or thigh pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": " \nThe article provided substantial information about potential side effects such as cancer of the esophagus and thigh fractures related to the use of bisphosphonates. However, it would have been useful for the article to also report the conclusion of the US Preventive Services Task Force that bisphosphonates are not consistently associated with serious adverse events.\n  \u00a0", "answer": 1}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\nBeing able to identify this lung cancer \u201csignature\u201d through a simple breath test has emerged as one of the most promising ways to diagnose the disease.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that the test could potentially reduce harms by reducing a patient\u2019s repeat exposure to radiation from CT scans. However, the harms of the test itself \u2014 i.e. false positive screens that cause substantial anxiety and necessitate additional testing \u2014 are not addressed. \nAs noted above under \u201cWhy This Matters,\u201d the concern is that using this test to guide surveillance testing (whether to order the CT) could be a problem if the test is not actually very accurate when used in that role \u2014 false positive and particularly false negative results could lead to harms. We have no data (certainly not from the study in question) that could address these concerns.", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms, which include not only the failure to identify someone who has depression, but also the \u201cfalse positive\u201d misdiagnosis of people who do not have depression. This is the difference between \u201csensitivity\u201d and \u201cspecificity\u201d \u2014 and it\u2019s important. Being told that one has a medical problem that one does not actually have can have implications in people\u2019s personal and professional lives. We did like that the story addressed privacy concerns, which can certainly lead to anxiety and other problems.", "answer": 0}, {"article": "For more information on statins, visit the U.S. National Library of Medicine.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\n\"Although the study does not have immediate clinical implications, our findings may suggest that patients who were prescribed statins and take it persistently may benefit from the many effects of statins, which go far beyond cholesterol reduction, including the reduction of rheumatoid arthritis risk,\" Chodick said.\nAmong those taking statins, there was only a small, short-term reduction in risk of development of osteoarthritis.\nThis work received no outside or corporate finding, the researchers noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story does not mention any side effects of statins or other concerns about the long-term use of the drugs.", "answer": 0}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nOne hour after treatment, less than 40 percent of all patients had significant pain reduction, meaning at least a 2-point decline on the 10-point scale.\nMore than 80 percent still had a pain rating of at least 4, the findings showed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story of possible harms from the use of acupuncture. While the risks may be slight in most cases, they are not negligible. Infection is always possible and some can be serious.\u00a0Also if a patient is not given an actual pain reliever and has to revisit the ER later, that is a harm.", "answer": 0}, {"article": "See original publication for details.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nThereafter, any woman who has been tested positive for a BRCA1 mutation could take RANKL blockade as prevention measure to reduce her dramatically increased breast cancer risk.\nOn average, women with this mutation have an up to 87% lifetime risk of developing breast cancer.\nIn the human cell culture, too, RANKL inhibition led to a significant reduction of growth and spreading of breast tissue cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Denosumab \u2014 as well as carrying out genetic testing \u2014 comes with harms, none of which are mentioned in the release. Denosumab is described as \u201can antibody with very few side effects,\u201d but this does not accord with the results of a online drug database\u00a0which\u00a0shows a lengthy side\u00a0effects list, some of which are serious.\nDenosumab was approved by the FDA for osteoporosis in postmenopausal women in 2010 and for giant cell tumor of the bone in 2013. It carries an increased risk of osteonecrosis (a painful condition caused by reduced blood flow to the bone which causes it to die) of the jaw and femoral hip fractures, increased infection susceptibility, and low calcium levels in the blood, among others. Women at risk might be expected to take such a drug for decades.", "answer": 0}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nShe says that people with certain health conditions, such as high blood pressure, should consult their physician before downing a can of Unwind or any of the other sleep beverages.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story raises the general issue of safety, suggests that\u00a0pregnant/nursing women\u00a0and children should not take\u00a0these drinks,\u00a0and warns against mixing these drinks with alcohol. It also suggests that people with certain health conditions check with their doctor before taking any of these drinks. We think that\u2019s thorough enough.", "answer": 1}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nIn a pilot study, the drug appeared to reduce symptoms of rheumatoid arthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides more quantification of potential harms than most stories we review. It provides a point by point breakdown of the harms in the same way it breaks down the benefits. It also flags a potentially huge Achilles heel for the drug. \"There\u2019s at least one theoretical concern about R788. Normally, the Syk enzyme helps suppress tumors. Women with breast tumors have low levels of Syk. It\u2019s not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\" This is more than a theoretical concern. Inceased cancer risk is one of the big reasons that drugs end up being pulled from the market after approval.", "answer": 1}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the BCG vaccine, an attenuated form of Mycobacterium bovis that has been used to treat tuberculosis for nearly 100 years, is considered extremely safe.\nThere are some rare side effects of the BCG vaccine (as for any medicine), so the article could have mentioned this, though.", "answer": 0}, {"article": "Newswise \u2014 Columbus, OH.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nA team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from the technology.\nAccording to an article in DermatologyTimes, \u201cPatients who are allergic or sensitive to silver, zinc and/or polyester should avoid using Procellera. In addition, patients undergoing magnetic resonance imaging, electrocardiogram or electroencephalogram should avoid using Procellera.\u201d The information was provided by a physician-consultant to the manufacturer. ", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a credible job of explaining that there are complications with any surgery. They did not explore the potential of surgery \u2013 even without complications \u2013 to leave a patient with reduced range-of-motion or other results that are less than desired outcomes.", "answer": 1}, {"article": "Most are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of Fernblock are mentioned. If the long-term safety is unknown, an acknowledgement of that or the potential harms of taking any herbal supplement would have sufficed.", "answer": 0}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes the drug\u2019s side effects, including the most common one which renders patients more susceptible to infections. However, it needs to be pointed out that the studies involved very small numbers of patients and the emergence of more serious side effects may not be seen until the drug is observed in a larger population.", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\nAll four monkeys responded to the vaccine, but the two that were receiving it a second time had a stronger response, hinting that their immune systems were already primed with the \u201cmemory\u201d of the compound.\n\u201cWe believe this vaccine candidate will prove safe for human trials,\u201d said Janda in a statement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes\u00a0\u201cThe researchers did not observe any harmful side effects from the intervention.\u201d Having said that, again the study was conducted in four monkeys under highly controlled lab conditions\u2013not in humans. The comment of one of the authors, \u201cWe believe this vaccine candidate will prove safe for human trials,\u201d feels premature. On what grounds does he believe this?\nTo have passed this criteria, the story should have said the harms are\u00a0unknown.", "answer": 0}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nHe added, however, that the studies confirm the potential of cancer vaccines.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for making an important point that waiting for the vaccine to be made might be detrimental to patients with advanced cancer. It says, \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four\u00a0months\u2014which may be too long from some patients with advanced cancer.\u201d\nThe story also notes that \u201cBoth vaccines were deemed safe\u201d but it doesn\u2019t discuss any side effects that may have shown up in the trials. What happened to the five patients who were not tumor free at 25 months?\nThe story does mention that more research is needed to identify potential harms.", "answer": 1}, {"article": "It's OK to ask the question,\" Hoberman said.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nThe \"wait and see\" approach has been enshrined in current guidelines from the American Academy of Pediatrics.\nTwo new studies add substantial weight to one side of a long-running controversy over whether to give antibiotics to young children suffering from ear infections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possibility of antibiotic resistance is raised but never quantified in any way. Other harms are not mentioned. This is a significant omission. Both studies list adverse events, and the Finnish study saw a large number of children with adverse events. As the authors note, \u201cAn adverse event occurred in 85 children (52.8%) in the amoxicillin\u2013clavulanate group and in 57 children (36.1%) in the placebo group (an increase of 16.7 percentage points with amoxicillin\u2013clavulanate\u201d. Of those who received the drug, 77 had diarrhea, 17 had vomiting and 14 had eczema. There also are harms from not taking the drugs, which were not mentioned.", "answer": 0}, {"article": "Neither option is considered ideal.\nResearchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nA new study shows stereotactic body radiation therapy (SBRT) effectively controlled more than 87% of early-stage inoperable non-small-cell lung cancer tumors for up to three years.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicates that 16% experienced significant but non-deadly side effects of treatment. But what were those side effects?\u00a0 How serious were they?\u00a0 Did they occur more or less often with SBRT than conventional radiation? ", "answer": 0}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention the possible harms of each intervention. While these methods are generally considered safe, no treatment is without risk of harm so we would like to see some discussion.\u00a0 The risks associated with acupuncture generally rest with the acupuncturist and can include soreness, infection, and in rare cases, organ injury if the needle is pushed in too far. Because the Alexander Technique calls for changes to posture and movement, it may cause harms to people with specific spinal injuries that are better left treated by licensed medical experts.", "answer": 0}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited one instance of harms, saying: \u201c\u2026\u00a0for people who started out with at least 20 nanograms of vitamin D per milliliter of blood, adding more vitamin D through supplements was associated with a greater risk of hip fractures.\u201d\nWe also wanted to see a mention of potential harms of calcium, such as kidney stones. Another common side effect is excess gas and one potential harm of high doses is cardiovascular complications such as heart attack.", "answer": 0}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nSome patients were continuing to respond to T-VEC three years later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harmful side effects, or side effects at all, is made. The original paper does indicate that side effects were minor and that most negative effects were either unrelated or due to disease progression rather than the treatment.\u00a0 However, a line indicating that most side effects were minimal would have been welcome. It would also have been reasonable to mention that virus- delivered therapies have been shown to have potential side effects that warrant caution, and that there is some worry that healthcare workers and others could be infected by these viruses. (though this one seems safe, at least from the studies performed to date).", "answer": 0}, {"article": "Lobular breast cancer forms in the milk glands.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms were discussed but this is not a serious issue in this case. ", "answer": 2}, {"article": "\"We need people to swim against the stream.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, \u201c11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn\u2019t.\u201d There could have been a little more discussion of the ramifications of a test with this kind of error rate.", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\n\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\nSmith-Bindman says neither doctors nor patients appreciate the amount of radiation exposure that U.S. patients are accumulating from CT scans.\nThat means many unsuspecting patients are getting considerably more radiation than they need for an adequate CT image.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harm of exposure to radiation due to CT scanning.\u00a0The story could\u00a0have also mentioned\u00a0other\u00a0harms from overuse of scanning, such as follow-up testing\u00a0and procedures to evaluate suspicious findings that\u00a0turn out to be benign.\u00a0", "answer": 1}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nRobert Maclaren, a professor of Ophthalmology at Britain\u2019s Oxford University and a consultant retinal surgeon at the Oxford Eye Hospital, who was not involved in this trial, said he was \u201cvery excited\u201d by Zrenner\u2019s results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on the implant requirements for the device\u00a0nor the potential downsides associated with this surgical procedure.", "answer": 0}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nIt is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned.", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\nUp until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is nothing in the release about the harms of ingesting or smoking marijuana. The release (nor the study) never mentions specifically how the HIV patients consumed their marijuana \u2014 whether through smoking, edibles, cannabis oil or other means, or any potential risks associated with any of the methods.\nAnytime we inhale smoke into our lungs we are taking a risk. At a minimum, some of those risks should be mentioned. And, better yet, if the study did not adequately track patients to assess the negative effects of marijuana smoking or otherwise ingesting, that should be acknowledged.\nIt\u2019s likely that the negative impact of marijuana was not mentioned because the study was in vitro (using blood samples). However, that underscores the fact that no true clinical correlation can reasonably be made from this study alone.", "answer": 0}, {"article": "Data on deaths was obtained from the U.K. Office for National Statistics.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\nThe database includes information on cancer and other medical conditions, including high cholesterol.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins have been identified with some serious side effects, including memory loss, muscle pain, and a condition known as rhabdomyolysis, and the story should have made some reference to this. In this article, the FDA\u00a0explains risks.", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that chocolate is laden with fat and calories, potentially harmful in people who are already overweight or obese.\n", "answer": 1}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause, says researcher Gary R. Elkins, PhD.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\nIn an earlier study, Elkins and his Baylor colleagues showed that hypnosis dramatically reduced hot flash and night sweat frequency in breast cancer patients with treatment-related symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any possible harms or side effects of the alternative therapy. It does, however, mention that hormone therapy comes with its own risks. The LA Times article, by comparison, correctly states there is no known risk of hypnosis.", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes in paragraph two the potential harms of over-screening\u2013that the testing led to stress, anxiety and some unnecessary treatments. \nThis point is emphasized by a quote in the following paragraph.\u00a0 ", "answer": 1}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\nThe researchers estimated there will be an extra 2,000 excess breast cancers just from CT scans done in 2007.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly describes the harm of radiation exposure from CT scanning. The story could have also mentioned that excessive CT scanning can also lead to unecessary follow-up testing and/or procedures for suspicious findings that turn out to be benign.", "answer": 1}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nDoctors need to weigh the risks and benefits, Edge added.\nEdge was a panel representative from the American Society of Clinical Oncology, which created the guidelines along with the American Society for Radiation Oncology and the Society of Surgical Oncology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does address the need to \u201cweigh the risks and benefits.\u201d The story notes: \u201cSide effects can include redness of the skin, swelling and skin breakdown severe enough to compromise future breast reconstruction.\u201d Those are important points, and we\u2019re glad the story made them.\nWe wish the story had also discussed that there can also be more serious health effects from radiation, including the possibility of increased risk of a second cancer. Also, surgical complications may be increased in patients who require radiation therapy.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out the potential adverse effects associated with this drug.\u00a0 ", "answer": 1}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nVolition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. How might the false positive rate compare with current practice? Even if, as the company hopes, this blood test might reduce the total number of men sent to have biopsies who turn out to have low-grade tumors, could this test send some men to biopsy who would not have been subjected to it based on current practice?\nOn the other hand, what is the false negative risk; that is, the chance that identification of a high-grade tumor might be delayed because a man was not referred for a biopsy based on the results of this blood test?", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nOn top of that, poor sleep itself can lead to psychological \"distress,\" such as depression symptoms, Black said.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions risks in the context of sleep medication, saying that sleeping pills \u201ccan have side effects that are particularly dangerous for older people \u2014 such as dizziness and balance problems that can lead to falls, and problems with attention and memory.\u201d By implication, the story is saying that the meditation showed no side effects. (For example, did it make it harder for any of the participants to sleep?) It would have been nice to have that issue clarified.", "answer": 1}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\n(CNN) How much -- or how little -- you eat could influence how long you live.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\nWhen cells in the body age, their ratios change and Longo believes the body's reaction -- and repair methods -- to fasting help restore them to when you were younger.\nTo him, diet underpins longevity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story should have explained to readers at least a few known potential harms of fasting\u2013which are very real, especially for people with certain health conditions, including common ones like diabetes. All we get is a quote that hints it might be dangerous to fast for more than five days:\n\u201cFive days is safe: going on for longer is difficult to do outside of a clinic,\u201d says Longo.\nBut fasting for 5 days would clearly be harmful for many people.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that one patient who received Stelara died from \u201cexcessive bleeding\u201d but that overall side effects were similar between Stelara and placebo patients. That\u2019s enough to earn a satisfactory rating here. However, it was fairly glaring to discuss a patient dying without explaining whether or not it was thought that this death was attributed to the treatment or the underlying disease.\nAlso the story would have been stronger if it had noted that Stelara affects the immune system, and can cause a host of other significant side effects. The story doesn\u2019t need to list every single risk, but a sentence addressing the risks would be worthwhile.", "answer": 1}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nA permanent artificial lens is then implanted to replace the natural lens and provide appropriate vision correction for each patient.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not discuss potential harms of femtolaser surgery or mention any adverse effect data reported in the studies\u00a0being discussed.\u00a0(Given the brevity of the presentations, it is perhaps not surprising that potential harms were not mentioned.) While there are no data for the use of the femtolaser in cataract surgery, the risks associated with its use are well described when used in vision correction surgery and could have been mentioned here.", "answer": 0}, {"article": "Recently, he says, urologists \"have begun to realize these criteria are not adequate.\nBut even when researchers allowed for these errors, they found the test doesn't predict how patients ultimately do.\nWhen these errors occur, the study says, doctors most often conclude the cancer is less serious than it really is.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nResearchers Say Common Test For Prostate Cancer May Not Work\n\nMore bad news on the prostate cancer front: A widely used test that's supposed to help doctors and patients predict the outcome of most prostate cancers is basically worthless.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that doctors \u2018erred 35% of the time\u2019 with clinical staging and this leads doctors to conclude that a given prostate cancer \u201cis less serious than it really is.\u201d\u00a0 However \u2013 this is only half of the story.\u00a0 There\u2019s also a significant harm that occurs from overtreatment of lesions that were never destined to be problematic. \u00a0To be balanced and complete, the story should have mentioned this as well because it is another important problem.\nFor example, a MedPageToday story addressed this issue:\u00a0 \u201cFor those men with prostate cancer found to have been staged incorrectly, the assigned clinical stage was too low 55.1% of the time \u2014 and too high in 44.9% of cases.\u201d", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nAvailability of a blood test for concussion will help health care professionals determine the need for a CT scan in patients suspected of having mTBI and help prevent unnecessary neuroimaging and associated radiation exposure to patients.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. In any screening test, there is always the harm of missing an injury that exists or finding a false positive that leads to unnecessary and sometime costly followup tests and treatments.", "answer": 0}, {"article": ".\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\nAccording to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily.\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cSide effects among patients taking the drug were similar to the placebo group.\u201d Dr. Alessandro Di Rocco also agrees with this statement, since the \u201ccompound is apparently well tolerated without significant side effects.\u201d However, the story could have been more thorough in letting the reader know exactly what those side effects are.", "answer": 1}, {"article": "It\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\nOther smaller growths in the brain continued to grow, however, so the patient received 10 more doses of the CAR T cells injected into the cavities in the brain, called the ventricles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes that CAR-T cell therapy has potentially dangerous side effects when used the way it was in in this trial, and acknowledges surprise on the part of the investigators as to why the patient did not develop them. The story might have been stronger if it had noted that the treatment is well known for serious side effects in experiments on patients with other forms of cancer. (See our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.)", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "New battery-free, easily implantable weight-loss devices developed by engineers at the University of Wisconsin-Madison could offer a promising new weapon for battling the bulge.\nThat means the device only stimulates the vagus nerve when the stomach moves.\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat existing unit, \"Maestro,\" approved by the Food and Drug Administration in 2015, administers high-frequency zaps to the vagus nerve to shut down all communication between the brain and stomach.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss potential harms, even though the similar, approved device has caused a number of harms, such as:\n\u201cNausea, pain at the neuroregulator site, vomiting and surgical complications were among the serious adverse events reported in the clinical trial. Additionally, some patients experienced pain, heartburn, problems swallowing, belching, mild nausea and chest pain.\u201d\nThe release should have addressed the possibility that this experimental device could present similar risks.", "answer": 0}, {"article": "Drs.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\nSo smokers who take bupropion are likely to be trying to quit--and coping with the weight gain that often accompanies attempts to quit smoking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With the exception of a mention that some people can\u2019t take buproprion (seizure disorder patients, for example), and the weight gain issue, the release makes no mention of the considerable side effects that accompany antidepressant use, or the often frustrating search patients and physicians must undertake to find an antidepressant that is both effective and tolerable for individual patients. Fatigue, insomnia, increased anxiety, headache and nausea are all fairly common when starting an antidepressant.", "answer": 0}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\nThe investigators pointed out that all other standard procedures for reducing the risk of infection after surgery, including giving preventive antibiotics beforehand, were the same in both groups.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t mention any harms associated with either of the antiseptics used in the study. If there were no skin reactions, or some with one but not the other, it would be good to note that. This is a minor omission.", "answer": 0}, {"article": "\u201cI\u2019ve had patients who wouldn\u2019t dream of not being treated,\u201d Dr. Berchuck said.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nThe group getting the test began chemotherapy a median of about five months earlier.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nBut she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the major harm of CA-125 testing, which is that it could lead to unnecessary treatment in women who would not benefit from it.", "answer": 1}, {"article": "What does that mean for men today?\nMany specialists say too many men today are undergoing side effect-prone treatment for tumors too small and slow-growing to ever threaten their lives.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention that screening itself is associated with harms, such as physical pain from subsequent biopsies, anxiety, and problems related to a false positive (a false alarm) screening result.\u00a0 While the story does mention that many experts believe too many men are undergoing side effect prone treatments for prostate cancers which would never harm them,\u00a0 those treatments or side effects are\u00a0 not mentioned.\u00a0 The treatments\u00a0commonly include surgery or radiation, both of which can cause problems with impotence/erections, bladder control, and bowel functioning. The side effects are not inconsequential and happen to a significant number of men (sexual problems seem to occur in a majority of treated men).\u00a0 The reader doesn't have any context for how serious or frequent these may be.\u00a0 ", "answer": 0}, {"article": ".\nA third also had scans to assess their brains\u2019 use of glucose.\nThe problem was to find a way to get more insulin to the brain but not to the body.\nThe lower dose seemed more effective than the higher one.\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story references potential adverse effects, and notes that this study was too short and small to reliably document the potential harms of treatment. However, it didn\u2019t mention the adverse effect data \u2014 limited though it may be \u2014 that was reported in the study. Adverse events were more common in the insulin-treated groups and were reported by 72% of patients receiving\u00a020 IU\u00a0of insulin,\u00a068% receiving\u00a040 IU, and\u00a057% receiving placebo.\u00a0The most commonly reported adverse event was a stuffy nose, but headaches and nosebleeds were also more common with insulin treatment.", "answer": 0}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAhlquist noted that the test still needs to be refined.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nAhlquist noted that the cost of the test has not yet been established.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story kept piling up the accolades \u2013 \u201cone more advantage\u201d and then \u201canother benefit is\u2026\u201d but in the end the story was all benefits and no harms. The New York Times story, by comparison, addressed false positives.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At first glance, it\u2019s hard to imagine there are any dangers: Chemicals in broccoli are harmless, right? But as revealed by this very study\u2013that\u00a0sulforaphane has the capacity to significantly change blood lab levels\u2013these chemicals can work like medication. That means they\u00a0also may carry harms, too. In this case, specifically, it\u2019s for people taking the blood thinner Coumadin (warfarin), who must be very careful when eating broccoli and other vegetables rich in Vitamin K.", "answer": 0}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe main benefit of the pills will be that they are easier to take.\nThese dangers are nothing new \u2014 the MS drug Tysabri was pulled from the market after some patients came down with rare brain infections.\nBut soon, it seems, they will have an alternative to this painful regimen: drugs that can be taken by mouth.\nThose painful welts are something he would happily do without \u2014 and the new pills could be the answer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential\u00a0 harms were listed but not quantified.\u00a0 How often do they occur?\u00a0 ", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\nAfter a year, Park's team tallied the number of adverse cardiac events the patients experienced, including death, heart attack and the need for a new angioplasty on the same artery in which the stent was placed.\n\"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy,\" said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s overlap between harms and benefits here because stents are designed to prevent harm. However, the study identifies the development of blood clots on the stent as a safety outcome (along with the numbers of heart attacks and death). While the article tells us that the rate of clots was significantly lower with one type of stent, it does not quantify the harms.", "answer": 0}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nThat warning was especially strong for those with a family history of allergies.\nThat advice has been amended, and newer evidence has shown that introducing foods earlier is actually better for preventing food allergies.\nEggs, too, showed this association when they were introduced between ages 4 and 6 months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the news release, the study authors say that we need \u201ca careful assessment of the safety and acceptability of early egg and peanut introduction in different populations\u201d before rolling this out widely. What are these safety concerns? The story doesn\u2019t say.", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of midwifery care could include risks both for the health of the baby, as well as the health of the mother.\u00a0 Maternal health outcomes are not addressed in the study, and not mentioned in the release.", "answer": 2}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not give any details about side effects. It is worth noting that the abstracts themselves fail to provide much details about treatment harms, which is one of the problems with basing a news story on medical meeting abstracts.", "answer": 0}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nFor the first time, however, patients such as Herry have options.\nAll improve survival by a few months.\nPatients with a limited time to live may not be so positive, Turnham says.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate discussion of potential harms from a couple of the drugs.\u00a0 Excerpts:", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the final paragraph, the story mentions that BMP is linked to more complications, particularly difficulty swallowing in surgeries done high on the spine.\nBut the story didn\u2019t explain how big were the potential harms.\u00a0 According to the results of the study, the use of BMP in anterior cervical fusion is associated with a 51.4% higher complication rate compared to patients who did not receive BMP (7.09% vs. 4.68%, respectively).\u00a0 However, these data were not presented in the story. ", "answer": 0}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nDuring 15 years of follow-up, 747 patients were diagnosed with lung cancer.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\nNonsmokers who used metformin for five years or longer had a 52 percent reduction in lung cancer risk, but this finding was not statistically significant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release about potential harms that may arise with the administration of metformin. The drug is known to produce harmful side effects in more than 10 percent of people taking it, largely affecting the stomach or bowel such as vomiting, diarrhea, and loss of appetite.", "answer": 0}, {"article": "October 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nThe improvement was similar for patients with and without prior shoulder surgery.\nFurther surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\nWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\nThe patients underwent follow-up examination between eight and 19 years after surgery (average 11.7 years).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states, \u201cHowever, complications occurred in 39 percent of the shoulders. Further surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\u201d\u00a0 It adds that, \u201cWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\u201d", "answer": 1}, {"article": "A month\u2019s supply costs about $12, while a month of hormone tablets runs between $40 and $60.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\nThe new study, published in the journal Menopause, is based on 90 Chinese women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a brief mention of harms that the National Institutes of Health list for soy supplements, but no mention of side effects experienced by women in the study.", "answer": 1}, {"article": "Lung cancer is the No.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nMetformin, an older and cheaper drug available generically, had a more powerful effect than newer drugs called thiazolidinediones, TZDs or glitazones, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study may not have addressed the harms of these drugs during its chart review, but they do have well-known side effects, which could\u2019ve been mentioned.", "answer": 0}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nThis happens in anywhere from 10% to 25% of women infected with HPV, Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nThe vaccine trains T-cells in the body to go after cervical cells with potentially cancerous genes embedded in them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cThe researchers did not observe any side effects.\u201d\u00a0 But the Philadelphia Inquirer reported: \u201cMost side effects of the vaccine were minimal and deemed unrelated to the treatment, the paper reported.\u201d", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study on which this release was based did reference \u201cminor complications\u201d and symptoms that required removal of the bands among some participants, the release ignores this information.", "answer": 0}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\n\"So it narrows the focus to a subgroup of [anti-inflammatory drugs].\"\n\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\nTagliati called the study \"eye-opening.\"\nStudy author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention that \"persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining.\"", "answer": 1}, {"article": "The study\u2019s median follow-up was 18.5 months.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only tells us that:\nSevere side effects were reported in 16.5 percent of the Keytruda patients, compared with nearly half of the chemotherapy group.\nBut what does severe mean? And how often did less severe side effects occur when patients were on Keytruda?\nAs we\u2019ve discussed in 6 tips for writing about immunotherapy, there\u2019s a tendency to underplay the harms of immunotherapy drugs.", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough one. The article does mention limitations, but doesn\u2019t specifically state that conceivably this chip technology could have unforeseen problems \u2014 that it may say everything is ok when it isn\u2019t and that could lead to harm. Given the early stage of this research, it would be prudent to include a caveat about potential for unknown or unpredictable downsides to the technology.", "answer": 0}, {"article": "The American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nRegular massages have been shown to make the immune system stronger, according to studies.\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although massage is generally considered a \u201csafe\u201d therapy, it is still an intervention and not free from risk, particularly among those with musculoskeletal issues. Massage can cause soreness and also directly cause new injuries, exacerbate existing problems, distract patients from more appropriate care and mildly stress the body.\nSince harms were not mentioned at all in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "CHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\nThe study was funded by the National Institutes of Health and the Bill & Melinda Gates Foundation.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vitamin supplement taken in very high doses can be harmful and some acknowledgment of this should have been made here. Even citing the author or another expert about a lack of observed or known harm would have been sufficient.", "answer": 0}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nWhen doctors recommend surgery, these data suggest that that decision is a good one.\"\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nThat can call into question the ultimate relevance of the findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story, along with the Associated Press we reviewed, failed to mention harms. We did appreciate, though, that NPR noted that \u201cdoctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\u201d", "answer": 0}, {"article": "Dental caries (tooth decay) is caused by bacteria on the tooth surface feeding on carbohydrates, then making acids as waste.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nDental decay was low in both groups.\nThose in the control group also reduced their risk to a lesser degree, simply by using over-the-counter products that also protect teeth and affect the bacteria.\"\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to quantify the potential harms from calcium, but, because the numbers were presented only in relative terms, we feel readers will not be able to adequately assess for themselves whether they need to change their behavior. For example, the story says, \u201cwomen who were randomized to take calcium and vitamin D as part of the study protocol had a modest 13 to 22 percent increased risk of cardiovascular problems, particularly heart attacks.\u201d Then it says, \u201cThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women. Now the increased risk for heart attack was 25 to 30 percent and, for a stroke, 15 to 20 percent.\u201d We\u2019re not sure why a 22 percent increased risk is considered \u201cmodest,\u201d while a 25 percent increased risk is cause for alarm. Some absolute numbers and even an explanation showing the number of women who would have to take calcium regularly in order to see one heart attack would have been good context.", "answer": 0}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThey verified that detailed quantification of the tested and retested tracer in those five patients with Alzheimer's and five older controls generated good and reproducible results.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\nTwo studies will be published back-to-back in the December issue of Journal of Nuclear Medicine--one as featured article of the month--describing testing of three candidate molecules in patients with Alzheimer's disease, as well as the use of one molecule to measure the accumulation of tau proteins.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there any risks associated with injecting these molecular markers into a study participant or patient? Even if there aren\u2019t, that in itself is worth addressing. The release also doesn\u2019t address two other potential harms (which are common to most, if not all, diagnostics): the failure to identify someone who has Alzheimer\u2019s and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d Missing someone who has Alzheimer\u2019s is problematic. And being told that one has a disease that one does not actually have can also have ramifications for future healthcare, with consequences both physical and financial.", "answer": 0}, {"article": ".\nThe study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did make clear that the OCT device was a light-only probe that carried no need for dyes or invasive procedures; it was \u201cswept\u201d across the tissue so that the microscopic tissue structures could be captured on video and analyzed or compared with the gold standard analyses in the path lab. But the release probably should have said whether the use of OCT added to time under anesthesia or was associated with little or no harm at all to patients.\u00a0In addition, there is the potential for harm in terms of an impact on cosmetic results if tissue is removed based on a positive reading that was found to be a false positive. One of the cases described in the study was a false positive.", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nOf melatonin, Dr. Seres warned, \u201cIf you take it while you\u2019re driving a car, you will find yourself in a ditch.\u201d\n\nMaybe.\nThat said, he would not advise eating Lazy Cakes, partly because he was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that dessert makers \u201care marketing their products as a harmless way to promote relaxation.\u201d\nWhile harms are not quantified, it\u2019s clear from the story\u2019s discussions about regulatory questions why that\u2019s impossible to do right now. The harms mentioned are largely hypothetical in that there isn\u2019t good evidence documenting these problems.\nBut the story does a good job in painting, with broad strokes, what might go wrong if one uses these products.", "answer": 1}, {"article": "All rights reserved.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\nThe publication has published a comprehensive review article exploring Irritable Bowel Syndrome (IBS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms, even though the trial of IBgard that is highlighted in the release specifically tracked adverse events including indigestion, flatulence and reflux. The article summarizing that trial knocked other brands of peppermint oil capsules for causing heartburn, nausea, anal burning and \u201cdose-dumping,\u201d which is the sudden release, rather than slow release, of the drug in the capsule.", "answer": 0}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nMore patients on the drug had the required improvement in symptom severity.\nThe company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\n\u201cWe knew the drug was safe and biologically active,\u201d H. Thomas Watkins, chief executive of the company, said in an interview.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not include any insight about potential harms or side effects that have been seen to date with the use of this drug.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nBut many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection.\nHigher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\nGreater blood flow is often a requirement of growing cancer cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. One conceivable concern is that \u201cprovid[ing] a better target for biopsies, especially for smaller tumors\u201d might lead to overdiagnosis \u2014 finding low-risk cancers that would never cause a problem. The patient is subsequently burdened with a cancer diagnosis and complication risks related to ensuing treatment/surveillance protocols.", "answer": 0}, {"article": "Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\nSignificant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\nThe paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing tumor that develops in the cerebellum at the base of the brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses some of the harms associated with the therapy and provides specific numbers\u00a0that are easy for readers to understand. It says, for example, \u201cOf 59 patients who enrolled, 12 died from their tumor during the study period and one from a traumatic brain injury. Significant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\u201d\nThe release didn\u2019t point out that all of the patients had additional treatments \u2014 including surgery and chemotherapy \u2014 so it\u2019s not possible to pinpoint years later where to place the blame for any hearing loss or cognitive deficits.\nWe think some of the harms from the therapy were given short shrift, but we address this in the \u201cQuality of Evidence\u201d measure.", "answer": 1}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nAn antidepressant can help alleviate hot flashes that plague many menopausal women, according to new federally funded research.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nThe hot flashes increased after the women stopped taking the drug but not among those taking a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the competing WebMD coverage at least mentioned the possibility that this drug could cause adverse effects, this blog post does not\u00a0acknowledge any potential downsides of treatment. We have a lot of good data on the adverse effects of antidepressants, and the story could easily have brought in\u00a0summary data from other studies, rather than relying simply on 8 week data from a relatively small number of women. Giving results from a single study, while ignoring data from hundreds of other relevant studies involving thousands of patients, is a frequent problem in reporting. See the WebMD review for a more thorough discussion of why this is important.", "answer": 0}, {"article": "www.petermunkcardiaccentre.ca\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\nSince it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No intervention is risk-free, especially ones that are invasive. On page 9 of the CardioMEMS user\u2019s manual, a slew of potential adverse effects is associated with this implantation procedure, including infection, bleeding, arrhythmias, blood clots, heart attacks, stroke and even death.\nSince the news release doesn\u2019t address harms, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\nHowever, seeing this type of success allows sports medicine physicians another option in older patients and serves as a predictable biologic joint preservation technique,\" said Crawford.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed at all. No surgery is completely without risks, so this is not an acceptable oversight. For example, as of 2007, Orthopedics Today was still highlighting the fact that \u201cDisease transmission also remains a worry for surgeons using allografts.\u201d", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that using the new drug brought on double vision among 50 percent of the patients by six months. Only 10 percent of the patients admitted double vision at the start of the trial.\u00a0 Also, the story states that \u201cHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\u201d", "answer": 1}, {"article": "Still, the extent of the benefit was not clear.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\nOn the other hand, a recent study of 162 adults found that those who took 2,000 IU of vitamin D everyday for 12 weeks were no less likely to develop respiratory infections than those given placebo pills.\nOn average, men who took vitamin D missed about two days from duty because of a respiratory infection, compared with three days in the placebo group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story cautions that vitamin D can cause problems including nausea, vomiting, constipation, poor appetite, weight loss and even higher blood pressure or heart rhythm abnormalities.", "answer": 1}, {"article": "\u201cIt can be the most interesting story in the world,\u201d he said.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nBut he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the story, which is too bad given that this product is apparently uNPRoven, both in labs and in the marketplace. Many would assume that there is no possible harm that could come from applying a natural product containing a seaweed compound. While that may indeed be true, there is no evidence to support that lack of any comments about potential harms. Since there are no data available about its use in premarket testing and the product has yet to reach the market, it would have been reasonable to point out that the potential harms of alguronic acid are unknown at the moment", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nMost Americans will at some point have a problem with their backs.\nIn other words, it's not that the J-shaped spine is the ideal one \u2014 or the healthiest.\nBelieve it or not, there are a few cultures in the world where back pain hardly exists.\nSo indigenous people around the world don't have a magic bullet for stopping back pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that an active lifestyle, and strong abdominal muscles, can reduce the risk of back pain. And there\u2019s a lot of evidence to support this. But not all exercises are created equal. Some exercises that people associate with abdominal strength may actually aggravate lower back pain. Full sit-ups can worsen back pain as can bilateral leg lengths. Also, poorly done Pilates or yoga can as well. All require some training. The same is true of a generally active life style \u2014 excessive squats, planks, core strengthening can worsen back pain. Some acknowledgement of that fact would have earned the story a Satisfactory rating here.", "answer": 0}, {"article": "So which one is right for you?\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nThe prep for both the virtual and actual colonoscopy is the same \u2014 the dreaded \u201ccolon cleanse\u201d that many patients find is the worst part of the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that virtual colonoscopy \u201cinvolves exposure to a small amount of radiation. But according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk. It\u2019s similar to [the exposure from cosmic radiation] you might get on a long airplane flight.\u201d\nThe USPSTF states:\u00a0\u201cRadiation exposure resulting from CT colonography is reported to be 10 mSv per examination. The harms of radiation at this dose are not certain, but the linear no-threshold model predicts that 1 additional individual per 1000 would develop cancer in his or her lifetime at this level of exposure. The lifetime cumulative radiation risk from the use of CT colonography to screen for colorectal cancer should be considered in the context of the growing cumulative radiation exposure from the use of other diagnostic and screening tests that involve radiation exposure. On the other hand, improvements in CT colonography technology and practice are lowering this radiation dose.\u201d\nWe think that broader context should have been provided to readers.", "answer": 0}, {"article": "Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\n(Reuters) - Merck & Co\u2019s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.\nThe U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When making decisions about health care treatment options, patients often consider three factors: cost, benefit, and quality of life (i.e., potential harms/side effects). Some patients may decide not to pursue treatment that may extend life for a short period of time if that treatment will also have a significant adverse effect on their quality of life. In short, discussion of potential harms is extremely important. The story notes only that \u201c[s]afety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients.\u201d Given that potential side effects include hepatitis, hypothyroidism, and Type 1 diabetes mellitus, it would have been worth devoting an additional sentence or two to possible harms.", "answer": 0}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nThe drug is the first treatment approved for Dravet syndrome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FDA release about the agency\u2019s approval lists the most serious side effects, many of which are common, including liver damage, depression, suicidal thinking, anorexia and insomnia. But the news story does not mention them.", "answer": 0}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nBut some also want Sarepta to make the drug available to more patients on a compassionate basis even before approval.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\nIf eteplirsen gets to market, it would come nearly three decades after the 1986 discovery of the gene responsible for Duchenne.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided some limited information on what is known about the potential harms, \u201cIt is also unclear how long the effects of the drug would last or if safety issues would arise with longer treatment.\u201d\u00a0 \u201cEteplirsen, which Sarepta says has shown no side effects so far,\u2026\u201d\u00a0\nThe company\u2019s press release noted: \u201cThe safety profile of eteplirsen was evaluated across all subjects through 48 weeks and there were no treatment-related adverse events, no serious adverse events, and no discontinuations.\u00a0Furthermore, no clinically significant treatment-related changes were detected on any safety laboratory parameters, including several biomarkers for renal function. \u201d We think that this information should have been included in the story, as it would have provided more meaningful details to back up the sparse comments on harms that were published.\u00a0 No, we don\u2019t expect a story to read like a journal.\u00a0 But we do draw a line between what we think is meaningful explanation to readers and what isn\u2019t.", "answer": 0}, {"article": "TUHS neither provides nor controls the provision of health care.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\nTheir superior performance suggested a successful reversal of memory deficiency.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms in a mouse model do not necessarily translate to humans but we do know what the side effects profile looks like. \u00a0The harms include alteration of liver function, sleep and behavioral disorders \u2014 to name a few.", "answer": 0}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\nThe lung cancer device Mazzone is testing, called an \"electronic nose\" sensor, changes color based on the chemicals in the breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s too early to say exactly what harms might result from the use of this test clinically, but at the very least, we know that some patients would be unnecessarily flagged for\u00a0additional tests and procedures based on a false-positive test. The story should have mentioned this.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the selling points of Reiki is how harmless it may be (lack of efficacy notwithstanding).\u00a0 The story could have addressed what might be the greater harm in people choosing Reiki for therapeutic benefit and forgoing other, proven treatment methods.\nWe\u2019ll again give the column the benefit of the doubt.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nNow, the task of estimating death or disease linked to diet is tricky.\nScientists at Tufts University identified the foods that seem to contribute the most to the risk.\nDiet was linked to nearly 319,000 of these deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The likelihood of suffering harm from adopting any of this diet advice seems low, though concerns have been raised about the health effects of cutting sodium to very low levels. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nIn many cases such big reductions were achieved even though the patients were already taking statins.\n(However, the PCSK9 drugs are taken by injection every two weeks or four weeks, which could deter some users.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentioned the drugs could cause memory problems and that long-term safety must still be assessed. The story would have been stronger if it had mentioned the actual rates of memory problems found in the studies. Some mention of the side effects seen with monoclonal antibodies used for other purposes would also have been useful.", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\nThere are three tests often used to look for breast cancer, Evers said.\nOlder age is a leading risk factor for breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are potential and actual harms to screenings, including unnecessary biopsies and other tests, anxiety and false negatives. Again, while new technologies have reduced some of these harms, they are not zero. The story doesn\u2019t mention any.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nColic affects up to 28% of infants and has no known cause or cure.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Probiotics are generally regarded as safe for healthy children. Nevertheless,\u00a0the mechanism through which these bacteria work are not well understood, and there have been\u00a0reports of severe infections attributable to probiotics in\u00a0critically ill or immunocompromised patients.\u00a0We don\u2019t necessarily think the story needed to get into this level of detail about potential adverse effects,\u00a0but some comment about the general safety (or lack thereof) of this probiotic strain should have been provided", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did provide potentially useful information about the kinds of people who should avoid consumption of probiotic containing foods. However, the story did not contain sufficient information about the nature of the evidence demonstrating this to be true. \u00a0Have there been any studies done comparing outcomes of people with \u2018weakened immune systems\u2019 (whatever that includes) who have and have not consumed probiotics?\nAnd while the story did mention that it is common for people who have begin to consume probiotic containing foods to experience uncomfortable bloating, it failed to report on more serious risks associated with probiotic use.", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nLange believes this brain scans can be done on younger children, as long as they can go to sleep in the scanner \u2013 on their own, without sedation (because you can't move during the test).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The same as with the Reuters story, CNN mentioned no harms in this story.\u00a0For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. The biggest harm, though, is the potential for false diagnoses, which should have been addressed.", "answer": 0}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nThe treated group also evaluated their quality of life as much better than before the procedure, despite a few persistent side effects like gait disturbance and paresthesia \u2014 the sensation of prickling pins and needles.\nIn the study, published in the New England Journal of Medicine on Wednesday, 76 patients were treated with focused ultrasound, and their tremor was evaluated after the first, third, sixth, and 12th month.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses adverse effects, and that\u2019s sufficient for a Satisfactory rating.\nWe do wish the story had quantified the harms that were measured in the study. The fourth paragraph says the procedure \u201cbrings lasting side effects in some patients\u201d and later the story quotes a physician who is not involved in the research as saying, \u201cIt\u2019s a pretty high incidence of side effects.\u201d But nowhere do exact numbers appear.\nRather than citing data from the study, the story quotes the physician as saying that \u201cover a third of patients actually experienced either gait disturbance or paresthesia,\u201d or numbness. This information isn\u2019t very useful because the story does not explain when these rates were measured. According to the study, three months after the procedure 36% of patients had gait disturbance and 38% had numbness. After 12 months, the numbers dropped, to 9 percent and 14 percent respectively.\nAlso worth mentioning is that one patient was reported to have permanent diminished sensation of the dominant thumb and index figure, which was categorized as a serious adverse event. That did not appear in the story.", "answer": 1}, {"article": "\"It was surprising, and exciting,\" Dr Belmer said.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\nAlcohol is specifically very damaging for neurons.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "When it comes to potential harms from using the drug, the release only offers the following:\u00a0 \u201cIt is commonly used there [in Asia] and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\u201d\u00a0 What are those limited effects?\u00a0 How often do they occur?\u00a0 Are they greater or lesser than the side effects of other drugs used in curbing heavy drinking?\nA caution on the the potential toxicity of the drug if taken with alcohol should have been included.", "answer": 0}, {"article": "...\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nBut if you're skimping on fiber, the health stakes are high, especially if you're a teenage girl.\nThis is a question Kristi King, a dietitian at Texas Children's Hospital, has thought about a lot.\nShe says it can be hard to get the attention of teenagers about healthy eating.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "New pathway to the heart\n\nElectrical stimulation of the spinal column may ease cardiac problems without drugs\n\nIn a possible new way to treat heart failure, Houston surgeons implanted a device and wire in a Pearland man Monday that will electrically stimulate portions of his spinal cord.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned \u2014\u00a0unacceptable when the whole point of the study being covered is to ensure the safety of the new device.\u00a0Known complications of implanted neurostimulation devices include wound infections at the surgery site and breakdown of the device or hardware requiring reoperation. Since these devices have never been studied in advanced heart failure patients, we don\u2019t know if these issues might cause more serious problems\u00a0in these patients than they do in healthier populations where neurostimulation has been tried before.", "answer": 0}, {"article": "Children with ADHD have trouble paying attention, focusing and can be hyperactive.\nNineteen of those children had a relapse in symptoms on the challenge test.\n\"Measuring IgG levels in kids doesn't seem helpful,\" Ghuman said, but it does look as if the elimination diet may help some children.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\nGhuman said that this study doesn't answer a number of questions, such as whether or not the elimination diet reduces symptoms long-term.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither this story nor the WebMD story we reviewed mentioned that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet.", "answer": 0}, {"article": "Symptoms can include sadness, insomnia, difficulty concentrating and making decisions, feelings of shame or guilt, as well as difficulty bonding with the baby or thoughts about harming the baby.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nOver the second half of the study, 34 mothers had at least one phone conversation with a peer counsellor.\nMothers who left the study said they no longer needed support, sought counseling from mental health professionals, or didn\u2019t have time for the phone calls.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention could be harmful, but the story does not address that possibility. The peer counselors might be less capable than professionals of detecting suicide risk, for example. Or, the counseling might provoke additional symptoms such as excessive anxiety.", "answer": 0}, {"article": "Anderson.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nWhile the optimal schedule of regular mammograms continues to be discussed by experts in the field, the critical message here is that all women starting at age 40 should talk to their doctor to understand the benefits and risks of screening and to understand what is best.\"\n\"Mammography has been shown in study after study to reduce breast cancer deaths in women aged 40 to 49,\" Obel added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a poor job discussing any harms of screening women starting at age 40.\u00a0 We are not told if women 40-44 had more false positive and unncessary biopsies ,or unncessary breast cancer surgery or treatments\u00a0 for pre-cancerious lesions. We are also not told of the risks of additional radiation exposure on the risk future of breast cancers.\u00a0 We are not given the number needed to harm (NNH) for additional radiation exposure over 10 years of screening. ", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nBut those who stuck with therapy had improved as much six months and one year later as those who had arthroscopic surgery right away, researchers found.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nAn imaging test showed a less severe tear and a different surgeon recommended physical therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only quoted a commentary in the journal that published the paper \u2013 referring to \u201cmillions of people are being exposed to potential risks.\u201d\u00a0 But the specific risks weren\u2019t qualified or quantified.\nThe paper itself reported:\n\u201cThere were no significant between-group differences in the frequencies of overall or specific adverse events. Over the 12-month period of follow-up, serious adverse events occurred in 3 participants assigned to arthroscopic partial meniscec-tomy and 2 participants assigned to physical therapy alone (including one death in each group); adverse events rated as mild or moderate in severity occurred in 15 participants in the arthroscopic-partial-meniscectomy group and 13 participants in the physical-therapy group. Total knee replacement (coded not as an adverse event but rather as an indication for discontinuation from the study) was performed in 5 participants assigned to arthroscopic partial meniscectomy and 3 participants assigned to physical therapy alone.\u201d", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n\n\nThe story does warn of risks. However, it doesn\u2019t tell readers how common they are. In fact, the researchers reported that 85 percent of patients reported at least one adverse event and that problems (including hospitalizations) occurred often enough in the first few weeks after treatment that it was only when researchers disregarded those treatment-related problems that they saw a net benefit during the first year. The researchers say their longer-term follow-up indicates patients report ongoing benefits according to some of the research measurements, but the story should have pointed out that the potential gains come only after enduring several weeks of recovery and elevated risk.\n", "answer": 0}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t give the details behind a physician\u2019s comment that \"there are relatively few downsides to trying statins\" and that statins are \u201crelatively safe.\" For the reader, who may not know much or anything about statins, what does that mean?\u00a0 What are the downsides?\u00a0 And how often do they occur? \nAlthough uncommon, statins may cause muscle soreness/damage or elevated liver enzymes.\nIn a shared decision-making environment, one would simply spell out the facts and let the reader/consumer/patient decide what \"relatively few\" and \"relatively safe\" means to them.\u00a0 ", "answer": 0}, {"article": "\"The new axons could actually be working,\" said Segura.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe gel was eventually absorbed by the body, leaving behind only new tissue.\n\"This study indicated that new brain tissue can be regenerated in what was previously just an inactive brain scar after stroke.\"\nThe brain has a limited capacity for recovery after stroke and other diseases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned and are relevant.\nThe gel is a foreign substance being introduced into the brain. Did it trigger any kinds of reaction in the surrounding normal tissue? Did it cause any systemic symptoms?", "answer": 0}, {"article": "[3] Yokell et al.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nThe following warnings and precautions should be taken when administering EVZIO:\n\u2022 Due to the duration of action, keep the patient under continued surveillance and repeated doses of naloxone should be administered, as necessary, while awaiting emergency medical assistance.\nEVZIO is not a substitute for emergency medical care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release lists a number of adverse reactions that have been identified during use of naloxone hydrochloride in postoperative patients, including\u00a0hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest.\nWhile we give the release credit for providing an extensive list of potential list of side effects, we question whether including a long laundry list of warnings under \u201cimportant safety information\u201d is sufficient to prevent accidents when untrained individuals are treating people who are suspected of opioid overdose. And yet this product is marketed for individuals without medical experience. In mentioning usability trials involving the product the release states that, on average, \u201cmore than 94% of users can correctly administer EVZIO without training, and 100% with training.\u201d We\u2019d like to know how many volunteers were involved and what is the effect of incorrectly administered Evzio.", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThe study supports CCTA use for an initial, noninvasive evaluation of patients with known or suspected stable coronary artery disease.\nDr. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.\nThe shear stress information could help identify lesions that do not yet have an impact on ischemia but will in the future.\nThe researchers hope to run a trial to show that hybrid imaging can have a positive impact on patient outcomes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t address harms, which at a minimum involve exposure to an additional radiation-based imaging technique that could increase the risk for cancer.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story could have pointed out that because the significance of telomere length is unclear, people who take the test may either get a false sense of a security from learning they compare favorably to the general population or experience unnecessary anxiety if they get a lower-than-average result.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBlindfolded, would you know the smell of your mom, a lover or a co-worker?\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The downsides of medical screening or diagnostic tools were left unmentioned. \u00a0This is an unfortunate lost opportunity to explain to readers that any diagnostic or screening technology, while potentially lifesaving, could potentially harm as well. What if, for example, it flags someone as sick when they\u2019re not \u2014 leading to unnecessary anxiety or treatment? And what if it detects a disease that would never cause the patient symptoms and yet the patient gets treated anyway? What if it misses someone who is sick and provides them with false reassurance?", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\nAll patients in the study \u2014 mostly women age 22 to 75 who are or were patients at the Perlmutter Cancer Center of NYU Langone \u2014 had either advanced breast, gastrointestinal, or blood cancers and had been diagnosed as suffering from serious psychological distress related to their disease.\n\u201cOur study showed that psilocybin facilitated experiences that drove reductions in psychological distress,\u201d says Bossis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is vague here, noting that patients \u201cexperienced no serious negative effects, such as hospitalization or more serious mental health conditions.\u201d But that doesn\u2019t mean they had no side effects. A look at the paper shows that 28 percent of patients, for example, suffered headaches or migraines and 14 percent had nausea. Did the benefits outweigh these effects? Many people might say yes. However, it\u2019s important for research institutions to describe the research \u2014 warts and all \u2014 and let people make informed decisions. If we think that\u2019s true for clinically available treatments, it should also apply to treatments in the earlier stages of testing.", "answer": 0}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\n\"Approximately 1 in 700 pregnancies there's an extra X or extra Y,\" she says, noting that these are mild conditions that would normally go undetected, unless a woman had an invasive test like an amnio.\nSeitz, in Alabama, thought it was a bonus that getting this new blood test would tell her if she was having a boy or a girl.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited several harms associated with the new screening tests, including the risk that some women may terminate a pregnancy based on the screening results alone without follow up diagnostic tests. It also noted that the tests can pick up minor genetic abnormalities that might previously have gone unnoticed.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\nBut they agree with the need to curb these tests particularly in children, who are more susceptible to radiation and more likely to develop cancer from it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to flesh out the quantification of the effect under study, namely additional risk of cancers.\u00a0 While the source study reports on \"attributable risk\" of cancer and cancer-deaths due to CT scanning, it would be helpful for the viewer to know what this means in terms of numbers of cancers and risk to the individual.", "answer": 0}, {"article": "Symptoms range from mild stomach or skin reactions to a constriction of the airways.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nAbout 3.3 million people are allergic to peanuts or tree nuts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the last line, the story warns that the children in the studies, who were allergic to peanuts, were under close medical supervision and that \"parents should not try the approach at home.\"\nThis is a satisfactory warning about potential harms. But it should have appeared earlier. \u00a0 \nThe author should also have mentioned whether those in the study who \"did not tolerate\" the exposure treatment needed epinephrine or some other intervention to quell the allergic reaction. ", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that most of the studies included in the\u00a0review didn\u2019t include enough information about potential harms \u2014\u00a0\"something everyone would certainly want to know.\"\u00a0\u00a0We\u2019ll call this satisfactory, but we wish it had included at least some information about the harms that were mentioned, such as heartburn in patients taking ginger and drowsiness in patients taking anti-nausea medications.", "answer": 1}, {"article": "An additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nThey also tried to consume no more than 20 percent of their calories from fat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only provided the information that the two groups did not differ in terms of rates for breast cancer recurrence, not survival. The story did mention that neither of the groups lost more weight, so such a high-fiber diet is not a guarantee for weight loss.\u00a0 The story does not mention any harms of a diet high in fiber and low in fat. Possible \"side effects\" of such a diet might include bloating, gas, and diarrhea or loose stools.\u00a0 \n\u00a0\n", "answer": 0}, {"article": "The F.D.A.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nThey say that their ability to do either procedure makes them the most unbiased source of information for carotid disease patients.\nBy contrast, they say, carotid surgery -- called endarterectomy -- has no significant room for improvement.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "See above \u2013 the piece does not provide \nabsolute rates for harms or side effects for various treatment options.", "answer": 0}, {"article": "Paul is on Procter & Gamble's advisory board but holds no stock in the company and will not profit financially.\nTwenty of the 44 children in the vapor rub group suffered mild side effects including skin irritation and burning sensation of the eyes and nose.\nThere were no side effects in the two other groups.\nThe current study shows that Vaporub is more effective than placebo.\"\nThe next day parents were questioned about their child's symptoms overnight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that almost half of the children who were treated with VapoRub reported side effects including skin irritation or a burning sensation, while none of the children in the other groups reported any side effects.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports the potential health risks linked to the patch, primarily breast cancer.\nThe story does a nice job presenting the actual number of events (breast cancer), 3/264 in patch group and none in the placebo group, and goes on to mention that, although not statistically significant, it does support concerns about breast cancer risk. ", "answer": 1}, {"article": "Paul Delios of Saugus, Mass.\nA big reason the operation works is because it seems to suppress appetite.\nYet most people who have this operation do not get skinny.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nBut here's something the medical world is just realizing: that the gastric bypass operation has other even more dramatic effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment mentions some harms of the surgery, including death, depression and suicide. ", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses the potential harms of adding MRI scans. It paraphrases an expert as saying there is no downside to getting an MRI, \u201cexcept perhaps an increased risk of false positives and perhaps a need to pay out of pocket.\u201d As noted above, the out of pocket costs of ongoing scanning could cost a woman thousands of dollars. The researchers reported that 9 percent of the women with a history of breast cancer underwent biopsies following their MRI scans. Two out of three of those women were found to not have cancer. The story should have been more clear about this false positive rate.", "answer": 0}, {"article": ".\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\nNew research indicates that dietary soy products are safe and even beneficial for women diagnosed with breast cancer.\n\"We now have evidence that soy foods not only prevent breast cancer but also benefit women who have breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a competent job of explaining the concerns about soy\u2019s estrogenic properties and the fact that the study was designed to look at overall deaths from any cases among the patients, and not at quality of life or morbidity.\nA careful reader would be able to discern in the release that gobbling up soy supplements is not encouraged by the results of this study or the scientists who conducted it; and that there is a difference between saying something is \u201cnot detrimental\u201d in women treated with hormone therapy and that something is completely safe for all women with breast cancer.\nWe would have liked the release to include a statement noting that women with breast cancer should consult their physicians about their tumor\u2019s potential sensitivity to estrogen and to discuss dietary soy with them. This is particularly important since the release ends by quoting an editorial that encourages wide consumption of soy.", "answer": 1}, {"article": "\u201cA.A.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nA.A. and other 12-step programs \u201care not cure-alls,\u201d Dr. Kelly said, \u201cbut I would say at a minimum, they help.\u201d\n\nDr. Edward V. Nunes, a professor of clinical psychiatry at Columbia, said research had demonstrated that certain elements of A.A. were effective.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of the harms of treatment, however, the story notes that A.A. and 12-step programs are not a panacea for alcohol dependence, as they do not work for everyone. The story does cite researchers in the field of addictions research and treatment who note that people often attend A.A.meetings as only one component of their treatment. ", "answer": 1}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point to the greater occurrence of a dry cough as a result of taking ACE inhibitors compared to taking ARBs but a quick web search for both drug types shows a much larger list of possible side effects including dizziness, headaches, drowsiness, nausea, vomiting, diarrhea, low blood pressure, weakness,\u00a0and skin rash, as well as increased potassium levels and possible sexual dysfunction. A similar omission is present in a HealthDay story that explained the same research.\nCough is the most common side effect of ACEI that is not generally seen with ARBs. The one other one is angioedema which is more common with ACEI. Otherwise studies show that other side effects are probably similar. This isn\u2019t stated explicitly, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nResearchers studied 78 children who were scheduled for the operation, and a control group of 27 children having other surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms associated with the surgery. The harms, although rare, include infection and respiratory complications, and are more common in children with obstructive sleep apnea, the target population in this story.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned weight regain as well as some of the side effects that occur with the use of this device. \u00a0For a more complete discussion, it should have included information about how frequently these occur.", "answer": 1}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\n\u201cDeciding between a non-operative program or going forward with surgery can be a challenging decision for medical professionals treating shoulder injuries in young athletes,\u201d noted the study\u2019s lead author Tyler J. Marshall, MD, from Alabama Ortho Spine and Sports in Birmingham, AL.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether there were any drawbacks associated with undergoing surgery. This quote from the lead author appears to acknowledge their existence:\u00a0\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nBut it does not spell out what those drawbacks might be.", "answer": 0}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\nFotuhi recommends his patients get 1,000 mg per day of DHA, a nutrient that increases blood flow in the brain, reduces inflammation in the brain, heart and elsewhere, and reduces the toxic aggregation of amyloid in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that DHA has the potential to cause problems in people taking blood-thinning medication.", "answer": 1}, {"article": "For more about blood pressure drugs, visit the American Heart Association.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nScientists at the NYU Langone Medical Center in New York City said their findings settle a longstanding debate about which of two types blood-pressure lowering medications studied are better.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No specific harms are mentioned, just a reference to tolerability. A Washington Post story on the same study at least mentions the dry cough that ACE inhibitors can cause, information which would be most helpful to readers who have been prescribed these medications. Several other side effects could have and likely should have been mentioned, but we\u2019ll give the benefit of the doubt.", "answer": 0}, {"article": ".\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nPast studies have suggested that flu antiviral therapy is safe and beneficial for pregnant women.\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\n\"All pregnant women should receive annual influenza vaccination to prevent influenza and associated complications for themselves and their infants,\" the study authors wrote.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms at all and that is an important omission considering the strong disagreement over the drug\u2019s side effects and effectiveness. The Centers for Disease Control and Prevention (CDC) and the Mayo Clinic both stress that the risks associated with oseltamivir are far outweighed by the benefits of using it to treat flu during pregnancy. And studies (like this one from 2010 or this one from 2013) have found no evidence that oseltamivir hurts the pregnancy or the unborn child. However, the Cochrane Collaboration, which reviewed numerous trial data found \u201cThe use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children.\u201d\u00a0 The study itself even acknowledged that the health risk to fetuses is unknown. \u201c\u2026the study does not answer the question as to whether early treatment is associated with lower rates of important adverse outcomes such as stillbirths and maternal deaths,\u201d the study states in a section describing limitations.\nThe medical society was remiss in not acknowledging the unknown safety issues and that health experts are in disagreement over oseltamivir\u2019s safety and effectiveness.", "answer": 0}, {"article": "\u201cYou could not have convinced me that I would ever have done this or continued with this,\u201d she said.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\nThe fibromyalgia study involved the yang style of tai chi, taught by a Boston tai chi master, Ramel Rones.\n\u201cI was used to being treated in a condescending manner because they couldn\u2019t diagnose me: \u2018She\u2019s menopausal, she\u2019s crazy.\u2019 \u201d\n\nBefore the study, \u201cI didn\u2019t know tai chi from a sneeze,\u201d said Ms. Petersen, who has diabetes and other conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0A big point of the story is that tai chi would be a much less onerous therapy with no harmful side effects. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The journal article on which the story is based clearly discussed this. ", "answer": 0}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nWith P-Cure, oncologists can develop a compact, gantry-less proton center for significantly less capital and operating costs, essentially making proton therapy more widely available and attainable.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms associated with this therapy. As noted above, it makes passing and not numerically defined, reference to the potential harms of standard proton therapy, meaning radiation hitting parts of the body that don\u2019t need radiation treatment.\nThe release states indirectly who this wouldn\u2019t work for by giving the cancers that may be treated. The question of harm/benefit also depends on what the goal of the device. Is it to help patients already selected for proton beam therapy or to bring in patients who otherwise would be treated using conventional radiotherapy? Consideration of benefits and harms would differ, but neither is addressed.", "answer": 0}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nOnce inserted, these long-acting methods remove the risk of patient error when a sexually active woman wishes to avoid pregnancy.\nGreater LARC use can reduce birthrates among adolescents and, for women of all ages, a reliance upon abortion to prevent unwanted births, the experts wrote in the October issue of Obstetrics & Gynecology.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential side effects of long-acting implants or IUDs. These include \u201cirregular bleeding and cramping\u201d as short-term impacts. We\u2019ll give the benefit of the doubt, but we would have liked an additional comment by someone not connected to the committee report on whether there are any long-term studies underway about downstream potential impacts for women 5 or 10 years after using these. In addition, rare but potentially serious complications of copper IUDs, such as perforation (when the IUD pushes through the wall of the uterus), could have been mentioned.", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nAn earlier analysis of the study concluded that women who ate five servings of fruit and vegetables and exercised 30 minutes a day had significantly improved cancer-free survival.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms associated with fruit and vegetable consumption, something some might think is unnecessary.\u00a0 But, for comparison, another story by another news organization did quote the lead investigator as saying there were no harms found with eating fruits and vegetables above a certain threshhold. It could have been addressed in this story. ", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call, but we\u2019re leaning toward satisfactory.\nOn one hand, the STAT story\u00a0does acknowledge the downsides, so far, of CAR-T therapy, by referring to the adverse events as \u201cnotorious\u201d and providing a link for more information.\nOn the other hand, the story only mentions that severe side effects have occurred\u00a0without telling us any of\u00a0those side effects and what the side effects (if any) were for the one patient treated. Instead it says the patient\u2019s side effects were \u201cfairly innocuous\u201d and quotes a researcher early in the story saying \u201cit\u2019s amazing how safe it was.\u201d Yet, this hardly proves it\u2019s safe.\nSee our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the release does address side effects, stating: \u201cfewer patients experienced serious side-effects from taking nivolumab than with conventional treatment \u2013 only 13 per cent compared with 35 per cent of patients who received chemotherapy.\u201d However, it doesn\u2019t explain what those \u201cserious side-effects\u201d might be. According to the website for one nivolumab drug, these side effects may include inflammation of the brain or nerve problems that lead to paralysis. Patients, families, and healthcare providers make decisions based on quality of life as well as length of life, and information like this is essential for anyone wanting to make informed decisions about treatment options. It\u2019s not enough to refer to \u201cserious side-effects,\u201d you need to explain what those side effects may include. Vague language does a disservice to the reader.", "answer": 0}, {"article": "Bernard M.Y.\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented information about the increased incidence of myopathy and the more severe rhabdomyolysis observed with higher dosage statin use.\u00a0The story did, however, contain an error in referring to creatine kinase as an indicator of kidney damage. \u00a0It is an indicator of muscle damage.", "answer": 1}, {"article": ".\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nOf those who do get to a health facility alive, only about 50 percent survive.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Despite the horror show picture painted in the opening sentence, there is no explanation of the harms associated with statin therapy. Some discussion of the impact of giving statins to someone not already taking them would have added value to the release.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\nPrior to starting each diet, subjects ate what the researchers deem an \"average American diet,\" which was made up of 34% of calories from fat, 16% from protein, while around half of calories were from carbohydrates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that avocados are typically consumed in the U.S. as guacamole, which is often eaten with corn chips that are high in calories and sodium. We\u2019ll call that good enough for a satisfactory rating on this criterion. The story could have gone one step further, as NBC did, and note that consumers should compensate for the extra calories from avocados by reducing intake of\u00a0nutrient-poor calories. Otherwise they\u2019re likely to gain weight.", "answer": 1}, {"article": "Eat as you dare.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\nAccording to Stewart, the meaning behind the numbers is clear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this is a story about a study of dietary habits, this is N/A.", "answer": 2}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the new approach made it \"easier and safer\" for dialysis.\u00a0 But such a statement can\u2019t be made definitively in a lead sentence of a story on such early research.\u00a0 Indeed, the story presented the picture of harms unevenly, stating that artificial vessels are \"prone to infection and inflammation,\" without explaining how often that happens.\u00a0 We don\u2019t think it helps reader comprehension to paint an existing approach with such a broad negative brush while painting the new and uNPRoven approach with such a broad positive brush. ", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.04.026.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes the authors saying the device is \u201cwell-tolerated and safe\u201d with a retention rate of 89 percent at six months. It also pointed out that some patients experienced itchiness and redness, which it describes as common adverse effects for patients taking glaucoma medication, and that the ring became dislodged in 15 patients, requiring it be replaced so therapy could continue.\nWhile the release adequately covers the known risks, in a study this small it would be good to remind readers that the device has not yet been tested on a large and diverse group of patients who might have different results. We also wonder how the ring would work in practice. Would patients who have difficulty following a treatment regimen in the first place be prompt about getting to a physician\u2019s office promptly to have a ring replaced?", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of potential harms from lactoferrin.\nReaders might be curious about the potential for intoxication (animal studies have been inconclusive in this area) or intolerance.\nWebMD mentions:\n\u201cLactoferrin can cause diarrhea. In very high doses,\u00a0skin rash, loss of appetite,\u00a0fatigue, chills, and\u00a0constipation\u00a0have been reported.\u201d", "answer": 0}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nThe medication also treats many of the symptoms associated with the disease such as tremors and poor muscle control.\nThis type of therapy increases levels of dopamine, a natural chemical in the body that sends signals to other nerve cells and can significantly decrease in cases of Parkinson's.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug nortriptyline has side effects. These include nausea, rare allergic reactions and liver toxicity in some patients. The release should have made some reference to potential harms, even if these are not well-known for this new therapy yet.", "answer": 0}, {"article": "But if we tailor treatments to the individual biology of the tumor and characteristics of the patient, we'll get the best results,\" Wolf says.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nWolf hopes future research will reveal a way to tailor treatment without the need for the induction chemotherapy.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\nOver 10 years, 153 stage 3 and 4 laryngeal cancer patients were treated at Michigan Medicine, with about half receiving the induction chemotherapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states: \u201cEven that single [initial] dose of chemotherapy can be debilitating and toxic for some patients.\u201d That\u2019s enough to earn it a marginal satisfactory mark here. The release would have been better if it had noted that radiation, surgery and chemotherapy all carry serious side effect risks. ", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\nKing and her team are the first to show that a modest increase in dietary zinc reduces oxidative stress and damage to DNA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We wish the news release mentioned that too much zinc is also harmful. According to the National Institutes of Health, increased zinc intake could lead to nausea, vomiting, loss of appetite, stomach cramps, diarrhea and headaches. When people take too much zinc for a long time, they sometimes have problems such as low copper levels, lower immunity and low levels of HDL cholesterol \u2014 sometimes referred to as the \u201cgood\u201d cholesterol.\nWhile this study was about food fortified with zinc, the news release was vague about how people should acquire their zinc, and this confusion could encourage people to reach for a bottle of zinc supplements.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nFor people who want to safely eat more seafood, the magazine recommended shrimp, scallops, sardines, salmon, oysters, squid and tilapia as the lowest-mercury seafood.\nThe report also acknowledges the risk of mercury exposure from certain kinds of seafoods, and notes that women who are pregnant, nursing or may become pregnant should avoid certain kinds \u2014 tilefish, shark, swordfish and king mackerel \u2014 because of their high mercury content.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does discuss the aforementioned 2005 study, which found that a baby\u2019s score on visual recognition memory tests was affected by the amount of mercury in the mother during pregnancy, so we\u2019ll give it a pass. However, the story would have been better if it had \u2014 even briefly \u2014 addressed the full suite of possible health risks associated with mercury exposure during pregnancy. Also, the story discusses the findings of the 2005 study by referring to mercury measured in parts per million, but discusses mercury levels in tuna in terms of micrograms per ounce. It would have been great if the story had used the same units of measurement in both cases, so that readers could understand the significance of the 2005 study\u2019s findings in regard to levels of mercury actually found in tuna. (A back-of-the-envelope calculation finds that if six ounces of tuna contains 60 micrograms of mercury, the mercury is present at a level of about 0.35 parts per million. But the story could have cited an expert.)\nIn addition, while the story does briefly discuss the advantages of eating fish, it does not really address the potential harms of not getting adequate amounts of omega-3 fatty acids or other nutrients found in tuna and other fish.", "answer": 1}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nBut less than a third of victims get this essential help.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\nNow the heart association has given equal standing to hands-only CPR.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The American Heart Assocation recommendations and the Circulation report provide contraindications for compression-only CPR, which the segment properly notes.\nThe report and recommendations cite no other risks of compression-only CPR. The published study cites the possibility that some unidentified subgroup of patients may benefit from traditional CPR, but says no research has demonstrated this.\nRib fractures are a potential harm, and the story could have mentioned this. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. \u00a0 ", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\nAgitation is a frequent symptom of advanced Alzheimer's, Lanctot explained.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A major strength of this news release is that it favors cautious, rather than hyped language.\nIt\u2019s clearly stated:\nAbout 45 percent of patients experienced sedation with nabilone, compared with 16 percent for placebo.\nWe very much appreciated how the story also anticipated that some readers might take the study findings as justification for self medicating with marijuana, and why that might be risky.", "answer": 1}, {"article": "Active older people resemble much younger people physiologically, according to a new study of the effects of exercise on aging.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nAs it turned out, the cyclists did not show their age.\nBut even so, both of those measures were higher among the oldest cyclists than would be considered average among people aged 70 or above.\nMany older people require at least 7 seconds to complete the task, with those requiring 9 or 10 seconds considered to be on the cusp of frailty, Dr. Harridge said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any comment about risks of injury or harms that might result from an active lifestyle riding miles on a bicycle.", "answer": 0}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\nDr. Papkostas, Dr. Nelson and other researchers involved in the study all disclosed several financial relationships with makers of prescription antidepressants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It only tells us that long-term safety in this setting is unknown. Since the study\u2019s benefits were presented, safety results should\u2019ve been mentioned too.\u00a0The study itself states that there were no serious adverse events, the SAMe and placebo groups had similar rates of discontinuation due to intolerance, and the SAMe group had a statistically significantly greater increase in blood pressure when lying down, an effect which \u201cif confirmed in future studies, may be of clinical relevance.\u201d\u00a0\nAt least, it could\u2019ve discussed if there are potential harms associated with SAMe in general. The editorial states that SAMe, like most antidepressants, carries a warning that it may induce mania in patients with bipolar disorder. This study was too short and too small to detect adverse events that emerge from longer-term use. ", "answer": 0}, {"article": "The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\n\"We thought that if aspirin can inhibit aromatase, it ought to reduce the likelihood that breast cancer would develop and it could also be an effective way to improve breast cancer patients' prognosis once they no longer take the more potent aromatase inhibitors.\"\nBernstein added, \"Aspirin also reduces inflammation, which may be another mechanism by which aspirin taken regularly can lower risk of breast cancer developing or recurring.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all \u2014 and regular use of low-dose aspirin isn\u2019t for everyone. As the Mayo Clinic notes, people with some medical conditions are at greater risk of complications associated with daily aspirin therapy.\nIt\u2019s well known that daily aspirin use can cause serious gastrointestinal bleeding in some people, which is why experts recommend a careful risk-benefit calculation even where benefits are more conclusively established \u2014 as in the prevention of heart disease. It\u2019s irresponsible not to mention those risks in the context of a speculative benefit such as breast cancer prevention.  ", "answer": 0}, {"article": "The disease causes patches of thick, red, inflamed skin that have silvery scales.\nThe current study included 317 people with moderate to severe psoriasis.\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\nHe said that in an earlier trial of briakinumab, some unexplained major adverse cardiac events occurred.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing WebMD story, this story quantified the serious infections and explained the two cancer cases seen in the briakinumab group.\u00a0 It also explained that an earlier trial of the drug showed \u201csome unexplained major adverse cardiac events.\u201d\u00a0 This was a more complete explanation than what WebMD provided.", "answer": 1}, {"article": "\"But we are optimistic that this new DNA Zika is a viable platform,\" Fauci said.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\nTo continue the development of the vaccine, the researchers will be partnering up with the largest pharmaceutical company solely devoted to vaccines, Sanofi Pasteur.\nThat vaccine \u2014 dubbed ZPIV for purified inactivated Zika virus \u2014 uses a more traditional vaccine approach and depends on dead virus particles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story notes that the killed-virus vaccine is safer than another line of vaccines under development,\u00a0but it does not address the presence or absence of any side effects or potential harms/shortcomings of the new experimental vaccine if and when this vaccine is tested in humans. One extremely important safety concern, for example, will be how it affects pregnant women and fetuses.", "answer": 0}, {"article": "\"My wife's family is from southern Illinois, too, so it's home,\" Reavill says.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nDennis adds that the catheter could prove useful in patients with sepsis, or blood poisoning, which strikes about 750,000 Americans every year.\nCalled the ReavillMED CV, the Food and Drug Administration-cleared device includes a catheter called a PICC line, IV tubing that sheathes it to provide sterility, and a transducer that can directly measure blood pressure to help determine needed fluid levels.\nIt reduces risks to an \"absolute minimum\" by moving the catheter insertion to the arm, the judges said, replacing a complex wire-guided procedure through the neck, which is typically used to monitor the heart during a hospital stay for very ill patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in the story. Placing a catheter into the central circulation and measuring pressure is not without the potential for harm.\u00a0 Although the risk of a catastrophic rare neck artery puncture may be avoided with the use of the arm approach, the risks of misplacement and infection may not be reduced.", "answer": 0}, {"article": "When Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\nMore testing showed she had anal cancer.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nFurther testing showed the baby was healthy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the WSJ article, there was not even a hint that widespread use of these tests might pose harms as well as benefits, as well as higher costs and ethical dilemmas.", "answer": 0}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nMerck has tested the vaccine in about 70,000 babies in 11 countries, one of the biggest vaccine trials ever conducted.\nMerck is selling the vaccine under the brand name RotaTeq.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author states that this vaccine appears to be safer than the previous one, however there is no evidence provided to support this claim. Although not statistically significant, there were more cases of intusussecption with the vaccine in the trials.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nA study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions several important potential drawbacks of PSA screening and correctly points out that many European countries do not routinely screen for prostate cancer. It also includes some important context, noting\u00a0\"a study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\"", "answer": 1}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this story and the Reuters Health story credit for at least mentioning some of the risks of taking bisphosphonates. \u201cThe researchers noted, however, that the risks of using bisphosphonates include the possibility, in rare cases, of osteonecrosis of the jaw (destruction of the jawbone or jaw tissue). Bisphosphonates used for osteoporosis have also been linked to a rare fracture of the thigh, according to the U.S. Food and Drug Administration.\u201d But neither story quantified the harms in any way. This story also failed to point out, as the Reuters Health story did, that \u201cearlier study from the UK had found no link between bisphosphonate and colon cancer. Indeed, it found a higher risk of throat cancer in patients on the medication.\u201d\n", "answer": 0}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nHere's what some top allergists say you need to know about these non-prescription options.\nPeople with mild to moderate symptoms have the best chance of full relief, he says.\nYou can tell by the sniffles and sneezes of the afflicted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes into the side effects of steroid nasal sprays, antihistamines and decongestants. Although none of these harms are quantified, we\u2019ll give the story the benefit of the doubt.\nThe line that caught our attention was: \u201cLabels caution that some children using the sprays may experience slower growth.\u201d What kind of slower growth (mentally vs. physically)? How many children encountered this side effect? And is it worth the risk to ever use a steroid nasal spray? A few figures here would have been helpful to put this in perspective, because \u201cslower growth\u201d sounds like one of the more serious harms that someone could experience.", "answer": 1}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nResults from the Phase 2 study, reported in the Journal of Neurosurgery on Dec. 18, 2015, demonstrated the safety of DBS in Alzheimer's patients.\nDuring the trial, 42 patients with mild Alzheimer's disease underwent the surgical procedure and were closely monitored for adverse effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release only reports the mild adverse effects, including headache and infection, which occurred in 11.9 percent or 5 out of 42 patients. It was a glaring omission not to report serious side effects that required some of the patients to undergo corrective surgery following the procedure. According to the published study:\n\u201cTwenty-six (61.9%) patients experienced 64 AEs related to the study procedure, of which 7 were serious AEs experienced by 5 patients (11.9%). Four (9.5%) patients required return to surgery: 2 patients for explantation due to infection, 1 patient for lead repositioning, and 1 patient for chronic subdural hematoma.\u201d", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nIf so, then those traits, not screening, might be responsible for their lower risk of dying from prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing from information produced by the USPSTF, the article concluded that the gains in prostate cancer detection \u201ccome at some cost to health, though: For every life saved, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them. In\u00a0other estimates, such \u201coverdiagnoses\u201d outnumber lives saved by 50-to-1.\u201d\nThe one harm that is often overlooked in widely-promoted screening programs is the psychological harm that perfectly healthy people may experience when they have had a \u201ccancer scare,\u201d and that even though their life is unlikely to be saved, the worry, anxiety, depression and angst do exact a substantial life-altering toll that goes unmeasured.", "answer": 1}, {"article": "All rights reserved.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nHospital admissions for heart attacks and strokes in those areas declined 6 percent starting three years after the bans, compared with counties without bans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nRydapt was also approved today for adults with certain types of rare blood disorders (aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm or mast cell leukemia).\nRydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\nThe safety and efficacy of Rydapt for patients with AML were studied in a randomized trial of 717 patients who had not been treated previously for AML.\nThe U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release effectively reports possible side effects experienced by AML patients receiving Rydapt, including \u201clow levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\u201d\u00a0 It also warns women who are pregnant or breastfeeding to avoid taking Rydapt.\u00a0 It also points out that the FDA approved the use of Rydapt for other patients with \u201ccertain types of rare blood disorders\u201d and provides a list of possible side effects they might experience.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no mention of potential harms associated with the use of statin medication.\u00a0 That\u2019s a significant omission.\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about a possible harm (increased cancer incidence) that the statin medications may result in.\u00a0 ", "answer": 1}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe body of the story details several potential complications including long-term fat loss that undoes any initial benefits, as well as the appearance of cysts, masses, nodules and scarring. The story also notes concern about fat grafts potentially interfering with breast cancer screening.\nHowever, the story should have at least referred to such problems higher in the story. It also neglected to mention reports of at least one death, as well as strokes and serious infections including septic shock, that were noted in the task force report.\n\n", "answer": 1}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nA much-cited VA database study that was published in JAMA in 2013 looked specifically at men with coronary artery disease; about 20 percent of the total study group of around 8,700 men had suffered a prior heart attack.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions an FDA advisory about possible increased risk of heart attack and stroke with testosterone therapy. We\u2019ll call this acknowledgment of possible risks good enough for a Satisfactory rating, although many other possible risks exist including exacerbating sleep apnea, skin reactions, and promoting noncancerous growths of the prostate. One of the researchers is quoted as urging individuals to get appropriate screening from a health professional before considering\u00a0testosterone therapy, but the reader does not learn why this is important. Bottom line:\u00a0we know the overall mortality was lower in the group that was treated to a normal testosterone level, so serious adverse events , within the time frame of the study, do not appear to outweigh benefits. However, prostate cancer, for instance, is slow growing and might not have manifested within the time frame studied.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "With its clear questioning of the evidence for lice control products, the story infers the harm of spending money on unproven products.", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story illustrates how hard it can be for a parent to enforce cognitive rest.", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report helpfully mentioned that \u201csome studies, but not all, discussed side effects such as gastrointestinal discomfort, dizziness, mild pain and decreased libido. When they were reported, the adverse effects were generally mild.\u201d\nIt would have been useful to note that the off-label use of SSRIs also involves some rate of adverse effects and that some foreign-sourced herbal treatments have been found to be adulterated with compounds from prescription drugs, and that quality control of herbal treatments is sometimes a problem.", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\nThese findings represent two of the five Phase 3 studies that comprise Janssen's treatment-resistant depression program with esketamine nasal spray.\nThe study in elderly patients with treatment-resistant depression was a Phase 3, double-blind, multicenter, active-controlled study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release discusses adverse effects.", "answer": 1}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nThat's better than the only other approved treatment for such advanced cancers.\nBut, after all, Provenge is just the first cancer immunotherapy on the market.\nAnd it's clear that experts are still scratching their heads about just how Provenge works.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms found in the studies. ", "answer": 0}, {"article": "And unfortunately there is no cure.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nNewswise \u2014 A change in diet can improve the lives of those diagnosed with a common, but hard-to-treat gut disorder.\nThe results were impressive: More than 50 percent of the patients on the low FODMAP diet had major improvement of their abdominal pain, compared with 20 percent of the control group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While a dietary intervention may seem relatively harmless, there are notable risks. Potential nutritional deficiencies and changes in gut bacteria following a low FODMAP diet long-term have not been studied. Some people may also find it\u00a0 inconvenient to be on a restricted diet that prohibits consuming their favorite foods.", "answer": 0}, {"article": "\"Some will benefit in a very large way.\nWhy would a woman at normal risk of breast cancer want to get routine mammograms?\nSo should U.S. women continue to get routine mammograms?\nThe obvious answer is that these tests save lives.\nIt is not wrong to want a routine mammogram, and it is not wrong not to want one.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n\"This study is a breakthrough for patients with hearing loss, and improvements in practice and techniques will allow them to enjoy many hearing benefits such as music enjoyment, listening in complex environments, and sound localization.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Drilling into your ear to implant a device can involve harm. \u00a0As for harms, we learn of them only obliquely with this phrase: \u00a0\u201cthe non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\u201d \u00a0Are we to presume that the wire electrode implants can be \u201cmore traumatic?\u201d More detail was definitely needed here.\nThe favored \u201cround window\u201d approach is also considered safer given that the news release reports that \u201cthe cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\u201d according to the lead researcher. \u00a0How much harm? We don\u2019t know.", "answer": 0}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned potential harms associated with the use of statin medication though didn\u2019t provide any insight about how commonly these occur. Is it 1 in 10?\u00a0 1 in 100?\u00a01 in a million? \u00a0", "answer": 0}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nBetter detection of these so-called adenomatous polyps could save lives, the study authors noted, as survival rates for colorectal cancer are better than 90 percent if the disease is detected early.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No foreseeable harms or side effects in listening to music during procedures.", "answer": 2}, {"article": "It matters.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\nThe drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the tumor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in this story \u2014 somewhat shocking when you consider that safety assessment is the primary objective of phase\u00a0I research.\u00a0The suggestion that this drug may substantially increase the risk of another, less invasive type of skin cancer, certainly warrants some attention. The accompanying editorial in the NEJM commented: \"Overall, PLX4032 had moderate toxicity, with rash of grade 2 or 3, fatigue, and arthralgia being the major dose-limiting toxic effects. Somewhat unexpectedly, cutaneous squamous cell carcinomas developed in a significant percentage of patients.\"", "answer": 0}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\n(fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The jury remains out about the potential long-term effects of what some refer to as endocrine disrupters. Readers of this release are told there were no \u201cserious\u201d side effects, but not what the side effects were.\nNor was there any mention of the ongoing scientific debate about the safety of phytoestrogens. Concerns have been raised about tumor promotion in estrogen-sensitive tumors from phytoestrogens (although plant estrogen is actually very weak compared to estrogen used for pharmacologic purposes).", "answer": 0}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more on sinusitis.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\n\"Certainly this reinforces our belief that sinus surgery increases the quality of life of patients, and I see that clinically as well as scientifically,\" added Dr. Jordan S. Josephson, a sinus and allergy specialist at Lenox Hill Hospital in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors did not report adverse effects of endoscopic sinus surgery, the news story should have mentioned that complications can include bleeding, bruising, swelling and infection. \u00a0Rare cases of vision problems, spinal fluid leaks and meningitis have also been reported.\u00a0 If you don\u2019t report harms and you don\u2019t report costs, you\u2019re not telling a very complete story. ", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story implies the likelihood of death after two years\u201342 percent. \nIt also cites potential harms that include inability to monitor blood pressure and potential damage to brain, kidneys and other organs. \nYet the story fails to mention other harms that were described in the New England Journal study: stroke [18 percent], infection [35 percent], sepsis [36 percent], transfusions and surgeries for bleeding, and replacements. After implantation, patients were in the hospital for an average of 27 days.\nThese are not insignifiant risks of harm. The story earns a satisfactory under this criterion only barely. ", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nThese show that altering how the gut works can change not only appetite in general, but also change how the brain responds when they see high-calorie foods, and how appealing they find the foods to be.\"\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Even if there were no direct harms/side effects of the supplements, it would have been useful to say so explicitly. It would also be useful to know if there\u2019s a risk from long-term use since there was the suggestion it might have an impact on the body\u2019s microorganisms. It also appears as if the MRI was a form of fMRI which may have carried some risks, however small.", "answer": 0}, {"article": "\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from taking ketamine. A British Journal of Clinical Pharmacology study of ketamine for chronic pain devoted a lengthy discussion to side effects from clinical ketamine use, dividing them into central nervous system (CNS)-related, cardiovascular and hepatic (liver).", "answer": 0}, {"article": "Recently a well-known Seattle Seahawks player and four of his teammates are sitting out a week of training camp to receive a blood-healing treatment from a European supplier an IRAP-based treatment solution.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nIt's a non-drug, non-surgical treatment derived from your own blood.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release mentioned no potential harms of the treatment, and emphasized multiple times the supposed safety of the treatment as a \u201cnon-drug, non-surgical treatment derived from your own blood.\u201d\u00a0\nBut just because it\u2019s from your body doesn\u2019t mean it\u2019s inherently safe\u2014further study would be necessary to determine the safety and risk of adverse reactions.\nThough probably safe if done in a sterile fashion, there is no information on the long-term impact of this treatment on the arthritic joint.", "answer": 0}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nTUESDAY, Oct. 11, 2011 (HealthDay News) -- A small, preliminary study finds that ginger root supplements seem to reduce inflammation in the intestines -- a potential sign that the pills might reduce the risk of colon cancer.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Barely satisfactory.\nThe story only says that previous animal research showed ginger \u201cisn\u2019t potentially toxic to the stomach like aspirin.\u201d\nWhat about in people?\nThe story states that the National Library of Medicine that ginger is \u201clikely safe\u2026although some people may develop side effects.", "answer": 1}, {"article": "The average age of children in the study was 7.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The problem with any diagnostic tool, including very early-stage diagnostic concepts like this one, is that while they can offer accurate diagnoses \u2014 they may also provide an inaccurate diagnosis. This is particularly relevant, since the release quotes one researcher as saying the work \u201craises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\u201d But here\u2019s the thing: in the event of a \u201cfalse positive\u201d diagnosis of ASD in a very young child, it may take months or years for the diagnosis to be disproven. That could cause unnecessary stress for the patient and family and \u2014 given the expense of ASD treatment for many families \u2014 could impose a significant economic burden as well. The\u00a0damage would be minimized by using the test, as any test should be, in the context of a good clinical evaluation.", "answer": 0}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nThe IRE treatment also had very low toxicity on the rectum and bladder, even in cases of advanced cancer infiltrating these structures in patients who were not candidates for surgery or radiation therapy anymore.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nFor the study, Dr. Stehling and his team of researchers evaluated data from 265 patients with primary (stages T1-T4) and recurrent PCa after surgery, radiation therapy and HIFU.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes several different claims about the superiority of this treatment method to others \u2014 but never brings up the potential of harm.\n\u201cThe patients we have treated in the Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\u201d the release states. [Italics ours].\nThe word \u201cdestroyed\u201d is not typically used in medicine. Even if there is a \u201clow incidence\u201d of side effects, we would like to know what those rare side effects are.\nFurther, the news release provides no information about how side effects were measured (e.g., standardized measures completed by patients, physician assessments\u2013which is not considered reliable), how many men actually completed reports of complications, the median length of follow-up\u2013saying \u201cup to \u00a04 years\u201d is very imprecise. (They could have been followed just 6 months, 1 year, and so on.)\u00a0 Another problem is that the recurrence group\u00a0included\u00a0men who had already been treated with surgery or radiation\u2013which do cause erectile dysfunction and urinary incontinence. To interpret complication data the reader needs to know the level of urinary control and sexual function before the IRE treatment. The release also does not describe how recurrence was defined, whether all men were evaluated, and\u2013again\u2013the median length of follow up.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the quoted source and the study authors cautioned that beta blockers carry some side effects and additional research is needed to determine if the drugs\u2019 benefits outweigh their risks for cancer patients. It specifically mentions risks for people with asthma. Other specific harms from beta-blockers for the general population include depression and diarrhea. Beta-blockers may also cause complications for people with diabetes.", "answer": 1}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\nFor information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\nRisk-based screening is a poor approach.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Overdiagnosis and overtreatment aren\u2019t discussed, but these are real and significant issues with mammography.", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of even potential harms in the story. Even the accompanying editorial raised one issue: \u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "It\u2019s a conversation that could save their life,\" he said.\nScientists have developed a spit test that could identify the men most at risk of developing prostate cancer.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned PSA tests. which detects antigens that can be present in men without the cancer and \u201ccarries a risk of returning a false positive that can kick-start unnecessary, life-changing treatment.\u201d\nHowever, the story didn\u2019t explain that a genetic test would not necessarily prevent these harms, without a better test to detect actual cancers. While men found to be at low risk might be spared additional testing, those with genetic markers for prostate cancer might be subject to more aggressive interventions that could harm them.", "answer": 0}, {"article": "(Reuters Health) - People struggling with irritable bowel syndrome (IBS) might feel better with antidepressants or psychotherapy, a recent study suggests.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nA family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nAnother drawback is that these studies weren\u2019t designed to prove how antidepressants or psychotherapy might directly improve IBS symptoms.\nStill, a psychological evaluation may make sense for IBS patients because it\u2019s possible their symptoms might be a byproduct of untreated depression, said Dr. Agnieszka Kulak-Bejda, a psychiatry researcher at the Medical University of Bia\u0142ystok in Poland who wasn\u2019t involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are also not addressed. This is particularly problematic for the sections of the piece that deal with antidepressants. For example, the story specifically mentions both tricyclic antidepressants (which have potential side effects ranging from constipation to sexual problems) and selective serotonin reuptake inhibitors (which can also pose health risks). We don\u2019t expect a story like this one to provide an exhaustive overview of risks associated with these classes of drugs, but we do think it should at least acknowledge that there are risks.", "answer": 0}, {"article": "\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\nThe scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u201cThe effects of psychedelics on the developing brain are still largely unknown, meaning they could still pose a threat to people with a predisposition to schizophrenia,\u201d says the story. But it does not add other possible drawbacks cited by the study, such as \u201cfeelings of anxiety, fear, panic and paranoia.\u201d Since potential harm is a big reason these drugs are not widely available, we think this was an issue worth discussing in more detail.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big hole. As noted earlier in this review, bariatric surgery is not without risk of complications, particularly in people with multiple morbidities and older age or very young age. It behooved the story to say something about this, including the risks and harms of untreated diabetes or diabetes and obesity in people who have tried everything and failed to resolve either condition.", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\n\"The effect of pulsed radiofrequency is fast and without adverse events.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release leads with a phrase we find problematic: \u201cminimally invasive.\u201d For many readers this connotes a quick, \u201csafe and effective\u201d intervention as mentioned in the release. But \u201cminimally invasive\u201d can potentially have more complications than a prior \u201cmore invasive\u201d approach.\nNo instrumentation close to the spine or its nerve roots is risk-free. Nerve damage and infection are two potential complications that should have been mentioned.", "answer": 0}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nAnd the women who were screened earlier had smaller tumors.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\nPort also looked at the 40- to 49-year-old age group, and found those who had never had a mammogram were much more likely to need chemotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of the harms of earlier or more frequent screening, which have been documented time and time again. More screening can mean more false positives or more finding of breast changes that lead to more testing, such as biopsies, more costs, and more worry.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nThe researchers found that women eating dried apples lowered their total cholesterol by 14 percent.\nThe daily serving of dried apples contained about 240 calories, according to the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t think of any potential harms, and the story stated that \u201cDespite the addition of several hundred calories a day to their diet, the apple-eating women didn\u2019t gain weight over the course of the study. In fact, they lost an average of 3.3 pounds.\u201d ", "answer": 1}, {"article": "(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAbbott said it expects the risks to lessen as surgeons gain experience with it.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that one clinical study found a higher risk of heart attacks and blood clots in participants, complications that Abbott Labs apparently blames not on the stent but on surgeons\u2019 lack of experience in using it.\nA weakness here, though, as noted in the \u201cbenefits\u201d segment above, is that there apparently have been no clinical trials that have lasted long enough for the stents to dissolve (about three years) in order to assess harms. The story should make that clear to readers.", "answer": 1}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis new approach places them right on the scalp.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n\"Whatever the cause, it dials down the pain on the brain center.\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment says there is some tingling and a sunburn-like lingering effect linked to the treatment. \nWhile this is accurate, TDCS is relatively new and the real side effect profile is unknown at the moment.\u00a0 There may well be cognitive and motor reflex effects with repeated use.\u00a0 \nA simple statement that there may well be other unrecognized side effects would have put this into context. ", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does report that some participants had headaches, dry mouth and drowsiness, and that this drug sometimes makes people drowsy during the day. However, since there were only 18 participants who took the active ingredient, the story would have been better if it had alerted readers that much larger numbers of patients would need to be studied in order to quantify the likelihood of less common adverse events. ", "answer": 1}, {"article": "But the F.D.A.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\nOther companies, still doing their studies, did not yet have data to examine.\nWhat if the same pattern occurred in people without Alzheimer\u2019s?\nAnd so plaque in the brains of people with normal memories has been a puzzle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No. There is nothing in this story about what it\u00a0would mean, for example, if everyone over a certain age started having their brains injected with radioactive dye on a regular basis. Everyone has a lifetime radioactive load limit, for one. What else might the dye do to people who have other chronic conditions or are taking medications?", "answer": 0}, {"article": "\u201cWe are not hopeful here.\u201d\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\n\u201cIf the company cuts the price of the product in its current orphan indications, then it instantly sacrifices sales which currently total about $400 million per year with the hope that future sales in a new CV setting will more than offset this,\u201d Anderson said in a note.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "From the get-go, readers are told there are risks to keep in mind. This was entirely absent from the TIME story we reviewed.\nThat said, we wish this Reuters story had discussed the harms more in-depth\u2013how frequent were they? How severe?", "answer": 1}, {"article": "Through a blood vessel in the groin, doctors snake a tube to a blocked heart artery.\nAbout 40 percent of patients in the study had a prior heart attack more than three months previously.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nHalf of these low-risk patients received stents and medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study mentions the risk of clotting with drug-coated stents, this is not adequate information on harms. Furthermore, the study does not mention any possible harms of medication.", "answer": 0}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nTurner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention side effects, but the study itself reported that adverse effects included nausea, diarrhea, and weight loss. In addition, there are some concerns that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners. It\u2019s worth noting that this absence of potential harms in the story is particularly problematic, given that a key goal of the study was to determine whether high doses of resveratrol are safe. Moreover, weight loss is already a significant concern among Alzheimer\u2019s patients, so anything that would exacerbate that is definitely worth paying attention to.", "answer": 0}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nIn an e-mailed statement, FDA spokesperson Sandy Walsh confirmed that the FDA\u2019s decisions are all \u201cbased on an assessment of the available data and whether the benefits of the drug outweigh its risks.\u201d That data can include the experience of patients like Max, Rowan and Charlie.\nBut there\u2019s still a chance the FDA could approve the drug.\nPTC Therapeutics founder and CEO Stuart Peltz says the statistics aren't a reason to reject the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text briefly mentions side effects associated with the drug, increases in blood pressure and cholesterol levels, an assertion contested by the drug\u2019s manufacturer, PTC Therapeutics. However, it would have been more helpful to quantify and more clearly describe these side effects, and tap independent experts for their viewpoints. We found the NCHR\u2019s testimony about the risks of combining this drug with other drugs these kids commonly take to be important, for example.", "answer": 0}, {"article": "Motivation matters a lot; so does a person\u2019s social environment, the amount of support from friends and family, and the rules enforced at the workplace.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\n\u201cSome studies have questioned these treatments, but the bulk of clinical trials have unequivocally endorsed them,\u201d said Dr. Michael Fiore, director of the \u2019s Center for Tobacco Research and Intervention and the chairman of the panel that wrote the guidelines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nThe implants are currently approved for three years, and the hormonal IUD used in the study is approved for five.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s strongly implied that an unintended pregnancy is a potential harm of keeping\u00a0either one of these prescription devices longer than the FDA-approved length of time. But that\u2019s fairly self-evident. We think the story\u00a0should have addressed other potential harms that come with having an IUD in the first place such as infection, ectopic pregnancy, or expulsion.\u00a0This could have been addressed succinctly in one extra sentence.", "answer": 0}, {"article": ".\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.\u201d Although the release does not go into specific detail about the number of patients who reported side effects, or the degree of severity of the side effects, the list of harms seems adequate for a drug just beginning the clinical trial process.", "answer": 1}, {"article": "We have to really ask the question: 'How low do you go?'\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nNabel stressed that while the death rate was higher in the intensive group, the rate in both groups was still lower than would be expected in patients at high risk receiving standard treatment.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about the new finding that more intensive management of sugar levels in high risk patients increases mortality risk. Differences in death rates were given in absolute terms. ", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\nThis appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is one sentence related to harms in the release, but it doesn\u2019t tell us what they are.\n\u201cThere were no treatment-related deaths or therapy discontinuations due to drug-related adverse effects.\u201d\nThe package insert lists the most common side effects as\u00a0fatigue, cough, nausea, diarrhea, constipation, anorexia, arthralgia (joint pain), pruritus (severe itching), and rash.", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nThe fat enters the lymphatic system, and is eventually used as energy, Dr. Maloney said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to point out the potential harms of these devices.\u00a0\n The devices claim to be based on scientific principles involving the cellular destruction of lipids and their elimination from the body. This is serious metabolic stuff, presumably with serious potential risks. The story fails to acknowledge this. ", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\n\"Because there's very robust evidence showing the cardiovascular benefit of linoleic acid.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not Applicable. The primary focus of the story was addressing the potential harm of consuming too much linoleic acid. The story should have quantified these harms better, but since we\u2019ve already docked points above under Benefits, we\u2019ll grade this N/A here to avoid dinging it twice for the same flaw.\u00a0 We can\u2019t give it credit for a satisfactory score, though, for the same reason.", "answer": 2}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the drug is associated with \u201cfew significant side effects,\u201d however, the specifics of these side effects are not provided. Six patients in the advanced basel cell carcinoma study experienced 8 grade 3 adverse events, including fatigue, hyponatremia, muscle spasms, and atrial fibrillation. One patient withdrew from the study citing adverse effects.", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nPeople who have a gastric bypass often have nutritional and vitamin deficiencies, Lenhard said.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nJust 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the weight-reduction procedures \u201ccarry the same risks as any surgical procedure, such as infections, blood clots and bleeding\u201d as well as nutritional and vitamin deficiencies. It also states that gastric banding \u201chas low effectiveness and a risk of the band slipping down the stomach.\u201d Note: The most risky complications (problems arising from general anesthesia) were not mentioned.", "answer": 1}, {"article": "Hospitals take over with more sophisticated cooling equipment.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\nBut Dr. David Rosenbaum, director of MetroHealth's heart and vascular center, said there is not enough research data to justify a regional system.\nWith more than 300,000 deaths a year in the United States from cardiac arrest, Rosenbaum said the focus should be on preventing deadly rhythm disturbances and improving access to defibrillation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of treatment. \u00a0The story ended with a plea to provide people who would otherwise die, with something. \u00a0However since there was no discussion of outcomes with people who were and were not provided this treatment, it is not possible to know whether there are any harms of receiving this treatment. Survival with brain damage could be increased, which could be considered a harm worse than death in some cases.\u00a0 What do the data show? ", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nIt's by far the more common form of diabetes and can lead to about $85,000 in medical costs.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Most interventions pose some kind of potential harms and Weight Watchers is no exception. For some, particularly those without access to a dedicated dietitian as the study participants had, the amount of sodium in a WW points-based meal plan may be too high, or the vitamins insufficient to maintain nutritional needs.", "answer": 2}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\nAt four months\u2019 follow-up there also was greater decline in self-reported GAD symptoms and depressive symptoms among participants in the telephone CBT, according to the results.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentioned no possible harms from this approach, although in fairness, supportive telephone conversations are unlikely to carry much risk. \u00a0 However, we wonder about\u00a0situations where the telephone therapy sessions may not detect some problems that might surface during a face-to-face consultation.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions potential harms associated with older sunscreen formulations (e.g. ashy color, ineffective when exposed to light)\u2014but says nothing about potential harms of the newer versions that are the story\u2019s focus. Do they cause allergic or photoallergic reactions? Could they give sun-lovers unwarranted confidence in the lotions\u2019 prowess? In an apparent paradox, increased use of sunscreen has been associated with the spiraling incidence of skin cancer. Is this because sunscreens are used improperly (as the article suggests)? Or do sunscreens have inherent weaknesses as well? ", "answer": 0}, {"article": "\u201cIf there is a financial incentive\u201d for promoting the newer technique, he says, \u201cit is that more patients will want the anterior approach, so that the surgeon does more surgeries, and therefore collects more professional fees for that.\u201d\n\nWilliam Hamilton, who operates at the Anderson Orthopaedic Clinic at Inova Mt.\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\nAccording to those who use this anterior technique, the benefits are substantial.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harms in this story is by way of showing that the more \u201cinvasive\u201d method of hip surgery is more damaging to muscle and tissue. Again, the story is framed as a risk-free operation that most surgeons are ignoring and an awful, damaging technique that leaves people teetering like Charlie Chaplin.", "answer": 0}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nTo be effective, all three compounds must be given together, the researchers said.\nIn addition, medical foods for Alzheimer's most likely won't be covered by insurance, he said.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\nPrevious experiments in animals showed that giving them the three compounds included in the drink increased the production of synapses improving brain function, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only paraphrased the researchers saying \u201cthere were no serious side effects.\u201d That\u2019s not good enough.\u00a0 What did the data show?\u00a0 What was observed?\u00a0 In how many people?\u00a0 Then let readers or independent observers judge what is serious or not. At a minimum, the percentage of people in the trial with any side effects should be given.", "answer": 0}, {"article": "It was Kyle Henn, recovering from his own PTSD after surviving the plane crash, who recommended eye movement desensitization and reprocessing therapy, or EMDR.\nBut after the whirlwind passed, unaddressed grief remained with her.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\nThe ordeal didn\u2019t end with the news of Nate\u2019s death.\nHenn was able to recall processed memories without feeling panic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not broached.", "answer": 0}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\nAbout half got the combined approach and half received treatment as usual.\nOver two years, both groups showed steady improvement.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s conceivable that changing the standard of care for patients by reducing drug doses may carry some risk. Could some patients\u2019 symptoms be less-well controlled? Then again, drugs are very much overused in this area. And on average the study showed better symptom relief with the lower doses. No harms were documented in the study\u2013no increase in hospitalizations at least. \u00a0So while we can\u2019t give credit here, we won\u2019t ding the story either. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Ellis also is a McNair Scholar at Baylor.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of the drug were mentioned. It was also glossed over that most of the patients in the trial did not seem to have any response to\u00a0neratinib. The release\u2019s only reference to harms was that \u201cNeratinib was well tolerated by most patients.\u201d Other research (including the peer-reviewed paper this release is based on) has shown diarrhea to be a significant side effect of neratinib.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\n\u201cWe thought it made sense to start them at the time of diagnosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nAnd the result is a life saved.\nThat means 66 people would have to get tranexamic acid to prevent one death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned there was no increase in deaths due to blood clots in the TXA group. We understand it\u2019s a blog brief \u2013 so this is sufficient. ", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\nBut in terms of their bacterial colonies, the infants swabbed with the microbes closely resembled vaginally delivered babies, she found, especially in the first week of life.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\nAnd all infants delivered by C-section were exposed to antibiotics, which also may have reduced the number and variety of bacteria colonizing them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that thus far the procedure \u201chas proved entirely safe,\u201d but we\u2019re talking about only four babies here!\u00a0The article assumes that all the bacteria in the mother\u2019s vaginal secretions are \u201cfriendly.\u201d \u00a0This is clearly not the case in all patients. Significant infections can be transmitted to the newborn from bacteria resident in the mothers vaginal secretions from less than friendly bacteria\u00a0including Chlamydia, Listeria and group B Strep to name a few. Suggesting that the procedure is not recommended but then pointing out that Dr. Brubaker had the procedure done for her newborn supports the notion that this is a harmless procedure \u2014 a potentially dangerous message.", "answer": 0}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a section on the safety of the new vaccine that offers substantial relevant information, as well as how to obtain more detailed information if desired.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThere is no such screening tool currently in use.\nOne expert said the study is an important step but definitely needs follow-up work.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions false positive results and unnecessary exploratory surgery as potential harms of the test.", "answer": 1}, {"article": "For more information, visit www.chronothera.com.\nTest group subjects had nicotine administered over a 30-hour time period via Chrono's prototype device that delivered nicotine according to Chrono's \"peaks and troughs\" profile.\nThe clinical trial was a randomized, double blinded study of 24 adult males who smoked 11 or more cigarettes per day, indicating a high level of nicotine dependence.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the subjects in the clinical trial did not have any adverse reactions to the device, and that a skin irritation assessment concluded there was no irritation or erythema. However, the study abstract provided by the news release issuer reported that 25% percent of the volunteers experienced itching.", "answer": 0}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\nSwaminath pointed out that even the new study found that \"low- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\"\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n\"A risk stratification tool is critical in helping physicians make appropriate screening recommendations for patients,\" Garbus said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm of a screening test such as this really is \u201cgetting it wrong\u201d in terms of predicting someone to be at low risk and finding them to have a higher risk polyp or malignancy. As noted above, the story cautions that \u201clow- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\u201d", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nThe paper is currently available in Chronic Respiratory Disease.\nThey also used the national Medicare database to study data from 253 men with COPD aged 66 and older who initiated testosterone replacement therapy between 2008 and 2013.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known dangers to TRT including raising the risk of prostate cancer but none of the risks are mentioned in the news release.", "answer": 0}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\nThe study appears in the Journal of Pharmacology and Experimental Therapeutics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release reported that treatment of rats with iberiotoxin \u201cdid not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\nThat\u2019s not quite right. The study itself says it only examined tremors and incontinence, and other adverse effects couldn\u2019t be ruled out.\nAlso, just because a particular adverse effect wasn\u2019t observed in rats doesn\u2019t mean it is safe for humans.", "answer": 0}, {"article": "Even better, she said, \u201cfor the first time I didn\u2019t feel any itch at all.\u201d\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nNearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that patients receiving dupilumab reported slightly more cases of conjunctivitis, and swelling around the injection site, than those receiving the placebo injections. The story would have been more complete if it had also noted that a few patients saw their eczema get worse and that many also reported upper respiratory infections, though the rates were similar to those receiving placebo injections.", "answer": 1}, {"article": "But there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release didn\u2019t address harms but we\u2019re not aware of any associated with assistive reading devices.", "answer": 2}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nThe WiSOR research team addressed this issue by having participants undergo tailored training to learn to use the WoundCheck app.\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t explored. The app mentions that there was one false negative result among the 40 patients studied, but doesn\u2019t explain why this happened or what the consequence was.", "answer": 0}, {"article": "\"When it finally happened, he just very calmly said, 'Yep, I felt it on my index finger,' \" Gaunt recalls.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nIt's a mind-controlled robotic arm that has pressure sensors in each fingertip that send signals directly to Copeland's brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any harms that may lurk in future applications of surgical implants to communicate with a potential robotic arm.\u00a0The most obvious way to approach this would be to talk about risks of neurosurgery generally;\u00a0accidental destruction of healthy tissue, for example, or stroke. But there may be others related to the technology\u2013essentially there are a lot of unknowns when the patient test group is one individual.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any effects, either positive or negative, of decreasing or eliminating cola consumption.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One shortcoming of the story:\u00a0 no discussion of harms from Abraxane.\nHere is the data from the Calgene press release:\n\u201cThe most common grade \u2265 3 treatment-related adverse events in the study for ABRAXANE plus gemcitabine vs. gemcitabine alone were neutropenia (38% vs. 27%), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). In the ABRAXANE plus gemcitabine arm, the median time to neuropathy improvement was 29 days. There was no difference in serious life threatening toxicity (4% in each arm).\u201d", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\nBut Sheiner was extremely committed to trying it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only discusses success rates but doesn\u2019t mention any potential harms. What are the actual problems people encounter when having \u201ca series of surgeries to completely treat apnea\u201d or when they have the more \u201chighly invasive surgery\u201d?\u00a0 And what has been found even in the limited series of robotic procedures?", "answer": 0}, {"article": "While some people are helped by over-the-counter medications like ibuprofen, others need prescription medications that may cause side effects, such as dizziness.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nThe aim of the medication is to stop a migraine before it even starts.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nMy entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no discussion of the drawbacks of this new experimental class of drugs.\nAt the very least, we know that the need to take injections will be a turn off for some sufferers.", "answer": 0}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story briefly mentions the potential for rejection, it fails otherwise to specify the potential side effects of the stem cell harvesting or infusion. This is surprising, given the fact that the Phase I trial is designed to prove safety. ", "answer": 0}, {"article": "\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nStudies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research.\n\u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n\nNo serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0states that no serious side effects of the probiotic were reported, and this is sufficient for Satisfactory rating.\nIdeally it would have provided additional\u00a0information about\u00a0what would\u00a0constitute\u00a0a \u201cserious\u201d side effect. With\u00a0the way the story is\u00a0worded, it\u2019s possible that other side effects were reported by study participants. This is important information to have in order to\u00a0compare to other treatments for depression or IBS.", "answer": 1}, {"article": "\"For many women with symptoms and especially with concerns about hormone replacement therapy, trying soy for six to 12 weeks to see if it relieves their symptoms could be a first line of treatment,\" says Melissa Melby, PhD, a professor of medical anthropology at the University of Delaware.\nThe study had no industry funding.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"I personally think foods [containing soy] are better.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harm.", "answer": 0}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nIn studies, clinically-tested, stimulant-free Capsimax was shown to significantly help improve body composition, promote thermogenesis and lipolysis, decrease appetite, accelerate metabolism and increase resting energy expenditure.\nProprietary Capsimax is made using OmniBead Beadlet Technology to encapsulate the beneficial heat of concentrated highly-active, natural capsicum in a controlled-release coating--delivering effective levels of capsaicinoids without the oral and gastric burning sensation of unprotected red hot peppers.\nThe MR Study was a placebo-controlled, crossover open label study with 40 healthy adults examining the effects of either 2 mg capsaicinoids from 100 mg of Capsimax or placebo on resting energy expenditure, heart rate and blood pressure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that multiple studies have shown the supplement is safe, however, the safety hasn\u2019t been evaluated or demonstrated in this or other research we could find. A search of PubMed found only three studies involving\u00a0capsicum supplementation. All were short-term and none were designed to look at safety.\nWebMD\u00a0says that taking capsicum supplements\u00a0is generally safe for adults if taken for a brief period of time. However, taking large doses for a long period of time can lead to serious harms including liver or kidney damage.", "answer": 0}, {"article": "The mantra 'time is brain' still holds true.\"\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\nThe trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any specific harms from either approach, nor what the rate of adverse effects was in either group. It\u2019s not enough to state only that there was no difference.\nThe release noted that there was \u201cno difference in mortality or other safety end points between the two groups of patients\u201d in the study (those undergoing clot removal and those getting medical only). But the release could have been much clear about specific \u201csafety end-points,\u201d complications of both the clot-removal procedure and drug therapy; and certainly more information about residual disability in both patient groups.", "answer": 0}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\nSpecialists at The Christie and The University of Manchester have made a breakthrough which could potentially improve detection and treatment of anal cancer, as well as have wider implications for other cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes refers to the harm of over treatment and side effects, but never quantifies them. A quote from a patient refers to \u201cjoint pain and continence issues\u201d suffered by some patients but it\u2019s unclear which treatments were responsible.", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one\u2019s a close call that we ultimately ruled unsatisfactory. The story is enamored with the greater accuracy that \u201creal-time\u201d imaging should provide for surgeons, but it doesn\u2019t acknowledge that the scalpel cuts both ways. With increased visibility, there\u2019s a greater chance that these scans will turn up so-called \u201cincidental findings\u201d \u2014 problems that no one was looking for and that could well be meaningless to the patient (for example, a slow-growing tumor that would never pose a real risk to the patient). Cutting based on such findings may, in fact, increase morbidity and mortality.\nThe story does get credit for thoroughly explaining the potential risks associated with MRIs. However, the story does not address the risks associated with CT scans at all. CT scans require exposure to a significant amount of radiation, and patients can suffer allergic allergic reactions to the contrast dyes.", "answer": 0}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nWhy The Research Is Interesting: Patients with DCIS are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from breast cancer.\nThe absolute risk reduction was 0.27 percent, making it necessary to treat 370 women to save one life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release briefly discusses harms. The release says patients who received radiation and lumpectomy had more \u201clocal\u201d recurrences of the cancer, but their overall survival was modestly better than patients who did not have radiation (a 0.27% reduction over 15 years).\nThe release should have given some mention to the harms of radiation treatment, particularly since the potential benefit of radiotherapy was very small.", "answer": 1}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nHowever, the study found the tablet triggered an increase in the hormone Aldosterone, which helps regulate both blood pressure and bodily fluids.\nThe study, presented by Australian heart researcher Philip Barter, who oversaw Pfizer's torcetrapib clinical trials, concluded torcetrapib caused \"off-target\" effects, including deaths, elevated blood pressure, cardiovascular problems and a possible link to cancers.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the increased risk of death, heart disease and elevated blood pressure with the failed drug. However, in the absence of evidence, the story should not be suggesting that a more \"clean\" version of the drug would not have such harms.", "answer": 1}, {"article": "Cao looked at data from over 86,000 women who were part of the Nurses' Health Study between 1980 and 2012 and over 43,000 men who were part of the Health Professionals Follow-Up Study from 1986 to 2012.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding. Studies have showed an increased risk of both when taking a daily aspirin.\u201d", "answer": 1}, {"article": "Kisco, N.Y.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nMore people in the bypass group had complications right after the surgery.\nIn Campos' study, roughly equal numbers of patients in each group experienced complications after one year (12 percent in the gastric bypass group compared to 15 percent in the lap-banding group); these included infection, internal bleeding and blood clots, but no deaths.\nMONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the LA Times, this story attached a number to the risk of complications observed during the study. It would have been interesting to see some discussion of the seriousness of these problems, as some data suggest that short-term\u00a0complications with gastric bypass are more grave than those with the band, while longer-term complications with the band may be more frequent and serious. This story mentioned that there were no deaths in either group in the bypass vs. band study, but as with the competing coverage, it didn\u2019t explain that there are well established differences in mortality risk associated with each procedure. We\u2019ll award a passing grade, but the story could have done better here.", "answer": 1}, {"article": "ABOUT ASTROThe American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\nOS rates were higher for patients with higher Karnofsky Performance Status (KPS), which measures a patient\u2019s functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91; p < 0.01).\nRecursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.\nFifty percent of patients who did not have a biopsy had a previous history of lung cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that just over one-third of the 58 patients experienced radiation pneumonitis (inflammation of lung tissue), and that two had cases severe enough to possibly require oxygen or steroid treatment. However, the release does not mention other harms of this sort of radiation treatment, which can include fatigue lasting for several weeks, neuropathic pain, rib fractures and other problems. There is no mention of any measurements of these other radiation effects.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nNews flash: Eggs are really good for you.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In just a line, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol), but that\u2019s probably splitting hairs. We\u2019ll call this not applicable since there aren\u2019t really any harms from eating a reasonable amount of eggs. Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "Attention, memory, and language improved.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be minimal to no health debits stemming from the Mediterranean diet, assuming one eats in moderation.", "answer": 2}, {"article": "The F.D.A.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions several risks of the procedure such as stroke risk and paravalvular leak, but hard numbers are missing. How many patients undergoing TAVR or conventional valve surgery suffer strokes? How common is leakage? All the story provides are generalizations: \u201cThere is some question about whether the process of inserting the new valves loosens debris that can cause strokes. One large study found a higher stroke rate in patients receiving valves without surgery compared with those receiving valves with surgery. Another large study did not find this effect. The valves also tend to leak slightly around the edges. New designs are ameliorating this problem, but not solving it.\u201d\nWe\u2019ll reward the story here for at least mentioning some potential risks. But it is disappointing that such a lengthy report includes only one-sided, glowing patient reviews of TAVR. Why is there not a single account of any patient who suffered a stroke or other serious complication?\nTo the article\u2019s credit, it also raises the issue of limited evidence about the valves\u2019 durability: \u201cFor now, evidence of the procedure\u2019s effectiveness exists only for the sickest patients and there are only five years of data on how long the valves last.\u201d", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that hypnosis comes with no known risks, unlike hormone replacement therapy.", "answer": 1}, {"article": "\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nChemotherapy may induce early menopause, and drugs that reduce estrogen levels may make hot flashes worse, the research team noted.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nHowever, he cautioned that its long-term effects aren't known.\nThe study found that women taking the medicine had an average of five fewer hot flashes a week, compared with three fewer among women taking a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that side effects included constipation, mild diarrhea, dry mouth, dry eyes, episodes of confusion and difficulty urinating. It\u2019s not noted if these side effects were seen in both the low-dose and high-dose groups. There is also no indication of which side effects were most common or how many women experienced them.\nImportantly, though, the article does note that the long-term effects of the drug aren\u2019t known and that oxybutynin is in a class of drugs that \u201chave been linked with mental decline\u201d and that previous studies have found \u201cthe drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients.\u201d\nInformation on ClincalTrials.gov about the trial suggests this study evaluated two doses in an effort to find an effective dose with fewer side effects.", "answer": 1}, {"article": "(\u201cEnjoyed\u201d?\nThe Baylor scientists were able to correct for those variables.\nThe research in question involved mice, not women.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nAnd that difference persisted into mouse adulthood.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of vigorous activity during pregnancy\u00a0were not discussed.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are \u201cimmune-mediated.\u201d We would have liked a bit more context on what this term means for patients.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said \u201cSide effects of cabozantinib included fatigue, high blood pressure and hemorrhage\u201d but it never explained how often these were seen.\u00a0 In 1% of patients?\u00a0 10%\u00a0 All of them? ", "answer": 0}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\nThe trial was conducted in India and paid for by Applied Food Sciences Inc. of Austin, Tex., a manufacturer of green coffee bean extract.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the HealthDay story on this criterion, quoting an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 1}, {"article": "The National Cancer Institute has more on prostate cancer.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\nA second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.\n\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\n\"A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential for harm associated with adopting any of the\u00a0aspects of prostate cancer testing and treatment covered in the story were not clearly or completely discussed.\nFor example \u2013 what are the consequences of a surgeon not being proficient with robotic surgery?\nWhat are the side effects for the medication Avodart? How often are they seen?", "answer": 0}, {"article": "Nonetheless, the doctors were pleased when M.R.I.\nDr. Boockvar said microcatheters should increase the odds of success by delivering a high dose of the drug directly to where it was needed most.\n\u201cNobody knows.\u201d\n\nIndeed, the death of the first patient was a reminder that glioblastoma can invade other parts of the brain and the spinal fluid and that the highly localized spray of Avastin might miss deadly seeds of cancer.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\nMr. Sugrue said he was all for it, even though Dr. Boockvar warned him that the drug was no magic bullet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the infusion method has not been proven safe\u2013indeed, that\u2019s what the current study is designed to find out. \nIn addition, the reporter cites the doctor\u2019s estimated risks of the treatment the featured patient faces: a 5 percent chance of becoming \"visibly weak\" and a 1 percent chance of left-side paralysis.\u00a0\n\u00a0", "answer": 1}, {"article": "However, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nCancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nBecause of the burden, doctors say, many choose to have mastectomies instead.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most important potential harm of brachytherapy would be a lack of efficacy\u2013that is, a patient would choose it due to its greater convenience, despite what could be a lower success rate. Given the lack of long-term data on efficacy available, this is a significant shortcoming.\u00a0 \nThe article does not acknowledge other potential harms of brachytherapy when used for breast and prostate cancer.\u00a0\u00a0 ", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is almost a throw-away line in the study that says, \" A recent study estimated the epidemiologic impact of DWI-based diagnosis would result in reduced annual TIA incidence (33%) and increased stroke incidence (7%) in the United States.\" Reducing these \"mini-strokes\" by 33% would indeed be a dramatic change, given the number of people who suffer from them, but these are \"warning strokes,\" that can actually force people to change risky behaviors or begin taking the right medications to avoid an actual stroke. Those strokes may have actually climbed by 7% in the theoretical model of a world where diffusion scans were the norm. A 7% increase in strokes could mean an additional 55,650 people suffering a stroke each year, by our count. Again, these numbers would be nice to see in the story.\u00a0", "answer": 0}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\nAnother big question, he added, is whether breath analysis could pinpoint people with colon polyps.\nWhat's more, he added, there are already several good ways to catch colon cancer -- or, even better, precancerous growths called polyps, which can then be removed before a tumor develops.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentioned that this test\u00a0would inevitably\u00a0produce\u00a0false-positive results that would lead to\u00a0needless invasive follow-up tests.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nMany other strategies will also reduce the risk of cancer, he says.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201ceven low-dose aspirin can lead to problems such as serious gastrointestinal bleeding.\u201d\n\u00a0", "answer": 1}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention potential adverse effects of TMS or state whether any adverse effects were seen in the study.", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nThe study is preliminary and doesn't prove cause and effect.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story failed to note any of the potential side effects of statins.", "answer": 0}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nRamakrishnan said it's probably too soon to recommend routine use of DHA supplements for pregnant women, because the findings weren't \"dramatic.\"\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that the babies whose mothers had recevied prenatal supplementation with DHA had bouts with vomiting or rashes that lasted longer than the babies born to mothers in the control group.\nThe story mentioned that the women in the study had low DHA intake which was also the case for women in the US. \u00a0This appears to be an overstatement of the need for DHA supplementation for women in the US and the story should have touched on whether excessive DHA consumption might have potential consequences for pregnant women such as bleeding or problems with vitamin E levels.\nIn addition, the comments by Dr. Wu suggested that women use this supplement along with prenatal vitamins even though this particular study did not begin supplementing until 18-22 wks. A large randomized clinical published in JAMA showed some adverse outcomes among the female infants exposed in utero (not males), namely lower language scores and lower adaptive behavior scores.\u00a0 We don\u2019t know why the story chose to interview Dr. Wu, but perhaps her comments needed to be addressed by other expert perspectives as well.", "answer": 0}, {"article": "CHICAGO (Reuters) - A computerized brain training program cut the risk of dementia among healthy people by 48 percent, U.S. researchers said on Sunday in reporting an analysis of the results of a 10-year study.\nThe institute is part of the National Institutes of Health, which funded the study.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nEdwards also was a paid consultant for the company for part of 2008.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine any serious harms from using brain games, other than time lost.", "answer": 2}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\n\"And other similar studies have looked at omega-3 and muscle preservation and have also suggested that fish oil can act to prevent inflammation caused by both disease and hardcore medications, like chemotherapy agents.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The independent perspective from the Texas dietitian did include this: \u201cBut I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot. Much much more than any recommended dietary allowance, along the lines of two to three servings of fish per week.\u201d\u00a0 But neither that comment nor any other line in the story explicitly mentioned the possibility of harm from the mega doses. Is it possible there could be interactions with drugs the lung cancer patients were taking?", "answer": 0}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit here for pointing out, as part of the explanation of the study\u2019s limitations, that a longer and larger study would be necessary to determine whether the drug is safe as a treatment for Alzheimer\u2019s. The competing Fox News story simply took the lead researcher\u2019s word for it that there were no harmful side effects.\nThat improvement aside, the story still had a responsibility to report on the harms that were documented in the study, which included dizziness and congestion. The story didn\u2019t do that, which is why we\u2019re rating it unsatisfactory here.", "answer": 0}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nNicolaides said the aspirin may help improve blood flow from the mother to the placenta.\nACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nWomen who delivered at less than 34 weeks were 82 percent less likely to have preeclampsia if they were taking 150 mg of aspirin, Nicolaides said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\u201d To its credit, it also adds, \u201cHowever, as with all drugs, women should talk to their doctor about the use of aspirin in pregnancy before taking up this regimen, because aspirin does increase the risk for bleeding.\u201d", "answer": 1}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nBut the FDA worries that this alkaline treatment could also \"affect the stability of added folic acid,\" the agency told The Salt in a statement.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the FDA\u2019s worry that a chemical used on corn flour could interact with the corn masa flour. It quotes the FDA which says:\u00a0\u201cThe FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\u201d It would have been nice for the story to explain more clearly what concerns are raised \u2014 this seems pretty vague \u2014 but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there are hypothetically potential harms of too much fiber in the diet, this story in this context didn\u2019t need to drill down on them.", "answer": 2}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nBacterial DNA from patients' skin is then analyzed in a lab to determine if the cream effectively reduced the amount of bad bacteria present.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from using the lotion are mentioned.\nCould there be allergic reactions? If the lotion does, indeed, reduce the amount of Staph. aureus on the skin, are there consequences to that? Or consequences to changing the skin\u2019s microbial balance in general?\nAlso, many eczema patients are acutely aware that their skin is not just fragile, but also may have open sores; should a bacterial lotion be applied to broken skin? And does this put them at risk of a bacterial infection that can spread?", "answer": 0}, {"article": ".\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nOpen windows and doors helped reduce carbon dioxide levels and improve ventilation and air flow, which was related to better sleep quality for the healthy young adults in the study.\nOverall, skin temperature and the bed temperature were higher in closed conditions than open conditions.\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be no immediate potential harms, but the story mentions indirect ones like extra noise or concerns about security.", "answer": 1}, {"article": "\u201cA whole world of freedom opens up [for these individuals] because you can move about a city like this (New York City) or anywhere much more easily, and the dogs can become your eyes,\u201d she said.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\nAfter toting around eye drops, Tomei said she has found a solution with Allergan\u2019s prescription drug RESTASIS\u00ae, which works by increasing the eyes\u2019 natural ability to produce tears.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nothing in this story discusses\u00a0any harms, but the product label tells us that \u201cIn clinical trials, the most common adverse reaction following the use of RESTASIS\u00ae was ocular burning (17%). Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).\u201d \u00a0The label also says: \u201creported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the vial tip touching the eye during administration).\u201d", "answer": 0}, {"article": "What happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nThe treatment doesn't work for those who have had cataract surgery.\nColby says that's also why patients need to learn to use the implanted telescope eye for near activities.\nThis is why the telescope is implanted in only one eye.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The fourth sentence talks about the potential harms, a rarity for any health story. In fact, the whole second paragraph should be part of a template for most health writing.\u00a0\"Findings from the clinical trials show that the telescope does improve vision for the majority of patients. Still, there are some concerns about corneal damage, since the telescope is relatively large inside the eye. And the population who might benefit from the new device is somewhat limited. The treatment doesn\u2019t work for those who have had cataract surgery. And for those who catch the disease early on, there may be better options.\" One of our reviewers just printed that out and taped it to his computer screen.", "answer": 1}, {"article": "It was really stimulation in the gateway to the hippocampus - the entorhinal cortex - where we got the beneficial effect in terms of memory,\u201d Fried said.\nIn a study published in the Annals of Neurology in 2010 researchers tested deep brain stimulation in six patients over the course of a year and found the treatment to be relatively safe.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nThey also saw signs the treatment might have an effect on memory.\nOne team has already tried deep brain stimulation in Alzheimer\u2019s patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While this story (unlike the HealthDay story we reviewed) at least mentions that deep brain stimulation is \u201cvery invasive,\u201d it should have listed at least some of the major risks of implanting electrodes into the brain connected to stimulation devices under a patient\u2019s skin, including bleeding, strokes and infections.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the news release. Some scientists are concerned that nanotechnology may have toxic effects on the body, especially the lungs.\nDepending on the nanotechnology, other organs may also be at a risk for damage. In particular, some nanoparticles may affect the endocrine system, leading to changes in hormone levels, sexual characteristics, reproduction and development.\nThe news release talks only about the benefits of nanoscience research without any description of its potential harms. Consequently, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nIn the case of her younger daughter, Downing said, a child psychiatrist put Candace on Zoloft after a very brief evaluation because the child was experiencing anxieties during tests.\nThe screening, unsurprisingly, found that Caroline's emotional problems were linked to her sister's death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While indicating that the use of SSRI medication by adolescents has been associated with increased risk of suicide, the story provided no quantitative information about how likely this is to occur. \u00a0The story did mention the potential for over-prescribing of antidepressants. \u00a0However, it did not mention other potential harms such as stigma, mis-diagnosis, distracting from more important health problems, and treatment without adequate follow-up potentially leading to net harm.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nHere\u2019s how he got out.\nAt 14, MS-13 was his family.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One expert is quoted saying, \u201cBut in general, the kind of exercise we\u2019re talking about is certainly not going to hurt.\u201d But suggestions for incorporating techniques such as walking backwards would seemingly come with some risk, especially in an unsupervised location.", "answer": 0}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nThis compares to just 21 percent for PSA alone, the researchers told a meeting of the American Urological Association in San Francisco.\nThey said Gen-Probe\u2019s Progensa PCA3 test caught about half the actual cases of prostate cancer in men who had abnormal PSA levels or digital rectal exams, and had about a 20 percent \u201cfalse positive\u201d rate.\nThis is far less sensitive than PSA, which catches 87 percent of tumors, but if the two tests are used together they can help rule out the need for unnecessary surgery or radiation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did include sufficient information to conclude that with this test, there were still both false positive and false negative results. \u00a0There was, however, no discussion about whether this test had any role in helping men who really didn\u2019t require treatment to avoid such treatment. ", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did discuss the main harm \u2013 the difference in bleeding \u2013 and that since\u00a0 ticagrelor must be taken twice a day, missing a dose can be very dangerous since the drug wears off so quickly.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\nThe vaccine under development is aimed at preventing recurrence in women who have a form of tumor known as HER2-positive, according to researcher Dr. Diane Hale, a research resident in general surgery at Brooke Army Medical Center at Fort Sam Houston, in San Antonio.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study did not discuss any potential side effects of the current vaccine.", "answer": 0}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\nIBS is the most common gastroenterological disorder in the United States, affecting nearly 40 million people.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100% accurate. A wrong test result may lead doctors to causes that may not actually be the problem. As such it may lead to inappropriate treatments. That\u2019s a harm that should have been mentioned.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable as we did for the competing stories, but with the caveat: Lycopene supplements haven\u2019t been well studied and might cause adverse effects.", "answer": 2}, {"article": "According to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes passing reference to risks, but it doesn\u2019t mention any specific problems and doesn\u2019t discuss how commonly they occur with DBS. This is, after all, brain surgery, and there are a host of things that can go wrong, ranging from obvious problems such infections,\u00a0bleeding, and strokes,\u00a0to more subtle effects such as cognitive impairment. The story should have explored these. The competing WebMD story, while failing to quantify the harms, at least listed quite a few of the potential problems.", "answer": 0}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\nThe American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nIt's called induced hypothermia.\n\"We know that people's neurologic outcomes are likely to be better if they get it but we don't completely understand what's happening in the brain for sure when the body is cooled.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms that might be associated with hypothermia treatment after a heart attack.\u00a0 There was no discussion of\u00a0conditions or medication use that might lessen or eliminate the benefit that this treatment might confer.\nAlthough one of the clinicians said \"ice packs can do the job\", there have been some studies to suggest that the percentage of surviving patients is lower in the group whose temperatures went too low.", "answer": 0}, {"article": "Load up on berries.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nIt's certainly not a perfect way to detect how certain foods may influence health, but it identifies important associations.\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both the HealthDay and TIME articles, the NPR story did not discuss potential harms. But all health interventions have harms, as well as benefits and costs. We looked the other way on costs but not on harms.", "answer": 0}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nThe focus was on disease-free survival.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported on the incidence of a serious side effect among the women taking zoledronic acid.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nHalf of them received traditional acupuncture treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 only of benefits.", "answer": 0}, {"article": "\"These cells proliferated rapidly, and were susceptible to damage to their DNA - both factors that help them transition towards cancer,\" she said.\nAustralian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all. Again, this is particularly problematic given that denosumab is already on the market and has well-documented potential harms. For example, the websites for both XGEVA and Prolia (denosumab\u2019s current trade names), note that the drug can cause a wide variety of problems, including (but not limited to): severe pain in muscles, bones and joints; serious infections that may require hospitalization; severe allergic reactions; osteonecrosis in the jaw; thigh fractures; and nausea.", "answer": 0}, {"article": "\"There will always be questions, and an ongoing need to individualize therapy,\" he says.\nFirst, only about 1 in 20 men in the Swedish study had a prostate cancer diagnosis based on a high PSA level.\nBy the way, 9 out of 10 prostate cancers in the U.S. these days is considered low risk.\nFor this group, surgery saved one life for every seven men who had prostatectomies \u2014 considered a favorable ratio.\nSecond, the Swedish study compared radical prostatectomy to watchful waiting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information comparing the rate of all cause mortality in the two groups; it also indicated that more men in the group that didn\u2019t have surgery had hormone therapy. \u00a0To be balanced, the story should have indicated\u00a0that there are commonly occurring side effects from surgery to remove the prostate such as incontinence and sexual problems.\nThe competing HealthDay and AP stories, by comparison, did a better job of this.\nThe story would have been better if it had indicated that for men with prostate cancer, taking hormone therapy means that the cancer has progressed; further providing readers with insight about the absolute rates at which men in the two groups needed hormone therapy would have provided a more complete picture.", "answer": 0}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nAromatase inhibitors are not effective in this age group, the experts note.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\nYes, in two areas: preventing recurrent disease in other parts of the body and in preventing a second, separate breast cancer.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "\"That's a very personal decision,\" Steiner said.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\nFurther, decades of research still have not produced good evidence that self-exams make any difference in breast cancer survival.\nA small study in Canada in 1997 found that self-exams seemed to improve survival among a subset of women using proper technique.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists the downsides of screening via a self-breast exam, namely,\u00a0 over treatment via biopsies for false positives and false reassurance that mammography is not needed. The story appropriately notes a woman\u2019s individual risk is a factor when choosing how and when to be screened. A woman at higher-risk may feel that\u00a0 monitoring tissue changes via self-breast exams is useful.\n\u00a0", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article makes no\u00a0mention of harms. The story makes clear that the new devices have not been tested in humans, but there must be\u00a0data on the risks of implanting the\u00a0current devices, the FDA-approved artificial retinas mentioned in the article. A brief\u00a0mention of such\u00a0risks would help give readers a sense of the risk-benefit balance should these high-tech devices make it to the market in the coming years.", "answer": 0}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nThe dose, now considered the highest, safe upper dose of the vitamin by the Institute of Medicine, reduced arterial stiffness the most and the fastest: 10.4 percent in four months.\nThe 4,000 upper-limit dose restored healthy blood level quicker - by eight weeks - and was also better at suppressing parathyroid hormone, which works against vitamin D's efforts to improve bone health by absorbing calcium, they reported.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nVitamin D also reduces inflammation, an underlying mechanism for obesity related development of coronary artery disease, says Raed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not delve into the side effects of taking high doses of vitamin D over a long period of time. These side effects include kidney stones, which should have been addressed. The study does note, though, that no side effects were reported in the trial.", "answer": 0}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nPeople with heart failure often take a combination of drugs, Lenihan said.\nOne patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.\nCimaglermin, however, may be such a drug, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly points out that side effects included nausea and headaches, and that one participant did experience abnormal liver function after receiving the highest dose, a side effect that eventually cleared up.", "answer": 1}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study does not mention any potential harms of botox injection. While the procedure is safe, there are some risks that would be important to mention and consumers should also be told that they should seek out a practitioner who is skilled and experienced in providing the injections.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nBut, she said, nutrition research like this has limitations because it relies on people's memories of what they ate.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s certainly possible that attempts to promote healthier diets could result in unintended harms. For example, some might argue (erroneously, in our view), that a tax on sugar-sweetened beverages, intended to promote healthier drink choices, would be regressive (i.e. disproportionately costly to lower income consumers). But we think a discussion of such issues is beyond the scope of this article, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\nHall felt nothing from the seconds-long bursts from 1,024 ultrasound beams aimed at different points around her skull, and an MRI scan confirmed that the brain barrier was successfully traversed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a single patient and the story does mention that \u201cno damage from the ultrasound was visible inside her brain.\u201d But breaching the blood brain barrier is a big deal and likely would entail harms, especially if done repeatedly as would need to be done in many clinical treatments. There\u2019s certainly a risk of bleeding as the news release mentions in a related Q&A. Some discussion of harms/tissue damage or lack thereof seen in animal studies would have been informative.\nThe story does contain information from someone who appears to be an independent voice\u2013Dr. Gordon Li\u2013cautioning the reader that the ability to get drugs into the brain now requires effort to determine \u201csafe doses\u201d of those drugs. \u00a0But that issue is given just a glancing blow \u2014 not enough for a Satisfactory grade here.", "answer": 0}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is recommended for optional use in boys and men.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides a single comment about the potential harms of the vaccine (\u201c\u2026thus far the vaccine appears to be safe.\u201d). Additional information concerning injection site reactions would have been useful. But we give the story credit for doing a good job of discussing the risks vs. benefits in the wider subject of universal vaccination of young men.", "answer": 1}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the imaging technique, either from the risks of the technique itself or from the implications of false positive or negative results. The article does imply that it isn\u2019t clear whether such findings would predict long-term cognitive improvement and the degree of improvement. However, little information is given about the test itself. It involves the use of a short-acting radioactive substance but is probably safe. The greater harm would be around providing false hope of recovery to family members.", "answer": 0}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nAs a result of the immune-system suppressing drugs, most of the patients in Gu's study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nEight teens who took part in the study have remained insulin-free for two years, on average.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\nAs a result of the immune-system suppressing drugs, most of the patients in Gu\u2019s study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nMost of those side effects disappeared within two to four weeks, and unlike in previous studies of the experimental therapy, none of the patients developed infections, pneumonia, low sperm counts, or organ damage.\nStill, patients have to be followed for years to ensure they do not develop known long-term complications of immune-suppressing drugs, including tumors and infertility, Gu says.", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nResearchers asked each participant to smoke one cigarette 30 to 40 minutes before undergoing an fMRI, or brain scan.\nNone of the study participants were enrolled in a smoking cessation program or were trying to quit.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned, but it\u2019s also difficult for us to envision what they might be in this case, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nThis suggests that including the scans in routine care would not lead to a surge in costly tests or additional heart surgery, the researchers say.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that CTA scans are \u201csafer\u201d than angiograms because CTAs don\u2019t require the insertion of tubes into the body.\nBut no other harms are mentioned and many readers may want to know about radiation exposure and allergic responses to the contrast dye used. \u00a0According to the study,\u00a0 those who did have a CTA scan ended up having more invasive coronary angiograms and coronary opening procedures in the months following the scan. These procedures carry considerable risks.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nIt's \"much too early\" for patients or caregivers to seek out DBS, said Fargo, who was not involved in the study.\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\nOn a broader level, he noted, this study highlights an important point: \"Alzheimer's disease is more than just amnesia.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t completely drop the ball, stating side effects \u201cincluded hot flashes, heart palpitations and burning sensations in the skin, which were reversed by adjusting the DBS settings.\u201d But any story on an implantable medical device should caution readers about the risks of surgery to both install and remove it and mention that medical devices are not required to undergo rigorous safety tests before they are allowed on the market. The lead\u2019s assertion that the device \u201cmay be safe\u201d neglects the inherent risks of implantable devices.\nThe story left out another known risk of deep brain stimulation: depression. All three subjects were treated with antidepressant medication. Although, as the study authors note, the DBS may not have caused the depression\u2013it is common in dementia, and treating it can improve people\u2019s cognitive and functional abilities. Such as described for patient \u201cLaVonne.\u201d", "answer": 0}, {"article": "Scientists working for Google\u2019s parent company Alphabet have used artificial intelligence to determine a person\u2019s risk of having a heart attack from their retinal scan.\nFurther tests are required before this latest method can be used within a clinical setting.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story offers no mention of potential harms that might arise from using this new approach and since it\u00a0would be\u00a0non-invasive, it is hard to imagine many.\u00a0 But the potential for incorrect assessments is always present as either false-positives or false-negatives and the harms from either of those can be considerable.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\nDr. Timmerman, Director of Image-Guided Stereotactic Radiation Therapy, Medical Director of Radiation Oncology, and holder of the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SBRT to treat other types of cancer, including cancer in the lung, liver, and spine.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nTo reduce the side effects associated with SBRT, current clinical trials at UTSW are using a unique and biodegradable rectal spacer gel to protect the rectum.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does include a paragraph about urinary side effects (among others) for patients in the trial. But the release deliberately seems to try to minimize these. (Editor added italics.)\n\u201cIn addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment. In the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment. Researchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments. Decrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.\u201d\nMany men might find a one-in-four chance of impotence a high price to pay for treatment for early-stage prostate disease. We have to complain that the release does not give us numbers for the harms \u2014 in any way that is meaningful and allows us to compare this new therapy to existing therapies.\nThe phrase \u201cnot necessarily different\u201d is not helpful. The phrase \u201ca small risk\u201d is not giving us a number we can use.\nAs noted above, a substantial proportion of the patients might not have needed treatment \u2014 so that even a \u201csmall risk\u201d of complications would be unacceptable. In the absence of a comparison group, no conclusions can be drawn as to whether this represents a less harmful active treatment option.", "answer": 0}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nCurrently, an early Alzheimer's diagnosis requires complex brain scans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Two harms of treatment, difficulty getting insurance when one has a prexising condition and not wanting to know that one was going to develop this disease, were mentioned in the broadcast.\nBut the story never addressed the issue of false positive test results \u2013 which could be a huge issue.\u00a0 Imagine being told erroneously that you test positive for Alzheimers disease! ", "answer": 0}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention potential harms at all. If anything, it does just the opposite, saying at one point that an observation of a woman with a genetic variation that naturally confers the effects of this class of drugs suggests that \u201ctherapies aimed at blocking [the protein targeted by these drugs] would not only be effective, but also safe.\u201d That\u2019s a good anecdote about the inspiration for the drug treatment, but it\u2019s problematic in a release that seems to focus almost exclusively on anecdotes. Particularly since the release does not tell readers that both evolocumab and alirocumab have potential adverse side effects. According to the press materials for evolocumab (Repatha), \u201cIn a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha-treated patients.\u201d And the press materials for alirocumab (Praluent) note \u201cPraluent can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital.\u201d What\u2019s more,\u00a0there could be less common, but more serious adverse effects that will only come to light after large numbers of patients take these drugs for long time. There is nothing in the release that says for how long the drug was used. These potential health effects are worth noting \u2014 especially in a release that focuses solely on the use of a new class of drugs.", "answer": 0}, {"article": "If nothing else, \"The Business of Being Born,\" with its indelible image of a naked, exhilarated Ricki Lake cooing \"Hi there!\"\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nDoctors such as Stark say we need a better sense of what goes on while the baby is still in utero.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantifies the risk of death in C-section versus vaginal birth. The story could have done more to describe other, more common risks, such as wound complications and infections.", "answer": 1}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nThe goal is to help the concussion patient feel better as the brain heals.\nIn addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no reported side effects while wearing colored glasses. It recommends against wearing colored glasses while driving since \u201ccertain colors make seeing stop lights or emergency vehicle lights difficult.\u201d", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story.\u00a0The adverse effects of the drugs in question would be key information\u2013do they outweigh the benefits put forth in this story?", "answer": 0}, {"article": "Melanoma is the most lethal form of skin cancer, killing almost 9,000 people in the U.S. last year, according to the National Cancer Institute.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\nUnfortunately, the technique \u2014 comparing people with melanoma to those without - is fraught with potential problems, said Asgari.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cNSAIDs \u2013 which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\u201d\u00a0 It didn\u2019t note whether study looked at side effects in those taking them for five years. Still, we\u2019ll rule this satisfactory for remembering to include some mention of potential harms.", "answer": 1}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nIn all patients, only one reduction technique was performed per patient.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address the incidence of harms with either method.\nBased on our review of the literature on the topic, there are potential complications seen with both techniques including painful scars, wound dehiscence (a surgical complication in which a wound ruptures along a surgical incision), infection requiring antibiotics, and corrective surgery if the original surgery is unsuccessful.\nThe published study does note a variety of side effects and how often they occurred and also states there was no statistical difference between the rate of harms. This would have been good to mention in the release.", "answer": 0}, {"article": "In other words, they are the precursors to muscle, fat, bone, and tendon tissue.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\nAlthough more than 75 percent of patients reported suffering headaches afterward, the researchers said it was probably due to the surgical procedure rather than the stem cells themselves.\nThey hypothesized that injecting stem cells into the brains of chronic stroke patients would increase their survival rates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly noted side effects.\u00a0 It\u2019s worth pointing out that the study only followed patients for about a year, and long-term effects are unknown and could be more severe.", "answer": 1}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nThe scans measure brain activity by tracking the uptake of a radioactive liquid injected into the blood.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned. As with all screening tests, there is a risk of a false-positive or a false-negative result. Either can create anxiety, confusion, and incorrect medical treatment.\nRegarding the PET scan itself, the American College of Radiology lists the following:\nThe small circular opening of the scanner can elicit anxiety in some patients that may require sedation or stopping the scan.", "answer": 0}, {"article": ".\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\nThe study is titled \"Dry Needling Versus Cortisone Injection in the Treatment of Greater Trochanteric Pain Syndrome: A Noninferiority Randomized Clinical Trial.\"\nThe study demonstrates that patients with GTPS can get similar results from dry needling as from a steroid injection.\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While no harms were reported in the study, the news release still should have mentioned typical side effects of dry needling such as temporary pain, bruising and post-treatment soreness. The release does mention the \u201cpotentially harmful effects of steroids\u201d but doesn\u2019t say what they are.\nThe concern over potential\u00a0complications from steroid injection seems to be magnified while any potential harms from dry needling is ignored.", "answer": 0}, {"article": "S. Bagla; R. Piechowiak; T. Hartman; J. Orlando; A. Isaacson; Vascular Institute of Virginia, Woodbridge, VA; UNC Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill.\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\nThe treatment was successfully completed in all 13 patients, with no adverse events.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss the potential harms associated with this procedure. The procedure is complex involving the catheterization of\u00a0 \u201cvery small arteries or capillaries within the lining of the knee,\u201d and carries inherent risks of penetrating those blood vessels. Potential complications include bleeding at the puncture site and pain. Long-term complications have yet to be determined but could include failure of the intervention to address the symptoms of knee OA, worsening of the pain in some individuals, and osteonecrosis (a bone disease that results from loss of blood supply to the bone). \u00a0Also yet to be established is the period of time it takes for healing to occur within the joints after the procedure.", "answer": 0}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nThat's significant, given that tamoxifen is used by hundreds of thousands of women worldwide, says Gray, whose study was presented Wednesday at the annual San Antonio Breast Cancer Symposium.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nStudies show that only 80% of women take tamoxifen for five years, Litton says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give the story the benefit of the doubt.\nGood points:\nRoom for improvement:\nThe story provided only one woman\u2019s tale of side effects.\u00a0 It provided no estimate of how often these occur. And the Young Survival Coalition pointed out another age-specific concern in the statement it released:\nFinally, a particular concern with this study is the impact that this study may have on young women\u2019s family planning.\u00a0 Many young women already wait until they have completed their five-year course of Tamoxifen before trying to start a family.\u00a0 Will this study cause that delay to become 10 years?\u00a0 And, are the modest benefits shown in this study worth that?\u00a0 That is a very personal decision and again, we recommend speaking with your physician.", "answer": 1}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nThe resource has been open to bona fide health researchers for 18 months.\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\nThey used a statistical survival model to assess the probability that 655 specific demographic, lifestyle, and health measurements could predict death from any cause and six specific causes, in men and women separately.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text does offer a brief cautionary note when it quotes from the commentary of a couple of UK scientists in The Lancet issue to the effect that \u201cwhether this will help individuals improve self-awareness of their health status\u2026or only lead to so-called cyberchondria, is a moot point.\u201d Cyberchondria refers to unfounded anxiety concerning the state of one\u2019s health brought on by visiting health and medical websites, so that term seems apt here. And \u201cmoot\u201d conveys the uncertainty surrounding outcomes as, again, the study can offer no evidence. We\u2019ll give a Satisfactory rating, though we wonder if it would have been more effective to say, \u201cit is unclear whether use of this information will lead to actions that will help or harm individuals.\u201d", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of medical risks and hardships of surgery. Along with the usual risks posed by surgery, there\u2019s a risk that lymph node transfer could cause lymphedema to develop in the part of the body where healthy nodes were extracted, according to Breastcancer.org. For many women those drawbacks may outweigh the potential for an uncertain benefit.", "answer": 0}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\nAn experimental vaccine that could hold off Alzheimer's disease showed promising results in animal testing, according to researchers at the University of Texas Southwestern Medical Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the vaccine is \u201csafe in mice\u201d and alludes to the fact that it hasn\u2019t been proven safe in humans. It also mentions \u201charmful side effects, such as brain inflammation\u201d with a previous Alzheimer\u2019s vaccine attempt.\nFor that, we\u2019ll give the story credit. But we think it could have better served readers by explicitly cautioning that safety in mice doesn\u2019t translate to safety in humans.", "answer": 1}, {"article": "Nov. 24, 2016.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nThe results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.\n\u201cThe value of this study is the comprehensive mutational analysis that helps us figure out which patients are likely to benefit.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly address harms from either decitabine or standard chemotherapy for AML. What are the common harms from chemotherapy and which of these side effects are reduced in decitabine? Because the focus of the release is on the trial results of a drug described as less toxic, we would have liked some context on what reduced toxicity means.", "answer": 0}, {"article": "Cerebrospinal fluid is a clear, colorless liquid that bathes the brain and spine.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nSuch a marker would allow doctors to identify infants at high risk of developing autism before symptoms are present.\nIt may be possible to predict autism in infants as young as 6 months who have older siblings with the disorder, according to a new study by a national network of researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the harms inherent in MRIs for infants. Some of the harms of MRIs have to do with the sedation that is required, which, ironically, may harm the developing brain.\nAlso, as with any screening test, there are the harms of \u201cfalse-positive\u201d and \u201cfalse-negative\u201d results. In this case, a false-positive finding would result in a healthy baby being diagnosed with autism. And for a false-negative result, a baby with autism wouldn\u2019t be diagnosed.", "answer": 0}, {"article": "It's a substantial number of women,\" Lyman said.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported that the study found no benefit for the more aggressive full axillary lymph node dissection (ALND)\u00a0among the 900 women studied with T1 or T2 breast cancer.\u00a0 Because ALND poses risk of infection and lymphedema, more patients would be harmed by continuing the currently recommended treatment.\u00a0 While the article mentions the potential complications of ALND, it does not quantify the incidence of infection or of lymphedema after ALND. Women should be told how often this occurs.", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nObviously, the process will have to be refined and optimized before it's actually used for treatment.\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\nThe researchers injected the cargo-laden nanoparticles into the patients, much as you would administer a flu or any other type of shot.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story paraphrased the researchers. \"The precision of the process is crucial to limiting side effects.\"\u00a0 But it never discussed what even the potential side effects of this approach might be.\u00a0 It would have been relatively easy for the story to have included a few words about the potential downsides, including \"off target\" side effects during an exaggerated immune response or the shuttinf off of non-targeted genes resulting in adverse outcomes. ", "answer": 0}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\nFor the current study, researchers wanted to see if bright light might help reduce driving impairments related to sleep deprivation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Exposure to light in this way isn\u2019t harmful, so we\u2019ll rate this N/A. However, such a therapy could encourage people to skip on an intervention that would be more effective such as sleep. Or it could inure a false sense of security.", "answer": 2}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nSo Stagl, now a clinical fellow at Massachusetts General Hospital, helped study a University of Miami program that taught 240 breast-cancer patients relaxation techniques and coping strategies.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss possible harms associated with participating in this stress management program, although the harms are likely to be minimal.\u00a0In theory, the program could have heightened anxiety about the breast cancer diagnosis by focusing on it frequently over the 10 weeks of the group. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cI am aware of the fact that given our level of ignorance, everything seems simple and straightforward,\u201d he says.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nWhat\u2019s more, they also surmised that only a specialized set of beta cells were equipped to make insulin, and that once diabetes set in, too few of these cells remained to pump out the critical hormone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story speculates extensively about the many benefits a treatment based on this preliminary research might confer. So we think it\u2019s only fair that the story at least mention the possibility that a\u00a0new treatment might also cause harm.\u00a0The researcher quoted in the story suggests that \u201canything that lowers blood sugar can make you healthier.\u201d Besides the obvious exception of hypoglycemia (which can be fatal),\u00a0recent experience with Avandia confirms that drugs which lower blood sugar can\u00a0sometimes have other undesirable\u00a0effects.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of treatment, such as anxiety from positive test results and the possibility that patients will fail to follow up on a positive initial screen.\u00a0It also fails to define the potential harm of providing false reassurance \u2013 the risk of false negative results, which is failing to identify an affected infant, which would be of concern to women who are seeking accurate answers.", "answer": 0}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe Partners PrEP study participants took either TDF/FTC, the drug tenofovir\u2013brand name Viread, or a placebo.\nPreliminary results showed both treatments significantly reduced transmission in couples where one partner was already infected with the virus.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that the\u00a0primary source was a press statement (the results haven\u2019t been published yet), the story provided about as much information about potential harms as could be expected. In one of the studies, the story notes that the\u00a0safety monitors\u00a0saw no evidence of safety concerns. The story also notes that subjects taking the active drug in the the other study\u00a0reported nausea, vomiting and dizziness.", "answer": 1}, {"article": ".\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses possible harms with use of this new formulation of the drug by saying, \u201cthe main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\u201d The study itself offers more detail and a breakdown of what proportion of participants experienced these effects but most were considered to be mild.", "answer": 1}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nResearchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nBecause it doesn't inflict the damage to healthy tissue caused by chemotherapy and radiation, immunotherapy's great appeal is its nontoxicity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that \u201cimmunotherapy\u2019s great appeal is its nontoxicity\u201d and that a patient has had no side effects. This is not enough information on the harms of treatment.", "answer": 0}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n\"However, since every prior study has found that people with schizophrenia exhibit reduced retinal wave forms and slowed retinal responses, our research shows that we closing in on an accurate test that is faster, less invasive, inexpensive and more accessible to patients.\"\n\"Our study should help generate further research into developing a test that clinicians - like psychologists, psychiatrists or nurses - can use in their offices to diagnose, treat and monitor the condition of people with schizophrenia.\"\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "What\u2019s known about the safety of this device? And what about the chances of false positives or false negatives? The news release didn\u2019t say. It only quoted a researcher stating the test was performed to be \u201cas noninvasive and quick as possible.\u201d", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nA few participants reported headaches following the session.\nOne-third of the participants had transient increases in blood pressure.\nSix months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\nMost participants had breast, upper digestive, GI, genitourinary or blood cancer, and each had been given a formal psychiatric diagnosis, including an anxiety or depressive disorder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a good job here, stating that \u201c15 percent of participants were nauseated or vomited, and one-third of participants experienced some psychological discomfort, such as anxiety or paranoia, after taking the higher dose. One-third of the participants had transient increases in blood pressure. A few participants reported headaches following the session.\u201d Well done.", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not go into any detail on the potential downsides of a very-high-saturated fat diet.\nFor example: Would most people enjoy and be able to adhere to a diet that includes lots of butter, cream, and cold-pressed oils? Some would no doubt savor such a diet, but others might be turned off.", "answer": 0}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story did mention some of the common side effects that occur following gastric bypass surgery, it actually neglected to mention some of the serious side effects of surgery.\nIn addition, since the story was about the impact of gastric bypass surgery on diabetes, it also should have mentioned that resolution of diabetes is not guaranteed to be permanent and reoccurs in as many as 30 out of 100 people who had improvement.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a half-hearted attempt here. It says that new over-the-counter enzymes are made\u00a0by fungi and haven\u2019t been tested in humans. And it suggests that anyone with a fungal allergy should \u201cuse the products with caution.\u201d\u00a0It also passes along a company spokespersons\u2019 observation that \u00a0\u201conly occasional side effects\u201d are reported by customers taking one of their supplements.\nBut the company phone line\u00a0is hardly an accurate tool for assessing possible harms and side effects of these products. And vague warnings about possible allergic reactions don\u2019t qualify as useful information for decision-making.\u00a0If there are safety concerns with any of these products, the story should have spelled them out more clearly and described what the risks are.", "answer": 0}, {"article": "\"We want to take the focus off pain and put it onto functioning, and finding pleasurable ways to spend time,\" Ilgen says.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nIlgen and his colleagues hope their results will help bring the techniques into addiction treatment settings, where the cognitive behavioral therapy approach is often used.\nThe ImPAT technique seeks to use integrated approaches both to help patients focus less on their pain and more on other aspects of life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms. But there don\u2019t appear to be potential harms associated with ImPAT, certainly none that stand out relative to other behavioral interventions. So we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential risks with the use of Paxil.", "answer": 0}, {"article": "In the early days of motherhood, women ideally build competency and confidence in their parenting.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nInterestingly, none of the patients who took the drug reported psychiatric side effects, such as abnormal dreams, insomnia, and anxiety \u2014 but 5 of the 11 women on the placebo reported such symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does report that the company said the only problems reported by patients were dizziness or a sedative effect (in both the treatment and placebo groups), it should have specifically cautioned readers that there could be other potential harms that cannot be identified by a one-month test in which only 10 patients received the active drug\u2013notably, if this drug can pass into breastmilk or affect babies in utero. Also, as noted above, the story fails to tell readers that the form of the drug used in this trial is given as an inpatient IV treatment, which carries risks.", "answer": 0}, {"article": "Women between 40 and 49 were screened every two years, and women 50 to 74 were screened roughly every three years.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n\u201cOur results indicate that in 1,000 women screened for 10 years, three breast cancer deaths would be prevented,\u201d Duffy said, adding that most of the deaths prevented would have occurred more than a decade after the screening had started.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story briefly discussed a few of the harms associated with mammograms, specifically the stress and anxiety caused by false positive results; however, it should have also mentioned the harms associated with unnecessary treatment of cancers that may not cause problems or be life-threatening.  Also, focusing on this issue of the \u201cstress\u201d for women who receive a false positive result puts too much emphasis on these psychological harms. Counterposing \u201cstress\u201d to \u201clives saved\u201d, though valid, is not persuasive.\n\u00a0", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing blood and injecting blood components into the vagina and clitoris are not without potential risk of pain, infection or other unknown complications. This should have been made clear.", "answer": 0}, {"article": "The woman would then be taken to the operating room area,\u201d Madrigrano said.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms from inserting the radar reflector. It mentions that it is performed on a day separate from the surgery, in a procedure similar to a needle biopsy.\u00a0 Uncommon but potential complications of a needle breast biopsy procedure include pain, syncope (fainting), bleeding, and infection.", "answer": 0}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nHe said the study methodology was thorough because it included people with high cholesterol as well as people with genetic familial high cholesterol, which is proven to be a result of impaired PCSK9 genetic function.\nTwo arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial.\nAll of those subjects were also receiving treatment with the statin Lipitor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the researchers found that the drug was safe and \u201cNone of the subjects who received REGN727\u00a0discontinued the study because of adverse effects.\u201d While true, it does not give the whole picture.\u00a0 Here\u2019s what the investigators said:\n\u201cThe proportions of subjects who had at least one treatment-emergent adverse event were similar among subjects who received intravenous REGN727 and those who received placebo. As compared with subjects who received placebo, a higher proportion of subjects who received subcutaneous REGN727 had an adverse event in the single-dose and the multiple-dose studies. Headache was the most common adverse event.\u201d\nIt didn\u2019t include the caveat that the MedPage Today story did:\n\u201cGiven the small number of subjects and the short duration of exposure, our ability to evaluate the safety profile of REGN727 in these trials was limited,\u201d the researchers cautioned.\nBut it did report:\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, (two editorial writers) caution that it will remain unclear how important this\u00a0class of drugs will be.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nIn patients with atrial fibrillation, the risk of stroke is usually measured using the so-called CHADS score, the researchers said.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because blood thinners work by interfering with blood\u2019s ability to clot, users are at some risk of dangerous heavy bleeding. This issue doesn\u2019t\u00a0make an appearance in the story.", "answer": 0}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\nAccording to Lucci, circulating tumor cells are also showing promise in predicting melanoma prognosis, so the method may be \"effective in several different tumor systems.\"\nAnd in an accompanying comment article, Justin Stebbing, a professor in the department of surgery and cancer at Imperial College in London, said that \"despite increasing evidence supporting the use of [circulating tumor cells] as biomarkers, how this information can be integrated into present practice is uncertain.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quotes from experts not connected with the study give readers valuable perspective on the current usefulness of the test.\u00a0 Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, notes that the presence of circulating tumor cells may not be sufficient predictive information.\nJustin Sebbing, a professor in the department of surgery and cancer at Imperial College in London, cautioned that it\u2019s currently uncertain \u201c\u2026how this information can be integrated into present practice.\u201d\nThe writer also notes that the American Society of Clinical Oncology does not recommend that clinicians measure circulating tumor cells in patients.\nThese three cautions should help readers understand that if accuracy is not established, use of a test to guide therapy decisions could lead people down the wrong path.", "answer": 1}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n\"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening methods typically include false positive results, which will require further testing that might include biopsy. The release did not mention this potential harm or any others from the proposed method of testing breath and urine.\nThis is not a 100% accurate test and there is no discussion on what happens when the test is wrong or why the test may not be accurate all of the time.", "answer": 0}, {"article": "(Sunlight stimulates production of vitamin D for people in sunnier climes.)\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nVitamin D, in combination with calcium, is good for your bones.\nThis practice isn't totally harmless.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that taking large doses of supplements (above 4,000 IUs) can increase your risk of kidney stones, calcification of blood vessels and cardiovascular disease. Vitamin D toxicity is rare, but given the current enthusiasm for supplementation, it\u2019s good for stories to voice some caution.", "answer": 1}, {"article": "Sept. 26, 2017.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\nCompared with patients receiving traditional warfarin dosing, patients dosed with the genetic approach had a 27 percent reduction in adverse events, which was statistically different.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them.", "answer": 1}, {"article": "Thirty women each received real acupuncture that also included a bit of an electric buzz or the inactive placebo pill, 32 women got sham acupuncture, and 28 women received gabapentin (Neurontin).\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is likely safe but we have no idea if the women who received it, the sham acupuncture or gabapentin experienced any adverse effects of those treatments.", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\nIn 2014, the first HIF-2 inhibitor, an oral drug known as PT2385, entered clinical trials in patients with advanced or metastatic renal clear cell carcinoma.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than explaining that some of the kidney cancers were \u2018resistant\u2019 to the drug\u2019s effects, we learn nothing about the potential adverse effects of the new treatment.\nWhile \u201cmice on sunitinib were sickly and lost weight,\u201d the mice on the new drug gained weight, according to the release. That is hardly sufficient information to know whether the new treatment was well tolerated. Perhaps weight gain was due to fluid retention.", "answer": 0}, {"article": "\"And in that case, I see this as just a waste of money.\"\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\nThe authors also noted that apart from an increased brain size among children diagnosed with autism, there are no apparent structural differences between the brains of autistic patients and patients who are not autistic.\nUsing MRI imaging, the team searched for differences in brain activity patterns in the microstructure of white matter tissue in 80 autism patients between the ages of 10 and 35.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does something worse than failing to quantify the potential harms of MRIs. It allows an autism activist to say, \"I\u2019m always glad to see there\u2019s more autism research underway, and there\u2019s certainly no risk to having an MRI.\" No risk? At the very least there is the potential for MRIs to lead to unnecessary procedures. A recent study showed, for example, that there was a direct correlation between the availability of MRIs in an area and the number of back surgeries. The study\u2019s authors concluded, \"if increased MRI availability is associated with increased early use of low back MRI as well as with subsequent use of low back surgery, both of which have questionable clinical benefit, then widespread MRI diffusion may put patients at risk of a decrease in the quality of care they receive.\" Another risk is for renal injury when MRI is performed with contrast dye.", "answer": 0}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that aspirin can increase risk for internal bleeding, and says that women should consult a doctor before beginning a daily-aspirin regimen. This is satisfactory\u2013but barely\u2013since the magnitude of this potential harm is not mentioned.", "answer": 1}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nScoring a minimum of 2,000 cells per slide, the IMSTAR Pathfinder\u2122 system was able to separate all individuals of the cancer group from the healthy control group with confirmed statistical significance.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\nUK researchers behind a potential 'universal' liquid biopsy blood test for cancer detection have licensed the technology to an industrial partner to take it to market.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release needed to provide more information on the risks that arise with cancer screening tests\u2013for example, of being told you have cancer when you do not; or the opposite, being told you\u2019re cancer-free when you actually have cancer. There is also the risk of overdiagnosis \u2014 finding and treating non-growing or slow-growing cancer that doesn\u2019t need to be treated.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the study might not have been long enough to detect serious risks with long term use. It says, \u201cIf it works, patients would likely have to take Bryostatin-1 for the rest of their lives. The main adverse event\u00a0was diarrhea.\u201d", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\n\u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\nNCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.\nThis work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tesar provides a cautionary note related to the potential harms of this approach; \u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\u201d Given the stage of research, we think this is sufficient to rate this criterion as satisfactory", "answer": 1}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\nGaining too much weight is tied to an increased risk of complications for both mother and child, according to the researchers, who completed the review for The Cochrane Collaboration, an international organization that evaluates medical research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one was borderline but ultimately deemed Not Satisfactory. The story addresses harms through quotes from an independent source who specializes in high-risk pregnancy. She says it \u201cwas very reassuring that [the paper says] there wasn\u2019t an increased risk of preterm birth with moderate exercise.\u201d However, we\u2019d note that the paper itself says that, while there was no difference between groups with regard to preterm birth overall, \u201cLimited evidence suggested that [the effect] may differ\u2026with a trend towards an increased risk for exercise-only interventions.\u201d That\u2019s not quite as reassuring as the source suggests, and we think the result deserved some discussion. In several places, the study authors noted that the issue of preterm birth needs more research so that safe guidelines can be established.\nA related concern is that there\u2019s no acknowledgment of the increased risk of low gestational weight gain seen in the diet and exercise groups or the associated harm that inadequate weight gain could potentially cause. Only the benefits of reducing excessive weight gain are discussed. To the story\u2019s credit, it does state the importance of talking to your doctor before starting a diet or exercise regimen.", "answer": 0}, {"article": "For more on obesity, visit the U.S. National Institutes of Health.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nThe authors said such side effects were typically \"mild.\"\nBut they also suffered more side effects than patients not taking the medication.\nAll study participants followed their treatment plan for one year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nice job mentioning side effects in the third sentence, followed by a paragraph later in the story\u00a0that spells them out: \u201cBut patients in both drug groups faced a higher risk for side effects, including diarrhea, headache, fatigue, nausea/vomiting, concentration and memory difficulties, anxiety, and depression-related symptoms.\u201d\u00a0 While we wish the story had quantified how much higher the \u201chigher risk\u201d really was, we\u2019ll give it the benefit of the doubt for the things it did satisfactorily.", "answer": 1}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no side effects from the treatments. We would have liked to have seen more detail on how long the patients were followed (we\u2019re only told that 8 have been followed for one year) and the types of side effects one might expect with this type of therapy. The subjects underwent cardiac surgery during which time cardiac tissue was recovered and the stem cells were injected into the heart via a catheter.\u00a0 Each procedure carries the potential for harm.\u00a0 In reporting on such a small, short-term study, we think the potential for harm is worth at least a line. ", "answer": 0}, {"article": ".\nHowever, all the women were alive and seemingly cancer-free by the end of the study after further treatment (either the IUD and GnRH treatment or a hysterectomy), the study reported.\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\nNine of the women in the study successfully delivered babies.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story accurately notes that the study reported no adverse effects. The study\u2019s authors reported only on adverse effects that were sufficient to require suspension of treatment.", "answer": 1}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nAlso unknown: whether men would opt for the treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno side effects\u201d from the procedure, but then goes on to explain that three men reported that their erections weren\u2019t as firm after the procedure.\u00a0Call us picky, but wouldn\u2019t that count as a side effect? We were pleased to see some mention of the potential for nerve damage if the procedure needs to be repeated in order to maintain its effectiveness. But there should have been some\u00a0acknowledgment that this study\u00a0was\u00a0far too small to accurately assess potential harms of the procedure. A mixed bag, but enough concerns were raised to give the benefit of the doubt on this one.", "answer": 1}, {"article": "Caused by defective genes, cystic fibrosis affects multiple organs.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nBut with antibiotics and other medical advances, the median age for people with the disease increased to 37 by 2008.\n\"Hopefully, this is going to encourage cystic fibrosis care providers to use it more frequently in patients at the lower end of weight and of short stature,\" Lapin said of the findings.\nHuman growth hormone is a promising tool in treating cystic fibrosis, a new University of Connecticut study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nThose deaths were related to the transplants, Saccardi said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on one potential adverse outcome: death. The story addresses this using clear, unambiguous language, which is good. In addition, the story notes: \u201cThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\u201d That\u2019s a key point to make. The story could have been stronger if it had addressed the potential for other, nonfatal outcomes, but we give it a satisfactory rating.", "answer": 1}, {"article": "High blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\nElaine Rush, a professor of nutrition at Auckland University of Technology in Australia, said that putting a spotlight on single trials and generalizing dietary advice for a single nutrient such as salt was \u201cnot helpful.\u201d\n\n\u201cWhat is helpful is for the food industry to reformulate products to reduce sodium and increase the nutrient quality of foods by using real ingredients,\u201d she said in an emailed comment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable in this story about reducing salt consumption.", "answer": 2}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\nThose benefits\u2014getting digested slower, being converted into fatty acids and sustaining colonies of gut bacteria\u2014set resistant starch apart.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re rating this N/A since it\u2019s about food choices. However, it is possible that the belief that a food contains resistant starch could paradoxically lead to that food\u2019s overconsumption.", "answer": 2}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\nThose with the nontransmitting device were seen in their doctor\u2019s offices every few months, the standard of care.\nIf successful, the smart device could have a big effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention the problem of potential information overload however there was no discussion of actual harm such as inappropriate shocks from implanted defibrillator devices, for example. \u00a0There was no questioning of the accuracy of the data potentially transmitted by devices.\nThis was a far too rosy picture \u2013 almost as if all the data was so terrific that the only downside could be the volume of terrific data.\u00a0 Other things can go wrong as past experience shows when you try to regulate the heart. ", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of not screening is implied to be an increased risk for prostate cancer mortality because diagnoses of high-risk cancers could be delayed. We\u2019ll award a Satisfactory here, although we\u2019d note that we don\u2019t have high quality data supporting this supposition. The PIVOT trial of surgery vs. watchful waiting for men who were mostly screen-detected was negative. \u00a0Only post-hoc analyses showed a potential survival benefit for aggressively treating high-risk cancers. \u00a0One modeling study\u00a0suggested that screening can be associated with net gain of quality-adjusted life years\u2013though the 95% confidence interval also includes a net loss.\nAnother potential harm associated with screening are the adverse effects of treatment (whether necessary or unnecessary). The release notes that \u201cradiation therapy and surgery have a negative impact on quality of life,\u201d but this is somewhat euphemistic as we\u2019re talking about potential for incontinence, impotence, and biopsy-related sepsis as well as death. \u00a0There are hard numbers citing the rates of incontinence and impotence related to prostate surgery, so those certainly could have been cited here discussing harms.", "answer": 1}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nDoctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story discusses the recent increase in bilateral mastectomy after the diagnosis of cancer in one breast.\u00a0 This may be overtreatment for some women.\u00a0 The story notes that physicians should provide women with accurate information about the survival benefit of all treatments, including less invasive options for reducing the risk of a recurrence. ", "answer": 1}, {"article": "All rights reserved.\nAdding the gene test put 100 men into that category, said another study leader, Dr. Matthew Cooperberg of UCSF.\nHe said a gene test may have made him more comfortable with that decision.\nConversely, the test also suggested some tumors were more aggressive than doctors had believed.\nThe gene test shifted about half of the men into either a lower or a higher risk category.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the potential limitations of the new testing approach.\n\u201cUnless you can be sure your biopsy has hit the most aggressive part that\u2019s in the prostate, you can\u2019t be sure\u201d how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\n\u2026\nUCSF just got a federal grant to see how men choose treatments and whether this test might sway them.\n\u201cWe throw all these numbers at them. Are they really going to make a better decision?\u201d Cooperberg said.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nAnd some patients may question whether they would want to know that the source of their mental troubles is Alzheimer's disease, said Weiner.\nWhile diagnosis by proton magnetic resonance spectroscopy is under study for early detection , accurate early detection by such noninvasive means is a ways away.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story hints at the potential harm of receiving a positive test result at a time when there are no effective treatment options for Alzheimer\u2019s. However, harms were not addressed directly enough to merit a satisfactory rating, in our opinion. As with any diagnostic test, this test may cause harm from a false-positive result, which may create unnecessary anxiety, or a false-negative reading, which may create a false sense of security and delay appropriate management steps. The test is also radioactive and contributes to the patient\u2019s lifetime radiation exposure and cancer risk. None of these downsides is discussed in the story.", "answer": 0}, {"article": "Oral and injectable medications are also prescribed.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\nThe authors are planning prospective efficacy studies of extended dose natalizumab.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than progressive multifocal leukoencephalopathy (PML) \u2014 the side effect targeted in this study \u2014 the other side effects of natalizumab therapy are not mentioned. The most serious include liver toxicity, and infections from immunosuppression.\nFurthermore, although many other therapies which cause immunosuppression can lead to PML, it might have been helpful for readers to know that natalizumab has proven particularly worrisome in this regard. It\u2019s been pulled from the market in the past because of PML concerns, and it\u2019s recommended by many in the MS field to be used in very limited circumstances.", "answer": 0}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nBut other studies Skaznik-Wikiel has done with mice suggests that these fats may lower levels of inflammation that can adversely affect ovarian function.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the researcher\u00a0\u201csays there isn\u2019t much harm in consuming more omega 3 fats;\u201d it adds that high doses of omega 3s, in rare cases, increase the risk of hemorrhage in people prone to bleeding problems. That is just enough to merit a satisfactory rating.\nIt does not mention, however, that omega 3 supplements can cause allergic reactions in people with allergies to either fish or to the plants, seeds or nuts from which the supplements are derived. MayoClinic.org also notes that \u201cthere is not enough information at this time regarding the safety of fish oils when used in amounts greater than those found in foods during pregnancy and breastfeeding,\u201d which suggests that the risks of supplement use could be higher among the most likely audience for this story: women who have been trying to get pregnant.", "answer": 1}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nIn the spinal cord - an area that's critical for walking -- they found a decrease in the expression of cholesterol synthesis genes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not explain whether there are any harms from changing the gene expression in the mice, let alone what the potential harms might be in humans.", "answer": 0}, {"article": "It will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThis time around, researchers tried to further optimize the process.\n\"The previous study was proof of principle: Can we elicit these kinds of changes and can we do it without interfering with sleep?\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0were no harms expressed in the article, nor was the word \u2018harm\u2019 mentioned in the published study. This is where an outside expert may have shined some light. As an expert quoted in a Reuters article stated, \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 0}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAnd it can boost older people's strength and balance.\nThe sport is also associated with good mental health and improving the overall health of those with disabilities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only potential harm from golf mentioned is an increased risk for skin cancer. It\u2019s an important inclusion that prompts us to give a barely passing grade.\nThis nebulous statement is also included: \u201cCompared with other sports, the risk of injury is moderate.\u201d (Rugby and mixed martial arts come to mind).\nWhat\u2019s not mentioned is a host of musculoskeletal injuries related to the repetitive and asymmetric nature of swinging a golf club.", "answer": 1}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe mean follow-up was 18 months for both heart failure groups and just over two years for both non-heart failure groups.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion about any potential harms associated with the use of plavix. \u00a0", "answer": 0}, {"article": "Novel standard for research in malnutrition may save lives\n\nProfessor Henrik Friis, the senior author on the paper, points to the importance of the collaboration between university researchers and humanitarian organizations:\n\n\"It has been a new way to conduct research, that we tested the effect of nutritional supplements used mainly by aid agencies, employing very advanced research methods in remote rural areas where humanitarian organization are working, and not at the university hospitals.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nResearchers from the University of Copenhagen and humanitarian organizations have conducted a large study in Burkina Faso in West Africa treating more than 1600 children with acute malnutrition.\nPrevious research has focused on treatment of severe acute malnutrition.\nAcute malnutrition is more life-threatening than chronic.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Many people\u2019s first question upon reading about a peanut buttery kind of nutrient supplement might be whether it produced any allergic reaction or other side effects in infants. In fact, it didn\u2019t, but the news release doesn\u2019t tell us that.", "answer": 0}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although evidence increasingly shows that patients with heart failure benefit from\u00a0physical activity, exercise is not without risk. Some patients with heart failure may experience worsening symptoms or cardiac arrhythmias related to exercise. There\u2019s also the potential for falls. The story should have noted that in this study, tai chi did not provoke any adverse events and seemed to be very safe for this group of patients with mostly mild heart failure.", "answer": 0}, {"article": "(A white light signals a \"moderate\" likelihood, while a blue light means the odds are low.)\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nOver those four months, the implants worked fairly well for eight patients -- correctly giving the high-risk warning anywhere from 56 percent to 100 percent of the time.\nTwo patients ultimately had the implants removed.\nThe study was funded by NeuroVista, the Seattle-based company developing the technology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was careful to explain:\n\u201cBut any benefits need to be weighed against the risks. Besides false alarms and unnecessary anxiety, the implant itself can cause problems. In this study, three patients had serious complications, including one with an infection and one whose chest device moved and caused her pain. Two patients ultimately had the implants removed.\u201d", "answer": 1}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\nPaul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that honey may cause an allergic reaction and that, rarely, it contains bacteria.", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include the potential harms of sleep deprivation, which are extensive.", "answer": 0}, {"article": "http://www.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\nSince 1922, funds raised have helped deliver exceptional care and support for children and their families by providing specialized paediatric care, equipment, education programs, therapy, rehabilitation services and research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned, but they certainly exist. We encourage releases on diagnostic and screening tests to address the potential for false positive (over-diagnosis) or negative results (under-diagnosis) that could have an impact on patient care.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is always a risk of false positives or false negatives with such tests, but the story didn\u2019t address those risks. It did do a good job discussing the harms of overtreating prostate cancer.", "answer": 0}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nLoeb says his team will continue to study herd immunity with different vaccine formulations by vaccinating children.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release makes no mention of possible harms that my follow the use of either the influenza vaccine injections or nasal spray, even though there are well-known restrictions on whom should and should not receive the nasal spray, and potential negative reactions to the injections among some people.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nThe next step, he said, is for group members to validate the predictive power of the markers his team found.\nSo what if it were possible to know before treatment which men might be more likely to suffer complications?\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable; given that this is still an unproven strategy, there are no data for harms.", "answer": 2}, {"article": "Observational studies in people living with HIV have shown positive emotion is related to a higher CD4 count (an indicator of less HIV-related damage to the immune system).\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "If the researchers believe the intervention is without harm, the release needed to spell that out. Harms were also not measured or\u00a0disclosed in the study itself, but it\u2019s something we encourage news release writers and journalists to seek to clarify.", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being told you are at increased risk for developing cognitive impairment is potentially distressing news. But as with many new reports on screening for disease, absolutely no mention is made of the potential harms associated with the tests. \u00a0And what about the potential for false alarms? Unnecessary emotional anxiety, increased doctor visits, and drug interventions could potentially have a very negative impact on someone who is experiencing normal aspects of aging.", "answer": 0}, {"article": "In fiscal year 2017, Penn Medicine provided more than $500 million to benefit our community.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\nSpironolactone is not approved for the treatment of acne by the U.S. Food and Drug Administration despite expert opinion supporting its use, and Barbieri says the findings of this study should be confirmed by a randomized controlled trial that directly compares the two treatment options.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms of the drug other than to say it \u201cmay have a better safety profile\u201d than oral antibiotics. Then again, it may not. Safety was not part of the study. There should be some language about spironolactone\u2019s known side effects, which include an allergic reaction and vomiting, among others listed by the National Library of Medicine.\nIn addition, there can be long-term consequences of lower androgens, such as decreased bone mass following continued use.\n\u00a0", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drinking milk is common enough that it hardly warrants an explanation of the associated harms.", "answer": 2}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nAmong elder women, the American Cancer Society and the United States Preventive Services Task Force recommend regular mammography for ages 65 to 74.\nThese linked files also permitted them to explore breast cancer mortality differences between elderly black or white women who self-selected for regular annual or biennial mammography screening.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms that might come from more frequent or aggressive screening of older women. As experts at the University of California-San Francisco and Harvard explained following their 2014 review of studies conducted from 1990 to 2014 on risk factors for women 65 and older and the value of mammography for women 75 and older, \u201cDoctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade.\u201d", "answer": 0}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\n\"Whether it's through counselling or medication, girls can manage their symptoms and decrease the risk of further complications such as fertility problems, hirsutism (excessive hair growth) and type-2 diabetes\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. While a blood test is a relatively low-risk procedure, this release could have mentioned the risk of under- or over-diagnosis leading to incorrect or no treatment based on reliance of this diagnostic test, if it makes it to the commercial stage.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a brief mention of side effects, so this skirts by as Satisfactory. However, it would have been helpful to explain that about 1 in 10 adults experience nausea, vomiting, or chills. Painful swelling in the injected arm that requires medical treatment is \u201crare,\u201d according to the CDC.\nThe reporter mentions there is no live bacteria, which is good, but probably should also have mentioned there is no thimerosal, a mercury-based preservative.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story hints at false alarms from the use of PET scans, this is insufficient information on the harms of scanning. What would a \u201cfalse alarm\u201d entail? What does it do to a person who receives this news? ", "answer": 0}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nResults from a small number of patients who received a high dose of the drug, called aducanumab, hint that it may also be able to slow the loss of memory and thinking.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is clear that the drug\u2019s effects on amyloid plaque are accompanied by potential harms:\nBut there\u2019s a downside. The process of removing plaque sometimes causes fluid to build up in the brain. In rare cases, it can also cause bleeding. These side effects are known as amyloid-related imaging abnormalities, or ARIA.\nWe\u2019re also told that about 20 participants dropped out of because of adverse effects.", "answer": 1}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This isn\u2019t covered in the release, but a look at the study leaves open a concerning question for us. Suicide prevention work is sensitive work: It\u2019s tricky for caregivers and stressful for patients, and while the study notes an institutional review board approved the study, it doesn\u2019t make clear how or whether the patients were counseled or debriefed before or after the study intervention (i.e. asking them a bunch of open-ended questions and recording audio of them speaking). This should have been made clear in the study as well as the release. There is also the potential\u00a0harm of a false negative result \u2014 in which case caregivers may receive false reassurance regarding someone who is, in fact, suicidal.", "answer": 0}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study sought to hold number of calories constant in order to examine the impact of reduced sugar. \u00a0While many health experts would point out that substituting pizza and bagels does not meet the criteria for an overall healthy diet, that was not a concern of this design.", "answer": 2}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\n\"These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,\" the study team noted in a news release.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential side effects of aspirin mentioned in the story \u2014 \u201cbleeding and stroke\u201d \u2014 are relegated to the last line of the story and are given nowhere near the prominence they deserve. For one thing, \u201cbleeding\u201d doesn\u2019t convey the seriousness of potentially fatal\u00a0gastrointestinal\u00a0hemorrhage that can result from daily aspirin. Second, the story didn\u2019t make any attempt to quantify these risks so that they can be balanced against benefits.", "answer": 0}, {"article": "\u201cBut how does the public deal with this information?\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nBut others worry that more frequent testing could exacerbate what is already a major problem: most prostate cancers grow so slowly that they would have been harmless if left alone.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did include mention of the harms that are associated with treatment of prostate cancer, namely impotence and incontinence, and that the treatment of prostate cancer may not be at all necessary because not all prostate cancers are life threatening. \u00a0As this is a very counter-intuitive thought (that not all cancers are deadly) it might have been emphasized more.\n\u00a0It is critical that people be aware that while a large clinical trial (the PIVOT study) is underway, it is not yet known whether aggressive treatment of early prostate cancer is effective or whether it may cause more harm than good. \u00a0So while the effectiveness of prostate cancer screening remains controversial,it\u2019s important to note that aggressive treatment of early prostate cancer remains controversial too. \u00a0", "answer": 1}, {"article": "\"Men need to learn as much as they can about the possible outcomes and benefits of the various treatments and the potential side effects, and choose which direction they are most comfortable with,\" Brooks said.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nProton beam therapy in particular is expensive, but according to this report, there isn't enough evidence to show it's any better than other option.\nThey concluded there was \"insufficient evidence\" to say with certainty whether radiation treatment compared to watchful waiting is more likely to save lives.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state:\u00a0\u201cRetrospective studies, however, found that radiation treatments were associated with increased urinary or bowel problems, compared with no treatment or no initial treatment.\u201d\u00a0 We wish it had provided more detail, but we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "Other Northwestern authors are senior author Dr. Ronald Ackermann and co-authors Mercedes Carnethon and Dr. Namratha Kandula.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nThis is the first study to report how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\nBut there has been little attention focused on this group's most recent diabetes screening guideline.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The considerable harms of overdiagnosis which include the risk of unnecessary followup tests and treatment that can cause adverse effects, are not mentioned. There are both benefits and harms associated with broad based screening programs.", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We liked the fact that the potential downsides of the bioabsorbable stent were included in the story.\u00a0The story notes that the bioabsorbable stent is thicker and may require patients to be on potent anti-clotting drugs, thus exposing the patient to a risk of bleeding. The story also notes that previous studies have shown a low rate of complications. We would have liked to have seen some information about the complications seen.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nThese women will suffer the harms of early screening.\nBut the vast majority of women will never develop breast cancer during their 40s.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention the risk of false positives and how this could affect whether women would still be inclined to get mammograms as they get older.", "answer": 1}, {"article": "This website is archived for historical purposes and is no longer being maintained or updated.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\n\u201cNaloxone is non-addictive, and expanding training on how to administer the drug can help basic emergency medical service staff reverse an opioid overdose and save more lives.\u201d\n\nNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release\u00a0does not say anything about the potential risks here. The fact that lower level EMS staff have been banned from administering this drug suggests that it could be dangerous. However, the reality is that the risks of intranasal naloxone are not significant, so this should have been mentioned. The risk of an intramuscular injection are also low \u2014 more or less the same as the risk of any injection (minor bleeding, hitting a nerve, etc). The release should have mentioned the lack of risk and perhaps provided context for the strict regulation of naloxone use (which again is more historical than rational).\nPart of what makes the release confusing is that it appears to be advocating for two things. It mentions multiple times that only staff with advanced training are allowed to administer the drug. And it says that \u201cNaloxone can be given nasally to a person suspected of overdose, allowing basic EMS staff to administer the drug without injection.\u2019 But then it also says that \u201cCDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\u201d Perhaps both statements are true, but the release does not make it clear whether the agency\u2019s strategy is focused on the training or the expansion to basic staff.", "answer": 0}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\n\"Our study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\"\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a strength. The release stated: \u201cMen who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\u201d\nThe news release also stated: \u201cThe risks of prostate removal, or prostatectomy, are well known and include higher chance of developing incontinence and erectile dysfunction. There are some risks associated with radiation treatment and hormone therapy, but they are less common, and are typically thought to have a lower impact on quality of life.\u201d", "answer": 1}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states VTP \u201conly caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\u201d While it\u2019s good that harms were mentioned, it\u2019s a disservice to patients to downplay their impact with the word \u201conly.\u201d\nFurther, the news release does not give the proportion of patients on VTP who experience adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, the news release glosses over the fact that over 1/3 of subjects needed repeat treatment within 2 years and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "Watching her patients undergo bone marrow transplant ?\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nThe study was supported by funding from the National Institutes of Health and spinoff Juno Therapeutics, of which Greenberg is a scientific co-founder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the release omit side effects or other potential harms from this type of treatment, it emphasizes the harms of conventional treatment, thus presenting an unbalanced comparison. The conference abstract summarizing the research noted that adverse events included short-term flu-like symptoms that are common to certain types of immunotherapy, as well as temporary reductions in white blood cell counts. In addition to failing to mention these reported harms, the release did not alert readers to potential life-threatening risks of immunotherapy which sometimes do not become apparent until the therapies have been given to many people over many years.\nOf note: a similar experimental immunotherapy trial by the same company (with acute lymphoblastic leukemia rather than AML patients) was halted after some patients died, according to this conference recap. The growing awareness of potential hazards of immunotherapy was recently highlighted in this post on HealthNewsReview.org.\nThe release should have mentioned that the absence of life-threatening complications in this small trial does not prove the treatment is safe.", "answer": 0}, {"article": "\"It's something that has become almost a community standard.\nBut the National Comprehensive Cancer Network and American Urological Association guidelines do recommend biopsies based on high PSA velocities, even in the absence of an elevated PSA or a suspicious digital rectal exam, according to background information in the study.\nHowever, the new study found that PSA velocity doesn't add any useful information beyond what physicians can already tell from other methods of prostate cancer screening, including the one-time PSA level test and digital rectal exams.\nIn the study, researchers used data on more than 5,500 men in their 60s and 70s who took part in a drug trial for a prostate cancer prevention drug.\nCurrent screening guidelines that recommend biopsies for men who have high PSA velocity but no other signs of prostate cancer -- such as a suspected abnormality during a digital rectal exam or high PSA level during a single test -- are leading to many unnecessary biopsies, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The competing AP story was much better on this point, reporting that using rising PSA levels, 1 in 7 men would have a prostate biopsy as compared with 1 in 20 men based solely on high PSA level. This suggests that change in PSA level results in 13/20 unnecessary prostate biopsies.\nThe story could have provided more detail on some of the possible complications resulting from prostate biopsies.\nIt did mention anxiety from tracking PSA levels over time. ", "answer": 0}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\n\"Today we have a new option to treat non-squamous lung cancer, incorporating Avastin in chemotherapy regimens and in maintenance therapy,\" said lead researcher Dr. Lucio Crino, director of medical oncology at S. Maria della Misericordia Hospital in Perugia, Italy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story reported on the potential harms associated with the addition of this drug to a treatment regimen. \u00a0Without information about what a patient might gain \u2013 it is hard to know whether the risk of these harms is worth the potential benefit. And the story could have provided more details about the severity and impact of the harms.\u00a0 Nonetheless, we give it a satisfactory on this criterion. ", "answer": 1}, {"article": "\"In the past we believed tooth decay was a rapidly progressive disease.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\nFeatherstone and Wendell say some dentists may be reluctant to embrace the preventive methods because they worry they'll lose money if they they do fewer costly procedures.\nOne of the biggest proponents of this approach is John Featherstone, dean of the University of California, San Francisco School of Dentistry.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fluoride for dental health has been extensively studied for decades and is considered safe, so we\u2019ll file this rating as not applicable to the story.\nBut, as some dentists might point out, there is an argument to be made for discussing one known\u2013though minor\u2013risk: Some people living in areas with naturally high levels of fluoride in their water may experience tooth discoloration or other issues if they are given additional fluoride treatment.", "answer": 2}, {"article": "But all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no complications in either group and goes on to say that the robotic surgeries took longer, making it more likely that surgeons would make mistakes (although they did not, apparently, make any mistakes.) It says in passing that \"the incision is smaller (and) the manipulations are more controlled\" when a surgeon works without a robot, a counter-intuitive piece of information that merited at least an additional sentence of explanation, even in a story this short.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states:\u00a0 \nWe wonder how well patients tolerate side effects of headaches, rashes and higher blood pressure. ", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story quantified the potential harms or any of the side effects found in the study itself. But this story did say, \u201c\u201dThe long-term effects are less well-known, however, and in rare cases it can cause bone death of the jaw, which would be important if healthy people were to take it.\u201d It also\u00a0was the only story to mention that an \u201cearlier study from the UK had found no link between bisphosphonate and colon cancer. Indeed, it found a higher risk of throat cancer in patients on the medication.\u201d", "answer": 1}, {"article": "AMD, the No.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\n\"Showing that L-DOPA causes this protective effect will require further investigation, but if confirmed, could lead to new drugs or combination therapies for AMD that target DOPA-responsive cells in the retina.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "At no point does the release mention any harmful effects from taking L-DOPA.\u00a0 And while patients might arguably be willing to face greater risks in order to retain their eyesight, it doesn\u2019t excuse the release for omitting relevant details. L-DOPA has been given to patients for years and the list of possible side effects \u2014 both physical and mental \u2014 is considerable. Patients reading stories or releases touting the possible treatment use of new drugs deserve to know the full story including possible negative effects of the drug\u2019s use.", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n\"What patients should do is talk about this with their doctor,\" said Michael Thun, a vice president emeritus at the American Cancer Society, who was not connected to the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story focuses on one potential harm of hormonal therapies given to men with prostate cancer. And while some specifics are included in the body of the story, the headline and lead of the story paint a much harsher picture of the potential risk than do the actual statistics reported by the researchers.", "answer": 1}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\nA large trial on torcetrapib was killed after investigators found an increased risk of death and other cardiovascular outcomes.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that anacetrapib did not show the type of harmful effects (including higher blood pressure and higher rates of cardiovascular problems and death) seen in trials of a similar drug, torcetrapib, which was pulled from testing. However, the story does not make it clear that this trial was designed to detect harms that were at least 25 percent more common in the treatment group than in the placebo group\u2026 so it was not powerful enough to rule out side effects that were less common than that threshold. ", "answer": 0}, {"article": "The study appeared online May 13 in The Annals of Rheumatic Diseases.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nA Swedish study suggests yet another health advantage of breast-feeding, this time for the mother: it reduces the risk of rheumatoid arthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe study cites the health advantages of breast-feeding. Are there no potential harms or disadvantages? For example, there is some research to suggest that pregnancy and breast-feeding may increase flares of RA.\n", "answer": 0}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe drug could be a good option for some people, but it's most likely not a silver bullet, said Dr. Melina Jampolis, CNNHealth's physician nutrition expert, who is not connected with the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story \u2013 while not quantifying harms \u2013 did a better job in discussing harms than the LA Times story, so we\u2019ll give it a satisfactory score. It reported:", "answer": 1}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms that could arise from taking a garlic supplement although a quick web search shows potential negative side effects including nausea, vomiting and diarrhea. There are also some indications that garlic may lower blood pressure, increase bleeding,\u00a0and possibly irritate the intestinal lining, issues that should be of concern to some who might potentially take this supplement.", "answer": 0}, {"article": "FDNA scientists published a paper in January showing that their algorithm could better identify Down syndrome after being trained with a more diverse set of faces, and Muenke and Linguraru have also published papers this year demonstrating their algorithm\u2019s ability to identify genetic disorders correctly in children across a variety of ethnic backgrounds.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\nHowever, the app won\u2019t give clinicians a yes or no answer to the question of, \u201cDoes my patient have a genetic disorder?\u201d\n\nThat\u2019s intentional.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms here, but with any screening test (or \u201creference informational tool\u201d as Face2Gene calls itself), there is a risk of overdiagnosis or incorrect diagnosis, without confirmatory genetic testing. That could be devastating to parents of affected children for example. Even though the company says that the software should not be used as a diagnostic tool, the allure to do so \u201coff label\u201d is there.", "answer": 0}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As\u00a0discussed above, the story doesn\u2019t attempt to quantify the harm of false-positive or false-negative diagnoses. It also doesn\u2019t explore the potential harm of labeling someone with borderline symptoms as having autism.\u00a0In addition,\u00a0it has now become clear that MRI with contrast is associated with kidney damage.\u00a0Physicians now check kidney function in all patients prior to an MRI and must weigh the need for the images vs the very small (but tangible) risk of kidney damage.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nevirapine crosses the placenta. Studies in pregnant women have shown that nevirapine decreases the chance of passing HIV to a child during labor and at birth. Liver toxicity has been observed with long term use of nevirapine in combination with other HIV drugs, though this is not mentioned in the article. Additionally, other studies have shown 20-40% resistance to the drug after taking one dose as a protective measure in labor, yet there is no mention of the rate of resistance in the main study discussed in the article. Nevirapine may be \u201ceasy to take\u201d, but quantification of side effects noted in this and other studies discussed is omitted. Given there is only a 3% absolute reduction in transmission in one study cited, the risks of the drug for newborns and their mothers needs to be discussed. ", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms here involve errors in diagnosis. More specifically, the story does not address the specificity or sensitivity of the biomarker testing. And this is important. Specificity indicates how good a test is at ruling out people who don\u2019t have a problem. Sensitivity addresses how good a test is at positively identifying people who actually have the problem. False positives can result in unnecessary treatments and costs. False negatives can result in patients not getting treatments that could help them. And if it\u2019s still too early to tell what the specificity or sensitivity of the tests are, they need to address that.", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nThe medicine, if approved, could hold promise for patients with moderate to severe persistent asthma that is not well controlled by standard drugs.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\nWenzel, director of the Asthma Institute at the University of Pittsburgh, said other drugmakers have tested medicines that block one or both of the proteins, but without success.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter takes it on the lead researcher\u2019s word that the \u201cdupilumab was well tolerated, with side effects similar to placebo. But she cautioned that longer trials are needed to fully assess the drug.\u201d We would have liked to have seen those side effect numbers. Similar to placebo? Does that mean 10 patients in the drug group had side effects and a dozen in the placebo group? Does it mean three and six? Just give us the numbers.\nImportantly, one subject receiving dupilumab developed angioedema, a serious and potentially life threatening allergic reaction presumably due to the drug.\nAnd even the accompany editorial in the New England Journal of Medicine drew attention to safety questions:\n\u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\n\"It will be very interesting to study how parvalbumin distributes within human tissues in more depth.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is dominated by suggestions that parvalbumin could help with Parkinson\u2019s and perhaps other neurodegenerative diseases including Alzheimer\u2019s, ALS and Huntington\u2019s but only at the very end do we learn it\u2019s been studied as a a cause of fish allergies.\nIs this the only harm? We don\u2019t know because harms aren\u2019t included.", "answer": 0}, {"article": "Sitting has been identified as a risk factor for early mortality, independent of the presence of a disease, such as cancer or diabetes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nParticipants in the study familiarized themselves with the workstations during one visit.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\nOn a second visit, researchers collected metabolic rate and heart rate data during three progressive stages: seated, seated with the device and standing.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms in the news release. It\u2019s likely that there aren\u2019t many, since low-impact seated activity is good for joints and can still burn some calories. But still, as we say in our review criteria:\u00a0if you\u2019re only hearing about the potential benefits of a test or treatment, run for the hills.", "answer": 0}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\n\"Barley has a lowering effect on the total bad cholesterol in these high-risk individuals, but can also benefit people without high cholesterol.\"\n\"Health Canada, the FDA and several health authorities worldwide have already approved health claims that barley lowers LDL cholesterol, but this is the first review showing the effects on other harmful lipids.\"\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are unlikely to be harms for most people if they increased their barley consumption, but upping their daily intake could also lead to gastrointestinal problems in some people. The recommended daily consumption of barley in Canada is 3 grams but the study recommends that it be increased to 6.5 to 7 grams daily. People diagnosed with Celiac disease have most likely already been advised that consuming barley (as well as other foods containing gluten) can cause complications.", "answer": 2}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address risks, but CBT carries few risks (if any). In addition, the release states that in this study, patients who needed additional therapy beyond CBT for mental health issues were referred for more assistance.", "answer": 1}, {"article": "; Walter Rocca, M.D.\nThe Mayo Clinic study used data from the Kronos study to determine the effects of menopausal hormone therapy shortly after menopause, during the critical window of rapid estrogen depletion \u2014 five to 36 months past menopause.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\n\u201cWomen with APOE e4, who have a greater genetic risk for Alzheimer\u2019s disease, particularly benefited from this therapy.\u201d\n\nMenopause is defined as occurring 12 months after a woman\u2019s last menstrual period and marks the end of menstrual cycles.\nIn contrast, the multicenter Kronos Early Estrogen Prevention Study tested the hypothesis that healthy and younger women would respond to menopausal hormone therapy more favorably.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Early in the text, the writer notes that one large, older study\u2014the Women\u2019s Health Initiative at NIH\u2014has found an association between use of estrogen and an increased risk of dementia among women 65 or older. The study highlighted here, in contrast, focuses on women five to 36 months past menopause, individuals predominantly in their 50s. The potential long-term effects of estrogen use by these younger women is not mentioned in the release.\nEstrogen carries a well-known small increase in risk for breast cancer and blood clots, which could have been briefly acknowledged. In addition, the National Library of Medicine states that estradiol, the form of estrogen used in transdermal patches, \u201cincreases the risk that you will develop endometrial cancer (cancer of the lining of the uterus [womb]). The longer you use estradiol, the greater the risk that you will develop endometrial cancer.\u201d Other minor side effects include head ache, breast pain and nausea, among others.", "answer": 0}, {"article": "Drinks such as POM have become increasingly popular with consumers in recent years, thanks in part to public health campaigns against soda that have been prompted by the obesity epidemic.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nThe bottom line is that consumers shouldn't believe everything they read on labels.\nAs long as consumers limit themselves to 8-ounce servings and products with no added sugar, juice can be an excellent source of vitamins and other nutrients, Gans says.\nMost health beverage drinkers aren't as enthusiastic as the realtor from Alaska who posted the above testimonial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story perhaps could have mentioned that too much POM juice might contribute to obesity and related health risks such as type 2 diabetes. But we can\u2019t really fault it for not discussing\u00a0the harms of pomegranate juice, because there really aren\u2019t any direct adverse effects that have been well established.\u00a0(The same is not necessarily true for antioxidant supplements, which may well be harmful in some cases.) We\u2019ll call this one not applicable.", "answer": 2}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nMultiple clinical trials using CURATE.AI-guided combination therapy for oncology and additional applications such as post-transplant immunosuppression are underway.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "AI is not perfect. AI programs can, and will, make mistakes. What might those mistakes mean in the context of cancer treatment? It\u2019s not clear, and the release doesn\u2019t address this. We know that clinical trials using \u201cCURATE.AI-guided\u201d therapies are underway, and that the patient highlighted in the news release is involved in a clinical trial. But we don\u2019t know how any of those trials are going. Will those trials identify any risks or potential harms? How will medication dosages be adjusted to reduce side effects? That remains to be seen, and the release should not simply ignore the issue. If this single patient\u2019s treatment was sufficient to warrant a news release, any potential harms (or even the absence of potential harms) should also be worth addressing.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nIn mice, probiotics have indeed been shown to improve learning and memory, and reduce anxiety and depression- and OCD-like symptoms.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although probiotics are considered to be safe for people who are generally healthy, they have been linked to severe side effects in people with underlying medical problems. According to the National Institutes of Health, the populations most vulnerable to adverse effects from probiotics include the critically ill, infants, and people with weakened immune systems, which often includes elderly men and women. Since this study was conducted in individuals aged 60-95 years with an underlying health condition, safety should have been addressed in the news release. And yet, no explanation of risks or potential harms was provided.\nEvaluation of all treatments, including benign appearing supplements, should include an assessment of harm. ", "answer": 0}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\nThe study did show a significant decrease in the risk of needing Mohs surgery to treat a BCC in the first year.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release describes harms in the following paragraph:\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged. After the study\u2019s first six months, 21 percent of the 5-FU group rated the side effects as \u201csevere,\u201d and 40 percent rated them as \u201cmoderate.\u201d", "answer": 1}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\nEighty-seven volunteers aged 16 to 34 with Down syndrome were enrolled in the phase 2, randomized, controlled trial.\nThe study was conducted at the IMIM-Hospital del Mar Medical Research Institute in Barcelona, Spain.\nKey Findings: Prevalence of Down syndrome in .\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although adverse effects were reported by by study participants (e.g bone and joint pain, headache, physical weakness and celiac disease), researchers commented in the study that these conditions were not related to treatment, since \u201cno differences were noted in adverse effects between the two treatment groups.\u201d\nBut if there are no side effects, then a simple acknowledgement that \u201cthere were no adverse effects\u201d would still be in order, and the release didn\u2019t provide this.", "answer": 0}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The harms of fish in the diet are not really in question, although some research has raised concerns about possible toxic effects of mercury found in some species.", "answer": 2}, {"article": "Newswise \u2014 Baltimore, Md.\nStudies have found that adding thermal therapy to standard treatments can significantly shrink tumors and can improve survival for some patients.\nRadiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.\nResearch has shown that thermal therapy can be especially useful in difficult-to-reach cancers in the abdomen and pelvic region.\nIt is a highly effective treatment for a wide range of localized tumors such as those found in the brain, base of the skull, head and neck area, eye tumors, tumors of the esophagus, lung, prostate, liver, breast, spinal cord, as well as gastrointestinal malignancies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release touts the potential benefits of both therapies, it says nothing about side effects or potential harms. According to the Mayo Clinic, possible side effects of proton therapy include fatigue, digestion problems and headaches. The National Cancer Institute lists possible side effects of hyperthermia, which include burns, blistering, vomiting, and and possible cardiac disorders.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nAnd I do a little twitch with my muscle in here.\nBack then, she couldn't even wipe the tears from her eyes \u2014 and there were plenty of tears shed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms or side effects. Because this is an invasive, implantable device, there are risks from the implantation alone. It is also unclear how long the device will last.", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nSo the doctor recommended tonsillectomy.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nAnd his snoring is gone.\nSo his parents took him to an ear, nose and throat doctor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The results have not previously been published or presented.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nDr. Ruhwald said another advantage of C-Tb is that the measurement of infection, a 5mm or larger induration, is universal across patients with different risk factors, including HIV infection.\nIn the second double-blinded trial, researchers were primarily concerned with testing how accurate C-Tb was in HIV-positive patients and in young children--populations in which the accuracy of the TST and the IGRA is known to be compromised.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0is no mention of potential harms with this new test, leaving readers to assume its safety. Although relatively minor, side effects have been noted in previous clinical trials including: \u201cLocal adverse reactions following C-Tb injection included transient itching and discomfort as expected components of the immune response.\u201d\nIn addition, as with most diagnostic tests, there is a risk of false-positive (over-diagnosis) or false-negative (under-diagnosis) results. This should have been mentioned along with data on the test\u2019s reliability. ", "answer": 0}, {"article": "The question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nGilead\u2019s regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the \u201cnuke\u201d, needs to be taken for at least eight weeks.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms from the drug. What were the drop out rates and adverse drug reaction rates? What was the severity of the reactions? The story does not address these issues.", "answer": 0}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThese diets could also be effective independent of caloric restriction.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems unlikely that personalizing a weight loss plan could cause significant harm. The most tangible downside is likely to be time and money wasted on a plan that might not be more effective than standard dietary advice. Still, a small risk of complications resulting from repeated blood draws or finger sticks is possible since glucose and insulin concentrations are measured from blood samples.", "answer": 2}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nMany migraines can be prevented by taking medication every day.\nThey were developed in conjunction with the American Headache Society.\nEach headache may last from four hours to two days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story was not specific enough on this point, it reminded readers that all drugs \u201ccan have side effects or interact with other medications.\u201d\u00a0 It didn\u2019t mention how serious they might be or how often they might occur. We\u2019ll give the story the benefit of the doubt however since the list of drugs is long and the incidence and severity of the side effects is complicated\n\u00a0", "answer": 1}, {"article": "The median age was 75 years (range 41to 94).\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nPatients were treated with SBRT for early-stage lung cancer between 2004 and 2014 and followed for a median of 1.7 years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release. The study alludes to harms in a quote, saying:\n\u201cOlder patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\u201d\nOk. So this starts getting at the fact that the treatment itself is harmful. Why not go further and explain to readers and journalists what the risks are from the treatment and how the risks played out with this study?\nKnown harms from this treatment include fatigue lasting 4-6 weeks, neuropathic pain, rib fractures and other risks.\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes the potential harms of screening. The story describes the radiation exposure from CT\u00a0as being equivalent to that of a mammogram. It is\u00a0not clear where this information comes from. CT scans generally have many times the\u00a0amount of radiation exposure of x-rays. There is also no discussion of the harms caused by false positives, which may lead to unnecessary biopsies, which may lead to further complications. ", "answer": 0}, {"article": "For more on the opioid epidemic, read Vox\u2019s in-depth explainer, the abridged explainer, or the maps and charts explainer.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs.\nStill, it\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions alternative treatments, but doesn\u2019t address potential harms of changing prescribing patterns. While reducing the risk of overdose may outweigh any potential negatives of taking patients off of a drug, it\u2019s still worth addressing any drawbacks.\nThe story\u00a0also does not explain how concurrent use of benzodiazepines and opioids cause harm (via the combined sedative effect which can lead to respiratory depression).", "answer": 0}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\nDr Henderson and her team at the University of Bristol studied 130 people with Parkinson's who had fallen in the past year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms or side effects but some commonly reported adverse events associated with rivastigmine include dizziness and nausea. It can also cause drowsiness and fatigue which in some patients might actually increase the risk of falling. In addition, this drug has potential interactions with commonly prescribed drugs for elderly patients (such as aspirin, some beta blockers, NSAIDs, and medications for urinary incontinence, among others). This is noteworthy because Parkinson\u2019s disease patients tend to be on multiple medications, increasing the likelihood of falls and of possible drug interactions.", "answer": 0}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nTheir rationale for testing resveratrol was evidence obtained three years ago that it could activate a genetic mechanism known to protect mice against the degenerative diseases of aging and to prolong their lifespan by 30 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that there were uncertainties about the safety of reservatrol in humans.\u00a0 In fact, to date, no clinical trials with this compound have been completed.\u00a0 At this time, a single trial looking at safety in colon cancer patients is recruiting subjects.\u00a0 The story should have emphasized the need for safety testing humans before any claims can be made. With some nutrients, such as Vitamin A, we know that small doses provide benefit, while large doses can be harmful.\u00a0 The story would have been strengthened by providing more sources with healthy skeptism to balance the overwhelming enthusiasm from other sources, many of whom had ties to the drug companies promoting the substance. ", "answer": 0}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The need to study the safety of WAY-316606 was mentioned, but should have been higher in the story. The story would have been stronger if it had mentioned whether the drug\u2019s safety has been studied previously, and what the results if any showed. It was a missed opportunity to highlight known harms of a drug already on market.", "answer": 0}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no mention of any potential downsides of the testing. False positive results, for example, could cause unnecessary worry and anxiety and lead to needless fertility treatments.", "answer": 0}, {"article": ".\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\nResearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release does state that \u201cresearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\u201d That\u2019s good. However, the release doesn\u2019t tell us what they mean by \u201ccomplications.\u201d Endoscopy, in general, is fairly low risk \u2014 but potential complications can include short-term pain and nausea, infection, organ tearing and bleeding.", "answer": 0}, {"article": "Ray added: \u201cThis is the strongest evidence yet that statins reduce the risk of heart disease and death in men with high LDL.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\n\u201cIt shows the enduring and long-term benefit of taking statins, including the extent to which they reduce the risk of dying from heart disease, which can only be seen in a study of this length.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of statins are mentioned, but they\u2019re significant. Taken over many years, let alone decades, those risks become even more significant considerations. The most common side effect \u2014 29% of people on statins report experience it \u2014 is damage to muscles and muscle pain (e.g. soreness, tiredness, and weakness), according to the Mayo Clinic. However, those on placebo report a similar rate of muscle pain and damage. Other, less common side effects (for which there\u2019s also less evidence that statins may be responsible) include liver damage, increased blood sugar or type 2 diabetes, and memory loss/confusion.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were a couple of openings for this story to better characterize the potential risks of this investigational procedure. At one point, the story says that the treatment \"doesn\u2019t come without risks,\"\u00a0but the only downside subsequently mentioned is that \"People will have to be trained to use the technique.\" Later,\u00a0an anchor says more directly, \"You are actually destroying some tissues in the lungs. Do they know anything about potential long-term complications?\" But the reporter responds that the treatment \"doesn\u2019t seem to limit pulmonary, lung function at all.\"\u00a0Faced with the\u00a0lack of any long-term data on how patients do with this procedure, we feel it would have been appropriate to at least discus the potential for adverse consequences or emphasize the uncertainty of the current evidence. Instead, the \"breakthrough\" framing came across as cheerleading. ", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nThe evidence is strongest for colorectal cancer, she says.\nBut the group is not expected to embrace the newer claims being made for vitamin D supplementation.\nThe fact that the government is funding the study is an indicator that the idea has traction.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While Dr. Holick is quoted in this story as commenting that \u00a0\u00a0\"\u2026there is no downside to increasing your vitamin D intake\",\u00a0he is also a co-author on a 1992 paper in the New England Journal of Medicine documenting a series of deaths due to accidental overdose of vitamin D.\u00a0\u00a0 The story did not give any weight to the potential for problems with over-consumption of vitamin D.\n.\u00a0", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\nWhile the study is too small to prove if lampalizumab really helps maintain vision, that\u2019s a bigger difference than the overall results suggested.\nAnd it\u2019s important for patients to know what type they have.\nThe experimental drug, lampalizumab, aims to slow the destruction of light-sensing cells in the retina, creeping lesions that characterize the stage of dry AMD called \u201cgeographic atrophy.\u201d When those cells die, they can\u2019t grow back \u2014 the vision loss is irreversible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were no \u201csafety concerns\u201d noticed during the trial. We\u2019re not sure what that means\u2013does that mean there were zero side effects? Or just no life-threatening ones? When we looked at the study, we did see that the drug caused side effects, which might not meet the researchers\u2019 definition of a \u201csafety concern\u201d but could certainly be of interest to patients taking the drug.", "answer": 0}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that women in the study reported no adverse effects.", "answer": 1}, {"article": "The American Heart Association reports that more than 80 percent of smokers say they want to quit.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address the potential harms of laser therapy, which was surprising given how careful the story is in other regards.", "answer": 0}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nThey also felt they had better communication with their doctors.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nOne of the patients texted the program 1,217 times.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There don\u2019t appear to be any harms associated with text messages, barring potential distraction while driving. Hence, this criterion doesn\u2019t apply.", "answer": 2}, {"article": "Prostate cancer is the most common cancer among men.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\nThe procedure was carried out under general anesthesia and most of the patients had hospital stays of less than 24 hours after the treatment.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that \u201cNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\u201d Again, this was not the whole story.\u00a0 17% of men developed urinary tract infections after the procedure and men required catheters for an average of 8 days.", "answer": 0}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nAfter six months, patients with the Obalon balloons had them removed.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\nWhether the weight loss will last over the long term isn't known, said lead researcher Dr. Aurora Pryor, director of the Bariatric and Metabolic Weight Loss Center at Stony Brook University in New York.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions these harms:\nAs for side effects, one patient had a bleeding stomach ulcer while taking high doses of pain pills after a knee replacement. Most patients (91 percent) suffered from stomach cramps and nausea, which nearly 100 percent said were mild or moderate.\nThe story would have been stronger if it had warned readers that a study that puts a device in only a couple of hundred people may miss problems that could appear after the device is placed in hundreds of thousands or even millions of patients. The documentation that the manufacturer will give patients lists several serious, even life-threatening, potential side effects, including intestinal and airway blockages. These potential risks should have been noted.", "answer": 1}, {"article": "Moffitt is the No.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\nCurrently, there are no studies that have analyzed the long-term effects of neoadjuvant radiation therapy on breast cancer patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no comment in the release about potential harms, although the study itself addressed the potential negative impact on healing.", "answer": 0}, {"article": "Glioblastoma is the most common and aggressive malignant brain tumor in adults.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\nDr. David Reardon, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute in Boston, says the Duke group's results may represent \"a good, solid, important step forward\" for patients with no alternatives.\nThe Duke researchers have started a follow-up study combining the treatment with a chemotherapy drug to try to improve the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported \u201csubstantial risks\u201d with the treatment, including \u201cdangerous swelling in the brain that can lead to seizures and other complications.\u201d It reported that one patient had a life-threatening blood clot in the brain that required surgery.\nThe story did not explain how many of the patients in the trial experienced the substantial risks. This was something NBC News handled better (see the review). We can look the other way on the benefits criterion, but the story should have given some estimate of how many people experienced harm from the treatment.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the progestin IUD is well tolerated and there were no adverse events in the study, the story makes no mention of any potential harms.\u00a0 The adverse effect outcome measure reported in the study was effects or complications severe enough to suspend treatment. The concurrent GnRH analog treatment does have side effects (temporary menopausal symptoms) that may be important to some women, while not warranting suspension of treatment.", "answer": 0}, {"article": "According to the World Health Organization's 2008 figures, at least one in three of the world's adult population is overweight, and almost one in 10 people is obese.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t reflect on possible harms that might be associated with consumption of a\u00a0\u2018Mediterranean diet\u2019.", "answer": 2}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nShe said the benefits of the online therapy include easy access to the treatment and flexibility in times for completing the sessions, which \"is really helpful for those juggling work and family demands.\"\nChronic insomnia is a strong risk factor for post-traumatic stress disorder, depression and substance abuse, absenteeism and occupational accidents, Taylor said.\nIt is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release. According to the scientific paper, \u201cAEs [adverse events] determined to be related to the research included one patient with an increase in insomnia after primary care physician reduced hypnotic medication and six patients with skin irritation from wearing the Actiwatch.\u201d While these appear to be minimal, releases should still try to address any potential harms.", "answer": 0}, {"article": "\u201cC.\nBut most importantly, the study found no difference in effectiveness between the two therapies.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nAn emerging treatment for a common hospital-acquired infection could be (slightly) less gross in the future.\nOther efforts to take the \u201cpoop\u201d out of the poop pills\u2014to just include the bacteria thought to be behind the benefits\u2014have failed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a satisfactory here for including the differences between the two methods of delivery: One source is quoted saying, \u201ccolonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body\u00a0and can be complicated for the people most at risk for C. difficile infections.\u201d\u00a0 It could have gone a step further and reminded readers that a colonoscopy is an invasive procedure with the inherent risks of infection and perforation that obviously aren\u2019t there when taking a pill. The story did not mention the other adverse events described in the paper such as nausea and vomiting, though.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\nGeorge said he hopes that by better understanding where TMS should be delivered and by figuring out the best dose and duration of treatment, success rates closer to those of ECT might be achieved.\nIn a second phase of the study, all patients were given the real TMS treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that people in the TMS and sham treatment groups were equally likely to experience side effects including headache, discomfort at the TMS site, and eye twitching. The story could have pointed out that we don\u2019t know much about long-term adverse effects of this treatment, and that a short-term study of 190 subjects has limited ability to identify rare but potentially serious adverse effects.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nThat's presumably why sufferers of plantar fasciitis feel the pain in the heel.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of side effects is the report of some bruising for\u00a0two days afterwards. Potential risks of this treatment include discomfort soon after the procedure. And then there is the possibility that the procedure may make the condition\u00a0worse. Some information acknowledging the risks \u2014 even if they are minor and temporary \u2014 is always appropriate.", "answer": 0}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gives no sense of what could go wrong if this technology malfunctions and delivers the wrong dose of insulin while someone is sleeping.\u00a0The consequences could be fatal. \u00a0", "answer": 0}, {"article": ".\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are addressed\u2013enough to be Satisfactory for this criteria. But the discussion is confusing. The story initially says nootropics have \u201csupposedly few side effects and low toxicity.\u201d Later it states:\nAs for newer nootropic drugs, there are unknown risks. \u201cPiracetam has been studied for decades,\u201d says cognitive neuroscientist Andrew Hill, the founder of a neurofeedback company in Los Angeles called Peak Brain Institute. But \u201csome of [the newer] compounds are things that some random editor found in a scientific article, copied the formula down and sent it to China and had a bulk powder developed three months later that they\u2019re selling. Please don\u2019t take it, people!\u201d\nIn contrast, consider these unequivocal cautions in a similar Mercury News story last fall, starting in the seventh paragraph:\nResearch into the cognitive benefits of nootropics is still in its early stages, and some experts worry about the long-term health effects of ingesting potent synthetic smart drugs, which are largely unregulated.\nSome users have reported side effects including headaches, upset stomach, insomnia, anxiety and depression.\nDr. Reid Blackwelder, past president of the American Academy of Family Physicians, said it concerns him that customers are ordering such drugs online without consulting a doctor, because some of the substances seem to have a powerful impact on the brain. And much of the research on the cognitive benefits of these substances is supported only by studies using animals, Blackwelder said.", "answer": 1}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\nAnd it's also important to note that this is not a cure.\nThe study found that to date, the new drug appears to be both safe and well-tolerated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThe study found that to date, the new drug appears to be both safe and well-tolerated.\u201d It also says, \u201cAdverse events, including serious events, were comparable to those in the placebo group, according to the researchers. The incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\u201d (That Comi paraphrasing also appears to be lifted directly from an American Academy of Neurology news release.) We would have liked to have seen some actual numbers attached to those adverse events. This is important context for readers.", "answer": 0}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nIts effects are temporary and typically wear off after three months.\nWhile Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible negative side effects. According to MayoClinic.com, possible side effects include \u201cpain, swelling or bruising at the injection site, headache or flu-like symptoms, droopy eyelid or cockeyed eyebrows, crooked smile or drooling, eye dryness or excessive tearing.\u201d In rare cases, the effect of botulinum toxin can spread to other parts of the body and cause botulism-like signs and symptoms.\nThere\u2019s another issue relating to potential harms that should have been mentioned here. Using botox to treat depression is still an off-label use, meaning that\u00a0its safety and efficacy as a treatment for depression have not been established by the FDA.", "answer": 0}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of hormone therapy \u2013 harms that may include osteoporosis, fractures, diabetes and heart disease.\u00a0 This is a significant oversight. ", "answer": 0}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\"\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nDr. Kmiec noted that while his team is working to move into human trials, the CRISPR application being developed for lung cancer does not involve directly editing a patient's genome --only the genes in the tumor.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\n\"Our goal is to see if CRISPR can be used with chemotherapy to provide a safe, affordable way to give patients who are not responding to treatment at least a fighting chance against this very challenging cancer,\" said Eric Kmiec, Ph.D., the principal author of the study and the director of the Gene Editing Institute.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t talk about specific harms but it does note that \u201cthe CRISPR application being developed for lung cancer does not involve directly editing a patient\u2019s genome \u2014 only the genes in the tumor.\u201d\nThe release calls this application a \u201crelatively conservative\u201d use of CRISPR and that it might \u201cprovide a level of safety and reliability that is reassuring for patients.\u201d\nThe release would have been better had it explained that there\u2019s potential for viral vectors that are used to carry genes into the body to infect healthy cells as well as cancer cells; the study cites a need for \u201cmore effective delivery methods of these genetic tools to lung tissue\u201d that would eliminate the potential for disrupting normal cells.\nIt would have been helpful to note why this is important: a germ line can be passed on to children while somatic mutations generally can not be passed on.", "answer": 0}, {"article": "It's crazy enough to laugh off.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\nThey found that by adding it to the high-fat diet, the compound would decrease the level of obesity in the animals and would increase their ability to deal with increased blood glucose levels.\nTo discover this, collaborators at Virginia Tech first fed the cocoa compound to animals on a high-fat diet.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Aside from mentioning that chocolate has a lot of sugar in it, harms are not discussed in the news release. Not only is eating lots of chocolate (stuffed with fat and sugar) likely to increase, not decrease, a person\u2019s risk of developing diabetes, the research paper states that other cocoa components they tested made things worse by decreasing insulin secretion.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms or the safety of the immunotherapy toothpaste in this story. \u00a0Does the product carry the risk of systemic reactions that one might see with allergy shots? Does the toothpaste make you drowsy like some antihistamines? There is no\u00a0statement that the product is FDA-approved, which might help readers gauge its merits.\u00a0 All we are given is the praise of one of the trial\u2019s participants and a comment from the product\u2019s inventor.", "answer": 0}, {"article": "They look impressive,\" said Dr. Gordon Weir of Joslin Diabetes Center in Boston.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nBurt and other diabetes experts called the results an important step forward.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of the new treatment whatsover, including no mention of how serious these harms were or how frequently they occurred.\u00a0\u00a0 ", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story compared the percentage of patients dying during the two procedures as well as the percentage who would need re-treatment at a later point in time. \u00a0But the story did not mention that there is evidence that the endovascular repair in those who are not physically well enough to undergo the open procedure does not provide benefit in terms of mortality. Thus for a subset of patients, undergoing the procedure and accompanying recovery involves the harm of discomfort and risk without benefit.", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t addressed. Again, this is unacceptable given that both drugs are already on the market. And these problems can be significant. The potential side effects associated with Bavencio include lung, liver and kidney problems. Potential side effects associated with Inlyta include heart failure and serious or fatal bleeding.", "answer": 0}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\nThis will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms of such a breath test. If the release is going to discuss potential unproven benefits, it should also mention the potential harms of screening tests including false positives, false negatives leading to over- or under-diagnosis. \nChief among these harms would be falsely labeling healthy people as possibly having cancer and then subjecting them to invasive testing or even treatments that turn out to be unnecessary. Based on the statistics in the study abstract, an 81% specificity suggests that almost one-out-of-five people taking the test would be labeled as possibly having cancer when they don\u2019t. However, the 80% sensitivity suggests that at present about one-in-five people with cancer would be missed. (Computed tomography (CT) screening for lung cancer is about that). The numbers get much worse, as discussed above, when we consider using the test in the general population of people who aren\u2019t likely to have stomach cancer.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The limitations and harms (from false positives, unnecessary biopsies, and unneeded surgery/radiation) from PSA screening and other current diagnostic procedures for prostate and other cancers are\u00a0pretty well known. It\u2019s unlikely that the newer nuclear imaging tests described in this article are without limitations and potential harms as well, including exposure to ionizing radiation, but there is no explicit/direct information about them. Also, finding low-risk cancers could pose psychological and physical harms from over diagnosis and over treatment.", "answer": 0}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nFurthermore, CAM2038 was well tolerated across the course of treatment.\nThe CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure.\nThe CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage).\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms was offered beyond saying the drug was \u201cwell tolerated across the course of treatment.\u201d What does that mean? We do not know.\nWe do know that the drug is not wholly benign. Here are some side effects listed by the U.S. government\u2019s Substance Abuse and Mental Health Services Administration: nausea, vomiting, constipation, muscle aches and cramps, cravings, inability to sleep, distress and irritability and fever.\nUntil this is tested in a larger cohort, we do not know the potential array of side effects.", "answer": 0}, {"article": "In 2016, he was ranked the No.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\nThe researchers caution that the reliable detection of small to moderate risks and benefits of drug therapies requires cogent data from large-scale randomized trials designed a priori to test the hypothesis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes results of the EAGLES study, which aimed to address concerns about the potential for Chantix users to experience related neuropsychiatric problems. However, there are significant concerns with both the EAGLES study and with the FDA\u2019s subsequent decision to remove the \u201cblack box\u201d warning from Chantix. Rather than trying to recap all of those concerns in this space, we refer you to a detailed piece by Alan Cassels that was published on HealthNewsReview.org\u2019s blog in January. Suffice it to say, the EAGLES study did not settle the debate over the safety of Chantix \u2014 and that debate warrants some discussion in a release like this one.\nThis release describes harms from smoking and specifically the harms of under-treating smoking. But it doesn\u2019t discuss side effects of Chantix. While those side effects may be much less severe than combusted tobacco smoke that does not excuse their elimination from the news release. Ideally, people are provided enough information necessary for realistic, rational shared decision-making with their doctor about pharmaceutical medications, not false reassurance that there are no risks to this type of treatment.", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any of the harms associated with the vaccine.\nWhile influenza vaccine is generally safe, there are some potential adverse reactions that are more common with the high dose formulation. According to a news release from Sanofi-Pasteur, the manufacturer of Fluzone, announcing updated prescribing information for Fluzone high-dose in patients 65 and older: \u201cThe most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever. Other adverse reactions may occur. Fluzone High-Dose vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.\u201d", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n\u201cSince this surgery I\u2019ve actually had another disc herniate, complicating everything.\nBut she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a big oversight. There was no mention of the risks involved with having surgery in the vicinity of the spine, which could include serious complications such as infection, as well as device failure. The story should have cautioned that medical devices are not required to undergo rigorous safety trials before they are allowed on the market, as we cover in our medical device primer.", "answer": 0}, {"article": ".\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since the release\u2019s main source does reference the possibility of these findings leading to future treatment methods, the release really should offer some information about the possible harms of stem cell applications, which include immune reactions and even cancer.", "answer": 0}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\nIn a recent report on ongoing work to improve kidney tumor classification, published in the April issue of the journal Clinical Nuclear Medicine, the team reports that the sestamibi SPECT/CT test\u2014short for 99mTc-sestamibi single-photon emission computed tomography/computed tomography(CT) \u2014 adds additional diagnostic information in conjunction with conventional CTs and MRI and improves physicians\u2019 ability to differentiate between benign and malignant kidney tumors.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nOverall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address harms in terms of reduced harms from adding the imagining technology to standard diagnostic tests:\n\u201cEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\u201d\nHowever, the potential harms from the test itself are not mentioned. Like CT, the test involves the use of ionizing radiation known to increase the risk of cancer. Though often minor, the contrast imaging agents (also called tracers or \u201cdye\u201d) injected prior to the test can cause allergic reactions, headaches, chest pain, dizziness, and other reactions.", "answer": 2}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nThey found that the brain circuitry is significantly different in those with autism compared to people with normal brain function, specifically in areas of the brain that are engaged in language and social and emotional functioning.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One would think from reading these stories that getting an MRI is as harmless as taking a shower. Neither this story nor the CNN story explained the real psychological and physical impacts of brain scans. For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. If this test is to become useful it would need to be conducted early in a child\u2019s life. This should have been conveyed to the reader.", "answer": 0}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\nOne of the moderately high-fat diets included a daily serving of one avocado.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nIn one sample meal plan, lunch was chicken salad with half an avocado, and dinner included turkey tacos with another half an avocado.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that eating avocados is linked to decreases in LDL cholesterol levels, but also clearly notes that eating avocados in conjunction with tortilla chips (as guacamole lovers are wont to do) would lead to a significant increase in calorie consumption.", "answer": 1}, {"article": "But the evidence that pot smoking actually helps with spasticity has been anecdotal.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included the important quote, \u201cWe can\u2019t say anything about long-term effects.\u201d\nAnd, short term, the story reported that the study found some patients had fatigue and dizziness.", "answer": 1}, {"article": "An estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\nWithout proof of a physical cause, some doctors considered IBS a psychological disorder.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100 percent accurate, and a false positive test can lead to additional diagnostic testing that can cause harm as well as unnecessary treatments. The story could have mentioned this.", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\nThe treatment works well for many kinds of tumors, including those found in the brain, esophagus, lung, head and neck, prostate, liver, spinal cord and gastrointestinal system.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "By focusing on proton therapy advantages, and offering little information on which side effects proton therapy does not ameliorate, the release effectively glosses over the fact that proton therapy can still cause a wide array of significant adverse side effects associated with radiation therapy.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nThe response was better with the highest dose of Temodar.\nHe appeared to be beating the cancer with the combination therapy.\nKennedy's tumor is thought to be inoperable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of whether the vaccine had any effects other than appearing to lengthen the time needed to observe cancer recurrence.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. We don\u2019t know what the harms of eating cherries might be.", "answer": 2}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects were reported in the research; however, the story briefly mentions the ethical and medical concerns that may be associated with a drug that erases memory. ", "answer": 1}, {"article": "So if you could reliably know when you've ovulated as a woman, and then you give that egg two or three days to die, any time after that in the cycle you will not get pregnant because there's no egg to fertilise,\" Dr Susan Walker, a senior lecturer in sexual health at Anglia Ruskin University, told BuzzFeed News.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nFor starters, it can only protect against pregnancy, not STIs.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nTo use the app, you need a monthly or yearly subscription, and a thermometer that you have to use to take your temperature each morning before you get out of bed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest harm to using this contraceptive method is getting pregnant. The article reminds readers that\u00a0another risk to using this method of birth control is it does not protect against sexually transmitted diseases, as condoms do. Otherwise, there is only the inconvenience of daily logging of one\u2019s temperature and entering menstrual cycle data.", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nAdverse effects were reported by seven patients in the study.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports the number of participants who had problems including \u201cpain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\u201d", "answer": 1}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article provides some explanation of the potential harms of ingesting live hookworms for therapeutic purposes. It warns against readers \u201ctrying this at home,\u201d especially in the cases of young children and pregnant women. No statement is made about the potential harms of treatments derived from hookworm spit or similar compounds, but at least most readers probably won\u2019t leave this article with the impression that buying hookworms overseas and self-infecting is a great idea.", "answer": 1}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\nSpecialty testing for dry eye is performed at the Dry Eye Relief Clinic at UAB Eye Care, in the School of Optometry.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible harms caused by the drug. But the package insert\u00a0for the drug, also known as Xiidra, notes that they exist: \u201cThe most common side effects of Xiidra include eye irritation, discomfort, or blurred vision when the drops are applied to the eyes, and an unusual taste sensation (dysgeusia).\u201d\u00a0 It appears that some of the side effects are the same as the symptoms that the drug is supposed to\u00a0relieve.\u00a0 \u00a0", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut is it something that we are in position to sort of ramrod down people's throats?\nHe's not only a dad, he's an expert on pediatric infectious diseases at the University of Chicago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any potential harms of the vaccine.", "answer": 0}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nWould the subjects still show the metabolic changes of starvation?\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nBut what if the researchers put people - fat and thin - on weight-reducing diets and gave them enough leptin to make their bodies think that they were still fat.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of any possible \nharms. What, if anything, happened after the study subjects stopped receiving leptin injections?", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nKetamine\u2019s potential for almost immediate if temporary relief is what makes it so exciting, said Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist who has used ketamine to treat depression patients since February.\nThe company filed a new drug application in September.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said ketamine can cause rapid increases in heart rate and blood pressure \u201cthat could be dangerous\u201d as well as hallucinations. It quoted one expert who said the drug \u201ccan be abused, so we have to be very careful about how this is developed.\u201d", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\n\"Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.\"\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\nA team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures - distinguishing cancer from benign conditions, and identifying patients with high-risk disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no great harms associated with taking a blood test, but we do know there are harms associated with screening tests. They can lead to false positives, additional tests and over-treatment of low risk prostate (and other cancers) that might never have caused harm.\u00a0Patients may also suffer psychological effects\u00a0if they are confronted with false positive test results. The side effects of\u00a0treatment for these tumors can be serious \u2014 impotence, incontinence and bowel dysfunction. Though one could argue this new test may decrease those harms, it is unproven at this point.\nWe rate this one Not\u00a0Satisfactory.", "answer": 0}, {"article": "JACC is ranked No.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because the interventions are largely educational and don\u2019t include drugs or therapies, we\u2019ll say that harms are unlikely. But is it theoretically possible that the intervention could have some unforeseen impact on these children that shows up years later? Fear of fat? Anorexia? We won\u2019t penalize the release for not raising the issue,\u00a0but saying something about downstream potential would have added depth and insight.", "answer": 2}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any of the specific harms from the drug.\nThis phase 1 safety trial demonstrated only that the drug is sufficiently safe to take to the next level of trials, not to use in practice.\nThe release mentions that \u201cnone of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\u201d This is a key finding of the study and readers would have benefited from a more thorough explanation of the harms. There were seven patients enrolled without the genetic mutation. Four patients experienced a grade 3 (severe) adverse event. No patients experienced a grade 4 or 5 adverse (life threatening) event. These are important results of the study because they support future testing of the drug in larger pediatric populations.", "answer": 0}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\n\"DaTscan is used in difficult-to-diagnose cases and must be used in conjunction with a clinical evaluation and a patient's response to medications,\" Rezak said.\nSince June, 25 men and women of all ages have been tested with DaTscan at Central DuPage, Rezak said.\nApproval of DaTscan followed two Phase 3 clinical trials in which 284 adult patients with tremors were studied.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention potential harms, including the potential cancer risk from radioactive iodine that is injected into patients as part of the DaTscan. The drug label warns that clinicians must use a blocking agent to prevent the patient\u2019s thyroid from taking up the radioactive iodine.\nThe story should have also reported that although adverse reactions were uncommon in clinical studies, some people did have hypersensitivity reactions such as rash and itching, and that less than 1 percent of patients reported mild to moderate headache, nausea, vertigo, dry mouth or dizziness. The story would have been better if it also noted that since the studies included fewer than 300 patients, side effects that occur only rarely might not have shown up.\nFDA-approved label for DaTscan:\nhttp://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no discussion of potential side effects or harms of this treatment approach, other than the patient\u2019s statement that he has had no side effects. He also called the\u00a0new intervention \u201ca breeze.\u201d\nIn truth, because the drug\u2019s safety is being evaluated\u00a0in this clinical trial, the researchers do not yet know what side effects might occur, a fact the story does not address. Also, there were likely some side effects measured in the animal studies.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release addresses the most common known side effects of the cooling system, which included cold-induced headaches, as well as neck and shoulder discomfort, chills and pain associated with wearing the cooling cap for an extended period of time.\nIt also mentioned another risk: the cold cap could cause chemotherapy drugs to \u201cmiss\u201d an isolated grouping of breast cancer cells in the scalp. However, the release points out that this is \u201cextremely rare.\u201d\nAlthough we would have liked some evidence-backed explanations on the latter harm, we feel the news release does a Satisfactory job here.", "answer": 1}, {"article": "In fact, Papa envisions the development of mobile devices that could diagnose concussions on the spot, much like the devices diabetics use to test their blood with a simple finger prick and a drop of blood.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nCT scans can provide a more definitive profile of the injury, \"however, they are expensive and are associated with radiation exposure,\" said Papa.\nThe biomarker this particular blood test looks for is known as glial fibrillary acidic protein (GFAP).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is silent on the potential harms that could result from an easy-to-use biomarker test, especially one that has a 47% specificity (the ability of the test to correctly identify those without the condition). A test with only 47% specificity means that more than half of positive results will be \u201cfalse positives.\u201d\u00a0The release does not address these \u201cfalse positives\u201d at all \u2014 meaning instances in which the test diagnosed a patient as having brain injury when there was no injury. A false positive could result in additional testing, which may create a financial burden, and \u2014 in the case of a CT scan \u2014 poses health risks of its own. Second, the release refers to the possibility of using the blood test to make brain injury diagnoses \u201con the spot.\u201d Quoting one of the researchers who did the study, the release says: \u201cThe idea is to get a point-of-care test that could be used on the field to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play.\u201d However, the journal article the release is reporting on notes that GFAP is detectable in the bloodstream \u201cwithin one hour of injury.\u201d The release does note that such a tool should only be used to \u201chelp\u201d adults make decisions about a child\u2019s health, but this still raises some significant questions. What if a coach, for example, takes a blood test before the GFAP has had time to become detectable in the blood stream? Would that give the coach a false sense of confidence that the child is fine and can re-enter the game?", "answer": 0}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\nClinical trials will need to be conducted to see if the effect researchers have observed is actually due to the meningococcal B vaccine.\nThere are vaccines for several Neisseria meningitidis strains, but designing a vaccine to protect against the B strain was a particularly difficult nut to crack.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vaccine has potential side effects, and these aren\u2019t mentioned. According to the CDC, more than half of the people who get meningitis B vaccines have mild problems such as headaches or soreness where the shot was given. Fainting, allergic reactions and shoulder pain are less common effects. Also, the vaccine appears to be only moderately effective, meaning people may get infected regardless.\nOverall, not much is known about this vaccine\u2019s safety\u2013whether it\u2019s being used for meningitis or gonorrhea. As Bloomberg News explained, many health experts decry the lack of data on the vaccine. Discussing this issue would have made the story stronger.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\nBut they also thought a drug to treat the disease was in reach.\nThat's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story. We think that it\u2019s especially important to include information about harms when you feature a patient who describes the benefits of the drug by saying\u00a0\u201csomething huge had happened. It was just something I had never felt in my life before.\u201d\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nThere are more than a few caveats when it comes to the treatment regimen.\nOverall, participants experienced fewer side effects during the study than the researchers had anticipated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes harms through the profile of one patient: \u201cEllis experienced stomach cramps and vomiting multiple times during the study,\u201d and once she had an anaphylactic reaction which required medical attention. And this was a successful patient story.\nThe story also reports that 11% of participants dropped out of the study as a result of side effects.\nHowever, it left out important issues such as the higher dropout rate \u2014 around 20%, mainly due to adverse events \u2014 among those who received the treatment, and unknown long-term effects.", "answer": 1}, {"article": ".\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nAlthough the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the possible adverse reactions to medications that lower blood pressure, although these are widely known.\u00a0 Nor does the release mention any adverse reactions among the study participants other than those that were used as endpoints for the study \u2014\u00a0myocardial infarctions, strokes and heart failure, for example.\nThe published research article notes that while treatment carried risk of side effects for both patient groups studied, the differences between the serious side effects (low blood pressure, fainting, acute kidney injury) encountered in each group weren\u2019t significantly significant.\nAnother issue not addressed in the release is that these patients were followed very closely by study staff and were examined initially every 3 months. In clinical practice, patients are often not seen that frequently which means that some patients might not get the level of monitoring needed to prevent or treat emerging complications.\nWe were pleased to see that the release cautioned patients to \u201ctalk to their doctor to determine whether this lower goal is best for their individual care.\u201d", "answer": 0}, {"article": "Xarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nOf those patients, 136 had bleeding in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms either \u2013 just vague \u201cincreased risk of potentially fatal bleeding.\u201d\nHow big a deal is this drug?\u00a0 The story never explains with any meaningful detail.\nThe story cites a talk at a recent conference that followed bleeding in patients in Xarelto or warfarin\u2026but never explained how many had bleeds on which drug \u2013 making the citation almost useless.", "answer": 0}, {"article": "\"They are a gateway out of smoking,\" says Etter.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\n\"The vast number of people using e-cigarettes are using them to stop smoking; [they're] about 60% more effective than going cold turkey or buying nicotine replacement therapy over the counter.\"\nThe number of people using a combination of tobacco and e-cigarettes is on the rise, according to Etter, resulting in smokers switching and consuming less tobacco each day.\nBut others in the field of tobacco control disagree, stating that whilst people -- including youth -- may have tried e-cigarettes, the evidence is lacking for their regular use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "On the harms possible from e-cigarettes, the story was not as thorough as it could have been. For example, there is a growing scientific literature on known harmful molecules in the vapor.\u00a0Nickel, for instance, is in some ENDS vapor and is known to be harmful in other inhaled scenarios. Concerns have also been raised about the quality of different brands of cartridges and the batteries used in some devices, which have in rare cases been reported to catch fire.\nBut we acknowledge that the story took the time to quote different experts by name and let them make their harms arguments, so we\u2019ll award a satisfactory rating. Jean-Francois Etter, professor of Public Health at the University of Geneva, urged people to see the benefit of e-cigarettes in cutting smoking as outweighing their harms. Another expert argues that while they may benefit adults who are trying to quit traditional smoking, \u201c[they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures. \u201d He adds that \u201cExposure to nicotine can harm adolescent brain development.\u201d", "answer": 1}, {"article": "The U.S. Preventive Services Task Force recommendations state that most women begin mammography at age 50.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThe analysis was designed to look at new breast cancer screening guidelines from the American Cancer Society and the American Society of Breast Surgeons.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms (outside of future breast cancer diagnosis) of women receiving a high score on the risk assessment. It is unfortunate because risk does not mean someone will absolutely get breast cancer and some women could receive false positive mammograms with attendant anxiety and risk of unnecessary follow-up tests and procedures.", "answer": 0}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nThese are not all of the potential side effects of phentermine.\nThese are not all of the potential side effects of phentermine.\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release lists nine separate possible side effects of the use of the drug in question and then adds to that the statement that, \u201cThese are not all of the potential side effects of phentermine.\u201d\u00a0 It then offers seven additional paragraphs with cautions, contraindications and warnings pertaining to taking the drug, all under the heading of \u201cImportant Safety Information.\u201d\u00a0 Readers will at least be informed, if not alarmed, after reading.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is a reference to how other ways of detecting Alzheimer\u2019s are \u201cinvasive\u201d but there is nothing in the release about the possible harms associated with this diagnostic tool. A false-positive diagnosis of dementia or Alzheimer\u2019s would be one such harm.", "answer": 0}, {"article": "\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that 4 percent of study participants who received acupuncture actually had twice as many hot flashes (\u201ca 100 percent increase\u201d). That\u2019s good. The release also refers to acupuncture as \u201clow risk.\u201d But that doesn\u2019t mean no risk. According to the Mayo Clinic, acupuncture can cause soreness, minor bleeding or bruising \u2014 and that may be exacerbated for patients who are taking blood thinners. There are also more serious risks involved, particularly if an acupuncture therapist has not been properly trained. Those risks include infection and possible organ damage. Since the release explicitly says \u201cwomen bothered by hot flashes\u2026may want to give acupuncture a try,\u201d it is especially important to be up front about potential risks and the importance of finding a certified acupuncture practitioner (as well as where that certification should come from).", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We always think harms should be addressed \u2013 even the absence of harms.\u00a0 Consumers need to be educated that no product making health claims is cost-free or harm-free.\u00a0 The story did not mention that there did not appear to be any differences among the various groups in terms of harms. \u00a0But since there were no differences, we\u2019ll simply rule this Not Applicable. ", "answer": 2}, {"article": "\"Many of the lifesaving drugs used in the treatment of heart attack patients work by inhibiting platelets and preventing blood clotting.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A source included a risk of blood thinners in general\u2013 that they can cause bleeding\u2013so the story gets a Satisfactory rating. But the story could have clarified that other potential harms are unknown at this point.", "answer": 1}, {"article": "Keep away from children.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nStudy 2 is a prospective, single-arm, multicenter, open-label clinical trial in which participants used TrueTear\u2122 to stimulate tear production for 180 days.\nINDICATION \n\nTrueTear\u2122 provides a temporary increase in tear production during neurostimulation in adult patients.\nThe direct clinical benefit of temporarily increasing tear production as a therapy for patients with dry eye disease was not assessed as part of these clinical trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We will give the release a satisfactory rating because it includes a list of adverse events and warns that there is no long term safety data. But the side effects are described only in percentages and there is no indication of the severity of the events. Other reports about the device indicate that the news release left out information about adverse events seen in other trials, as well as speculation about potential long term effects.\nAn article published in Clinical Ophthalmology, which describes an experiment that appears to be a precursor to \u201cStudy 2\u201d in the news release, describes three device-related adverse events, including one migraine headache in a patient with a history of migraines, along with two cases of nasal discomfort that lasted a day or two.\nAn article written by a doctor who said he tested the device reports that \u201cThe exact mechanism of action of OD-01 is still under investigation, because there is some suggestion that the device may produce long-term effects. One proposed mechanism is that neurostimulation works to kick-start the system through some form of lacrimal gland remodeling.\u201d Well, if use of the device could cause long term effects, including changes to the glands that produce tears, the release should have mentioned that potential.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potentional harms of the vaccine.", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\nSamit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes the head of cancer drug development for Novartis as saying, \u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have liver effects.\u201d\nWhat any of this means is not clear. As much diarrhea as compared to what? Were they expecting CNS or liver effects? Do other PI3K inhibitors have those side effects? None of that is spelled out.\nOnce again, we returned to the ESMO news release and abstract to learn more. This told us the most frequent side effects were hyperglycemia, nausea; decreased appetite and rash.", "answer": 0}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms or comparisons of the harms between three cognitive training activities examined in this study.\u00a0 Perhaps there were none, but the story did not address the issue.\u00a0 The story included the example \"Knowing how to figure out directions and find a new route on a map, for example, could allow someone to retain mobility even after their night vision deteriorates\" though maintenance of this cognitive component might give someone false security about driving under conditions where they are physiologically not up to the tasks.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pushes back against misleading claims of safety and notes that kratom has been linked to at least 44 deaths. It also notes one confirmed instance of fatal kratom overdose, which contradicts one advocate\u2019s statement that \u201cyou can\u2019t take enough to hurt yourself.\u201d", "answer": 1}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall focus of the original research and\u00a0this article was on the potential harms of insulin pump use by adolescents and the need to address safety concerns.\u00a0 Potential causes of adverse events related to patient use and education and device malfunction were appropriately described.\u00a0 This article could have been improved by including the importance of parental oversight in preventing adverse events, particularly since three of the five deaths occurred at times when there was no parental supervision.", "answer": 1}, {"article": "Consider the case of Allie Orlando, a 23-year-old social service coordinator, who has received a plethora of diagnoses since she first saw a psychologist at 14.\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\nThe uncertainty can lead to dangerous misdiagnoses.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no potential harms mentioned, and yet screening carries the potential for harm because of false positive and false negative rates that may lead to the wrong intervention.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the new procedure were mentioned. The lone patient who underwent the procedure called it \u201ca difficult surgery\u201d and anticipated feeling better after recovery but we\u2019re not told if the procedure was successful or how long recovery took.\nAs we\u2019ve written, minimally invasive is still invasive \u201cand thus pose potential harms associated with anesthesia, infection, and bleeding.\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article fails to mention the small but real risks of total knee replacement, which include blood clots in the leg and lungs, joint infections, and (rarely) death. Because of the risks, costs, and inconvenience of knee replacement, many people prefer nonsurgical remedies. While the story entertains the idea of knee replacement in younger people, such procedures are likely to require another operation during a person\u2019s lifetime \u2013 something not mentioned at all.\u00a0 \n", "answer": 0}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly discusses what is, by far, the most common side effect of SDF treatment \u2014 which is that the area of the tooth affected by the cavity becomes darkened after treatment. There are, however, other potential harms. A 2016 paper noted that 3 out of 1,493 patients in studies they reviewed developed \u201ca small, mildly painful white lesion in the mucosa,\u201d which disappeared after 48 hours. However, that\u2019s such a small effect size, that it\u2019s not clear whether the lesions were caused by SDF, so we don\u2019t fault this story for not mentioning it. There can be more significant adverse health effects if SDF is inhaled or swallowed \u2014 including respiratory problems, vomiting and diarrhea. But those effects are only relevant if SDF is not handled properly, so, again, we don\u2019t fault the story for not mentioning it.", "answer": 1}, {"article": "The research was led by Naila Rabbani, reader of experimental systems biology at the University of Warwick, who said: \u201cOur discovery could lead to earlier diagnosis and intervention.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\nResearchers at the University of Warwick said the test, believed to be the first of its kind, could lead to earlier diagnosis of autism spectrum disorders (ASD) in children who could then be given appropriate treatment much earlier in their lives.\nScientists said their research found a link between ASD and damage to proteins in blood plasma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although potential harms from blood or urine tests are quite minimal, the story suggests the research findings could lead to routine screening for autism.\nScreening tests are never completely benign; in particular \u2014 in this case \u2014 if a \u2018false positive\u2019 result led parents to believe their child had ASD when they did not \u2026 or \u2026 if a \u2018false negative\u2019 result offered false assurance that there was no ASD present.", "answer": 0}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\nAll HSRx OTC drug products utilize natural ingredients in their formulations.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned. Most OTC acne medications come with a warning to start slowly with small amounts until you know how your skin will react. Common side effects include dryness, redness, peeling, itching, burning, and rashes.", "answer": 0}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nMothers were first asked about their alcohol use when the kids were 9 months old.\nChildren in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to quantify the harms of drinking too much alcohol. The whole study was about whether alcohol harms kids, and this should have been quantified in some way.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nPatients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\nPatients should not get live vaccines if receiving Ilaris.\nThe U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms warranting a borderline satisfactory rating. But the side effects information is similar to that found on product labeling \u2014 it follows the regulatory requirements concerning product labels \u2014 but provides no data on harms from the trials behind the drug\u2019s approval. It could have been more informative with a few more details.\u00a0 In addition, the information on harms appeared to be contradictory. One paragraph says common responses to the drug were minor reactions and susceptibility to colds; the next paragraph lists serious side effects.", "answer": 1}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThere are currently no proven therapies for these cases.\nNewswise \u2014 Boston, Mass \u2013 Physicians at Massachusetts Eye and Ear have, for the first time, induced a sense of smell in humans by using electrodes in the nose to stimulate nerves in the olfactory bulb, a structure in the brain where smell information from the nose is processed and sent to deeper regions of brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As with cost, it is far too early to create a laundry list of potential side effects associated with nerve stimulation to induce sensations of smell. However, there are things that could be said. For example, the study itself found that volunteers reported discomfort and occasional pain associated with the electrode stimulation. And the potential for inducing olfactory hallucination needs to be considered. \u00a0Dysosmia may be less desirable than anosmia.", "answer": 0}, {"article": "So you do not get the impression that the world is moving or that you are moving, you actually do not feel anything,\u201d Bergquist explained.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms, though the study itself says that the intervention resulted in increased nausea in two patients.", "answer": 0}, {"article": "\"The band has a spotty history,\" Deveney said.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nAnd that it'll take longer to achieve the weight loss, because with gastric bypass most of the weight loss occurs over the first year, while with a band it takes five to six years.\"\nThe procedure \"appears to result in relatively poor long-term outcomes,\" the researchers concluded.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information about the harms observed in the study population who had had gastric banding surgery. It says, \u201cHowever, 39 percent of the patients had experienced serious complications, including abnormal pouch expansion (9), band erosion (23) and band infection (1). Another 22 percent experienced relatively minor complications. Almost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery. The procedure \u201cappears to result in relatively poor long-term outcomes,\u201d the researchers concluded.\u201d", "answer": 1}, {"article": "\"There is a fairly active and vocal group of families in Colorado who are using cannabidiol oils that are made artisanally,\" she said.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nCannabidiol is a major chemical component of marijuana, said Dr. Orrin Devinsky, a neurologist at NYU Langone Medical Center's Comprehensive Epilepsy Center in New York City and co-author of one of the studies.\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The subheadline declares that \u201cdrug interactions remain a concern,\u201d and story includes reference to a study that found cannabidiol to interact \u201cbadly\u201d with anti-seizure medications currently approved for epilepsy treatment. It later specifies the drugs that may be affected. We think this nod in the direction of harms is sufficient for a Satisfactory rating, although we\u2019re concerned that the story mentions no other side effects from the treatment. A news release noted that \u201cAdverse events occurred in more than 10 percent of participants with the most common being somnolence, diarrhea and fatigue and led to discontinuation in 4 percent of patients.\u201d", "answer": 1}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nThose who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\nHowever, the team did observe one appreciable difference: patients on gemcitabine were less likely to experience serious side effects as a result of their chemotherapy treatment than those on the fluorouracil/folinic acid treatment (7.5 percent versus 14 percent).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms and tolerability are discussed, and the rates of serious side effects for each group are provided. Specific examples of those serious effects would\u2019ve been ideal, such as were provided in the JAMA editorial: \u201cmore stomatitis and diarrhea [were] observed in the fluorouracil and leucovorin group and more myelosuppression in the gemcitabine group.\u201d", "answer": 1}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\nShe owns her eggs, no question.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar has a list of bullets of \"things to consider before freezing your eggs\" that is, in essence, a list of potential harms. ", "answer": 1}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\nDr. Anne Moscona of Weill Cornell Medical Center in New York and colleagues tested varying doses of the drug, also known as DAS181, in lab dishes and on cotton rats, a species accepted by scientists for testing parainfluenza.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nThe potential for harm is notably absent in the story. Now, the study design was such that toxicity could not be evaluated and as a  result it was not addressed in the publication. However, the story should\u00a0 have noted that the harms of the drug are unclear at the present time. \n ", "answer": 0}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nMice that got the ZIKV-LAV injected as well saw a significant delay in tumor development.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that the treatment had \u201cno health effects on the mice, no weight loss, and no behavioral abnormalities such as loss of appetite, depression, lethargy, or self-injury. The mice also functioned normally in tests for anxiety and motor function.\u201d\nHowever, we interpret \u201charms\u201d to mean harms to humans. The release doesn\u2019t describe any potential harms to humans.", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\nResearchers studied a treatment group of 23 people aged 19-64 who had Type 1 diabetes for up to 23 years and had no evidence of heart disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any side effects or harms to participants from the use of metformin, although a host of minor-to-moderate side effects\u00a0may be routinely seen with this drug. The research paper itself limits discussion of side effects to \u201cany major or severe episodes of hypoglycemia,\u201d which it defines as instances of low blood sugar \u201crequiring intervention of another person to resolve the event,\u201d or any episode of hypoglycemia \u201cresulting in a loss of consciousness.\u201d\u00a0Although none were reported, both instances seem substantively more serious than minor side effects. Gastrointestinal side effects, for example, are commonly reported by patients taking metformin. And there are some relatively commonly found metabolic adverse effects of metformin (metabolic acidosis) that could have been looked for to determine if there is an increased incidence in this \u2018vulnerable\u2019 group.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Most doctors opt for screening women for cervical cancer more often than guidelines suggest, according to a new study.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\nIn addition, Roland added, some doctors might be afraid of missing very early cervical cancer and getting sued if they screen less frequently.\nBut, he added, \u201ca single negative HPV test is very good at ruling out disease.\u201d\n\nEven when doctors use just a Pap test, Roland said, a woman who has had a few normal tests in a row can go two or three years before her next screening.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job explaining that there can be harm from screening too often \u2013 something that often isn\u2019t explained in screening stories:\n\u201c\u2026any extra screening increases the chance of getting a \u201cfalse positive\u201d result on a test \u2014 meaning the test finds something that doesn\u2019t turn out to be cancer. In that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cSome of it is, don\u2019t go looking before you need to go looking because you\u2019ll find stuff that you\u2019d rather not find,\u201d said (one observer), who was not involved in the new study.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms from a cheek swab are unlikely there is a potential harm in framing the genetic testing results as guiding the choice of one antidepressant over another. Patients may focus solely on pharmaceutical options, to the exclusion of non-pharmaceutical ones.\nAntidepressants have well-documented side effects and drug interactions.", "answer": 0}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nThe Medicare review might be more designed to limit off-label use of the expensive drug, such as for patients who already have symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention harms. The clinical trials reported that patients treated with Provenge experienced infusion reactions and infections. The review for Medicare also noted that the FDA ordered further study of strokes in people who get Provenge.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOf that group, 85 percent had small tumors that had not spread.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nUltimately, 535 were biopsied to see if they were lung cancer -- and 484 were.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that abnormal scans can lead to biopsies\u00a0and that the scans may pick up cancers that \"grow so slowly they will never pose a health problem.\"\u00a0 The story should have also mentioned radiation exposure as a potential harm and described the consequences of false positive test results.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nDupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.\nThe U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gets an acceptable rating in this category since it mentions that the drug can cause serious allergic reactions and eye problems including conjunctivitis (pinkeye) and keratitis (inflammation of the cornea). It also cautions that people with asthma shouldn\u2019t use the drug since it hasn\u2019t been tested for safety in these patients.\nThe release should also have noted that regulators don\u2019t know if there are any long-term harms associated with Dupixent use. None of the trials exceeded 16 weeks.", "answer": 1}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\nTo see if Chantix, which is manufactured by Pfizer, could help smokers quit without going cold turkey, Ebbert and colleagues randomly assigned 1,510 people at 61 centers in 10 countries to receive either the drug or a placebo for 24 weeks.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends several paragraphs discussing potential side effects associated with Chantix \u2014 including the fact that the FDA has placed its black box warning on the drug in light of its possible neuropsychological effects. The story does not mention concerns related to possible cardiovascular health effects that were raised by the FDA in 2012.", "answer": 1}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nWith this new analysis, many prostate cancer specialists, including Dr. Scardino, say their view of the drug has completely changed.\nThe concern was that the drug might be preventing cancers that never spread.\nNow, though, prostate cancer specialists have a new problem: How can they change the drug\u2019s image?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did raise an important question about harms:\u00a0 \"Should healthy men take a drug for the rest of their lives to avoid getting and being treated for a cancer that, most often, would be better off undiscovered and untreated?Is it worth risking a chance that unanticipated side effects may emerge years later if millions of men with no prostate problems take this drug\u2026\"\u00a0 Although the balance of the story was out of whack \u2013 citing more proponents of using the drug than opponents \u2013 we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "\"Our goal is to reach 100 percent.\"\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nThat test, which looks at two different DNA markers (instead of the one marker used by PreGen-Plus), is the one with which Markowitz is more familiar.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a brief pass at discussing harms when it says: \"Compared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often. If results are abnormal, a colonoscopy would still be required.\" But readers should be told how many cancers does the test miss (false negatives)? What is the rate of false positives\u2014and how many people will believe they have colon cancer, when in fact they don\u2019t? How many people will find themselves hospitalized with a serious complication caused by a follow-up confirmatory colonoscopy?\u00a0 ", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nThe chemo failure was the latest in a string of personal setbacks.\nThere are side effects, of course.\nThe pills have kept her cancer from growing.\nThey all found the same thing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article describes only one side effect of vemurafenib, the drug that targets the BRAF mutation in cancer. (\u201cShe\u2019s lost some peripheral vision, though she\u2019s been able to compensate.\u201d) However, the piece does link to the NIH-run MedlinePlus description of the drug, including a full list of side effects and other important information\u2013for a cursory online story, this is helpful and very responsible.", "answer": 1}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\nZiman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\n(CNN) Australian researchers have developed an experimental blood test they say is the first blood test capable of detecting melanoma -- an aggressive form of skin cancer -- in its early stages with a high degree of accuracy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like many other stories about screening tests, the reader is not provided with any comments on the potential harms. Even with a 90% sensitivity and specificity (a high mark for such a test), there would be many\u00a0people with both false positive and false negative results. Read more about this issue in our primer:\u00a0Understanding medical tests: sensitivity, specificity, and positive predictive value\nThese cancers are frequently overdiagnosed, so a diagnostic test that finds a lot of low-risk cancers could be harmful by leading to overtreatment. Ideally, we want know that the test is leading to finding early-stage, high-risk cancers that require and would benefit from treatment.", "answer": 0}, {"article": "Suboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nIt's an orange pill that's dissolved under the tongue.\nexplained Dr. Marc Gourevitch.\n\"None,\" he said.\nFor Brian, life now involves not only counseling and but a personal inventory as well.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The drug has considerable safety issues, yet the story didn\u2019t discuss any of them. ", "answer": 0}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nOthers have such high cholesterol that taking statins alone is not enough.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Every class of drugs has side effects, and there has been substantial concern about the possibility of neurocognitive side effects with this class of drugs. The fact that these drugs have to be injected under the skin could also potentially affect use and adherence to a medication regimen. We understand that this story is fewer than 300 words long, but there could have been a statement such as, \u201cMore study is needed to assess the potential side effects of this new class of drugs.\u201d", "answer": 0}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\nWhy endovascular treatment wasn\u2019t better is a mystery that the researchers are struggling to explain.\nWe wanted the superiority of endovascular treatment.\u201d\n\nWhether the findings will cause physicians to abandon the practice is uncertain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harm was this:\n\u201cmany practitioners think that newer clot-retrieving devices work better than the ones used in the three trials. Because endovascular procedures were shown to be no more dangerous than IV thrombolytics, physicians may continue to perform them and assume the outcomes can only get better.\u201d\nSince no benefit was seen with the invasive clot retrieving devices, we would have liked to have seen some additional information on the adverse events directly related to the placement of the device.", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Something missing from the studies mentioned were any sort of placebo controls or comparisons to alternative screening techniques. Too much screening can lead to unnecessary surgeries that have their own risks. The story does say, \"the additional polyps found may result in more biopsies, raising costs.\" But it should have also talked about the potential downsides of screening and any potentail side effects from undergoing this procedure.", "answer": 0}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Sonata is in the midst of an ongoing phase\u00a0II\u00a0clinical trial, designed to assess both effectiveness and safety of the procedure. But the story still makes a good effort to address risks and related concerns. For example, the story states that \u201csuch minimally invasive procedures require a lot of skill to perform safely\u201d and quotes an expert as saying \u201cYou need a really experienced surgeon\u2026.Will it translate to the average ob/gyn?\u201d In addition, the story notes that, while uterine fibroids are rarely malignant, in a small number of cases they can be cancerous \u2014 and \u201cbecause tissue is not removed with the Sonata method, it cannot be biopsied.\u201d\nWith a little more digging, the reporter might have found the Gynecological Surgery paper mentioned above. In that trial of 50 patients, there were 34 \u201cadverse events.\u201d Most were not severe, but incorporating some of that information would have made the story even stronger.", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nBut drinking tequila won't help, the study authors noted.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a word about potential harms.\u00a0 ", "answer": 0}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\nWomen tend to have smaller hearts than men and Moss said the treatment works better in smaller hearts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the use of the device.", "answer": 0}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nThat is, long-term users have a risk of about a tenth of 1 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NPR does a good job of parsing the harm described in the JAMA article. Extra credit for including the notion of a \u201cdrug holiday\u201d that is a practical reaction from treating physicians to a confusing landscape of discoveries about these drugs.", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cEbselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does,\u201d said Grant Churchill of the department of pharmacology at Britain\u2019s Oxford University.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the side effects from lithium, saying, for example, \u201cBut it is very toxic \u2013 at only twice the right dose it could kill a patient, Churchill said \u2013 and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\u201d We\u2019d rather have hard data \u2013 e.g., if 100 or 1,000 people with bipolar disorder took lithium for five years, how many would be expected to die from lithium toxicity?\u201d\nWe would have liked to have seen some side effect information for ebselen. Instead, the story states that the drug \u201cmay be a swift answer\u2026since it is already known to be safe.\u201d Data, please?", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\nBut one-quarter of those given CT scans were found to have anomalies, nearly all of which were benign.\nHad the screening continued for 10 years, as many as 80 percent of lung cancer deaths could have been averted, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe final paragraph of the story points out that there is a risk of harms from the radiation used for the CT scans and that the scans cause false positives and may lead to tests and treatments done on people who actually don\u2019t have dangerous tumors. We wish some attempt had been made to quantify these harms \u2013 even if it meant drawing from past research \u2013 but we\u2019ll give the story the benefit of the doubt.\n", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nBased on these findings, Hennekens and colleagues are drafting an investigator initiated research grant proposal to the National Institutes of Health (NIH) under the direction of co-author Patrick E. McBride, M.D., M.P.H., professor of medicine and interim associate dean for faculty affairs at the University of Wisconsin School of Medicine and Public Health.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. While regular toothpastes come with a standard warning to keep away from young children and to avoid ingesting, we aren\u2019t told if the disclosing agents used in Plaque HD\u2019s \u201cTargetol technology\u201d pose any additional harms for people with sensitivity or mouth problems. It would be good to be told either way.", "answer": 0}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\nThey see the potential of these games to not only make money \u2014 but to save money, too.\nBut, Ehlers still thinks game designers should go through the same FDA tests and trials as drug manufacturers.\nRight now, screening for Alzheimer's is subjective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. There is strong debate about whether recreational video games affect social development or behavior. Such games certainly can displace physical activity\u2026 playing outdoors\u2026 that is important to the health of children in particular. The story would have been better if it at least mentioned that video games may not be entirely benign.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nMore than a decade of research on NR metabolic pathways and health effects in mice and rats had convinced him that NR supplementation had real promise to improve human health and wellness.\nThe experiments also revealed more detail about NAD+ metabolic pathways.\nThe trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are addressed. The news release said there were \u201cno serious side effects with any of the doses,\u201d though there were four cases of potential flushing we address under quality of evidence. But it should have pointed out that no safety data exists on long-term use. Nor is there data on the impact of taking this supplement along with other medications or in greater amounts than the tested doses. Also, the people in this study were all healthy, so it\u2019s unclear what impact this substance might have on people with health conditions. That\u2019s an important point since the researchers plan to study NR\u2019s effects on elevated cholesterol, obesity and diabetes as well as people at risk for chemotherapeutic peripheral neuropathy.\u00a0 Also, just because something occurs naturally in the human body doesn\u2019t mean it\u2019s safe.", "answer": 0}, {"article": "The results were published in the New England Journal of Medicine.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nIn a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cThe combination of the two drugs also led to far higher levels of side effects, such as colitis and inflammation of lung tissue, at 54 percent versus 24 percent for Yervoy alone. Patients were also more likely to stop taking the combination of drugs.\u201d\u00a0 That is useful information but a bit incomplete.\u00a0 The numbers reflect the percentage of patients who suffered grade 3 and 4 side effects and not just colitis and lung inflammation. \u00a0But the story missed the most significant potential harm of all: death. As the paper itself notes, out of fewer than 100 patients who received the drug combination, \u201cThree deaths were related to the combination therapy according to investigator assessment.\u201d That\u2019s worth mentioning.", "answer": 0}, {"article": "Dr. John Richmond disagrees.\nHowever, Richmond says patients considering viscosupplementation should discuss this as a treatment option with their doctor.\nDr. Richmond, who has independently reviewed the same research when the AAOS was drafting their recommendations to treat osteoarthritis of the knee, argues that despite infrequent instances of those side-effects, viscosupplementation remains a solid treatment choice for some patients.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\nIn a meta-analysis of 177 reports that included data on more than 12,000 patients with osteoarthritis in the knee, researchers at the Institute of Social and Preventive Medicine at the University of Bern in Switzerland concluded that the treatment \"has minimal benefits and potential for harm.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, the story states that the meta-analysis found \u201cpotential for harm.\u201d\u00a0 Further, it reported:\nThe most common side effects patients undergoing\u00a0viscosupplementation\u00a0may endure are flare-ups \u2013\u00a0 where the knee becomes hot and swollen within 24 hours after the injection \u2013 and effusions, where excessive joint fluid collects inside the knee.\u00a0 The researchers in\u00a0Switzerland reviewed the existing studies and\u00a0concluded\u00a0that\u00a0viscosupplementation was associated with an increase in these and other adverse events.\nBut there was no description of how often this was seen \u2013 making the issue almost useless to readers. Is it 1 in 100 patients?\u00a0 10 in 100?\u00a0 50 in 100?", "answer": 0}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\nRegulators in the U.S. and Europe were highly skeptical of the safety and efficacy of such treatments.\nAt the time, only one gene therapy had been commercially approved in the world: a cancer drug in China.\nThe drug is the fruit of Gao\u2019s 23-year career in gene therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one is difficult to evaluate, since most of the current research relates only to animal studies. However, early in the story, the writer reflects on the well-publicized death of a clinical trial participant in 1999 that brought gene therapy trials to an abrupt halt in the United States.\u00a0 Other passages in the story also suggest caution,\u00a0as does a source later in the story, who notes that risk accompanies many therapies. These details are sufficient to indicate there could be significant harms if these methods move into human testing, and that\u2019s enough to rate as Satisfactory. However, it could have been made clearer that researchers\u00a0really don\u2019t know the harms yet.", "answer": 1}, {"article": ".\nRaybuck, who learned to perform the procedure in Quebec 12 years ago, estimates he uses it fewer than two dozen times annually, and only when circumstances require it.\nSome senior interventional cardiologists say they worry that the method may be hyped.\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that arterial spasms tops the list of complications with this procedure and indicated that it was particularly problematic in \"little old ladies.\"\u00a0 Beyond this, the story did not give the reader any idea of how common this sort of problem was, making it difficult for readers to evaluate.", "answer": 0}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nCollaborators on the study included first author Dr. Erin Howden, Research Fellow with UT Southwestern's Graduate School of Biomedical Sciences and the IEEM and now a faculty member at the Baker Heart and Diabetes Institute in Melbourne, Australia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does an excellent job of outlining the exercise regime employed in the study. However, it does not mention that the study specifically recruited subjects between the ages of 45 \u2013 64 who were sedentary. Given that one of the exercise sessions recommended in the study focuses on high-intensity interval training (HIIT) \u2014 and such training does come with potential risks for deconditioned individuals \u2014 it might have been advisable to mention that supervision for HIIT training should be strongly considered.", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nJolly said the lesson from his team's trial is that clot removal should be used only as a rescue treatment when an angioplasty fails to clear an artery.\nIn the 30 days after the procedure, 0.7 percent of the patients who had clots removed suffered a stroke, as did 0.3 percent of those who only had angioplasty, Jolly's team found.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly states that there is no apparent benefit for clot removal and that there is some increased occurrence of strokes with the procedure. The absolute percentage of subjects who had a stroke in each group is also provided, so readers get a very clear picture of how often this occurs and the difference between the groups.", "answer": 1}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 There wasn\u2019t any discussion of potential harms and we can\u2019t think of any \u2013 besides the obvious one of unnecessary glaucoma screening in some cases.", "answer": 2}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n\u201cDoctors could use this modified form of vancomycin without fear of resistance emerging,\u201d said Boger, whose team announced the finding today in the journal Proceedings of the National Academy of Sciences.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the modified vancomycin hasn\u2019t been tested in human trials. As such, it\u2019s not clear what the potential harms may be. The release doesn\u2019t mention this. And there will almost certainly be potential harms, given that conventional vancomycin has a range of potential side effects, from nausea and diarrhea to kidney damage. Could risk of these potential harms decrease if the modified vancomycin can be used in smaller doses to address bacterial infection? If so, that\u2019s something the release could have addressed.\nWe also understand that some side effects would we a trade-off people might be willing to accept if it turns out the drug could prevent death or painful treatments that can come with an overwhelming bacterial infection. ", "answer": 0}, {"article": "About the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): NICHD conducts and supports research in the United States and throughout the world on fetal, infant and child development; maternal, child and family health; reproductive biology and population issues; and medical rehabilitation.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The blood test itself is virtually harmless, and overall fairly reliable, but results can be skewed by a variety of unrelated diseases and lifestyle factors, resulting in false positives and negatives.", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the main side effect of BMS-790052 in early testing was headache. But considering that this was a phase 1 study designed primarily to collect information about drug safety, we think it\u2019s unfortunate that the story chose to emphasize a secondary test result \u2013reduction in viral load \u2014 and downplay potential safety issues.\u00a0\nThere is also no discussion of the potential harms associated with the\u00a0other experimental drugs that the story suggested would help treat\u00a0hepatitis C. If a story is going to pass long claims that unapproved drugs are\u00a0going to cure hepatitis\u00a0C, we feel it also needs to\u00a0provide\u00a0the full picture of the harms these treatments may entail. \u00a0", "answer": 0}, {"article": ".\nThe experience supports a growing body of research showing good outcomes with surgery for chronic temporal headaches.\nUsing an incision originally designed for another purpose, surgeons can gain direct access to the nerves involved in some types of chronic temporal headache, according to the report by ASPS Member Surgeon Dr. Ziv M. Peled of Peled Plastic Surgery, San Francisco.\nDr. Peled found that this short incision, placed in the temple behind the hairline, provides direct access to the ZTBTN and ATN.\nAs in previous studies, surgery provided significant relief from chronic temporal headaches.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated that \u201cNone of the patients experienced complications, and there was little or no visible scarring.\u201d\u00a0But the published study noted that neurapraxia (a temporary loss of nerve function) lasting several weeks was a risk. Although none of the 19 patients experienced complications, it would have nevertheless been helpful to describe possible risks in the news release. \nMost interventions carry risks, and the Gillies incision used in this procedure is no exception. Complications from the procedure could result in injuries to the wall of the eye and cosmetic deformities, as well as limitations in jaw movement.", "answer": 0}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As is so often the case with news releases about cancer screening tests, what usually gets highlighted is the sensitivity; in this case, that early stage cancers resulted in a positive test 90% of the time.\nBut what\u2019s not highlighted \u2014 and can cause significant emotional harm \u2014 is that 10% of the time\u00a0the test will be negative in someone who has cancer. That \u201cfalse-negative\u201d result provides false reassurance that there\u2019s no cancer present. In addition, there may be a small number of\u00a0\u201cfalse-positive\u201d tests leading to inappropriate procedures. Readers need to know how often false positive results occur with the test, and that\u2019s something a small study such as this can\u2019t confidently address.", "answer": 0}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nA mere sip would leave her vomiting and gasping for breath.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that 4 individuals in a study of 33 had to withdraw from the study due to allergic reaction.\u00a0 \nThere was also a strong word of caution to readers NOT to try desensitization on their own. \u00a0 ", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not told about any of the risks of epidurals.Those risks include a drop in blood pressure (which can complicate an otherwise normal pregnancy), severe headache (in less than 1% of women), slowing of labor due to lying on one side for too long (unless a \u201cwalking\u201d epidural is used, though the procedure is rare), shivering, backache, ringing of the ears, nausea, trouble urinating, and the increased likelihood of interventions like forceps and cesarean section (since it can be harder to push). Epidurals also require a catheter to drain urine, which significantly increase the risk of urinary tract infections.", "answer": 0}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\nSpellberg also said people who used the drug this way would be exposing the bacteria they have in their gastro-intestinal tracts \u2014 their own gut flora \u2014 to regular doses of doxycycline.\nThe men were tested regularly for STIs, and in the nine or so months they were followed, the rates of some sexually transmitted infections fell dramatically in the treatment group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The body of the story spells out many of the potential harms, but the story would have been stronger if warnings had been included in the headline and lead paragraphs. The headline refers to \u201craising tough new questions\u201d and the second sentence in the story says the strategy \u201ccould spark a controversy.\u201d The potential harms would have been clearer to readers if the headline and lead had bluntly stated that routine use of doxycycline could undermine the effectiveness of antibiotics for a range of infections, not just the sexually transmitted diseases these researchers looked at.", "answer": 1}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that probiotics are generally considered safe except for individuals with a compromised immune system. That\u2019s accurate.", "answer": 1}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nThe stem cell procedure is in the earliest stages of development, said Celiz.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential for risks when using stem cells to grow dental tissue.\u00a0As with many reports on new research, this story suffers from its optimism. \u00a0The new material has been tested in cell cultures and has yet to even make it to an animal model, so predicting harms is difficult but it is easy to come up with some concerns: Will this material be as durable as existing fillers? Has the material been tested for long-term safety? If the material fails, how will that impact a subsequent root canal? \u00a0Clearly these questions cannot be answered but\u00a0we think that any good story should point out the unknowns and not just the potential positives.", "answer": 0}, {"article": "At the end of the study, the group of volunteers who had used the dapivirine ring had 27% fewer HIV infections than a control group who had a placebo ring with no drug, the study found.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\nThese age differences are probably due in part to how the women used the drug, the researchers say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would have liked to see some mention of whether there might be any harms associated with this. It is possible that long-term use might pose risks that don\u2019t show up in shorter studies. The story does not even say, \u201cWe don\u2019t know of any harms.\u201d", "answer": 0}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\n\"These are the only treatments approved by the [U.S. Food and Drug Administration],\" he added.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists adverse effects commonly seen with both classes of medication discussed in the story. It adds, \u201cUp to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit.\u201d", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nResearchers found that the treatment -- dubbed IdeS -- quickly wiped out the dangerous antibodies, allowing all but one of 25 patients to have a successful transplant.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nThose patients face a tough situation: They harbor immune system antibodies that are primed to attack a donor organ.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article makes clear the patients were \u201csuccessfully treated\u201d if sensitizing antibodies returned, it does not give any information about side effects, from the enzyme infusion nor the anti-rejection drugs subsequently used.", "answer": 0}, {"article": "The Centers for Disease Control and Prevention recognizes many diabetes prevention lifestyle change programs, delivered both in-person and online, including Vida, which bills itself as a \"health transformation team\" that is data and tech-driven.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nNot every Omada Health participant makes the progress they're aiming for.\nThere is some evidence that these kinds of programs are working.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not consider potential harms of the program, but because they do seem relatively minor, we\u2019ll rate this N/A.\nThings we did ponder related to risks of using the app: The study results implied that 25% of participants dropped out, but readers are not told why. Was following the program too difficult or not specific enough? Will this be simply one way for people trying to lose weight to fail and give up on improving their health? Do people get any portion of their money back if things don\u2019t work out?", "answer": 2}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nBut for many women, being told they need a C-section is unpleasant news.\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\nSometimes the situation is truly life-threatening.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did not address specific harms per se, it did mention that there was a lack of clinical studies on this topic \u2013 implying that nobody really understands the potential risks of this approach compared to a typical C-section. The piece also pointed out that infection control is a potential concern with family-centered C-sections, and that hospitals would be slow to change their routines without hard evidence on infection rates. We think that\u2019s enough to merit a satisfactory rating here.", "answer": 1}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\nMARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no explanations of potential harms of integrating 3D mammography\u00a0into current breast cancer detection or that this technology does not appear to benefit women with extremely dense breasts. It is unclear if this technology could result in false positives (over-diagnosis) or what the negative predictive value of the test is (the probability that subjects with a negative screening test don\u2019t actually have the disease).\nIf these tests lead to over-diagnosis then women face the harms (and costs) of unnecessary treatment.", "answer": 0}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\nThat means that patients are tried on a succession of different drugs for 12 weeks or more and experience prolonged periods of ineffective treatment because their medication does not benefit them.\nCurrently it is impossible to establish who should or should not be given antidepressants, or combinations of them.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions no potential harms. However, as with all screening tests, false-positive and false-negative results can be harmful in a number of ways.", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nThe study's findings have been met with cautious optimism by dementia organizations.\n\"What we do know is that the blood supply in the brain is incredibly important, and that maintaining a healthy heart and blood pressure is associated with a lower risk of developing dementia,\" said Carol Routledge, Director of Research at Alzheimer's Research UK, who was not involved in the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest risk with a screening test like this is incorrect results\u2013false positives and false negatives, which the story never explains. There is significant harm that can result if a person thinks they are at high risk of dementia when they aren\u2019t, or thinks they\u2019re at low-risk when they\u2019re high risk. These are otherwise known as a test\u2019s\u00a0sensitivity and specificity and they should have been discussed, especially how these unknowns will guide next steps for future research.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\nBut, berries are protective in both men and women,\" said the study's lead author, Dr. Xiang Gao, a research scientist at the Harvard School of Public Health and an associate epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston.\nBut, when the researchers looked at the dietary compounds individually, it was clear that berries could benefit both men and women, lowering the risk of Parkinson's disease by about 25 percent for those who had at least two servings of berries a week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends most of its time discussing the potential health benefits of berries. We\u2019re not aware of any harm attributable to berry consumption (provided they are the edible kind).\nAnd the story included this quote from the author:\n\u201cThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\u201d Gao added.", "answer": 1}, {"article": "St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.\nShe said that the findings could have important applications for prevention, prognosis and treatment.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nThey found that AIM2 deficiency causes uncontrolled proliferation of intestinal cells.\nHowever, AIM2's established function in the cell was not in the machinery of cancer, said one of the paper's first authors Si Ming Man, Ph.D., a postdoctoral fellow in Kanneganti's laboratory.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This work is so far removed from clinical use in human subjects that it may be difficult to adequately assess potential risks for human patients. However, as noted above, the release does mention interferon treatment and transferring \u201cgood\u201d bacteria populations into human patients. Every treatment carries some risks, and those are worth discussing.\nThe human digestive system is awash in colonies of different bacteria, all striving to maintain dominance in their environment.\u00a0 An imbalance between these different strains can cause a host of intestinal problems ranging from simple discomfort to life-threatening conditions.\u00a0 The release\u2019s cavalier mention of possibly transferring \u201cgood bacteria\u201d does readers an injustice by ignoring risks.\u00a0 While fecal transplants have shown some success in early research, they do carry substantial risks, and while some colon cancer patients may be willing to accept that risk, the release should at least mention that it exists.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned for either of the newer brand-name approaches mentioned \u2013 the drug Solesta or the device InterStim.\nThe Solesta website states:\nThe most common risks of treatment with SOLESTA are mild pain or discomfort in the rectum or anus, (experienced by about 27 out of 100 patients) and minor bleeding or spotting from the rectum following treatment (experienced by about 16 out of 100 patients). Some patients experienced a fever (7 out of 100), abdominal pain (3 out of 100), or diarrhea or constipation (6 out of 100) after treatment.\nMore serious risks including infection and inflammation of the tissues in the anus may occur, but these are not common. In clinical studies, about 4 of 100 subjects experienced infection and 3 of 100 subjects experienced inflammation.\nMedtronic\u2019s InterStim website states:\nThe InterStim Therapy system has risks similar to any surgical procedure, including swelling, bruising, and bleeding. Complications can include pain at the implant site, new pain, infection, lead (thin wire) movement, technical or device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation. Any of these situations may require additional surgery or cause your symptoms to return.", "answer": 0}, {"article": "But the F.D.A.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nSo injecting it is an off-label use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t get specific as to how often harms should be expected with the various treatments discussed, but\u00a0it does mention some of the more common problems that can occur, including recurrence of the varicose vein or\u00a0the creation of new\u00a0varicose veins in the same area. Still, the story goes to significant\u00a0lengths to make readers think this is a benign procedure (including\u00a0a quote about one patient\u00a0feeling a \"a little tiny pinch\"), when long-term consequences of superficial vein ablation on risks of deep vein issues such as clots are unknown.\u00a0\u00a0Overall, because the story didn\u2019t give any sense of the scope of the problems \u2013 how often someone considering the various approaches may experience harms if they do \u2013 we must rule this unsatisfactory. ", "answer": 0}, {"article": "\"We have found the same thing with all of our trials.\"\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nAll the participants reported eating about 2,000 calories a day when the study began.\nBut as researchers noted, if participants ate as little as they said, all the groups would have lost much more weight.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a concern with the Atkins diet that it would result in increased LDL cholesterol but that the study did not find this to be the case.\nThe article on which the story was based reported on the reasons people did not complete the study; there were no serious medical harms found.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nDo melatonin supplements really help people sleep?\nBut the scientific evidence has been slim.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from the use of melatonin were mentioned. (It may be problematic for those taking warfarin or individuals with epilepsy.)", "answer": 0}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention studied here involves a last-ditch emergency effort to revive a person who is dying. There are some potential harms if the resuscitated person survives, and the story didn\u2019t mention those, but given the measured approach of this story and the nature of the research, we feel this one is N/A.", "answer": 2}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nHuman trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes a researcher saying it\u2019s \u201cmisinformation\u201d to tell smokers that vaping is dangerous. That\u2019s just not true. E-cigarettes contain nicotine, which can harm fetuses and adversely affect brain development. They also contain a host of other chemicals, including some potential carcinogens and lung irritants, which have not been adequately studied. The relative amount of harm from vaping versus smoking remains uncertain.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the only significant adverse event for those on estriol was irregular menses. It could have gone into more detail, perhaps, but this passes muster. The point is that estriol is essentially a weak form of estrogen that has been shown in previous studies to be fairly safe, and whatever risks exist are likely outweighed by benefits in women with MS.", "answer": 1}, {"article": "MDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe use of MDMA in psychotherapy has been studied for decades, but research in the U.S. all but ground to a halt after the drug became illegal.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It does not quantify the potential harms. It does, at least, mention a few of the dangerous effects of the drug. \"Don\u2019t try this experiment at home. Ecstasy use can cause depression, severe anxiety, and potential cognitive problems, according to the National Institute on Drug Abuse. And when purchased on the street it can be contaminated.\" The possibility of an overdose would have been a nice mention.", "answer": 0}, {"article": "The skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nBecause the surgery is still relatively new, there are few studies of complication rates.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nSeven weeks after surgery, Baez concluded the pain and effort had been worth the result: an end to the recurrent skin infections in her thighs and abdominal folds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article details what are described as \u201chuge scars\u201d after surgery, along with \u201ca long and painful recovery\u201d. Contouring is described as \u201criskier\u201d and \u201crequiring longer recovery time\u201d than bariatric surgery, though again \u2013 there was no quantification provided. The artilce mentions that some patients will have revision done to improve upon the original contouring procedures. Again, no data were given on how common this really is, other than to say that it, in the view of one plastic surgeon, it has \u201cdramatically increased\u201d.", "answer": 0}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\nBut one of the biggest obstacles in understanding CTE has been the inability to diagnose it in the living.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"The findings of this study are the early steps toward identifying CTE during life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a story is going to speculate about the potential clinical benefits of a new research finding (and this one does), the story should also discuss the harms. It\u2019s worth pointing out, for example, that any test such as\u00a0this would produce false-positive and false-negative results. Such results could cause unnecessary concern and anxiety and perhaps the loss of a lucrative career \u2014 or false reassurance that nothing is wrong when a degenerative process is underway.", "answer": 0}, {"article": "The findings are published in TheJournal of the American Medical Association.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wasn\u2019t thorough enough in its exploration of potential harms. The only adverse effect noted is the potential loss of libido discussed in the last line of the story. At one point, the story seems to dismiss the\u00a0potential for harm by noting that\u00a0 \u201cno serious adverse events were reported\u201d in the study.\u00a0However, minor adverse effects take on greater importance when a drug provides only a modest benefit over placebo \u2014 which is the case with this medication.\u00a0The study should have provided more detail on what harms were observed (even \u201cminor\u201d ones), and how frequently. Lexapro, when used for depression, commonly results in gastrointestinal disturbance such as nausea, vomiting, loose stools, and indigestion. A variety of\u00a0other adverse effects are possible, including include difficulty sleeping and headaches. It is quite conceivable that an increase in these\u00a0problems might outweigh the small benefit associated with the reduction in hot flashes, so the story\u00a0should have provided this information.\nAnother issue not addressed by the story is the potential for uncomfortable withdrawal symptoms when stopping this medication. This point is particularly relevant to make here because Lexapro hasn\u2019t been extensively studied in women who are healthy and don\u2019t have symptoms of depression. We know that some people with depression experience withdrawal symptoms after they stop taking the drug, but we don\u2019t\u00a0have much evidence on what happens to healthy non-depressed people when they stop taking it.\u00a0The risk of a discontinuation syndrome increases the longer\u00a0antidepressant therapy lasts, so an 8-week study may not capture the problems that women\u00a0may experience with longer-term use of Lexapro for relief of hot flash symptoms. The story could have mentioned that\u00a0women should never abruptly stop taking an antidepressant\u00a0medication like Lexapro, as this can increase the risk of\u00a0more severe withdrawal symptoms.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of \u201charm\u201d does not appear to be relevant here. Individuals may find text messages to be annoying, of course, but the study itself notes that participants \u201coverwhelmingly\u201d reacted positively to the intervention. That doesn\u2019t make it into the story.", "answer": 2}, {"article": "It is known as BMS-790052.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says study participants who took the drug exhibited \"few side effects.\" But what were those side effects and how serious were they?\u00a0The story doesn\u2019t say. While the implication here is that the drug seems to be safe \u2014 a conclusion that we can\u2019t really draw based on a small, early phase test \u2014 the story does include a\u00a0cautionary quote from an expert about the need for additional testing to demonstrate safety.\u00a0It also noted that patients taking this drug might still need to be treated with interferon, which many individuals can\u2019t tolerate because of side effects. A close one, but we\u2019ll call it satisfactory.\u00a0\u00a0", "answer": 1}, {"article": "For more details and to read the full study, please visit the For The Media website.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nSeveral measures of quality of life also improved compared with those in the sham laser group, including general vision and independence.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in the release. Laser treatment can produce such irritants as \u201cdry eye\u201d and temporary visual halos, and a small number of patients have experienced increased eye pressure and the development of cataracts. These harms are apparently rare, but they deserve attention. The published study noted that there were few adverse effects and they were minor, but that the small sample size and length of follow-up were not adequate to make any firm statement about harms.", "answer": 0}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have mentioned some of the potential harms of screening, ranging from anxiety over a worrisome result to bleeding, colon perforation, sedation-related events and other problems. Also, since the story specifically included comments lauding colonoscopy, it should have also mentioned that colonoscopy accounts for most of the serious harms caused by colon cancer screening.", "answer": 0}, {"article": "For most people, \"the lower your blood pressure, the better you are.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nShe stressed that the study results should not be viewed as license to gorge on chocolate.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit, this piece did allude to weight gain as a potential problem with advocating consumption of chocolate.\u00a0 It could have mentioned that with the portion of dark chocolate used in the study, no weight gain was seen during the 18 weeks of study.", "answer": 1}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any potential risks. Light therapy is generally safe, according to the Mayo Clinic, but mild side effects could include eyestrain, headaches, nausea, irritability, and agitation. Light therapy poses special risks for people with certain medical conditions or on medications such as antibiotics that can cause skin or eyes to be sensitive to light, and it can trigger mania in people with bipolar disorder.", "answer": 0}, {"article": ".\nLuzi said scientists now know that an impaired gut microbiota can alter the brain's signals for appetite and satiety, or fullness.\nHe and his co-workers studied whether dTMS could improve the gut microbiota composition in obese persons and, if so, by what underlying mechanisms.\nPituitary hormones play a key role in regulating appetite, and recent research shows that norepinephrine and other neurotransmitters affect microbiota composition, Luzi said.\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Specific risks are not discussed, though it\u2019s mentioned that dTMS is currently approved in the U.S. for treating major depression and is being studied in other countries for treating neuropsychiatric disorders. Unlike deep brain stimulation, this technique does not require an operation or implantation of electrodes, so we can deduce that the potential harms are lower than other neurostimulation procedures. Nevertheless, a brief\u00a0mention of harms would give readers a sense of the risk-benefit balance should dTMS rise in popularity and availability in the coming years.", "answer": 0}, {"article": "Being around for my daughter, my son, my wife.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give this story a barely satisfactory rating because it does report that there were treatment-related deaths and side effects\u00a0including \u201cflu-like symptoms and confusion.\u201d But no other numbers or side effects are mentioned\u2013though there were many more\u2013and the story doesn\u2019t elaborate that CAR-T therapy can be fraught with unpredictable\u00a0problems.\u00a0Interviewing a patient who experienced these problems would have made the story more reflective of the true experience of receiving CAR-T.", "answer": 1}, {"article": "Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\nThe ongoing refinement of the technology makes treatment more precise and extremely reliable.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most we get is that patients felt \u201cminimal discomfort.\u201d But could ICE3 leave cancerous tissue behind without a clinician knowing? And are there any other side effects? We aren\u2019t told, and this seems strange given that the \u201ccosmetic\u201d benefits are so well-known and touted so frequently in the text. The National Cancer Institute does describe a few potential harms of cryoablation (which they classify as a type of cryosurgery), including hemorrhaging and bad interactions with chemotherapy. These probably should be mentioned in the release.", "answer": 0}, {"article": "Use our submission form, or ask @juliaoftoronto on Twitter.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\nBeyond public health measures (making sure you have good hand hygiene and avoiding the office when you're sick), the flu shot is the best medical intervention we have for preventing infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the risks of negative reactions to getting a flu shot usually center on inflammation at the site of the injection, a comparatively minor side effect.\u00a0 It emphasizes that given such a minimal risk, there are very few harms for getting this protection, minimal though it may be in some years.", "answer": 1}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release falls short in its description of harms of the recommended treatment. Sucking on zinc lozenges can have a number of minor but unpleasant side effects, like\u00a0leaving a metallic\u00a0taste in your mouth, and, less commonly, vomiting, stomach cramps, and diarrhea. The article warns that certain other ingredients in lozenges can cause zinc not to be absorbed. However,\u00a0it would have been better to spell out that zinc can interfere with the absorption of some classes of antibiotics, making those medications less effective as well.", "answer": 0}, {"article": "[Who should take statins?\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nThe recommendations also support the position of the American College of Cardiology and the American Heart Association, which in 2013 radically shifted their advice from suggesting that doctors focus on the level of a patient\u2019s low-density lipoproteins (LDL) or \u201cbad cholesterol\u201d to looking at a more comprehensive picture of risk based on things such as weight and blood pressure, as well as lifestyle factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentions\u00a0\u201cmuscle pain and\u00a0cataracts [and] an increased risk for diabetes in women.\u201d This is sufficient, but the story would have been stronger if it had discussed frequency of these side effects, and mentioned the more serious (and thankfully more rare) risks of rhabdomyolysis and muscle breakdown.", "answer": 1}, {"article": "RELATED: What we know about how cancer starts could all be wrong\n\nIn January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease.\nBut Landon appeared to be among a small percentage of children with leukemia for whom the treatment was unbearable, excruciating.\nBut to do that, the family would need to leave Utah, where all cannabis is illegal.\nFor most of the kids who go through the entire course of treatment, the illness turns out to be a mere blip on the screen of childhood.\nIt also allowed sick children to access the drug under professional guidance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms of long term treatment with cannabis oil. Also, it does not clearly explain that early discontinuation of conventional treatment might increase the risk of relapse.", "answer": 0}, {"article": "The dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nOne pain specialist not involved with the study saw the benefits of this procedure.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nThe goal of this study, he said, was to judge the effectiveness of the therapy over a long period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the procedure \u201cwas not without complications. Five patients needed to have the wires implanted again, two patients had them removed because they were infected, and one had the device removed because of a complication.\u201d\nThe story didn\u2019t describe the complication, which was a foot drop. It could have also gone a step further by cautioning that the FDA often does not require new medical devices to prove that they are safe or effective in order to be used in people.", "answer": 1}, {"article": "Delyth Morgan, chief executive at Breast Cancer Now, which funded the research, said: \u201cThis is a really crucial discovery.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins are among the most commonly prescribed drugs in the U.S. but do carry risks including muscle damage, diabetes and memory loss. This isn\u2019t addressed in the story.", "answer": 0}, {"article": "Kappelmann, N et al.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\nDr Khandaker and colleagues believe that anti-inflammatory drugs may offer hope for patients for whom current antidepressants are ineffective.\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers note that \u201csome existing drugs can have potentially serious side effects, which would need to be addressed.\u201d\u00a0 Because each of these drugs differ, consideration of the side effects of each would be something a patient should consider based on the benefits and evidence.\nThe side effects of anti-inflammatory medications can be serious. They may increase cancer risk and through suppression of the immune system, increase susceptibility to infection. The release would have been stronger had it offered more specifics about potential harms.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the weak points in this story \u2013 and in many of the stories we saw on this study, frankly \u2013 was that, while harms or complications were mentioned, they were not defined nor quantified.\u00a0 What harms?\u00a0 And how often do they occur? This story had a quote that \u201cI don\u2019t think we\u2019ve educated [people] well enough\u201d about the possible risks \u2013 but the story itself didn\u2019t do so.\nThe AP story, by comparison, at least mentioned \u201crisks that occur more often with older patients, including complications from sedation, accidental performation of the colon and bleeding.\u201d", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that either product poses any particular harms. We\u2019ll rate this Not Applicable. However, it\u2019s worth mentioning that just like no one is sure if these devices help, we also don\u2019t know if they hurt. For example, using these products\u00a0may give false reassurance and lead individuals to stay glued to their devices even longer than they currently are \u2014 perhaps exacerbating an existing problem.", "answer": 2}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the rate of false positive diagnoses in the pilot studies described here were quite low, they still occurred.\u00a0 The story would benefit from directly addressing that and other possible debits of the test.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told that\u00a0experts fear that these tests could lead to unnecessary surgery or delayed diagnosis, and that\u2019s sufficient for a Satisfactory rating.\nThe story could have delved into a bit more of the specifics: What is the evidence\u00a0for these concerns? What are the false positive and false negative rates? These details are\u00a0useful\u00a0because the point of the story is that clinicians are not using these tests to try to improve outcomes of ovarian cancer patients. \u00a0Are the possible debits\u2013or\u00a0uncertainties driven by lack of clinical data\u2013contributing to these decisions?", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nDec. 1, 2011 (Chicago) -- An experimental treatment that involves spinal injections of ozone gas and steroids relieved pain in over two-thirds of 327 people with back problems related to a herniated disc.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that no side effects were observed and that a small percent of patients had more pain after the injection.\nBu the story does not talk about the potential risks of ozone gas to individuals as well as the environment. Ozone is a toxic gas and one would expect that the benefit of its use as a medical treatment would need to be clearly demonstrated prior to recommending it as a routine treatment option. Even if that is done, one would want to know that this gas can be safely generated and administered without causing toxicity to those administering it and to the environment itself. In this context, the mention of no risks seen in the study needs to be taken with considerable caution.", "answer": 0}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release briefly describes the symptoms reported in the children taking part in the trial. The common side effects were thirst, urination and constipation.\nOur reviewers thought it should be pointed out that the risks and long-term effects of treating children with oxytocin are unknown.", "answer": 1}, {"article": "Hupin D, Roche F, Gremeaux, et al.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. David Hupin comments, \u201cThe level of physical activity in the elderly was negatively associated with mortality rate in a \u201cdose-dependent\u201d way.\u201d He also adds, \u201cEven a little [exercise] is good, and more may be better.\u201d\nBut exercise is painful for many older adults with arthritis or other physical ailments, and can also lead to falls, which aren\u2019t mentioned. We\u2019re not saying this is a major omission, as the release does emphasize the benefits of low doses that are less likely to cause harm. But it\u2019s still not up to our standard.", "answer": 0}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quantified harms are not as pertinent since this a blood test. However, one could infer indirect harms, the false positives and false negatives, from the data provided.", "answer": 2}, {"article": "\"Try a serving in a snack bag.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned is that walnuts can cause weight gain because they are high in calories. Because walnuts are a common food, there are no real expected harms except for those who are allergic to them.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Clearly elaborated.", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n\u201cPomegranate juice was shown in the last three years to contain the highest levels of polyphenols among a variety of products,\u201d Kristal said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job.\u00a0 The story states that the \u201cteam had found no side effects, but added that kidney patients should be aware of the high potassium content in the juice, given the delicate balance of nutrients in their blood, and talk to their doctor if they consider drinking it.\u201d", "answer": 1}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nBut the authors of a new study believe giving it early may slow and even reverse some disease-related disability.\nThe decision to start Lemtrada should be made in the context of the risks, including infusion-associated reactions, infections, and autoimmune adverse events, she said.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of infections (including herpes), the need for monthly blood and urine tests for four years after the last dose, the risk of developing \u201canother autoimmune disease,\u201d such as\u00a0Graves\u2019 disease (a thyroid disorder) and a bleeding/bruising disorder called idiopathic thrombocytopenic purpura.\nWe\u2019d have preferred to see a statement that\u00a0long-term harms have not been determined, but this is otherwise a satisfactory description of the harms.\nAlso, the drug was initially refused approval by the FDA\u00a0for safety reasons, a very revealing\u00a0fact that would have provided patients with some context on how serious the side effects are.", "answer": 1}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\nThe authors report that the dead tissue required surgical removal.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention that one patient in the study had a serious complication that required surgery to repair the bladder. \u00a0However \u2013 since the study population was small and men were only followed for \u2018an average of nine months\u2019 after the procedure \u2013 the story could have been even more explicit and emphatic that it is too soon to know the harms associated with this procedure. It did include one independent expert\u2019s comments to that effect.\nMore bothersome: the story described the complications of TURP without informing the reader about how often they occur or bothering to note that other, widely available treatments that have been around for a decade or more have reduced risks of these complications.\nAny story whose first words are \u201ca minimally invasive procedure\u201d may paint an unjustified picture of guaranteed safety.\u00a0 Special caution should be taken to counter this.\nOne last point on harms:\u00a0 the major \u201charm\u201d that the study could not address (and the story ignored) is the possible eventual need for requiring additional treatment.", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms associated with deep brain stimulation.\u00a0 There are some minor or temporary problems that may occur as well as risk of brain hemorrhage. There is no mention of complications of foreign material in the brain, of stimulators\u00a0 housed in the chest, \"mild anesthesia\" and of the insertion of wires into the brain.\u00a0 \nHowever \u2013 in its description of the benefit for Parkinson\u2019s disease, the story mentioned that it was not beneficial for end-stage symptoms and indicated that the benefits of treatment were temporary for this degenerative condition.\u00a0 This provides an important perspective about limits of benefits.", "answer": 0}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nKey Findings \n\n In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Here again, the release and abstract include specific rates of treatment-related adverse events, but only buried deep in the text and without important context or explanation. It is not enough to glibly pass off higher rates of serious side effects as \u201cmanageable\u201d and \u201cconsistent with known safety risks.\u201d The release states that there were grade 3-4 adverse events in 68% of the patients receiving atezolizumab in addition to chemotherapy, compared to 57% of the patients receiving chemotherapy alone. But there is no explanation of what these numbers mean. Grade 3 usually means severe and a grade 4 adverse event is typically life-threatening. There is also no mention in the release itself of the finding that 20.4% of the immunotherapy patients suffered \u201cserious\u201d treatment-related adverse events, compared to 10.5% of those who received only chemotherapy.", "answer": 0}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nSuch research has become critically important as the number of children diagnosed with autism has soared in recent decades to 1 in 68.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\nHundreds of millions of dollars of state and federal funding are being spent each year to provide help to children and adults with autism and being able to pinpoint children at risk in the early years could help direct those public resources to where they could do the most good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided no description of potential harms from this scanning approach. The chief potential harm would be a false positive or false negative scan. If the scan is wrong, that may trigger unnecessary additional anxiety or false reassurance for parents regarding their child\u2019s likely outcome. It may also lead parents and doctors to implement the wrong kind of therapy for autistic children. The researchers on this study have suggested that\u00a0non-verbal therapies may be more appropriate for the children whose scans suggest they are not \u201clanguage-ready\u201d (and vice-versa). But if the scan is wrong, these children may be offered the wrong kind of treatment \u2014 possibly leading to a worse outcome than if they hadn\u2019t been scanned at all.\nThe story also could have noted some of the challenges involved with getting MRI images on young children. MRI scanners make loud banging noises which can be frightening to children and sedation is sometimes required. \u00a0The researchers in this study were able to do the scans while the children were asleep, which didn\u2019t require sedating the children.", "answer": 0}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nShe noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nThe patients were randomly assigned to receive either TAK-875 (303 patients), placebo (61 patients), or another diabetes drug called glimepiride (brand named Amaryl).\nThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are numbers attached to the potential harms, but there is so little context that it would be hard for readers to make any sense of the numbers. It says, \u201cThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\u201d\u00a0 What does this mean, exactly?\u00a0 What specific types of side effects were experienced, and were some of them severe?", "answer": 0}, {"article": "...\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no information about possible harm. In general, we might expect a news release about this kind of study to include the most common side effects found at rates considerably higher than placebo. Here those side effects include insomnia, dry mouth, and nausea. The rate on insomnia, which occurred in 14-15% of patients on drugs and <2% on placebo, is especially cogent, as it\u2019s a symptom that can really affect people\u2019s lives.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no explanation of the potential harms from unnecessary screening, the intervention that\u2019s at the heart of this story. Unnecessary screening can produce false positive results that may lead to anxiety, unnecessary curtailing of activities, and needless treatment and follow-up that can cause harm. We acknowledge that the story does mention the harms from some specific bone density drugs. For example: \u201cBisphosphonates, sold under brand names such as Fosamax and Actonel, are highly effective. But because of some\u00a0possible, rare side effects\u2014an unusual type of fracture of the thigh bone and a deterioration of the jaw bone\u2014the medication often isn\u2019t prescribed for more than five years.\u201d But we\u2019d note that it isn\u2019t clear how one should extrapolate data on potential harms seen in post-menopausal women to men.", "answer": 0}, {"article": "Testing cholesterol in toddlers and babies?\nNinety percent of them started taking preventive medicines after finding out.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nIf a child was found with the disorder, parents were tested.\nOne in 270 children had the gene mutations; others were identified through cholesterol levels alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of screening including false positives and negatives, overdiagnosis, overtreatment, inappropriate disease labelling and so on are not mentioned.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible drawbacks to use of the Watchman device.\nBut federal regulators have made clear that they have concerns. In a letter dated March 13, 2015, the Food and Drug Administration told the manufacturer, Boston Scientific, that its approval was\u00a0contingent upon the submission of periodic reports on the safety of the device.\n\u201cThe primary safety endpoint is treatment of the patient without the occurrence of life-threatening events as determined by the Clinical Events Committee, which would include events such as device embolization requiring retrieval, bleeding events such as pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion and any bleeding related to the device or procedure that necessitates an operation,\u201d the letter says.\nIt also notes that the device maker agreed to carry out a study to assess \u201cwhether the rates of safety and effectiveness during the early commercialization of the WATCHMAN device in the United States are consistent with the premarket findings.\u201d", "answer": 0}, {"article": "Wu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed. If it\u2019s too early to tell the rates of false positives, we need to know that. The article draws a picture of a tool with no potential downsides.", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this story puts forth the idea that certain foods (especially coffee and wine) are good for microbial diversity\u2013and that\u2019s a health claim\u2013there should be an acknowledgement that\u00a0these foods also can carry harms. There was no mention\u00a0of the size of the dose\u2013how much coffee? How much wine? And people may take that lack of dosing to mean whatever they want, including having more than is beneficial and veers into unhealthy or dangerous.", "answer": 0}, {"article": "\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nHis team calculated that a woman who gets a yearly mammogram starting at age 40 cuts her risk of dying from breast cancer by 71 percent compared to a 23 percent reduction in risk if a woman followed the task force recommendations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not include information about the potential harms resulting from routine, annual mammography beginning at age 40.\u00a0 Readers, especially women who may decide to begin annual screening at age 40, need to be told about the possibility of false positives and unnecessary biopsies. Authors such as Welch and Esserman have referred to overdiagnosis and overtreatment.", "answer": 0}, {"article": "The researchers, Drs.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nAlso, he said, erectile dysfunction can also be a factor of aging and can be treated in most cases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms associated with various approaches to treating prostate cancer as well as the increased risk of prostate cancer progression and death seen in the cohort of men who followed the watchful waiting approach were discussed.", "answer": 1}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, but since these are likely to be minimal and we\u2019re at such an early stage in development, we\u2019ll call it not applicable. We think we\u2019re being lenient here (but we were with the AP story as well) because any new drug delivery system runs the risk of causing some harms and side effects \u2013 things that can\u2019t be known before human testing \u2013 and a point the story could have made. ", "answer": 2}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports:", "answer": 1}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms. It states that \u201ctenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.\u201d\u00a0 It also says that researchers \u201cfound no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\u201d\u00a0 Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment.", "answer": 1}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\n\"I would still recommend screening mammograms starting at age of 40,\" because cancers caught earlier would be more curable.\nThat decrease, Hardesty said, \"is a statistically significant difference,\" but it also showed more doctors were discussing mammograms with patients.\nShe found that fewer clinicians were recommending annual mammograms after the task force's guidelines were issued.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We wouid have like to have seen more discussion of the potential harms in 85% of biopsies being non-cancerous.\u00a0 But since the story did actually quantify the number of false positives, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published study mentions \u201cno reported adverse events,\u201d but the news release does not address harms.\nHarms are relevant since we\u2019re guessing many readers might be wary of swallowing an electronic transmitter and hope \u201cthis too shall pass\u201d (without incident).\nAnother harm that isn\u2019t mentioned is the risk of false-positive findings that may\u00a0lead\u00a0to unnecessary antibiotic treatment for some people. Such treatment poses risks to individual patients and contributes to the growing problem of antibiotic resistance.", "answer": 0}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nAll content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any harms. Some of the \u201cclassic\u201d dietary recommendations have a small harm profile (potassium, protein), and this is also not discussed.", "answer": 0}, {"article": "He was not involved in the research.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explicitly discuss harms from a potential \u201csniff\u201d test by dogs or machines imitating dogs.\u00a0 It does discuss contradictory research on whether cancer-sniffing dogs can achieve high accuracy. The obvious \u201charm\u201d of inaccuracy is that a patient goes untreated for cancer, or conversely, is exposed to invasive testing because of a false positive. Without early detection by dogs, patients are already getting exposed to tests such as computer tomography and bronchoscopy.", "answer": 0}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAccording to Dr. Kuhl, interval cancers exhibit an adverse biologic profile and are the main driver of breast cancer mortality.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not state any potential harms of MRI screening. False positives from MRIs aren\u2019t uncommon and can lead to anxiety and additional invasive testing. That\u2019s harmful for patients.\nWe\u2019d like to see news releases and stories start to acknowledge potential harms, particularly since the country is moving toward more universal breast cancer screening with MRI.\nOver the past few years, studies have been coming out noting concerns about the gadolinium (a heavy metal) contrast material that is used during breast MRI. The contrast is necessary to demonstrate areas of increased tissue vascularity (the state of blood vessel development and functioning). Recent reports note that gadolinium may deposit in the brain. We do not know the long-term significance of this. The FDA is studying the effects \u2014 if any\u2013 on \u201crepeated use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI).\u201d", "answer": 0}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nHe hopes the new treatment will eventually replace bone-marrow transplantation, an even more arduous, risky and expensive procedure that is now the last hope when other treatments fail in leukemia and related diseases.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\nSome patients have had the cells for years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some of the adverse effects of treatment in great detail, and mentions that patients treated successfully have compromised immune systems and must undergo ongoing therapy\u00a0with immunoglobulins. The story could have noted that we have\u00a0little idea what kind of long-term challenges these patients might face as a result of the alterations made to their immune systems.", "answer": 1}, {"article": "The results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\nStill, it did not eliminate all symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify/explain the extent of \u201csignificant reactions during the treatments that make the therapy unfeasible\u201d in the new sublingual approach.", "answer": 0}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nBut Don't Think Of This As Birth Control Even though Clue\u2019s marketing director happened to find out she was pregnant from her Fitbit, the point of the study was to demonstrate that it's possible to use Fitbit as a conception tool, not as a pregnancy test, H\u00f6gqvist Tabor said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear what any potential harms might be in this case, though one possibility is that some women may delay taking steps to diagnose possible fertility problems in order to use this technology. Another possible \u201charm\u201d is the bother and cost of using this device by\u00a0women who would become pregnant anyway without any problem.\nWhile the story doesn\u2019t address those issues, we give kudos to the story for addressing another possibility: that women may use the technology to track their ovulation cycle in order to avoid becoming pregnant. The story tackles this issue head on.", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nOne small study found an elderberry extract called Sambucol could shorten the duration of flu symptoms after a person gets sick by about 3 days.\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\nRaw or unripe elderberries, as well as other parts of the plant, contain a toxic compound related to cyanide.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit here for making it clear that raw elderberries are poisonous. However, the story is about commercially-prepared elderberry extract, not raw berries. There was no discussion of possible harms of extracts. While the few clinical trials of elderberry extract did not report adverse events, the story could have at least noted that supplements are exempt from most FDA regulations. The lack of inspections and independent quality control checks means that consumers are almost entirely dependent on the internal procedures of manufacturers. Thus, there is no independent guarantee that the potentially poisonous elderberries are being properly prepared.", "answer": 1}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nIt could be that the whipworm larvae weren't prepared correctly.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt may depend on a person's genes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says one person found that having worms in his body \u201cwasn\u2019t pleasant,\u201d and he experienced diarrhea and cramps. But potential risks are not adequately addressed. According to a story in The New York Times Magazine, for example, severe whipworm infection can result in anemia, clubbed fingers and stunted growth in children.", "answer": 0}, {"article": "Sanofi said this was mainly due to neutropenia, a blood disorder people can get from chemotherapy treatment, and its complications.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned that:", "answer": 1}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nThe study showed that women in this age group were still protected from HPV infections.\nThese study results are essential to new approaches in cancer prevention, particularly those that are investigating combined approaches of cervical screening and vaccination in adult women.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThe international study found that it protects against HPV infection in women older than 26 years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention harms, and that\u2019s a troubling omission in a summary of a study devoted to a drug\u2019s safety and efficacy. The published study states the following:\n\u201cSerious adverse events related to vaccination occurred in five (0\u00b72%) of 2877 women in the vaccine group and eight (0\u00b73%) of 2870 women in the control group.\u201d", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\nIt is not known if the differences between these studies are due to differences between the medications or other factors.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that, \u201cSide effects were mild to moderate and participants taking Prozac did not show increases in suicidal thoughts or ideas.\u201d\u00a0 It could have noted, though,\u00a0 that 12 weeks may not be long enough for side effects to emerge.", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nNone of the patients experienced any serious side effects as a result of selenium supplementation.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story was a little confusing\u00a0on this point. It initially says that\u00a0selenium\u2019s\u00a0safety \u201chas not been studied,\u201d but later quotes a researcher who says there is an increased risk for type 2 diabetes with selenium supplements in individuals whose\u00a0blood levels are already high. The story does note that there were no serious side effects in the selenium supplement users participating in this study, but it\u00a0could have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use.\u00a0Too much\u00a0selenium can also, in rare cases, result in condition called selenosis, which\u00a0includes symptoms such as\u00a0gastrointestinal upsets, hair loss, white blotchy nails, garlic breath odor, fatigue, irritability, and mild nerve damage.\nA toss-up here, but since the story indicated that this was not a risk-free intervention and reported on the study findings as appropriate, we\u2019ll rule it satisfactory.", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, and given the lack of details on what the topical medication is made of, it would be difficult find out via independent research.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nPatients with Crohn\u2019s disease should not use Siliq.\nHealth care providers should also evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Siliq.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We could have rated this release unsatisfactory on this criterion, since no numbers are given about the extent of the problems found in the trials. But we\u2019ll give it the benefit of the doubt because of the extent of discussion on potential harms \u2013 despite the absence of numbers.\nThe release mentions that completed suicides occurred in patients treated with Siliq during clinical trials, which is why the drug\u2019s label will include a boxed warning. Although the release states cause and effect hasn\u2019t been established, some patients \u2014 especially those with a history of depression \u2014 seemed to show an increased risk for suicidal ideation and behavior.\nThe release uses language that may confuse readers\u00a0about harms. In one place it says \u201cA causal association between treatment with Siliq and increased risk of suicidal ideation and behavior has not been established\u201d and in the next sentence claims that \u201cBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Black Boxed warning\u2026.\u201d\nPatients may also experience more infections, or allergic/autoimmune conditions, as Siliq targets the immune system. Other side effects associated with the drug include joint pain, headache, fatigue, diarrhea, throat pain, nausea, muscle pain, injection site reactions, influenza, low blood cell count and fungal infections, the news release adds.\nAlthough we would have liked to have seen some numbers indicating how often these side effects occurred, and clarity about whether or not they were observed, we believe the news release does an adequate job addressing harms, as a significant chunk is devoted to this issue. This is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is focused on the potential harms of the drug and it does a fairly good job explaining the differences between the risks for different bad outcomes from the drug and from a placebo. We give very high marks to the story for providing both comparisons using percentages but also using absolute numbers throughout. So, for example, the story said,\u201dThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\u201d\nIt also does a nice job of explaining, at least in one instance, that some of the comparisons between the drug and placebo are not statistically significant. For example, the story said that, \u201cThere was also no significant difference between Januvia and placebo in infections, cancer, kidney failure or severe hypoglycemia, which is dangerously low blood sugar, researchers reported.\u00a0Acute pancreatitis, a concern with some diabetes drugs, was uncommon but higher with Januvia, 23 versus 12. That was not statistically significant.\u201d\nWith that being said, we wish the story had mentioned that three-year follow up may not be long enough to catch some potential harms. And while the pancreatitis issue was downplayed, a larger and longer study might have shown the concern to be statistically significant if the trend continued. An independent expert analyst may well have commented on such concerns, but no such expert was quoted.", "answer": 1}, {"article": "47(5) pp.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\nSix months after the balloons were removed, 89.5 percent of the average total weight lost during the treatment period was maintained.\nUp to three balloons may be placed over the first three months, but the entire treatment period lasts six months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release reports that one trial participant had a gastric ulcer and almost all reported mild to moderate cramping and nausea, the release doesn\u2019t warn readers that this sort of balloon could cause serious, even fatal, complications including esophageal tears, intestinal blockages that require surgery, life threatening allergic reactions, heart attack, cardiac arrest or airway blockage. The FDA approved a package insert that lists these potential risks (see page 11 of the Patient Labeling). The release should have also mentioned the most important risks.", "answer": 0}, {"article": "With brachytherapy, also known as internal radiation therapy (RT), implants are surgically inserted in or near cancerous tissue to deliver a curative radiation dose directly to the tumor while limiting exposure for surrounding healthy tissue.\nNo patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nNo patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.\nIn this study, researchers found that patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release provided detailed information on harms: \u201cWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%). No patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity. Rates were similarly modest for long-term side effects. Six patients (10.3%) experienced chronic grade 2 urinary toxicity and one patient (1.7%) experienced grade 3 chronic GI toxicity that subsequently resolved. No patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.\u201d\nBut given that many oncology experts would consider the treatment unnecessary, any level of toxicity\u00a0could be considered unacceptable.\nThe lay reader would have benefited from a description of what \u201cgrade 2 or grad 3+\u201d levels of toxicity means.", "answer": 1}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nMore and more clinical trials will spring up to test PARP inhibitors in combination with other cancer treatments, such as immunotherapy, said Dr. Christina Annunziata, an investigator at the National Cancer Institute who studied the efficacy of Lynparza in ovarian cancer patients.\nOther groups of patients treated with the drug also had significantly better outcomes than control groups.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nIt showed that patients with recurrent ovarian cancer treated with the drug got an extra 15 months without their disease getting worse, compared to a control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story about the side effects or harms traceable to either the three new drugs, or to the one approved drug also mentioned for the treatment of ovarian cancer.\u00a0 A quick web search yields a host of possible side effects, including nausea, anemia, fatigue, joint pain and many others. Especially with stories touting potential new drugs, information should be provided about potential harms the medications may present, not just the positive results of taking the drug.", "answer": 0}, {"article": "America needs to catch up.\nThe U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\nThe Home Access HIV-1 Test System lets patients collect blood at home, but it must then be sent to a clinic for testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is an egregious disregard of harms. Imagine the trauma of receiving a preliminary test indicating you may be infected with HIV, without any counseling or other support. A false positive test would inflict at least temporary anxiety, but if a person did not seek follow-up testing the trauma of an inaccurate test could be long-lasting. It\u2019s possible self-testing could harm people if it means they are less likely to seek care than if they had been tested in a setting that offers counseling. Also, the test may not detect infection that occurred within the previous three months, so a person who was recently infected, but gets a negative test result, may incorrectly believe he or she is uninfected and then expose others.\nSome of the challenges of home testing are covered in this review article.\u00a0(Dr. Ganguli is a co-author). In addition to the above, there is the issue of the test being used more by\u00a0the worried well and the affluent than by those at highest risk for the disease. In surveys, Americans report that they do not want to spend more than $15 on an HIV test.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The \u201cgenerally safe\u201d line is too vague for us.\u00a0 There are side effects and risks associated with probiotic use.", "answer": 0}, {"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\nFever is another area where acetaminophen can help, said Moore.\n(He advised people to see their doctor if they're taking any of these painkillers for more than a few days \u2014 particularly if they're on other drugs already.)\n(Ibuprofen also has potential side effects; more on that below.)\nTo be more exact, he said, \"I can't imagine why anybody would take acetaminophen.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story comprehensively describes the harms from each drug based on different uses and patient populations. We especially liked this quote:\u00a0\u201cDon\u2019t believe that just because something is over-the-counter, it\u2019s safe.\u201d", "answer": 1}, {"article": "Anderson Cancer Center in Houston, at a Wednesday news conference.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least the story noted, \"no one knows if metform in safe in non-diabetic populations but some clinical trials are starting to look at the issue.\" ", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\nOne way to address this gap by the transplant community worldwide has been to extend the criteria of those donor kidneys used for transplantation.\nThe new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplantation poses a number of risks, from infection to rejection of the donor organ to the kidney failing to work normally. The release refers to the phenomenon known as \u201csleepy kidney,\u201d in which a newly transplanted organ takes some time before it begins functioning. However, it doesn\u2019t address other health risks in a meaningful way, not does it offer any insight into how the new technique may affect those risks. Could ex vivo organ perfusion reduce those risks? Increase those risks? We\u2019re not told.", "answer": 0}, {"article": ".\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that idarucizumab \u201cdoesn\u2019t seem to carry with it any tendency to increase clotting,\u201d but does not tell readers anything else about potential harms. Could idarucizumab contribute to other problems? Readers don\u2019t know. Even if there are no health risks associated with idarucizumab, it\u2019s important to tell readers that. And, according to the Praxbind website, there are potential adverse effects.", "answer": 0}, {"article": "Women choosing to have both breasts removed face higher surgery costs and slightly higher risks of post-surgery complications and infections.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\n\u201cIf I didn\u2019t do as much as possible to eliminate the cancer, I would feel like I was almost waiting for the other shoe to drop.\u201d\n\nWomen removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report mentions slightly higher risks of surgical complications and infections. It would have been useful to specify how serious and frequent these outcomes are, but this is not a serious flaw. ", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nThe new treatment uses a coating of mild acid that is applied to the decay to open up a route to the pores and clear out decayed enamel.\nAvoiding the drill has the advantage of preserving and extending the life of the natural tooth.\nA new procedure used by Phark and other doctors claims to stop the progress of cavities without drills or Novocain.\nIt's intended for patients whose decay has not gone beyond the tooth enamel.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story does not mention any harms from this product, so we would typically rate it as Unsatisfactory. However, a review article published last year on this sort of sealant also did not mention any side effects. The article did mention that there was a great deal of variation in how these products are used in different countries indicating that there is no clear consensus on how they should be used.\nReference:Sealants in Dentistry: Outcomes of the RCA Saturday Afternoon Symposium 2007Caries Research 2010;44:3\u201313http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000271591&Ausgabe=253776&ProduktNr=224219&filename=000271591.pdf", "answer": 2}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\n\"It's not clear whether this would be effective at all in children or in young adults who had intellectual problems,\" warned Young.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nThe long-term effects of the hormone are also uncertain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms are not quantified in the\u00a0published study\u00a0itself, this story does well to emphaszie the importance \u2014 and current lack \u2014 of safety data for an alluded-to use of oxytocin in children with autism. \nWe do know a good deal about the toxicity of oxytocin when given to women to induce labor and for a few hours. In addititon to possible severe allergic reactions, water intoxication is an important side effect.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story\u2013although weight loss medications were discussed.", "answer": 0}, {"article": "\"It's not.\"\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\nAfter 24 weeks, some of the doses were adjusted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What does \u201cappears to be safe\u201d and \u201cno serious adverse effects directly attributable to the drug\u201d mean?\nHere\u2019s what the study abstract stated:\u00a0 \u201cWe noted serious adverse events in two of 54 (4%; 95% CI 3\u00b70\u20144\u00b74) patients in the placebo group, one of 55 (2%; 1\u00b73\u20142\u00b73) in the 600 mg ocrelizumab group, three of 55 (5%; 4\u00b76\u20146\u00b73) in the 2000 mg group, and two of 54 (4%; 3\u00b70\u20144\u00b74) in the interferon beta-1a group.\u201d\nWhy didn\u2019t the story report this?\nWhat side effects were seen?\u00a0 Tell readers/patients and let them decide if they are serious or not.\u00a0 And how did researchers know that whatever was seen was not directly attributable to the drug?\nAnd what\u2019s the safety record been of the drug the Mayo expert described that has a longer track record?\nInsufficient information on harms.", "answer": 0}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nAlthough any treatment that works by blocking the immune system\u2019s ability to mount an inflammatory response should be carefully monitored for its potential to render the body vulnerable to infectious disease, there were few observed differences in this category between recipients of placebo versus active drug given every four weeks, Genovese said.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn that \u201cfew serious adverse events were reported for patients receiving the drug, or the placebo\u201d but a close reading of the actual abstract shows that 7 percent of patients taking the drug every two weeks (versus 3 percent on placebo) had serious adverse\u00a0events. If the absolute effects on benefits are reported why are not the absolute effects of the harms? We think it is important to at least list the major adverse events that occurred during the trial.", "answer": 0}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Starting with the headline, this story extols the\u00a0health-promoting\u00a0properties of the antioxidants found in chocolate, and it isn\u2019t until the last sentence that we receive\u00a0a hint of a warning about\u00a0potential downsides of chocolate, such as high saturated fat\u00a0and total calorie content.\u00a0The story states, somewhat euphemistically, that dark chocolate is a \u201cpotential superfood to be enjoyed in moderation.\u201d The story should have cautioned that you will have to limit yourself to\u00a0just\u00a0a small square of chocolate per day \u2014\u00a0a fraction of a standard chocolate bar, and much less than what the average person consumes as a snack \u2014\u00a0to achieve any potential health benefits. If you eat any more,\u00a0the weight gain caused by the additional calories will most likely negate any benefits from the health promoting antioxidants.", "answer": 0}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nNor is it clear why the results differed for men and women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms aren\u2019t discussed but we don\u2019t know what they\u2019d be.", "answer": 2}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nThe researchers found 55 percent of patients with psoriasis and 62 percent of patients with psoriatic arthritis reported improvements in their disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Sadly, no harms related to bariatric surgery were mentioned, nor were the likelihood of complications due to the surgery and the rate of reversals that are often necessary.\nPsoriasis is an important problem but clearly bariatric surgery would not be a first-line treatment for the condition. The trade-offs in terms of risks of complications and required lifestyle changes after bariatric surgery are critical considerations for a patient hoping to reduce their psoriasis symptoms.", "answer": 0}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\nThe new study was funded by Picato manufacturer LEO Pharma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In an odd line, the story states \u201cBecause the new gel is only used for a few days, any irritation is usually short-lived.\u201d\u00a0 But it doesn\u2019t describe the irritation in any detail \u2013 nor\u00a0 how often it occurs.\u00a0 This isn\u2019t telling readers much of anything useful.", "answer": 0}, {"article": "Botox and Myobloc carry labels warning of possible adverse reactions near the injection site such as drooping eyelids, and of severe difficulty swallowing in patients with neuromuscular disorders.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nNot surprisingly, these \"preclinical tests\" (that is, those performed before testing on humans) were especially rigorous for botulinum.\nBotox's manufacturer, Allergan, thinks those older studies are more credible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a clear report on the potential harm to rats receiving Botox injection into whisker muscle. But the story went beyond a reasonable argument to suggest a link between the study results and harms to patients. \u00a0 While the implication of the study is that there is the potential of systemic effects following local treatment with botulism toxin, the story didn\u2019t really make clear what this meant.", "answer": 0}, {"article": "Instead, they used a weaker method comparing the before-and-after differences within each group.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\n\u201cThe efficacy of our nutritional supplement was demonstrated by rigorous studies,\u201d said Nathalie Piccardi, of Laboratoires Inneov, who worked on the study.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms found in the trials so far, but then the evidence in the trials so far is being called into question.\u00a0 We\u2019ll give the story credit for exposing the potential harm of consumers (and dermatologists) being misled by unsubstantiated claims. ", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\nThe researchers expected that if the extra drugs and procedures were actually helpful, the treated people would have a lower rate of serious heart problems in the future.\nBy contrast, it\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the competing Wall Street Journal story, this story was clear about the potential harms: \u201cit\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer. And the dyes used to enhance the images cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\nNone of the patients experienced graft rejection or required long-term immune suppression -- two potential side effects with human donor corneal transplants.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that none of the patients \"experienced graft rejection or required long term immune suppression \u2014 two potential side effects with human donor corneal transplants.\" It could have discussed what it might mean for these patients if these grafts ultimately fail.\u00a0Does it prevent them from then undergoing a human corneal transplant, which has a more established record of long term success?", "answer": 1}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nMore than 200 different symptoms have been associated with PMS, including emotional symptoms such as: stress, anxiety, insomnia, fatigue, mood swings, emotional sensitivity and/or changes in libido.\nThese symptoms qualify as PMS in 20% to 30% of pre-menopausal women.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no description of potential harms. The company CEO is quoted saying there are \u201cno reported side-effects.\u201d\nHowever, a look at a commonly used scientific database for CAM product ingredients reveals there are side effects associated with phosphatidilserine, the active ingredient found in the product. Those include nausea, gastric distress and insomnia. There also may be an increased risk for acquiring infectious diseases, such as bovine spongiform encephalopathy (mad cow disease) if the phosphatidilserine is derived from bovine cortex, according to the database site.", "answer": 0}, {"article": "Raji presented the findings here at the annual meeting of the Radiological Society of North America.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing HealthDay story, at least WebMD reminded readers:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 1}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nUltimately, a candidate molecule called ICEC0942 suppressed tumour growth in a wide range of cancer types in lab tests.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nIn a bid to come up with new forms of treatment that work in a distinct way from established ones, chemists, biologists and clinicians at Imperial College London collaborated on creating a new drug, the properties of which are reported in the journal Molecular Cancer Therapeutics.\nIt is this molecule, in oral pill form, that was taken forward by Carrick as CT7001 and is currently in Phase I clinical trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms that might preclude this treatment from coming to market.\nFrom other examples of cancer drugs, it is most\u00a0likely that there\u00a0would be some undesirable effects and the release could have at least acknowledged that harms are unknown.\u00a0  ", "answer": 0}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\nBeyond annoyance and embarrassment, many patients and their surgeons fear that the squeaky ceramic hips may signal that the joints are wearing out prematurely.\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story focuses on one main harm\u2014squeaking in hip implants made of ceramic\u2014and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. ", "answer": 1}, {"article": "Dr.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\nDr. Ahlquist said he was very pleased with the new results, especially the 64 percent detection rate for precancerous polyps, since these are best targets for intervention.\nThe practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two tests the Times reported on were done on blood and on stool, which, in theory, should not harm anyone during the screening. But there is potential for harms as a result of screening. The story states that with the Exact Sciences DNA test \u201c12 percent of the time the patient will be given a false alarm.\u201d\u00a0 And, regarding the Epigenomics blood test, the story states that \u201cmore false positives could be generated so you could end up doing more harm than good.\u201d", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there was an increased number of people taking Crestor who developed diabetes during the study.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that no serious side effects have been reported.", "answer": 1}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThese surprise attacks are due to inherited problems that children are born with.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nCardiologist Douglas Zipes, past president of the American Academy of Cardiology, says the problems kids suffer are typically electrical, like abnormal heart rhythms, or structural, like a thickening of the heart muscle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nApart from a passing reference to costs, there is no discussion of the potential downsides to screening, which are numerous and include overtreatment of benign abnormalities, unnecessary exclusion of children from sports and other health-promoting physical activities, and creation of undue anxiety in children who have no reason to worry about their hearts.\u00a0\u00a0 \n1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n", "answer": 0}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated, \u201cResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\u201d\nSince this was a safety trial, we expected more detail on what those expected side effects were.\nWere \u201cexpected side effects\u201d the same as those observed in patients getting T-VEC for melanoma? Are the flu like symptoms the worst?", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nA clinical trial funded by the National Institutes of Health revealed a \"significant effect of treatment\" when patients received TMS treatment.\nIt can cost as much as $400 for a 37-minute session and require multiple treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t provide any specifics about potential harms of the treatment, \u00a0We are told, \u201c\u2026treatments are more effective than medications with far fewer side effects,\u201d \u00a0\u201c\u2026but for the most part, it is safer in general than taking a medicine. You\u2019ve got less seizure risk than taking a medicine. You\u2019ve got less side effects than taking a medicine.\u201d \u00a0Exactly what are the risks and how often do they occur? \u00a0Here is a listing of side effects from \u00a0the NIMH website:(http://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml )\n\u201cSometimes a person may have discomfort at the site on the head where the magnet is placed. The muscles of the scalp, jaw or face may contract or tingle during the procedure. Mild headache or brief lightheadedness may result. It is also possible that the procedure could cause a seizure, although documented incidences of this are uncommon. A recent large-scale study on the safety of rTMS found that most side effects, such as headaches or scalp discomfort, were mild or moderate, and no seizures occurred.\u00a0Because the treatment is new, however, long-term side effects are unknown.\u201d", "answer": 0}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nAnd they consider themselves lucky.\nGot milk?\nNo?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned safety concerns associated with consumption of raw milk, especially by individuals who may have heightened vulnerability. \u00a0(The story also included comments from people who are fans of raw milk who claim these concerns are overblown.) However, this is one area where this story could have been improved. \u00a0Raw milk has the potential to make people quite ill, especially children (which was mentioned in the story) but also pregnant women, those whose immunity is compromised as well as the general public. \u00a0It should have included more information about infection rates among people consuming raw milk.", "answer": 0}, {"article": "\u201cThey should speak with their doctor.\u201d\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If we were tough on the \u201cevidence\u201d criterion grade, we go a little easy on this one.\nThe story notes that Celebrex users were more likely than the placebo group to develop polyps once they stopped taking the drug, and it quantifies this risk appropriately in absolute terms. However,cardiovascular risk \u2014 which is the main concern with this drug \u2014\u00a0is described only in\u00a0relative terms. The story states\u00a0that those treated with the drug had a 66% higher risk of serious cardiac disorders. Although we acknowledge that this is a picky point,\u00a0the story should have\u00a0reported the absolute rate of these problems in both groups and the associated difference in risk. This would have helped\u00a0readers understand how common cardiovascular events were in the study overall and how concerned they should be about the increased risk in the Celebrex group.\nNonetheless, because of the overall handling of harms and repeated mention of safety concerns, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are never discussed in the story. The story does mention that cupping \u201cshouldn\u2019t be done on pregnant women, people with heart conditions or people with bleeding disorders,\u201d but why not? There are other possible harms, such as spread of resistant bacteria by not properly cleaning instruments.", "answer": 0}, {"article": "\u201cI would be with Ava during the day, and then when Jay got home, he would stay with Ava, and I would spend time with Audrey,\u201d she said.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nThe doctors assured the family that it was typical leukemia \u2014 and curable.\n\u201cWe\u2019re kind of up against the edge.\u201d\n\nFry thinks she might be able to undergo a second round of her latest immunotherapy, as long as her cancer is still producing CD22 proteins.\nThey immediately stopped the medication when they learned Ava might get her T-cell therapy in January \u2014 she actually needed a high level of leukemia in her body to participate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses potential harms. Early on, the it notes that \u201ccomplications can be lethal,\u201d and refers to a study in which several patients died due to brain swelling. Much lower down, the story refers to one patient\u2019s \u201cintense immune reaction that followed treatment,\u201d involving a fever of 106 degrees Fahrenheit. Those aren\u2019t all the risks, but it\u2019s some of the major ones.", "answer": 1}, {"article": ".\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nThis expanded cord-blood technique has been a \u201chuge home run\u201d for patients, said Colleen Delaney of the Fred Hutchinson Cancer Research Center in Seattle, who helped create it.\nWhat eventually saved her, though, was an experimental transplant using stem cells from the blood of a baby\u2019s umbilical cord, an approach that can be used without perfectly matching blood types.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely raises the risk of cord blood transplantation and the risk of standard cancer therapies throughout the piece. For example, it says, \u201cBecause each umbilical cord produces only a tiny number of stem cells, umbilical-cord transplants take longer to work than standard transplants, which makes patients more likely to get fatal infections. And if cells from several umbilical cords are used, the chances of immunity problems increase.\u201d\nWe do wish that the story made it clear earlier on that the new approach is preceded by intensive chemotherapy and the inherent side effects it entails.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is pretty clear on this, noting early on that \u201crecent studies have found increased rates of complication such as blood clots that travel to the lung, an increased need for blood transfusions, and a higher risk of death with the bilateral procedure.\u201d Later the story refers to two different studies. One, published earlier this year, found \u201cincreased overall complications and risk of subsequent surgery within 30 days\u201d for patients who had the bilateral replacement. The other, published in 2014, found that \u201cbilateral patients were at increased risk of both minor and major in-hospital complications as well as death.\u201d Again, it would have been great to include links \u2014 or citations \u2014 for the relevant studies.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\nWe don\u2019t know what the harm would be, other than consumers pursuing a costly approach for which the evidence base is questioned.\n\u00a0", "answer": 2}, {"article": "\u201cThere is a lot more to be done to fill in the research on the biological mechanism,\u2019\u2019 Dr. Horne said.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only discussion of potential harms of fasting was this: \u201cAny fast should include water because dehydration can raise risk for stroke.\u201d\u00a0 Over what period of time?\u00a0 What\u2019s the evidence base?\u00a0 In what kinds of people? What could happen if people at risk for cardiovascular disease, such as diabetics, fast?\nEven the previous line in the story suggests a broader issue than that when it said \u201cfasting is causing some major stress.\u201d\u00a0 What does that mean, and what are the broader implications for potential harms?", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nAt the start of the study, 80 percent had chest pain.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nThe stunning results found angioplasty did not save lives or prevent heart attacks in non-emergency heart patients.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the percent of individuals in each group that initially had angina and then compared that with the percent affected at 3 and 5 years.\u00a0 It also mentioned the rates of heart attack and death in both treatment groups.\nWhile the story mentioned 1/3 of those in the medication-only group later went on to have a stent put in or had coronary bypass surgery, it could have compared this with the number of individuals in the stent and medication group who went on to either have an additional stent placed or had bypass surgery.\u00a0(30% vs. 20%)\u00a0", "answer": 1}, {"article": "She exercised.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nEven more promising are the findings from the seven patients with early pancreatic cancer that were detectable through their protein levels.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nFurther, levels dropped when patients had surgery to remove their tumors, so the marker could also be used to follow the progression of the disease, Kalluri said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm from screening and treatment is an important issue \u2014 these are major surgeries (which are best performed by skilled surgeons at high-volume centers) that are associated with mortality rates of around 4% and multiple morbidities. While the test was 100% sensitive and specific in the study, in the real world there will be false negatives and false positives\u2013and possibly indeterminate results. We also do not know whether there is any risk of overdiagnosis (detecting cancers that would never cause a problem).\nBut there was no mention in the story of the potential harms. The logical extension of the approach advocated in this piece is that all people should be screened for pancreatic cancer. If that is what the researchers and the other commentators in the piece believe, then they should also address the issue of unnecessary surgeries, side effects from treatments, and the anxieties caused by mass screening.\u00a0A more reasonable point of discussion in the piece might have been to suggest developing a screening protocol for populations known to be at risk. For example, people who smoke, are obese, or who have diabetes are all more likely to be diagnosed with pancreatic cancer. An\u00a0effective and cost-effective screening program would need to determine which people to target (including whether a person is healthy enough to undergo surgery) and at what age.", "answer": 0}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nLanser says it can be tricky to diagnose food allergies.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nBut the vast majority of patients, 86 percent, did not have an allergic reaction.\nIn Jula's case, her allergists at National Jewish Health in Denver, Colo., repeated the standard allergy blood tests last summer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story explains, patients who experienced either mild or serious allergic reactions to the oral food challenge were treated with antihistamines or epinephrine respectively. For the 86% of patients who passed their food challenges with no adverse reactions, no harm was involved.", "answer": 1}, {"article": "\u201cMoving forward, our goal is to formally validate our findings with a larger sample size that includes both adults and children for future use in the clinical arena.\u201d\n\nArticle reference: Danielle Fortuna, D Craig Hooper, Amity L Roberts, Larry A Harshyne, Michelle Nagurney, Mark T Curtis, \u201cPotential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders,\u201d PLOS ONE, DOI: 10.1371/journal.pone.0205501, 2018.\nAdditionally, within the patients identified with central nervous system infections, the CSF cytokine fingerprint was different in cases of viral infection compared to those with non-viral pathogens, such as bacteria or fungi.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Getting a \u201cspinal tap\u201d to extract a sample of CNF is nothing to sneeze at.\nAlso called a lumbar puncture, the roughly 45-minute procedure involves inserting a needle into a patient\u2019s lower back, navigating it between two spinal vertebrae, and barely slipping the tip into a sac near the spinal cord. This location allows a doctor to suck out the nervous system\u2019s fluid, which is shared from the brain case down through the spinal cord.\nBut during or after the procedure, there\u2019s up to a 25% chance that fluid will leak into nearby tissues and trigger headaches, according to the Mayo Clinic. Dizziness, nausea, and vomiting up to two days after the procedure can also occur, and the headaches can last as long as a week. Back pain can be an issue, too, as can bleeding at the site of the puncture.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While mentioning that one child with cirrhosis was able to reduce the number of medications he needed from 11 to 4, the story did not provide any information about side-effects and potential harms associated with liver transplantation. \u00a0In addition, the story indicated that this child had failed to lose weight after the transplant, though it failed to discuss that the high dose of steroids after transplant needed to avoid organ rejection likely contributed to this situation. \u00a0Lastly, as liver transplant just replaces the diseased liver but doesn\u2019t change the underlying circumstance that lead to the condition \u2013 the story should have discussed the potential future need for organ replacement.", "answer": 0}, {"article": "Muscles all over the body break down as the patient grows up, the heart included.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nPatients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene,\u201d the researchers wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story fails to mention any of harms of sildenafil, which include:\u00a0\u00a0\u00a0 * sudden severe loss of vision (see below for more information)\u00a0\u00a0\u00a0 * blurred vision\u00a0\u00a0\u00a0 * sudden decrease or loss of hearing\u00a0\u00a0\u00a0 * ringing in ears\u00a0\u00a0\u00a0 * erection that is painful or lasts longer than 4 hours\u00a0\u00a0\u00a0 * dizziness or lightheadedness\u00a0\u00a0\u00a0 * fainting\u00a0\u00a0\u00a0 * chest pain\u00a0\u00a0\u00a0 * worsening shortness of breath\u00a0\u00a0\u00a0 * itching or burning during urination\u00a0\u00a0\u00a0 * rashSildenafil may also interact with other prescription drugs.\nWhat\u2019s more, the story failed to note that the continual administration of sildenafil over many months used in this study (and the sort of life-long daily treatment that would be envisioned in human patients) is more like the way the drug is used in patients with pulmonary hypertension and completely different from the occasional doses of the Viagra brand form of the drug used by men to treat erectile dysfunction.", "answer": 0}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nConducted by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, this study found that incorporating pecans into a typical American diet significantly improved insulin sensitivity and had a significant effect on markers of cardiometabolic disease in otherwise healthy overweight and obese adults with excess belly fat.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any possible harms from adding pecans to the diet. A brief mention of nut allergies and the high fat and calorie content of nuts would be appropriate in a release advocating daily pecan supplementation.", "answer": 0}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nLoyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic surgery or open surgery to remove cancerous bladders.\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that patients who had robot-assisted surgery spent more time in the operating room than those having open procedures (seven hours vs. six hours). It also reports overall rates of adverse effects (67 percent in the robot group vs. 69 percent in the open group), along with listing the most common problems: urinary tract infections and intestinal obstructions. It would have helped if the release had pointed out that these complication rates were not statistically different.", "answer": 1}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We appreciate that, at the end of the piece, it includes a section on risks. It says, \u201cThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\u201d We think a number here would have helped. How rare is rare? One in 1,000? One in 1 million? According to the Centers for Disease Control, there are about 110 cases of infant botulism annually. While the cause of the infection is not entirely clear, both honey and corn syrup have been implicated. SInce the story suggests that sweet substances might be useful, the addition of corn syrup to the risks would have been helpful to readers.(see:http://www.bt.cdc.gov/agent/botulism/clinicians/epidemiology.asp)", "answer": 0}, {"article": "The study is in the Sept. 22 issue of JAMA.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nIn combination, they are used to treat pseudobulbar affect, a neurological disorder involving involuntary crying or other emotional displays.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, despite the fact that significant side effects occurred during the study, and in more than one or two people \u2014 most frequently falls, diarrhea, dizziness, and vomiting. The drug is also well known to have significant side effects on heart rhythm \u2014 hence the exclusion of patients with heart rhythm problems \u2014 and also to raise the levels of commonly used drugs such as digoxin and some of the SSRI class of anti-depressant/anti-anxiety drugs.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\nVitrakvi will run further tests of the drug's safety and effectiveness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. An FDA news release mentioned fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and elevated enzyme levels that might indicate liver damage. The FDA said patients should have regular liver tests and warned against treating women who are pregnant or breastfeeding because of potential harm to their fetus or baby.", "answer": 0}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\nFor Alyssa Gold, the AMH test was a wakeup call.\nThe test has traditionally been offered to women who are struggling to get pregnant and helps assess the possible next steps, such as getting pregnant sooner or freezing eggs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, though they exist. To name a few, women may act upon the test results\u2013for example, undergoing invasive and expensive treatments like egg retrieval and freezing\u2013when those actions may have not been necessary. Or they may experience anxiety over test results that show low levels of the hormone, and consider themselves \u201cinfertile\u201d when that is not at all certain.", "answer": 0}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nThe data was presented at the American Surgical Association annual meeting in San Diego.\nIRE was successfully administered to all patients.\nThe NanoKnife\u00ae IRE system is approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue.\nPerioperative 90-day outcomes, local failure, and overall survival were recorded and compared to standard of care data for Stage III LAPC.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are alluded\u00a0to, e.g. \u201c[19] percent sustained complications with a median grade of 2 (range 1-3),\u201d but they\u2019re not discussed or explained in sufficient detail. What\u2019s a \u201cmedian grade 2\u201d complication? It would have helped this release to cite, for example, the\u00a0American Cancer Society\u00a0on the side effects of\u00a0ablative therapies for pancreatic cancer. Generally, according the ACS, those harms can \u201cinclude abdominal pain, fever, nausea, infection, and blood clots in nearby blood vessels\u201d with a\u00a0potential for serious complications.", "answer": 0}, {"article": "The new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\nHer knee was wrapped in antibiotic plastic and tourniquets \u2014 to cut down on bleeding and the possibility of infection.\nLess than two hours later the operation was over.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms resulting from this procedure.", "answer": 0}, {"article": "The paper, published in the , followed more than 22,000 healthy Norwegian adults without symptoms of anxiety or depression for an average of 11 years, asking them about their exercise habits and symptoms of depression and anxiety at the beginning and end of the study.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this N/A since the risks associated with light exercise are fairly minimal. However, we think it\u2019s always a good idea to discuss the potential harms of an intervention. In this case, the story implies that very light and infrequent exercise provides this benefit. Does this encourage people to exercise less and to then lose out on other health benefits of more exercise? Injuries are also an issue for those going from no to some exercise.", "answer": 2}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nThis study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk.\"\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms from the test are not explained. The primary medical risks from the use of such a test would stem from inaccurate identification of an individual\u2019s risk of addiction. This could lead to individuals identified as being at low risk potentially being less careful about their use of opioids, leading to addiction; conversely, inaccuracy could identify an individual as being at higher risk when, in fact, they were at low risk and would benefit from being prescribed opioids.", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\nThe test may cost $150 to $250, Graves said.\nPhysicians will \"be able to use a simple blood test and then know that this woman is at increased risk or reduced risk of a preterm birth,\" said Graves, whose laboratory performed the research in the study.\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentioned that the false positive rate was 20%, so we\u2019ll give it a passing grade. We wish, though, that it had included some expert comment on the significance of a false positive rate that high.", "answer": 1}, {"article": "\"Unfortunately, that is not the case.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nThey have designed a \"granular jamming cap\" filled with coffee grounds that does a better job of tracking patient head movements than current methods.\nTheir tests showed that these models could reduce the targeting error by about 50 percent.\nThey designed three tests to determine how well this \"granular jamming cap\" performed relative to the current headband in reducing targeting error:\n\u2022 They \"bumped\" both them from a number of different directions with a tennis ball filled with plastic particles swinging on the end of a string.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the cap is \u201cnoninvasive\u201d but doesn\u2019t say whether there are any potential harms. Silicone allergies are purportedly rare, but they do exist.\nThe news release is silent on the issue of potential harm which is movement from anatomic landmarks. We aren\u2019t sure that the lower error rate seen with the coffee cap is really an advantage. \u00a0An earlier publication from the group concluded:\nOur results show that our granular jamming fixation prototype reduces registration error by 28%-68% (depending on bump direction) in comparison to a standard Brainlab reference headband.. Indeed the method appears to be better than the headband approach but it is unclear how it performs in comparison to anchored fiducial markers.", "answer": 0}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\nHe added that creating an actual test for use by doctors will require collaboration on the part of researchers.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nPossibly, then, the drugs may be a potential 'confounding' variable, they wrote, meaning that medication may influence test results and symptoms, adding an element of confusion to the study and its possible interpretation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not directly address potential harms. The harms with screening tests are false-negative results\u2013in this case, concluding a child doesn\u2019t have a concussion when she really does\u2013and false-positive results\u2013concluding a child needs treatment when she doesn\u2019t.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nThat\u2019s the most Mr. Skjoth will say about it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of this mystery substance aren\u2019t addressed. The story quotes a dermatologist who says \u201cthe best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\u201d But how does a dermatologist \u2014 or anyone \u2014 really know since the company won\u2019t say exactly what\u2019s in its product?", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the devices can produce ozone which, in some concentrations, can be harmful.\u00a0 It also cites one case where a similar device exploded during an air flight, mentioning that no one was seriously injured.\u00a0 It seems fair to consider the story satisfactory for this criterion.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain that the use of MRI technology might result in 'false signals'.\u00a0 It should have explained that this means that some patients who did not have clots that could cause a cardiopulmonary embolus\u00a0would have been treated as if they did.\u00a0 There was no discussion about the harms associated with this treatment; nor was there any discussion of the mental anguish that might accompany the diagnosis in the absence of the condition.\nSimilarly \u2013 the story included no discussion of the possible harms associated with the Angiojet.\u00a0 Although it appears, from the summary of safety and effectiveness data filed with the FDA, that the risks of bleeding complications, heart attacks, and death are less with the Angiojet than with the treatments for large deep vein thrombosis with which it was compared, there was no discussion of the harms associated with this device in the story.", "answer": 0}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nRose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\n\"Honey is not a panacea,\" she said in a telephone interview, but it has been used by British doctors for several years, and with its growing use elsewhere in the world, \"health-care professionals will be more likely to consider honey in treating wounds, and so more data will accumulate.\"\nThe South African Medical Journal reported in 2006 on a trial among gold miners in which honey worked as well as, and was more cost-effective than, a standard gel on shallow wounds and abrasions.\n(And there's wide agreement among medical professionals that people should not test the treatment themselves by slathering their cuts and burns with honey from the pantry shelf.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of using honey. Reports indicate that topical use of honey can cause a burning or stinging sensation and there is some concern about infection.", "answer": 0}, {"article": "For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re on the fence here. We\u2019re not suggesting that breastfeeding causes serious harm to mother or child, except perhaps in some cases of infectious disease transmission. However, breastfeeding isn\u2019t always the peaceful scene of contentedly suckling infant often portrayed in the media. Cracked nipples, nipple pain, engorgement, mastitis (breast infections) are not uncommon and can reduce breastfeeding success. In addition, breast milk is low in vitamin D, and exclusive breastfeeding may increase the risk of rickets. Some acknowledgment of these issues could potentially encourage steps to prevent and address these problems, which would be beneficial.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm of treatment mentioned was that the patient interviewed for the story feels a little sleepy in the afternoon after treatment. \u00a0However the experience of a single individual cannot be considered sufficient information on the possible harms associated with a treatment.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned.\nThe FDA said side effects of Gilenya in pediatric trial participants were \u201csimilar to those seen in adults,\u201d with the most common being headache, liver enzyme elevation, diarrhea, cough, flu, sinusitis, back pain, abdominal pain and pain in extremities.\nThe FDA added there are other serious risks with the drug including slowing heart rate, infections including a rare brain infection, vision problems, swelling and narrowing of the blood vessels in the brain, respiratory problems, liver injury, increased blood pressure and skin cancer, as well as potential harm to a developing fetus.", "answer": 0}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of side effects that may accompany long-acting contraceptive methods, nor of those associated with the birth control pill/patch/ring.\u00a0While effectiveness in preventing pregnancy is a paramount concern, women also weigh side effects in making a decision about which method to use.", "answer": 0}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No human testing was apparently done.\u00a0 In point of fact, it\u2019s far too early for the story to talk about either benefits or harms.", "answer": 2}, {"article": "The W.H.I.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\nstudy actually had nothing to do with menopausal symptoms.\nfindings, many new analyses and studies have prompted experts to rethink the wisdom of avoiding hormone replacement, especially for women within a few years of menopause whose personal and family history do not place them at high risk of breast cancer.\nMost of the 27,347 women entering the study were already in their 60s and 70s, already a decade or more past menopause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is trying to compensate for bad communication in years past, and so we believe it should meet a high standard when communicating the perspective it says is \u201cnew.\u201d\nHere is one harms statement that could use more careful writing and more numbers. The italics were added by us:\n\u201cIn an analysis in 2013 in the American Journal of Public Health, Dr. Philip M. Sarrel and his co-authors calculated that, based on reduced death rates among women taking only estrogen in the W.H.I. study, avoiding hormone replacement resulted in the premature deaths of 18,601 to 91,610 women in the decade after the study\u2019s release.\u201d\nThere is a lot of leeway between 18,000 and 90,000. The claim of deaths due to misinformation begs for a more accurate description of the equation used in the 2013 paper, as well as limitations of the analysis. It would also be\u00a0important to explain why this recommendation differs from that of the independent U.S. Preventive Services Task Force, which still recommends against the use of HRT for the prevention of chronic diseases. Their recommendation includes a\u00a0detailed description of harms and benefits on their web site.\nThe entire story is about the \u201charm\u201d possibly done by the warning years ago that hormone replacement therapy had been hyped inaccurately as a cure-all. But the story is remarkably silent on the potential \u201charm\u201d that still exists from hormone replacement for some women under some circumstances. The point that every woman should calculate her own personal risk versus benefits with her physician seemed buried.", "answer": 0}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\nTo determine if coronary artery calcium scores could inform blood pressure recommendations too, the researchers used data from 3,733 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) who had systolic blood pressures between 120 and 179 millimeters of mercury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states: \u201cThe scans use radiation, so there is a very small cancer risk for susceptible individuals.\u201d While the mention of cancer risk is laudable, we aren\u2019t clear what\u2019s meant by \u201csusceptible individuals.\u201d Also, it does not mention that CT scans are not recommended for pregnant women due to possible risk to the fetus. In addition, harms can also arise from medications prescribed to treat these calcium scores.", "answer": 1}, {"article": "Half of the group engaged in resistance training twice a week, while the other half continued to live their lives normally without systematic training.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nOn the other hand, the study indicates that systematic physical training can be a far more important supplement during treatment than has so far been assumed.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out that MS patients were advised against exercise in the past for fear of exacerbating the condition. But only positive effects correlated with the study are addressed in the release, with no mention of potential harms. Weight training and other types of exercise have the potential to cause injury, which might be more likely in MS patients with reduced muscle function, impaired balance, or other issues. Consequently, we give the news release, a Not Satisfactory rating here.", "answer": 0}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\nThe test involved using functional MRI to measure brain responses to spoken words in sleeping children.\nThis allowed the investigators to see which parts of the brain were being activated in typical children versus children with autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It makes a pass at this by saying the screening may inadvertently detect other brain problems and lead to misdiagnoses,\u00a0but it\u00a0doesn\u2019t develop the theme. Although fMRI does not use ionizing radiation, the procedure is long and the subject\u2019s head need to be restrained for the scans to be taken,\u00a0 In addition, the scan itself produces a good deal of noise (loud thumping)\u00a0requiring the subject to wear protective earphones.\u00a0 And, the test will take up to one hour to complete. ", "answer": 0}, {"article": "\u201cIt\u2019s not a decision made on a single visit,\u201d she said.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story mention psychological issues facing women who undergo mastectomy and early menopause that results from ovary removal, but the brief reference to harms and lack of important details understates the trauma, side effects and complications that preventive surgery causes women.\u00a0 There are also potential harms from the increased surveillance, for example, with ensuing biopsies. ", "answer": 0}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nThis work was supported by the National Institutes of Health (1R01CA195500, 1R01CA193380).\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\nAsiedu is also working to automate the screening process.\nHer laboratory has developed an all-in-one device that resembles a pocket-sized tampon with lights and a camera at one end.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No possible harms are described. While it is difficult to imagine how this device could cause direct harm, screening and diagnostic tests always involve the possibility of harm from false-negative and false-positive tests. A brief mention of this was warranted.", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will rate the story as satisfactory because it does clearly point out that the surgery is hazardous, sometimes triggering a stroke, and that some patients die soon after the procedure. However, the story reports stroke and death rates at the lower end of the ranges reported in medical literature. The story says a major task force report estimated the risk of stroke and death within 30 days after surgery as less than 3 percent overall, but up to 5 percent at some hospitals. However, the lower figure in that task force report uses data only from clinical trials, which typically involve highly skilled surgeons and have better outcomes than typical clinical care. That report also said that some observational data indicates a risk of stroke and death of almost 7 percent at some hospitals. The evidence review mentioned above concludes that the 30-day risk of stroke and death is 7 percent in clinical trials of carotid endarterectomy.\nThe story does warn readers that few hospitals and surgeons publish their individual results.\nThe story would have been stronger had it mentioned that there are harms that can occur if we started screening anyone, regardless of whether they had symptoms. As the USPSTF explains, \u201cFor the general primary care population, the magnitude of benefit is small to none. Adequate evidence indicates that both the testing strategy for carotid artery stenosis and treatment with [surgery or stenting] can cause serious harms.\u201d", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nIn the second study, Kaare Harald Bonaa of the University of Tromso in Norway and colleagues researchers gave 3,749 patients who had had a heart attack within the previous week the vitamins or a placebo for more than three years on average.\nThe new findings undermine a theory that taking B vitamins to reduce levels of an amino acid in the blood called homocysteine could protect against heart attacks and strokes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any harms associated with consumption of vitamin B supplements, although such harms would occur from vitamin B intake unlike that studied, so this gets a satisfactory grade. ", "answer": 1}, {"article": "The U.S. National Cancer Institute has more about colon and rectal cancer.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms of prolonged aspirin use, such as stomach bleeding and gastrointestinal ulcers.", "answer": 0}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\nThe study, funded by the National Institutes of Health, was designed to see if changing the type of diet people consumed helped with weight maintenance because dieters often regain lost weight.\nThe authors note a downside to the low-carb diet: It appears to raise some risk factors for heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the low-carb diet raised some risk factors for heart disease.", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nThe study is published in the online edition of Archives of Neurology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than its HealthDay competition in that WebMD actually told us how many people experienced harms in the study.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports: \u201cThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\u201d\nWhat were those side effects, how severe were they, and at what rate did they occur? The story doesn\u2019t say.\nWhile the news release doesn\u2019t say what specific side effects were observed, there are array of potential side effects with blood pressure medication that the story could have mentioned, such as nausea and fatigue.", "answer": 0}, {"article": "The non-contact sports included were cheerleading, cross country, cycling, tennis and track.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion,\" said Hamilton.\nThe study found that the advanced version of TCD ultrasound was able to differentiate between healthy and concussed athletes 83 percent of the time.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harmful effects, most notably false positive and false negative results, of the ultrasound procedure are not mentioned. A false positive could result in unnecessary follow-up tests and treatments while a false-negative result could lead to an athlete resuming on-field play too soon, greatly increasing their risk of head injury complications and severity.", "answer": 0}, {"article": "Newswise \u2014 Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not quantify whether there is any reduction in progression-free survival or \u201ccure\u201d rate with reduced radiation. The release also does not quantify what is meant by the words \u201creduced radiation.\u201d Is it half of normal doses, or reduced frequency but the same dose?\nThere may be potential harms in reducing a therapy aimed at a cure, but the release does not address this except in vague terms:\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee. \u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Neither the news release nor the original study on which it reported provided any detailed information about the safety of the investigational drug, other than to say that the estrogen product used has been shown to be \u201csafe and effective.\u201d\nThe product being discussed may offer a lower dose of estrogen than other currently available alternatives, but nonetheless, full disclosure requires some discussion of potential risks.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\nAfter three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity.\nOnly 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release leaves the impression that there were no ill effects, but the study summary itself notes that some women in the acupressure group experienced bruising, nausea, dizziness or chest pressure.\nAccording to the study, 15 participants experienced an adverse effect.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states, \u201cWomen taking estrogen in pill form saw an increase in HDL or \u201cgood\u201d cholesterol and a decrease in LDL or \u201cbad\u201d cholesterol, but an increase in triglycerides.\u201d But what does that mean? Would an increase in triglycerides be harmful to one\u2019s health? The article does not mention any other adverse effects, but it may have been beneficial to reinforce the notion that the study lacks the absolute numbers and statistical power to claim, \u201cNo significant differences in adverse events.\u201d", "answer": 0}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention any potential harms of insulin pumps, even though the researchers reported that two patients were hospitalized because of infections at the site of the pump insertion.", "answer": 0}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nThe 504 patients treated with the antibiotic nose gel mupirocin, also known as Bactroban, and washed with chlorhexidine, a common ingredient in mouthwash, developed an S. aureus infection 3.4 percent of the time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of the drugs, potential false positives from screening, deaths during the study, and impact of such a prophylactic protocol on antibiotic resistance are not discussed.\u00a0 \nThe\u00a0study publication\u00a0mentions adverse reactions due to local irritation of the nose or skin, which resolved after treatment was discontinued.\u00a0 \nWe believe harms always warrant at least a brief mention. ", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nThe Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health has awarded four grants through its New Investigator Program.\nFor the first time in Wisconsin, a research team will test a personalized cell therapy to treat a common and serious complication in bone-marrow transplant patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release does note that the study population was limited to post-menopausal women due to the effect of Lupron on sex steroid production, it does not mention potential harms associated with the drug combination among post-menopausal women or possible interactions with other drugs that may be used by this population. The study itself found that\u00a077 of 109\u00a0patients or (71%) experienced at least one adverse event. Three serious adverse events (2 cases of gastrointestinal hemorrhage and one case of deep vein thrombosis) were judged to be potentially related to the drug.\nEmphasis on or exaggeration of potential benefits, coupled with minimizing or totally ignoring harms, have been hallmarks of a majority of the ~2,000 news stories that we\u2019ve reviewed in the past 9 years. \u00a0News releases could help turn news stories in a different, more helpful, more complete direction. \u00a0That\u2019s our hope and expectation with this new feature of reviewing health care news releases.", "answer": 0}, {"article": "When nicotine enters the body, it binds to the same receptors in the brain that acetylcholine binds to, resulting in smoking's rewarding and reinforcement effects.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that people may become ill when taking the AD drugs. A source is quoted in the release says, \u201cWe know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and that this will limit their compliance.\u201d", "answer": 1}, {"article": "The rate was 26 percent lower in counties with screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAlthough this story does not go into detail about the potential harms of screening mammography, it does include comments from independent experts who point out that the scans do lead to the diagnosis and treatment of women whose tumors would never have become life-threatening.", "answer": 1}, {"article": ".\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nThis data highlighted compelling early results using the company's MRIdian system for the treatment of inoperable, locally advanced pancreatic cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy.", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Eating walnuts isn\u2019t harmful per se, but they are\u00a0packed with fat and protein,\u00a0and so they\u00a0should be eaten in moderation. The\u00a0amount participants in this study were eating (2.5 oz per day)\u00a0provides about 450 calories and is more than the amount of nuts that is generally recommended for daily consumption (1.5 oz).\u00a0It could\u00a0lead to weight gain if\u00a0not counterbalanced by\u00a0decreased intake of other\u00a0foods. The story\u00a0should have mentioned this.\u00a0 Of course the California Walnut Commission, which partially funded this study, would love to see people eat as many walnuts as possible.\u00a0 Why was the studied designed with this level of walnut consumption?", "answer": 0}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\nSimmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None were mentioned.\u00a0The other side of the early identification/screening coin is that labeling a child with a mental illness early on and with minimal evidence also has adverse effects with regards to self-image and development.", "answer": 0}, {"article": "With Cognivue, patients sit before a video screen that shows a series of images, such as a group of dots, that move around and fluctuate in clarity.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\nThe Pittsford, N.Y.-based company\u2019s FDA application included data from a comparative study involving 401 people recruited from 13 communities for older adults.\nDuffy said his tool holds promise as a relatively inexpensive and easy way to test people\u2019s memory and ability to think.\n\u201cI think it\u2019s a really potentially valuable tool,\u201d said Leslie Algase, an internist who tends about 2,000 patients in Rochester, at least 30 percent of whom are older than 65.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA approved this test on the basis of \u201clittle risk.\u201d But we really aren\u2019t told anything about what those risks are. Here\u2019s what the FDA had to say: \u201cThe risk of a false positive result may result in result in the clinician conducting a more detailed and extensive medical work-up to determine if a subject actually has cognitive impairment that would not be expected for his/her age and educational level. The risk of a false negative result would also be considered minimal. Clinicians would still be responsible for conducting a diagnostic work-up for patients presenting with cognitive impairment symptoms regardless of the Cognivue device result.\u201d\nOne thing both the story and FDA neglect to mention is that a\u00a0false positive can produce patient/family anxiety regarding a devastating condition with no effective treatments. We\u2019re not sure that qualifies as \u201clittle.\u201d", "answer": 0}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nThe new study involved 52 patients with floaters who received one session of either the YAG laser treatment or a \"sham\" placebo laser treatment.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms by saying, \u201cThere were no differences between the two groups in harmful side effects, according to the study.\u201d\nBut that\u2019s not enough\u2013What are the potential risks? The small size of the study (52 patients) makes it hard to exclude the possibility of side effects. As with any new surgery, doctors will have to learn how to do the procedure. Would you want to be an eye doctor\u2019s first patient to get the new procedure?", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Sales rose 82 percent from 2008 to 2009, reaching $430 million.\nAnd there is evidence that excess calcium can increase the risk of heart disease, the group wrote.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nBut, the committee concluded, a level of 20 to 30 nanograms is all that is needed for bone health, and nearly everyone is in that range.\nMost people need to take supplements to reach levels above 30 nanograms per milliliter, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, contrary to the claims of many advocates for increased supplemental vitamin D, there is evidence that\u00a0high levels of vitamin D may\u00a0have adverse\u00a0effects, such as increased risk for fractures and an increase\u00a0in the overall death rate. The story also explained that too much calcium has been linked to increased risk of kidney stones and, more tentatively, heart disease.", "answer": 1}, {"article": ".\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThey then exposed the tissue to bitter substances.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of preterm birth are explained, but nothing is said about the possible harm of the drug \u2014 even to pregnant mice and fetuses.", "answer": 0}, {"article": "Inflammation can make urination difficult.\nSymptom scores on the IPSS test also showed improvement.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nDuring the periodontal care, the men received no treatment for their prostate conditions.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly assumes readers will understand there is potential harm from untreated gum or prostate disease and that is probably reasonable. It might have described the risks and limitations of repeated PSA screening and biopsies (which can lead to false-positive results and unecessary treatment), but we don\u2019t think that was an essential part of this analysis. Nonsurgical treatment of periodontal disease has a low potential for harm, something the release could have mentioned. The release does point out the risk to heart patients and pregnant women of untreated periodontal disease.", "answer": 1}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nParticipants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the increased risk of getting a cold with not enough sleep \u2014 with the attendant sometimes debilitating symptoms that are all-too-familiar to many. But mainly the story is advocating for more sleep \u2014 and could there be risks to getting more sleep or trying to stay in bed for 8 hours if you\u2019re only hardwired to sleep for 6 hours? That\u2019s unclear, but the story could have clarified that although more sleep is associated with fewer colds, that doesn\u2019t necessarily mean that increasing your amount of sleep will reduce the number of colds you get. Proving that would require a different study. We\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nIndiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release encourages people to add magnesium through their diets and through supplementation but doesn\u2019t tell them what the recommended daily allowance is. In the United States, the current magnesium recommended intakes are 400-420 mg/day for men and 310-320 mg/day for women.\nExceeding the recommended levels of magnesium through supplementation can cause side effects. Although these are not likely to be life-threatening, excessive intake of supplemental magnesium is harmful to\u00a0 individuals with impaired kidney functions. In addition, magnesium can interfere with certain medications so patients should always consult with their doctor before adding a supplement.\nFrom WebMD: \u201cDoses less than 350 mg per day are safe for most adults. When taken in very large amounts, magnesium is POSSIBLY UNSAFE. Large doses might cause too much magnesium to build up in the body, causing serious side effects including an irregular heartbeat, low blood pressure, confusion, slowed breathing, coma, and death.\u201d", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lays out a few harms of hormone blockers \u2014 which it notes is also called chemical castration in men \u2014 including hot flashes, breast growth and sexual problems.", "answer": 1}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\n\"Walking was the cornerstone of the program,\" says Thomas Gill, a professor of geriatrics at the Yale School of Medicine and an author of the study, which appears in Annals of Internal Medicine.\nCardinal says older adults need to realize that exercise can greatly improve their quality of life by maximizing function as long as possible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story basically recommends physical activity for the elderly, which most experts would support. But the study in question focused on \u201csedentary people between 70 and 89 years old who had some functional limitations, but who could walk about a quarter of a mile in 15 minutes or less, unassisted by another person or a walker. (Canes were OK.)\u201d\u00a0 There is obviously a great deal of variation in a population that broad and many included in that age bracket may also have balance, pain or stability\u00a0issues that might preclude jumping into a similar program.\u00a0\u00a0We would have been happier if the story focused early on any new program of physical activity being clearly linked to an initial consult with the person\u2019s physician.\u00a0 While the story does mention at the end that the authors of an accompanying editorial advised physicians that, \u201cPrescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\u201d that seemed insufficient compared to the consequences of physical-activity-induced injury among the elderly.", "answer": 0}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\nMore studies will be needed to determine whether this method can be used as a widespread treatment for other brain-related disorders, but if today\u2019s research is any indication, TMS could be a key to improving the lives of Americans suffering from a multitude of disorders.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are a feature of this story.", "answer": 1}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\nThe current study included 7,625 French adults age 65 and older who reported on their diets and other lifestyle factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the harms of hormone therapy, which include a higher\u00a0risk of heart disease, stroke and breast cancer (but see \"quantification of benefit\" criterion below).", "answer": 1}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\nIt's estimated that every year 12 million Americans go to the doctor seeking help for headaches.\nBernstein says she sees lots of desperate patients like Bradford.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A strong point of this story is that it does explore the potential harm from unnecessary diagnostic tests. We applaud the mention, as too few stories address this phenomenon, but the facts that are presented to help the audience understand why a test would be harmful are somewhat confusing. The story says:\nMafi\u2019s study did not include patients with tumors or other serious problems that can cause headaches. He only looked at otherwise healthy patients who suffered chronic headaches. And in these cases, repeated diagnostic testing can lead to further unnecessary procedures like biopsies.\u00a0On top of that, exposure to radiation in tests like CT scans adds up over time and can increase the risk of certain cancers.\nIn other words, diagnostic tests could find something like a tumor that is causing a headache or early bleeding in the brain prior to an aneurysm, for example. But those people weren\u2019t part of this study so we have no way to make a true comparison to people who had a test and found a problem versus people who had an unnecessary test.\nThe story should have explained the exclusion of patients with tumors more clearly. The patients here are chronic headache patients, as opposed to people who have developed headache as a new symptom or a new type of headache. Depending on their presentation, the latter two may need a series of tests.", "answer": 1}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nBut ultimately she decided she didn't want to go through more surgery.\nSo you have to at least expect that sometime in your life, you are going to need a reoperation.\nWhat's more, he says few of them follow the recommendations to get routine MRIs to screen for leaks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed common problems, but was silent on:\nHalf the story on harms just isn\u2019t good enough in this case.\n", "answer": 0}, {"article": "Or eat turkey or bananas, both of which contain tryptophan, which is believed to trigger sleepiness.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\n-- Practice good sleep hygiene.\nOkay, so just how long are we supposed to stay asleep?\nInstead, choose whole-wheat crackers, which can control insulin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms don\u2019t seem to apply in this case. ", "answer": 2}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nIt may need to be followed with the physical colonoscopy later, as well.\nThis new wave of radiology-based colonoscopy could improve those odds further.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nMore routine DNA tests and stool sampling, which show signs of bleeding caused by irregular growths, can also help detect colon polyps and indicate that the need for a full colonoscopy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions radiation exposure and the potential for the need for a follow up colonoscopy if a suspicious lesion is found. In reality almost one third of routine colonoscopies identify a suspicious lesion that is either removed or is biopsied. That means that roughly one in three people undergoing a bowel preparation for a CT colonoscopy will need to undergo a second round for removal or biopsy of a suspicious lesion. That is a significant downside that should have been emphasized in the story.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In presenting the lack of harms associated with even the high doses of antigen needed to trigger the desired immune response, the article included an important caveat about elderly individuals typically faring worse than the healthy young people tested.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms in a comment by the lead surgeon who describes complications from the procedure as \u201crelatively minor\u201d but it could have just as well have said \u201crelatively serious\u201d for all the insight the phrase gave us about harms and risks from the robotic surgery. The surgeon also is quoted saying \u201ceven with a minimally invasive approach, the surgical management of severe cancers in mostly elderly patients will likely involve complications.\u201d Again, we are not told what those complications are and their impact on the patient.", "answer": 0}, {"article": "And all of this ultimately improves general quality of life,\" she added.\nOther studies have demonstrated beneficial health and quality of life effects from yoga interventions in cancer patients.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether anyone felt that yoga may have caused any harms. Injuries from the practice of physical yoga (as opposed to meditative) are, in fact, quite common, although most are minor and include pulled muscles and sprains but can extend to more serious injuries such as a ruptured disk in the lower back.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article addressed the safety issue of of the three diets, which was a main outcome of the research study.\u00a0 There had been concern among medical and health professionals that low carbohydrate diets like the Atkins Diet, which allow large amounts of meat and cheese, could cause harmful increases in LDL (\"bad cholesterol\") and increase the risk of heart disease.\u00a0 An important message of this article is that alternative dietary approaches can be safe and beneficial to reduce serious health risk of overweight and obesity.", "answer": 1}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nMerck said trial results would be presented at an upcoming medical meeting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When you\u2019re simply passing along information spoonfed to you by a drug company, you\u2019re not likely to explain or quantify the potential harms. \u00a0And, indeed, Reuters didn\u2019t even nod in the direction of discussing harms.\nMerck\u2019s news release unhelpfully said the \u201csafety profile of Keytruda in this trial was consistent with that observed in previously reported studies.\u201d\nIn our 6 tips for writing about immunotherapy, we note that harms of immunotherapy drugs \u2014 which can include serious adverse effects such as diarrhea and pneumonitis \u2014 are often downplayed", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that \"There was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\" \nBut the story did not provide a clear picture of the view from patient perspective about how the two treatment approaches differed.", "answer": 1}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention any harms of using daily aspirin (like bleeding). ", "answer": 0}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nResearchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\nAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was badly incomplete and confusiong in reporting on harms.\nFirst, it inaccurately reported that \u201cthe quality of life for patients on FOLFIRINOX was not as good\u2026.After six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\u201d\u00a0 That\u2019s wrong.\u00a0 The researchers reported:\u00a0\u201cAt 6 months, 31% of the patients in the FOLFIRINOX group had a definitive decrease in the scores on the Global Health Status and Quality of Life scale versus 66% in the gemcitabine group. Significant increases in the time until definitive deterioration in the quality of life were also noted in the FOLFIRINOX group for all functional and symptom scales.\u201d\u00a0 So quality of life was BETTER, not worse in the Folfirinox group.\nAnd the reporting of harms was oddly incomplete.\u00a0 The story stated:\u00a0\u201cAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\u201d\nWhy did the story report that statistic instead some of these easily explained in the journal article:\n75 of those in the Folfirinox group (46%) had neutropenia compared with 35 in the Gemcitabine group (21%) 21 of those in the Folfirinox group (13%) had diarrhea compared with 3 in the Gemcitabine group (2%) 15 of those in the Folfirinox group (9%) had sensory neuropathy compared with 0 in the Gemcitabine group \u00a0 ???", "answer": 0}, {"article": "Bright-colored berries have long been a part of any healthy diet, owing mainly to the anthocyanins that give them their vibrant color and act as antioxidants to fight off damage to cells.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\nThe results are particularly encouraging because they showed that a change in diet could affect heart-disease risk for relatively young women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both HealthDay and NPR, TIME also did not discuss potential harms. But all health interventions have harms, as well as benefits and costs.\nWe looked the other way and gave a N/A score for no discussion of costs, but we can\u2019t do so with harms.", "answer": 0}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nAnd there\u2019s another major problem with the use of many antidepressants in children: They may increase suicidal thoughts and behavior.\nIt\u2019s notoriously hard to treat depression in kids\u2014the antidepressants we rely on to treat adults seem to be less effective and more dangerous when used on younger minds.\nA comment attached to the Oxford paper, written by Dr. Jon Jureidini, a child psychiatrist at the Women\u2019s and Children\u2019s Hospital in Adelaide, Australia, goes even further in decrying the use of antidepressants in kids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some harms and uncertainty associated with antidepressant use in young people whose brains are not fully developed, including an increased risk of suicide.\nBut, unfortunately, the story goes\u00a0beyond the evidence, and includes erroneous information.\nThe story says: \u201cSince 2004, the FDA has advised\u00a0that antidepressants not be prescribed to individuals under 24 due to the increased risk in suicidality.\u201d This is not true\u2013the FDA did not make such a blanket statement\u2013they note the increased risk of suicidality, but leave it up to physicians to weigh the possible risks vs possible benefits.\nIt also says: \u201cFDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\u201d But, FDA doesn\u2019t address brain development in their evaluation of drugs.\nThe story then says: \u201cresearch on antidepressants suggest they negatively affect brain plasticity\u00a0and memory\u201d and cites two rather dated animal studies that that don\u2019t seem well described by the story.\u00a0\u00a0Antidepressants do seem to affect brain plasticity, but in a good way, as opposed to stress. We\u2019re aware of no adverse effects on memory documented in humans with antidepressant treatment (although depression adversely affects memory).\nAlso, the reference the author cites for antidepressants sparking a chemical reaction to increase the risk of suicide is about psychosis, not suicide, at least as far as we can tell from the abstract.", "answer": 0}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nHe is a consultant for EMD Serono Inc. and receives funding from Bristol-Myers Squibb to perform biomarker studies in MCC clinical trials.\nDr. Paul Nghiem, affiliate investigator of the Clinical Research Division at Fred Hutch, and the George F. Odland Endowed Chair in Dermatology at the University of Washington School of Medicine, is a senior investigator on the clinical trial that led to the FDA approval and the senior author on the Lancet Oncology article that preceded the approval.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The same study named in the release shows that multiple patients had side effects from the drugs. These are not mentioned in the release.\nThe side effects occurred in two patients who developed lymphopenia (abnormally low white blood cells), one who had an increase in blood creatine phosphokinase which could indicate muscle inflammation or damage, and other disorders.\nThere were also \u201cserious treatment-related adverse events\u201d in five patients, including enterocolitis [inflammation of the small intestine and the colon], infusion-related reaction, aminotransferases [enzymes related to the liver] increased, chondrocalcinosis [calcium deposits in cartilage], synovitis [joint inflammation], and interstitial nephritis [inflammation of the kidneys].", "answer": 0}, {"article": "\u201cToday I\u2019d say he has \u2018autism light,\u2019 \u201d he added.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nWilliam E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nDr. Arnold said that if the results bore out that neurofeedback was making the difference, he would seek financing for a broader study, with as many as 100 subjects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story the benefit of the doubt on this criterion because it did at least mentions that there are potential harms, but the story would have been better if it had given more detail about the type and frequency of harms. It should have also clearly noted that risks exist even when a treatment is supervised by a skilled practitioner.One of the potential harms raised is this uNPRoven treatment may be favored over proven options like behavioral therapy and medication. \u00a0The story mentioned readily available neurofeedback packages while at the same time had stern warning from a society spokesperson that people can have seizures or anxiety attacks if they use equipment that they get from ebay and use without supervision. No information about how commonly problems such as these occur. ", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was at least the acknowledgement that these drugs do carry side effects \u2013 but none was specified nor quantified.", "answer": 0}, {"article": "It is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\nAfter three months the results were promising, the company said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story explained that there were no adverse events reported up to three months later but that risks may become evident much later. That\u2019s an appropriate and important reminder.\nBut the story didn\u2019t go far enough in providing available context.\u00a0 The coronary stents are well known to have problems with clotting \u2013 generating a new generation of more expensive \u201ccoated\u201d stents and the need for prolonged treatment with expensive oral medications to prevent clotting. The story could have addressed this \u2013 extrapolating that coronary artery complications could occur in penile arteries is not unreasonable. However, the trade-offs of stent risks \u2013 protecting the heart vs. protecting erectile dysfunction are quite different (and implicitly equating them smacks of another element of disease-mongering).", "answer": 0}, {"article": "If necessary, he suggests finding an indoor place to move, whether it's the gym, a staircase or a shopping mall.\n\"Just 30 minutes a day of walking, riding a bike, doing yoga -- anything active, really -- can result in significant reduction of asthma symptoms.\"\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out some precautions people need to take before exercising. The study\u2019s lead author explains that patients should use \u201creleaver medication\u201d (sic) before they exercise and adds they should take the time to cool down afterward. He also says people could exercise indoors during the winter months, since cold air provides another trigger for asthma symptoms. It would have also been helpful to note that any physical activity triggers asthma symptoms in some people. In these cases, patients may have to take medicines before they exercise. The National Heart, Lung and Blood Institute recommends easing into physical activity with a warm-up period and also wearing a mask or scarf over the mouth when exercising in cold weather. More detail would have been appreciated here, but we feel the news release had enough for a Satisfactory rating.", "answer": 1}, {"article": "\"What was unique about this study is the very large number of children studied,\" Dawson noted.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\nThe children with autism also had increased connectivity between brain regions that were farther apart, which might be a mechanism developed to compensate for reduced short range connectivity, the researchers said.\n\"The hope is that early behavioral intervention can help mitigate these functional impairments, helping to form the connections that natural develop in typical children.\"\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nor is it clear what the potential harms might be. The rise in autism diagnoses has been controversial in part because once a child is put \u201con the spectrum\u201d they may be treated differently by the educational system, not to mention other kids.\nIf EEG is used inappropriately and \u2018overdiagnosis\u2019 is a concern, this could be a problem.", "answer": 0}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe prostate study sought a better way to use PSA tests, which are troublesome because PSA can be high for many reasons besides cancer, and doctors don't know which cancers need treatment or whether screening saves lives.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe results don't apply to using these tests on women with symptoms of ovarian cancer or abnormal physical exams.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the strengths of the piece, that it takes harms head-on in a screening story, instead of assuming that early screening could do nothing but prevent disease and death. The story does a good job quantifying the harms for some of the screenings mentioned and, for others, explains that the studies did not address harms. It says in its third bullet point,\u00a0\u201cScreening women with no symptoms for ovarian cancer with a blood test and an ultrasound exam is harmful. It didn\u2019t prevent deaths and led to thousands of false alarms, unneeded surgeries and serious complications.\u201d Later, the story becomes more specific, saying, \u201cAfter 13 years, there were no major differences in ovarian cancers found or deaths from the disease. Screening found only 212 cancers while giving 3,285 false alarms that led to 1,080 unneeded biopsy surgeries and 163 serious complications.\u201d", "answer": 1}, {"article": "\"It is very big.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\n\"Researchers have been working on this and similar technologies for some time, and others have predicted a day when we will be able to diagnose cancers before they are otherwise visible by current techniques,\" said Dr. Len Lichtenfeld, the group's deputy chief medical officer.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nCapturing and counting those cells can provide information to patients and doctors about prognoses with certain types of metastatic cancers, the statement said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms, not even the obvious possibility that this sort of test could detect cells that don\u2019t actually present a serious health threat or aren\u2019t susceptible to treatment. It perpetuates the myth that early detection is always beneficial and turns a blind eye to the harms of overtreatment.\nBy comparison, see what Dr. Susan Love said on the ABC News website:\n\u201cHaving the cells in the bloodstream does not necessarily mean that the cancer will spread and kill you. Just because you find them does not mean you know what to do with the information. \u2026We all have cancer cells in our body that are dormant,\u201d Love said. \u201cWe need to be careful not to over react to the presence of cancer cells when the treatment may actually be worse than the cure.\u201d \n\u00a0", "answer": 0}, {"article": "Professor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\nIn addition, the team found that even patients who have had Type 2 diabetes for up to 10 years can reverse their condition.\nOverall, 12 patients who had had diabetes for less than 10 years reversed their condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might arise from this approach. There are risks that come with very low calorie dieting \u2014 which was done for 8 weeks according to the release. Potential harms of extreme dieting should have been mentioned including whether there were any health issues in the 30 patients over the six months study period.\nThe most common side effect of very low calorie dieting is gallstones, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Minor, short-lasting side effects include fatigue, constipation, nausea and diarrhea. The Institute recommends that patients following a very low calorie diet that results in rapid weight loss should be monitored by a doctor.", "answer": 0}, {"article": "Watson shares were up 50 cents, or 1.2 percent, to $43.20 in morning trade.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nData shows the one-pill treatment, called ella and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.\nThe agency\u2019s reviewers also said the company\u2019s studies showed no unexpected side effects in women, although reports of nausea, headache and abdominal pain were common.\n\u201cThere is a medical need for an efficient emergency contraceptive product which acts consistently over a prolonged time period,\u201d HRA Pharma said in a separate document released by the FDA.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA found no unexpected adverse events and describes the side effects of the drug including nausea, headache and abdominal pain as \"common.\" The package insert for EllaOne describes these side effects as affecting more than 10% of users. It would have been helpful if the story had cited that stat. ", "answer": 1}, {"article": "The older people tended to have more activity in several inflammation-related genes compared with the younger group \u2014 no surprise, since as people get older, inflammation throughout the body tends to rise.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\nCaffeine inhibits this circuit and turns the inflammatory pathway off, the researchers say.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\n\u201cClearly in aging something is breaking down, and we become less effective at managing this inflammation,\u201d says Mark Davis, director of the Stanford institute.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t addressed at all \u2014 and there are potential harms associated with drinking, as the story says, \u201cmore than five cups of coffee a day.\u201d As the Mayo Clinic notes: \u201cEven among adults, heavy caffeine use [more than around four cups of coffee per day] can cause unpleasant side effects [including fast heartbeat and muscle tremors]\u2026.Some people are more sensitive to caffeine than are others. If you\u2019re susceptible to the effects of caffeine, just small amounts \u2014 even one cup of coffee or tea \u2014 may prompt unwanted effects, such as restlessness and sleep problems.\u201d", "answer": 0}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\nHundreds of patients who received the model have had to undergo new operations to replace it.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nAlthough the researchers pointed out in their journal article that \u201cthe initial experience includes several cases of problems such as lead migration, lead dislodgement, and inappropriate sensing,\u201d the story does not refer to any potential harms.", "answer": 0}, {"article": ".\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nIn another study scheduled to be presented at the meeting, researchers found that high-frequency ultrasound with elastography can help distinguish between cancerous and benign skin lesions, which could improve the efficiency of skin cancer diagnosis.\n\"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\nSiegel and his colleagues used ultra-high-frequency ultrasound to image cancerous and benign skin lesions on 40 people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned no harms of elastography, which are similar to conventional ultrasonography. Excessive false positive results could lead to needless biopsies in the case of both skin and breast lesions.\u00a0 Alternatively, false negative results of the new test could lead to undiagnosed breast or skin cancer.\u00a0 The story focuses on the reduced likelihood of biopsy in both cases failing to comment on the potential downside. ", "answer": 0}, {"article": "In 2005, she was told she was having a boy, and she chose a name, bought boy clothes and told everyone.\nThe study \u201chas wide-reaching implications,\u201d said Dr. Louise Wilkins-Haug, director for maternal-fetal medicine and reproductive genetics at Brigham and Women\u2019s Hospital in Boston, who was not involved in the research.\nMost tests that were highly accurate were conducted on a mother\u2019s blood, not urine.\nOne potential worry is that women might abort fetuses of an undesired sex.\n\u201cIndividuals need to be careful\u201d to ensure that companies use rigorous laboratory procedures and support accuracy claims with data, she added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story lists potential harms. These range from inaccuracy, because the tests are unregulated and the laboratories don\u2019t have to meet medical standards, to the potential for abortions based on fetal gender.", "answer": 1}, {"article": "\u201cWhy would we?\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\nSeamus Kennedy, president and co-owner of Hersco Ortho Labs in New York, said there was an abundance of evidence \u2014 hundreds of published papers \u2014 that orthotics can treat and prevent \u201cmechanically induced foot problems,\u201d leading to common injuries like knee pain, shinsplints and pain along the bottom of the foot.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nAs for \u201ccorrective\u201d orthotics, he says, they do not correct so much as lead to a reduction in muscle strength.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article focused largely on the potential upside of shoe inserts\u2014and didn\u2019t explicitly address potential harms from the use of orthotics.\u00a0It mentioned that inserts could increase muscle work requirements but didn\u2019t discuss the significance of this point in terms of pain and function.\nSome of the potential harms\u2014 such as exacerbating injury risk and/or pain and dysfunction\u2014are obvious. There are more subtle harms as well, such as creating the expectation among athletes that they cannot safely exercise, perform normal daily activities, and work\u00a0 without the aid of an orthotic.\n\u00a0\n", "answer": 0}, {"article": "The outcomes are getting better and better.\"\nThe clinical protocol also examined how to best use a steroid formulation called decadron to treat high-risk ALL patients.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nPrevious studies by the Children's Oncology Group showed that in standard risk ALL patients--those with low white blood cell counts or under 10 years of age--decadron prevented relapse in both the spinal fluid and in the bone marrow.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone \u201cwere at much higher risk for a debilitating bone condition called osteonecrosis,\u201d although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well.", "answer": 1}, {"article": "In addition to his CHOP position, Margaritis is a faculty member at the Perelman School of Medicine at the University of Pennsylvania.\nBased on previous work by Margaritis, the UNC team identified dogs for this gene therapy study.\nThe treated dogs had expressed levels of clotting factor VII that would be therapeutic in humans, with long-term stability.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms in a couple of places, as in this excerpt:\n\u201cThe FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\u201d\nand in a quote by the lead researcher:\n\u201cBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\u201d\nBut as this study was done in canines, we would have liked a bit more detail on how harms might\u00a0 manifest in human clinical trials.", "answer": 1}, {"article": "Both are reasonable options.\u201d\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nResearchers randomly assigned 241 women with urinary incontinence to daily medicine and a placebo injection, or a Botox injection and a daily placebo pill.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does detail the side effects of dry mouth, urinary infections and incomplete emptying of the bladder, but these are never quantified. But language like \u201cmuch more common\u201d or \u201cmore likely\u201d is unhelpful in its lack of specificity.\u00a0 The paper itself revealed:\nDry mouth occurred in significantly more participants in the anticholinergic group than in the onabotulinumtoxinA group (46% vs. 31%, P=0.02). Intermittent catheterization was recommended according to protocol criteria at scheduled visits in the onabotulinumtoxinA group only (in 5% of the participants at 2 months, 3% at 4 months, and 1% at 6 months). However, additional women in both groups performed catheterization off-protocol . More women in the onabotulinumtoxinA group than in the anticholinergic group had a urinary tract infection (33% vs. 13%, P<0.001).\nMaybe 15 percentage point differences\u00a0 or 20 percentage point differences are things we should tell readers about and let them judge.", "answer": 0}, {"article": "\u201cMany have been told all their lives that if they ingest peanuts they will have a severe reaction and die,\" he said.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nIn the second phase of a drug trial, half of participants wearing the highest dose \u201cpeanut patches\u201d for a year were able to consume the equivalent of four peanuts without reacting, researchers reported Sunday at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.\nIt could be several more years before the patch will be available for consumers.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story handles this aspect well, by noting side effects of the patches and explaining the difficulties experienced by two participants forced to drop out of the study.", "answer": 1}, {"article": "\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThey plan to continue modifying the test to improve the urine sensitivity to that of the cervical tissue samples.\nUsing methylation as a value to diagnose malignancy, the three genes together showed a 90 percent sensitivity, meaning that their presence was able to predict a true positive cancer sample this percentage of the time.\nThe researchers tested the value of these genes as markers using 214 cervical cell samples collected from women undergoing Pap smears at Hospital Dr. Hernan Henriquez Aravena in Chile.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does make\u00a0it clear that this small urine test study correctly identified those without cancer 83% of the time, a considerable improvement over the false positive rate of the more traditional Pap test.\nBut the real risk of this new test is that it may indicate a false negative \u2014 suggesting all is well \u2014 when it isn\u2019t. Under the best of scenarios, the new test gets it wrong 10 in 100 times. When applied to a more usual practice setting, it gets it wrong 15 to 25 in 100 times. Here getting it wrong may mean missing an advanced pre-cancerous lesion or even a cancerous one. One can argue that even 1 in a 100 times is too much, but in developing countries this may be better than current practice. However, we don\u2019t believe the risk of false negatives has been clearly or addressed.", "answer": 0}, {"article": "A role for dietary macroalgae in the ameliorating ration of certainement Risk Factors Associated with cardiovascular disease.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nBy adding seaweed to processed foods we can make food healthier.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nIt can even enhance the flavor of the food, they argue.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are some vague references to harms in a list of bullet points at the end of the release. We do not think this satisfies the criteria but, instead, creates more confusion. It says:\nWhat is one to make of that?", "answer": 0}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nRazzini didn't know how much American patients might have to pay for such treatment, but added, \"Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t mentioned at all. The Mayo Clinic notes that risks associated with acupuncture range from soreness to infection to organ injury. Further, the clinic warns that some patients are at higher risk than others, such as patients who have pacemakers or bleeding disorders.", "answer": 0}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nEven if bone density did not increase, improvements in posture and balance that can accrue from the practice of yoga can be protective, Dr. Fishman said.\nA decade after the start of the study, bone density measurements were again taken and emailed to the researchers; many participants also had repeat X-rays done.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides insight into the downsides of bisphosphonate therapy but says nothing about the potential dangers of yoga. It is true that, done correctly, yoga is not likely to produce significant injuries. However, the subjects in the study were not supervised nor was their positioning for each of the poses determined. Incorrect alignment can cause joint strain and joint and injury. In fact, the Times itself has previously reported that yoga can wreck your body!", "answer": 0}, {"article": "\"To make any form of health care work and to truly power economic mobility, we have to get healthy,\" says Levin.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nTaking small steps, like those proposed by the National Cholesterol Education Program Adult Treatment Panel 3, which include assessing heart disease risk, making lifestyle and dietary recommendations, and assessing the need for future follow-up appointments and pharmaceutical interventions, could prevent approximately 20,000 heart attacks, 10,000 cases of coronary heart disease, and save almost $3 billion in medical costs each year.\nWe hope to empower patients with new research about the long-term cardiovascular health benefits of a vegetarian diet, which include a reduced risk of a heart attack, stroke, and premature death.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms but does suggest registered dietitians and the menus found in federal recommended dietary guidelines could help people transition to a plant-based diet. There is mounting evidence that plant-based diets may be associated with reduced risk for many health conditions, as long as one eats a balanced diet and in moderation. We\u2019ll rate this one Not Applicable.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nOne year after starting treatment, all participants had improved vision.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\nHowever, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nothing is reported about adverse effects either locally in the eye or systemically. While these drugs are standard treatments, a line about potential for infection or other potential harms should have been included. Information about completion rates and reasons for dropouts would also have been welcome.", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nAbout 6,000 have taken courses in dry needling in the past few years, Zylstra says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We like that the story called out risks specifically, which is something we don\u2019t see often. It says, \u201cNeedling can produce minor bleeding and some soreness, but in trained hands, and with the use of sterile needles and gloves, \u201cit\u2019s a very safe procedure,\u201d Briggs says.\u00a0In rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\u201d\nThe story would have been stronger if it had quoted a source with no vested interest in discussing risks. Also, it\u2019s worth pointing out that these risks are real whether \u201ctrained hands\u201d do the procedure or not.", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. The story could have mentioned the potential for excessive folic acid intake to interfere with vitamin B12 uptake which, though unlikely in a teen population, could mask symptoms of B12 deficiency. But we\u2019ll give it the benefit of the doubt on this.", "answer": 2}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nFor those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Close call here, but the story goes a step further than WebMD when discussing the possible\u00a0adverse effects of consuming too much chocolate. In addition to warning that chocolate has a lot of fat, sugar and calories, it explicitly notes that eating too much of it\u00a0\u201ccould be counterproductive.\u201d WebMD offers no comparable warning and suggests that eating more chocolate than\u00a0was\u00a0consumed in this study would\u00a0result in similar\u00a0health benefits.", "answer": 1}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nThe main side effect from the device is that people can wake up with a sore tongue.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\nLights out for the 69-year-old meant sleeping for a couple of hours before being jolted awake in the middle of the night and lying there electrified.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the main side effect from the device is \u201cthat people can wake up with a sore tongue.\u201d We\u2019ll give this a barely passing satisfactory. (What about people who may have suffered adverse reactions or complications from surgery?)", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fainting and abnormal potassium levels were mentioned as harms of treatment, though there was no indication of how common these harms might be. Another harm not mentioned was that it is known from other studies that labeling someone as \u2018hypertensive\u2019 can severely affect their quality of life (self perception). ", "answer": 1}, {"article": "The fibers within the tendons fray.\nWhy then does a cortisone shot, an anti-inflammatory, work in the short term in noninflammatory injuries, providing undeniable if ephemeral pain relief?\nBut this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provided adequate detail on the main harms associated with steroid injections: disruption of the long-term healing process and relapse into pain and disability. It might have been useful to also mention other potential side effects and potential harms related to steroid injections.\n", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nCalled angiotensin receptor blockers, these drugs have a greater protective effect against dementia than ACE inhibitors, the study found.\nCaution was urged by Dr. Richard B. Lipton, vice chairman of neurology at Albert Einstein College of Medicine in New York City, who has done work on the genetics of Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One harm was mentioned \u2013 \"There are potential hazards, such as too-low blood pressure that can lead to damaging falls.\"\u00a0 That\u2019s an incomplete listing, but we\u2019ll give the story the benefit of the doubt in at least nodding in the direction of potential harms. ", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThe study did not look at possible side effects of kampo herbs.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nHe says it was accidentally discovered that kampo herbs could wipe out symptoms in many people while testing the ancient remedy against an allergic skin disorder known as atopic dermatitis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained:\nThe study did not look at possible side effects of kampo herbs. But a major problem facing kampo medicine is herbal product quality. There have been cases in which poisonous plants found their way into the herbal mix, resulting in kidney damage, for example.", "answer": 1}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\nFor the study, researchers analyzed data in the National Inpatient Sample (NIS) database of more than 75,000 adults who underwent either laparoscopic or open fundoplication for GERD between 2000 and 2013.\nPaula D Strassle, MSPH Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC also participated in this study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release names complications associated with both types of surgery for GERD, while stating that patients undergoing laparoscopic procedures encountered fewer of them: \u201cpostoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\u201d", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that deep breathing may cause people with asthma or panic disorders to hyperventilate and that a different breathing pattern is often recommended for these patients. The story could have mentioned exercise or psychological techniques for reducing stress and improving health, many of which are supported by stronger evidence.", "answer": 1}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\n\"Right now we don't have any good evidence that there is anything we can do to reduce the risk of developing Parkinson's disease, but research is ongoing,\" added Isaacson, also an associate professor of neurology at Florida International University's Herbert Wertheim College of Medicine in Miami.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for noting the potential side effects of statins up high.\u00a0 And later it reported:\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood. Co-Q10, an antioxidant, is thought to have benefits for people with Parkinson\u2019s disease.\nBut we wish the story had gone the extra step of actually quantifying the harms from this study or other studies.\u00a0 And it could have cited the recent FDA update on the risks associated with statins.", "answer": 0}, {"article": ".\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\nOppenheim said the next step would be clinical trials to validate whether MRIs serve as a \"surrogate clock\" for stroke onset.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated this application of MRI technology.\u00a0 Although the harms would likely be small, the harm that may arise from incidental findings is worth noting.\u00a0 The more you scan \u2013 something being proposed in this study \u2013 the more you find, including things you didn\u2019t need to find. That\u2019s worth at least a line.", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe other 13 people in the study had previously received a type of immunotherapy before the study.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a dose-escalation study that was conducted to determine the safest dose. This means the focus was symptoms and side effects. And the news release states that. Yet, none of the symptoms or side effects patients in the study experienced are described in the news release. This is a major deficiency of this release.", "answer": 0}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nAs to whether circumcision reduces sexual sensitivity, Perera said there's no evidence that it affects sensation when performed on adults.\nNot so, write the Australian researchers, who examined eight studies for a review in the latest issue of the Annals of Family Medicine.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nThe highest-quality studies, known as randomized controlled trials, don't report whether infant circumcision affects sensation, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nThe disease most often strikes adults after age 20, but it can develop in children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know if any of the mothers who reported a high intake of vitamin D experienced adverse effects; however, it\u2019s worthwhile to mention that excessive intake of vitamin D supplements is associated with harms, including nausea, vomiting, constipation, and weakness. Additionally, information about how to safely get enough sun exposure to convert vitamin D to its active form would have been helpful.", "answer": 0}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\nRobert \"Skip\" Cummins, Cyberonics's CEO, dismissed such criticism and said his company, whose sole product is VNS, faced similar skepticism after the device was approved for epilepsy in 1997.\nThe device has also attracted attention on Capitol Hill, where the Senate Finance Committee has spent two years looking into decision-making at the FDA.\n\"There is nothing out there as safe and effective,\" Cummins said, adding that a company-financed study showed that the effectiveness of VNS improved over time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Very thorough discussion of potential harms. The story mentions cardiovascular problems that can be life-threatening. It says the device must be replaced every five years or so when the battery runs low. The story also profiles a patient who \u201cfrequently lost her voice while she was talking and felt a persistent constriction in the back of her throat. Both are common side effects of VNS treatment.\u201d It states that \u201cWorsening depression and suicide attempts were reported by one-third of patients in one study funded by Cyberonics, according to data presented to the FDA.\u201d The story also suggests that while the device generator may be removed from the chest of a person who wants to stop VNS use, the \u201celectrodes in her neck must remain forever; doctors tell VNS patients that removing them is too risky because tissue grows around them As a result, VNS recipients cannot undergo a full body MRI or therapeutic ultrasound.\u201d", "answer": 1}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job providing information about the common harms, along with the percentage of individuals affected.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the procedure, which should be a factor in weighing the risks and benefits of any intervention.", "answer": 0}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\nWith further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\nBeta-blockers may also reduce cancer-related psychological distress in newly diagnosed patients, according to the study authors.\nFuture trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms at all. Side effects can range from diarrhea to depression, may trigger asthma attacks in asthmatic patients, and can cause complications for patients with diabetes. Some of these side effects may seem relatively inconsequential when compared to EOC mortality, but they\u2019re worth mentioning.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article, like others covering the study that we reviewed, ignored the potential harms from screening tests. In the real world, all screening tests carry the risk of false negatives, false positives and inconclusive results that could lead to more invasive tests and over-aggressive treatments.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. On one hand,\u00a0the story does address harms from false-positive tests: \u201cJust as important, the tests were remarkably good at avoiding false-positive signals, which would needlessly alarm women and lead to riskier and more-invasive tests to confirm a diagnosis. For both types of cancer, the PapSeek test\u2019s \u201cspecificity\u201d \u2014 its ability to accurately recognize the absence of disease \u2014 approached 100%.\u201d\nYet\u00a0the story glossed over the high false-negative rates and how a patient might (incorrectly) interpret a result \u2014 i.e. by testing negative, they may wrongly believe they do not have a uterine or ovarian cancer.", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nThe PSEQ has been used to study treatment outcomes in patients with a wide range of pain conditions.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\nThat's in contrast to patients with musculoskeletal problems such as low back pain, in whom low PSEQ scores predict poor treatment outcomes.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is perhaps one of the most egregious omissions of the news release: not mentioning any potential harms of a surgery that directly impacts the nerves and muscles of the face. While the method of this surgery is not included in the news release, a look at the Mass General web page where the lead author works describes the surgery as a \u201crelease\u201d of nerves in the eye, forehead, back of head, and nasal regions. Depending on the extent of the surgery, a patient may be required to undergo anesthesia in an operating room. The risks are not mentioned on this page either, but a look at the risks of the similar brow-lift procedure shows that complications may include facial nerve damage or paralysis, infection, and scarring.", "answer": 0}, {"article": "Dr. Claudia Henschke of New York Presbyterian/Weill Cornell Hospital says CT scans offer hope to many people who are at-risk for the disease, including current smokers, former smokers, and in some cases people were never smokers but exposed to second-hand smoke.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nIt turned out to be cancer.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms \u2013 such as radiation exposure, the harms of biopsies and the consequences of a false positive result.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nFurther, the protective association of seafood was even stronger among individuals with a common genotype (APOE-\u03b54) that increases the risk of developing Alzheimer's disease.\nThe age-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study population in this specific study was made up of older adults (mean age of 81.4 years old). There are few, if any, risks associated with eating one seafood meal per week for older adults. However, the release might have warned that both the FDA and the EPA, while encouraging pregnant and breastfeeding women to consume two to three servings of fish weekly, now recommend that they choose fish that is low in mercury (which include salmon, shrimp, pollock, tuna (light canned), tilapia, catfish, and cod).", "answer": 2}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\n\"In addition to the clinical outcomes, we now have a clear understanding of the mechanisms through which limited BCG vaccine doses can make permanent, beneficial changes to the immune system and lower blood sugars in type 1 diabetes.\"\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\nThe researchers also found that BCG could reduce blood sugar elevations in mice that were caused by means other than autoimmune attack, raising the possibility that BCG vaccines could also be beneficial against type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the vaccine are mentioned.\nIt\u2019s been given to humans since the 1920s and side effects, including allergic reaction to this live vaccine, have been well documented. It should be avoided in anyone with decreased immune function.\nOf note, a\u00a0 point is made that in those study subjects who received the vaccine, there were \u201cno reports of severe hypoglycemia.\u201d", "answer": 0}, {"article": "One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\nAmong the 11 patients who received either 10 million or 20 million dendritic cells per injection, six had clinical benefit.\nPreclinical studies, which were previously published in the AACR journal Cancer Research, showed that this type of vaccine could eradicate large, established tumors as well as lung metastases in mice.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the release was some injection site discomfort. The release also mentioned that the patients were tested to see if there was cardiotoxicity (heart dysfunction or muscle damage) and none was found.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The AP report provides no details on potential harms. The New England Journal of Medicine study reported mostly minor side effects of the vaccines and one serious complication attributed to the nasal spray\u2014hospitalization for acute inflammation of the tissue surrounding the heart and great vessels (acute pericarditis). It's also worth noting that pericarditis has also been reported (rarely) with the inactivated vaccine.", "answer": 0}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nUsing electrical impulses to stimulate a part of the brain critical for memory function significantly improved patients' navigational ability, reflecting improved spatial memory, the small study from the University of California, Los Angeles (UCLA) suggests.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even though the researchers did not report any harms to participants in this study, the story should have mentioned that while similar treatments are considered safe enough in the right circumstances, implanting electrodes and electrical stimulation devices can cause bleeding, strokes, infections, mood changes, movement disorders, sleep problems and other harms.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.\n\u00a0", "answer": 0}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of the immunotherapy it describes. Immunotherapy frequently causes a flu-like syndrome. Among the potential complication are devastating infections. The published case study hints at these, observing that the patient\u2019s initial reaction to the therapy was \u201ctransient lymphopenia, low-grade fever, and myalgia.\u201d Other adverse events commonly reported after immunotherapy include diarrhea, rash, adrenal insufficiency, and liver test abnormalities.", "answer": 0}, {"article": "Dr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\nAdverse events were generally mild to moderate in severity and similar to those observed in previous SHP465 studies and with other amphetamine compounds.\nSHP465 was also superior to placebo in the key secondary efficacy analysis on the clinical global impression improvement scale (CGI-I), with an LS mean difference from placebo at Week 4 of -0.8 (95% CI: -1.1 to -0.5, p<0.001), indicating a significantly higher proportion of patients were rated improved on the CGI-I rating scale.\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\nThe completion of SHP465-305 addresses an FDA requirement to evaluate the safety and efficacy of SHP465 in children and adolescents prior to filing a Class 2 resubmission of the medicine for FDA approval.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The adverse effects are clearly listed and equated with those of other amphetamine drugs. The adverse effects that occurred in more than 5 percent of the subjects included decreased appetite, headache, insomnia, irritability, nausea, weight decrease and dizziness and were similar to those observed with other amphetamine compounds.", "answer": 1}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nThose people taking the drug also saw reduced cholesterol levels and waist size, changes that have been linked to lessening cardiovascular risk factors such as blood pressure.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nArena has conducted safety studies on the drug, and no heart valve problems have been reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although mentioning the heart valve problems which were seen to occur with the use of a different weight loss medication, there was no mention in this story of the side effects (headache, nausea, and dizziness) which were seen to occur with this medication during the relatively short period of time it was used. \u00a0The story also failed to mention whether weight re-gain was common after use of the medication was stopped. Harm is of particular concern with obesity drugs, particularly given the experiences with Fen-Phen which had a similar mechanism of action.", "answer": 0}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\nThe test may be particularly valuable for families that harbor sex-linked genetic disorders like hemophilia, they add.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this a barely passing grade, because the story does quote one ethicist raising doubts about how parents may use the test.\u00a0She points out: \u201cRemember, gender is not a disease.\u201d Reuters does not use the word \u201cabortion.\u201d Seems to be a bit light on the harms side of the social equation.", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nThe company hopes to win FDA approval to market the new drug later this year.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Stronger points: \nWeaker points:\u00a0", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\nThe patients who received AMG145 had 41 percent to 63 percent reductions in \"bad\" (LDL) cholesterol and did not experience significant muscle-related side effects, said study leader Dr. David Sullivan, of the Royal Prince Alfred Hospital in Australia, and colleagues.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will score this story as meeting the minimum requirement of this criterion because the story did briefly note that \u201cthe reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins,\u201d which would imply to alert readers that the number wasn\u2019t zero. However, the point of the trial was to find a way around side effects that statins cause some patients, so it is irksome that the story fails to point out that a trial this small probably wouldn\u2019t have detected the statin-caused problem, and that much larger trials will be needed to rule out similarly uncommon problems with this new drug.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.\nThe research team is now looking to fund a full clinical trial.\nWorking in collaboration with the University of the West of England's (UWE Bristol) Urological Institute team at Southmead Hospital and Bristol Royal Infirmary, the pilot study included 155 men presenting to urology clinics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release speculates about potential benefits, but never acknowledges that the test might have downsides similar to the PSA test. False-positive results could lead to unnecessary biopsies and take a psychological toll on men who are tested \u2014 the release should have mentioned this.", "answer": 0}, {"article": "I couldn't get anything done,\" Ham said.\nCannabis could have limited benefits as a treatment alternative, said Harvard Medical School's Dr. Kevin Hill, who last year authored the JAMA study that found benefits in using medical marijuana to treat chronic pain, neuropathic pain and spasticity related to multiple sclerosis.\nThen, a friend mentioned marijuana, which Maine had legalized in 1999 for chronic pain and scores of other medical conditions.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\nAdvocates argue a growing body of scientific literature supports the idea, pointing to a study in the Journal of Pain this year that found that chronic pain sufferers significantly reduced their opioid use when taking medical cannabis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some known or suggested harms of chronic marijuana use, yet there was not much\u00a0mention of those harms in this story. \u00a0The one harm mentioned is a significant one: marijuana also can\u00a0be addictive.\nHowever, the article didn\u2019t mention others risks of inhaling marijuana, such as lung disease,\u00a0as well as effects on motivation, and other cognitive\u00a0issues, especially when the dose isn\u2019t being well controlled when smoked.", "answer": 0}, {"article": "They were then monitored for 24 hours.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss potential harms. We\u2019re not aware of any harms associated with drinking beet root juice, but there are concerns that getting too much nitrate could have have toxic effects, such as increasing the risk for cancer. (That\u2019s why nutritionists often advise against eating meats cured with nitrates such as hot dogs.) The story could also have warned of possible adverse effects from supplements that contain nitrate or nitrite salts, which can be highly toxic.\u00a0There is no information on Medlineplus.gov about beetroot. \u00a0Medication interactions are also possible. Harm is always possible, even with nutritional supplements. We stand by our same hard line as with the \u201ccosts\u201d criterion above.\u00a0 All interventions have potential harms; some discussion is warranted.", "answer": 0}, {"article": "The excruciating pain in her right knee made simple tasks like grocery shopping impossible.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\nA new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are identified.\nHowever, we think it would have been worth pointing out that there is little scientific\u00a0literature about applying this old technology to a new\u00a0part of the body. So, it\u2019s unclear what the eventual risks are.\nAlso, the article is not quite clear what radiofrequency ablation is doing: killing nerves, for at least 6 months. There could be permanent loss of nerve sensation, or maybe the nerves will grow back years later, either normally or in an altered state (which has happened in some other medical and surgical situations).", "answer": 1}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\nA study published earlier this year \u2014 and not included in the current analysis \u2014 found that during that post-treatment year, Grazax patients had one-quarter fewer hay fever symptoms than those who had been given a placebo for comparison.\nAcross the studies, which included a total of 2,971 adults and children with grass-pollen allergies, immunotherapy reduced symptoms by about 20 percent to 30 percent, on average.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story provides a list of the most common side effects associated with sublingual immunotherapy; however, a more complete report would have also mentioned more serious, albeit rare, reactions. It would also be useful for readers to know that in the 1518 patients who received sublingual immunotherapy, there were 3286 reported adverse events (2.6 per person), compared to 1570 reported adverse events in the placebo group (1.34 per person). Furthermore, 54 (3%) patients in the sublingual immunotherapy group dropped out of the studies due to adverse events, compared to 12 (1%) in the placebo group.\n", "answer": 0}, {"article": "1 Yiou et al.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\nThe goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms of the stem cell treatment. Although stem cell clinics often tout the safety of stem cells because they come from within the patient\u2019s own body, that does not mean that there are no risks to stem cell procedures. Only one stem cell procedure (a blood-derived stem cell treatment used for treating cancer and blood-illnesses) is currently approved by the FDA. All other stem cell therapies in the U.S. are experimental and unregulated by the government, including this\u00a0CaverStem procedure. On his blog, UC Davis stem cell scientist Paul Knoepfler reminds patients seeking stem cell therapy that every medical procedure has side effects. \u201cDifferent kinds of stem cells have variable risk profiles,\u201d writes Knoepfler, \u201cbut if someone tells you that the stem cell treatment they are selling has no risks then that is a big red flag and I would walk away.\u201d\nGiven the small number of men tested and the limited duration of follow-up, it is difficult to deem that this is a safe treatment.", "answer": 0}, {"article": "They then moved each patient's head forward and shook it from side to side for about 15 seconds.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\nThirty-five study participants had this form of vertigo.\nOf these, one-third saw their symptoms reduced or they recovered completely.\nIn some cases, the cause is unclear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the diagnosis of a suspected new form of vertigo so possible false diagnoses are a possible harm. And, the unnamed medication likely carries side effects.", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nAnother concern was that doctors could misinterpret the device's feedback, particularly error messages when a mole cannot be scanned.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\nThe agency also worried about its use by general doctors not accustomed to identifying suspicious skin moles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s a bit confusing, but the story explains that the device also makes the wrong call too often, giving too many false positives. \u201cHowever, the device did not raise an alarm about non-melanoma growths only about 10 percent of the time; that was still better than doctors in the study who correctly ruled out melanoma in less than 4 percent of such cases, on average.\u201d Just presenting the false positive and false negative rates would have been more helpful to readers.", "answer": 1}, {"article": "\"Like many things, the evidence changes over time,\" says Hensrud.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nHowever, coffee alone may not be the answer according to some experts.\nOur hope is that much will be learned from the sharing of useful information and personal experiences based on the medical and health topics of the blog.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least this story did what the WebMD story didn\u2019t do in discussing some of the potential harms from drinking a lot of coffee. ", "answer": 1}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nIt's also not clear if this kind of program could be scaled up.\nOf the 406 participants that began the study, 335 completed the telephone follow-up at the end of 12 months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms, but there are few potential harms associated with the relevant interventions\u2013other than temporary discomfort, stress or anxiety that can come along with addressing difficult feelings. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings.\nA once-a-day drug being developed to treat women with low libido proved to boost desire and led to better sex among female patients participating in late-stage studies, according to publications presented today during a medical meeting in Lyon, France.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects of the drug were reported in the story.\u00a0 Safety data reported indicates that potential side effects include dizziness, nausea, fatigue, somnolence, and insomnia. ", "answer": 0}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\nThe therapy was also able to increase brain activity in the insula, a part of the brain that helps monitor how the body feels psychologically.\nAfter the 12-week experiment, Cotton and his colleagues found mindfulness therapy increased neural activity in a part of the brain that plays in a role in processing cognitive and emotion information known as the cingulate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms. However, that may be because there are few (if any) risks associated with cognitive therapy for anxiety disorders. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "According to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nFor people in this group, taking low-dose aspirin daily can help reduce the risk of heart attack, stroke, and colorectal cancer.\"\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained, and that\u2019s sufficient to rate as Satisfactory.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in describing the side effects seen with Lamisil, a drug approved for this use. Unfortunately it does so with a bit of an apparent bias, \u201c\u2026.If you are willing to risk side effects, \u2026\u201d in its discussion. Although the laser treatments are generally well tolerated, some people have mild pain and a sense of warmth. We would have been willing to give the benefit of the doubt but the suggestion that there are absolutely no side effects associated with the laser treatment leads us to rule this unsatisfactory.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All interventions carry risks, and the news release does not mention any potential harms that may accompany major surgery. These include complications related to anesthesia \u2014 including blood clots and pneumonia, infection at the incision site, fluid build-up under the skin, bleeding, scarring and nerve damage.\nAs mentioned in the \u201cbenefits\u201d section, the news release also does not point out the patient subgroups who did not experience a marked improvement in their quality of life.\nFor these reasons, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story meets the minimum requirement of this criterion by reporting some of the side effects seen in this drug trial. However, it should have noted that the trial was too small to see less common side effects. Indeed, a trial this small would be unlikely to detect the muscle pain and weakness that cause serious problems for some similar patients when they take statin drugs to reduce cholesterol and heart-related risks.", "answer": 1}, {"article": ".\nAfter 18 months, the women who received the placebo halted the injections.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nThe researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life.\nThe women were between the ages of 50 and 70 when they were recruited for the decade-long study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention potential harms at all. Given the wide range of potential side effects from growth hormone use \u2014 from headache and joint pain to weight gain and weakness \u2014 this is a significant oversight.", "answer": 0}, {"article": "From this series of compounds they narrowed down a list of 14 sugars, fats and amino acids that were different in the women who developed the condition.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\nIt detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The preliminary nature of the research makes it difficult to accurately assess potential risks associated with the diagnostic test. At the same time, high in the story the lead author touts the huge potential benefits of the research. \"Such a \"metabolic fingerprint\" test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\" With all screenings and \"early warning sign\" tests there are opportunities for overtreatment and potentially harmful treatment, this should have been addressed in some fashion. For example, the main treatment right now for preeclampsia is magnesium sulfate. As the Preeclampsia Foundation, which is quoted in this story, points out on its website, \"Nevertheless, magnesium sulfate, is not a benign drug and must be used by a skilled health care provider with appropriate support facilities. Overdoses can and do occur.\"", "answer": 0}, {"article": "\u201cNow translate that concept to emotions,\u201d he continues.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\nHis book is likely to spark even greater interest \u2014 and funding \u2014 in TMS as a non-medicinal way to treat symptoms associated with disabilities like autism, epilepsy, ADHD, and dementia.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0does describe harms that affected the man highlighted in this piece. While that\u2019s important for understanding his story, the descriptions provided do not help the reader determine how common these harms may be nor\u00a0the severity of the negative aspects identified. Studies of TMS for the treatment of other disorders\u2013for example, depression\u2013could have been cited to establish common risks and side effects.", "answer": 0}, {"article": "Past studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\nThe therapy involves an educational component where patients learn about the emotion-pain connection.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nIn addition, the control group received no active therapy to serve as a comparison.\nNone of the women in the control group had a comparable improvement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll grade this one not applicable because the story didn\u2019t mention any potential harms of psychotherapy \u2013 which is understandable since these are generally thought to be small.\u00a0 But there are some theoretical risks which the story could have mentioned.\u00a0 ", "answer": 2}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes potential harms from the vaccines: \u201cThe level of serious adverse events was higher in the placebo group than either vaccine group, and \u2018most of the serious adverse events were attributed to malaria.'\u201d", "answer": 1}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. Statins do have side effects, contrary to their glowing press. And, although the story does say that more study is needed, it makes no mention of the fact that cancer patients may be taking a host of other drugs that could interact poorly with statins.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explains possible harms from using the devices by soliciting opinions from the Heimlichs, the namesake of the famous Heimlich maneuver:\n\u201cAny action that delays use of the Heimlich maneuver or complicates the rescue can be deadly.\u201d\nTo balance this perspective, the article also discusses the use of these devices as a backup to other standard procedures:\nThe LifeVac and the Dechoker are both intended to be used if standard rescue treatments fail, the companies say. One person can get the device while another person starts the Heimlich maneuver, suggests Sean Pittman, Dechoker\u2019s director of strategic development.", "answer": 1}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\nAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group.\nAbraham, along with lead author Dr. Maria Rosa Costanzo at Advocate Heart Institute in Naperville, IL, led the study at 31 hospitals in the United States, Germany and Poland.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains this short phrase \u201cwithout causing serious side effects\u201d in reference to potential harms. We find that inadequate considering that CSA is serious condition that occurs in already very ill people. Presumably, they would be susceptible to a range of risks for side effects from the surgical placement of the device.\nThe release also states that 10 study enrollees were \u201cexcluded due to non-study related medical issues or deaths, exiting the study or missing visits,\u201d and \u201cAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\u201d\nWe think a discussion on why some patients exited the study (was it due to intolerance?) and some details on \u201ctherapy-related discomfort\u201d were warranted here.", "answer": 0}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nMen in the trial had periodic blood tests that measured three different forms of PSA, including pro-PSA, a molecule in which two of the amino acids that make up the protein have been clipped off.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not provide insight about the individuals who were incorrectly diagnosed in the study reported on. \u00a0What percentage of men had aggressive tumors that the test failed to detect? \u00a0And what percentage of men received treatment because the test identified them as having aggressive tumors but actually did not need to be treated?", "answer": 0}, {"article": "More than 2.2 million men in the U.S. are living with prostate cancer.\nMen who took acetaminophen for less than five years saw no protective benefit.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nThe findings are in line with previous research suggesting that physical activity may help reduce the risk of disease-related death in certain cases of prostate cancer.\nAdditionally, daily acetaminophen was associated with a 51% reduced risk of developing an aggressive form of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No drug \u2013 not even acetaminophen \u2013 is without risk.\u00a0 So, when the story starts in cavalier fashion \u2013 \u201cPop a Tylenol\u2026\u201d it should also find time and space somewhere to mention that popping pills comes with some risk \u2013 especially given that the safe daily maximal dose of acetaminophen has been lowered in recent years.", "answer": 0}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nNo drug in this class is approved to treat patients with dementia-related psychosis.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\nNuplazid was granted for the treatment of hallucinations and delusions associated with Parkinson\u2019s disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that Nuplazid has a \u201cBoxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.\u201d Other harms observed in the very brief (6-week) trial are swelling due to the accumulation of excessive fluid in the tissue, nausea\u00a0 and confusion. The release would have been stronger had it given us an idea of how common or rare these side effects are.", "answer": 1}, {"article": "Presenting at the meeting, Shraddha Sapkota, a graduate student in neuroscience at University of Alberta, and her colleagues described how they carefully analyzed the saliva of a group of volunteers participating in an aging study.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Direct harms from a simple saliva test seem improbable at best, given its non-invasive nature.\u00a0 But the competing HealthDay story pointed out that even a saliva test could produce false positives that could cause real anxiety in patients, something that clearly could harm them.\u00a0There is also the potential for false negative results, which would falsely reassure patients about their status. Even an accurate positive finding could cause harm, since it would inform people about their risk of a future condition without giving them the ability to do much about it.", "answer": 0}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes potential harms, stating \u201cImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur.\u201d\u00a0 There was no other discussion of potential harms.\nIn fact, the researchers reported:\n\u201cDBS was associated with several adverse events, only one of which (seizure during programming, roughly 2 weeks after surgery) was serious. Other related adverse events were panic attack during surgery, nausea, air embolus, and pain.\u201d", "answer": 0}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the setting of heart attacks, the major harms of the drugs are related to their benefits \u2014 how well they prevent future cardiovascular tragedies. However, all the drugs in this article, including aspirin, impart a risk of bleeding, which is part of the comparison in PLATO and this follow-up analysis. It was good that the article gives a mention, albeit a brief one in the quote from Dr. Berger, of the increased risk of bleeding with higher doses of aspirin.\u00a0", "answer": 1}, {"article": "Almost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\n\u201cThis screening does not prevent lung cancer and it does not protect the large majority of subjects from death by lung cancer,\u201d Varmus said.\nThe researchers said their findings could save thousands of lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story misses the mark completely in its handling of the potential harms of the test.\u00a0It does provide the important caveat that \u201cCritics of the scans fear that smokers may not be motivated to quit if they believe screening can save their lives if they do get cancer.\u201d\u00a0\u00a0It fails to note the relatively high false positive rate (25% to 60%) and the implications on unnecessary additional testing. This is especially disappointing because the NCI press release provided the information.", "answer": 0}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story promises so much of this compound, including that it could be\u00a0less harmful to healthy cells than existing treatments. But it\u2019s hard to know what side effects might exist because the drug has apparently never been tested in animals or humans. The release does mention the many side effects associated with existing chemotherapies, but we wish there had been a caution: \u201cThere may be side effects with FY26 that remain to be discovered.\u201d", "answer": 0}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nThis is the first to correct an inherited genetic mutation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms of the therapy. We do think the story should have mentioned that we don\u2019t know much about the long-term effects and safety of using this technology, however.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nLike many patients his age, he didn't expect there would be any effective treatment.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nOne year after surgery, more people had died from other causes than died from lung cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article admits the conventional wisdom is that older patients don\u2019t tolerate surgery for lung cancer, but from headline to the final sentence\u00a0the NPR story is about older lung cancer patients thriving, based on a personal story and and experts\u2019 opinions. There is no meaningful discussion of the harms of surgery.", "answer": 0}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nBased on these results the company expects to submit a New Drug Application (NDA) for VYXEOS with the U.S. Food and Drug Administration (FDA) later this year and submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the first quarter of 2017.\nIn the intent-to-treat population, Grade 3 or higher, non-hematologic adverse events were similar across all organ systems, including cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release noted that serious harms from the drug were comparable to the standard therapy and listed the adverse events including infections, febrile neutropenia, bleeding, cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nOne word of caution about the harms. The study was not blinded (according to its listing on ClinicalTrials.gov) and these adverse effects may have been subjectively\u00a0found, potentially biasing the results. \u00a0We are not given enough information about this in the news release.  ", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job listing the potential harms of the procedure.\u00a0 The story gives appropriate caveats that this stem cell and fat grafting is relatively unstudied in women with a history of breast cancer, a population possibly more vulnerable to long-term harms of fat injections in the breast area. The story notes the potential need for multiple revision surgeries if the fat transfer does not take.\u00a0 The story notes that women looking for increased bresat volume beyond 1 cup size would likely not be candidates.\u00a0 The story appropriately lists potential long-term harms, including obscured mammograms due to nercrosis and calcifications from the fat. ", "answer": 1}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of possible harms associated with the use of multivitamins. \u00a0In an era where so very many foods are fortified with various nutrients, the consumption of yet another source of micronutrients may not be without potential down sides.", "answer": 0}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.\nIf Botox is eventually approved for this MS symptom, LaRocca said it will be important for doctors to get training in how to give the injections \u2014 since the drug has to go into carefully chosen locations in the muscle.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\nMuscle weakness was the most common side effect in this study, van der Walt said. It affected 42 percent of the study patients, though it went away within two weeks.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.", "answer": 1}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nWomen suspected of having breast cancer after initial screening are usually referred for a biopsy to determine whether the lesion is cancerous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions \"complications\" and \"side effects\" but does not discuss exactly what these include with either procedure.\u00a0 Surgical biospy is more invasive and risks include infection, scars and slower\u00a0 wound healing compared with CNB.\u00a0 Women who have CNB and are diagnosed with breast cancer have fewer surgeries than women diagnosed via surgical biopsy.\u00a0 Women at higher risk of developing breast cancer (genetic factors, prior pre-cancerous lesions or biopsies, older age)\u00a0may feel more confident of their results via surgical biopsy v. CNB.\u00a0\u00a0", "answer": 0}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study was of relatively short duration and no side effects were reported. The story does note that more research in children particularly is needed on the safety of oxytocin.\u00a0However, the story could have noted that oxytocin is not without side effects based on usage in adults. ", "answer": 1}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of mentioning the side effects of Victoza, even pointing towards whether effects were statistically\u00a0significant. One omission was that the story did not mention the higher incidence of gallstone disease, a side effect that was highlighted as significant in the paper.", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nNor is it clear if the study results are applicable to all smokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story points out that such scans can produce false positive results, lead to further tests and treatments that don\u2019t always benefit patients and have their own risks, and that CT scans expose people to radiation that may raise the risk of other types of cancer.\u00a0 It explains that the NCI is \u201cstill compiling the rates of false alarms and other risks\u201d\u00a0but estimates could have been drawn from past research.\n", "answer": 1}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This potential treatment is still in mouse trials, so there\u2019s not a lot that can be said at this point about potential harms. The author quotes the researchers, who pointed out that the lights as they were used in the trial \u201cwould not be offensive at all for people to have in the background.\u201d", "answer": 2}, {"article": "The study is in the Clinical Journal of the American Society of Nephrology.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nOld age is not necessarily a barrier to kidney donation.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplants vary in success rates according to many factors. There is no mention of harms that might come to a patient from receiving a kidney from a much older deceased donor. Or the harms that an older donor might face compared with a younger donor.", "answer": 0}, {"article": "Weight training or cardio?\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nThis is the latest study from the Cooperative Lifestyle Intervention Program (CLIP-II), a single-blind, randomized controlled trial.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\n\"A lot of older adults will walk as their exercise of choice,\" said Kristen Beavers, assistant professor of health and exercise science at Wake Forest and lead author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address harms. We believe the release should have encouraged seniors, especially those with documented cardiovascular disease, to be assessed by a physician before starting a new exercise program.\nThis example of an exercise readiness questionnaire covers some of the considerations that seniors should discuss with a physician prior to embarking on a new exercise regimen.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article failed to mention that calcium and vitamin D supplementation increased the risk of kidney stones. Although the experts quoted were clear that the trial was not a ringing endorsement for the use of these supplements to reduce fracture rate, they also cast the use of these supplements in a light more positive than the current study suggested.", "answer": 0}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the NPR Shots story, this one failed to provide a clear number about harms. It says, \u201cPrevious research has linked aspirin with reductions in heart attacks and strokes, but doctors have been wary when recommending whether people should take daily doses of aspirin because of the risk of gastric bleeding. Rothwell says, \u201cThe size of the effect on cancer I think is such that it does more or less drown out those sorts of risks.\u201d\u201d ", "answer": 0}, {"article": "Instead of shrinking as expected, as part of the normal aging process, the memory center in the brains of seniors maintained their size and, in men, grew modestly after two years in a program that engaged them in meaningful and social activities, new Johns Hopkins Bloomberg School of Public Health-led research suggests.\nShe says the program increases involvement in so many different kinds of activities that retired people may not have engaged in otherwise.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nCarlson says it's not entirely clear which elements of Experience Corps account for the improved memory function and increased brain volumes.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Due to the nature of the intervention\u00a0 \u2013 which was volunteering in a school setting \u2013 it\u2019s difficult to imagine harms occurring. There was no mention of harms in the release, but we won\u2019t penalize the release for that omission.", "answer": 2}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nPatients in the study had minimally-invasive surgery that fixes the problem by inserting a replacement valve to send blood around the damaged valve while leaving it in place.\nThe results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story portrays this procedure as minimally invasive and less risky than traditional surgery, but does not describe any risks.\nAlthough TAVR is considered to be lower risk than surgeries that cut open the heart, it\u2019s long-term durability is unknown because the procedure has only been approved in the U.S since 2011.\nMinimally invasive TAVR is still risky. The rate of death within 30 days ranges from 1 to 4%, for example, and it increases the risk of a stroke or heart attack, in addition to other potential vascular and valvular complications, according to UpToDate.com.", "answer": 0}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\nSpira and Bild put together results from two ongoing trials of smokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nUnfortunately, the story does not mention harms or lack thereof associated with myo-inositol. And are there any harms from collecting cells from the windpipe with a brush? The story didn\u2019t address this question. \n ", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nWe do this where it is needed most - right at the heart of the community.\nInternational students constitute approximately 50% of our student body.\nThis research is exciting as it suggests that an activity as simple as singing could reduce some of this stress-induced suppression, helping to improve wellbeing and quality of life amongst patients and put them in the best position to receive treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms but it\u2019s very unlikely there\u2019s any harm in this activity.", "answer": 2}, {"article": "\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues still not determined after such a small study.", "answer": 0}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nChapin and other critics argue that the scientific evidence is questionable.\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\nThey liken the procedure to female genital mutilation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only specific harm mentioned in the story was critics\u2019 comparison to genital mutilation.\nBut the story didn\u2019t cite what the AAP wrote in its statement:\n\u201cComplications are infrequent; most are minor, and severe complications are rare.\u201d\nOr what appears on the AAP website:\n\u00a0", "answer": 0}, {"article": "ORMD-0801 goes from the gut to the liver, while injected insulin circulates throughout the body before it gets there.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\nA safe and effective oral insulin, if approved, is expected to become a multibillion-dollar product.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states that there were \u201cno reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar.\u201d", "answer": 1}, {"article": "Good overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nIn a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cautions that higher levels of alcohol intake are not protective, remedying an important\u00a0deficiency in the competing WebMD coverage. But\u00a0it\u00a0doesn\u2019t really address the\u00a0uncertainty about whether moderate alcohol intake might increase the risk for some diseases such as breast cancer or pose other potential harms. As such, it doesn\u2019t fulfill the criterion.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nIt did find enough new data to recommend for the first time against screening for older men.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without quantifying the frequency, the story mentioned the common side effects of treatment for prostate cancer.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We particularly like how the article treated this criterion. It is made clear early in the story that aggressive medical treatment in premature babies may be a double-edged sword, since \u201cthese infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.\u201d\nWe also like the fact that the article differentiates between survival and a \u201cfunctional, fully participatory life.\u201d An independent pediatrics professor, Dr. Elizabeth Rogers, is quoted as saying she wouldn\u2019t change her clinical practice based on the research because \u201cthe risks of poor outcome outweigh the possibility of a really good outcome for families,\u201d especially for babies born at an early gestational age.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were mentioned:\nCellulaze leaves tiny scars\u2014about two millimeters long\u2014which fade with time, surgeons say. Typically, compression garments are recommended for at least two or three weeks to prevent fluid buildup. And there will be bruises, so patients typically need to wait three to six weeks before venturing out in a bathing suit, surgeons say.\nThe procedure can cause a buildup of fluid in the area that has been treated, which can last for months and needs to be drained regularly by a doctor.\nIn a written statement, Cynosure says \u201ca few\u201d patients in early trials had the buildups, called seromas, adding that they need to be drained to prevent infections and other complications. The company says it has since lowered the recommended laser dosage and it isn\u2019t aware of any seromas since the device hit the U.S. market.\nBut none of these harms was quantified, so the scope of the potential harm wasn\u2019t clear.\u00a0 What does it actually mean when the story uses vague terms such as \u201ctypically\u201d\u2026\u201dcan cause\u201d\u2026\u201da few patients\u201d ?", "answer": 0}, {"article": "A drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nMild strokes -- characterized by such symptoms as clumsiness in the hand, weakness of an extremity, some slurred speech, temporary loss of vision, and/or dizziness -- account for more than half of strokes in the U.S.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not good enough.\u00a0 The story only says the drug isn\u2019t without risks, chiefly brain bleeding.\u00a0 How often does this occur?\u00a0 This is a big issue. If even one of the 4 people whose records show they got tPA in this analysis had problems after hospital discharge, that could throw any potential benefit out the window.", "answer": 0}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\nThe team further observed that people who ate baked or broiled fish weekly displayed better so-called \"working memory,\" enabling them to more effectively execute routine tasks.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not as good as the competing WebMD story, which stated:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 0}, {"article": "63 senior respondents of a mean age of 80 were studied during 3 consecutive weeks.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\nMelatonin also decreased the overall variability in BP.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is clearly a downside to any supplement use, particularly in older people who may already be on multiple interacting medications.\nAlthough melatonin is probably safe for many adults, according to the University of Maryland Medical Center, a physician should be consulted before taking melatonin if you\u2019re already taking medications for high blood pressure, antidepressants and blood thinners, among others.\nA Web MD article states that melatonin can worsen symptoms in those suffering from bleeding disorders, diabetes, and seizures, and, perversely, may increase blood pressure levels in individuals taking medication to control those levels. Given the availability of melatonin supplements, ignoring the downsides for individuals with these common health problems is significant.", "answer": 0}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nAs such, the technique potentially could be used to distinguish healthy people from people with brain diseases or disorders, and provide insight into variations in cognitive ability and personality traits.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of discomforts or potential dangers associated with MRIs.", "answer": 0}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nAlso, at two years after surgery, data were available for less than half the patients.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nA year after surgery more than 80 percent of patients were no longer taking any of the diabetes medicines they had been on before the operations.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story does report that some patients died and 21 percent had to be readmitted to a hospital within a year after surgery.\u00a0 Since the story was about the study, we\u2019ll give it a satisfactory score for reporting the harms reported in the study.\u00a0 But such stories could (and we wish would) always include even a line about other side effects and complications of stomach-reduction surgery, which include nutritional deficiencies, gallstones, stomach ulcers, hernias, food intolerance, kidney stones, low blood sugar, blood clots, leaks in stomach staples, pneumonia, dumping syndrome (nausea, vomiting, diarrhea, dizziness and sweating caused by food moving too quickly through the small intestine) and other problems.\n", "answer": 1}, {"article": "However, \"I don't want women who chose mastectomy to think they did the wrong thing,\" Hwang said.\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\nThe study was observational, Hwang stressed.\nThe study is scientifically sound in many ways, Kruper said.\nThis may indicate that the women who underwent lumpectomy were generally healthier, Hwang said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of possible harms from either treatment. \u00a0In particular, there was no mention of the possible long-term dangers of radiation.", "answer": 0}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms weren\u2019t addressed at all. While lidocaine is most often used to numb sunburn, bug bites, and other skin pain, the Mayo Clinic\u00a0describes it as a last resort for relieving topical pain in kids under the age of 3. Lidocaine can be toxic when ingested by children when used for oral pain relief during teething. The FDA has tracked some cases of seizures and even death linked to use of the drug.", "answer": 0}, {"article": "Miner continued.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the ONCOblot test itself involves just drawing a blood sample, the results of the test could produce life-threatening harms if it overdiagnoses people. In other words, a person told they have tested positive for these biomarkers for mesothelioma might start treatment too early or unnecessarily. Mesothelioma treatment is notably damaging. Let\u2019s put the study into perspective: there were a total of 32 people enrolled (17 with known malignant mesothelioma and 15 without). Hardly a large enough sample size on which to make the claims made. Although as we noted previously, early detection does offer a small survival advantage, it comes at a cost. The American Cancer Society notes that chemotherapy for mesothelioma can cause hair loss, mouth sores, loss of appetite, nausea and vomiting, diarrhea, increased risk of infections, easier bruising or bleeding, fatigue and long-lasting nerve damage. Radiation treatment also can cause many of the same problems, as well as lung damage. Combining radiation and chemotherapy often makes side effects worse.\nIt won\u2019t be known whether starting treatment earlier offers any benefits to people at risk for mesothelioma, but it is certain that treating more people earlier would cause more treatment-related harm.", "answer": 0}, {"article": "\"It's clear we need more efficacious drugs with milder side effects.\"\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\nThose on medication gained an average of 20 pounds during the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions primary harms of treatment as weight gain seen in this short-term trial, but there is no mention of the long term side effects or safety of Zyprexa. Diabetes and complications of the metabolic syndrome have been noted in many patients taking newer anti-psychotic medications like Zyprexa. This may be a result of the significant weight gain from the drugs. The FDA has issued an additional warning about patients developing hypoglycemia and diabetes as a result of taking Zyprexa: http://www.fda.gov/medwaTCH/SAFETY/2004/zyprexa.htm", "answer": 0}, {"article": "The iron in the blood increases infants' iron storage, and iron is essential for healthy brain development.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\nBut Rabe said these infants may actually benefit most from the practice.\nThis study is among the few looking at healthy, full-term infants in a country high in resources, as opposed to developing countries where iron deficiency may be more likely.\nDelayed cord clamping has garnered more attention in the past few years for its potential benefits to the newborn.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hooray for this story including two potential harms and reporting with experts outside of the study authors. The story calls the potential for harms \u201cunclear\u201d and that is one of way of giving the reader some balance even if there isn\u2019t much information available. Both jaundice and polycythemia are listed as potential harms.", "answer": 1}, {"article": "Follow her on Twitter @drfernstrom.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\nThe new report, which analyzed 40-year-old data from the Minnesota Coronary Experiment, found no association between lower cholesterol levels and longer life, suggesting that reducing the amount of saturated fat in the diet isn\u2019t enough to reduce risk of death from heart disease.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention in the study (eating more unsaturated fat)\u00a0is unlikely to cause adverse side effects, risks, or\u00a0complications, so we\u2019re rating this\u00a0N/A.\u00a0The story did point out the surprising association between lower cholesterol levels and increased risk of death, though that could have been\u00a0explained more clearly.", "answer": 2}, {"article": "Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nBiomarkers of inflammation were measured at the beginning and end of the study.\nAt the end of the study, all of the participants had reduced levels of inflammation, regardless of whether they took vitamin D, \"which highlights the importance of weight loss in reducing inflammation,\" Duggan said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because some of the participants were vitamin D-deficient and the dose of vitamin D provided was modest (2000 IU/d), this was a tough call. But supplementation is often so misunderstood, overhyped and oversold that some statement cautioning readers to pay attention to the specifics of this study and not apply its recommendations to everyone seems prudent.", "answer": 0}, {"article": "Jean-Charles Sanchez says.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention harms, such as missing an injury due to a false negative or having a false positive result that leads to unnecessary and potentially expensive follow-up tests and treatments.\nWith 100% sensitivity there will be no false negatives, but that is a suspect result. It\u2019s not clear what actions are (or are not taken) as a result of this test so it is hard to assess potential harms.", "answer": 0}, {"article": "B vitamins, including B12 and folate, have been shown to help lower homocysteine levels, so high levels of the amino acid suggest low levels of B12.\nThe relationship between vitamin B12 and Alzheimer's risk is \"complex,\" says Dr. Sudha Seshadri, M.D., an associate professor of neurology at the Boston University School of Medicine and the author of an editorial accompanying the study.\n\"Lowering these in general is important for cardiovascular health, and this study strengthens our knowledge about its role in risk for Alzheimer's disease.\"\nDr. Sam Gandy, M.D., the associate director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, in New York City, says that it may make sense for people to get blood tests to measure their levels of B12 and folate.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "The surgically reconstructed knees and the conservatively treated joints experienced similar (and high) levels of early onset knee arthritis, a common occurrence after an A.C.L.\nBut large-scale, randomized controlled studies, the gold standard of medical research, may be difficult to orchestrate, in part because people with shredded A.C.L.\u2019s can balk at being denied surgery.\ntreatment is \u201ccontroversial,\u201d The New England Journal study\u2019s authors, Richard Frobell, Ph.D., and Stefan Lohmander, M.D., Ph.D., of Lund University, wrote in their e-mail.\nThe treatments were almost identical, too, in terms of whether the athletes could return to sports and whether they reported subsequent knee problems.\nIt may be years, unfortunately, before we know if such expectations are justified or if unreconstructed injured knees can be fine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several of the outcomes in this study straddle the line between benefit and harm (or lack of harm), so please see the \"Benefit\" criterion below, too.\u00a0Overall,\u00a0this story\u00a0covers the authors\u2019 key safety messages from the\u00a0published NEJM article, particularly as they refer to the rates of adverse events between the two groups. The piece says in general terms\u00a0that ACL surgery has risks like any surgery.\u00a0It would\u2019ve been better to include some more details.\u00a0A mention, if not quantification, of specific risks would\u2019ve added more balance to the discussion. The study\u00a0itself did consider surgical and anesthetic adverse events in its analysis. \nIt also could have been clearer about the uncertainty about the lack of long-term outcomes. We don\u2019t know how the two treatment groups will compare in terms of development of arthritis and future surgeries (e.g., more meniscectomies) farther out than 2 years. The challenge is that such long-term outcomes may be decades off in this young population.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nThose who received acupuncture along with their daily medication for three months were able to walk longer without becoming breathless, compared to those who got the sham acupuncture treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tong-Joo Gan of Duke University hints that there are few downsides to acupuncture, but the story does not specifically point out any harms or side effects from acupuncture. Probably the key point is at the very end where the acupuncturists say don\u2019t try acupuncture first.", "answer": 0}, {"article": "We aim to answer these questions with future research.\"\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nWhen the T cells stay resting, it's referred to as being immune quiescent.\nThe implants were tested in an animal model and the team observed a significant reduction in T cell activation, meaning that the vaginal tract was demonstrating an immune quiescent state.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that the news release opens with\n\u201cScientists at the University of Waterloo have developed a new tool to protect women [emphasis added] from HIV infection\u201d\nit might lead some interested women to ask about side effects.\nThe question of harms is never addressed. That\u2019s a huge oversight given that the device is implanted and there are many risks associated with such procedures: pain, bleeding, infection, the device becoming dislodged, follow-up surgeries to remove the implant.\nNo potential risks are mentioned.\nIn addition, if the device is not effective in comparison to existing preventive strategies then there\u2019s a potential harm in relying on the device and acquiring HIV.", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\n\"These findings are interesting, and show that vitamin D may have a role in improving outcomes in cancer care.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes it clear that patients should not take supplements to increase vitamin levels if they are already normal, thus preventing harms from oversupplementation. However, we wish the story had specifically mentioned potential side effects of high dose vitamin D.", "answer": 1}, {"article": "Learn more about both types of diabetes and treatments from the National Institute of Diabetes and Digestive and Kidney Diseases.\nThis finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nAfrezza may have an impact on lung function, but Leone-Bay said once people stopped taking Afrezza, this effect went away.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All the claims are qualitative. That alone would earn an unsatisfactory rating, but the article goes further. Harms are not only presented without quantities, they are described in a vague, unclear, and overly optimistic way. We\u2019re told, in general, that the safety studies \"came out clean.\" That\u2019s overly simplistic without any further detail; even placebos are associated with harms in studies. Then there are the specific issues.\n First, consider the potential cancer risks. The only data described are, it seems, from short-term animal studies. The cancer risks that hung over Exubera were not revealed until after it was yanked from the market, and ultimately the association to Exubera wasn\u2019t definitive. To say that Afrezza holds an advantage over Exubera for these reasons based on short-term animal data is unsubstantiated.\n\nSecond, pulmonary function. The pulmonary function problems for Exubera are detailed as one of its major flaws, with the implication that they contributed to its ultimate failure. In the second-to-last paragraph, the VP acknowledges that Afrezza \"may have\" pulmonary harms; however, \"once people stopped taking Afrezza, this effect went away.\" In several\u00a0studies\u00a0of Exubera, lung function declines were also reversible after people stopped taking it. Without providing any evidence, the article\u2019s general coloring of Afrezza safety being superior to that of Exubera is speculative and wholly inappropriate.", "answer": 0}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\nMM36 was also associated with improvement in patient-reported outcomes, most notably rapid and sustained itch relief, with Visual Analog Scale scores showing improvement from moderate to mild within the first week (36.4% mean change; p=.0011).\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\nThe majority of affected individuals have resolution of disease during childhood, although 10% to 30% of patients maintain the condition throughout their lives.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published research report clearly reports that some subjects experienced a worsening of symptoms, or no real change, but the release fails to mention any data on side effects. According to the study, the harms were about the same in the high dose group and the placebo, but were greater in the low dose group (and that difference was statistically significant).", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed, nor is it mentioned that the safety profile in humans has yet to be established. The article would have done well to continue the Dr. Eck quote from the\u00a0press release\u00a0to include his acknowledgment that \"we still have much to learn about their potential liabilities,\" referring to this new class of compounds.\nThe \"hope\" that the compound will have fewer harms than currently available drugs appears to be based largely on in vitro\u00a0data.", "answer": 0}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\nStopping that autoimmune attack appears to be crucial to any treatment that hopes to cure or reverse type 1 diabetes.\nIf we can control the autoimmunity, we may reverse the diabetes.\n\"In the absence of complete remission, there are very sizable advantages to having some beta cell function,\" Inverardi noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To claim a treatment is safe after testing it in only a dozen patients at a single hospital in China is to ignore the long history of treatments that appeared to be beneficial after initial tests, then later revealed serious, even lethal, harms. Even though the researchers declare the treatment to be safe in their journal article, journalists should be skeptical of such broad claims that are based on such slim evidence. There is a vast gulf between stating that 12 individuals did not appear to be harmed during a 40-week trial and proclaiming that a treatment would be safe for millions of patients over the course of decades.", "answer": 0}, {"article": "But from the beginning, Mr. Hladik resisted.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHis doctors managed his heart disease and hypertension with drugs.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained in terms of the side effects of the dialysis, the pain, nausea and feeling \u201cdizzy, washed out.\u201d \u00a0It was good that the article explained that the harms of dialysis are also measured in other ways: the disruption to a person\u2019s life, the need to travel and go in and out of facilities, and the effects on their independence, which can be debilitating for older people.", "answer": 1}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nThe researchers randomly assigned nearly 600 women with heavy menstrual bleeding to receive either the IUD or standard medical care.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\nThe scale goes from 0 to 100, with lower scores indicating more severe symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The explanation of side effects was not satisfactory. \u00a0There are a list of side effects on the manufacturer\u2019s website that were not mentioned in the story.\nAs correctly stated in the story, the most common side effect of Mirena is irregular bleeding. Since the purpose of the study was to compare overall effectiveness and side effects of Mirena vs. other medical therapies, it was adequate to the study\u2019s purpose to simply state that serious adverse effects were no different between the groups. But the story provides little detail provided about adverse effects of the other therapies, as well as Mirena. It would be useful to the reader to have a better sense of the kinds of side effects associated with both types of treatment.\n\u00a0", "answer": 0}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nThe study wasn't really designed to answer the question of which screening regimen is best, study researcher Rebecca Hubbard, PhD, says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The piece states that the researchers noted that \u201c\u2026false positive recalls may cause inconvenience & anxiety and biopsies can cause pain and scarring.\u201d", "answer": 1}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nEight participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is clear in mentioning the side effects of the use of this drug in the study: \u201cSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity. The most common side effects in the CBD group were vomiting, fatigue and fever. Eight participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.\u201d", "answer": 1}, {"article": "\"I say, 'Go for it!'\nThat's because surgery doesn't touch the root cause of chronic sinusitis.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nThat, he says, will be the next big advance in sinus treatment.\nBut surgery rarely cures them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers off-handedly to the possibility of\u00a0\"poking through to the brain or into the orbit of an eye,\" but it fails to explain that these events are very rare but real risks of the surgery. While extremely unlikely, it\u2019s possible for surgeons to accidentally\u00a0damage\u00a0the optic nerve, resulting in blindness, or to puncture the base of the skull, resulting in cerebrospinal fluid leakage. Other less serious,\u00a0but more common complications are also possible. The story didn\u2019t mention\u00a0any of them.", "answer": 0}, {"article": "Nothing worked.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nEven as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a great job in not only providing a listing of potential harms, it also provides information on their frequency and impact on the subjects in the clinical trials.", "answer": 1}, {"article": "HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.\nBorges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nTwenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least \"stable disease\" at 24 or more weeks after the start of treatment.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "According to the original study, 30% of the patients had to have their treatments \u201cinterrupted,\u201d usually due to effects on liver function, although the study says the drug treatment was \u201calmost always\u201d re-initiated, and no one had to be removed from the drug entirely. None of these problems was mentioned in the news release, which also offers no specific information about the frequency or severity of side effects.", "answer": 0}, {"article": "\u201cThe findings were exciting,\u201d she said.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nThe researchers found that the breathing exercise group\u2019s saliva had significantly lower levels of three cytokines that are associated with inflammation and stress.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The National Center for Complementary and Integrative Health says relaxation techniques such as deep breathing exercises \u201care generally considered safe for healthy people, although there have been a few reports of\u00a0negative experiences such as increased anxiety. People with serious physical or mental health problems should discuss relaxation techniques with their health care\u00a0providers.\u201d\nIt\u2019s also possible that some people with serious disorders may not seek other proven treatments in the belief that deep breathing will help them.", "answer": 0}, {"article": "JACC is ranked No.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\nThey also looked a several early indicators of heart disease.\nResearchers from Emory University Hospital in Atlanta set out to learn more about the relationship between depressive symptoms and heart disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t delve into harms but we\u2019ll rate this Not Applicable since the release doesn\u2019t give us any specifics on the types of exercise the study volunteers took up. Some exercises are riskier than others.", "answer": 2}, {"article": "Chan\u2019s project aims to find out who will.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nBy identifying potential patients far earlier than is possible at present, researchers hope it should then become easier in the long term to develop treatments aimed at halting or slowing their condition.\nThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\nSome will have a gene that puts them at risk of the condition or will come from a family with a history of Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The big risk here, as with any screening test, is incorrect results. Even if the study hasn\u2019t happened yet, and important data sets like sensitivity and specificity can\u2019t yet be quantified, they should be addressed in the story. What are sensitivity and specificity? Sensitivity measures how often a test correctly generates a positive result for people who have the condition that\u2019s being tested for. Specificity measures a test\u2019s ability to correctly generate a negative result for people who don\u2019t have the condition that\u2019s being tested for. In other words, there are two possible harms inherent in diagnostic and risk assessment tools: the failure to identify someone who has Alzheimer\u2019s; and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. Either mistake can have significant costs \u2014 financial and personal \u2014 for patients.", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study reported some cases of pain at needle insertion sites and bleeding, but the story didn\u2019t mention this.\u00a0 Even with a treatment that is generally very safe, women should be aware of any risks.", "answer": 0}, {"article": "The editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We thought that NBC did a better job detailing some of the potential harms from statin use, but we give the Times credit here for framing the story as a discussion of risks vs. benefits and making it clear that experts critical of the new guidelines believe that they \u201cwould lead millions of additional people to take statins, exposing them to potential side effects such as\u00a0muscle pain\u00a0or damage with little to gain.\u201d", "answer": 1}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nIn the clinical trials there were no serious side effects, Novalar said.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that when used for high blood pressure the drug can cause heart attacks and occlusion of blood vessels in the brain. \nBut the report does not challenge the drugmaker\u2019s claim that those side effects would not apply for this use of th drug. And again, since the data is unpublished it is a leap of faith to accept this conclusion. ", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nTumor growth rate was also significantly slower in the walnut group compared to the control group.\nThe CWC is mainly involved in health research and export market development activities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The limited study did not appear to investigate potential harms, and the release didn\u2019t comment on them. For humans, consumption of too many calorie-dense walnuts could precipitate weight gain. But the equivalent of two ounces a day doesn\u2019t sound like it could be very harmful. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from any aspect of the treatment studied. This is a major oversight in any story, but especially one dealing with a surgical procedure.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nBasically, it would be pushing a \"reset\" button on the child's body, with the hope of wiping autistic symptoms away.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nAt the outset, patients would be only the sickest children, who have not responded to other treatments.\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article doesn\u2019t discuss the very real risks of the proposed experiment and does not seek out any disinterested expert resource.\u00a0 A hallmark of autism spectrum disorders is problematic social interaction.\u00a0 One can speculate that transfer of affected children out of the home and into a hospital \"clean-room\" runs counter to the effort to improve socialization that is a current, mainstream treatment for the disorders.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nMandato stressed that no one in the study required sedation to undergo the procedure.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any harms in the story.\u00a0Lead author Dr. Kenneth Mandato commented on the nasal spray as being \u201csafe, convenient and innovative.\u201d Such statements without any mention of the drug\u2019s potential harms gave the story an overly positive spin. Side effects of lidocaine include flushing or redness of the skin and bleeding at the application site. And while the procedure may be \u201d simple\u201d and \u201cminimally invasive\u201d to an interventional radiologist, anyone who\u2019s had these catheters wending into their sinus cavities may not agree.", "answer": 0}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t mention that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet. We do appreciate, too, that this story at least mentioned in passing concerns about malnutrition.", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nIt\u2019s sometimes mistaken or dismissed for regular period pain.\nThe drug\u2019s side effects also concerned her, as did the lack of knowledge about its long-term impact.\nSo it\u2019s no surprise it takes between three and 11 years after the onset of symptoms to diagnose endometriosis.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause.", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nSWE technology is already used in diagnosing breast cancer and liver diseases.\nThe new method aims to get round the problems by targeting the prostate with ultrasound.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might come from use of this new approach.\u00a0 And while the story claims that the new technique \u2014 shear wave elastography (SWE)\u00a0\u2014 is non-invasive, there are clear harms that can come from false negatives or false positives with any screening technique.", "answer": 0}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nThe drug also comes with a more serious warning, as well.\nIn order to prescribe it, doctors must be certified with the program and must counsel patients about this risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a strong point for the story. In the\u00a0second paragraph, it states that the drug will be sold with a \u201cblack box warning\u201d because of \u201can association with suicidal thoughts and behaviors\u201d among those who took it. It goes further, later on, by saying, \u201cThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\u201d\nAs well, the story spends at least two additional paragraphs discussing the link between use of the drug and suicide, and finally, it cites its effect on the immune system and how it should not be taken by people with some chronic conditions, such as Crohn\u2019s disease.\n(For more on the checkered history of this drug\u2019s side effects as noted in\u00a0clinical trials, see this same criterion in our news release review for the FDA approval of Siliq.)", "answer": 1}, {"article": "\"The results can now be immediately put to clinical use to the considerable benefit of the patients.\"\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes.\nA new study from Karolinska Institutet in Sweden shows that short-course preoperative radiotherapy combined with delayed surgery reduces the adverse side-effects of rectal cancer surgery without compromising its efficacy.\nIt also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. The news release refers to harms/adverse effects from radiotherapy at least four times but does not name even one potential harm, so we\u2019re rating it unsatisfactory for the omission. \nAccording to the study, the most common postoperative complication was infection, which occurred in 18 percent of patients. The study also mentions bowel obstruction and pelvic abscesses. About 7 percent of patients whose surgery was delayed were hospitalized for radiation toxicity.\nThe news release (and the abstract of the journal article) avoid a thornier question. Could delaying surgery after radiation treatment of rectal cancer increase the chance that rectal cancer will come back? The study found rectal cancer recurred in 2.8% of patients an average of 19 months after delayed surgery and in 2.2% of patients an average 33 months after\u00a0surgery at the usual time. The small\u00a0difference seems to\u00a0favor the usual\u00a0timing of surgery. The authors take a scientifically valid\u00a0position that if the difference in rate between options could have happened up to 5 percent of the time by random chance, then the new\u00a0option is \u201cnoninferior\u201d to the standard treatment, as is the case here.\u00a0It is quite possible that cancer outcomes are slightly worse for the new timing of treatments, but justified by a much bigger improvement in complication rate. The absolute difference in local cancer recurrence is only 0.6% (with a large margin of possible error) whereas surgical complications were reduced by an absolute 12% (41 vs. 53%).\nThe study notes that one potential drawback of delaying surgery is that it delays the start of chemotherapy in\u00a0 regimens that include chemotherapy after a tumor has been removed. But it says chemotherapy could be more effective if administered before surgery, so a delay would present an opportunity to administer chemo. Whether that would help patients would need to be determined by another research study.", "answer": 0}, {"article": "Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nShe says some patients get caught in a \"push and crash\" cycle.\nBateman takes also issue with CBT's implication that chronic fatigue syndrome is psychosomatic.\nA study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no attempt to quantify harms, even though harm rates were mentioned in the study. It does talk about the potential harms, though, in quoting a physician who treats chronic fatigue patients in Salt Lake City.", "answer": 0}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any harms that might occur from the use of probiotics. \u00a0Are there specific groups for which these products could be dangerous? \u00a0And if constipation is as serious as the story suggested, is there harm in first attempting self management with ineffectual products?", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nA genetic test would be \u201cthe Holy Grail of personalized medicine,\u201d said Rob Lenz, Amgen\u2019s global development lead for neuroscience, but no one has made one yet.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nTargeting CGRP is not a particularly new idea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the companies has reported \u201cserious side effects,\u201d according to the story, which does go on to note that the studies so far have been short-term, 12-week trials and that an understanding of the impact of the drugs \u201cwill take years.\u201d\nHowever, we find this lacking. Even if there weren\u2019t \u201cserious\u201d side effects, readers still want to know what the potential downsides are, and surely there were noted side effects that would have to be weighed against the benefits.", "answer": 0}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nPublic health experts consider medicated-assisted treatment the gold standard of opioid addiction treatment.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nMethadone may be the best-known form of medicated-assisted treatment, but it requires patients to have the drug administered daily in a clinic.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both Vivitrol and Suboxone have side effects that are not compared\u2014or even mentioned\u2014in this story.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article mentioned overuse of the treatment, there wasn\u2019t an explicit mention of the type of harms associated with using hyperbaric therapy.", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\n\"No study has, however, specifically addressed the extent and type of sexual bother in this patient category.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are mentioned here, and we appreciate that. We do think, though, that some hard numbers should have been put to the risks associated with more of the enhancement procedures. We give it a pass, though, for at least providing harms data for the penile extenders that are touted as the method with the biggest benefit. It says, \u201cMore than 70 of them used penile extenders, with six experiencing minor problems such as bruising, pain and itching. These devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\u201d", "answer": 1}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\n\"Rather, its technology has the potential to help Parkinson\u2019s patients manage symptoms that impede regular functions.\nEmma Watch remains a prototype, Microsoft says, but the developers are working with a neuroscience research team to undertake trials with a small group of Parkinson's sufferers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed, and there\u2019s no study to suggest what those might be. But presumably the physical harms here would be minimal, given that thousands if not millions of people wear vibrating smart watches without any known ill effects.", "answer": 2}, {"article": "They were then randomized to receive either Forteo or a placebo.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In our opinion, the risks of Forteo are not described in sufficient detail. It does note that Forteo may prompt further spread of bone cancer, but what about the more common side effects? The Forteo prescribing information, for example, lists a number of more common side effects, and it includes\u00a0a black box warning with a broader caution about bone cancer, concluding that this drug should only be prescribed for patients in whom the potential benefits outweigh the risks.\n While this particular study observed no significant differences regarding adverse events, including no serious adverse events, the article should have noted, as the investigators do, that the study was too small to accurately assess safety. Absent such a discussion, the article might be read as implying a green light for safety.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no discussion of potential harms, which is unacceptable for a story based on a drug that already has a known risk profile and for which new claims are being made. ", "answer": 0}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\nBut the MarginProbe is another tool that might help reduce the odds of needing a subsequent surgery, she said.\n\"We looked at whether we could lower the [repeat surgery] rate by using this device,\" Boolbol said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply \u2013 but inadequately \u2013 stated that \u201cresearchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control group patients.\u201d\nIt would be useful to have a more quantitative sense of how much more tissue was removed using the MarginProbe device. What does \u201cnot much more\u201d mean?\u00a0 Would it mean the same thing to all women? That would help the reader balance the benefit of avoiding a second surgery against the risk of removing more breast tissue when the device is used, which could negatively affect\u00a0the appearance of the breast after surgery.", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nThis determined the most effective treatment frequency.\nThe current study reports clinical trial results for optimal use frequency.\nThe team found that a suitable combination of mild electrical stimulation (MES) with heat shock (HS) activated HSP72 more efficiently.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The belt device is claimed to be well tolerated, but no details on potential harms are given. The release notes: \u201cThe team found that a suitable combination of mild electrical stimulation (MES) with heat shock (HS) activated HSP72 more efficiently.\u201d What is the electrical stimulus and how uncomfortable is it? \u00a0Exactly what is a delivery of heat shock? What temperature is used? And finally is the device battery operated or is it a plug in? \u00a0All of these unanswered questions seem relevant to understanding the device.", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not mention that 13% of the individuals in the study were unable to complete the test due to claustrophobia and that for 17% of the individuals tested, there were technical difficulties which made their test results unusable.\u00a0 \u00a0\n", "answer": 0}, {"article": "Type 2 diabetes is the most common form of the disease and is linked to obesity.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\n\u201cIt is probably going to be a more popular drug because of that.\u201d\n\nSanford Bernstein analyst Tim Anderson more than tripled his annual sales forecast for Jardiance and combination drugs containing it to $2.7 billion by 2020.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t mention any harms associated with Jardiance, a type of SGLT2 inhibitor. Some mention of potential adverse effects is always appropriate in stories about new drugs.", "answer": 0}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nary a mention of the potential risks of caffeine, particularly in an older population. Caffeine is associated with\u00a0headaches, tachycardia (rapid heart rate), and anxiety to name a few.", "answer": 0}, {"article": "\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\nIt is not a diagnostic test for Down syndrome, she says.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does quantify potential harms in one way by noting, \u201cThere were no false-negative results with the new test.\u201d We wish the story also spoke about false positives. False positives are certainly part of the stress and harms from any screening test that need to be considered. In this case, it appears the false positives were low but not negligible.", "answer": 1}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\nAnd no cancer developed in the transplanted tissue, Jensen said.\nOf 32 women who had ovarian tissue frozen and transplanted in this study, 10 women -- or 31 percent -- had a child, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely mentions the risk \u2013 which it says is not increased \u2013 of a return of cancer. Since that\u2019s likely the main concern with this procedure, we\u2019ll go ahead and award a Satisfactory. But we\u2019d add that women who have\u00a0their own ovarian tissue removed and then reimplanted in a new surgery could potentially have complications of\u00a0those procedures (all surgeries carry some risk). No such complications are addressed in the study that\u2019s the basis for this story, and it\u2019s not clear if adverse effects (beyond cancer recurrence) were tracked by the study authors. We wish the story had asked about, and covered, those potential harms.", "answer": 1}, {"article": ".\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n\"When focusing on those studies which have used large daily doses of zinc, there is strong evidence that zinc lozenges shorten the duration of colds.\"\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests that, \u201cNo prior studies showed zinc lozenge use \u2014 even up to 150 mg per day \u2014 might cause harm aside from bad taste or constipation\u201d We give it a pass since it does note the major side effects seen.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\nAt the highest level of stimulation, 58 percent of the people who started out with moderate to severe pain reported little or no pain after treatment.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects are minimal but worth mentioning \u2014 and this story doesn\u2019t lay them out. Some users can be allergic to the sticky pads of a TENS system, and those with heart conditions, metal implants, epilepsy, or other\u00a0neurological conditions might be poor candidates for it.", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s too early to quantify harms, as it\u2019s not clear there\u2019s a physical test yet, no matter a final roster of biomarkers.\nYou might say the potential harms of a blood test are low, but what about the odds that the test will screw up? Not all tests are created equally, and some test results can be equivocal, inconsistent, or wrong. That\u2019s why we need to study the test\u2019s reliability in the DOD trial. We don\u2019t know\u00a0how many people with severe brain damage will slip past this test (its sensitivity) and how many it will wrongly diagnose (its specificity). Poor sensitivity or specificity cause harms when warning signs are missed and when people get treatments or follow-up tests, sometimes invasive ones, they don\u2019t need.", "answer": 2}, {"article": "Other sources include pink grapefruit, watermelon, and guava.\nTomatoes are not the only food that is rich in this antioxidant.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nDuring that time, 67 men had a stroke.\n\u201cThis study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\u201d says researcher Jouni Karppi, PhD, of the University of Eastern Finland in Kuopio.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from eating tomatoes.", "answer": 2}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nThere are many other causes of bedwetting, Lakshmanan said.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\nPremature birth was the greatest predictor of continued bedwetting after surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big omission in the story. Any story about surgical procedures needs to address the potential harms from surgery.The basic risks of surgery, including infections, bleeding, and complications of anesthesia should have been mentioned.", "answer": 0}, {"article": "That was longer than we expected, and it's great news for this group of women.\"\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did not quantify any harms associated with bone density testing, with osteoperosis or with waiting too long to have ones bones tested.", "answer": 0}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nAmong patients receiving the combination treatment, the development of side effects such as skin rash and a less dangerous type of skin cancer called squamous cell carcinoma was similar to that typically seen in patients taking only one of the drugs.\nThe study was conducted at 14 sites in the United States and Australia and included 162 patients who received different dose combinations of the drugs: two daily 150 milligram (mg) doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone.\nThe phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u2019s discussion of harms tends to\u00a0downplay their importance.\u00a0It quotes an expert who says there were no \u201cuntoward side effects\u201d with the combination treatment, and\u00a0it reports that\u00a0skin rashes and rates of squamous cell carcinoma were\u00a0\u201csimilar to that typically seen in patients taking only one of the drugs.\u201d\nThat\u2019s one take, we suppose, but the study itself reported much higher rates of drug induced fevers and chills\u00a0in the combination groups, which was serious enough to require hospitalization in 19% of low-dose and 26% of high-dose combination group patients (compared with 2% of monotherapy patients). Other\u00a0side effects reported more frequently in the\u00a0combination groups were\u00a0fatigue (in 53% of patients), nausea (44%), vomiting (40%), and diarrhea (36%).\u00a0Those certainly sound like \u201cuntoward\u201d side effects to us.", "answer": 0}, {"article": "COLUMBIA, Mo.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\nThe study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention or explain any harms that might be associated with these surgeries. This strikes us as especially disappointing because some of the side effects of surgery are known to influence patient decisions about treatment. The two side effects that get the most attention are incontinence and impotence.\nThe researcher is quoted acknowledging the fear that patients have, but does not offer any measures for post-surgical outcomes related to quality of life. We found that disappointing.\n\u201cBecause radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\u201d Pokala said. \u201cHowever, this study shows that it is a viable treatment option. This can bring a renewed hope and peace of mind to men living with prostate cancer.\u201d\nHarms for either surgery or radiation alone such as urinary, bowel, and sexual dysfunction, can adversely affect quality of life. The literature suggests that salvage prostatectomy can cause even more worrisome complications such as damage to pelvic structures, blood clots, and bleeding. \u00a0Unfortunately, these data are not available in the SEER database so the authors could not assess\u2013an important\u00a0limitation of the study.", "answer": 0}, {"article": "...\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\nElliott Antman, chair of the American Heart Association's Scientific Sessions program committee, praised NIH for doing the study.\nStephen Kopecky, a Mayo Clinic cardiologist who participated in the trial, says he's also concerned about the reliability of its findings.\nThat could lead to a bias in favor of chelation, Atwood says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chelation is risky and\u00a0dangerous, and\u00a0notes that at least 30 patients have died from off-label chelation therapy since the 1970s. But then it quotes the\u00a0director of the National Heart, Lung, and Blood Institute calling the study a \u201cbreakthrough\u201d \u2013 not for proving that chelation works, but for \u201cestablishing that this chelation therapy regimen can be administered in a safe manner in the context of a clinical trial.\u201d Without some data or an explanation, readers are going to have a hard time\u00a0reconciling these\u00a0contradictory views about the safety of chelation. And since the NHLBI quote ends the piece, it\u2019s the take-home that may have the biggest influence on readers.", "answer": 0}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nBesides certain foods containing EPA and DHA, supplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects, he added.\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some fatty and farm fish contain significant levels of mercury, PCBs, and other contaminants and experts recommend limiting their consumption and avoiding them entirely if you\u2019re pregnant. That isn\u2019t mentioned. The release also conveys an endorsement of fish oil tablets, which can have side effects such as heartburn, nosebleeds, hot flushes, leg cramps, nausea and bad breath.", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of harms that may come with increasing the amount of Vitamin C one consumes in their diet. While mega doses of Vitamin C supplements are known to be harmful, this release and study stress that the focus here is on obtaining Vitamin C through food sources.", "answer": 2}, {"article": "\"Take some individual responsibility to stay healthy during the flu season,\" said Health and Human Services Secretary Kathleen Sebelius, who scheduled her own seasonal shot for Friday.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nThe U.S. has ordered 195 million doses, based on the hope that 15 micrograms was indeed the right dose.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story says that the participants in the H1N1 flu vaccine trials reported side effects similar to those seen with seasonal flu vaccination; that is, almost half had some soreness or rash at the injection site or a headache.\n However, the story should have pointed out that these small and very brief trials don\u2019t reveal whether the new H1N1 flu shots may be linked to the sort of rare cases of Guillain-Barre diseases that were seen during the rushed attempt to vaccinate people against a variety of swine flu in 1976.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It talks about the potential side effects, but it limits that discussion to what the study found in a very small group of men. Are there long term effects from lidocaine exposure that have been found in other studies? Does the body build up resistance to lidocaine? This isn\u2019t a short term problem that can be solved with a few weeks of therapy. It is\u00a0usually a\u00a0life long problem, and the story should be framed that way both in discussing the benefits and the harms.", "answer": 0}, {"article": ".\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\n\"This study confirmed that Enclomiphene can maintain spermatogenesis while restoring testosterone levels to normal.\"\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nFull citation: \"Oral Enclomiphene Citrate Raises Testosterone and Preserves Sperm Counts in Obese Hypogonadal Men, Unlike Topical Testosterone: Restoration Instead of Replacement.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release\u00a0did not include any mention of adverse events from the trial in question. \u00a0We always look for an explicit discussion of potential harms. Excerpts from the\u00a0journal manuscript:\n\u201cThere were 53 (21%) men in the studies who had adverse events\u00a0considered by the investigators to be possibly, probably, or definitely related to the study drug. None of these were severe and none were serious\u2026.\nOther than a\u00a0road traffic death, the only death was in the ZA-304 study. This was a 59-year-old Caucasian with secondary hypogonadism who was treated in a \u2018blinded\u2019 fashion with 12.5 mg enclomiphene citrate for 34 days before an ischaemic stroke\u2026.His high number of risk factors and limited exposure made it highly unlikely that the study medication was the cause of his death in the opinion of the investigator.\u201d\nRegarding the researchers\u2019 statement that none of the adverse events were severe or serious, we always think that\u2019s in the eye of the beholder \u2014 the patients, who, of course, are not heard from.\nBut what we\u2019re reviewing is the news release, which is silent on potential harms.\nOur reviewers noted that the FDA has issued a safety alert to add information to labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone. If enclomiphene raises testosterone levels it\u2019s hard to accept the investigator (with a possible financial conflict) dismissing the possibility that the drug caused the stroke.", "answer": 0}, {"article": "It has not been all good.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\n(The drug\u2019s name comes from V600E mutation in RAF.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job explaining signifcant potential harms of both drugs \u2013 something competitors didn\u2019t do at all.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\nIron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not talk about potential harms to the newborn, such as jaundice, although it does mention the original rationale for quick cord-clamping, to limit the blood loss to the mother.", "answer": 0}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t include a discussion of actual safety results of the study drug, although this is the primary goal of the study. \u00a0Was this safe? \u00a0Were there any adverse events? The discussion about \u201cresistant virus\u201d found in some patients is not well described. Was this a resistance identified at the beginning of the trial or related to use of 10-1074?", "answer": 0}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nAnd blood tests before and after breakfast confirmed nitrite levels in the body.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nThe high-nitrate breakfast included 16 ounces of beet juice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from consuming high concentrations nitrates.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss the possible harms of higher LDL cholesterol \"or perhaps higher incidence of cardiovascular disease\" from chocolate. But it didn\u2019t provide any evidence.\u00a0 Nonethless we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n\u201cHowever, it should not replace other therapy such as quad strengthening exercises, and weight loss, which we know will provide benefit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chondroitin is not associated with the dangerous side effects seen with NSAIDs, but we were left wondering: What were the\u00a0adverse events seen with this supplement?", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no numbers were provided to give a sense of the scope of the potential harms of taking the extracts.\u00a0\u00a0 All the story said was, \"Side effects vary greatly.\"\u00a0 What were they?\u00a0 How many people had them?\u00a0 ", "answer": 0}, {"article": "Co-authors are Erin Van Blarigan, ScD, of the departments of Urology, and Epidemiology and Biostatistics at UCSF; Howard Sesso, ScD, MPH; Edward Giovannucci, MD, ScD; Meir Stampfer, MD, DrPH, and Julie Batista, ScD, all of Harvard T.H.\nThis study was supported by grants from the Prostate Cancer Foundation and the National Institutes of Health.\n\"It's interesting that vigorous activity had the highest potential impact on prevention of lethal prostate cancer.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms. But the lifestyle choices at issue here are (for the most part) so broadly defined that it would be difficult to say what the harms would be. What harms are associated with eating tomatoes, avoiding processed meats, or not smoking? We\u2019ll rate this one not applicable.", "answer": 2}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses both common side effects and severe ones, while also noting which patients may be at increased risk of those side effects. The coverage would have been even stronger with some mention of the rate at which these problems occurred.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did mention concerns about anxiety and depression; how often these occur and whether the drug increases their prevelance\u00a0are relevant peices of information. It would have been useful to hear how often these side effects occur. ", "answer": 1}, {"article": "Normally, cells in the pancreas work to release insulin, a hormone that can process sugar and either send it to cells that need it for energy or store it as fat for future energy needs.\nNearly half of people in the study who were given a six-month diet plan and lost an average of 30 pounds went into remission and no longer had diabetes.\nMost importantly, 46% of the people in the diet group went into remission with their diabetes, compared to just 4% in the control group.\nAfter a year, most of the people in the diet group lost about 22 pounds, compared to two pounds in the control group.\nAll of the people had been diagnosed with type 2 diabetes in the six years preceding the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the very restricted diet were not mentioned. Were there any problems resulting from months on the liquid diet? Did subjects have trouble adhering to the restrictions?\nThere were quite a few side effects during treatment. According to the study, during the intervention, most common side effects/complaints were constipation (56%), headache (45%), increased cold sensitivity (44%), dizziness (42%). These tended to dissipate over time.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nThe study did not examine whether the medication improved cognitive functioning.\nDr. Merriam said Merck and other companies also are investigating similar treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that further study of growth hormone in otherwise healthy older adults is needed due to a lack of safety information, however none of the potential harms are mentioned. We do not know the long-term effects of growth hormone in older adults; however, it may pose an increased risk of prostate cancer for older men and decrease longevity (Vance, M. L. (2003). Can growth hormone prevent aging? N Engl J Med, 348(9), 779-780.).", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThe side effects of traditional treatment were not worth it to me, and I wasn\u2019t afraid to try the most cutting-edge technology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harms discussed are those in relation to competing treatments.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story failed to mention that excess vitamin D is stored in the body and that excessive intake can be fatal.", "answer": 0}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nThe test diagnosed tuberculosis in 99.2 percent of the patients, the researchers found.\nFurther trials of the new test are planned, the researchers said.\nA report on the researchers' work was published in the Sept. 2 issue of the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the new test apparently does a very good job\u00a0of ruling out individuals who don\u2019t have TB, the study reported that 5 out of 609 patients without TB received a false-positive TB diagnosis. These individuals may be subjected to additional tests and treatments that have the potential to cause harm. The story didn\u2019t mention this. ", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of Erbitux are accurately presented.", "answer": 1}, {"article": "The Lancet.\nCommunity screening for osteoporosis could prevent more than a quarter of hip fractures in older women, according to new research.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\nA new study, published in The Lancet, has shown that a simple questionnaire, combined with bone mineral density measurements for some, would help identify those at risk of hip fracture.\n\"Our data has the potential to influence national policies around prevention of hip fractures, which is particularly relevant in our ageing society.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this news release addresses effectiveness of a community screening effort rather than a treatment, harms are likely to be few. However, we think potential harms deserved some attention.\nHarms could arise from medication complications \u2014 which for bisphosphonates (the most commonly used drug class for treating osteoporosis) can paradoxically include atypical fractures. This is a risk calculator, so we\u2019re not as concerned about over-diagnosis. The expectation is that the risk information should be incorporated into discussions of treatment options. The bigger concern would be under-diagnosis \u2014 how many fractures occur in women whose FRAX score is low and then don\u2019t go on to bone density scanning (DXA) so the opportunity to diagnose and treat osteoporosis is lost.", "answer": 0}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nIf the test is negative, its accuracy will allow doctors to wait and watch a lesion.\nIf it shows a malignancy, a biopsy still would be needed to confirm the cancer.\nThe next logical question is whether those changes might be detected early enough to predict and prevent lung cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the additional maneuvering of the bronchoscope to collect cells for the genomic testing adds less than a minute to a bronchoscopy procedure. But it doesn\u2019t make clear that bronchoscopy itself carries some risks (mainly of infections). In addition, a company news release reports that the test has a relatively low specificity of 47%, which means there will be many false positive results. The story doesn\u2019t explore this beyond saying that there will still be biopsies. These false positives will result in unneeded surgical or needle biopsies in those who turn out not to have cancer.\u00a0Any story about a new test \u2013 rather than dwelling on \u201caccuracy\u201d \u2013 should explain both the sensitivity and specificity of the test.", "answer": 0}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nThe Henry Ford therapists are trained to break that barrier.\nThe list includes her therapists' phone numbers.\nWhen patients came in talking about suicide, health providers took notice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story looks at an overarching strategy for identifying and treating depression; screening patients to identify those at risk and then pursuing \u201cappropriate care.\u201d While individual drugs or other treatment options can have potentially adverse side-effects, the story does not attempt to evaluate specific courses of treatment. For that reason, exploring the potential harms associated with individual treatment options doesn\u2019t seem relevant in this case.", "answer": 2}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nThe juice is a beautiful wine-red color and tastes delicious.\nBut is it especially healthful?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article failed to mention any harms or ill-effects that might be associated with ingestion of pomegranate or pomegranate-containing products. There are several case reports of pomegranate allergies in the medical literature.", "answer": 0}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\nAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category.\nAfter 12 weeks of treatment, as compared to vehicle, Seciera\u2122 showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p<0.0001).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does acknowledge harms by saying, \u201cAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category,\u201d that offers no useful information for readers as to what those adverse events are, or how troublesome they might be to those using the product. The U.S. National Library of Medicine lists these possible side effects from cyclosporine ophthalmic: \u201cburning, itching, stinging, redness, or pain of the eyes, overflow of tears, red eyes.eye discharge, blurred vision or other vision changes, feeling that something is in the eye.\u201d", "answer": 0}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\nMango consumption helped relax blood vessels in as little as two hours after intake.\nMeasurements were taken during each visit, including heart rate and blood pressure, blood samples and breath samples, which are increasingly used in nutrition studies to evaluate gut health status.\nAdditionally, some of the participants showed favorable changes in the production of breath methane, an indication of the potential influence on gut fermentation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Mangoes are a fruit. Eating fruit is generally a good idea \u2014 as long as it is part of a balanced diet. The \u201cbalanced diet\u201d part is missing from the release. Mangos are not inherently unhealthy, but they do contain a significant amount of sugar. So, if one is going to increase one\u2019s mango consumption, that should be offset by reducing other sources of sugar in the diet. Adding two cups of mangoes a day at 214 calories is not insignificant unless calories are cut back elsewhere in the diet. To be clear, we don\u2019t think mangoes need a warning label \u2014 but a simple note that mango consumption should be incorporated into a balanced diet would have been valuable.\n\u00a0", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are really no harms to discuss when addressing these dietary changes, particularly given the extremely broad definitions of the vegetarian diet in the relevant study. Not applicable.", "answer": 2}, {"article": "Moffitt is the No.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nThe researchers previously developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that the vaccines were \u201cwell-tolerated and patients only experienced low-grade toxicities. The most common adverse events were fatigue, injection site reactions, and chills.\u201d\u00a0 The release would have been better if it had told us how often these side effects occurred in the patient volunteers.", "answer": 1}, {"article": "For more information, click here.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nThe objective of the Orbera system is the make the patient feel partially satiated so they eat smaller, but more nutritious portions.\nThe most common side effect of installing the balloon is nausea that lasts a few days.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends more time playing down potential risks than it does addressing what risks are posed by Orbera. Risks are summed up with a line that says: \u201cThe most common side effect of installing the balloon is nausea that lasts a few days.\u201d It also says that patients are kept under \u201cmild to moderate\u201d sedation when Orbera is put into the stomach. The story adds that Orbera eliminates \u201crisks involved with more invasive options,\u201d effectively playing down the risks associated with sedation. The story also doesn\u2019t address risks such as \u201cvomiting, abdominal or back pain, acid reflux, influence on digestion of food, blockage of food entering the stomach, bacterial growth in the fluid filling the balloon which can lead to infection, injury to the lining of the digestive tract, stomach or esophagus,\u201d etc. \u2014 all of which are discussed on Orbera\u2019s website.\nHowever, the most problematic line in the story related to harms states: \u201ceven if the balloon were to pop, the saline would be absorbed and pose no harm to the patient. The balloon would be removed in the same way it is at the six month mark.\u201d Readers might think that this mean a popped balloon in the stomach is a trivial event. However, Orbera\u2019s directions for use \u2014 which are also available online \u2014 note that \u201cBowel obstructions have been reported due to deflated balloons passing into the intestines and have required surgical removal. The risk of obstructions may be higher in patients who have diabetes, a dysmotility disorder, or who have had prior abdominal or gynecological surgery, so this should be considered in assessing the risk of the procedure. Bowel obstruction can result in death.\u201d Not necessarily such a trivial event after all.", "answer": 0}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\n\"We worked closely with Moy Park, Waitrose and the Royal College of Surgeons in Ireland, to deliver an innovative, nutrient-rich food, that increases omega-3 levels in consumers, naturally.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the release a Not Applicable in this category since the study involved eating a moderate amount of chicken and eggs in their normal diet.\u00a0 Based on what little the release actually tells us about the trial, it\u2019s hard to see where people would be harmed from eating this amount of these particular foods.", "answer": 2}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nNewswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives only a very brief mention of harms, citing nausea and vomiting as the most common adverse events reported. However, with a catheter patients might experience irritation in their esophagus or stomach (which could lead to bleeding or ulcers) or infection from bacteria surrounding the balloon. A concern for this type of balloon, which is intended to deflate, would be improper deflating and obstruction of the intestine \u2014 a potentially serious complication.", "answer": 0}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nThat's why the device requires training every time Burkhart uses it.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\n\"It will be years until a paralyzed patient will be able to control neural prostheses independently from caregivers, but there is nothing that should make this improvement impossible.\"\n\"What we'd really like is a system that's plug and play and will work daily without needing to be recalibrated.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even if the technology is experimental and only tested on one patient, the\u00a0story should have included some discussion of risks of the implantation surgery and the implant itself.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No specific description is provided of potential harms. One potential harm is that this technique still misses some malignant lesions.", "answer": 0}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\nDavidovitch's goal is for patients to return to their normal level of activity as quickly as possible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story a Satisfactory rating on this criterion because it includes comments from a surgeon who warns about the risk of serious complications during the first night after surgery.\nHowever, the most prominent voice in the story is a surgeon who dismisses those concerns by saying, \u201cif the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital. It really doesn\u2019t make sense.\u201d\nWe\u2019re not given any information or data that proves this \u201cdoesn\u2019t make sense,\u201d though.\nWe also think potential harms that could have been included are falling at home due to dizziness, or otherwise not being adequately prepared for managing under major surgery.", "answer": 1}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\nLess than 1 percent of patients treated with cryoablation were hospitalized for a recurrence of the disease, compared with 6 percent in the drug group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention several of the harms associated with the use of this device along with the incidence with which they were observed.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\nPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who'd been less active, the study found.\nThat finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\nBut the study couldn't prove that more exercise actually caused death risk to drop.\n\"Our findings show that physical activity can have a positive impact on survival in lymphoma patients,\" she said in a Mayo news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In general, we feel that it is important to discuss potential risks even if those risks are minimal. In this case, you\u2019re talking about a group of people with a very serious illness taking very serious drugs\u2013what should they know about the risks of increasing their physical activity?", "answer": 0}, {"article": "BLOOMINGTON, Ind.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not make any mention of potential side effects of stimulants used to treat ADHD. Common side effects include headache, upset stomach, increased blood pressure, dizziness, decreased appetite, insomnia and dry mouth.", "answer": 0}, {"article": "\u201cThe difference is, the length of stay is cut in half,\u201d he said.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention negative outcomes that may be associated with the daVinci machines. It does not indicate whether complication rates are higher, lower or equal.\u00a0 \nThe story also fails to mention the potential harm if the machine is used to justify a hospital\u2019s investment or support surgical revenues regardless of whether it\u2019s the best use for a particular patient. ", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nAnd cancer sometimes returns even after that much time has elapsed.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms or side-effects that have been experienced with this form of treatment. ", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t say much about potential harms when all that\u2019s been reported is an experiment on 9 human organ donor lenses.\u00a0 But the story didn\u2019t even capture what the authors wrote:\u00a0", "answer": 0}, {"article": "U.S.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities.\nThe healed tear could not be penetrated by the probe.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release\u2019s statements (mentioned above) refer to positive outcomes and mention no adverse effects, readers can\u2019t draw any conclusions about the safety of the procedure, given it\u2019s a single case study and a short-term follow-up.", "answer": 0}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\nAsthmaNet studies are currently being conducted in 14 states.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\n\"Results from this randomized controlled study showed that in young children with mild asthma, acetaminophen used as needed was not associated with increased asthma flares or more asthma symptoms.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by asthma exacerbation rate, number of days of asthma control, need for \u201crescue\u201d medication and unscheduled medical visits for asthma, as the news release points out. As mentioned above in the \u201cQuantify Benefits\u201d section, this release\u00a0does not lay out any supporting quantitative data for these benchmarks. It only states, \u201cThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\u201d\nFor these reasons, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "GlaxoSmith Kline and Eli Lilly supplied Lovaza and Raloxifene, respectively.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\nManni added that, with obesity-related cancers on the rise, the findings could have implications beyond breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release fails to mention harms at any point and, while a widely consumed, readily available supplement like omega-3 fatty acids isn\u2019t likely to cause major problems, it is not free from side effects that are worth mentioning. The research paper itself points to more than a half-dozen participants in the study who withdrew because of adverse effects including hot flushes, leg cramps and\u00a0nausea. Readers rightly deserve to know possible negative impacts found in research studies.", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out that a major side effect of the new drugs is anemia, and more than 40% of patients in the boceprevir studies required erythropoietin to combat it; however, the story should have noted that over 20% of patients in the control groups also became anemic. In addition, there was a high drop-out rate in the two trials, which should have been mentioned. Why did so many drop out? \n ", "answer": 0}, {"article": "\"I'm like, well, I gotta do something, you know.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won't just be obese people taking them.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nWe're talking about medications to help those who are struggling with the health impact of obesity,\" Nadglowski says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story sidebar notes \u2013 from the FDA briefing documents: \u201cThe review noted continued concerns that Qnexa can increase the risk for several possible side effects, including increased heart rate, birth defects and thinking problems such as memory lapses and confusion.\u201d\nIt also included these caveats:\n\u201cThere\u2019s been a long history with obesity drugs that we\u2019ve had to take off the market. You recall the fen-phen episode where a significant number of people got heart-valve defects,\u201d says Janet Woodcock, a top FDA official.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won\u2019t just be obese people taking them.\n\u201cWhen you\u2019re talking about a drug where it could go into literally tens of millions of Americans, there has to be attention to safety,\u201d Woodcock says.\nWhat might look like a rare problem now could turn into another public health disaster, she says.", "answer": 1}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from increased pasta consumption. The problem is not with pasta\u2019s nutrients but with potentially filling up on high-calorie pasta and excluding other healthy foods (not named in the release) from your diet.", "answer": 0}, {"article": "Resveratrol is a naturally occurring compound found in foods such as red grapes, raspberries, dark chocolate and some red wines.\nTurner says the study also found that resveratrol was safe and well tolerated.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nAn \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions resveratrol\u2019s most common side effects, which include nausea, diarrhea and weight loss. It would have been helpful to know how commonly these effects occurred. It also lists loss of brain volume as an effect, but states it could interpreted as either a benefit (since it could have reduced inflammation) or harm.", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms criteria with the following statement:\u00a0 \u201cTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\u201d\nWhile we\u2019ll award a borderline satisfactory, we wish that the release had cautioned that a study of 52 people is incapable of identifying harms that might occur with a larger and broader sample of patients.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nAccording to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n\u201cThis is consistent with overdiagnosis of pulmonary embolisms that may have caused very little harm, may not have caused death,\u201d said Dr. Renda Soylemez Wiener of Boston University, who worked on the study.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained: \u201cthe blood-thinning drugs used to treat blood clots increase the risk of bleeding in the brain or gastrointestinal tract, for example. According to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\u201d It also reported: \u201cCT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer. And the dyes used to enhance the scan also cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "Tobacco use accounts for some 85 percent of lung cancer cases in the U.S., and one estimate puts a smoker\u2019s lifetime absolute risk of developing lung cancer between 12 percent and 17 percent.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nThe data are \u201cconsistent\u201d with earlier studies but there are still many issues to resolve regarding lung cancer screening, Johnson said.\nAnd for lung cancer, doctors know there is a high false-positive rate and have a set protocol to follow in order to determine which lesions are dangerous, added Johnson.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWhile too many news reports take a \u201cwhy not?\u201d attitude toward medical screening tests, this story confronts some of the potential harms. It refers to a recent report that more than one in five \u201cinitial lung CT scans show suspicious lesions that turn out not to be cancer, but lead to needless invasive follow-up procedures and radiation exposure, as well as stress and anxiety for patients and their families.\u201d", "answer": 1}, {"article": ".\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\nTechnically known as single-port cryosurgery, the technique is used only for cancers no bigger than an inch and a half wide that haven't spread beyond the kidney, Lee said.\nThat was the first thought on Davis' mind as he returned to consciousness in the recovery room, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential \"mishaps\" but what does that mean? How often do they occur? How often will the surgeon need to revert to open surgery? What are the long-term risks?", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did say, \u201cBut even as some experts hailed the new study as a breakthrough, others urged caution, warning people not to start a regimen of aspirin without first consulting a doctor about the potential risks, including gastrointestinal bleeding and bleeding in the brain (hemorrhagic strokes).\u201d It could have put a number to these harms, as the NPR Shots story did. ", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Irwin Rosenberg was quoted as stating that taking too much vitamin B12 is unlikely to cause harm. \u00a0However \u2013 there are specific conditions where the use of injectable vitamin B12 can be problematic (e.g. in those with Leber\u2019s disease or allergy to cobalt) and any regular injections are associated with risk of blood borne infection.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although highlighted in the NEJM paper describing the neratinib trial, the news release doesn\u2019t mention that 38% of patients receiving the drug experienced severe diarrhea, requiring a change to the trial protocol.\nA related NEJM editorial also noted that a\u00a0phase 3 trial including trastuzumab, pertuzumab and neratinib (compared to standard of care trastuzumab and pertuzumab) could result in significant side effects when added to chemotherapy, and they raise concerns of over-treatment of a large number of patients.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states both the severe and mild side effects of taking this drug. We\u2019ll rule this Satisfactory since there was a good-faith attempt to address the criterion. However,\u00a0while the array of side effects are listed they are not quantified. We do not know what proportion of those taking the medication get each side effect. Nor do we know how severe they are, or how many stopped the medicine die to the side effects. More detail would have been welcome.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that patients receiving Deplin during a short-term study reported no increase in side effects compared with those receiving a placebo. However, the story did not mention that there are potential harms associated with the administration of synthetic folate that would not show up in a small, short-term study such as this one.\u00a0There are concerns, for example, that too much folate might increase the risk for colorectal cancer or hasten cognitive decline in individuals with poor vitamin B-12 status. At the very least, the story should have noted that current studies are not capable of identifying potential adverse effects of long-term Deplin therapy.", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nIf they're right, we all may soon be taking a pill that could give us an extra decade or two of healthy old age.\nAnd he had shown that you could extend life span in yeast.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms, potential or known.", "answer": 0}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\nPostmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms associated with hormone replacement therapy. These are well documented in multiple studies and include a heightened risk of breast cancer and other types of cancer.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because the study failed to prove that the Oncotype DX test could identify the patients most likely to benefit from chemotherapy, the risk is that the test would be used for this purpose anyway.\u00a0\nThis triggers the risk of \"false reassurance\"\u2013that a resassuring test result would lead to no aggressive treatment yet a bad outcome.\u00a0 \nThe story fails to warn about the potential risks of clinical over-use and over-reliance on a test that may not improve survival rates. ", "answer": 0}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nMarybeth Thorsgaard, a Medtronic spokeswoman, said the company was close to completing a clinical trial involving the use of Infuse in anterior cervical fusion.\nIn a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe harms associated with the use of bone-growth proteins in fusions to treat upper spine pain are the headline of the story \u2013 and the study it is based on. The story specifically notes that patients have reported life-threatening complications, including difficulty breathing and swelling of the neck.\nThe story would have been better if it had included some explanation of the number needed to treat in order to see an additional case of harm.", "answer": 1}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nTraining with the system improved McGlynn's speed when it was turned off to 23 yards per minute, indicating therapeutic benefit.\nBoth men gained strength and endurance through repeated use of the systems and fine-tuning by the researchers.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\nWith the technology switched on, he covered far more ground and his pace was twice as fast during his 30-week study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms, such as the risk of infection from implanted electrodes.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned.\nA bone density scan is a non-invasive and safe test, but the news release is silent on the issue of harms from false-positive or false-negative results \u2014 either of which could lead to over- or under-treatment.", "answer": 0}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nAnd experts aren\u2019t even entirely sure why it works for Parkinson\u2019s in the first place.\nSince the procedure is experimental, there may be some unknown risks as well.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Near the end, the story does mention that \u201cDBS is a type of brain surgery, and comes with risks like bleeding, infection and need for more surgeries\u201d so it earns a Satisfactory rating. It also points out some harms may be unknown. But we would have been happier if the risks were not buried in the last paragraph of the story by which point, odds are, some\u00a0people would have stopped reading.", "answer": 1}, {"article": "Even today, in much of the developing world, people exercise through activities such as farming and fetching water that are necessary for survival.\nWe may tend to attribute the health of this group to their running habits.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nEven if we dismiss the possibility that running harder is worse, it is probably useful to note that running harder or farther doesn\u2019t seem to be better.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even moderate jogging carries health risks \u2014 more for some people than others. Running can cause joint problems, shin splints, and aggravate lower back strains, among other things (it\u2019s done all three things for at least one of our reviewers). And people with heart disease, arthritis, asthma, diabetes, lung disease, kidney disease or other serious ailments should consult a physician before embarking on an exercise regime \u2014 even a low-impact one \u2014 because they are at higher risk of incurring more serious health problems. Any story that effectively encourages readers to engage in moderate exercise several times a week (which is laudable), should also caution readers about the potential risks involved and how to begin such an exercise regime safely.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nDuring each treatment, participants were asked about their pain, sleep patterns, mood, and overall quality of life.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story actually quantified the harms, but they both noted there were side effects. This story did a better job, though, by noting that the only dose that seemed to work also seemed to produce the most side effects and by raising the issue of long-term safety concerns. It also was the only story to answer the question that readers surely would have when reading about an illegal narcotic being used as medicine. Did these patients feel high as a result? This story says that most did not. Because of the additional information and context, the rating here is satisfactory.", "answer": 1}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nBut it\u2019s not a foregone conclusion that later start times will ensure teens sleep more.\nThere are some limitations to mention about the new meta-analysis.\nFor one, teens need more sleep than adults: about eight or nine hours a night, compared with about the six or seven their parents require.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some drawbacks\u00a0associated with delaying school start times, and the story does a good job of discussing them.", "answer": 1}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms covered in the study were glossed over in the release, in particular by this sentence: \u201c[P]atients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\u201d\nGiven what was left out, we\u2019ll mark this one unsatisfactory.\nWhat\u2019s not mentioned is that 16% patients in the adalimumab group dropped out compared to less than 7% in the placebo group. We also learned that some of the adverse events that triggered dropout weren\u2019t included in the release: \u201cAdverse events leading to discontinuation of participation in the trial were more common in the adalimumab group and included choroidal neovascularization, blurred vision, reduced visual acuity, fatigue, malaise, and suicidal ideation.\u201d\nSomething simple\u00a0that the release could have characterized about the\u00a0adalimumab treatment\u2019s harms, but didn\u2019t: it had three times the rate of \u201cadverse events\u201d and twice as many serious adverse events.\nIncluding any of these numbers \u2014 and some of the harms that taking corticosterids like prednisone can cause (the best we get is \u201cmany unwanted side effects\u201d) \u2014 would have put the harms and benefits of the adalimumab treatment into clearer context.", "answer": 0}, {"article": "Independent committees look at the details of the patients and how well they are doing in drug trials like these.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\nKeytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey \u2013 costing about $150,000 a year for a course of treatment.\nKeytruda was being tested for the first time in 305 lung cancer patients who had not been treated at all yet.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says about the whole class of drugs to which Keytruda belongs, \u201cThe new drugs are less toxic and more precise than standard chemotherapy. But they are not free of side-effects. Some are severe and can damage the lung, colon, liver, kidneys, hormone-producing glands and the brain, the FDA says.\u201d", "answer": 1}, {"article": "\"That time frame is not anything to write home about,\" Gulley says.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions side effects in a satisfactory way.", "answer": 1}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\nWhen patients do make their way to Kate Scarlata, a Boston area registered dietitian who specializes in the diet, the first thing she tells them is that it \u201cis a dietary experiment.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the diet is restrictive, in the sense that it asks patients to eliminate a wide array of foods eaten in a normal diet (before cautiously adding them back later in the process). It also hints that because of all the unknowns with this relatively new, not-fully-researched diet, \u201cit\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\u201d", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story presented information about one side effect, dizziness, it did not do an adequate job address potential harms associated with treatment.\nFrom the company's own website, it was possible to learn that:\nThe most common adverse events occurring during all controlled clinical trials for patients taking LYRICA vs those taking a placebo were dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention).\nThese might be important to patients or investors. \u00a0", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not talk about any harms related to high doses of Vitamin D.\n\u00a0", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harm in this case would be that, by avoiding whole-brain radiation, a patient may shorten his or her life. The story addresses this. For example, the story does a good job of articulating differences in overall survival for those who received whole-brain radiation and targeted therapy versus those who only received targeted therapy \u2014 and it gets bonus points for explaining that the observed differences in survival time were not statistically significant. The story also quotes one source as saying that there are some circumstances in which whole-brain radiation may still be beneficial.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It seems that harms to the mice were not discussed in the research paper (not surprising as the mice were all killed as part of the study) that\u2019s the basis for the story. A brief search didn\u2019t turn up anything overly concerning regarding the harms of ginger, but then again, it\u2019s not clear what the dosage given to the mice would translate to in human terms. A high-enough dose of anything can be dangerous. But while it might have been helpful to mention harms to humans attributed to powdered ginger, this may also have propagated the questionable notion that the findings are applicable to humans. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\nCAD is becoming more widespread, said Dr. Joshua Fenton, an associate professor of family and community medicine at the University of California, Davis, and lead study author.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Beginning with the headline \u201cAre Pricey Computer-Aided Mammograms Worth It?\u201d and continuing throughout the piece, the potential problems with CAD are noted. \u00a0The article includes several quotes from Dr. Joshua Fenton, lead author of the study, on three key problems with CAD. \u00a0Dr. Fenton observed that \u201cthe (overall) rate of invasive breast cancer diagnosis was no different with or without CAD.\u201d \u00a0 In addition, \u201cCAD was also associated with increased diagnostic testing among women who turned out not to have breast cancer.\u201d \u00a0These women had additional mammography, or ultrasound, or biopsies. \u00a0Finally, because CAD led to increased diagnosis of DCIS, Dr. Fenton observed that \u201cIf you are an older woman, (there is) the risk of over-treatment of noninvasive lesions.\u201d", "answer": 1}, {"article": "You have to be really low on your iron storage before you're going to flag as anemic.\"\nSekhar and colleagues hoped to determine risk factors for iron deficiency without anemia that could pinpoint which women could benefit most from this more costly testing.\nHowever, the only risk factor significantly associated with iron deficiency without anemia in young women in this study was having had a period for more than three years.\nTaken together, the studies suggest that risk factors and assessments should not be used to determine which young women should receive testing for iron deficiency.\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening is not without harms. The release does not mention any potential harms or downsides from identifying more teens with iron deficiency, or pre-anemia. Would a positive screen result in iron supplementation or a change in eating habits? Some research has suggested that mild iron deficiency is protective.\nIron supplementation is associated with constipation and too much iron is harmful to the liver, heart and other organs. A harm to society might be more financial drain on an already strained health care system if widespread screening were adopted.", "answer": 0}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nThose studies involved too few participants or produced conflicting results to draw any meaningful conclusions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While it\u2019s not an invasive treatment and seems to be safe for most people, yoga can cause harm.\u00a0The story, however, doesn\u2019t address this possibility or state whether the studies included in the review assessed potential adverse effects\u00a0of treatment.", "answer": 0}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nAnd they might want to offer the test to people with milder symptoms who want to know whether they are developing the devastating brain disease.\nDoctors might want to use the test in cases where they want to be sure of the diagnosis.\nThey note that it is not reliable enough \u2014 results can vary by lab \u2014 and has been studied only in research settings where patients are carefully selected to have no other conditions, like strokes or depression, that could affect their memories.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis rating is a close call. The story does highlight concerns about testing people for a disease for which there is no effective treatment. It also obliquely refers to the risk of erroneous results mislabeling people as destined to develop Alzheimer\u2019s Disease. However, the story includes comments from experts who downplay the risks to spinal taps without noting the number of people who experience severe pain, bleeding, infections or other problems. The discussion of potential harms seems imbalanced. ", "answer": 0}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nI\u2019m also not suggesting that people start drinking coffee by the gallon.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story warns that adding sugar and fat to coffee may negate any potential health benefits. The story also mentions \u201cjitteriness\u201d and the fact pregnant women should limit consumption, but doesn\u2019t describe the potential harms of excess caffeine in pregnancy that have been well described in the literature. And there are a number of studies suggesting that caffeine seems to trigger symptoms in people with anxiety disorders. More generally, what about the research on the ill effects of coffee on insomnia,\u00a0or urinary incontinence.\u00a0or dependence? \u00a0What about withdrawal headaches and the problems of \u201cstopping\u201d coffee drinking? \u00a0We\u2019ll give the benefit of the doubt here as we usually do on borderline calls, but the exploration of harms was not nearly as thorough as the coverage of benefits.", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harms. ", "answer": 0}, {"article": "He was not involved in the study.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nResearchers said they planned to continue to follow the study group to monitor the effect of vitamin intake over time, and said additional studies would be needed to see if there were similar benefits for women or younger men.\n\u201cIt doesn\u2019t seem like there is any particular risk associated with taking a vitamin and there might be a small benefit,\u201d said Dr. David Weinberg, chief of the department of medicine at Fox Chase Cancer Center in Philadelphia.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said that taking a multivitamin \u201cappears to have no dangerous side-effects,\u201d\u00a0which we\u2019ll call good enough for a satisfactory. In addition, it describes the results of previous studies that have suggested harm from other vitamin formulations. However, it didn\u2019t emphasize that the study was conducted in relatively healthy non-smoking\u00a0men, and that\u00a0certain vitamins may cause problems for people who\u00a0smoke or who are taking medications. The AP explained this nuance.", "answer": 1}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\nThe study appears in the September issue of the journal PLoS Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nEven though the authors of the research study commented on the risks of statin use in order to place this potential additional use into context, this story failed to include any mention of the potential harms.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes the most common side effect of the newer sublingual drops treatment and the rare risk of serious side effects from allergy shots. The article could have been strengthened by including information on the side effects of OTC and prescription drug treatments.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\n\u201cAlthough CTCA removes diagnostic uncertainty and halves the rate of subsequent heart attacks, quality of life can be negatively impacted in those who are worried about their health and are found to have nonobstructive coronary artery disease,\u201d Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\nIf a doctor is faced with a patient who is already on an aspirin and statin with an unconfirmed and questionable clinical diagnosis of angina due to coronary heart disease, he said, then CTCA would be useful because finding normal heart anatomy means that more invasive testing can be avoided, treatment could be stopped and quality of life improved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes a cautionary quote about the type of patient who might end up feeling worse after CTCA testing. The story would have been better if it noted that this type of scan can inadvertently find suspicious shadows, especially in the lungs, which may then lead the patient into further, possibly invasive, testing. The story could have also included some reference to concern about harms from X-ray radiation.", "answer": 0}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nResearchers stress the findings are preliminary and that men with the cancer should not reach for the aspirin bottle in an attempt to improve their health.\nAspirin and other anticlotting medications carry risks of their own, chiefly bleeding, Zietman says.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story mentions that the drugs carry risks, including bleeding. However, the story should have been clear that such bleeding can be lethal in some cases and that these drugs also raise the risk of prostate cancer patients suffering complications during treatments.\u00a0", "answer": 0}, {"article": "\"We should offer all women the possibility of a cure.\"\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\nDr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced-stage ovarian cancer:\n\u2022 Chemotherapy should be offered after the surgery, rather than before.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms. For example, there is no discussion of the risks associated with aggressive surgery to remove ovarian cancer tumors. As the Mayo Clinic notes on its site, ovarian cancer surgery \u201cgenerally involves removing both ovaries, the fallopian tubes, the uterus as well as nearby lymph nodes and a fold of fatty abdominal tissue (omentum) where ovarian cancer often spreads.\u201d All surgery poses some risk, and this surgery is extensive. Chemotherapy also poses risk. In addition, the release stresses a specific order in which treatment should be given. It states \u201cwomen should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\u201d While the surgery first technique may well have greater chances of survival, reducing tumor bulk with chemotherapy first reduces the peri-operative complications. This trade-off is not discussed.\nWhen a news release is explicitly advocating for a very specific standard of treatment, it\u2019s important to articulate the risks as well as the potential benefits, so that healthcare providers and patients can make informed decisions.", "answer": 0}, {"article": "According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nResearchers found that after eight weeks, women who received depression-specific acupuncture were more likely to have a treatment response \u2014 meaning the severity of their symptoms fell by at least half and they no longer met all of the criteria for diagnosing major depression.\nOverall, 63 percent responded to the therapy, versus 37 percent of the \u201ccontrol\u201d acupuncture group and half of the massage group, according to findings published in the medical journal Obstetrics & Gynecology.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\nIn the new study, the Baylor group investigated whether anogenital distance differed in fertile and infertile men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 But this story promotes a \u201csimple\u2026noninvasive way to test testicular function and reproductive potential in adult men.\u201d\u00a0 So presumably one would act on the basis of what this simple test shows.\u00a0 That opens questions about the sensitivity and specificity of this approach \u2013 neither of which are addressed and both of which raise issues of potential harm, overtesting and overtreatment for the man.\nMaybe not so \u201csimple\u201d as described.", "answer": 0}, {"article": "\"That's about 20 pounds,\" Smith said.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\nFDA briefing documents posted online Tuesday acknowledged Qnexa's effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\nAfter one year, 47.5 percent of those taking lorcaserin had lost 5 percent or more of their body weight.\nSmith's team noted that for those taking lorcaserin, there was no increase in heart valve problems as had been seen with the discredited diet drug Fen-Phen.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give this a barely satisfactory score. This story is the only one of the three that we reviewed on this study that buries the fen-phen connection. And none of them take the time to spell out how much damage fen-phen really caused. As with the other stories, it breezes past any side effects or other long-term problems by saying, \"(the) team noted that for those taking lorcaserin, there was no increase in heart valve problems as had been seen with the discredited diet drug Fen-Phen. However, common side effects included headache, dizziness and nausea.\" Although, unlike the other stories, it points out about a competing drug, \"FDA briefing documents posted online Tuesday acknowledged Qnexa\u2019s effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\" \nBut, again, connected with our \"Evidence\" criterion comments above, was the study rigorous enough to answer tough questions about safety? We wish the story had explored this more deeply. Can we be sure this drug is safe, since so many prior weight loss drugs fell down on this point?", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\nThe authors reported no serious side effects associated with selenium during the study.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that high levels of selenium have been linked with\u00a0increased risk of type 2 diabetes. It notes that no serious side effects were reported with selenium use in this particular study, but it\u00a0should have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use. It might also have noted that selenium supplements have the potential to cause a rare syndrome called selenosis when taken at very high doses.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\nmentions harms and the frequency of surgical complications in this study, however, the discussion is limited when compared to\nthe discussion of untreated hernias. Does not mention the harm that a hernia can recur even with the surgery (1.4% in this\nstudy.) The most significant harm reported may be the one case of nerve injury, which was not mentioned in the story. While\nthe story states 20% had complications, three of them life-threatening, readers could have used more detail.", "answer": 0}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "One of the investigators is quoted acknowledging the challenges inherent in using drugs like doxycycline to prevent PTSD, but there is no mention in the release about the many serious adverse side effects and drug interactions that come with the use of tetracycline antibiotics.\nDoxycycline has been tried\u00a0long-term for aortic aneurysms (as a matrix metalloproteinase or MMP inhibitor, the same reason it was tried here)\u00a0and as an antibiotic for acne, recurrent urinary infections and other conditions. Although generally considered safe to use, over a long term it can cause allergic rashes, antibiotic resistance, changes in friendly gut bacteria,\u00a0possible weight gain and other problems.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that mild heartburn was the only side effect seen in the study, and that larger long-term studies are needed to establish safety. \u201cI would tell a patient the caveat is, \u2018If you want to try it, you need to be aware that we don\u2019t really know its side effects,'\u201d a researcher says.\nWe\u2019d also add that the herbal supplement industry is not regulated or controlled in the same way as the pharmaceutical industry, i.e. there are fewer restrictions and enforcement, so relying on supplements to treat a condition can pose additional risks from potentially poor-quality or contaminated products.", "answer": 1}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nResearchers at Sheffield University found that in postmenopausal women during the first 10 years after diagnosis of breast cancer, the drug could reduce the risk of death by 18 per cent.\nThe researchers wrote in the study that a substantial number of the trial participants switched from tamoxifen to aromatase inhibitors after they heard that it could reduce recurrence, which affected their results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t really addressed in this report, except for the last sentence, which states the \u201cmain side effect of aromatase inhibitors is an increase in bone loss and fractures.\u201d\nBut aromatase inhibitors also carry the risk of exacerbating menopausal symptoms (including sexual side effects and sleep problems) and of serious muscle and joint pain, which has caused some women to stop taking the drug in the past.\nBisphosphonates long term can cause bone fractures (paradoxical \u2013 they build bone but not always normal bone) and rarely can cause jaw osteonecrosis (\u201cbone death\u201d). This is more common after dental work, but can also happen sporadically and is devastating.\nSince these details are missing in the report, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention possible harms of introducing low-nicotine cigarettes, namely that it might encourage current smokers to smoke more to get their usual dose or make people think the cigarettes aren\u2019t as harmful, so they aren\u2019t as cautious about intake. In that scenario, smokers would be inhaling more of the toxic smoke that causes damage to the lungs. We think it\u2019s important to share with readers if researchers have looked into this, and if it\u2019s indeed a concern, as NPR did.", "answer": 0}, {"article": "RA Nash et al.\nThree participants died during the study; none of the deaths were related to the study treatment.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized.\nThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does the bare minimum here, stating:\n\u201cThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections. Three participants died during the study; none of the deaths were related to the study treatment.\u201d\nStill, we think more could have been said about the side effects of chemotherapy. For example, How many patients experienced them and how bad were they? And the news release does not say how long treatment and recovery takes. The process by which the deaths were categorized is not given and leads to uncertainty about whether these patients may\u00a0have died as a result of the immuno-suppression of their bone marrow.", "answer": 1}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThese associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.\nWeak grip strength is linked with shorter survival and a greater risk of having a heart attack or stroke, according to an international study involving almost 140000 adults from 17 culturally and economically diverse countries [1].\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As mentioned in the section on benefits, the release does not explain how the test results might be used. If the intent is to steer people identified as being at higher risk toward more testing or treatment, then the release should have mentioned the risk of doing more harm through overtreatment.\u00a0", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes a serious side effect of low blood sugar and tells readers that the number of low blood sugar episodes with the new drug is lower than that for older drugs. Yet, this could be a serious complication and the actual rate of this complication is not reported. The story does describe actual rates of some side effects for the new drug when combined with an existing drug (metformin). These included diarrhea (10% of participants) and nausea (8% of participants). The story describes sore throat, headache, and runny nose as \u201cless common,\u201d with no quantification. Yet the story does not mention side effects for the new drug individually, so readers don\u2019t know whether these side effects reported may be related to the existing drug metformin. The story also claims that there appear to be no big safety problems, which is probably a premature statement given the relatively long lag time often needed to see safety problems. ", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentions the heightened risk of further damage from activity in the days and weeks after a concussion, and the unknowns/uncertainties of this risk.", "answer": 1}, {"article": "Digital tomosynthesis (DBT), or 3D mammography, does slightly better, detecting approximately 25 percent more cancers, or roughly 5 cancers in 1,000 women screened.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors mentioned that whole breast screening ultrasound produces high rates of false positives, there was no information provided about the rate of false positives for the abbreviated breast MRI.", "answer": 0}, {"article": "The results were striking.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nThere is little dispute that people feel better after receiving the treatment, in which thin needles are inserted deeply into the skin at specific points on the body.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "      \n\n\n \n\n \nThe article didn\u2019t discuss or quantify potential harms associated with acupuncture. However, potential adverse effects would not likely serve as an obstacle to wider utilization of this treatment. When performed with sterile disposable needles by competent practitioners, acupuncture appears to be a relatively safe treatment approach.\n ", "answer": 0}, {"article": ".\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\nNAC is available over the counter and does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician's supervision.\nThis trial is the first to use NAC as a pharmacotherapy for PTSD and a broad range of SUDs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release explains that the drug used \u201cdoes not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician\u2019s supervision.\u201d However, the published study notes a higher incidence of adverse events in the N-acetylcysteine treated group that in those treated with placebo (66.7% vs. 47.1%). N-acetylcysteine can cause \u201cnausea, vomiting, and diarrhea or constipation. Rarely, it can cause rashes, fever, headache, drowsiness, low blood pressure, and liver problems,\u201d according to WebMD.", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nBut he said the studies called attention to the inconsistent quality of Her2 testing in many small laboratories.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harms of treatment (i.e. slight increased risk of heart failure in some women).\u00a0 The story also mentions that even women diagnosed as positive are not guaranteed benefit from the drug.", "answer": 1}, {"article": "They are made from the same material that's used to create dissolving stitches.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nWhen researchers attach specific proteins to the particles, they say they're able to teach the body not to attack its own tissues.\nIf the approach succeeds in human studies, it may one day lead to more targeted treatments not only for multiple sclerosis but also for other kinds of autoimmune disorders, including type 1 diabetes and rheumatoid arthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unfortunately, the story bounces from an older approach, using white blood cells, to the use of microparticles.\u00a0 So, it is easy to get the wrong impression of results.\u00a0 Harms were not addressed in the results of the study using microparticles.\u00a0 Dr. Miller\u2019s quote, \u201c\u201dThere [were no side effects], there was no re-triggering of disease, and we actually showed that immune responses in patients were decreased,\u201d were related to the ongoing and unpublished study using white cells as carriers.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nOver the next six weeks of testing, I came down to earth as I realized that while the sensor enabled me to drastically cut my usual number of lows, it did not eliminate them.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nBut none are as accurate as a standard blood-sugar test.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Through one man\u2019s story-telling, harms are described and included malfunctions with the machine leading to recalibration or inserting new catheters, trouble relying on machine recommendations for insulin dosages, potential for infection at the injection site, and inconvenience of being awakened or disturbed by the beeping or buzzing alarm. Of course, it\u2019s not clear whether these are the only harms, but they seem reasonable. The story could be improved by reporting on actual harms reported in clinical trials. ", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe underlying premise of this device is that it cooks cancer cells by heating metallic nanoparticles. If the nanoparticles used in this approach collect in normal tissue, those tissues could also be cooked by the radio waves.\n The researchers wrote in an article in the journal Cancer in 2007 that while rabbits in their tests did not appear to suffer any irreversible toxic effects, the safety of this approach in humans \u201ccannot be assumed.\u201d The portrayal of this experimental device as lacking potential harms is inaccurate.", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nStill, the therapies can produce at least some offsetting savings.\nStill, he noted, the study has some limitations.\nAnd its effects lasted; after a year and a half, the longest patient follow-up, the therapy was continuing to work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does not address harms directly\u2013and should have\u2013it does note that one of the worrying side effects of gene therapy\u2014spurring the body to attack itself\u2014was not present in this study.", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\nBeginning in 2016, surgeons used the standardized risk prediction model and treatment algorithm developed at NYU Langone, which factored in data collected from preoperative imaging taken while the patient was sitting and standing, and other measures that might affect risk for dislocation, including presence of a previous lumbar fusion.\nA novel risk assessment tool helps identify which patients undergoing total hip replacement may be at higher risk for an implant dislocation after surgery, according to a new study from researchers at NYU Langone Health and described in the Best Poster in the Adult Reconstruction Hip at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting in New Orleans.\nUsing the risk assessment tool, the researchers identified 192 of 1,009 patients as high risk for a dislocation after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any risks associated with hip replacement surgery in general, nor does it address potential harms specific to dual mobility cups, which are described in the release as the recommended approach to reduce risk for dislocations. The release notes that dual mobility cups may carry risks \u201cif implanted unnecessarily\u201d but doesn\u2019t describe or quantify those risks. Of note, there is some concern that this type of replacement joint may release higher levels of metal ions than conventional joints when implanted in younger, more active patients.\nAs presented, the only downside of these newer devices are the increased cost. It would be helpful to know if there are any other risks. Newer devices may have some risk simply due to not having long-term experience with them. Current hip replacement devices have been shown to work for 20+ years. It will take considerable time to know whether the same may hold for these newer devices.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential harms of Botox treatment, which include a droopy eyelid, muscle weakness, headache, headache, respiratory infection, flu-like symtoms and redness and pain at the injection sites.\u00a0 \nThe risk of these side effects may be reduced if the treatment is provided by a licensed dermatologist. This should have been stated.\u00a0 ", "answer": 0}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Cardiac side effects are reported as less serious than those seen in patients who were treated with Herceptin and chemotherapy. However, this comparison with Herceptin is not a fair one. In trials of Herceptin, the incidence of cardiac problems was about 4% at 3 years, so the reduction to 2.5% with lapatinib appears to be an improvement, but there is not enough information in this story on length of time patients took lapatinib and Herceptin to get those figures (and whether those are statistically different). Although long-term cardiac problems are less of an issue for metastatic patients, this side effect is potentially a big issue for early-stage breast cancer patients \u2013 a group of women for which this drug is already being tested as an alternative to Herceptin. ", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\nThe DRCR.net enrolled 305 participants (394 eyes) with PDR in one or both eyes at 55 clinical sites across the country.\nAbout 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that one study volunteer in the Lucentis group developed an eye infection and stated that \u201cserious systemic adverse events,\u201d namely cardiac arrest and stroke, occurred at similar rates among the two groups undergoing the two different procedures. We\u2019ll rate that satisfactory for the disclosure although the release might have gone even further by mentioning the other side effects named in the study including inflammation and elevated intraocular pressure which occurred in both treatment groups.", "answer": 1}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\nAs to apixaban's expected higher price tag, Ansell said that since the drug does not require monitoring and the incidence of stroke and major bleeding are less, savings in doctors' visits and stroke treatment should more than compensate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided good insight about possible problems associated with apixabane in patients with coronary artery disease who were simultaneously taking two blood thinners in addition to apixabane.", "answer": 1}, {"article": "Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\nAbout half of those patients will develop AF after surgery.\nTo avoid bias, neither patients nor doctors knew whether the injections contained Botox or saline.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story appropriately points out that there were no additional harms seen in the group injected with the botulinum toxin compared to those who received saline other than those associated with the surgery.\n\u201cNo complications from the Botox injections were reported,\u201d according to the release. \u201cBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\u201d", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nIn the study, De Meyer and colleagues analyzed spinal fluid from 114 adults with normal brain function, 200 who had mild cognitive impairment \u2014 a precursor to dementia \u2014 and 102 who had Alzheimer\u2019s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention any potential harms of either the spinal tap procedure itself or from the interpretation of the test results. The spinal tap harms include pain and bleeding. The harms of the test could include insurance or employment discrimination, as well as the consequences of mistaken diagnoses.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nOther estimates are far higher.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions there are potential harms, including death.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nBecause of this, Weiner said, three-dimensional letters and numbers, perhaps made out of plastic or clay, help a dyslexic child grasp the shapes better.\nIt is hard to know who will be able to improve reading skills over time, and how much extra help is necessary.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\nA study led by Fumiko Hoeft, psychiatry researcher at Stanford University School of Medicine, used brain imaging to answer this question.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nMRI brain scans are generally considered to present little physical risk, so the issue here is really the potential negative effects of the information the test produces. At least the story raises that issue by including comments from parents who worry that this sort of scanning could further stigmatize children who have trouble reading or writing. ", "answer": 1}, {"article": "And exercise does seem to be protective -- even if you don't lose all the weight, it absolutely has beneficial effects,\" she said.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nA study looked at the effects of weight-loss surgery on obese women most at risk for cancer.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms or risks in the release. Bariatric surgery has many well-documented short- and longer-term risks.\u00a0According to the Mayo Clinic, risks associated with the procedure may include excessive bleeding, infection, blood clots, and leaks in the gastrointestinal system, to name a few. Long term risks of the procedure include bowel obstruction, vitamin deficiencies and malnutrition, and stomach perforation.", "answer": 0}, {"article": "\u201cIt\u2019s an important part of this challenge,\u201d Frank said.\nMaybe the opioids themselves caused problems that negatively impacted function or quality of life, \u201csuch as constipation, fatigue, poor sleep, and depressed mood.\u201d It\u2019s possible that opioid dose reduction also resolved what\u2019s known as opioid-induced hyperalgesia, \u201ca paradoxical response in which patients receiving opioids become more sensitive to painful stimuli.\u201d\n\nOr, the researchers suggested, the observational studies simply showed reverse causation \u2014 \u201cthat is, patients successfully tapered opioids because pain severity decreased.\u201d\n\nThe findings do not mean that doctors can now simply yank patients off opioids and expect them to get better.\nCrucially, the studies also looked at what happened when these reductions in opioid doses were paired with alternative treatments, including alternative medicines like acupuncture, interdisciplinary pain programs, and medication-assisted treatment for addiction.\nFocusing on the \u201cfair-quality\u201d studies, they found that after opioid dose reductions, patients on average saw improved pain, function, and quality of life.\nSome patients are at unusually high risk for addiction, while many \u2014 most, in fact \u2014 aren\u2019t.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms are addressed right away: Come off opioids too quickly, and patients can suffer by having little recourse to deal with chronic pain. Some even resort to illicit drugs or commit suicide.\u00a0One of the study\u2019s authors is also quoted as recommending doctors and patients to exercise caution if tapering is being attempted, and another explains that not all patients respond the same way (and do poorly with tapering).", "answer": 1}, {"article": "This is sent to the USB stick, which shows the result on a computer or electronic device.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nCurrent AIDS drugs, called anti-retrovirals, reduce virus levels in a patients blood to near zero.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The physical harms are pretty obvious, as the story\u2019s comparison to a diabetes blood sugar test makes clear: Patients need to get a spot of blood onto the sensor. But the more important harm isn\u2019t discussed here, where a simple \u201cthis isn\u2019t ready for the field\u201d statement would have covered. More than 11 in 100 HIV-positive people getting a false-negative test is not very comforting; they could be misled to think their anti-retroviral therapy is still working when it might not be.", "answer": 0}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similar to the HealthDay piece, the story provides no information about the potential adverse effects of orlistat or a low-carbohydrate diet.", "answer": 0}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nIn addition to demonstrating increased overall survival, the researchers showed a higher objective response rate - the number of patients who respond to the treatment - with nivolumab.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nIn the randomized phase III clinical trial, patients whose disease progressed on antiangiogenic therapies were treated with either nivolumab or everolimus.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that there were \u201cfewer treatment-related adverse events, including fatigue and nausea, and improved quality of life with nivolumab.\u201d But that\u2019s not really a satisfactory accounting of the harms of treatment. As the\u00a0article in the NEJM notes, \u201cTreatment related adverse events of any grade occurred in 319 of the 406 patients (79%) treated with nivolumab and in 349 of the 397 (88%) treated with everolimus.\u201d The release should have given readers more insight into what these harms are and how often they occur.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states: \u201cPossible side effects are less severe than for chemotherapy, but serious problems can include blood and bone marrow cancers. Common side effects include nausea, fatigue, respiratory infections and blood count problems.\u201d\nAlthough this would be a rare concern, the FDA also says: \u201cLynparza can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception. Women taking Lynparza should not breastfeed as it could cause harm to a newborn baby.\u201d", "answer": 1}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nSuch food studies can be unreliable, since they rely on self-reported surveys.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms discussed, but both of these food choices are safe and likely to be well tolerated. ", "answer": 2}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nTo assess safety, people who received the vaccine were observed for 30 minutes after vaccination, and at repeated home visits up to 12 weeks later.\nAfter interim results were published showing the vaccine's efficacy, all rings were offered the vaccine immediately and the trial was also opened to children older than 6 years.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release also accurately quantifies the harms associated with this vaccine, noting that more than half of those vaccinated reported mild side effects, including short-term headaches, fatigue and muscle pain. The release also\u00a0identified two serious negative reactions (a high fever and an allergic reaction) associated with the vaccination and a flu-like illness that might have been a result of the vaccine.\u00a0This is a particularly strong point of the release in that many releases on drug/vaccine studies don\u2019t quantify the adverse event rates very clearly or completely.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nParticipants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release made no mention of potential harms of magnesium supplements although it notes the treatment is safe on two\u00a0occasions. \u00a0The actual results, however, were not quite as straightforward. The authors noted in the published study, \u201cThe most common reason for a negative response was that \u201cmagnesium did not help mood\u201d (46%), followed by side effects (20%). The most common side effect, diarrhea, was reported by 8 participants. In addition, the published study notes that people with gastrointestinal disorders or\u00a0kidney disease could not participate in the study since high levels of magnesium are not safe for these patients.\u00a0", "answer": 0}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\nIn the study, even experienced radiologists at major cancer centers had a high rate of false positives, suggesting that the rate would be even higher in the real world.\nIn the release, Dr. Norman E. Lepor said the scans were an \u201cindispensable\u201d part of annual exams for patients who have smoked for 10 years.\nBut now cancer and screening experts are worried that the limited findings will be used by private screening centers to promote the test to a broader group than was studied.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear on this:\nIn a rarity for such a story, \u201cdownsides\u201d was even in the headline.\u00a0 The third paragraph read:\u00a0 \u201cBut now cancer and screening experts are worried that the limited findings will be used by private screening centers to promote the test to a broader group than was studied. That, in turn, could lead to thousands of unnecessary lung scans, causing excess radiation exposure and unnecessary biopsies and surgery.\u201d", "answer": 1}, {"article": "\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nWhile there were no significant differences in body composition across the different dosage groups, the researchers found children who had vitamin D stores above the threshold recommended by the Canadian Paediatric Society (CPS) averaged around 450 grams less body fat at 3 years of age.\nThe researchers found that higher doses did not provide any additional benefit -- at least not in terms of bone development.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\nFurther analysis also indicated a correlation between lean muscle mass and the average level of vitamin D in the body over the first three years of a child's life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no warning that in rare cases vitamin D overdoses can cause calcium to rise to harmful levels, which can weaken bones and cause kidney stones and other problems. Some of the reported cases have been linked to manufacturing errors which meant the drops given to children contained far more vitamin D than listed on the label.", "answer": 0}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nAlthough most people get shingles only once, it can happen again, especially if you have a weakened immune system, which most everyone does with advancing age.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\nWhat makes Shingrix so much better is the inclusion of a substance called an adjuvant that boosts the body\u2019s immune response to the vaccine.\nHere\u2019s how it compares to its predecessor Zostavax, which over all reduces the risk of shingles by 51 percent and of PHN by 67 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author tells her personal story and a few common harms. She notes that \u201cthe shot itself is painful and can cause a sore arm for a day or two. Some people develop immune-related side effects like headache, fever or an upset stomach that last less than three days, according to the manufacturer, GlaxoSmithKline. My only reaction beyond local soreness was an acid stomach for a day or two.\u201d\nThis is a good start, but the story didn\u2019t recognize that significant adverse effects are actually more common than the benefits, making the story imbalanced.\nThe study shows that the severity of the side effects of the vaccine were much more intense than what the Times implies. In it, 17% of the patients injected with the vaccine, versus 3% on placebo, had \u201cgrade 3\u201d symptoms. These are defined as symptoms that \u201cprevented normal everyday activities.\u201d The absolute rate therefore is 14% or a NNH (number needed to harm) of seven. While the author of the Times story might not have been that sore after the vaccine, according to the data in the trial, for every seven persons injected with the vaccine, one person will have \u201cgrade 3\u201d symptoms and have difficulty functioning in everyday activities.", "answer": 0}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nThe mosaic approach seems promising in very early clinical research\n\nIn the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans.\nBut with the new HVTN trial, researchers hope some tweaks to the vaccine might boost the efficacy rate.\nIn a trial on the RV144, 31 percent of people who got the vaccine did not develop HIV \u2014 too small a number to be useful.\nInterestingly, in the early human study, the immune response was comparable to the rhesus monkey one, which gave the researchers hope that the vaccine might be similarly effective in people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the Ad26 vaccine was the \u201cbest tolerated\u201d of several approaches, but doesn\u2019t tell us what may have occurred in people who didn\u2019t tolerate it so well. The potential indirect harms of\u00a0a vaccine program could also have been mentioned. The vaccine is expected to work only about 50 to 60 percent of the time, according to the researchers. If people feel less pressure to employ other proven measures to control HIV (condoms, etc) because of the vaccine, then it\u2019s possible some harm could occur due to false reassurance.", "answer": 0}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nThe ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nThe findings may come as a rude surprise to many cardiologists, who have come to believe that opening a blocked artery, even days or weeks after a heart attack, is bound to be good for patients.\nDr. Hochman emphasized that angioplasty was still the best treatment for many heart attack patients who go to the hospital early, within 12 hours of when the attack began.\nHer report is the latest warning from researchers who suspect that stents are being overused and may even be causing heart attacks and deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms associated with the use of drug coated stents were presented in this story.\u00a0 The reader needed to infer that a harm associated with stents was the propensity of the artery to \"close again\".\u00a0 Ideally, a story should mention both the frequency and severity of adverse effects.\u00a0 But since the focus of this story was on a study showing that the rates of heart attack and death were comparable for different approaches\u00a0 (\"either heart medicines only or balloon treatment and stents with heart medicines\"), we consider this as satisfactory. \n\u00a0\n\u00a0", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that despite burning more calories, the low-carb group had increases in some markers of cardiovascular disease.", "answer": 1}, {"article": "\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nResearchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "But at least we know it can be done.\"\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Were any harms \u2013 besides the lack of protection in most trial participants \u2013 reported in the Thai trial?\u00a0 We don\u2019t know from the story.\u00a0 ", "answer": 0}, {"article": "Such screening is increasingly used in research.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were expressed through the quote from Mount Sinai Hospital\u2019s Dr. Samuel Gandy, who said giving preventative medication to people at a young, healthy age \u2014 as early as age 30 \u2014 would be exposing them to possible drug side effects for decades.\nThe article also notes that some experts cautioned against early screening of pre-symptomatic people because no drug exists to prevent or treat Alzheimer\u2019s. This is important to point out, since it would be very distressing for most people to learn that they have incipient Alzheimer\u2019s and that they have no current way to treat it.", "answer": 1}, {"article": "\"I just didn't want to do that for my children.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story does not mention any of the harms of treatment. Although it could be assumed that readers understand that mastectomy and ovary removal are traumatic, this story does not inform them about other substantial harms, such as premature menopause. Indeed, most of the women included in this study had decided not to have surgery, presumably because of concerns about the heavy consequences. While the results of this study may lead many women with BRCA1/2 mutations to reevaluate the balance of benefits and harms, the story should have offered at least some overview of the reasons the decision to undergo these preventative procedures is so difficult.\n", "answer": 0}, {"article": "The results were published in Wednesday\u2019s edition of the Journal of the American Medical Assn.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nThese children were more likely to be born to women who did not take folic acid.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough call.\nThe US Preventive Services Task Force and other expert bodies state that there is no evidence of potential harm from recommended levels of folic acid supplementation. But there are hypothetical, yet plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story could have mentioned this.\nThe point is that there are always potential harms.\u00a0 This is not a risk-free substance.\u00a0 Stories may not always find the time/space to delve into hypothetical/plausible potential harms, but we wish they would.", "answer": 0}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\nTo learn more, Dr. Iacconi and colleagues reviewed records from 2,021 patients with newly diagnosed breast cancer who underwent biopsy after preoperative MRI.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote near the top of the release notes that some women may be overtreated. But the release provides no specifics about what that means. In the case of an MRI-detected additional cancer, it could mean an unnecessary mastectomy. We\u2019ll give a borderline satisfactory rating here, although more detail would have been welcome.", "answer": 1}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\nThe company is awaiting results of a second trial of the drug, this one in younger children.\nShe said other results of the trial were encouraging.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\nBut she said more reserach is needed to see if everyone benefits from it.\nA new study could change the way doctors treat patients at high risk for skin cancer.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nWiese thinks the vitamin study sounds promising.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told via the study\u2019s author that twice-daily nicotinamide is \u201csafe,\u201d but that it\u2019s \u201cnot something we\u2019d recommend at this stage for the general population.\u201d The author\u2019s\u00a0claims to safety can\u2019t be verified without a look at the actual study data (which haven\u2019t been published yet), but since the references we\u2019ve consulted generally support the idea that adverse effects are minimal, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was discussion of hypothetical harms that might results from eliminating a cache of subcutaneous fat.\u00a0\u00a0It flags this early on by saying, \"Eliminating fat cells without also eating less or exercising more may make fat crop up elsewhere and ultimately do more harm than good.\" However, the story does not\u00a0provide\u00a0any data about whether\u00a0the harms considered have been demonstrated to occur.", "answer": 0}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\nThe study \"shows that the gastric bypass procedure compared to sleeve gastrectomy or adjustable gastric banding produces more weight loss and it was sustained over the long term,\" Gould said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms. Bariatric procedures can lead to an array of complications that are worth considering. And on the flip side, it\u2019s worth noting that research also has\u00a0indicated that\u00a0bariatric surgery can both extend quantity and quality of life when compared to not having surgery.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No information is included about possible over-diagnosis that may occur if this device is used to determine if very small lumps that are possibly benign or malignant.\u00a0 Recent studies have focused on the harm done by over-diagnosis and the resulting over-treatment of DCIS and early breast cancers.", "answer": 0}, {"article": "\u201cIf you\u2019re taking the drugs and you\u2019ve been on them for a while, but aren\u2019t sure if you\u2019re at high risk, you should ask your doctor about it,\u201d Park-Wyllie advised.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nBut some experts worry that negative media coverage might have led to more fractures and possibly deaths by dissuading patients from taking the drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of telling the reader how few women suffered the unusual thigh fracture. They further give some context by explaining how those on the drugs reduced their harm from more-typical fractures by 24 percent.", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\nThe story does not mention harms.\n\u00a0\nWhile the researchers reported that there were no adverse events during the trial, it is possible that exercise classes could lead to falls or sports injuries, so the story should have addressed this point.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nImplants of stem cells that make fresh neurons in the brain were found to put the brakes on ageing in older mice, keeping them more physically and mentally fit for months, and extending their lives by 10-15% compared to untreated animals.\nThe next step is to create human neural stem cells in the lab for testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the potential harms that might arise from this approach. Since this has never been tested in humans, we have no idea what they risks are. The story needed to point this out.\nTheoretically, the stem cells would have to be delivered into human brains via injections, which would make the intervention incredibly risky and possibly a non-starter. In the original paper, the stem cells were injected into the hypothalamus of the mice using viruses as \u201cvectors.\u201d The researchers used lentiviruses, which are used often as vectors for research, but can be deadly in humans. Some discussion of this hurdle also was warranted.", "answer": 0}, {"article": "The weight range was 38 to 173 kg (mean weight: 68.7 kg) and mean BMI was 25.3 kg/m2 (range 15.2\u201357.6 kg/m2).\nWhen Kyleena is removed, menstrual periods should return.\nThe clinical trial had no upper or lower weight or BMI limit.\nAfter using Kyleena for a while, the number of bleeding and spotting days is likely to lessen.\nThe pregnancy rate calculated as the Pearl Index (PI) in women aged 18-35 years was the primary efficacy endpoint used to assess contraceptive reliability.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release goes into this at length, which is good. What would have been even better would have been for the release to compare the likelihood of potential side effects for Kyleena with the likelihood of side effects for other products on the market.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story covers directions for Hello, Peanut!\u2019s use in great detail, and also emphasizes that if a baby develops a reaction, parents should discontinue use and contact their pediatrician. The story also discusses potential harms of the product specifically in terms of unintended use. Quoted sources worry that consumers might mistake the product as a cure for peanut allergies as opposed to a preventative tactic. Feeding the product to a child with an existing peanut allergy would likely cause an allergic reaction.", "answer": 1}, {"article": "These findings provide hope for people who thought, 'This is as good as my recovery is going to get' and for the medical community who have yet to find a way to objectively measure a patient's recovery,\" he said.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nPrevious studies have shown that cortical thickness and rsFC can be potential markers for training-induced brain changes.\nIndividuals in the strategy-based reasoning training showed a greater change in cortical thickness and connectivity compared to individuals who received the knowledge-based training.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed. While presumably there is little risk from participating in brain training, cognitive training can have its downsides. Harms such as the time investment, frustration over speed or lack of progress, costs, etc. could have been mentioned.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms that might arise from the use of such a test. A blood draw is a low risk procedure; the real potential harm comes from over- or under-diagnosis and that should have been clarified.", "answer": 0}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\nAccording to Amin, improved technology has allowed wrist access to become a viable route to the coronary arteries, even for complex cases, and should be considered for more patients.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not discuss any possible downsides associated with the new technique. Although the disadvantages of using the wrist rather than the groin approach\u00a0are minor and perhaps not clinically relevant for most people, it would have been better for the release to at least mention them.", "answer": 0}, {"article": "\"Now I feel relieved.\"\n\"It does bolster our confidence that it's effective in the real world,\" said Dr. Bruce Hirsch, an attending physician in infectious diseases at North Shore University Hospital in Manhasset, N.Y., who was not involved with the study.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\nTseng's team wanted to test the vaccine's real-world performance, so they compared 75,761 vaccinated members of the Kaiser Permanente health plan to 227,283 members who elected not to have the shot.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story briefly refers to this vaccine providing protection against shingles \u201cwithout many side effects.\u201d While many stories would stop there (if they even acknowledged the potential for side effects), this report goes further to include the comment from an independent source that \u201cI think it\u2019s a very good vaccine, and it\u2019s a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people.\u201d ", "answer": 1}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\nBut this study suggests these methods also can help reduce spinal pain, she said.\n\"People with chronic neck and/or back pain should be educated about their pain, [and] should be reassured,\" said lead researcher Anneleen Malfliet.\n\"The experimental therapy, focusing on functionality, not using pain as a reliable symptom, and not as a guideline to adapt movements or activities, leads to better treatment outcomes,\" Malfliet said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although physical therapy and a 12-week program of education about the origins of pain designed to reshape people\u2019s understanding of the pain pathway are not likely to cause harm, it would have been useful to know if any experimental treatment subjects dropped out, failed to finish the program, or felt worse than those in the control group. There is also the potential in such studies for \u201cvictim blaming,\u201d or imposing the onus of attitude change on pain patients. Some of the comments of the principal investigator in the article (i.e. patients \u201cshould learn to put pain into the right perspective and\u2026avoid fear of moving\u201d) may impose additional burdens on some pain patients.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nSome study limitations should be considered.\n\"These results add to the large body of evidence that outline the many benefits of a healthy diet for women.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\nThis research was supported in part by the California Walnut Commission (CWC).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As we stated in a recent review of a news release about walnuts and heart health, a brief mention of nut allergies and the high caloric content of nuts would be appropriate.", "answer": 0}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nHe was nervous about this because, being left-handed, he favors his left ear and was worried that he wouldn't be able to do one of his favorite pastimes: talking on the telephone.\nEventually, he decided to get another cochlear implant in his left ear.\nWhen Priddy's implant was turned on six weeks later, he couldn't decipher the sounds he was hearing, but he was definitely hearing them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the harms of surgery are few\u2014mainly the dashed hopes of those it doesn\u2019t help and the chance that some people may need a reoperation if the first implant stops working. It\u2019s not completely clear that if the surgery fails, a partially deaf person is likely to be permanently deaf. Can it cause infections or facial paralysis or affect a person\u2019s taste? Yes, it can\u2014but readers will have to do their own research to find out. ", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nThis information is essential for making rational guidelines for aspirin in primary prevention.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nThat means for some low-risk individuals, taking daily aspirin could do more harm than good.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As above, Hennekens gave a description of the absolute harms involved in aspirin, particularly related to gastrointestinal bleeding, and several of the other sources also discussed this important harm.", "answer": 1}, {"article": "Of those, 2,148 had taken lithium, 1,670 had used valproate, 1,477 had been on olanzapine and 1,376 had taken quetiapine.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nResearchers claim that although the drug does carry some health risks, its overall effectiveness, especially its ability to reduce self-harm and suicide, mean it should be much more widely used.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in outlining the side effects seen with the four drugs in question and provides them in context.", "answer": 1}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\nBut it\u2019s never been clear exactly how much inflammation adds to heart disease risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hardly a word about the real and unknown harms of the drug, which are more carefully outlined in a Reuters piece. The TIME article emphasizes the positive news\u2013that anti-inflammatory drugs like the one described in the trial may well represent the future of substantial reductions in heart disease and cancer mortality. But there are caveats that needed much attention not paid in this story.", "answer": 0}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nWhile it seems almost silly to worry about potential harms of eating more fruits and vegetables, the story does not include caveats that would help readers see how misinterpretation of the study results might cause harm. The story mentions that \u201cstudies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\u201d It should have pointed out that an earlier round of observational studies of fruit and vegetable intake similar to this one produced rampant enthusiasm for beta-carotene, but then actual experiments had to be cut short because some participants taking the supplements had higher rates of lung cancer. Any story about potential benefits of specific components of foods should clearly remind readers that in some cases supplements containing these same components have been shown to be useless or even hazardous.", "answer": 0}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the research article from which this release stems notes that \u201cadverse effects will need to be compared not only for metabolism and obesity but also for immune suppression and osteoporosis,\u201d the release makes no mention of possible harms.", "answer": 0}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nThat difference helps explain why there are so few studies doing head-to-head comparison of CT versus MRI, he said.\nCT is the preferred noninvasive technology for assessing the condition of heart arteries, whether there is narrowing that might end with the total blockage that causes a heart attack, Schoepf said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story highlights the presumed advantages of CT scans, there isn\u2019t a single word about potential harms. That includes the radiation exposure leading to risks for cancer, which are acknowledges in the introduction to the\u00a0published study. (According to the most recent estimates, the risks may be in the neighborhood of one case of cancer for every 800 individuals scanned.)\u00a0The story also leaves out\u00a0the specificity results of this research, ignoring the rates of false positives and their potential harms.", "answer": 0}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nThose factors do not prevent Campbell from dreaming.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention any potential harms, including risks of the surgery and whether remaining vision, or retinal and surrounding tissue, could be damaged. ", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cBut the study showed an increase in the number of device- or implantation-related complications within 30 days of implant: 118 among 888 patients with the new device, compared to 61 of 898 in the standard defibrillator group.\u201d This is beyond what the LA Times did, and we think it is adequate for this score.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article focuses on the associations between hormone use, heart disease, and the ages at which women begin using hormones. It does not mention other known harms of hormone use. For example, the statement, \"This new analysis tells us that hormones have no or very little risk for women when started within 10 years of menopause\" is not accurate; there IS an increased risk of breast cancer if used for more than a few years.\u00a0", "answer": 0}, {"article": "Early opposition to Gardasil was based on concerns it could encourage sexual activity in the young.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nThe vaccine also protects against two other virus types that cause 90 percent of genital wart cases.\nMerck said the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex.\nAlso, the drug does not protect against infection from the many other virus strains not included in the vaccine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms, and this is a very important omission. To do this right, you would need to immunize 70 million people. Varicella vaccine has a serious event rate of about 4%. If this vaccine is in the same ballpark, there would be 2.8 million people with serious reactions. Some discussion of possible harms is necessary. ", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Story says \"few eye-related complications\" were reported in the Lucentis group, but didn\u2019t say what few means or what they were.\u00a0 We don\u2019t think that\u2019s quite adequate. ", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\nEarlier studies had proved that low-calorie diets could reduce weight and alter metabolism in obese people.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article does a good job of highlighting the weight regain that occurs when peoples\u2019 adherence to a dietary program that provides all the food ends. However, there was no mention of potential side-effects or harms of long-term calorie restriction such as decreased testosterone, muscle mass or bone density.", "answer": 0}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know of any harms that can result from eating tomatoes,\u00a0so we\u2019ll rule this not applicable. However, the story could have cautioned against trying to get lycopene from supplements,\u00a0which could have unknown side effects and harms.", "answer": 2}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article meets the standard by including this sentence: \u201cThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\u201d\nIt also notes, \u201cclinical trials have shown that the risk of brain bleeding for people who received tPA and then went through mechanical clot removal is no greater than for people who just receive the blood thinner.\u201d Some caution about the fact that we don\u2019t know if that risk will be as low when the procedure is rolled out more widely (as opposed to being used in a highly controlled study environment) would have been welcome.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of possible harms that might come from blocking a gene. The story calls the gene a \u201crogue\u201d and a \u201cculprit\u201d but does little to explain what it does. It says it is both inside cancer cells and outside them, destroying \u201ca naturally-occurring protein in the body which normally prevents cancer cells from spreading.\u201d As anyone who has been through cancer treatment knows, knocking out cancer cells through radiation and chemotherapy can take a heavy toll on a person. People can die from infections and other complications. One question might have helped answer the harms question: \u201cWhen you blocked this rogue gene, what happened to all of the normal cells around the cancer cells?\u201d\u00a0Anything that alters cell function in tumors could have powerful effects on normal tissue, too. The researchers noted in their article that they have yet to \u201cestablish normal and disease expression patterns of all three WWP2 isoforms\u201d. If they don\u2019t yet fully understand the normal form and function of WWP2, the potential for unanticipated effects is a serious concern that the story should have addressed.", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nBut there\u2019s been surprisingly little evidence that it really is highly \u201cspecific\u201d to colon cancer, according to Dr. Yi-Chia Lee of National Taiwan University Hospital, one of the researchers on the new study.\nBut as far as cutting the risk of death from colon cancer, stool testing is similarly effective, according to the U.S. Preventive Services Task Force.\n\u201cIt is a strong support to iFOBT as an effective screening tool.\u201d\n\nThe researchers also found that iFOBT had \u201cspecificity\u201d for colon cancer of close to 90 percent, meaning the test would accurately give a negative result to almost 90 percent of people who did not have colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike many stories on screening tests, this one included information on false positive findings and the need for further testing. Story was careful to include the fact that in the study 10% of all participants had a false-positive finding on the stool test.", "answer": 1}, {"article": "The greatest risk was found for drugs that target gonadotropin-releasing hormone: 159.4 cases of diabetes per 1,000 person-years, compared with 87.5 for men who did not have androgen deprivation therapy, as well as a 35 percent increased risk for sudden cardiac death, a comparable increase in heart attack risk and a 22 percent increased risk for stroke.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\n\"It does save lives or delay progression for men with metastatic prostate cancer so the trade-offs there are reasonable.\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story included quantitative information about the harms associated with androgen deprivation therapy. However, it mixed uses of relative risks and absolute risks within the same sentence, which we think can only confuse readers. Excerpt:\u00a0\nWe urge journalists to use absolute risk throughout every story.\u00a0 See our primer on this topic.\u00a0 \nNonetheless, we\u2019ll give the story the benefit of the doubt on this one.\n", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\nWhat\u2019s more, the hormone, which was provided free by the manufacturer in the study, today costs $700 for a single shot, Baker said.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits, we wish the story had quantified the side effects observed in the study, but since side effects were acknowledged and since the following caveat was included, we\u2019ll give it a satisfactory score on this criterion:\n\u201c\u2026more work is needed to gauge the long-term consequences of GHRH injections. It\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\n\u201cIs it going to work in the long run and is it going to be safe? That is still unknown,\u201d said Petersen. \u201c", "answer": 1}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nThe average weight loss seen with either gastric bypass or duodenal switch will improve or reverse obesity-related ills like diabetes, sleep apnea and knee arthritis, according to Livingston, who wrote an editorial published with the study.\nBut the risks of nutrient deficiencies are greater with duodenal switch, and include some not seen with gastric bypass, Livingston pointed out.\nIn this study, one-quarter of gastric bypass patients still had a BMI that high two years after surgery \u2014 versus none of the duodenal switch patients.\nHe pointed out, though, that larger, longer-term studies are still needed to show whether the extra weight loss with duodenal switch ultimately improves severely obese patients\u2019 health and extends their lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story shines in its details about the delicate weighing of risk vs. benefits for weight-loss surgery in general, and then for the duodenal vs. gastric bypass method in particular. Some readers might find it confusing that the story includes two separate publications about weight-loss surgery. The story leads with the small study comparing duodenal with gastric bypass, published in the Annals of Internal Medicine, but then delves into a larger Veterans Administration study from the Journal of the American Medical Association that looked at the longer-term results of all surgeries for obesity. We salute Reuters for providing the context and the controversy within medical practice, and quoting a principal investigator on the VA study, Edward Livingstone, who wrote an editorial that appeared in the Annals beside the duodenal paper.", "answer": 1}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nAbout two weeks after the gene therapy, patients began to experience \u201ctumor lysis syndrome\u201d \u2014 chills, nausea and fever \u2014 caused by the break-down products of dying cancer cells.\nThe leukemia patients in the Phase I trial had to be treated with an immunity-boosting drug since the targeted molecule, CD-19, is also present on certain normal immune-system cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gave short shrift to potential harms. The WebMD story stated more plainly that patients suffered debilitating side effects and, in one case, had to be treated with steroids that may have hindered the effectiveness of the cancer therapy.", "answer": 0}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nThe hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\nSeveral weeks later, the participants came back for another meal and switched overnight regimens.\nHovorka's team is one of several working to produce an effective artificial pancreas, also known as a closed loop system or closed loop delivery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No risks or harms from statins are mentioned in this story. Statins are a well tolerated class of drugs with a relatively low risk profile, but all drugs carry risks and have side effects. When you start talking about extending statin use to a much larger percentage of the population, those risks become magnified. We felt that some mention of risks was warranted.", "answer": 0}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\nMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that bariatric surgery \u201cis also much safer nowadays than it was even a decade ago.\u201d It also refers to the \u201cwell-documented safety and effectiveness of bariatric surgery.\u201d But there are still potential harms, such as bleeding, infection and \u2014 in rare cases \u2014 surgical problems that can be fatal. After surgery, there also is the long-term risk of nutritional deficiencies.\nIf a story aims to offer a complete picture of bariatric surgery it needs to address all aspects, including risks. And if the risks are low, articulate how low those risks are. This allows readers to make more informed decisions about their personal health.", "answer": 0}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\nThough the claim was met with some skepticism by other clinicians, the idea that ACell\u2019s powder, which has been approved by the government, could facilitate new hair growth has breathed new life into the race to clone hair.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned harms in passing but did not quantify them. We wish it would have. The problem here is that we are talking about off label use, but, at a minimum, some of the harms related to the other, more established products could have been quantified. Instead, the story gives the harms question short shrift, saying, \u201cOne advantage of Latisse is that it needs to be applied only once a day (Rogaine needs to be applied twice; Propecia is taken once daily), and does not seem to cause reactions in people who are allergic to minoxidil.\u201d", "answer": 0}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe microparticles are inserted using a catheter run through a pinhole-sized incision, in a procedure that lasts between 45 and 90 minutes, Bagla said.\nThose eight patients averaged a 58-point decrease in pain, as measured on a 100-point visual scale used to estimate pain, Bagla said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the lead researcher saying \u201cthere were no adverse events related to this treatment\u201d and no side effects were expected because the procedure \u201conly blocks additional blood flow to the knee, rather than cutting it off altogether.\u201d\nIn a preliminary study such as this with almost no follow-up, we think the above statement is inappropriate. There is so little known about it to say \u201cno side effects are expected\u201d is hubris, and the story should have pointed that out.", "answer": 0}, {"article": "\"Overall, it does look like there are at least a couple of genes here, either the mother's genotype or the child's genotype, that show this interaction ... magnifying the size of the effect from not taking the vitamins,\" Hertz-Picciotto says.\nTaking prenatal vitamins was found even more protective for mothers and children who had a high-risk genetic makeup .\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\nThe risk rose if the mothers or the children had a high-risk gene form.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0should have been some discussion of\u00a0the possible downsides of\u00a0getting too high a dose of certain vitamins, and that more is not necessarily better when it comes to supplements.\u00a0Especially now that many foods are fortified with folic acid, there is some concern about women receiving folic acid doses that could overwhelm the body\u2019s systems for metabolizing this vitamin, which\u00a0could lead to\u00a0unknown adverse effects on the fetus. Some women also report gastrointestinal problems, including nausea and constipation, when taking prenatal vitamins.", "answer": 0}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nThe new research tests both standard PET scans and a newer approach that involves injecting a different tracer substance.\nThis experimental imaging relies on a familiar hospital workhorse: PET scans, typically used for things like detecting cancer or revealing the effects of a heart attack.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report should have mentioned the radiation doses used in PET scans. While these are not large\u2013about the amount of a typical X-ray\u2013they are worth noting. \nPET scans are not indicated for women who are pregnant.\u00a0 \nIf multiple PET scans were to become part of a treatment or diagnositic protocol the radiation dose could become significant. \nIn addition, there is no mention of the possibility that a scan might erroneously identify a treatment as ineffective, causing an unwarranted and harmful change in the treatment approach.", "answer": 0}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\n\"This paper importantly suggests that some of the best strategies for controlling weight and promoting health may have little directly to do with either,\" said Katz, who wasn't involved in the study.\nHealth benefits, including weight loss, seem to be a byproduct of the program, said Dr. David Katz, director of the Yale University Prevention Research Center.\n\"It [also] may be that when kids go to Head Start, it reduces stress in the household and frees up time and resources at home to dedicate to healthier eating patterns,\" she noted.\n\"We know that better sleep is linked with less obesity,\" she added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in this article. However, it is difficult to ascertain possible risks or harms in a case like this.", "answer": 2}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story does not quantify the harms of either the diet plans or of obesity.", "answer": 0}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nFibroids may cause severe abdominal pain, heavy bleeding, and interfere with fertility in some women.\nIt is effective for up to five days after unprotected sex.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of elevated liver function test results. However, it does not explain\u00a0 that women commonly experience abdominal pain, headaches and nausea with this drug.", "answer": 0}, {"article": "Of these, 85 percent were mild or moderate.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nThe other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.\nBut only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug.\nBut no problems were seen with lower doses.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that some patients taking the higher does of the drug experienced\u00a0headache, memory loss, hallucinations, reduced coordination or other symptoms. \u00a0From the information in the story, it appeared that 8% (21/262) of patients participating in a second study using the lower dose of the medication had some anomalies on MRI scan but no reported symptoms.", "answer": 1}, {"article": "Male condoms and oral pills dominate the $5.5 billion contraceptive market in the United States.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this a just-passing satisfactory score because side effects were briefly mentioned: \u201cno serious side effects were observed in the study.\u201d Still we\u2019d like to see mention of less serious side effects, especially for a birth control intervention, because they\u2019re often a significant factor in women\u2019s choices.", "answer": 1}, {"article": "\u201cThey showed it was safe and tolerable treatment at least for this small number of people,\u201d Fargo said.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nThere was no measurable effect on memory or thinking, the team told the Clinical Trials on Alzheimer\u2019s Disease conference in Boston.\nAny actual treatment would not involve whole plasma, McCracken said.\nResearchers trying to answer the question say they found the treatments are at least safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of harms anywhere in this story. Transfusions are invasive procedures and carry with them certain unpredictable risks.\u00a0 While the story does say at the end that any eventual product would be cleansed of components that mandate blood-type matching, there is no other discussion related to potential harms.", "answer": 0}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nThat would be good for the Alzheimer's Association and the National Institute on Aging, which sponsored the work on the new criteria.\nAnd it's also because there are no treatments that can prevent, slow or stop early signs of Alzheimer's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAs the story makes clear, lab tests and brain scans looking for signs of Alzheimer\u2019s are not ready for clinical use, so it is reasonable to defer discussion of the potential harms of such tests. The story does mention that the revised guidelines do \u201cleave one wondering if a lot more worry will be generated by the notion of \u201cpreclinical Alzheimer\u2019s,\u201d when science and medicine can\u2019t offer anything to ease those fears.\u201d", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\nHe also believes the test will be used by specialists for Parkinson's patients who \"do not exhibit a very typical symptomatology\" or do not respond as expected to treatment.\n\"A lot of time, people come in and say they or a family member has a tremor, and they believe it's Parkinson's disease,\" said Wright, who also was not involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the experimental test were not discussed. One important potential harm here is that there may be a much higher false-positive or false-negative rate once you use this test in the general public. For now, it\u2019s only been tested in controlled situations where the health status of the study participant was known.", "answer": 0}, {"article": "THC interacts with receptors in the brain\u2019s endocannabinoid system, which is involved in many physiological functions, including pain, mood, memory and appetite.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\nHowever, when treated with THC, the older groups improved at the task, while the young mice fared far worse.\nThe team argues that while they do not yet know if these findings would be same in humans, it could lead to new treatments to prevent cognitive decline in older people: \u201cCannabis preparations and THC are used for medicinal purposes,\u201d they write.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report might have mentioned if any or all of the test mice sustained any ill effects (physically or mentally) but it did quote a scientific expert about the potential adverse effects for humans using cannabinoids.", "answer": 1}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nHe's subtracted forever from the men whose first diagnosis was late-stage disease, even though screening could not save his life.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential harms of screening at the very end.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Radiation treatment can cause secondary cancers and other problems. The story mentions this and clearly explains that the incidence of such cancers is low. But, as noted above, existing studies do not track patients long enough to make a determination of harms feasible.", "answer": 1}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nThe study suggests that to prevent one case of psychosis, four high-risk young people must be treated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, fish oil supplements are not associated with serious side effects, unlike antipsychotic drugs that can lead to weight gain and sexual dysfunction.\u00a0 The story might have noted that some people taking fish oil supplements have reported mild gastrointestinal side effects (e.g. diarrhea). ", "answer": 1}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 We don\u2019t know what harms there might be in mice on metformin, but we shouldn\u2019t have to wonder!\u00a0 After all, we weren\u2019t the ones writing about \"strong\" benefits of metformin in mice! ", "answer": 0}, {"article": "The results are published in the journal PLOS ONE.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nThe researchers studied rates and patterns of tumor recurrence after hormone, radiation and chemotherapy among African-American and European-American breast cancer patients.\n\"We found that African-American breast cancer patients responded better to neoadjuvant chemotherapy than European-American patients.\n\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not discuss any harms of\u00a0providing cancer treatment in this order\u2013chemo first, surgery second.\u00a0 We\u2019re not aware that neoadjuvant chemotherapy is more harmful than standard treatment but it\u2019s a valid question and the release would have been more helpful had it clearly stated that one way or the other.", "answer": 0}, {"article": "The goal is to find what's right for you.\"\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\nBut Northwestern researchers hope participants will provide confidential feedback, via four weekly questions, that will be used to further develop the system.\nThe IntelliCare algorithm recommends new apps each week to keep the experience fresh, provide new opportunities for learning skills and avoid user boredom.\nThe data will help the system make even better recommendations and provide more personalized treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there\u2019s little harm associated with using any app on the face of it, relying on an app instead of seeking professional help could be harmful. The release should have acknowledged this, and done a better job of explaining who is most likely to be helped by a smartphone app and which individuals have symptoms severe enough to warrant seeking professional medical assistance. There are many different types of depression that range in severity. The National Institute of Mental Health describes several \u2014 seasonal affective disorder, persistent depressive disorder, major depressive disorder, psychotic depression, postpartum depression.\u00a0 ", "answer": 0}, {"article": "However, antibiotics do come with significant side effects including diarrhea, rashes, yeast infections and vomiting.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nIn treatment outcomes for pain, there was no difference, he notes.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nThe children in these latest trials had their ear infections confirmed by experts (otoscopists).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although we\u2019re tempted to give this story a pass for providing a detailed list of potential harms and a better explanation of why limiting antibiotic use can be beneficial (it can \u201cincrease the chance the future use of antibiotics will be effective\u201d), the expectation here is that the story will provide a quantitative estimate if available. These figures were easily obtainable from the original studies, and should have been provided.", "answer": 0}, {"article": "The agency is also responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nFor patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.\nThe U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the most common side effects of Epclusa are headache and fatigue. It also explains that Epclusa carries a warning that \u201cserious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\u201d The FDA also warns that certain drugs may reduce the amount of Epclusa in the blood which would reduce its effectiveness.", "answer": 1}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nThey found some of these hormones had an effect on bone mass.\nBut how do mice models translate to human treatments?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not tell readers whether the antibody experiment had any adverse effects on the health of the mice, much less what potential there may be for harms in humans. Again, we know that there have been no human studies yet, so it is impossible to say what potential harms have been found in human subjects. However, it is worth \u2014 at the very least \u2014 specifically acknowledging this point. And one could do more, such as asking about the various roles that the FSH plays in the human body (which likely vary across sex, age range, etc.).", "answer": 0}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nGilbert says the combination stopped her illness in its tracks.\nThe move was based on preliminary studies that found the drug increased the time that patients went without symptoms getting worse.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\nSusan G. Komen For the Cure, the largest group, issued a statement in support of Avastin and has helped to circulate a petition asking that it still be made available.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that Avastin is associated with serious side effects, such as high blood pressure and internal bleeding; however, it did not provide data on how many women in each treatment arm experienced these side effects. ", "answer": 0}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nYet changing medical practice can be difficult.\nAnd doctors, he added, have many inducements to screen.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does address the harms of overdiagnosis and treatment, though does not provide quantitative data. We\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This test may have harms that warrant mention. It is possible that this test could mislead doctors, just as any test that isn\u2019t perfect could. It wasn\u2019t 100 percent sensitive. So the 15 percent who had a normal test but turned out to have sepsis could have been sent home inappropriately. Or antibiotics could have been delayed where they otherwise might not have. Similarly, it wasn\u2019t 100 percent specific either, so some patients may have received treatments they didn\u2019t need or weren\u2019t given ones that they should have been. A researcher is quoted saying that he envisions this as an add-on to current tests, but until it is studied prospectively in real practice settings, one can\u2019t be sure if it will help more than it may harm.", "answer": 0}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nIn fact, there's enough research that the Cochrane Collaboration was able to put together a review of the evidence.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would normally look for some statement about potential harms but in this case we don\u2019t think the requirement is applicable: TENS, when used according to directions, have a low harm profile.", "answer": 2}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\nMore than two decades of research has shown that walnuts may help lower cardiovascular risk factors by decreasing LDL (bad) cholesterol by 9-16%2 and diastolic blood pressure by 2-3 mmHg2, as well as reducing total cholesterol2,3,4, raising HDL cholesterol2,3, reducing inflammation as measured by C-reactive protein5, and improving arterial function2.\nTrials directly provided nuts to the intervention group rather than relying solely on dietary advice to consume nuts.\nThese factors are major contributors to heart disease risk, and reducing them is a critical step toward a healthier heart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A brief mention of nut allergies and high caloric content of nuts might be appropriate here since walnuts are being recommended as a daily health supplement for people with Type 2 diabetes. Diabetics and cardiovascular disease are often comorbidities of being overweight.", "answer": 0}, {"article": "Collaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\nSuch patients have a fibroid recurrence rate of more than 60 percent after myomectomy, making UFE an important option.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nDespite its less invasive nature, UFE has yet to be fully embraced in the medical community as a fertility-preserving treatment for women with symptomatic fibroids due to concerns that the procedure may cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release cites concerns that UFE \u201cmay cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries\u201d as the reason the procedure isn\u2019t more widely used. This is a bit hard to interpret by the layperson and it isn\u2019t until later in the release\u00a0that we learn this essentially means there are risks of infertility associated with conventional UFE.\nThe release should have spelled out the known complications, which, in addition to infertility, include pelvic pain, fever and vaginal discharge, all of which are usually temporary. Death from an embolism (an artery blocked by blood or an air bubble or some other foreign body) following the procedure has been reported but is extremely rare.\nAlso, one of the reported findings\u00a0is fairly misleading:\nComplication rates were 14.6 percent for partial UFE and 23.1 percent for conventional UFE.\nThe original research article discloses that this observed difference is not significantly significant.", "answer": 0}, {"article": "Those consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\n\"We found that cocoa flavanol intake may reduce dyslipidemia (elevated triglycerides), insulin resistance and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.\"\nBut taking into account some of these heterogeneities across studies, the team's meta-analysis summarizing data from 19 trials found potential beneficial effects of flavanol-rich cocoa on cardiometabolic health.\nThe meta-analysis in the Journal of Nutrition, an assessment of the combined evidence from all 19 RCTs, focused on whether consumption of flavanol-rich cocoa products was associated with improvements in specific circulating biomarkers of cardiometabolic health as compared to consuming placebos with negligible cocoa flavanol content.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We think that you can\u2019t have a release that talks about how \u201ctempting\u201d the results of a new chocolate-is-good-for-you story without talking about the countervailing wind that is the high calorie count of so many chocolate products. If everyone starts having a chocolate milkshake at lunch after reading this study, our obesity epidemic is going to be even worse.\nThe release included a quote from the study author who noted that \u201cthe findings from the current study apparently shouldn\u2019t be generalized to different sorts of chocolate candies or white chocolates, of which the content of sugar/food additives could be substantially higher than that of the dark chocolate.\u201d\nBut that didn\u2019t go far enough. We think there was an opportunity here to discuss the real health implications of adding cocoa flavanols to the diet in whatever form it might take.\nOnly 37% of all releases we\u2019ve reviewed are graded satisfactory on harms. The discussion on an intervention\u2019s harms needs to start somewhere, and a news release is often the headwaters of the news stream.", "answer": 0}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a significant oversight of the story.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nMRI measurements of brain activity in the subjects suggested that the difference was related to a surge in negative emotions.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nAn international team of researchers led by Dr. Kenneth Mukamal and Joline Beulens sought to find out how moderate drinking affects cardiovascular disease in people with high blood pressure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does mention excessive drinking as a harm (it could raise blood pressure), it does not mention any of the other potential adverse effects.", "answer": 0}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nThe research showed that using 'liquid biopsies' that measure cancer DNA circulating in the blood to detect PIK3CA, and tests for blood hormone levels, the palbociclib combination worked in all types of hormone-receptor positive, HER2 negative breast cancer.\nThe study also aimed to assess whether cancers with particular genetic traits responded less well or better to the combination than others.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release downplays a number of side effects named in the journal article. According to the news release, the drug combination apparently has few severe side effects. The news release identifies a drop in white blood cell count as a common, but non-severe, side effect. But when we looked at the study\u2019s table of side effects we found a considerable number of grade 3 or 4 (more serious) adverse events. Some of this is confusing to interpret. For example, the study says that grade 3 or 4 adverse events\noccurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group. The most common grade 3 or 4 adverse events were neutropenia [low white blood cell count] (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anaemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).\nThe study later says,\n\u201cSerious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.\u201d\nThe study may be drawing a distinction between \u201cserious\u201d and \u201csevere\u201d events and including or not including grade 3 events in these different tallies. Regardless, the\u00a0release misleads by omission when it calls severe side effects \u201crare\u201d while not mentioning these relatively common less-severe effects. And that\u2019s leaving aside the issue of grade 1 and 2 side effects that appeared to be quite common and more frequent in the experimental treatment group. The study notes, for example, that \u201cInfections, fatigue, nausea, anaemia, thrombocytopenia,\u00a0alopecia, rash, and stomatitis, among others, were also\u00a0more common in the palbociclib group.\u201d", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAmong people who stuck with the trial, those on the fiber supplement lost 15 pounds, on average, compared to 11 pounds in the placebo group.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nFive people taking the fiber gel left the study due to problems with stomach bloating, nausea and diarrhea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear about the unpleasant nature of the supplement \u2013 and how it contributed to study dropouts. And the story mentioned concerns about long term safety \u2013 with some study participants having bloating, nausea, and diarrhea.\u00a0 The story also noted that blood pressure did not drop as much in the supplement group as with placebo, perhaps due to the sodium content of the supplement.", "answer": 1}, {"article": "Grocers shelves add new coconut-water products regularly.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\n\u201cIf you focus on coconut oil, you lose out on the fiber and you are focusing on a concentrated source of calories.\nCoconut fats are not an exception.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to do one thing helpful for readers. It provided a comparison, of sorts, of different coconut parts. It says, for example, that \u201d\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated. A tablespoon of butter, by comparison, contains 102 calories and 11.5 grams of fat; 7.3 of those grams are saturated.\u201d But it provides no context about what this means. We read this and assumed that we should avoid all coconut oil products and stick with butter, but the story hypes coconut oil and coconut milk so much that readers are likely to miss this nuance.\n\u00a0\nOne quote in the story refers to calories, but the matter of high-calorie food of any sort, including coconut oil, contributing to obesity is not explained.", "answer": 0}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\nAnd DeGiorgio says he's found an interesting benefit to trigeminal nerve stimulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes on at some length to talk about the side effects from drugs, yet allows the researcher/inventor to make the claim that there are no side effects from this device. With all the framing about the promise of the approach, we would hope for more discussion of what\u2019s not known about safety profile after such limited experience to date. Even an additional line would suffice. We only hear the one positive patient\u2019s experience.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nTrulance should be avoided in patients six years of age to 18 years of age.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should not be used in children less than six years of age due to the risk of serious dehydration.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We rate this Satisfactory because the release includes the restrictions on pediatric use and the risk of severe diarrhea. The release would have been even better if it had mentioned how often the volunteers experienced side effects and the full scope of side effects.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter makes clear the serious risks of surgery, including death rate, and their\u00a0frequency not well-known. \nIt would have been useful to include the risks of death and serious side effects\u00a0for the more invasive intestinal surgery likely to be used on diabetics. The story states that one reason for the decline in bariatric surgery risks generally is\u00a0increased use of the\u00a0less invasive procedure. ", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story says the company reported a \u201cside effect profile consistent with the drug\u2019s currently approval label\u201d, it did not tell readers what that means. The most important adverse event reported in other studies of Vascepa is joint pain, affecting up to about one in 25 patients. The story does not mention warnings about possible allergic reactions in people allergic to seafood or interactions with anti-clotting drugs, which many heart patients take.", "answer": 0}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that that no serious adverse events were reported in the trial. It would have been useful to note that 12 weeks is too little time to determine how an asthma drug might affect patients over decades of use.", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this is a follow-up report focused on newly released data, a discussion of the potential harms of the vaccine is not necessary.", "answer": 2}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\nAlthough second- and third-line targeted therapies can often return the disease to remission, some patients don't benefit from these drugs or develop severe side effects.\nAlthough adding Ezh2-targeting agents to the standard drug regimen for CML has the potential to dramatically shorten the treatment period for many patients, ethical considerations may lead to the agents' first being tested in patients who don't respond to Gleevec and similar drugs, either initially or after drug resistance develops, Orkin remarks.\nIt offers a promising approach to shortening the duration of therapy in order to achieve a cure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are mentioned for imatinib, but never detailed. And this is a major oversight that would have benefited the\u00a0crux of the release (i.e. a need for alternatives to imatinib-like drugs). One 2010 study\u00a0assessed a flotilla of side effects, including muscle cramps, nausea, diarrhea, headaches, abdominal pain, joint pain, and more in greater than 10% of patients who take it for CML. But it also notes\u00a0a rare few can be \u201csinister\u201d in less than 1% of patients: heart\u00a0damage, kidney failure, muscle degeneration, secondary cancers, and even\u00a0cerebellar edema, which can cause fainting, seizures, and even put someone into a coma.\nThe side-effects of Ezh2 inhibitors also aren\u2019t noted since it seems\u00a0the most promising one is still in clinical trials. Since the new drug hasn\u2019t been tested in humans there is really no way to gauge side effects but all cancer drugs have them, often very serious ones as noted above.", "answer": 0}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe revved-up immune system [that results from the CAR T-cell treatment] becomes a potent cancer-fighting agent but also a dangerous threat to the patient. Serious side effects abound, raising concerns about broad use.\u201d The story then goes on to discuss those potential harms more thoroughly.\nOrdinarily, this would be sufficient for a Satisfactory rating. But given the severity and frequency of serious, life-threatening events, the story needed numbers: What percentage of patients in the trial experienced a serious immune reaction? How many died?\nThere are also plenty of unknowns with a new cancer treatment, such as lack of data on long-term prognosis.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nTheir study, published in the Jan. 25 issue of the Archives of Internal Medicine, found that both diets helped participants lose almost 10 percent of their body weight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any of the known\u00a0adverse effects\u00a0of orlistat, which include gastrointestinal\u00a0upset that can limit the drug\u2019s tolerability.\u00a0It could also have mentioned some of the concerns (such as potential for nutrient deficiencies)\u00a0that many health professionals have about diets that are high in meat\u00a0and protein and very low in carbohydrate.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n\u201cThese patients were referred for colonoscopy, most commonly due to symptoms,\u201d Lieberman said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify potential harms from colonscopies, such as colon perforation.", "answer": 0}, {"article": ".\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nThe exacerbation rate in the low eosinophil group treated with the biologic did not differ from placebo.\nIn a second, simultaneous trial, termed METREO, the team assessed the effect of a higher dose of mepolizumab in 675 patients with elevated eosinophil levels.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t describe any possible side effects from the use of mepolizumab, even though there are several. They include headaches, back pain, fatigue and flu symptoms, urinary tract infections, abdominal pain, itching, eczema, and muscle spasms.\nTo its credit the release does say that the side effects encountered from the drug and the placebo were similar. \u201cThe safety profile of mepolizumab did not differ from placebo in either trial,\u201d it says.", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nTumor samples taken from three people with melanoma showed the nanoparticles found their way inside tumor cells.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says this was a phase 1 clinical trial \u2013 the main purpose of which is to determine safety of an experimental intervention.\u00a0 Yet the story says the lead investigator could not say if there were any safety concerns.\u00a0 Huh?\u00a0 We can understand not leaping to conclusions after tests on just three tumor samples (although, as noted,\u00a0 the story tended to do anyway), but shouldn\u2019t the story have at least probed for potential safety concerns with this approach?\u00a0 \nIn fact, the use of siRNA in experiments like this is in its infancy and as such little is known about the existing side effect profile.\u00a0 High on the list is the potential for the agent to have unexpected and non specific effects called off-targeting.\u00a0 Off-targeting is the potential largest liability of the approach, possibly resulting in inadvertent turning off or on of non-targeted genes.\u00a0 This collateral damage is a significant challenge to the use of siRNA even with nano-directed treatments.\u00a0 A more balanced story would have noted the potential downside of the approach.", "answer": 0}, {"article": "The world\u2019s biggest maker of cancer drugs is counting on growing sales of Tecentriq, which notched 487 million Swiss francs in 2017, to help offset falling revenue from its older cancer medicines Avastin, Rituxan and Herceptin whose patent expirations are exposing them to rivals\u2019 cheaper copies.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, there is no information in the story about side effects, patient exclusions, or other potential harms of Tecentriq or the chemotherapies included in the cocktail.\nAlso, the common talking point around immunotherapy includes the claim that it is less toxic than traditional chemotherapy, so why would a person take both, instead of just one or the other? What does that do to the side effect profile?", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe study shows that receiving little to no nutrition during the first week in intensive care makes children recover faster.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study report goes into substantial background detail about potential harms of malnutrition and overfeeding, and the release \u2014 although without specific data \u2014 more or less describes the concerns. The release could have been strengthened even more if it had informed readers about the rigorous informed consent obtained from parents, and the efforts to maintain basic nutrient levels in all the children.", "answer": 1}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call for us: Harms are discussed, but briefly and anecdotally. The brief portion comes in the same quote mentioned above, noting that the body of evidence regarding therapy animals \u201csometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress\u201d (emphasis added). A little more information there would be welcome.\u00a0There\u2019s also the issue of immunosuppressed patients coming into contact with therapy animals, and possible harm to the animals, who could be over-worked or subjected to aggressive or harmful treatment from even well-meaning people.\nStill, some harms are at least acknowledged.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nThe researchers randomly assigned more than 1,700 people with ulcerative colitis to one of three phase 3 trials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Over the course of three paragraphs, the story discusses a variety of adverse health effects experienced by patients participating in the clinical trials, including infections, nonmelanoma skin cancer, \u201cheart problems,\u201d and an increase in cholesterol levels.\nAs with benefits, the story compares the number of adverse health events in those taking Xeljanz with the number of adverse events in those taking placebo \u2014 which is useful for helping readers place the risk in context.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no broad discussion of safety or side effects.\u00a0 But one issue was raised that was not in the NYT story:\u00a0\n\"Women in the fish-oil group had lower rates of pre-term births, particularly births earlier than 34 weeks of gestation. But, there was a trade-off: More women who took the supplement needed their labor to be induced or had caesarean sections because the babies stayed in the womb longer, said Dr. Makrides.\"\nBecause it at least nodded in the direction of a specific potential harm issue, this story gets a satisfactory score on this criterion.", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nThe test can be done at home without dietary restrictions or bowel preparation.\nPatients must often take time off work and need transportation home from the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms.", "answer": 0}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nIn general, dietary patterns are consistent for at least seven or eight years, Scarmeas said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of harms, but we\u2019re not sure of any from this diet \u2013 so we judge this criterion Not Applicable in this case. ", "answer": 2}, {"article": "Kychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.\nSome 15% of women on flibanserin, and 7% of those on placebo, stopped treatment due to side effects.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0provided statistics on common side effects including\u00a0daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia.\u00a0 These side effects resulted in 15% of those\u00a0taking flibanserin vs 7% taking placebo withdrawing from the study.", "answer": 1}, {"article": "An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\nDuring the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site.\nMillions of CoolSculpting treatments have been performed in more than 80 countries.\nThe CoolSculpting procedure is not a treatment for obesity.\nFollowing the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CoolSculpting.com states the procedure is proven to be a safe and effective. However, there are risks associated with this treatment. The addendum to the release does contain information about potential harms so we rate this as Satisfactory.\nAccording to CoolSculpting\u2019s patient safety document, subjects may have redness, blanching, bruising, tingling and stinging immediately after the procedure. One to two weeks after treatment, patients could also experience cramping, numbness, skin sensitivity and \u201csensations of fullness.\u201d In addition, cold exposure to certain nerves may cause tongue deviation, lower lip weakness, dry mouth and a decrease in saliva production. Some rare side effects include late-onset pain, first and second degree frostbite, fainting, nausea, dizziness, nodules in the treatment area and hyperpigmentation. Some patients have even experienced \u201cparadoxical adipose hyperplasia,\u201d meaning they experience the reverse reaction and end up with more fat cells in the area.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that\u00a0nausea that made some patients drop out of the study, and explained that\u00a0gastric ulcers were seen in the stomachs of more than one-third of patients. Since the device appeals to a consumer who \u201cdoes not qualify\u201d for medical obesity treatment and has only temporary benefit, we believe the story should have quoted at least one critic.\nGiven that the patients in this study are those who \u201cdo not qualify\u201d for the medical management of obesity, one might raise questions about the ethics of\u00a0an intervention that isn\u2019t medically indicated. Given the temporary nature of the device, the risks should\u00a0be expected to\u00a0outweigh the benefits \u2013 especially since the benefits in turn, unless marked behavior changes are permanently undertaken, will, by definition, be temporary. This can be viewed as\u00a0an extreme intervention in the name of non-medically necessary weight loss \u2013 the kind of approach that runs the risk of encouraging people to pursue all sorts of nonsensical, and, at times, dangerous diets and interventions.", "answer": 1}, {"article": "The Pear Bureau Northwest was established in 1931 as a nonprofit marketing organization to promote the fresh pears grown in Oregon and Washington.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study looked at a possible association between pear eating and obesity but the protocol did not have a way to determine harms of eating or not eating the fruit. In any case, it\u2019s hard to imagine any.", "answer": 2}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Older adults are susceptible to sexually transmitted diseases like anyone else. Increased sexual activity might increase those risks.\nWe acknowledge that we\u2019re holding the bar high here, but unapologetically, especially with recent studies showing rising rates of STDs in seniors.", "answer": 0}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nStill, said Dr. Richard Schilsky, who serves as the chief medical officer of ASCO and who was not involved in the study, \u201cthere\u2019s a substantial benefit\u201d to continuing aromatase inhibitors out to 10 years to lower the chance of cancer developing in the other breast.\nThirteen of the women taking the drug for an additional five years developed breast cancer in the opposite breast during the study, compared with 31 taking the placebo; 55 and 68, respectively, developed a recurrence of cancer in the original breast.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "First, we applaud the story for recognizing\u00a0the difference between absolute and relative benefits.\nBut because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nThe story also clearly understands that the absolute benefit of the treatment must be weighed against the side effects:\nAromatase inhibitors cause side effects in some women, especially night sweats, hot flashes, and sexual dysfunction. Women receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\nOne thing that would have made this even stronger: Including the rates of the different side effects.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nA recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms from both CBT and antidepressants. While promoting the advantages of CBT over medications, the release discusses some harms from antidepressants (\u201cconstipation, diarrhea and dizziness\u201d) but didn\u2019t touch on the more serious harms associated with SSRIs, particularly when going through withdrawal.", "answer": 1}, {"article": "Uterine serous carcinoma makes up less than 10 percent of all cancers of the endometrium, or lining of the womb, diagnosed in the United States each year, but it accounts for more than a third of the 10,000 endometrial cancer deaths annually.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\nShe notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\nFader cautions that a larger study of the drug combination, or other combinations, is needed to confirm the findings and potentially extend survival even more.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not addressed. This trial was relatively small, with only 58 patients, and the relevant journal article notes that the trastuzumab \u201cwas well tolerated\u201d by study participants. However, because trastuzumab is already in clinical use for treating other cancers, we know that it is associated with some risks. And those risks are not insignificant. For example, Herceptin\u2019s manufacturers note that the drug \u201ccan result in sub-clinical and clinical cardiac failure\u201d \u2014 and that is in addition to more common, but less severe, adverse reactions.\nAlthough practices vary, patients need to be monitored with an echocardiogram while on trastuzumab.\nSometimes patients with existing heart problems may be precluded from getting this drug. The abstract, but not the release, addressed risks but only in part, when it states: \u201cToxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.\u201d", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBefore ketamine, James was unable to work or focus his thoughts.\nAnd that could explain why patients like James usually stop overheating once they are taking ketamine.\nThey inhaled a nasal mist containing ketamine about twice a week.\nThe fear was \"overwhelming,\" he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms in the story. The Johnson & Johnson news release cited in the story lists a number of side effects: \u201cThe most common treatment-emergent adverse events (>10%) reported in the esketamine group were metallic taste, nausea, vertigo, dizziness, headache, drowsiness, dissociation, blurred vision, paraesthesia (tingling sensation) and anxiety.\u201d\nA recent journal article that was not mentioned in this story reported side effects so severe that all the participants quit taking an inhaled form of ketamine.", "answer": 0}, {"article": "For more information about the study contact ket.study@unsw.edu.au or call 02 9382 9509.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\nPrevious studies into ketamine treatments for older people with depression - which are limited to just five case reports - show mixed success, with findings limited by small sample sizes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release doesn\u2019t say how widespread side effects were in the study population, it does mention some of the side effects and it\u2019s clear to readers that ketamine is not a trouble-free drug.", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nAfter the procedure, the airways no longer are so prone to constricting, studies show.\nSince then, about 650 patients across the country have had the procedure.\nBut several five-year studies showed no long-term safety issues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers to 5-year studies suggesting that the procedure is safe, and suggests that short-term problems consist of\u00a0\u201ctemporary coughing, mucus and other respiratory symptoms brought on by irritation of airways.\u201d This understates the severity of adverse effects\u00a0seen\u00a0while patients are receiving active treatment. In the trial mentioned above, 16 patients\u00a0in the bronchial thermoplasty group had to be hospitalized for asthma-related complications during treatment,\u00a0compared with only 2 patients in the control group.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nRestaurants, office parties, potlucks, meals while traveling -- they're a minefield for people with celiac disease and gluten sensitivity who can suffer from stomach pain and upset, swollen joints, and other debilitating health problems when they ingest even a little bit of gluten.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without any evidence one way or the other about the \u201cmini chemistry test\u2019s\u201d accuracy, it\u2019s hard to know if there might be any false positive or negative readings, and thus any harms from eating food that has more gluten than the test user thinks. The story doesn\u2019t discuss this.", "answer": 0}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\nO'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the researcher believed the drug was well-tolerated, the article should have included information about demonstrated side effects, even minor ones.\u00a0 The author also should have noted if the study was powered to detect differences since the study cohort was so small.", "answer": 0}, {"article": ".\nA new study shows that electro-acupuncture may be effective in providing some relief.\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of potential harms or side effects from the use of electro-acupuncture, which like traditional acupuncture, is considered to be of relatively low risk.\u00a0 But neither is without risk entirely, given that infection is possible along with bleeding or other injury.\u00a0 Electro-acupuncture is not suggested for people with heart problems, strokes, seizures or epilepsy, nor should it be used by patients with cardiac pacemakers since the small current used can disrupt the function of these devices. These risks should have been included in the release.", "answer": 0}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nThe trouble with overdiagnosis is that while the cancers doctors find wouldn't have harmed their patients, the treatment and stress that result from the diagnosis probably will.\nYou can see this clearly in the chart below: The number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is mainly about harms and the fact that increased breast cancer screening was not associated with lower mortality rates in the study \u2014 suggesting that there is a high rate of overdiagnosis of breast cancer. \u201cThe trouble with overdiagnosis is that while the cancers doctors find wouldn\u2019t have harmed their patients, the treatment and stress that result from the diagnosis probably will,\u201d the story says. The story adds that estimates of the scope of the problem are \u201cfrustratingly broad \u2014 from less than 10 percent to 50 percent or more of women who get screened. In other words, we don\u2019t actually know how bad the problem is.\u201d", "answer": 1}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nEating bitter melon could also have a beneficial effect, Ray said.\nBut their work was done in a laboratory, not in humans, she noted.\nFor the study, Ray's team treated human breast cancer cells with bitter melon extract, which is sold in U.S. health food stores and over the Internet.\nIf so, human trials might follow.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 You can\u2019t talk about harms from an agent that\u2019s only been tested in a petri dish.\u00a0 But, then again, you really can\u2019t say much at all. Yet they made a news story out of this. ", "answer": 2}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of taking a statin are not addressed, even though they carry side effects, and these effects may have been a reason people stopped taking them before surgery.\nAlso, as\u00a0implied in the news release from The Society of Thoracic Surgeons, patients may have been told to stop their statins by a doctor\u2013why is that sometimes the case? Was it because of a potential perceived harm? This context isn\u2019t provided.\n(It appears, for example, that drug labels for statins used to recommend stopping them before surgery because of the risk of muscle breakdown, known as rhabdomyolysis. There\u2019s some indication that doctors have been slow to catch up with newer guidelines that state statin use should be continued.)", "answer": 0}, {"article": ".\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms of this screening tool. Just to mention one hypothetical case, it is possible that caregivers relying on the blood levels alone may err and fail to test in other ways for brain injury. In general, medical tests have two potential harms. The first is that the test does not demonstrate the presence of injury when in fact there is one. This would lead to under-diagnosis. The second is the test demonstrates the presence of injury when it does not exist. That would lead to over-diagnosis. While obvious, the report should have included some caveats to its otherwise glowing comments.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nAnd, as the debate over PSA testing shows us, early diagnosis is only useful if early treatment can help patients live longer and healthier lives, preventing progression to advanced-stage cancer down the line, but without increasing the risks of other health problems too much in the process.\nMany health experts think that\u2019s too much risky treatment to justify the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "WebMD\u2019s story quantified the potential harms in a more helpful way.\nWe also take issue with the statement that it is an \u201calbeit small risk of sexual dysfunction and urinary leakage from eventual treatment.\u201d\nThe discussion of harms was incomplete.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story the benefit of the doubt here. It mentions that adding chemo exposes patients \u201cto side effects and other health risks,\u201d but it doesn\u2019t detail what those effects are. Two other people mentioned in the story refer to \u201ccomplications\u201d and chemo being \u201cnot pretty,\u201d but the story does not elaborate on these comments. The National Cancer Institute lists a slew of side effects from undergoing cancer treatment, such as bleeding, fertility problems and hair loss.\nOn the flip side, researchers mentioned it\u2019s possible that patients in the low risk group could experience relapses in the future, and it\u2019s unclear if early administration of chemo would have helped in these cases. We address this point in the \u201cQuality of Evidence\u201d section, since researchers addressed this as a study limitation in their paper.", "answer": 1}, {"article": "Healthy cartilage that covers the bone surfaces in the knee joint transfers these high loads from the lower leg to the upper leg.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential harms.", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nAddiction specialists not involved in the study said the findings are promising, although side effects such as trouble concentrating, tingling and itching caused about one in five people to drop out of the study.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\nThe Topamax group cut back to six drinks a day, on average, assuming everyone who dropped out of the study relapsed into heavy drinking.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention some of the unpleasant side effects that people taking the drug experienced; although it did not provide information about how frequently they occurred, it mentioned that 20% of the people dropped out of the study which provides a composite of sorts.\u00a0 ", "answer": 1}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story mentions neither the potential harms of statin drug treatment that have been reported in studies of adults nor the fact that the safety of these drugs has not been studied in children.", "answer": 0}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that aspirin and NSAIDs can cause bleeding and are associated with adverse cardiovascular effects. However, maybe these important caveats should have come sooner than paragraph eight of a nine-paragraph story. Moreover, the story could have provided some sense as to how frequently these adverse events occur and if they are common enough to counterbalance the apparent decrease in cancer associated with these drugs.", "answer": 1}, {"article": "\u201cBut this is going to help you improve the quality of your life and prevent serious diseases.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nEven after the Women\u2019s Health Initiative news broke, some women couldn\u2019t face the changes without hormone treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that conclusions of the Women\u2019s Health Initiative have been discredited by subsequent studies but fails to state any of these studies or acknowledge potential side effects of HRT. \u00a0The article instead points out some of the limitations of the Women\u2019s Health Initiative, but we don\u2019t think \u201cdiscredit\u201d is appropriate in this case.\u00a0 It was further analysis of the WHI data \u2013 not new studies \u2013 that showed that risks are different in the younger postmenopausal women (women in their 50s) compared with the older population.", "answer": 0}, {"article": "It was a turning point, and for the next year I continued to get better.\u201d\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states:\nSide effects including anxiety, headache, fatigue, muscle tension, and insomnia, were generally minor and limited to the days following the MDMA sessions.\nReaders might have concerns regarding the long-term consequences of pharmaceutical grade MDMA, but this is unknown. The article does make it clear that the MDMA-assisted psychotherapy model used in the study only involves taking the drug on 2-3 occasions.\nAlso, the article anticipates that some people may (and already do) turn to street sources of MDMA (aka \u201cEcstasy\u201d or \u201cMolly\u201d) to self medicate. It\u2019s made clear that this could could be dangerous, or even fatal, since street sources can be laced with other psychoactive drugs.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nCalled Zostavax, the shingles vaccine is made by Merck.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that earlier research identified side effects of the vaccine, including redness and pain at the injection site. But an inquiring story would have asked about side effects in the new study.\n", "answer": 1}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable, as the potential harms of eating eggs are minimal. In just a line, though, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol). Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n\u201cExercising, eating healthy and trying novel ways to improve your health is something you should definitely explore and bring up with your physician.\u201d\n\nEnvironmental factors could play a role in glaucoma risk as well, said Dr. Ahmad Aref at the University of Illinois at Chicago.\nCoffee, or caffeine in general have previously been linked to increased glaucoma risk, although recent studies don\u2019t agree, Coleman and her colleagues write.\nIn this group, Coleman\u2019s team found that just over 5 percent, 82 people, had glaucoma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Only potential harm to be considered would be those people who respond to this study by abusing caffeinated tea thinking that more consumption might offer more protection from glaucoma. Excess caffeine can have deleterious health effects. Not including this unlikely scenario in the story seems reasonable.", "answer": 2}, {"article": "I didn\u2019t even know I had cancer until after the surgery to remove the tumor,\u201d Hopper told NBC News.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\n\u201cThe average survival rate for all malignant brain tumor patients is only 34.7 percent,\u201d the group says.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\nA modified version of the polio vaccine, infused straight into aggressive brain tumors, helped some patients live for years longer than they normally would have, doctors reported Tuesday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the NPR story that we also reviewed, NBC did a good job of spelling out harms, stating 19% of patients had \u201cnotable adverse events\u201d and more than a quarter experienced brain damage affecting speech and communication. Again, though, we think it\u2019s better to give readers the absolute number of adverse events \u2013 how many out of how many?", "answer": 1}, {"article": "For more on stroke, visit the National Stroke Association.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\nBleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of patients, regardless of which drug they received, Campbell said.\n\"Tenecteplase is likely to become the preferred medication for clot-dissolving in stroke patients,\" said lead researcher Dr. Bruce Campbell, head of the stroke department at the Royal Melbourne Hospital in Parkville.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a feared complication of clot-busting stroke drugs: often-fatal brain bleeds, which it said occurred in 1% of patients regardless of which drugs they received. It did not say that one of the two patients in the study who had a brain bleed died from it.", "answer": 1}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nTheir finding is published in the Journal of Neuroscience.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of changing one\u2019s sleeping pattern is not addressed. While there are people with certain health conditions that can\u2019t sleep on their side, it doesn\u2019t seem like an applicable criteria for rating this release.", "answer": 2}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nResearch published today in Scientific Reports shows that light from RayVio's 293nm ultraviolet (UV) LED is more efficient than sunlight at producing vitamin D3 in skin samples.\nA vitamin D3 producing UV LED device could be used on skin areas that experience less exposure to sunlight such as upper legs and arms and abdomen and back thus minimizing risk for developing non-melanoma skin cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms, although only to discuss how it would reduce risk compared with sunlight exposure. It states: \u201cA vitamin D3 producing UV LED device could be used on skin areas that experience less exposure to sunlight such as upper legs and arms and abdomen and back thus minimizing risk for developing non-melanoma skin cancer. The UV LED device also emits a much narrower band of UVB light and thereby decreasing likelihood of skin damage that can occur when the skin is exposed to higher wavelengths of UV radiation.\u201d\nAlmost all interventions are associated with potential harms, and light therapy is no different. Although light therapy is considered generally safe, it may cause eyestrain, headache, nausea, irritability or agitation, and mania, euphoria, hyperactivity or agitation associated with bipolar disorder. Specifically, UV light can cause eye and skin damage, as well as increase one\u2019s risk of skin cancer.\nSince harms from UV LED aren\u2019t addressed in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "She recommended that older adults get regular eye checkups, and have any vision symptoms checked out and treated promptly.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the debits of traditional eye exams are minor, more substantive \u201cfixes\u201d of vision problems mentioned in the story (such as cataract surgery) do bring with them possible risks.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\nThe other imaging test Agatston recommends is an ultrasound of the carotid artery, looking at plaque in the main blood vessel leading to the brain.\nThese new tests give patients a chance to make major changes in their diet and lifestyle, and give doctors an opportunity to treat them with medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, this story mentions harms, yet generally misleads readers. While the story emphasizes potential long-term benefits of screening, there is no mention of the downstream risks of tests and treatments triggered by the initial screening scans. For example, someone found to have a high coronary calcium score may be referred for an invasive coronary angiography exam, which in rare cases can cause serious injury or death. This story fails to point out the typical downsides of screening, especially for low-risk individuals who are less likely to gain important benefits.", "answer": 0}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nThey were all taking part in the Physician\u2019s Health Study, a giant, ongoing research project that follows thousands of male doctors over their lives.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We won\u2019t flag the story for not discussing the potential harms a Mediterranean style of eating \u2014 which don\u2019t really merit much discussion.", "answer": 2}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201cSide effects include headaches and hypomania.\u201d And it included the warning: \u201cUsing a light box is not as simple as it may appear. Experts recommend consulting with a knowledgeable health care provider.\u201d\nAnother point the story could have raised is that a person with a disorder that does not respond to light may self-diagnose and fail to seek more effective therapy or advice.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\nShe said she and her colleagues included the results of the unpublished studies because sometimes negative studies of a drug don't get published.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We learn the drugs have side effects but nothing about the fainting, falls and somnolence that are known side effects of the drug.\nThe patient with the testimonial is\u00a0quoted saying: \u201cI should be able to choose whether the side effects are worth the benefit.\u201d\nWe agree. But we also agree that anyone reading this article should get a sense of what those side effects are likely to be\u00a0and how often they occur.", "answer": 0}, {"article": "Previous studies have connected high levels of inflammatory markers in the blood to bone loss and to fractures in older women and men, which prompted Orchard and her colleagues to wonder what they'd find if they took one more step back - to the dietary choices that contribute to inflammation in the body.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\nWomen with the least-inflammatory diets had lower bone mineral density overall at the start of the study, but lost less bone than their high-inflammation peers, the researchers found.\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nVedat Yildiz of Ohio State's Center for Biostatistics also worked on the study, which was supported by the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release but it\u2019s hard to envision harms that could occur from an improved diet.", "answer": 2}, {"article": "It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThere's a growing body of research to suggest that both are probably good for you.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A claim is made in the article that by enjoying tea of the best quality, you are probably doing more good than harm. The article did not mention any potential harms associated with consumption of green tea, even if that would be to say that there are no known risks associated with green tea consumption.", "answer": 0}, {"article": "\u201cWith medicine, you always want to optimize a patient\u2019s outcome,\u201d Shastri said.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nPlus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nAlthough IVF is considered the standard of care, experts say some women may benefit from IVM.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article notes that for \u201csome women\u201d the hormone injections required for IVF (and presumably IVM as well) can be \u201cdownright dangerous,\u201d it doesn\u2019t say exactly how they are dangerous, what the dangers are, or what the dangers are of the rest of the IVF/IVM procedure in terms of fetal outcomes\u00a0or biological/psychological tolls on women.", "answer": 0}, {"article": "All rights reserved.\nIf approved, Tykerb \u2013 known as Tyverb in Europe \u2013 will be used along with another drug that prevents hormones from making cancer cells multiply.\nApproval as an initial treatment likely would boost that sharply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nGlaxoSmithKline is seeking to market Tykerb as an initial treatment for hormone-sensitive breast cancer that has spread.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that Tykerb can damage the liver and harm a fetus.\u00a0 But that\u2019s an incomplete listing.\u00a0 Tykerb can cause rare but very serious problems with heart failure and pulmonary toxicity. The drug can also cause diarrhea, skin rash, swelling, redness, pain and or peeling of the skin on the hands and feet, anemia, nausea and vomiting \u2013 along with a host of less common side effects. The story was way off in this regard. ", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nIntriguingly, it appeared to be more effective among people with two copies of the APOE4 gene, a genetic combination that increases risk for Alzheimer\u2019s by a factor of 20 or higher.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\u00a0 \u201cThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\u00a0 However, patients on nicotine did lose a few pounds, which is a known side effect.\u201d The study also reported a small drop in systolic blood pressure in subjected treated with nicotine \u2013 an unusual finding which the story did not report.\nWe like that the story, unlike the MSNBC piece, noted that \u201cnicotine might enhance the cancer-causing properties of other substances.\u201d", "answer": 1}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nIn a systematic review of the available scientific literature a team from Cardiff University's School of Medicine found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment (average study follow-up length over 5 years).\n\"There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,\" said Professor Peter Elwood who led the research published in the journal PLOS ONE.\nPatients receiving cancer treatment could increase their chance of survival by up to 20% and help stop their cancer from spreading by taking a low-dose of aspirin, new research suggests.\nAs a result of the review, the team say their study highlights the need for randomised trials to establish the evidence needed to support low-dose aspirin as an effective additional treatment of cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only risk of harm in the release is a passing mention of intestinal bleeding in cases of colorectal cancer.\nBriefly mentioning the handful of other risks would have greatly improved this release. Even small doses (80-325 mg) of aspirin can reduce the body\u2019s ability to clot wounds, and consequently promote bleeding. Giving aspirin to patients being treated for cancer may be presumed to increase bleeding risk, especially if the patient has low platelets as a result of chemotherapy.\nSome people are also allergic to aspirin, which can complicate asthma. A regular dose of aspirin can also increase the risk of bleeding stomach ulcers.\nImportantly, 21 out of 36 studies included in the meta-analysis of aspirin and the three cancer types had no data on bleeding.", "answer": 0}, {"article": "Source: Brightling C, et al.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nThe drug, known as Fevipiprant (QAW039), was shown to reduce asthma symptoms as well as inflammation, and it improved lung function and repaired airway linings.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No serious adverse effects were reported in trial participants who took fevipiprant, a fact the story does not mention. The story also should have mentioned\u00a0mentioned that it remains to be seen whether fevipiprant is safe over decades of continuous use, which is typical for as asthma drug, as well as for patients of various ages and health conditions.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story squeaked by on this one by pointing out that there are some sudden deaths associated with sauna use, usually in relation to alcohol use. But the story also mentions that previous studies have suggested that sauna bathing might have some harmful effects. We wonder what those effects were, and why we should trust the new study\u2019s assurance that there are no such effects.", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n\u201cStatins are a vital medicine for people with \u2014 or at high risk of developing \u2014 heart disease,\u201d he said.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to ding the story for not actually calculating the potential harms, given that the piece is based on an editorial. In all, we think the story did a fair job pointing out the problems with using statins as a subsitute for exercise and a healthy diet. It could have at least mentioned some of the side effects of long-term statin use.", "answer": 1}, {"article": "BOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms mentioned by this story include PPHN, newborn withdrawal from antidepressants, and \u201ca small risk of heart defects.\u201d This is responsible \u2013 and enough for a Satisfactory rating. The story could have gone further by quantifying these harms and mentioning the potential harms of untreated depression, which aren\u2019t noted in the story.\u00a0As noted by the study author in the competing HealthDay story: \u201cUntreated depression or anxiety during pregnancies has been linked to different adverse health outcomes, such as miscarriage, preterm birth, pre-eclampsia and smaller newborns,\u201d Huybrechts said.", "answer": 1}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThe hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nPatients will be monitored for relapse at the molecular level, before disease becomes again symptomatic.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of risks or harms of the experimental approach, but part of the function of a phase 2 trial is to evaluate harms. Not only does each drug in the experimental cocktail include its own risks (including increased risk of heart attack and stroke, nerve damage, blood clots, low white blood cell and platelet counts, fatal spikes in blood pressure), but the effect of the combination of drugs could exacerbate the harms or even create new ones. While multiple myeloma patients may be aware of and acknowledge the risks of individual drugs as part of standard treatment, the unknowns of the experimental drug combination should have been pointed out in the release.", "answer": 0}, {"article": "Then they took tests involving memorizing words.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that some earlier studies found that caloric restriction was linked to memory decline. \nBut it fails to mention one very important practical warning relevant to the study populations: That older patients are at increased risk for malnutrition, and should not restrict their caloric intake without medical superivision.\u00a0\nFurther, it\u2019s not known whether caloric restriction is safe for slightly overweight or normal weight adults regardless of age.\u00a0 ", "answer": 0}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms from a dairy enriched diet.\nSince the release is encouraging greater dairy consumption, including up to 4 servings of cheese a day, it would be important to mention that there are potential harms from consuming more saturated fats found in many dairy products.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nWhy, Dr. Anderson asked the company executives, couldn\u2019t there be a polymer to put on skin?\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\nDr. Anderson listed what would be needed: \u201cIt has to be nearly invisible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions harms indirectly by citing a lack of irritation or allergic reactions among those test subjects that used it. This at least clarifies the findings about some of the obvious potential harms, so we\u2019ll rate this Satisfactory.\nBut, we do think the the story could have pointed out that long-term effects are still unknown. For example, what happens if you get some of this in your eye?", "answer": 1}, {"article": "According to Hazinski, one easy way to remember the rhythm is that it is roughly equivalent to the beat of the 1977 Bee Gees' disco hit \"Stayin' Alive.\"\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nOnly about 6 percent of victims whose hearts stop outside of a hospital survive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news article explains that when CPR is performed with chest compressions only (without mouth-to-mouth resuscitation) the main harm is rib fractures induced by energetic chest thumping. ", "answer": 1}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss the harms of this treatment. It\u2019s full of language \u2014 \u201ca simple zap to the spine,\u201d \u201cscalpel-free,\u201d \u201cnoninvasive,\u201d \u201cless risky\u201d \u2014 that might mislead readers into being falsely assured.\nA procedure that introduces instruments close to the spine and makes contact with major nerve roots carries risks of infection and nerve damage. Those should have been mentioned.\nThe story does say that \u201cdiagnostic uncertainty can undermine the ability of surgery to get at the true source of a patient\u2019s pain.\u201d However, we think the story should have underscored the point that low back pain is often treated unnecessarily. Even if a herniated disk shows up in imaging \u2014 which is common \u2014 it might not be the cause of a patient\u2019s pain. That opens the possibility that some patients will undergo a procedure that won\u2019t help them, but could do harm.", "answer": 0}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\n\"This study adds to the literature on vaginal laser therapy for GSM.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned and extremely relevant based on this June, 2018 publication by the FDA:\nFDA warns against use of Energy-based devices to perform vaginal \u2018rejuvenation or vaginal cosmetic procedures\nThis includes \u201cprocedures intended to treat vaginal conditions and symptoms related to menopause, urinary incontinence, or sexual function\u201d\nSide effects listed include: \u201cvaginal burns, scarring, pain during sexual intercourse, and recurring/chronic pain.\u201d", "answer": 0}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nSeparately, Italian researchers reported that advanced lung cancer patients given the targeted therapy drug Tarceva as so-called maintenance treatment \u2014 after they finished a course of standard chemotherapy \u2014 lived a little bit longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms of iloprost or erlotinib are mentioned.\u00a0In the\u00a0iloprost study, 11% of subjects receiving the drug reported serious adverse events. That\u2019s a pretty big omission. ", "answer": 0}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nResearchers found that the drug could lead to consistent and sustained loss of more than 5 percent of weight in nearly 40 percent of patients at risk for heart attacks, strokes and death from cardiovascular disease without increasing the likelihood of such events, according to a report published recently in the New England Journal of Medicine.\nPeople need to realize that in obesity treatment, just as in hypertension therapy, one drug won\u2019t fit all, Aronne said.\nThey won\u2019t make a morbidly obese patient model-thin, but they\u2019ll shave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol, experts say.\n\u201cThe challenge with lifestyle interventions is that patients tend to lose weight up front, and then the weight is regained, sometimes beyond the original weight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story kept referring to weight loss drugs as a group, the story focused mostly on lorcaserin, including a\u00a0three-year study that showed lorcaserin didn\u2019t increase the risk of bad heart events versus a placebo in patients at high risk of heart disease. However, the story didn\u2019t mention side effects and uncertainty about long-term use of that drug.\nAn accompanying editorial to the lorcaserin study said that the drug \u201cmay best be used on a cautious basis according to the needs of individual patients,\u201d and mentioned uncertain safety of its long-term use as well as side effects such as headache, fatigue, dizziness, diarrhea, and nausea that led some patients stop using it.\nOther research has raised concern about an increased risk of depression and other side effects that might outweigh lorcaserin\u2019s benefits.", "answer": 0}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nThe results suggest that people eat a healthy diet with \u201cmagnesium-rich foods such as green leafy vegetables, nuts, beans and whole grains,\u201d she added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t discussed, but we\u2019re not sure there any substantial harms of a diet rich in leafy green vegetables, nuts and beans worth mentioning.", "answer": 2}, {"article": "For more information on biopsies, visit the U.S. National Library of Medicine.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nMoreover, by 2008, 67 percent of these biopsies were being done through the skin with the help of CT scans, ultrasound and MRI, Kwan's group found.\nThat's an annual growth of 3 percent in number of biopsies, the researchers noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\"Minimally invasive\" does not equate to \"no harm.\"\u00a0 Yet no discussion of potential harms \u2013 either in traditional biopsies or in the minimally-invasive variety made it into the story.\u00a0 No medical intervention with any level of invasiveness is without harm.\u00a0 So potential harms must be discussed to make the story complete. ", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses a few\u00a0potential side effects, at least to the same extent as discussed in the related journal article \u2014 namely, the need to wear a catheter for a few days after treatment, and issues in some patients related to ejaculatory volume. It also talked about the need for more long-term data.\nThat said, it would have been helpful to specifically address other potential treatment side effects\u2013bleeding, infection, etc.", "answer": 1}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nA co-author of the 2013 study linking heavy coffee drinking to higher mortality called the new one \u201cvery good,\u201d especially since it controlled for the deadly effects of smoking, which the earlier one did not.\nThis same Nurses Health Study, for instance, infamously found a correlation between post-menopausal hormone therapy and lower risk of cardiovascular disease and death, here and here.\nEven the 5-plus\u2019s had 12 percent lower mortality.\nIf you do want to infer causation from this latest study, know that drinking coffee reduced the absolute mortality risk from 6.8 deaths a year per 1,000 people to, at best, 5.8.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This STAT story explained the slightly increased risk of death in those participants in the current study who drank\u00a0very high\u00a0amounts of coffee,", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nWith these findings, it appears the I-Portal goggle may be a solution.\nThe research findings published by PLOS ONE help support their objective.\nHowever, to best manage mTBI, researchers have felt it critical to develop objective tests to substantiate the diagnosis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms that may be associated with the goggles. Almost every health care intervention carries risks, although the severity may vary. The main potential harms are those\u00a0arising from a false positive or false negative test. This could lead to unnecessary treatment or exclusion from play in the first case or no treatment for an injury in the second and potential for much more severe effects from a second head injury. \nSince harms weren\u2019t even addressed, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": ".\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe Dallas-based association officially launched in 1998 as a division of the American Heart Association.\nThe association makes no representation or warranty as to their accuracy or reliability.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release skimmed over the harms associated with the procedure. As discussed in a previous review, there are adverse effects attributable to this procedure, including the risk of tearing an artery which could cause bleeding in the brain.", "answer": 0}, {"article": "\"There was no significant difference,\" Boden said.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\nAlthough about one-third of patients who initially got medical treatment later turned to angioplasty, the findings show how much medical treatment of heart disease has improved, Boden said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states the procedure is considered \"safe\" but that it does carry some risks.\u00a0 However, what those risks are and their frequency or severity is not discussed.\u00a0 ", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story emphasizes the upside but makes no mention of what could go wrong with an automated system.\u00a0The potential adverse effects of a malfunction, such as hypoglemic shock and death,\u00a0are\u00a0serious.", "answer": 0}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nFor the same reason, patients should get an HIV test periodically while on the drug.\nBut those who said they took the drug at least 9 out of every 10 day had a 73 percent lower risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several clear points were made about harms:", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss the potential harm due to the increase in radiation exposure, but was then followed by a quote from the VP of breast health at the company making the device dismissing some of the concern related to the increase in radiation.\nThe article did not mention rates of false positives or false negatives with the new imaging.\u00a0\u00a0It could be that it finds lots of new things\u00a0that\u00a0lead to many more biopsies but not all cancer (i.e. they report the recall rate, but what about the biopsy rate for traditional vs. 3-D?)\nSo despite the headline that addresses false positives, the story doesn\u2019t give any evidence on that question.", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\nThe implant is permanent.\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\nMerlo had Esteem implanted in her left ear in September.\nEven with one implant, Merlo called the results \"surreal.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information about potential harms of the surgery (requiring general anesthesia) or of the device once implanted.\u00a0 The study reported ongoing adverse events related to the device and the surgery including dizziness, taste disturbances, facial weakness/paralysis, ear pain, tinnitus (ringing in the ear) and middle ear effusions (build up of fluid).", "answer": 0}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to compare key risks\u2013of death, complications, need for additional surgeries,\u00a0infection rates, etc.\u2013of robot-assisted to conventional surgeries. Again, since the article raises the comparison between stenting and robotic surgery, these risks should have been compared too. Because the story uses anecdotes that suggest better outcomes and fewer side effects, the reporter should have looked for data to compare those anecdotes to.", "answer": 0}, {"article": "\"Patients don't get a lifetime certificate saying you're cured,\" Calkins said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\nIn certain patients, catheter ablation may reduce symptoms, improve quality of life and increase exercise capacity, though the impact on death and hospitalization risk is still being evaluated, he noted.\nIt causes 20 to 30 percent of all strokes and can decrease quality of life due to palpitations, shortness of breath, tiredness, weakness and psychological distress, the study authors explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out the caveats that should be remembered when considering ablation.\u00a0 It explains some of the complications that can occur, and that the procedure may only be a short-term fix.\nHowever, there was definitely a missed opportunity to dig more deeply, and report the scope of the harms as clearly as the benefits. For example, the story didn\u2019t explain 1 out of 10 people had to go back for a repeat procedure during the study. Nor that there were 280 in-hospital complications (7.8%) and 577 complications over the 12 month follow-up (16.3%). Some of the complications were quite serious, including 47 perforations of the surrounding heart tissue.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good discussion of concerns and ongoing monitoring of the drug\u2019s safety.", "answer": 1}, {"article": "For example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\n\"Pre-hab\"\u2014building up strength before the surgery\u2014is just as important as re-hab afterward, they say.\nPatients say that regaining function after surgery requires enormous mental and physical effort.\nThe fastest-growing group is patients 46 to 64, according to the American Academy of Orthopaedic Surgery.\nLast year, one manufacturer, Smith & Nephew , won clearance from the Food and Drug Administration to market its latest technology as a \"30-year knee\" based on tests mimicking 30 years of wear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article included only general references to the harms associated with knee and hip replacement. It did not specify rates of mortality, blood clotting, infection, and other potential adverse events associated with primary and revision knee and hip replacement operations. These are important issues in this age group since early joint replacement will likely involve more problematic revision procedures down the road. Detailing the complications and adverse events that can be expected in revision procedures would have helped balance the article.\n", "answer": 0}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\nThis study shows that people are more likely to lose weight when not impeded by sleep deprivation, stress or depression, he said.\nThose in the second phase of the trial continued their diet and exercise program.\nThe important message is that weight loss should not be looked at with tunnel vision, Katz said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was reporting on the impact of getting adequate amounts of sleep on weight loss. \u00a0While there was no overt discussion of the harm of obtaining adequate amounts of sleep, there doesn\u2019t appear to be any harm involved in adequate sleep.", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\n\u201cThis is the first time researchers used real populations to compare the effects of treatment and mammography in the modern era of treatment,\u201d Dr. Kramer said.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story notes that screening mammography exposes women to false alarms scares as well as the risks and harms of treating tumors that actually would not have become life-threatening.", "answer": 1}, {"article": "D.C.I.S.\nTo Dr. Norton, the most important conclusion to be drawn from the study is that more research on breast cancer prevention is needed.\nBut Dr. Leslie Ford, an associate director for clinical research at the cancer institute, said that the differences could not be ignored because they came so near to being significant.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nAnother issue is that the message from the cancer institute seemed to play down a shortcoming of raloxifene that cancer doctors consider important.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides sufficient information on the harms of raloxifene compared to tamoxifen. The story does explain that one downside of raloxifene is that it does not appear to reduce the risk of ductal carcinoma in situ (DCIS), which tamoxifen does. There is one error in the story \u2013 about 50% of DCIS will progress to invasive cancer, not 10% as stated in the story.", "answer": 1}, {"article": "That\u2019s the good news.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nA new analysis of the landmark Women\u2019s Health Initiative, the federal study that discovered the health risks, indicates that women who stopped using estrogen after the dangers were uncovered are no longer at increased risk for strokes and blood clots about 10 years after they stopped.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe Post tries but fails to do justice to the mixed picture of longer-term outcomes for women who took estrogen-only therapy. There is no quantitative statement about the risks, or the benefits. Some of the findings are misstated: \u201cRisk for heart disease during the follow-up period was similar to that seen while women were taking the hormone.\u201d The point of the study is that there was no increased risk in heart disease in estrogen-alone users (as opposed to findings with estrogen/progestin arm); and longer followup confirmed no increase. As stated, the story seems to imply there was an increased risk for heart disease that did not diminish during followup.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The first line of the story says that this cream \"promises instant anti-impotence with no side effects.\" It also quoted a researcher:\u00a0 \"Our initial studies show that it is safe to use multiple times.\"\nWhat does that mean? \nThe story should have at least briefly mentioned that \"safety\" in ten rats does not automatically equate to safety in people. \u00a0\nAll drugs have side effects. \u00a0\u00a0", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nTMS uses magnetic pulses to the brain, and has been shown to be effective in several psychiatric conditions.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "TMS is generally regarded as a low-risk treatment. That does not, however, make it a no-risk treatment. According to the Mayo Clinic, the use of TMS to treat depression can have side effects ranging from headache and lightheadedness to (in rare cases) seizures and hearing loss. We don\u2019t think the release needs to include a laundry list of potential risks, but it does need to address the risk of potential harms in some meaningful way \u2014 even if it is only to highlight that there is a low risk of significant harms.", "answer": 0}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThis independent, multicenter, blinded study is one of the first studies to validate that a liquid biopsy test can predict therapeutic response and demonstrate a survival benefit.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nAdditionally, the authors validated the test within a prognostic risk group, to ensure that the biomarker effect was due to the biomarker rather than other clinical variables.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The potential risks of blood tests are minor, although the potential of a false result could have serious consequences if it leads to a patient getting an ineffective or potentially harmful treatment.", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a small bit of information on harms at the bottom of the story for one of the two drugs: pain at the site where the ointment is applied in a small number of individuals. This squeaks by with a Satisfactory rating.\nBut, a reader will be hard pressed to find any information about the possible long-term harms of the injectable drug of interest here\u2013this is concerning because these types of drugs are known to have serious\u00a0side effects like increased infection or even cancer risk, as this Nature Review\u00a0article notes.\u00a0We\u2019re not looking for an exhaustive list, but some acknowledgment that possible long-term harms are plausible and haven\u2019t been studied would have been helpful.", "answer": 1}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\nJohn O\u2019Donnell, a retired math teacher in Piscataway, N.J., was one of those who tried the combination therapy, but ultimately responded only to Imlygic.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\n\u201cIt\u2019s a low-toxicity treatment, and for the right patients you see quite stunning results,\u201d said Robert Coffin, a virologist who created Imlygic at BioVex, the Woburn-based company he founded.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a close call, but we think the story downplays the significance of the harms attributable to these drugs. The story quotes a researcher who calls one drug \u201clow-toxicity\u201d and lists 3 adverse effects, but does not say with what frequency they occurred. According to the linked study, 11% of patients developed grade 3 (severe) and 4 (life-threatening) adverse events related to the treatment. We don\u2019t think that\u2019s what readers have in mind when they hear \u201clow-toxicity.\u201d", "answer": 0}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\nBecause of this, there is a large consensus that preventing this kind of toxicity would be an effective treatment strategy.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\nCompelling evidence shows that toxic protein aggregates called A\u03b2 oligomers selectively target and disrupt the points of communication between brain cells, impairing memory in people suffering from the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does point out that preventive treatment with anti-rejection drugs suppresses the immune system. \u00a0But exactly what does that mean? \u00a0What are the implications of this effect? The release does not provide any description of the potential problems that could occur. And that is not the only issue with these drugs. Both tacrolimus and cyclosporine have an extensive its of side effects.", "answer": 0}, {"article": "And I've seen patients who have gotten up in the middle of the night and they trip and fall on the tubing,\" he explained.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\nThe researchers found that catheter infection rates in the new program dropped 14 percent overall in general wards (non-ICU).\nAs for improving infection control in intensive care units, Huang said, \"further analysis may help us understand why this intervention didn't work.\"\nShe said, \"While we've known the correct care processes for managing urinary catheters, we haven't been able to reliably reduce catheter-related infections.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed in this story, but improved caretaker education on when and when not to use a catheter, and how to insert one while reducing the risk of infection, doesn\u2019t seem to warrant it.\u00a0\u00a0Although there may be some harms from this \u201cbundle,\u201d the study itself was not set up to look for them.", "answer": 2}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t quantify the harms of something that hasn\u2019t advanced beyond the lab and has not yet been done in humans.\u00a0 Of course, you can\u2019t say much at all at this stage, which raises the question of why the story was published now in a consumer health section that is labeled, \"Health & Parenting.\"\u00a0 ", "answer": 2}, {"article": "Doctors spin a few tablespoons of a patient's own blood, separating out the platelets.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nIt's called Platelet Rich Plasma therapy \u2014 or PRP.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only said\"\u00a0 \"reported side effects were minor. The biggest complaint so far?\u00a0 Needles hurt.\"\u00a0 Let viewers judge which side effects were minor by naming them and listing how often they happened.\u00a0 Even more important, though, the story should have emphasized that really nothing can be said about side effects when the very preliminary experimental approach is still undergoing clinical trials. ", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms in its lead sentence, referring to \u201csuch serious side effects as sudden bone fractures.\u201d As noted above, the entire story is essentially about comparing the benefits and risks of bisphosphonate use for treating osteoporosis. The story does a good job of discussing potential (and serious) side effects such as sudden fracture of the femur and osteonecrosis of the jaw. However, the story doesn\u2019t mention the less serious (but more common) side effects such as heartburn or other gastrointestinal problems.", "answer": 1}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening.\u00a0 Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy).\u00a0 ", "answer": 1}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nWhile most women in the hormone study were taking combination hormone therapy, women without a uterus took estrogen alone or a placebo for about six years and were followed for nearly 11 years.\nAlthough all the women in the estrogen study stopped using the treatment in 2004, the investigators have continued to monitor their health, as is typical in large clinical trials.\nNobody knows why estrogen treatment alone appeared to lower breast cancer risk in the study, but one explanation may be that in menopausal women with low levels of natural estrogen, the effects of estrogen drugs induce cell death in existing tumors.\nDr. Rowan Chlebowski, another author of the study and a medical oncologist at Los Angeles Biomedical Research Institute, said the findings underscored the fact that the risks and benefits of menopause hormones change depending on a woman\u2019s health status, her age and the type of hormone used.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nKudos to the The Times for parsing risk carefully. Among these: estrogen alone carries different risks than estrogen-with-progestin,\nestrogen-alone for older women is much riskier than for younger women and risks for women who still have a uterus (unlike those who have had a hysterectomy) are also different. Last, but still important, the form of estrogen used in the study is not typically used now, so conclusions about benefits cannot be assumed to follow to the current form (estradiol.)", "answer": 1}, {"article": "The paper \"Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening\" is available at: https:/\n\nTo request a copy of the study, please contact: Daniel Luzer\n\n daniel.luzer@oup.com\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\nA new paper in the Journal of the National Cancer Institute finds that testing for cervical cancer using HPV testing in addition to the Pap smear is unlikely to detect cancer cases that wouldn't be found using HPV testing alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly explain the harms of cancer screening. The release addresses the harm of omitting one test, but this wasn\u2019t enough to meet our standard.\u00a0The release states that HPV is \u201cmore sensitive than the Pap test for detecting precancer.\u201d But it doesn\u2019t discuss the flip side, which is that many pre-cancers may not go on to become cancer even though all are treated.", "answer": 0}, {"article": "Alcohol consumption may also protect people who already have the autoimmune disease from developing a more debilitating form.\nNor do the study authors advise drinking as a cure for arthritis.\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nBecause the researchers assessed drinking frequency, rather than the amount of alcohol consumed, it is not clear how much alcohol might be helpful, they said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms of alcohol consumption. ", "answer": 0}, {"article": "Learn more about alcoholism and how it is treated at the U.S. National Institute on Alcohol Abuse and Alcoholism.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that Chantix carries a \u201cblack box\u201d warning and that there are concerns about depression, suicidal thoughts, and the risk of heart attacks and strokes.", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nAlthough testosterone can cause overgrowth of the prostate, studies have not shown harm to urinary function, Dr. Morgentaler said.\nStill, this study will not answer the question of whether it is safe to use the hormone for years, even decades, which would be necessary to maintain any benefits.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0notes that a recent study was halted because of an unexpectedly high rate of cardiac problems in the testosterone group. It also mentions the possibility that testosterone therapy can result in thickening of the blood and may increase the risk of prostate cancer.\nThe story isn\u2019t precise about\u00a0how often these harms occur, and it also\u00a0didn\u2019t mention\u00a0some of the \"minor\" side effects associated with testosterone use, including acne, hair loss on the scalp, hair growth on the face, increased breast size, and testicular atrophy.\nA close one here. Overall, we felt the story called appropriate attention to the harms and did not try to minimize them \u2014 enough\u00a0to earn a satisfactory.\u00a0\u00a0\u00a0\u00a0", "answer": 1}, {"article": "\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nResearchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nWhile noting that many people are reluctant to undergo spinal taps, this story includes only comments that downplay the potential harms, including pain or bleeding. The story fails to discuss the potentially serious consequences of using this sort of test before symptoms appear, such as insurance or employment discrimination.\nFinally, the story downplays that importance of the relative lack of specificity of the method. While testing of apparently healthy older people for the presence of the markers may be appealing, the reality is that based on the study up to a third of those may be falsely labeled as having the disease. This may subject a significant number of older Americans to the potential side effects of newer treatments to say nothing of the financial impact of a third of the population in this age group.", "answer": 0}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\nAt 10 weeks, six months and 12 months after treatment, patients were asked about perceived levels of pain and depression and their physical and mental quality of life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of potential harms from the use of acupuncture although the research paper clearly\u00a0identified some \u201cmild adverse events\u201d affecting participants. These included headaches, pain and bruising at the acupuncture sites, and an aggravation of some fibromyalgia symptoms. While these are far from serious harms, readers deserve to know that they are possible outcomes.", "answer": 0}, {"article": "Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nThe researchers wrote that study results support the hypothesis that oxidative stress caused by cigarette smoking reduces the amount of ascorbic acid, a component of vitamin C, available to the body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from vitamin C use.\u00a0Since some readers may take license with these preliminary findings \u2014 and think more vitamin C is better (ie. improve their infant\u2019s lung function) \u2014 the potential harms of vitamin C should have been included.\nPeople can have allergic reactions to vitamin C at even low doses. At higher doses it can be problematic in people with kidney disease, and could be detrimental to fetuses.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nThe dieters ate enough calories to maintain their weight during the off period.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\nHowever, it\u2019s important not to think of them as cheat days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this N/A since it\u2019s hard to imagine harm from restricting a third of normal calories for two week cycles over 16 weeks.", "answer": 2}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\n\u201cTogether, the three analyses appear to point toward a potential inverse association between multivitamin use with ASD with intellectual disability,\u201d say the authors.\nBut results from previous studies have been inconsistent, suggesting that other unmeasured factors (confounding), such as a mother\u2019s overall health and lifestyle, could also play a role.\nHowever strengths included the relatively large population-based sample size and the advanced analytical methods used to gauge the robustness of findings.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms \u2014 or lack of harms, if that\u2019s the case \u2014 from taking multivitamins or extra iron were mentioned in the release.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although uterine cancer and blood clots are mentioned as harms of treatment, there is no mention of how often they occur. Other harms such as cataracts and stroke are not mentioned.", "answer": 0}, {"article": "Anal Cancer Fund, and a philanthropic donation.\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nThe study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This news release makes no mention of potential harms. According to the Chemocare.com website, more than 30 percent of patients on nivolumab may experience fatigue, low white blood cells, low sodium, shortness of breath, musculoskeletal pain, decreased appetite and cough.", "answer": 0}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nMr. S. left the hospital eight days later, happy to have undergone the treatment.\nBut doctors added it may be if it is described merely as chemotherapy.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that one study showed that \u201c8 percent who got the surgery and Hipec died from the treatment itself.\u201d\u00a0 And it stated:", "answer": 1}, {"article": "Separate strands of material become stronger when they link up.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\n\u201cFor now, there is no magical cream that can make you look younger.\u201d\n\nOlivo will work first to develop the product to deliver drugs to the skin \u2013perhaps allergy or eczema medication, or long-lasting sunscreen, MIT said.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells us that\u00a0\u201cRepeated daily wear resulted in no report of irritation or other adverse events resulting from the XPL use.\u201d That\u2019s at least a nod toward discussing potential harms, so we\u2019ll consider this Satisfactory.\nBut, we think the story would be stronger if it had been more specific about what \u201crepeated\u201d meant. We\u2019re also wondering about things that could inevitably occur with regular use, like the product getting into the eyes.", "answer": 1}, {"article": "It is also not available for pregnant women, people with heart conditions or very high blood pressure, patients with kidney disease or clotting disorders, patients on blood thinners, patients with a history of strokes or brain tumors and people with substance abuse issues.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe trial participants all had tried existing medications, without success.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms in this statement: \u201cThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\u201d\u00a0 But that is by no means enough. More than a third of the patients in the study developed gait problems or numbness, or both, that in some cases persisted for 12 months. Others developed ataxia, unsteadiness and weakness that was persistent. The release seems to go overboard in downplaying these adverse effects and amplifying the positive outcomes. Releases should never cherry-pick the data from a study.", "answer": 0}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nAbout 1,500 patients at 61 clinics in the United States and abroad participated in the study.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically focuses on the use of varenicline, which goes by the trade name Chantix, but does not mention any of the possible adverse health effects associated with the drug. These possible side effects include changes in mood, suicidal thoughts, and cardiovascular problems \u2014 all of which are worth mentioning.", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\nTheir labeling does not contain language about suicide.\nMerck said it recently added reports of suicide to Singulair's label, which already listed suicidal thinking and behavior as reported side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is fundamentally about alleged harmful side effects of the drug, so this criterion is clearly established. ", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\nBefore implantation, patients will be trained with an external telescopic device to see if they may benefit from the product.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did quantify the harms:\u00a0 \"the IMT is large enough to pose a threat to the cornea of the eye, leading to extensive loss of cells essential for maintaining the clarity of the cornea. In the study, 10 eyes had unresolved corneal edema, or swelling, caused by trapped fluid. Five such cases resulted in corneal transplants. The FDA says the five-year risk for unresolved corneal edema, corneal decompensation, and corneal transplant are 9.2%, 6.8%, and 4.1%, respectively.\"", "answer": 1}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nHe hopes the surgery will be available to the general population within four to five years.\nShe also had questions about how the procedure was done with such a tiny incision.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss short- or long-term harms that may arise from this new approach.\u00a0It may be too soon for researchers to determine potential long-range harms from this approach, but saying that would have offered readers some perspective.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that various organizations and experts consider the chemical/medicinal treatments to be highly safe as well as effective.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story ends with a Duke fitness expert warning that \u201ctoo much caffeine \u2014 such as the high doses found in Zantrex \u2014 could cause jitteriness, anxiety, spikes in blood pressure and rapid heartbeats in some people.\u201d", "answer": 1}, {"article": "\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\nHe added, however, that meditation would work as well among whites and other populations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Same observation we made in reviewing the TIME.com story: An important indirect harm is that of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants \u2013 less than $18,000 annually.\u00a0 The story didn\u2019t address this.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the most serious harm of the treatment, an increased risk\u00a0of atrial fibrillation. Other risks include post-infusion reactions, including fever,\u00a0headache, flu-like symptoms and joint pain.", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\nThis research builds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nVahia cited several examples of the tablet's potential to improve a patient's condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addressed harms by saying \u201cresearchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\u201d", "answer": 1}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nThese new nanoparticles stopped the course of a MS-like disease in mice, the researchers found.\nBut Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\nIt\u2019s also clear the approach would not repair any damage already done by the disease, so the best candidates would be patients having their very first symptoms.\nWhat\u2019s great about the approach, Miller says, is that it can be used to treat any autoimmune disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explore potential harms, which is too bad. As the story points out, mice do have much shorter life spans than humans, and if humans have to be on this type of therapy for the long-term there are many potential risks involved.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nThe story demonstrates an all too familiar bias with regard to screening tests; there are no down sides.\u00a0 A couple of words of caution (again the CNN story got it right) about the implications of testing and test results would have been useful.\u00a0 If, for example, the fMRI and DTMRI scans are as accurate as this study indicates, might treatment be withheld from children who do not have the brain scan results that promise likely improvement?", "answer": 0}, {"article": "\u201cWe\u2019ve seen individuals who have lost significant amounts of weight in the six-month period.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\nWhile the FDA\u2019s clinical hold prevented Zafgen from completing its trial, Dennis D. Kim, the company\u2019s chief medical officer, said it was largely finished.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article discloses the possible side effects of beloranib related to blood clotting along with the caveat that Prader-Willi patients are predisposed to clotting issues. Two deaths out of 100 patients is a significant issue, even if they can\u2019t be linked definitively to the drug, so it\u2019s good that this is a focal point. But the story mentions no other adverse effects that were observed in the study, and it should have. We\u2019ll give the benefit of the doubt and hope for improvement next time.", "answer": 1}, {"article": "\u201cShe couldn\u2019t get over the background buzzing,\u201d Dr. Kaufman said.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nDoctors say simple adjustments to the device may solve that problem.\nThe syndrome may follow 5 percent of all injuries, according to the Reflex Sympathetic Dystrophy Association, an advocacy group for people with chronic pain.\nBut spinal cord stimulators offer significant relief to only about half the patients who try them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes some annoyances and potential problems with the device (e.g. the \u201cbuzzing\u201d vibration and the need for reoperations to replace dead batteries), but neglects to mention others. For example, the authors of the 2007 trial noted that electrode migration occurred in some 10% of patients and infections in 8%. A 2004 review by a leading group of pain experts noted that complications occur in about one-third of patients. Additional problems included pain near the site where the device is implanted, tears of the membrane that surrounds the spinal cord (the dura), and malfunctioning equipment. (Pain 2004;108:137-47)\u00a0 ", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nThe study, in 234 patients, was the largest trial of the drug in lung cancer.\nIn addition to melanoma and lung cancer, this brake-release approach has been shown effective in early trials against bladder, kidney, head and neck cancers, and some blood cancers.\nFor other patients, researchers expect other drugs will be needed, too.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms associated with Opdivo, despite the fact that the Bristol-Myers Squibb release notes a variety of possible adverse side effects (and that 41 percent of patients receiving Opdivo had adverse reactions). These possible side effects included immune-mediated pneumonitis (i.e., lung inflammation \u2014 including fatal cases), hypothyroidism, colitis, and hepatitis, among others.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nIn the new study, researchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it.\nHe expects the pacemaker \"will likely be utilized for some select patients\" after more testing.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that:\n\u201cresearchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it. \u2026one patient died of a stroke while convalescing after suffering a heart injury during implantation and another had the pacemaker replaced with a defibrillator.\u201d\nOne independent expert in the story said the new device \u201cmay pose special risks of its own.\u201d\nAnother said, \u201cWhen the battery of the implanted leadless pacemaker is exhausted, a new implant is necessary, with all the potential risks associated with this. It is not known if it will be feasible to safely retrieve the old device. If the old device is left in place, it is not known what the long-term effects of this will be.\u201d", "answer": 1}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nThis gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know what the harms would be of the idealized \u201ctailored medicine\u201d approach described in the piece.", "answer": 2}, {"article": "None did.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nAfter the patients died, their brains were shipped to Phoenix, where a pathologist sliced them into about 100 tiny pieces and sent them off for analysis of plaque.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0Although the story did mention that the test involved a radioactive tracer, there was no information about the level of radioactivity exposure involved in the test or whether there were any adverse events reported with the use of this particular dye.", "answer": 0}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nPatients were provided with novel oral anticoagulants and were instructed to start taking the medication if they suspected or detected an AF episode lasting longer than one hour.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\nFollowing this procedure, patients are often prescribed long-term, daily oral anticoagulation medications -- also known as blood thinners.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions the bleeding harms that come with taking anticoagulants, a harm that increases with chronic use. However, the release suggests that the therapy was proven safe when that wasn\u2019t clearly established.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Solid job reviewing most common side effects and links to other, rare but life threatening problem.", "answer": 1}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms \u2013 only a discussion of benefits.", "answer": 0}, {"article": "medical personnel.\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nInterestingly, uninjured athletes are almost always faster at reading the numbers during games or practices, because physical exertion sharpens the kind of visual performance being tested.\nIf an athlete hits his or her head and is then slower than baseline by even a fraction of a second at reading off the numbers, Dr. Galetta said, it is very probable he or she has a concussion and needs to be taken from play and seen by a doctor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quoting a researcher, the story suggests that parents and coaches should \u201cabsolutely consider\u201d using the test. However, the small number of young athletes tested and the testing that occurred under the supervision of research personnel (who won\u2019t be on the sidelines of youth sports games to train parents and volunteers doing this test on their own) all suggest that it would be inappropriate to state that this test has in any way been shown to be safe.\u00a0Only testing in a large number of students with potential injuries, across a range of ages, backgrounds and sports, with attention to measuring cognitive outcomes in a uniform fashion could lead to this test being demonstrated to be\u00a0the\u00a0same or better than current practice. In addition, we\u2019d note that a potential harm of this test is that it could give parents and coaches a false sense of security. There is no evidence that any of this actually prevents\u00a0young athletes from developing long-term cognitive impairment. While this is true for current practice as well as for this new test, seeing children getting tested on the sidelines more frequently might give false reassurance. One could argue that the safest thing\u00a0for a concerned parent is to avoid contact sports that are prone to involve head injuries.", "answer": 0}, {"article": "that its retinal cells contained virtually no residual embryonic stem cells.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites a company assurance that the new drug is \u201cequally safe\u201d compared with\u00a0its\u00a0FDA-approved competitor. To which we respond:\u00a0How safe is that?\u00a0\u00a0Injecting\u00a0substances into the eye\u00a0is associated with rare but potentially serious risks such as infections of the interior eye. There\u2019s also some evidence that\u00a0Lucentis\u00a0is associated with increased risk of stroke. Does the new drug carry the same\u00a0risks? The story should have provided more details. \u00a0 With over 2000 patients in the trials the company could have reported on the minor and major complications that were observed in the 2 trials.", "answer": 0}, {"article": "Infertility affects up to 12 percent of the male population worldwide.\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t discussed, and there\u2019s a significant one: a man receiving a false-negative test (he believes his sperm count is too low, when it\u2019s actually normal) or a false-positive (his sperm count is low, but a test tells him it\u2019s normal) \u2014 and telling his partner this incorrect information. For a\u00a0couple that\u2019s trying desperately to conceive, that could be crushing news or deceptive false-hope. Any news story about a new screening test should discuss the false-negative and false-positive rates.\nFor example, a story at LiveScience\u00a0captures these well, telling readers that about 98% of people with no training could detect abnormal sperm samples from a fertility clinic with the new device. The sensitivity of the test\u2019s ability to actually detect a sample with a low sperm count was 99.3%, but only 89.4% of normal-sperm-count samples were correctly read by the device. This means more than 10% of men with a normal sperm count might be lead to believe their numbers are abnormal.", "answer": 0}, {"article": ".\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nThis is the first randomized controlled study to assess comprehensive changes in gut microbial composition with prebiotic intervention in children who are overweight and obese.\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote indirectly suggests that the prebiotics are \u201cnon-invasive\u201d but that doesn\u2019t tell us a lot. Bloating and gas are often at least a temporary problem. It would have been useful to know how well children in the study tolerated the supplement.\nAnd if the parents of children with obesity are not changing their diet (avoiding high fructose corn syrup, excessive prepared foods, and overfeeding), and letting the supplement do the work, that\u2019s not teaching kids to eat healthily, which is an unintended consequence.", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\nThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients' ability to perform everyday tasks - possibly the most troubling aspects of the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know the possible risks associated with drinking an amalgam of different food products. And this release provides no insights. Previous studies have suggested that the nutritional product is well tolerated and did not appear to cause any harms. That being said, we think that this should have been noted in the report.", "answer": 0}, {"article": "Studies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nIn many ways, Sarah is a perfect case study in how to think about the benefits and risks of running versus walking.\nAnd a lot of running (i.e., ultramarathon training) can well be harmful, while the same is never true for walking.\nI wanted to see what the highest-quality evidence \u2014 trials and reviews are the gold standard \u2014 said about the relative risks and benefits of these two forms of exercise.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story does a very good job of quantifying the potential risks of running and of comparing the likelihood of injury from running to those for walking.", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although it discusses the potentially catastrophic side effects of acute treatment,\u00a0the story did not explain that these patients have compromised immune systems following treatment and need ongoing therapy with immunoglobulins for an unknown amount of time. That\u2019s a considerable omission.\nThe New York Times story, which we also reviewed, did a better job on this.\n\u00a0", "answer": 0}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nEven some people who don\u2019t have celiac disease feel better when they don\u2019t eat wheat.\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the strongest aspect of the story and the area where readers are likely to find some value. The story explains that the low-FODMAP diet has drawbacks, since foods high in FODMAPS are thought to stimulate growth of certain bacteria associated with digestive health. We\u2019d add that anything that restricts consumption of fruits and vegetables has the potential to reduce the quality of your diet and potentially impact your health. This is especially true for children. The story rightfully\u00a0stresses that a low-FODMAP diet should be used \u201cto reduce specific symptoms, not as a way to improve health.\u201d", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nAnd during Victoza treatment, patients needed less and less insulin.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nPatients who continued treatment for 24 weeks had further decreases in insulin doses, and lost an average of 10 pounds.\nAdding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pays appropriate attention to potential harms. It notes that the weight loss caused by the drug could be detrimental to thin patients, and that the drug causes\u00a0abdominal pain, nausea, and vomiting.\u00a0\u00a0The study author notes\u00a0that adverse effects cause about 5% of type 2 diabetes patients to stop taking the drug. The story probably should have mentioned that the drug is administered by injection, something which can\u2019t be very appealing to type 1 diabetics who\u00a0may already be giving themselves multiple injections daily or, as in this study, are using insulin pumps that only require a needle to be inserted every few days.", "answer": 1}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nThe snack was administered after school as students were boarding the school bus to go home.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that care was taken not to give these snacks to children who had nut allergies.", "answer": 1}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\n\"At present the only way to diagnose esophageal cancer or stomach cancer is with endoscopy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself\u2013if an exhaled breath is all it involves\u2013is unlikely to carry immediate harms. But with any lab test used to detect disease, the potential harm is if the test fails the patient\u2013by either flagging them as having cancer when they don\u2019t, or flagging them as not having cancer when they do. The first scenario can cause anxiety and lead to extra, unnecessary testing, and the second means the cancer is going untreated. We always hope to see a nod to this in any story about testing, and it\u2019s why we often say \u201cthere is no such thing as a simple medical test.\u201d", "answer": 0}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nThe reduction of symptoms in the patients receiving brexanolone injection was maintained throughout the last study visit at Day 30.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains one somewhat vague sentence on harms.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\nReaders would also be interested in details on whether the drug is safe for nursing infants. That\u2019s not mentioned.", "answer": 1}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nImportantly, the benefit of treatment was strongly driven by improvements in pain and discomfort as well as self-care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It would be most useful to know why radiosurgery is typically a \u201csecond line treatment to be used following the medication\u201d and so one wonders if this is due to the harms involved with this type of surgery which can include fatigue, skin problems, and difficulty swallowing, none of which are mentioned in the news release. At a minimum, if there weren\u2019t any side effects among the patient volunteers, the release could have stated that there weren\u2019t any. Additionally, since the treatment involves radiation and radiation can promote cancer, the study should have mentioned this and why or why not it is an issue with this specific treatment.", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThe work offers the first evidence that the compound hydroxycitrate (HCA) is an effective inhibitor of calcium oxalate crystal growth that, under certain conditions, is actually able to dissolve these crystals.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call. The release notes that some people are unable to tolerate the side effect of citrate and it says that safety studies of hydroxycitrate are needed, but there is no discussion of what potential harms the proposed treatment might pose.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nAmong the antidepressants, Paxil seemed to have the strongest evidence of benefit.\nOf 10 studies on antidepressants, for instance, the researchers judged only two of the studies to be good, and the rest fair or poor.\nShe took a cautious view because she and her colleagues found that there was relatively little reliable data on using the drugs for hot flashes.\nThere were only two studies for Effexor, just one of which suggested it might help.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions side effects of the non-hormonal treatment under study, as well as the risks associated with hormone replacement therapy. There is no mention of the incidence of these side effects. However, this was a meta-analysis of 43 studies, so side effects varied by medication and each study. ", "answer": 1}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nAnd all of the people in this study are white, so that's a limitation.\nBut this does raise the prospect of whether it may soon be time to tweak the official definition of normal, healthy weight.\nThe BMI has been vilified as a poor measure of an individual's health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job describing why some people with low BMI might be at higher risk of dying\u2013 i.e., they may be suffering from cancer or another disease that could cause weight loss.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nThe 2009 H1N1 (\"swine flu\") pandemic sparked influenza cases around the globe, resulting in nearly 18,000 deaths, the authors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions adverse effects that have been associated with ephedra, one of the constituents of the herbal treatment being tested. It also says that minimal side effects were seen in all treatment groups of this\u00a0study. The story could have\u00a0commented on other possible side effects of herbals, such as potential\u00a0interactions with other medications.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nMucke acknowledged that there are very few medical treatments for patients once they are diagnosed with Alzheimer's.\nThe test initially will be used in research labs, where scientists are trying to learn more about the memory-wasting disease that is one of the most feared consequences of aging.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did acknowledge that there are very few medical treatments for patients once they are diagnosed with Alzheimers\u2019s, it failed to address the burden of such knowledge for the patient and the patient\u2019s family.\u00a0 There could be insurance ramifications, there should likely be\u00a0a consulting component to go hand in hand with the test, and there is the possibility of false positive results.\nThe story did not do an adequate job of addressing the potential harms of this test.", "answer": 0}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nA case in point is mindfulness-based therapy to prevent a relapse into depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story alludes to the harms of mindfulness mediation for some patients who have had fewer than 3 episodes of depression (according to one study). The story also notes the general harms of a new practice becoming a fad when there are few standardized training programs, and it has not been studied long enough for all conditions for which it is currently being promoted. ", "answer": 1}]